

[Continued on nextpage]

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.1 7(H))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

MICROORGANISMS FOR THE PRODUCTION OF INSECT PHEROMONES AND RELATED COMPOUNDS

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application Serial No. 62/507,654, filed on May 17, 2017, which is hereby incorporated by reference in its entirety.

STATEMENT REGARDING THE SEQUENCE LISTING

[0002] The Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the Sequence Listing is PRVI__020__01WO__SeqList__ST25.txt. The text file is about 240 KB, was created on May 17, 2018, and is being submitted electronically viaEFS-Web.

TECHNICAL FIELD

[0003] This application relates to recombinant microorganisms useful in the biosynthesis of unsaturated C₆-C₂₄ fatty alcohols, aldehydes, and acetates which may be useful as insect pheromones, fragrances, flavors, and polymer intermediates. The application further relates to methods of producing unsaturated C₆-C₂₄ fatty alcohols, aldehydes, and acetates using the recombinant microorganisms, as well as compositions comprising one or more of these compounds and/or the recombinant microorganisms.

BACKGROUND

[0004] As the global demand for food grows, there is an increasing need for effective pest control. Conventional insecticides are among the most popular chemical control agents because they are readily available, rapid acting, and highly reliable. However, the overuse, misuse, and abuse of these chemicals have led to resistant pests, alteration of the natural ecology, and in some cases, environmental damage.

[0005] The use of insect pheromones to control pest populations has gained increasing popularity as a viable, safe, and environmentally friendly alternative to conventional insecticides. Since their discovery in the late 1950s, these molecules have shown efficacy in reducing insect populations through a variety of methods, including mass trappings, attract and kill, and mating disruption. The latter method in particular represents a non-toxic means of pest control and utilizes the ability of synthetic pheromones to mask naturally occurring pheromones, thereby causing confusion and mating disruption.

[0006] Although pheromones have significant potential in agricultural insect control, the cost of synthesizing pheromones using currently available techniques is very high, which prohibits widespread use of this sustainable technology beyond high-value crops. Thus, there is an existing need to develop novel technologies for the cost-efficient production of insect pheromones and related fragrances, flavors, and polymer intermediates. The present inventors address this need with the development of recombinant microorganisms capable of producing a wide-range of unsaturated C₆-C₂₄ fatty alcohols, aldehydes, and acetates including synthetic insect pheromones from low-cost feedstocks.

SUMMARY OF THE DISCLOSURE

[0007] The present application relates to recombinant microorganisms having a biosynthesis pathway for the production of one or more compounds selected from unsaturated C₆-C₂₄ fatty-alcohols, aldehydes, and acetates. The recombinant microorganisms described herein may be used for the production of at least one compound, such as an insect pheromone, a fragrance, or a flavoring agent, selected from unsaturated C₆-C₂₄ fatty alcohols, aldehydes, and acetates.

[0008] In one embodiment, the recombinant microorganism comprises a biosynthesis pathway for the production of an unsaturated C₆-C₂₄ fatty aldehyde or fatty alcohol. Accordingly, in a first aspect, the application relates to a recombinant microorganism capable of producing an unsaturated C₆-C₂₄ fatty aldehyde or fatty alcohol from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acyl-CoA, wherein the recombinant microorganism expresses (a): at least one exogenous nucleic acid molecule encoding a fatty-acyl desaturase that catalyzes the conversion of a saturated C₆-C₂₄ fatty acyl-CoA to a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA; and (b): at least one exogenous nucleic acid molecule encoding a fatty aldehyde forming fatty-acyl reductase that catalyzes the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA from into the corresponding mono- or poly-unsaturated C₆-C₂₄ fatty aldehyde. In some embodiments, the mono- or poly-unsaturated C₆-C₂₄ fatty aldehyde is an insect pheromone. In some embodiments, the mono- or poly-unsaturated C₆-C₂₄ fatty aldehyde is a fragrance or flavoring agent. In some embodiments, the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol from (b) into a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty acetate. (c) at least one exogenous nucleic acid molecule encoding a fatty alcohol forming fatty-acyl reductase that catalyzes the

conversion of the mono- or poly-unsaturated C_6-C_{24} fatty acyl-CoA from (a) into the corresponding mono- or poly-unsaturated C_6-C_{24} fatty alcohol. In some embodiments, the mono- or poly-unsaturated C_6-C_{24} fatty alcohol is an insect pheromone. In some embodiments, the mono- or poly-unsaturated C_6-C_{24} fatty alcohol is a fragrance or flavoring agent. In some embodiments, the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase or an alcohol dehydrogenase, wherein the alcohol oxidase or alcohol dehydrogenase is capable of catalyzing the conversion of the mono- or poly-unsaturated C_6-C_{24} fatty alcohol from (b) into a corresponding mono- or poly-unsaturated C_6-C_{24} fatty aldehyde. In some embodiments, the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated C_6-C_{24} fatty alcohol from (b) into a corresponding mono- or poly-unsaturated C_6-C_{24} fatty acetate.

[0009] In some embodiments, the fatty-acyl desaturase is a desaturase capable of utilizing a fatty acyl-CoA as a substrate that has a chain length of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 carbon atoms.

[0010] In some embodiments, the fatty-acyl desaturase is capable of generating a double bond at position C5, C6, C7, C8, C9, C10, C11, C12, or C13 in the fatty acid or its derivatives, such as, for example, fatty acid CoA esters.

[0011] In one exemplary embodiment, the fatty-acyl desaturase is a Δ^{11} desaturase. In various embodiments described herein, the Δ^{11} desaturase, or the nucleic acid sequence that encodes it, can be isolated from organisms of the species *Agrotis segetum*, *Amyelois transitella*, *Argyrotaenia velutiana*, *Choristoneura rosaceana*, *Lampronia capitella*, *Trichoplusia ni*, *Heliothis virescens*, or *Thalassiosira pseudonana*. Further Δ^{11} -desaturases, or the nucleic acid sequences encoding them, can be isolated from *Bombyx mori*, *Manduca sexta*, *Diatraea gratiosella*, *Farias insulana*, *Farias vittella*, *Phitelia xylostele*, *Bombyx mori* or *Diaphana niidalis*. In exemplary embodiments, the Δ^{11} desaturase comprises a sequence selected from GenBank Accession Nos. JX679209, JX964774, AF416738, AF545481, EU152335, AAD03775, AAF81787, and AY493438. In some embodiments, a nucleic acid sequence encoding a Δ^{11} desaturase from organisms of the species *Agrotis segetum*, *Amyelois transitella*, *Argyrotaenia velutiana*, *Choristoneura rosaceana*, *Lampronia capitella*, *Trichoplusia ni*, *Heliothis virescens*, or *Thalassiosira pseudonana* is codon optimized. In some embodiments, the Δ^{11} desaturase comprises a nucleotide sequence selected from

SEQ ID NOs: 9, 18, 24 and 26 from *Trichoplusia ni*. In some embodiments, the Z11 desaturase comprises an amino acid sequence set forth in SEQ ID NO: 49 from *Trichoplusia ni*. In other embodiments, the Z11 desaturase comprises a nucleotide sequence selected from SEQ ID NOs: 10 and 16 from *Agrois segetum*. In some embodiments, the Z11 desaturase comprises an amino acid sequence set forth in SEQ ID NO: 53 from *Agrois segetum*. In some embodiments, the Z11 desaturase comprises a nucleotide sequence selected from SEQ ID NOs: 11 and 23 from *Thalassiosira pseudonana*. In some embodiments, the Z11 desaturase comprises an amino acid sequence selected from SEQ ID NOs: 50 and 51 from *Thalassiosira pseudonana*. In certain embodiments, the Z11 desaturase comprises a nucleotide sequence selected from SEQ ID NOs: 12, 17 and 30 from *Amyeloid transiella*. In some embodiments, the Z11 desaturase comprises an amino acid sequence set forth in SEQ ID NO: 52 from *Amyeloid transiella*. In further embodiments, the Z11 desaturase comprises a nucleotide sequence selected from SEQ ID NOs: 13, 19, 25, 27 and 31 from *Helicoverpa zea*. In some embodiments, the Z11 desaturase comprises an amino acid sequence set forth in SEQ ID NO: 54 from *Helicoverpa zea*. In some embodiments, the Z11 desaturase comprises an amino acid sequence set forth in SEQ ID NO: 39 from *S. inferens*. In some embodiments, the Z11 desaturase comprises an amino acid sequence set forth in GenBank Accession nos. AF416738, AGH12217.1, AF21943.1, CAJ43430.2, AF441221, AAF81787.1, AF545481, AJ271414, AY362879, ABX71630.1 and NP001299594.1, Q9N9Z8, ABX71630.1 and AIM40221.1. In some embodiments, the Z11 desaturase comprises a chimeric polypeptide. In some embodiments, a complete or partial Z11 desaturase is fused to another polypeptide. In certain embodiments, the N-terminal native leader sequence of a Z11 desaturase is replaced by an oleosin leader sequence from another species. In certain embodiments, the Z11 desaturase comprises a nucleotide sequence selected from SEQ ID NOs: 15, 28 and 29. In some embodiments, the Z11 desaturase comprises an amino acid sequence selected from SEQ ID NOs: 61, 62, 63, 78, 79 and 80.

[0012] In certain embodiments, the Z11 desaturase catalyzes the conversion of a fatty acyl-CoA into a mono- or poly-unsaturated product selected from Z11-13:Acyl-CoA, E11-13:Acyl-CoA, (Z,Z)-7,11-13:Acyl-CoA, Z11-14:Acyl-CoA, E11-14:Acyl-CoA, (E,E)-9,11-14:Acyl-CoA, (E,Z)-9,11-14:Acyl-CoA, (Z,E)-9,11-14:Acyl-CoA, (Z,Z)-9,11-14:Acyl-CoA, (E,Z)-9,11-15:Acyl-CoA, (Z,Z)-9,11-15:Acyl-CoA, Z11-16:Acyl-CoA, E11-16:Acyl-CoA, (E,Z)-6,11-16:Acyl-CoA, (E,Z)-7,11-16:Acyl-CoA, (E,Z)-8,11-16:Acyl-CoA, (E,E)-9,11-16:Acyl-CoA, (E,Z)-9,11-16:Acyl-CoA, (Z,E)-9,11-16:Acyl-CoA, (Z,Z)-9,11-16:Acyl-CoA,

(E,E)-11,13-16:Acyl-CoA, (E,Z)-11,13-16:Acyl-CoA, (Z,E)-11,13-16:Acyl-CoA, (Z,Z)-11,13-16:Acyl-CoA, (Z,E)-11,14-16:Acyl-CoA, (E,E,Z)-4,6,11-16:Acyl-CoA, (Z,Z,E)-7,11,13-16:Acyl-CoA, (E,E,Z,Z)-4,6,11,13-16:Acyl-CoA, Z11-17:Acyl-CoA, (Z,Z)-8,11-17:Acyl-CoA, Z11-18:Acyl-CoA, Ell-18:Acyl-CoA, (Z,Z)-11,13-18:Acyl-CoA, (E,E)-11,14-18:Acyl-CoA, or combinations thereof.

[0013] In another exemplary embodiment, the fatty-acyl desaturase is a Z9 desaturase. In various embodiments described herein, the Z9 desaturase, or the nucleic acid sequence that encodes it, can be isolated from organisms of the species *Ostrinia furnacalis*, *Ostrinia nobilalis*, *Choristoneura rosaceana*, *Lampronia capitelia*, *Helicoverpa assulta*, or *Helicoverpa zea*. In exemplary embodiments, the Z9 desaturase comprises a sequence selected from GenBank Accession Nos. AY057862, AF243047, AF518017, EU152332, AF482906, and AAF81788. In some embodiments, a nucleic acid sequence encoding a Z9 desaturase is codon optimized. In some embodiments, the Z9 desaturase comprises a nucleotide sequence set forth in SEQ ID NO: 20 from *Ostrinia furnacalis*. In some embodiments, the Z9 desaturase comprises an amino acid sequence set forth in SEQ ID NO: 58 from *Ostrinia furnacalis*. In other embodiments, the Z9 desaturase comprises a nucleotide sequence set forth in SEQ ID NO: 21 from *Lampronia capitelia*. In some embodiments, the Z9 desaturase comprises an amino acid sequence set forth in SEQ ID NO: 59 from *Lampronia capitelia*. In some embodiments, the Z9 desaturase comprises a nucleotide sequence set forth in SEQ ID NO: 22 from *Helicoverpa zea*. In some embodiments, the Z9 desaturase comprises an amino acid sequence set forth in SEQ ID NO: 60 from *Helicoverpa zea*. Other Z9 desaturases of the present disclosure include SEQ ID Nos: 95, 97, 99, 101, 103, and 105. In some embodiments, the overexpression of a Z9-18 specific desaturase can increase the membrane fluidity to improve the diffusion of fatty alcohols into the supernatant.

[0014] In certain embodiments, the Z9 desaturase catalyzes the conversion of a fatty acyl-CoA into a monounsaturated or polyunsaturated product selected from Z9-11:Acyl-CoA, Z9-12:Acyl-CoA, E9-12:Acyl-CoA, (E,E)-7,9-12:Acyl-CoA, (E,Z)-7,9-12:Acyl-CoA, (Z,E)-7,9-12:Acyl-CoA, (Z,Z)-7,9-12:Acyl-CoA, Z9-13:Acyl-CoA, E9-13:Acyl-CoA, (E,Z)-5,9-13:Acyl-CoA, (Z,E)-5,9-13:Acyl-CoA, (Z,Z)-5,9-13:Acyl-CoA, Z9-14:Acyl-CoA, E9-14:Acyl-CoA, (E,Z)-4,9-14:Acyl-CoA, (E,E)-9,11-14:Acyl-CoA, (E,Z)-9,11-14:Acyl-CoA, (Z,E)-9,11-14:Acyl-CoA, (Z,Z)-9,11-14:Acyl-CoA, (E,E)-9,12-14:Acyl-CoA, (Z,E)-9,12-14:Acyl-CoA, (Z,Z)-9,12-14:Acyl-CoA, Z9-15:Acyl-CoA, E9-15:Acyl-CoA, (Z,Z)-6,9-15:Acyl-CoA, Z9-16:Acyl-CoA, E9-16:Acyl-CoA, (E,E)-9,11-16:Acyl-CoA, (E,Z)-9,11-

16:Acyl-CoA, (Z,E)-9,11-16:Acyl-CoA, (Z,Z)-9,11-16:Acyl-CoA, Z9-17:Acyl-CoA, E9-18:Acyl-CoA, Z9-18:Acyl-CoA, (E,E)-5,9-18:Acyl-CoA, (E,E)-9,12,18:Acyl-CoA, (Z,Z)-9,12,18:Acyl-CoA, (Z,Z,Z)-3,6,9-18:Acyl-CoA, (E,E,E)-9,12,15-18:Acyl-CoA, (Z,Z,Z)-9,12,15-18:Acyl-CoA, or combinations thereof.

[0015] In some embodiments, the recombinant microorganism may express a bifunctional desaturase capable of catalyzing the subsequent desaturation of two double bonds.

[0016] In some embodiments, the recombinant microorganism may express more than one exogenous nucleic acid molecule encoding a fatty-acyl desaturase that catalyzes the conversion of a saturated C_{6-C24} fatty acyl-CoA to a corresponding mono- or polyunsaturated C_{6-C24} fatty acyl-CoA. For instance, the recombinant microorganism may express an exogenous nucleic acid molecule encoding a $\Delta 11$ desaturase and another exogenous nucleic acid molecule encoding a $\Delta 9$ desaturase.

[0017] In some embodiments, the recombinant microorganism may express a fatty-acyl conjugase that acts independently or together with a fatty-acyl desaturase to catalyze the conversion of a saturated or monounsaturated fatty acyl-CoA to a conjugated polyunsaturated fatty acyl-CoA.

[0018] In one embodiment, the disclosure provides a recombinant microorganism capable of producing a polyunsaturated C_{6-C24} aldehyde or fatty alcohol from an endogenous or exogenous source of saturated or monounsaturated C_{6-C24} fatty acyl-CoA, wherein the recombinant microorganism expresses: (a) at least one exogenous nucleic acid molecule encoding a fatty acyl conjugase that catalyzes the conversion of a saturated or monounsaturated C_{6-C24} fatty acyl-CoA to a corresponding polyunsaturated C_{6-C24} fatty acyl-CoA; and (b) at least one exogenous nucleic acid molecule encoding a fatty aldehyde or fatty alcohol forming fatty-acyl reductase that catalyzes the conversion of the polyunsaturated C_{6-C24} fatty acyl-CoA from (a) into the corresponding polyunsaturated C_{6-C24} fatty aldehyde or fatty alcohol.

[0019] In another embodiment, the recombinant microorganism expresses at least two exogenous nucleic acid molecules encoding fatty-acyl conjugases that catalyze the conversion of a saturated or monounsaturated C_{6-C24} fatty acyl-CoA to a corresponding polyunsaturated C_{6-C24} fatty acyl-CoA.

[0020] In a further embodiment, the disclosure provides a recombinant microorganism capable of producing a polyunsaturated C_{6-C24} fatty alcohol from an endogenous or

exogenous source of saturated or monounsaturated C₆-C₂₄ fatty acyl-CoA, wherein the recombinant microorganism expresses: (a) at least one exogenous nucleic acid molecule encoding a fatty-acyl desaturase and at least one exogenous nucleic acid molecule encoding a fatty acyl conjugase that catalyze the conversion of a saturated or monounsaturated C₆-C₂₄ fatty acyl-CoA to a corresponding polyunsaturated C₆-C₂₄ fatty acyl-CoA; and (b) at least one exogenous nucleic acid molecule encoding a fatty alcohol forming fatty-acyl reductase that catalyzes the conversion of the polyunsaturated C₆-C₂₄ fatty acyl-CoA from (a) into the corresponding polyunsaturated C₆-C₂₄ fatty alcohol.

[0021] In another embodiment, the recombinant microorganism expresses at least two exogenous nucleic acid molecules encoding fatty-acyl desaturases and at least two exogenous nucleic acid molecules encoding fatty-acyl conjugases that catalyze the conversion of a saturated or monounsaturated C₆-C₂₄ fatty acyl-CoA to a corresponding polyunsaturated C₆-C₂₄ fatty acyl-CoA.

[0022] In yet a further embodiment, the fatty-acyl conjugase is a conjugase capable of utilizing a fatty acyl-CoA as a substrate that has a chain length of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 carbon atoms.

[0023] In certain embodiments, the conjugase, or the nucleic acid sequence that encodes it, can be isolated from organisms of the species *Cydia pomonella*, *Cydia nigricana*, *Lobesia boirana*, *Myelois cribrella*, *Plodia interpunctella*, *Dendrolimus punctatus*, *Lampronia capitella*, *Spodoptera litura*, *Amyelois iransitella*, *Manauca sexta*, *Bombyx mori*, *Calendula officinalis*, *Trichosanthes kirilowii*, *Punica granatum*, *Momordica charantia*, *Impatiens balsamina*, and *Epiphyas postvittana*. In exemplary embodiments, the conjugase comprises a sequence selected from GenBank Accession No. or Uniprot database: A0A059TBF5, A0A0M3L9E8, A0A0M3L9S4, A0A0M3LAH8, A0A0M3LAS8, A0A0M3LAH8, B6CBS4, XP_013183656.1, XP_004923568.2, ALA65425.1, NP_001296494.1, NP_001274330.1, Q4A181, Q75PL7, Q9FPP8, AY178444, AY178446, AF182521, AF182520, Q95UJ3.

[0024] In various embodiments described herein, the fatty alcohol forming acyl-CoA reductase, i.e., fatty alcohol forming fatty-acyl reductase, or the nucleic acid sequence that encodes it, can be isolated from organisms of the species *Agrotis segetum*, *Spodoptera littoralis*, *Hebcoverpa amigera*, *Spodoptera exigua*, *Euglena gracilis*, or *Yponomeuta evonymellus*. In exemplary embodiments, the reductase comprises a sequence selected from

GenBank Accession Nos. JX679210 and HG423128, and UniProt Accession No. I3PN86. In some embodiments, a nucleic acid sequence encoding a fatty-acyl reductase from organisms of the species *Agrotis segetum*, *Spodoptera littorahs*, *Helicoverpa amigera*, *Spodoptera exigua*, *Euglena gracilis*, or *Yponomeuta evonymellus* is codon optimized. In some embodiments, the reductase comprises a nucleotide sequence set forth in SEQ ID NO: 1 from *Agrotis segetum*. In some embodiments, the fatty acyl reductase comprises an amino acid sequence set forth in SEQ ID NO: 55 from *Agrotis segetum*. In other embodiments, the reductase comprises a nucleotide sequence set forth in SEQ ID NO: 2 from *Spodoptera littorahs*. In some embodiments, the fatty acyl reductase comprises an amino acid sequence set forth in SEQ ID NO: 56 from *Spodoptera lateralis*. In some embodiments, the reductase comprises a nucleotide sequence selected from SEQ ID NOs: 3, 32, 40, 72, 74, 76 and 81. In some embodiments, the fatty acyl reductase comprises an amino acid sequence set forth in SEQ ID NO: 55 from *Agrotis segetum*. In other embodiments, the fatty acyl reductase comprises an amino acid sequence set forth in SEQ ID NO: 56 from *Spodoptera littorahs*. In some embodiments, the fatty acyl reductase comprises an amino acid sequence selected from SEQ ID NOs: 41 and 57 from *Helicoverpa armigera*. In some embodiments, the fatty acyl reductase comprises an amino acid sequence selected from SEQ ID NOs: 73 and 82 from *Spodoptera exigua*. In some embodiments, the fatty acyl reductase comprises an amino acid sequence set forth in SEQ ID NO: 75 from *Euglena gracilis*. In some embodiments, the fatty acyl reductase comprises an amino acid sequence set forth in SEQ ID NO: 77 from *Yponomeuta evonymellus*.

[0025] In some embodiments, the present disclosure teaches using multiple fatty acyl reductase enzymes. In some embodiments, the present disclosure teaches recombinant microorganisms comprising multiple copies of the same fatty acyl reductase. In other embodiments, the present disclosure teaches recombinant microorganisms comprising two or more different fatty acyl reductases. In some embodiments, the different fatty acyl reductases utilize different co-factors. For example, the fatty acyl reductase from *Euglena gracilis* (SEQ ID NO: 75) uses NADH instead of NADPH as reducing equivalent. In some embodiments, this can allow for co-factor balancing using two or more different reductases.

[0026] In some embodiments, the fatty acyl reductase is a mutated fatty acyl reductase and comprises an amino acid sequence selected from SEQ ID NOs: 42-48. In some embodiments, the fatty acyl reductase is a mutated fatty acyl reductase and comprises a nucleotide sequence selected from SEQ ID NOs: 83-89.

[0027] In certain embodiments, the fatty alcohol forming fatty-acyl reductase catalyzes the conversion of a mono- or poly-unsaturated fatty acyl-CoA into a fatty alcohol product selected from (Z)-3-hexenol, (Z)-3-nonenol, (Z)-5-decenol, (E)-5-decenol, (Z)-7-dodecenol, (E)-7-dodecenol, (E)-8-dodecenol, (Z)-8-dodecenol, (Z)-9-dodecenol, (E)-9-dodecenol, (Z)-9-tetradecenol, (E)-9-tetradecenol, (Z)-9-hexadecenol, (Z)-11-tetradecenol, (Z)-7-hexadecenol, (Z)-11-hexadecenol, (E)-11-hexadecenol, (E)-11-tetradecenol, or (Z,Z)-11,13-hexadecadienol, (1Z,13E)-hexadecadienol, (E,E)-8,10-dodecadienol, (E,Z)-7,9-dodecadienol, (Z)-13-octadecenol, or combinations thereof.

[0028] In some embodiments, the recombinant microorganism may express more than one exogenous nucleic acid molecule encoding a fatty alcohol forming fatty-acyl reductase that catalyzes the conversion of a mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA to a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty alcohol.

[0029] In a further embodiment, the disclosure provides a recombinant microorganism capable of producing a mono- or poly-unsaturated \leq Cis fatty alcohol from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid, wherein the recombinant microorganism comprises: (a) at least one exogenous nucleic acid molecule encoding a fatty acyl desaturase that catalyzes the conversion of a saturated C₆-C₂₄ fatty acyl-CoA to a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA; (b) at least one exogenous nucleic acid molecule encoding an acyl-CoA oxidase that catalyzes the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA from (a) into a mono- or poly-unsaturated \leq Cis fatty acyl-CoA after one or more successive cycle of acyl-CoA oxidase activity, with a given cycle producing a mono- or poly-unsaturated C₄-C₂₂ fatty acyl-CoA intermediate with a two carbon truncation relative to a starting mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA substrate in that cycle; and (c) at least one exogenous nucleic acid molecule encoding a fatty alcohol forming fatty acyl reductase that catalyzes the conversion of the mono- or poly-unsaturated \leq Cis fatty acyl-CoA from (b) into the corresponding mono- or poly-unsaturated \leq Cis fatty alcohol. In some embodiments, the fatty acyl desaturase is selected from an *Argyrotania velutinana*, *Spodopiera litura*, *Sesamia inferens*, *Manduca sexta*, *Ostrinia niibialis*, *Helicoverpa zea*, *Chonsioneura rosaceana*, *Drosophila melanogaster*, *Spodopiera littoralis*, *Lamproma capitella*, *Amyeloides transitella*, *Trichoplusia ni*, *Agrotis segetum*, *Ostrinia furnicalis*, and *Thalassiosira pseudonana* derived fatty acyl desaturase. In some embodiments, the fatty acyl desaturase has at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%,

71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, 50%, or 50% sequence identity to a **fatty** acyl desaturase selected from the group consisting of: SEQ ID NOs: 39, 49-54, 58-63, 78-80 and GenBank Accession nos. AF416738, **AGH12217.1**, AII21943.1, CAJ43430.2, **AF441221**, AAF81787.1, AF545481, AJ271414, AY362879, ABX71630.1, NPOO 1299594.1, Q9N9Z8, ABX71630.I and **AIM4022 1.1**. In some embodiments, the **acyl-CoA** oxidase is selected from **Table 5a**. In other embodiments, the **fatty** alcohol forming fatty acyl reductase is selected from an *Agrotis segetum*, *Spodoptera exigua*, *Spodoptera tittoralis*, *Euglena gracilis*, *Yponomeuta evonymellus* and *Helicoverpa armigera* derived fatty alcohol forming fatty acyl reductase. In further embodiments, the fatty alcohol forming fatty acyl reductase has at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, **78%**, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, **50%**, or 50% sequence **identity to a fatty** alcohol forming fatty acyl reductase selected from the group consisting of: SEQ ID NOs: 1-3, 32, 41-48, 55-57, 73, 75, 77 and 82. In some embodiments, the recombinant microorganism is a yeast selected from **the** group consisting of *Yarrowia lipolytica*, *Saccharomyces cerevisiae*, *Candida albicans*, *Candida tropicalis* and *Candida viswanathii*.

[0030] In some embodiments, the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an **acyltransferase** that preferably stores \leq C₁₈ **fatty** acyl-CoA. In some embodiments, the acyltransferase is selected from the group consisting of **glycerol-3**-phosphate acyl transferase (GPAT), **lysophosphatidic** acid acyltransferase (LPAAT), **glycerolphospholipid** acyltransferase (GPLAT) and **diacylglycerol acyltransferases** (DGAT). In some preferred embodiments, the acyltransferase is selected from **Table 5b**.

[0031] In some embodiments, the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an **acylglycerol** lipase that preferably **hydrolyzes** ester bonds of >C₁₆, of >C₁₄, of >C₁₂ or of >C₁₀ acylglycerol substrates. In some embodiments, the acylglycerol lipase is selected from **Table 5c**.

[0032] In some embodiments, the recombinant microorganism comprises a deletion, **disruption**, mutation, and/or reduction in the activity of one or more endogenous enzymes that catalyzes a reaction in a **pathway that** competes **with** the **biosynthesis** pathway for the production of a mono- or **poly-unsaturated** \leq C₁₈ fatty alcohol. In further embodiments, the

recombinant microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous enzyme selected from: (i) one or more acyl-CoA oxidase; (ii) one or more acyltransferase; (iii) one or more acylglycerol lipase and/or sterol ester esterase; (iv) one or more (fatty) alcohol dehydrogenase; (v) one or more (fatty) alcohol oxidase; and (vi) one or more cytochrome P450 monooxygenase.

[0033] In some preferred embodiments, one or more genes of the microbial host encoding acyl-CoA oxidases are deleted or down-regulated to eliminate or reduce the truncation of desired fatty acyl-CoAs beyond a desired chain-length. In some embodiments, the recombinant microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous acyl-CoA oxidase enzyme selected from the group consisting of *Y. lipofytica* POX1 (YALI0E32835g), *Y. lipolytica* POX2 (YALIOF10857g), *Y. lipolytica* POX3 (YALI0D24750g), *Y. lipolytica* POX4 (YALI0E27654g), *Y. lipolytica* POX5 (YALI0C23859g), *Y. lipolytica* POX6 (YALI0E06567g); *S. cerevisiae* POX1 (YGL205W); *Candida* POX2 (Ca019.1655, Ca019.9224, CTRG_02374, M18259), *Candida* **POX4** (Ca019.1652, Ca019.9221, CTRGJ32377, M12160), and *Candida* POX5 (Ca019.5723, Ca019.13146, CTRG_02721, M12161).

[0034] In some embodiments, a recombinant microorganism capable of producing a mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol, fatty aldehyde and/or fatty acetate from an endogenous or exogenous source of saturated C_6 - C_{24} fatty acid is provided, wherein the recombinant microorganism expresses one or more acyl-CoA oxidase enzymes, and wherein the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the activity of one or more endogenous acyl-CoA oxidase enzymes. In some embodiments, the one or more acyl-CoA oxidase enzymes being expressed are different from the one or more endogenous acyl-CoA oxidase enzymes being deleted or downregulated. In other embodiments, the one or more acyl-CoA oxidase enzymes that are expressed regulate chain length of the mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol, fatty aldehyde and/or fatty acetate. In other embodiments, the one or more acyl-CoA oxidase enzymes being expressed are selected from Table 5a.

[0035] In some embodiments, the recombinant microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous acyltransferase enzyme selected from the group consisting of *Y. lipolytica* YALI0C00209g, *Y. lipolytica* YALI0E18964g, *Y. lipolytica* YALIOF19514g, *Y. lipolytica* YALI0C14014g, *Y. lipolytica* YALI0E16797g, *Y. lipolytica* YALI0E32769g, and *Y. lipolytica* YALI0D07986g,

S. cerevisiae YBL011w, *S. cerevisiae* YDL052c, *S. cerevisiae* YOR175C, *S. cerevisiae* YPR139C, *S. cerevisiae* YNR008w, and *S. cerevisiae* YGR245c, and *Candida* 1503_02577, *Candida* CTRG_02630, *Candida* CaO19.250, *Candida* Ca019.7881, *Candida* CTRG_02437, *Candida* Ca019.1881, *Candida* CaO 19.9437, *Candida* CTRG_01687, *Candida* CaO19.1043, *Candida* Ca019.8645, *Candida* CTRG_0475Q, *Candida* Ca019.13439, *Candida* CTRG_04390, *Candida* Ca019.6941, *Candida* CaO19.14203, and *Candida* CTRG_06209.

[0036] In some embodiments, a recombinant microorganism capable of producing a mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol, fatty aldehyde and/or fatty acetate from an endogenous or exogenous source of saturated C_{6-C24} fatty acid is provided, wherein the recombinant microorganism expresses one or more acyltransferase enzymes, and wherein the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the activity of one or more endogenous acyltransferase enzymes. In some preferred embodiments, one or more genes of the microbial host encoding GPATs, LPAATs, GPLATs and/or DGATs are deleted or downregulated, and replaced with one or more GPATs, LPAATs, GPLATs, or DGATs which prefer to store short-chain fatty acyl-CoAs. In some embodiments, the one or more acyltransferase enzymes being expressed are different from the one or more endogenous acyltransferase enzymes being deleted or downregulated. In other embodiments, the one or more acyltransferase enzymes being expressed are selected from Table Sb.

[0037] In some preferred embodiments, one or more genes of the microbial host encoding acylglycerol lipases (mono-, di-, or triacylglycerol lipases) and sterol ester esterases are deleted or downregulated and replaced with one or more acylglycerol lipases which prefer long chain acylglycerol substrates. In some embodiments, the recombinant microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous acylglycerol lipase and/or sterol ester esterase enzyme selected from the group consisting of *Y. lipolytica* YAL10E32035g, *Y. lipolytica* YALiOD17534g, *Y. lipolytica* YALiOFiOOiOg, *Y. lipolytica* YALiOC14520g, and *Y. lipolytica* YALiOE00528g, *S. cerevisiae* YKL140w, *S. cerevisiae* YMR313c, *S. cerevisiae* YKR089c, *S. cerevisiae* YOR081C, *S. cerevisiae* YKL094W, *S. cerevisiae* YLL012W, and *S. cerevisiae* YLR020C, and *Candida* CaO19.2050, *Candida* CaO 19.9598, *Candida* CTRG_01138, *Candida* W5Q_03398, *Candida* CTRG_00057, *Candida* CaO 19.5426, *Candida* Ca019.12881, *Candida* CTRG_06185, *Candida* CaO 19.4864, *Candida* Ca019. 12328, *Candida* CTRG_03360, *Candida* CaO19.6501, *Candida* Ca019.13854, *Candida* CTRG_05049,

Candida Ca.019.1887, *Candida* Ca.019.9443, *Candida* CTRG_01683, and *Candida* CTRG_04630.

[0038] In some embodiments, the recombinant microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous cytochrome P450 monooxygenases selected from the group consisting of *Y. lipolytica* YALI0E25982g (ALK1), *Y. lipolytica* YALI0F01320g (ALK2), *Y. lipolytica* YALI0E23474g (ALK3), *Y. lipolytica* YALI0B13816g (ALK4), *Y. lipolytica* YALI0B13838g (ALK5), *Y. lipolytica* YALI0B01848g (ALK6), *Y. lipolytica* YALI0AI5488g (ALK7), *Y. lipolytica* YALI0CI2122g (ALK8), *Y. lipolytica* YALI0B06248g (ALK9), *Y. lipolytica* YAU0B207G2g (ALK10), *Y. lipolytica* YALI0C10054g (ALK11) and *Y. lipolytica* YALI0A20130g (ALK12).

[0039] In some embodiments, a recombinant microorganism capable of producing a mono- or poly-unsaturated \leq Cis fatty alcohol, fatty aldehyde and/or fatty acetate from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid is provided, wherein the recombinant microorganism expresses one or more acylglycerol lipase and/or sterol ester esterase enzymes, and wherein the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the activity of one or more endogenous acylglycerol lipase and/or sterol ester esterase enzymes. In some embodiments, the one or more acylglycerol lipase and/or sterol ester esterase enzymes being expressed are different from the one or more endogenous acylglycerol lipase and/or sterol ester esterase enzymes being deleted or downregulated. In some embodiments, the one or more endogenous or exogenous acylglycerol lipase and/or sterol ester esterase enzymes being expressed prefer to hydrolyze ester bonds of long-chain acylglycerols. In other embodiments, the one or more acylglycerol lipase and/or sterol ester esterase enzymes being expressed are selected from Table Sc.

[0040] In some embodiments, the fatty acyl desaturase catalyzes the conversion of a fatty acyl-CoA into a mono- or poly-unsaturated intermediate selected from E5-10:Acyl-CoA, E7-12:Acyl-CoA, E9-14:Acyl-CoA, E11-16:Acyl-CoA, E13-18:Acyl-CoA, Z7-12:Acyl-CoA, Z9-14:Acyl-CoA, Z11-16:Acyl-CoA, Z13-18:Acyl-CoA, Z8-12:Acyl-CoA, Z10-14:Acyl-CoA, Z12-16:Acyl-CoA, Z14-18:Acyl-CoA, Z7-10:Acyl-CoA, Z9-12:Acyl-CoA, Z11-14:Acyl-CoA, Z13-16:Acyl-CoA, Z15-18:Acyl-CoA, E7-10:Acyl-CoA, E9-12:Acyl-CoA, E11-14:Acyl-CoA, E13-16:Acyl-CoA, E15-18:Acyl-CoA, E5Z7-12:Acyl-CoA, E7Z9-12:Acyl-CoA, E9Z11-14:Acyl-CoA, E11Z13-16:Acyl-CoA, E13Z15-18:Acyl-CoA, E6E8-10:Acyl-CoA, E8E10-12:Acyl-CoA, E10E12-14:Acyl-CoA, E12E14-16:Acyl-CoA, Z5E8-

10:Acyl-CoA, Z7E10-12:Acyl-CoA, Z9E12-14:Acyl-CoA, Z11E14-16:Acyl-CoA, Z13E16-18:Acyl-CoA, Z3-10:Acyl-CoA, Z5-12:Acyl-CoA, Z7-14:Acyl-CoA, Z9-16:Acyl-CoA, Z11-18:Acyl-CoA, Z3Z5-10:Acyl-CoA, Z5Z7-12:Acyl-CoA, Z7Z9-14:Acyl-CoA, Z9Z11-16:Acyl-CoA, Z11Z13-16:Acyl-CoA, and Z13Z15-18:Acyl-CoA. In further embodiments, the mono- or poly-unsaturated \leq Cis fatty alcohol is selected from the group consisting of E5-10:OH, Z8-12:OH, Z9-12:QH, Z11-14:QH, Z11-16:OH, Z11-14:OH, E8E10-12:OH, E7Z9-12:OH, Z11Z13-16QH, Z9-14:OH, Z9-16:OH, and Z13-18:OH.

[0041] In some embodiments, the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an aldehyde forming fatty acyl-CoA reductase capable of catalyzing the conversion of the mono- or poly-unsaturated \leq Cis fatty acid into a corresponding \leq Cis fatty aldehyde. In some preferred embodiments, the aldehyde forming fatty acyl-CoA reductase is selected from the group consisting of *Acinetobacter calcoaceticus* A0A1C4HN78, *A. calcoaceticus* N9DA85, *A. calcoaceticus* R8XW24, *A. calcoaceticus* A0A1A0GGM5, *A. calcoaceticus* A0A117N158, and *Nostoc punctiforme* YP_001865324. In some embodiments, the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase or an alcohol dehydrogenase capable of catalyzing the conversion of the mono- or poly-unsaturated \leq Cis fatty alcohol into a corresponding \leq Cis fatty aldehyde. In some preferred embodiments, the \leq Cis fatty aldehyde is selected from the group consisting of Z9-16:Ald, Z11-16:Ald, Z11-13-16:Ald, and Z13-18:Ald.

[0042] In some embodiments, the recombinant microorganism further comprises: at least one endogenous or exogenous nucleic acid molecule encoding an enzyme selected from an alcohol oxidase, an alcohol dehydrogenase capable of catalyzing the conversion of the mono- or poly-unsaturated \leq Cis fatty alcohol into a corresponding \leq Cis fatty aldehyde; and at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated \leq Cis fatty alcohol into a corresponding \leq Cis fatty acetate. In some preferred embodiments, the mono- or poly-unsaturated \leq Cis fatty aldehyde and \leq Cis fatty acetate is selected from the group consisting of E5-10:Ac, Z7-12:Ac, Z8-12:Ac, Z9-12:Ac, E7Z9-12:Ac, Z9-14:Ac, Z9E12-14:Ac, E11-14:Ac, Z11-14:Ac, Z11-16:Ac, Z9-16:Ac, Z9-16:Ald, Z11-16:Ald, Z11Z13-16:Ald, and Z13-18:Ald.

[0043] In some embodiments, the disclosure provides a method of engineering a microorganism that is capable of producing a mono- or poly-unsaturated \leq Cis fatty alcohol

from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid, wherein the method comprises introducing into a microorganism the following: (a) at least one exogenous nucleic acid molecule encoding a fatty acyl desaturase that catalyzes the conversion of a saturated C₆-C₂₄ fatty acyl-CoA to a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA; (b) at least one exogenous nucleic acid molecule encoding an acyl-CoA oxidase that catalyzes the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA from (a) into a mono- or poly-unsaturated \leq C₁₈ fatty acyl-CoA after one or more successive cycle of acyl-CoA oxidase activity, with a given cycle producing a mono- or poly-unsaturated C₄-C₂₂ fatty acyl-CoA intermediate with a two carbon truncation relative to a stalling mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA substrate in that cycle; and (c) at least one exogenous nucleic acid molecule encoding a fatty alcohol forming fatty acyl reductase that catalyzes the conversion of the mono- or poly-unsaturated \leq C₁₈ fatty acyl-CoA from (b) into the corresponding mono- or poly-unsaturated \leq C₁₈ fatty alcohol. In some embodiments, the microorganism is MATA ura3-302::SUC2 Δ po χ 1 Δ po χ 2 Δ po χ 3 Δ po χ 4 Δ po χ 5 Δ po χ β Afadh Δ adh1 Aadh2 Aadh3 Aadh4 Δ adh5 Δ adh6 Aadh7 Δ fao1::URA3.

[0044] In some embodiments, the disclosure provides a method of producing a mono- or poly-unsaturated \leq C₁₈ fatty alcohol, fatty aldehyde or fatty acetate from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid, comprising: cultivating a recombinant microorganism described herein in a culture medium containing a feedstock that provides a carbon source adequate for the production of the mono- or poly-unsaturated \leq C₁₈ fatty alcohol, fatty aldehyde or fatty acetate. In some embodiments, the method further comprises a step of recovering the mono- or poly-unsaturated \leq C₁₈ fatty alcohol, fatty aldehyde or fatty acetate. In further embodiments, the recovery step comprises distillation. In yet further embodiments, the recovery step comprises membrane-based separation.

[0045] In some embodiments, the mono- or poly-unsaturated \leq C₁₈ fatty alcohol is converted into a corresponding \leq C₁₈ fatty aldehyde using chemical methods. In further embodiments, the chemical methods are selected from TEMPO-bleach, TEMPO-copper-air, TEMPO-PhI(OAc)₂, Swern oxidation and noble metal-air. In some embodiments, the mono- or poly-unsaturated \leq C₁₈ fatty alcohol is converted into a corresponding \leq C₁₈ fatty acetate using chemical methods. In further embodiments, the chemical methods utilize a chemical agent selected from the group consisting of acetyl chloride, acetic anhydride, butyryl chloride, butyric anhydride, propanoyl chloride and propionic anhydride in the presence of 4-*N*, *N*-

dimethylaminopyridine (DMAP) or sodium acetate to esterify the mono- or **poly-unsaturated** $\leq C_{18}$ fatty alcohol to the corresponding $\leq C_{18}$ fatty acetate.

[0046] In a further embodiment, the disclosure provides a recombinant *Yarrowia lipolytica* microorganism capable of producing a mono- or poly-unsaturated **C6-C24** fatty alcohol from an endogenous or exogenous source of saturated **C6-C24** fatty acid, wherein the recombinant *Yarrowia lipolytica* microorganism comprises: (a) at least one nucleic acid molecule encoding a fatty acyl desaturase having at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, **82%**, 81%, 80%, 79%, **78%**, **77%**, 76%, 75%, 74%, 73%, 72%, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, 50%, or 50% sequence identity to a fatty acyl desaturase selected from the group consisting of SEQ ID NOs: 54, 60, 62, 78, 79, 80, 95, 97, 99, 101, 103, and 105 that catalyzes **the** conversion of a saturated **C6-C24 fatty acyl-CoA** to a corresponding mono- or poly-unsaturated **C6-C24** fatty acyl-CoA; and (b) at least one nucleic acid molecule encoding a fatty alcohol **forming** fatty acyl reductase having 95% sequence identity to a fatty alcohol forming fatty acyl reductase selected from the group consisting of SEQ ID NOs: 41-48, 57, 73, 75 and 77 that catalyzes the conversion of the mono- or poly-unsaturated **C6-C24 fatty acyl-CoA** from (a) into **the** corresponding mono- or poly-unsaturated **C6-C24** fatty alcohol.

[0047] In some embodiments, the recombinant *Yarrowia lipolytica* microorganism comprises a deletion, disruption, mutation, and/or reduction in **the** activity of one or more endogenous enzymes that catalyzes a reaction in a pathway that competes with the **biosynthesis** pathway for **the** production of a mono- or poly-unsaturated **C6-C24** fatty alcohol. In some preferred embodiments, the recombinant *Yarrowia lipolytica* microorganism comprises a deletion, disruption, mutation, and/or reduction in **the** activity of one or more endogenous enzyme selected from the following: (i) one or more **acyl-CoA** oxidase selected from the group consisting of **YALI0E32835g** (POX1), **YALI0F10857g** (POX2), **YALI0D24750g** (POX3), **YALI0E27654g** (POX4), **YALI0C23859g** (POX5), **YALI0E06567g** (POX6); (ii) one or more (fatty) alcohol dehydrogenase selected from **the** group consisting of **YALI0F09603g** (FADH), **YALI0D25630g** (ADH1), **YALI0E17787g** (ADH2), **YALI0A16379g** (ADH3), **YALI0E15818g** (ADH4), **YALI0D02167g** (ADH5), **YALI0A15147g** (ADH6), **YALI0E07766g** (ADH7); (iii) a (fatty) alcohol oxidase **YALT0B14014g** (FAO1); (iv) one or more cytochrome P450 enzyme selected from the group consisting of **YALI0E25982g** (ALK1), **YALI0F01320g** (ALK2), **YALI0E23474g** (ALK3), **YALI0B13816g** (ALK4),

YALI0B13838g (ALK5), YALI0B01848g (ALK6), YALI0A15488g (ALK7), (YALI0C12122g (ALK8), YALI0B06248g (ALK9), YALI0B20702g (ALK10), YALI0C10054g (ALK11) and YALI0A20130g (Alkl2); YAS1 (YALI0C03349), Yas2 (YALI0E32417), Gsy11 (YALIOF18502), HFD1 (YALI0F23793), HFD2 (YALIOE15400), HFD3 (YALI0A17875), HFD4 (YALI0B01298), SDR (YALIOA19536); and (v) one or more diacylglycerol acyltransferase selected from the group consisting of YALI0E32791g (DGA1) and YALI0D07986g (DGA2). In other preferred embodiments, the recombinant *Yarrowia lipofytica* microorganism comprises a deletion of one or more endogenous enzyme selected from the following: (i) one or more acyl-CoA oxidase selected from the group consisting of YALI0E32835g (POX1), YALI0F10857g (POX2), YALI0D24750g (POX3), YALI0E27654g (POX4), YALI0C23859g (POX5), YALI0E06567g (POX6); (ii) one or more (fatty) alcohol dehydrogenase selected from the group consisting of YALI0F09603g (FADH), YALI0D25630g (ADH1), YALI0E17787g (ADH2), YALI0A16379g (ADH3), YALI0E15818g (ADH4), YALI0D02167g (ADH5), YALI0A15147g (ADH6), YALI0E07766g (ADH7); (iii) a (fatty) alcohol oxidase YALI0B14014g (FAO1); (iv) one or more cytochrome P450 enzyme selected from the group consisting of YALI0E25982g (ALK1), YALI0F01320g (ALK2), YALI0E23474g (ALK3), YALI0B13816g (ALK4), YALI0B13838g (ALK5), YALI0B01848g (ALK6), YALI0A15488g (ALK7), (YALI0C12122g (ALK8), YALI0B06248g (ALK9), YALI0B20702g (ALK10), YALI0C10054g (ALK11) and YALI0A20130g (Alkl2); and (v) one or more diacylglycerol acyltransferase selected from the group consisting of YALI0E32791g (DGA1) and YALI0D07986g (DGA2).

[0048] In some embodiments, the fatty acyl desaturase catalyzes the conversion of a saturated fatty acyl-CoA into a mono- or poly-unsaturated intermediate selected from Z9~14:Acyl-CoA, Z11-14:Acyl-CoA, Ell-14:Acyl-CoA, Z9-16:Acyl-CoA, and Z11-16:Acyl-CoA. In other embodiments, the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol is selected from the group consisting of Z9-14:OH, Z11-14:OH, Ell-14:OH, Z9-16:OH, Z11-16:OH, Z11-13-16:OH, and Z13-18:OH.

[0049] In some embodiments, the recombinant *Yarrowia lipofytica* microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase or an alcohol dehydrogenase capable of catalyzing the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol into a corresponding C₆-C₂₄ fatty aldehyde. In some embodiments, the alcohol dehydrogenase is selected from Table 3a. In some embodiments,

the C₆-C₂₄ fatty aldehyde is selected from the group consisting of Z9-14:Ald, Z11-14:Ald, E11-14:Ald, Z9-16:Ald, Z11-16:Ald, Z11Z13-16:Ald and Z13-18:Ald.

[0050] In some embodiments, the recombinant *Yarrowia lipolytica* microorganism further comprises: at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase or an alcohol dehydrogenase capable of catalyzing the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol into a corresponding C₆-C₂₄ fatty aldehyde; and at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol into a corresponding C₆-C₂₄ fatty acetate. In some embodiments, the mono- or poly-unsaturated C₆-C₂₄ fatty aldehyde and C₆-C₂₄ fatty acetate is selected from the group consisting of Z9-14:Ac, Z11-14:Ac, E11-14:Ac, Z9-16:Ac, Z11-16:Ac, Z11Z13-16:Ac, Z13-18:Ac, Z9-14:Ald, Z11-14:Ald, E11-14:Ald, Z9-16:Ald, Z11-16:Ald, Z11Z13-16:Ald and Z13-18:Ald.

[0051] In some embodiments, the fatty acyl desaturase does not comprise a fatty acyl desaturase comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 64, 65, 66 and 67. In other embodiments, the fatty acyl desaturase does not comprise a fatty acyl desaturase selected from an *Amyelois transitella*, *Spodoptera littoralis*, *Agrotis segelum*, or *Trichophisia ni* derived desaturase.

[0052] In some embodiments, the disclosure provides a method of engineering a *Yarrowia lipolytica* microorganism that is capable of producing a mono- or poly-unsaturated C₆-C₂₄ fatty alcohol from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid, wherein the method comprises introducing into the *Yarrowia lipolytica* microorganism the following: (a) at least one nucleic acid molecule encoding a fatty acyl desaturase having at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, 50%, or 50% sequence identity to a fatty acyl desaturase selected from the group consisting of SEQ ID NOs: 39, 54, 60, 62, 78, 79, 80, 95, 97, 99, 101, 103, and 105 that catalyzes the conversion of a saturated C₆-C₂₄ fatty acyl-CoA to a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA; and (b) at least one nucleic acid molecule encoding a fatty alcohol forming fatty acyl reductase having 95% sequence identity to a fatty alcohol forming fatty acyl reductase selected from the group consisting of SEQ ID NOs: 41-48, 55, 56, 57, 73, 75 and 77 that catalyzes the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA from (a) into the corresponding mono- or poly-unsaturated C₆-C₂₄ fatty alcohol. In some

embodiments, the microorganism is MATA *ura3-302::SUC2 Δpoχ1 Δpoχ2 Δpoχ3 Δpoχ4 Δpoχ5 Δpoχ6 Afadh Δadh1 Aadh2 Aadh3 Aadh4 Aadh5 Aadh6 Aadh7 Afaol::URA3*.

[0053] In some embodiments, the disclosure provides a method of producing a mono- or poly-unsaturated C₆-C₂₄ fatty alcohol, fatty aldehyde or fatty acetate from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid, comprising: cultivating a recombinant microorganism described herein in a culture medium containing a feedstock that provides a carbon source adequate for the production of the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol, fatty aldehyde or fatty acetate. In some embodiments, the method further comprises a step of recovering the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol, fatty aldehyde or fatty acetate. In further embodiments, the recovery step comprises distillation. In yet further embodiments, the recovery step comprises membrane-based separation.

[0054] In some embodiments, the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol is converted into a corresponding C₆-C₂₄ fatty aldehyde using chemical methods. In further embodiments, the chemical methods are selected from TEMPO-bleach, TEMPO-copper-air, TEMPQ-Phi(QAc)₂, Swern oxidation and noble metal-air. In some embodiments, the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol is converted into a corresponding C₆-C₂₄ fatty acetate using chemical methods. In further embodiments, the chemical methods utilize a chemical agent selected from the group consisting of acetyl chloride, acetic anhydride, butyryl chloride, butyric anhydride, propanoyl chloride and propionic anhydride in the presence of 4-*N,N*-dimethylaminopyridine (DMAP) or sodium acetate to esterify the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol to the corresponding C₆-C₂₄ fatty acetate.

[0055] In addition to the biosynthetic pathway described in the first aspect above, the present application provides an additional biosynthetic pathway for the production of an unsaturated C₆-C₂₄ fatty alcohol utilizing a saturated C₆-C₂₄ fatty acyl-ACP intermediate derived from a C₆-C₂₄ fatty acid. Accordingly, in a second aspect, the application relates to a recombinant microorganism capable of producing an unsaturated C₆-C₂₄ fatty alcohol from an endogenous or exogenous source of C₆-C₂₄ fatty acid, wherein the recombinant microorganism expresses (a): at least one exogenous nucleic acid molecule encoding an acyl-ACP synthetase that catalyzes the conversion of a C₆-C₂₄ fatty acid to a corresponding saturated C₆-C₂₄ fatty acyl-ACP; (b) at least one exogenous nucleic acid molecule encoding a fatty-acyl-ACP desaturase that catalyzes the conversion of a saturated C₆-C₂₄ fatty acyl-ACP to a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty acyl-ACP; (c) one or more endogenous or exogenous nucleic acid molecules encoding a fatty acid synthase complex that catalyzes the conversion of the

mono- or poly-unsaturated C₆-C₂₄ fatty acyl-ACP from (b) to a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty acyl-ACP with a two carbon elongation relative to the product of (b); (d): at least one exogenous nucleic acid molecule encoding a fatty aldehyde forming fatty-acyl reductase that catalyzes the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty acyl-ACP from (c) into a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty aldehyde; and (e) at least one endogenous or exogenous nucleic acid molecule encoding a dehydrogenase that catalyzes the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty aldehyde C₆-C₂₄ from (d) into a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty alcohol. In some embodiments, the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol is an insect pheromone. In some embodiments, the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol is a fragrance or flavoring agent. In some embodiments, the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase or an alcohol dehydrogenase, wherein the alcohol oxidase or alcohol dehydrogenase is capable of catalyzing the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol from (e) into a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty-aldehyde. In some embodiments, the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol from (e) into a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty acetate.

[0056] In some embodiments, acyl-ACP synthetase is a synthetase capable of utilizing a fatty acid as a substrate that has a chain length of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 carbon atoms.

[0057] In various embodiments described herein, the acyl-ACP synthetase, or the nucleic acid that encodes it, can be isolated from organisms of the species *Vibrio harveyi*, *Rhodotorula glutinis*, or *Yarrowia lipolytica*.

[0058] In some embodiments, the fatty-acyl-ACP desaturase is a soluble desaturase. In various embodiments described herein, the fatty-acyl-ACP desaturase, or the nucleic acid that encodes it, can be isolated from organisms of the species *Pelargonium hortorum*, *Asclepias syriaca*, or *Uncaria tomentosa*.

[0059] In some embodiments, the recombinant microorganism may express more than one exogenous nucleic acid molecule encoding a fatty-acyl desaturase that catalyzes the

conversion of a saturated C₆-C₂₄ fatty acyl-ACP to a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty acyl-ACP.

[0060] As described above, fatty acid elongation enzymes, *i.e.*, a fatty acid synthase complex, can be utilized to extend the chain length of a mono- or poly-unsaturated C₆-C₂₄ fatty acyl-ACP by two additional carbons at the alpha carbon. In some embodiments, the two additional carbons are derived from endogenous malonyl-CoA. In one embodiment, the one or more nucleic acid molecules encoding a fatty acid synthase complex are endogenous nucleic acid molecules, *i.e.*, the nucleic acid molecule(s) is/are native to the recombinant microorganism. In another embodiment, the one or more nucleic acid molecules encoding a fatty acid synthase complex are exogenous nucleic acid molecules.

[0061] In various embodiments described herein, the fatty aldehyde forming acyl-ACP reductase, *i.e.*, fatty aldehyde forming fatty-acyl reductase, or the nucleic acid sequence that encodes it, can be isolated from organisms of the species can be isolated from organisms of the species *Pelargonium horiorum*, *Asclepias syriaca*, and *Uncaria tomentosa*.

[0062] As noted above, the recombinant microorganism according to the second aspect comprises at least one endogenous or exogenous nucleic acid molecule encoding a dehydrogenase capable of catalyzing the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty aldehyde from (d) into a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty alcohol. In one embodiment, the dehydrogenase is encoded by an endogenous nucleic acid molecule. In another embodiment, the dehydrogenase is encoded by an exogenous nucleic acid molecule. In exemplary embodiments, the endogenous or exogenous nucleic acid molecule encoding a dehydrogenase is isolated from organisms of the species *Saccharomyces cerevisiae*, *Escherichia coli*, *Yarrowia lipolytica*, or *Candida tropicalis*.

[0063] In addition to the biosynthetic pathway described in the first and second aspects above, the present application provides an additional biosynthetic pathway for the production of an unsaturated C₆-C₂₄ fatty alcohol utilizing a saturated C₆-C₂₄ fatty acyl-ACP intermediate derived from a CVC₂₄ fatty acid. Accordingly, in a third aspect, the application relates to a recombinant microorganism capable of producing an unsaturated C₆-C₂₄ fatty alcohol from an endogenous or exogenous source of C₆-C₂₄ fatty acid, wherein the recombinant microorganism expresses (a): at least one exogenous nucleic acid molecule encoding an acyl-ACP synthetase that catalyzes the conversion of a C₆-C₂₄ fatty acid to a corresponding saturated C₆-C₂₄ fatty acyl-ACP; (b) at least one exogenous nucleic acid

molecule encoding a fatty-acyl-ACP desaturase that catalyzes the conversion of a saturated **CVC24** fatty acyl-ACP to a corresponding mono- or poly-unsaturated C_{6-C24} fatty acyl-ACP; (c) at least one exogenous fatty acyl-ACP thioesterase that catalyzes the conversion of the mono- or poly-unsaturated **C6-C24** fatty acyl-ACP from (b) to a corresponding mono- or poly-unsaturated C_{6-C24} fatty acid; (d) one or more endogenous or exogenous nucleic acid molecules encoding an elongase that catalyzes the conversion of the mono- or poly-unsaturated C_{6-C24} fatty acyl-CoA derived from CoA activation of the mono- or poly-unsaturated C_{6-C24} fatty acid from (c) to a corresponding mono- or poly-unsaturated **C6-C24** fatty acyl-CoA with a two carbon or greater elongation relative to the product of (c); and (e): at least one exogenous nucleic acid molecule encoding a fatty alcohol forming fatty-acyl reductase that catalyzes the conversion of the mono- or poly-unsaturated C_{6-C24} fatty acyl-CoA from (d) into a corresponding mono- or poly-unsaturated **C6-C24** fatty alcohol. In some embodiments, the mono- or poly-unsaturated C_{6-C24} fatty alcohol is an insect pheromone. In some embodiments, the mono- or poly-unsaturated C_{6-C24} fatty alcohol is a fragrance or flavoring agent. In some embodiments, the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase or an alcohol dehydrogenase, wherein the alcohol oxidase or alcohol dehydrogenase is capable of catalyzing the conversion of the mono- or poly-unsaturated C_{6-C24} fatty alcohol from (e) into a corresponding mono- or poly-unsaturated **C6-C24** fatty aldehyde. In some embodiments, the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated **C6-C24** fatty alcohol from (e) into a corresponding mono- or poly-unsaturated C_{6-C24} fatty acetate

[0064] In some embodiments according to this third aspect, a fatty acyl-ACP thioesterase can be utilized to convert a mono- or poly-unsaturated **C6-C24** fatty acyl-ACP into a corresponding mono- or poly-unsaturated C_{6-C24} fatty acid. In some embodiments, soluble fatty acyl-ACP thioesterases can be used to release free fatty acids for reactivation to a CoA thioester. Fatty acyl-ACP thioesterases that can be included within the embodiment include, but are not limited to, including Q41635, Q39473, P05521.2, AEM72519, AEM72520, AEM72521, AEM72523, AAC49784, CAB60830, EER87824, EER96252, ABN54268, AA077182, CAH09236, ACL08376, and homologs thereof may be used. In some embodiments, the mono- or poly-unsaturated **C6-C24** fatty acyl-CoA may serve as a substrate for an elongase, which can be utilized to extend the chain length of a mono- or poly-

unsaturated C₆-C₂₄ fatty acyl-CoA by two additional carbons at the alpha carbon. In some embodiments, the two additional carbons are derived from endogenous malonyl-CoA.

[0065] As described above, in some embodiments, the recombinant microorganism according to the first, second, or third aspect further comprises at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase capable of catalyzing the conversion of a mono- or poly-unsaturated C₆-C₂₄ fatty alcohol into a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty aldehyde. In certain embodiments, the alcohol oxidase, or the nucleic acid sequence that encodes it, can be isolated from organisms of the species *Candida boidinii*, *Komagataella pastoris*, *Tanacetum vulgare*, *Simmondsia chinensis*, *Arabidopsis thaliana*, *Lotus japonicas*, or *Candida tropicalis*. In exemplar} embodiments, the alcohol oxidase comprises a sequence selected from GenBank Accession Nos. Q00922, F2QY27, Q6QIR6, Q8LDP0, and L7VVFV2.

[0066] As described above, in some embodiments, the recombinant microorganism according to the first or second aspect further comprises at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of a C₆-C₂₄ fatty alcohol into a corresponding C₆-C₂₄ fatty acetate. In certain embodiments, the acetyl transferase, or the nucleic acid sequence that encodes it, can be isolated from organisms of the species *Saccharomyces cerevisiae*, *Danaus plexippus*, *Heliotis virescens*, *Bombyx mori*, *Agrotis ipsilon*, *Agrotis segetum*, *Euonymus alatus*. In exemplar}' embodiments, the acetyl transferase comprises a sequence selected from GenBank Accession Nos. AY242066, AY242065, AY242064, AY242063, AY242062, EHJ65205, ACX53812, NP_001182381, EHJ65977, EHJ68573, KJ579226, GU594061, KTA99184.1, AIN34693.1, AY605053, XP_002552712.1, XP_503024.L XP_505595.1, and XP_505513.1.

[0067] In alternative embodiments, the fatty alcohol may be converted into a fatty acetate using chemical methods, e.g., via chemical catalysis utilizing a chemical agent such as acetyl chloride, acetic anhydride, butyryl chloride, butyric anhydride, propanoyl chloride and propionic anhydride.

[0068] In some embodiments, the recombinant microorganism comprising a biosynthesis pathway for the production of an unsaturated C₆-C₂₄ fatty alcohol, aldehyde, or acetate may further be engineered to express one or more nucleic acids encoding protein or polypeptide which, when expressed, is toxic to an insect. Exemplary toxicant producing genes suitable for the present disclosure can be obtained from entomopathogenic organism, such as *Bacillus*

thiiringiensis, *Pseudomonas aeruginosa*, *Serratia marcescens*, and members of the genus *Streptomyces*. In an exemplary embodiment, the recombinant microorganism comprising a biosynthesis pathway for the production of an unsaturated C₆-C₂₄ fatty alcohol, aldehyde, or acetate may further be engineered to express a nucleic acid encoding a *Bacillus thuringiensis* ("Bi") toxin. In additional or alternative embodiments, the recombinant microorganism comprising a biosynthesis pathway for the production of an unsaturated C₆-C₂₄ fatty alcohol, aldehyde, or acetate may further be engineered to express a nucleic acid encoding other toxic proteins such as spider venom.

[0069] In some embodiments, the recombinant microorganism comprising a biosynthesis pathway for the production of an unsaturated C₆-C₂₄ fatty alcohol, aldehyde, or acetate may further be engineered to express an RNAi molecule which, when expressed, produces an oligonucleotide that is toxic to an insect.

[0070] In some embodiments, the recombinant microorganism comprising a biosynthesis pathway for the production of an unsaturated C₆-C₂₄ fatty alcohol, aldehyde, or acetate may further be engineered to express a metabolic pathway which, when expressed, produces a small molecule that is toxic to an insect. Non-limiting examples of toxic small molecules include azadirachtin, spinosad, avermectin, pyrethrins, and various terpenoids.

[0071] In various embodiments described herein, the recombinant microorganism comprising a biosynthesis pathway for the production of an unsaturated C₆-C₂₄ fatty alcohol, aldehyde, or acetate may be a eukaryotic microorganism, such as a yeast, a filamentous fungi, or an algae, or alternatively, a prokaryotic microorganism, such as a bacterium. For instance, suitable host cells can include cells of a genus selected from the group consisting of *Yarrowia*, *Candida*, *Saccharomyces*, *Pichia*, *Hansenula*, *Clostridium*, *Zymomonas*, *Escherichia*, *Salmonella*, *Rhodococcus*, *Pseudomonas*, *Bacillus*, *Lactobacillus*, *Enterococcus*, *Alcaligenes*, *Klebsiella*, *Paenibacillus*, *Arthrobacter*, *Corynebacterium*, *Brevibacterium*, and *Streptomyces*.

[0072] In some embodiments, the recombinant microorganism comprising a biosynthesis pathway for the production of an unsaturated C₆-C₂₄ fatty alcohol, aldehyde, or acetate is a yeast. Examples of suitable yeasts include yeasts of a genus selected from the group consisting of *Yarrowia*, *Candida*, *Saccharomyces*, *Pichia*, *Hansenula*, *Kluyveromyces*, *Issatchenkia*, *Zygosaccharomyces*, *Debaryomyces*, *Schizosaccharomyces*, *Pachysolen*, *Cryptococcus*, *Trichosporon*, *Rhodotorula*, or *Myxozyma*. In certain embodiments, the yeast

is an oleaginous yeast. Exemplary oleaginous yeasts suitable for use in the present disclosure include members of the genera *Yarrowia*, *Candida*, *Rhodosporula*, *Rhodospiridium*, *Cryptococcus*, *Trichosporon*, and *Lipomyces*, including, but not limited to the species of *Yarrowia lipolytica*, *Candida tropicalis*, *Rhodospiridium toruloides*, *Lipomyces starkey*, *L. lipoferiis*, *C. revkaufi*, *C. pulcherrima*, *C. utilis*, *Rhodotorula minula*, *Trichosporon pullans*, *T. cutaneum*, *Cryptococcus curvatus*, *R. glutinis*, and *R. graminis*.

[0073] As will be understood in the art, endogenous enzymes can convert critical substrates and/or intermediates upstream of or within the unsaturated C₆-C₂₄ fatty alcohol, aldehyde, or acetate biosynthesis pathway into unwanted by-products. Accordingly, in some embodiments, the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the activity of one or more endogenous enzymes that catalyzes a reaction in a pathway that competes with the unsaturated C₆-C₂₄ fatty alcohol, aldehyde, or acetate biosynthesis pathway.

[0074] In one embodiment, the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the activity of one or more endogenous enzymes that catalyzes the conversion of a fatty acid into a ω -hydroxyfatty acid. In the context of a recombinant yeast microorganism, the recombinant yeast microorganism is engineered to delete, disrupt, mutate, and/or reduce the activity of one or more enzyme selected from XP_504406, XP_504857, XP_504311, XP_500855, XP_500856, XP_500402, XP_500097, XP_501748, XP_500560, XP_501148, XP_501667, XP_500273, BAA02041, CAA39366, CAA39367, BAA02210, BAA02211, BAA02212, BAA02213, BAA02214, AA073952, AA073953, AA073954, AA073955, AA073956, AA073958, AA073959, AA073960, AA073961, AA073957, XP_002546278, or homologs thereof. In the context of a recombinant bacterial microorganism, the recombinant bacterial microorganism is engineered to delete, disrupt, mutate, and/or reduce the activity of one or more enzyme selected from BAM49649, AAB80867, AAB77462, ADL27534, AAU24352, AAA87602, CAA34612, ABM17701, AAA25760, CABS 1047, AAC82967, WP_01 1027348, or homologs thereof.

[0075] In another embodiment, the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the activity of one or more endogenous enzymes that catalyzes the conversion of a fatty acyl-CoA into α,β -enoyl-CoA. In the context of a recombinant yeast microorganism, the recombinant yeast microorganism is engineered to delete, disrupt, mutate, and/or reduce the activity of one or more enzyme selected from CAA04659, CAA04660, CAA04661, CAA04662, CAA04663, CAG79214, AAA34322, AAA34361, AAA34363,

CAA29901, BAA04761, AAA34891, or homologs thereof. In the context of a recombinant bacterial microorganism, the recombinant bacterial microorganism is engineered to delete, disnpt, mutate, and/or reduce the activity of one or more enzyme selected from AAB08643, CAB15271, BAN55749, CAC44516, ADK16968, AEI37634, WP_000973047, WPJ325433422, WP_035 184107, WP_026484842, CEL80920, WP_0268 18657, WP_005293707, WP_005883960, or homologs thereof.

[0076] In embodiments where the recombinant microorganism is a yeast microorganism, the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the activity of one or more enzyme involved in peroxisome assembly and/or peroxisome enzyme import. The recombinant yeast microorganism is engineered to delete, disnpt, mutate, and/or reduce the activity of one or more enzyme selected from XP_505754, XP_501986, XP_501311, XP_J504845, XP_503326, XP_504029, XP_002549868, XP_002547156, XP_002545227, XP_002547350, XP_002546990, EIW11539, EIW08094, EIW1 1472, EIW09743, EIW08286, or homologs thereof.

[0077] In another embodiment, the recombinant microorganism is manipulated to delete, disnpt, mutate, and/or reduce the activity of one or more endogenous reductase or desaturase enzymes that interferes with the unsaturated C₆-C₂₄ fatty alcohol, aldehyde, or acetate, *i.e.*, catalyzes the conversion of a pathway substrate or product into an unwanted by-product.

[0078] In another embodiment, the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the activity of one or more endogenous alcohol oxidase or alcohol dehydrogenase enzymes that catalyzes the unwanted conversion of the desired product, *e.g.*, unsaturated C₆-C₂₄ fatty alcohol into a corresponding unsaturated C₆-C₂₄ fatty aldehyde.

[0079] In another embodiment, the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the activity of one or more endogenous enzymes that catalyzes a reaction in a pathway that competes with the biosynthesis pathway for one or more unsaturated fatty acyl-CoA intermediates. In one embodiment, the one or more endogenous enzymes comprise one or more diacylglycerol acyltransferases. In the context of a recombinant yeast microorganism, the recombinant yeast microorganism is engineered to delete, disrupt, mutate, and/or reduce the activity of one or more diacylglycerol acyltransferases selected from the group consisting of YALI0E32769g, YALI0D07986g and CTRG_06209, or homolog thereof. In another embodiment, the one or more endogenous

enzymes comprise one or more glycerolphospholipid acyltransferases. In the context of a recombinant yeast microorganism, the recombinant yeast microorganism is engineered to delete, disrupt, mutate, and/or reduce the activity of one or more glycerolphospholipid acyltransferases selected from the group consisting of YALT0EI6797g and CTG_04390, or homolog thereof. In another embodiment, the one or more endogenous enzymes comprise one or more acyl-CoA/sterol acyltransferases. In the context of a recombinant yeast microorganism, the recombinant yeast microorganism is engineered to delete, disrupt, mutate, and/or reduce the activity of one or more acyl-CoA/sterol acyltransferases selected from the group consisting of YALIOF06578g, CTRG_01764 and CTRG_01765, or homolog thereof.

[0080] In another embodiment, the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the activity of one or more endogenous enzymes that catalyzes a reaction in a pathway that oxidizes fatty aldehyde intermediates. In one embodiment, the one or more endogenous enzymes comprise one or more fatty aldehyde dehydrogenases. In the context of a recombinant yeast microorganism, the recombinant yeast microorganism is engineered to delete, disrupt, mutate, and/or reduce the activity of one or more fatty aldehyde dehydrogenases selected from the group consisting of YALIOA17875g, YALIOE15400g, YALIOB01298g, YALIOF23793g, CTRG_05010 and CTRG_04471, or homolog thereof.

[0081] In another embodiment, the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the activity of one or more endogenous enzymes that catalyzes a reaction in a pathway that consumes fatty acetate products. In one embodiment, the one or more endogenous enzymes comprise one or more sterol esterases. In the context of a recombinant yeast microorganism, the recombinant yeast microorganism is engineered to delete, disrupt, mutate, and/or reduce the activity of one or more sterol esterases selected from the group consisting of YALIOE32035g, YALIOE00528g, CTRG_01138, CTRG_01683 and CTRG_04630, or homolog thereof. In another embodiment, the one or more endogenous enzymes comprise one or more triacylglycerol lipases. In the context of a recombinant yeast microorganism, the recombinant yeast microorganism is engineered to delete, disrupt, mutate, and/or reduce the activity of one or more triacylglycerol lipases selected from the group consisting of YALIOD17534g, YALIOFIOOIOg, CTRG_00057 and CTRG_06185, or homolog thereof. In another embodiment, the one or more endogenous enzymes comprise one or more monoacylglycerol lipases. In the context of a recombinant yeast microorganism, the recombinant yeast microorganism is engineered to delete, disrupt, mutate, and/or reduce the activity of one or more monoacylglycerol lipases selected from the group consisting of

YALI0C14520g, CTRG__03360 and CTRG_05049, or homolog thereof. In another embodiment, the one or more endogenous enzymes comprise one or more extracellular lipases. In the context of a recombinant yeast microorganism, the recombinant yeast microorganism is engineered to delete, disrupt, mutate, and/or reduce the activity of one or more extracellular lipases selected from the group consisting of YALI0A20350g, YALI0D19184g, YALI0B0936Ig, CTRG__05930, CTRG__04188, CTRG__02799, CTRG_03052 and CTRG_03885, or homolog thereof.

[0082] In embodiments where the recombinant microorganism is a yeast microorganism, one or more of the exogenous unsaturated C₆-C₂₄ fatty alcohol, aldehyde, or acetate pathway genes encodes an enzyme that is localized to a yeast compartment selected from the group consisting of the cytosol, the mitochondria, or the endoplasmic reticulum. In an exemplary embodiment, one or more of the exogenous pathway genes encodes an enzyme that is localized to the endoplasmic reticulum. In another embodiment, at least two exogenous pathway genes encode an enzyme that is localized to the endoplasmic reticulum. In yet another embodiment, all exogenous pathway genes encodes an enzyme that is localized to the endoplasmic reticulum.

[0083] In additional embodiments, the present application provides methods of producing an unsaturated C₆-C₂₄ fatty alcohol, aldehyde, or acetate using a recombinant microorganism as described herein. In one embodiment, the method includes cultivating the recombinant microorganism in a culture medium containing a feedstock providing a carbon source until the unsaturated C₆-C₂₄ fatty alcohol, aldehyde, or acetate is produced and optionally, recovering the unsaturated C₆-C₂₄ fatty alcohol, aldehyde, or acetate. Once produced, the unsaturated C₆-C₂₄ fatty alcohol, aldehyde, or acetate may be isolated from the fermentation medium using various methods known in the art including, but not limited to, distillation, membrane -based separation gas stripping, solvent extraction, and expanded bed adsorption.

[0084] In some embodiments, the recombinant microorganism, *e.g.*, a yeast, may be recovered and produced in dry particulate form. In embodiments involving yeast, the yeast may be dried to produce powdered yeast. In some embodiments, the process for producing powdered yeast comprises spray drying a liquid yeast composition in air, optionally followed by further drying. In some embodiments, the recombinant microorganism composition will comprise the unsaturated C₆-C₂₄ fatty alcohol, aldehyde, or acetate when dried.

[0085] As described herein, preferred recombinant microorganisms of the disclosure will have the ability to utilize alkanes and fatty acids as carbon sources. However, as will be understood in the art, a variety of carbon sources may be utilized, including but not limited to, various sugars (*e.g.*, glucose, fructose, or sucrose), glycerol, alcohols (*e.g.*, ethanol), organic acids, lignocellulose, proteins, carbon dioxide, carbon monoxide, as well as the aforementioned alkanes and fatty acids. In some embodiments, the recombinant microorganism will convert the carbon source to the unsaturated C₆-C₂₄ fatty alcohol, aldehyde, or acetate under aerobic conditions.

[0086] As highlighted above, the present application provides methods of producing one or more unsaturated C₆-C₂₄ fatty alcohols, aldehydes, or acetates using a recombinant microorganism as described herein. In some embodiments, the product is an insect pheromone. As will be appreciated by the skilled artisan equipped with the instant disclosure, a variety of different exogenous and endogenous enzymes can be expressed in a recombinant host microorganism to produce a desired insect pheromone. Exemplary insect pheromones in the form of fatty alcohols, fatty aldehydes, or fatty acetates capable of being generated using the recombinant microorganisms and methods described herein include, but are not limited to, (Z)-11-hexadecenal, (Z)-11-hexadecenyl acetate, (Z)-9-tetradecenyl acetate, (Z,Z)-11,13-hexadecadienal, (9Z,11E)-hexadecadienal, (E,E)-8,10-dodecadien-1-ol, (7E,9Z)-dodecadienyl acetate, (Z)-3-nonen-1-ol, (Z)-5-decen-1-ol, (Z)-5-decenyl acetate, (E)-5-decen-1-ol, (E)-5-decenyl acetate, (Z)-7-dodecen-1-ol, (Z)-7-dodecenyl acetate, (E)-8-dodecen-1-ol, (E)-8-dodecenyl acetate, (Z)-8-dodecen-1-ol, (Z)-8-dodecenyl acetate, (Z)-9-dodecen-1-ol, (Z)-9-dodecenyl acetate, (Z)-9-tetradecen-1-ol, (Z)-11-tetradecen-1-ol, (Z)-11-tetradecenyl acetate, (E)-11-tetradecen-1-ol, (E)-11-tetradecenyl acetate, (Z)-7-hexadecen-1-ol, (Z)-7-hexadecenal, (Z)-9-hexadecen-1-ol, (Z)-9-hexadecenal, (Z)-9-hexadecenyl acetate, (Z)-11-hexadecen-1-ol, (Z)-13-octadecen-1-ol, (Z)-13-hexadecenyl acetate, and (Z)-13-octadecenyl acetate, and (Z)-13-octadecenal.

[0087] In another embodiment of the present application, compositions comprising one or more of the insect pheromone-producing recombinant microorganisms described herein can be provided. In certain embodiments, the composition may further comprise one or more insect pheromones produced by the recombinant microorganism. In further embodiments, the may additionally comprise one or more toxic proteins or polypeptides produced by the recombinant microorganism.

BRIEF DESCRIPTION OF DRAWINGS

[0088] Illustrative embodiments of the disclosure are illustrated in the drawings, in which:

[0089] Figure 1 illustrates the conversion of a saturated fatty acyl-CoA to an unsaturated fatty alcohol.

[0090] Figure 2 illustrates the conversion of a saturated fatty acid to a mono- or poly-unsaturated fatty aldehyde, alcohol, or acetate.

[0091] Figure 3 illustrates an additional pathway for the conversion of a saturated fatty acid to a mono- or poly-unsaturated fatty aldehyde, alcohol, or acetate.

[0092] Figure 4 illustrates a pathway for the conversion of a saturated fatty acid to various trienes, dienes, epoxides, and odd-numbered pheromones.

[0093] Figure 5 shows Z11-hexadecenol production from W303A and BY4742 Δ POX1. Strain expressing empty vector (EV), *S. littoralis* reductase (FAR-SL), *H. arrnigera* reductase (FAR-HA), *A. segetum* reductase (FAR-AS). Error bars represent standard deviation derived from $N=2$ biologically independent samples.

[0094] Figure 6A-Figure 6B shows sample chromatograms of biotransformation product of Z11-hexadecenoic acid using *S. cerevisiae* expressing either an empty vector (Figure 6A), or *Helicoverpa arrnigera* alcohol-forming reductase (Figure 6B). Black lines: no substrate added. Purple line: Z11-hexadecenoic acid was added as substrate.

[0095] Figure 7A-Figure 7B shows a comparison of GC-MS fragmentation pattern of Z11-hexadecenol authentic compound (Figure 7A), and Z11-hexadecenol biologically derived (Figure 7B).

[0096] Figure 8 shows biomass at the time of harvesting for product analysis of W303A (wild type) and BY4742 Δ POX1 (beta-oxidation deletion mutant). Strain expressing empty vector (EV), *S. littoralis* reductase (FAR-SL), *H. arrnigera* reductase (FAR-HA), *A. segetum* reductase (FAR-AS). Error bars represent standard deviation derived from $N=2$ biologically independent samples.

[0097] Figure 9 shows a Z11-hexadecenol calibration curve constructed using an authentic standard. The samples were generated with the extraction and analysis method described in Materials and Methods of Example 3. Error bars represent standard deviation derived from $N=3$ samples.

[0098] Figure 10 shows a pOLEI cassette comprising an extended OLEI promoter sequence (light yellow), OLEI promoter (orange), OLEI leader sequence (dark grey), a synthon such as an insect desaturase sequence (light grey), and the VSP13 terminator sequence (blue).

[0099] Figure 11A-Figure 11E shows validation of the pOLEI cassette, and complementation assay. Figure 11A: YPD + palmitoleic acid; Figure 11B: YPD - palmitoleic acid; Figure 11C: CM-Ura glucose + palmitoleic acid; Figure 11D: CM-Ura glucose - palmitoleic acid; Figure 11E: Map of strains in Figure 11A-Figure 11D. Dasher = GFP synthon.

[0100] Figure 12A shows complementation of AOOLEI growth without UFA on YPD.

[0101] Figure 12B shows complementation of AOOLEI growth without UFA on CM-Ura glucose.

[0102] Figure 13A shows the full fatty acid spectrum of a AOOLEI strain expressing: *S. cerevisiae* OLEI desaturase (blue), chimeric *T. ni* desaturase (red).

[0103] Figure 13B shows a focused fatty acid spectrum within 5.5-min - 8-min retention time of *S. cerevisiae* AOOLEI strain expressing *S. cerevisiae* OLEI desaturase (red) and chimeric *T. ni* desaturase (blue).

[0104] Figure 14A-Figure 14B shows a comparison of GC-MS fragmentation pattern of (Z)-11-hexadecenoic acid from an authentic compound (Figure 14A) and biologically derived (Figure 14B).

[0105] Figure 15 shows C16 fatty alcohol production from AOOLEI expressing various fatty-alcohol pathway variants in culture supplemented with palmitic and palmitoleic acid. Error bars represent 5% uncertainty of metabolite quantification accuracy.

[0106] Figure 16 shows representative chromatograms of biotransformation product C16 fatty acids using *S. cerevisiae* expressing fatty alcohol pathways TN_desat - HA_reduc when fed with palmitic acid (black) and when fed with palmitic and palmitoleic acids (orange). Profile of a negative control strain (harboring an empty vector) fed with palmitic acid (purple).

[0107] Figure 17 shows that (Z)-11-hexadecenoic acid was detected in the cell pellets of *S. cerevisiae* expressing fatty alcohol pathways TN_desat-SL_reduc (blue), SC_desat-HA_reduc (red), TN_desat-HA_reduc (green), SC_desat-SL_reduc (pink).

[0108] Figure 18 shows C16 fatty alcohol production from AOOLEI expressing various fatty alcohol pathway variants in culture supplemented with palmitic acid only. Error bars represent 5% uncertainty of metabolite quantification accuracy.

[0109] Figure 19A-Figure 19C shows detection of (Z)-11-hexadecenol. Figure 19A: Fragmentation pattern of an authentic standard. The m/z 297.3 was used in follow up experiments to selectively detect the alcohol. To also detect the internal standard, the masses 208 and 387.3 were included too. Figure 19B: In addition to the detection of the specific mass fragment, the retention time was used as second stage confirmation. The retention time is 6.22. Figure 19C: Comparison of the two different regioisomers 9Z- and 11Z-hexadecenol when detected in SIM mode (297.3) with the same method.

[0110] Figure 20 shows pXICL expression cassette architecture. The *C. albicans* OLE1 leader-*Δ*1. *segetum* desaturase fusion is also shown.

[0111] Figure 21A-Figure 21D shows mCherry control integration. Figure 21A: Negative (water-only) control transformation plate. Figure 21B: pPVO137 mCherry transformation plate. Figure 21C: Patch plates from negative control clones. Figure 21D: Patch plates from pPVO137 clones.

[0112] Figure 22 shows integration efficiency as a function of total observed colonies. A control plate with no DNA added to the transformation was observed to have 350 colonies (indicated by orange line). The fraction of clones confirmed to be positive integrants is positively correlated with total colony count. A sharp increase is observed above 6,000 total colonies. The data suggests that the presence of positive integrants increases the observed background growth. For some transformations the efficiency was high enough that the background population was small relative to the positive integrant population.

[0113] Figure 23 shows a chromatogram overlay of *Candida tropicalis* SPV053 strains. Compared to the mCherry (red) control experiment a clear peak at 6.22 min is observable for the *A. transitella* (blue) and *H. zea* (green) desaturase. Therefore, the formation of Z-11-hexadecenoic acid is only observable in strains expressing an active Z11-desaturase.

[0114] Figure 24A-Figure 24E shows confirmation of the 11Z-regioisomer. Figure 24A: The specific peak with an ion fragment of 245 m/z was only observed in *C. tropicalis* SPV053 expressing either the Z11-desaturase from *A. transitella* or *H. zea*. Figure 24B: The fragmentation patterns of the authentic standard. Figure 24C: The fragmentation patterns of the newly formed compound in samples with expressed desaturase from *H. zea* match those of the standard. Figure 24D: The fragmentation patterns of the newly formed compound in samples with expressed desaturase from *A. transitella* match those of the standard. Figure 24E: The fragmentation patterns of the mCherry control significantly differ from those of Figure 24B, Figure 24C and Figure 24D.

[0115] Figure 25A-Figure 25B shows a GC-FID chromatogram of different *C. tropicalis* SPV053 strains incubated with methyl tetradecanoate. Figure 25A: Overall spectrum. The occurrence of the ZH-C16:1 peak is observable for the strains expressing the Z11-desaturases from *A. transitella* and *H. zea*. Figure 25B: Zoom of the C14 to C18 area. A new peak is visible at 4.8 min, which could correspond to Z11-C14:1. Another peak near Z9-C18:1 is also visible, which could correspond to Z11-C18:1.

[0116] Figure 26 shows only codon optimized *H. zea* desaturase variants produce detectable Z11-hexadecenoic acid in SPV140 screen. control=pPV101 integrants of SPV140, *T. ni* native -*T. ni* Z11 desaturase with native codon usage (pPV195), *T. ni* HS opt = *T. ni* Z11 desaturase with *Homo sapiens* codon optimization (pPV196), *T. ni* HS opt Y1 leader = *T. ni* Z11 desaturase with *Homo sapiens* codon optimization and swapped *Y. lipolytica* OLE1 leader sequence (pPV197), *H. zea* native ~*H. zea* Z11 desaturase with native codon usage (pPV198), *H. zea* HS opt = *H. zea* Z11 desaturase with *Homo sapiens* codon optimization (pPV199), *H. zea* HS opt Y1 leader = *H. zea* Z11 desaturase with *Homo sapiens* codon optimization and swapped *Y. lipolytica* OLE1 leader sequence (pPV200), *A. transitella* native*A. transitella* Z11 desaturase with native codon usage (pPV201). All data average of 3 biological replicates. Error bars represent standard deviation.

[0117] Figure 27 shows only codon optimized *H. zea* desaturase variants produce detectable Z11-hexadecenoic acid in SPV300 screen. Labels indicate parent strain and plasmid of desaturase expression cassette. pPV101=nrGFP control, pPV198=*H. zea* Z11 desaturase with native codon usage, pPV199=*H. zea* Z11 desaturase with *Homo sapiens* codon optimization, pPV200=*H. zea* Z11 desaturase with *Homo sapiens* codon optimization and swapped *Y. lipolytica* OLE1 leader sequence, pPV201=*A. transitella* Z11 desaturase with native codon usage.

[0118] Figure 28 shows final cell densities for desaturase screen in SPV140 and SPV300 backgrounds. SPV300 strains with integrated desaturase cassettes grew to higher cell densities.

[0119] Figure 29 shows individual isolate Z11-hexadecenoic acid titers for SPV140 and SPV300 strains expressing *H. zea* Z11 desaturase with *H. sapiens* codon optimization.

[0120] Figure 30 shows a chromatogram overlay of extracted metabolites for Z11-160H producing strain (SPV0490) versus control strain (SPV0488) of *Candida viswanathii* (*tropicalis*).

[0121] Figure 31 illustrates pathways that can be deleted or disrupted to reduce or eliminate competition with the biosynthesis pathway for the production of a mono- or poly-unsaturated C_{6-C₂₄} fatty alcohol, aldehyde, or acetate.

[0122] Figure **32A-Figure 32B** shows Z9-160H and Z11-160H titers in YPD (Figure 32A) and Semi-Defined C:N=80 (Figure 32B) media for pEXP clones. Ten isolates expressing the *H. zea* desaturase under the TEF promoter and *H. armigera* reductase under the EXP promoter from two independent competent cell preparations (Comp. Cell Preparation 1, Comp. Cell Preparation 2) were compared to a parental negative control (SPV300) and a desaturase only negative control (SPV459 Hz_{desat} only). Error bars represent the SEM (standard error of the mean) measured from technical replicates for each strain and condition (N=2). *One replicate from Clone 5 and Clone 18 under the Semi-Defined C:N=80 condition was lost during sample work-up so the titers for that condition are from a single data point (N=1, Comp. Cell Preparation 1 Clone 18 and Comp. Cell Preparation 2 Clone 5).

[0123] Figure **33A-Figure 33B** shows profiles of 16-carbon fatty acid species in YPD (Figure 33A) and Semi-Defined C:N=80 (Figure 33B) media for pEXP clones. The 16-carbon lipid profiles of 5 select clones expressing the *H. zea* desaturase under the TEF promoter and *H. armigera* reductase under the EXP promoter are compared to a parental negative control (SPV300) and a desaturase only negative control (SPV459 Hz_{desat} only). Error bars represent the SEM (standard error of the mean) measured from technical replicates for each strain and condition (N=2).

[0124] Figure 34 shows Z9-160H and Z11-160H titers in Semi-Defined C:N=80 media for pTAL clones. Nine isolates expressing the *H. zea* desaturase under the TEF promoter and *H. armigera* reductase under the TAL promoter were compared to a parental negative control (SPV300) and positive Bdr pathway controls using the EXP promoter to drive *H. armigera* FAR expression (SPV575, SPV578). Error bars represent the SEM (standard error of the mean) measured from technical replicates for each strain and condition (N=2).

[0125] Figure 35 shows profiles of 16-carbon fatty acid species in Semi-Defined C:N=80 medium for pTAL clones. The 16-carbon lipid profiles of 5 select clones expressing the *H. zea* desaturase under the TEF promoter and *H. armigera reductase* under the EXP promoter are compared to a parental negative control (SPV300) and positive Bdr pathway controls using the EXP promoter to drive *H. armigera* FAR expression (SPV575, SPV578). Error bars represent the SEM (standard error of the mean) measured from technical replicates for each

strain and condition (N=2). * indicates clones for which one of the replicates was lost during sample processing, N=1.

[0126] Figure 36 shows full Bdr pathway pTAL1 screen (strains expressing *H. zea* Zll desaturase (pTEF) and *H. armigera* FAR) full lipid profiles in Semi-Defined C:N=80 medium after 48 hours of bioconversion. Error bars represent the SEM (standard error of the mean) measured from technical replicates for each strain and condition (N=2). * indicates clones for which one of the replicates was lost during sample processing, N=1.

[0127] Figure 37A-Figure 37B shows SPV471 (H222 APAAAF expressing native *Y. lipolytica* OLE1 and *H. armigera* FAR) Z9-160 H (Figure 37A) and fatty acid (Figure 37B) titers in Semi-Defined C:N=80 medium after 24 hours of bioconversion. Error bars represent the SEM (standard error of the mean) measured from technical replicates for each strain and condition (N=2).

[0128] Figure 38 shows SPV471 (H222 APAAAF expressing native *Y. lipolytica* OLE1 and *H. armigera* FAR) full lipid profiles in Semi-Defined C:N=80 medium after 24 hours of bioconversion.

[0129] Figure 39A-Figure 39B shows SPV471 (H222 $\Delta P\Delta A\Delta P$ expressing native *Y. lipolytica* OLE1 and *H. armigera* FAR) Z9-160 H (Figure 39A) and Z9-16Acid (Figure 39B) titer time courses. Bioconversion of 16Acid was conducted in Semi-Defined C:N=80 medium using a methyl palmitate (16Acid) substrate.

[0130] Figure 40 shows examples of acyl-CoA intermediates generated through selective β -oxidation controlled by acyl-CoA oxidase activity.

[0131] Figure 41 shows Zll- 14Acid (methyl myristate fed - 14ME) and Zll-16Acid (methyl palmitate fed - 16ME) titers of characterized All desaturases. SPV300=desaturase library integration parent. SPV298=prototrophic parent of SPV300, negative control. SPV459=SPV300 with current best desaturase (*Helicoverpa zea*, SEQ ID NO: 54), positive control. The desaturase in DST006 is genetically equivalent to the *H. zea* desaturase expressed in SPV459 and served as an internal library control.

[0132] Figure 42 shows C14 and C18 product profiles of SPV298 (negative control, parent strain) and SPV459 (SPV298 lineage with *H. zea* desaturase, SEQ ID NO: 54) fed on either methyl palmitate (16ME) or methyl myristate (14ME).

[0133] Figure 43 shows bioinformatic analysis of potential serine, threonine and tyrosine phosphorylation sites of the *H. armigera* FAR enzyme (SEQ ID NO: 41). The horizontal line resembles the threshold for potential phosphorylation.

[0134] Figure 44 shows bioinformatic analysis of potential serine and threonine phosphorylation sites of the *Helicoverpa amigera* derived FAR enzyme upon expression in yeast. The used server (world wide web address: ebs.dm.dk/serac6s/NetPhosYeast/; Blom, N., Gammeltoft, S. & Brunak, S. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. *J. Mol. Biol.* 294, 1351-1362 (1999)) predicts phosphorylated amino acids specifically in yeast. The horizontal line resembles the threshold for possible phosphorylation sites.

[0135] Figure 45 shows analysis of the Z9/Z11-16OH titers of HaFAR mutant library upon expression in *Y. lipolytica* SPV603. * Indicates a second copy of the HaFAR enzyme in addition to the existing copy of the parental strain.

[0136] Figure 46 shows analysis of the Z9/Z11-16Acid titers of HaFAR mutant library upon expression in *Y. lipolytica* SPV603. * Indicates a second copy of the HaFAR enzyme in addition to the existing copy in the parental strain.

[0137] Figure 47 shows analysis of the fatty alcohol titers of selected strains expressing HaFAR and derived mutants. Strains were cultivated in shake flasks over a period of 72h after addition of 10 g/L methyl palmitate. * Indicates a second copy of the HaFAR enzyme in addition to the existing copy in the parental strain. The analysis is based on technical quadruplicates.

[0138] Figure 48 shows analysis of the fatty acid titers of selected strains expressing HaFAR and derived mutants. Strains were cultivated in shake flasks over a period of 72h after addition of 10 g/L methyl palmitate. * Indicates a second copy of the HaFAR enzyme in addition to the existing copy in the parental strain. The analysis is based on technical quadruplicates.

[0139] Figure 49 shows analysis of the fatty alcohol titers of selected strains expressing HaFAR and derived mutants. Strains were cultivated in shake flasks over a period of 20h upon addition of 10 g/L methyl palmitate. The analysis is based on technical quadruplicates.

[0140] Figure 50 shows analysis of the fatty alcohol titers of selected strains in a time course experiment in shake flasks. A copy of the enzyme HaFAR or HaS195A was introduced into the strains SPV1053 (Adgal AURA, ALeu, leu2::pTEF-HZ_Z11_desat_Hs-tXPR2_loxP) and SPV1054 (Adga2 AURA, ALeu, leu2::pTEF-HZ_Z11_desat_Hs-tXPR2_loxP). Cultivation was performed as biological triplicates in shake flasks. Strains were cultivated in shake flasks over a period of 72h upon addition of 10 g/L methyl palmitate.

[0141] Figure 51 shows analysis of the fatty acid titers of selected strains in a time course experiment in shake flasks. A copy of the enzyme HaFAR or HaS195A was introduced into the strains SPV1053 (Adgal AURA, ALeu, Ieu2::pTEF-HZ_Zll_desat_Hs-tXPR2_loxP) and SPV1054 (Adga2 AURA, ALeu, Ieu2::pTEF-HZ_Zl1_desat_Hs-tXPR2_loxP). Cultivation was performed as biological triplicates in shake flasks. Strains were cultivated in shake flasks over a period of 72h upon addition of 10 g/L methyl palmitate.

[0142] Figure 52 shows analysis of the fatty alcohol titers of new strains in a FAR library screening in 24 well plates. A copy of each respective FAR enzyme from Table 24 was introduced into the strain SPV1054 (Adga2 AURA, ALeu, Ieu2::pTEF-HZ_Zll_desat_Hs-tXPR2_loxP). Cultivation was performed as biological quadruplicates in 24 well plates. Strains were cultivated over a period of 96h upon addition of 10 g/L methyl palmitate.

[0143] Figure 53 shows analysis of the fatty acid titers of new strains in a FAR library screening in 24 well plates. A single copy of each respective FAR enzyme from Table 24 was introduced into the strain SPV1054 (Adga2 AURA, ALeu, Ieu2::pTEF-HZ_Zl1_desat_Hs-tXPR2_loxP). Cultivation was performed as biological quadruplicates in 24 well plates. Strains were cultivated over a period of 96h upon addition of 10 g/L methyl palmitate.

[0144] Figure 54 shows a biosynthetic pathway capable of using tetradecyl-ACP (14:ACP) inputs to produce a blend of E- and Z- tetradecenyl acetate (El 1~14:OAc and Z 11-14:OAc) pheromones in a recombinant microorganism of the present disclosure.

SEQUENCES

[0145] A sequence listing for SEQ ID NO: 1 - SEQ ID NO: 105 is part of this application and is incorporated by reference herein. The sequence listing is provided at the end of this document, and is separately provided in computer readable format.

DETAILED DESCRIPTION

Definitions

[0146] The following definitions and abbreviations are to be used for the interpretation of the disclosure.

[0147] As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a pheromone" includes a plurality of such pheromones and reference to "the microorganism" includes reference to one or more microorganisms, and so forth.

[0148] As used herein, the terms "comprises," "comprising," "includes," "including," "has," "having," "contains," "containing," or any other variation thereof, are intended to cover a non-

exclusive inclusion. A composition, mixture, process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, mixture, process, method, article, or apparatus. Further, unless expressly stated to the contrary, "or" refers to an inclusive "or" and not to an exclusive "or."

[0149] The terms "about" and "around," as used herein to modify a numerical value, indicate a close range surrounding that explicit value. If "X" were the value, "about X" or "around X" would indicate a value from 0.9X to 1.1X, or, in some embodiments, a value from 0.95X to 1.05X. Any reference to "about X" or "around X" specifically indicates at least the values X, 0.95X, 0.96X, 0.97X, 0.98X, 0.99X, 1.01X, 1.02X, 1.03X, 1.04X, and 1.05X. Thus, "about X" and "around X" are intended to teach and provide written description support for a claim limitation of, *e.g.*, "0.98X."

[0150] As used herein, the terms "microbial," "microbial organism," and "microorganism" include any organism that exists as a microscopic cell that is included within the domains of archaea, bacteria or eukarya, the latter including yeast and filamentous fungi, protozoa, algae, or higher Protista. Therefore, the term is intended to encompass prokaryotic or eukaryotic cells or organisms having a microscopic size and includes bacteria, archaea, and eubacteria of all species as well as eukaryotic microorganisms such as yeast and fungi. Also included are cell cultures of any species that can be cultured for the production of a chemical.

[0151] As described herein, in some embodiments, the recombinant microorganisms are prokaryotic microorganism. In some embodiments, the prokaryotic microorganisms are bacteria. "Bacteria", or "eubacteria", refers to a domain of prokaryotic organisms. Bacteria include at least eleven distinct groups as follows: (1) Gram-positive (gram+) bacteria, of which there are two major subdivisions: (1) high G+C group (*Actinomycetes*, *Mycobacteria*, *Micrococcus*, others) (2) low G+C group (*Bacillus*, *Clostridia*, *Lactobacillus*, *Staphylococci*, *Streptococci*, *Mycoplasmas*); (2) Proteobacteria, *e.g.*, Purple photosynthetic +non-photosynthetic Gram-negative bacteria (includes most "common" Gram-negative bacteria); (3) Cyanobacteria, *e.g.*, oxygenic phototrophs; (4) Spirochetes and related species; (5) Planctomyces; (6) Bacteroides, Flavobacteria; (7) Chlamydia; (8) Green sulfur bacteria; (9) Green non-sulfur bacteria (also anaerobic phototrophs); (10) Radioresistant micrococci and relatives; (11) Thermotoga and Thermosipho thermophiles.

[0152] "Gram-negative bacteria" include cocci, nonenteric rods, and enteric rods. The genera of Gram-negative bacteria include, for example, *Neisseria*, *Spirillum*, *Pasteurella*, *Brucella*,

Yersinia, Francisella, Haemophilus, Bordetella, Escherichia, Salmonella, Shigella, Klebsiella, Proteus, Vibrio, Pseudomonas, Bacteroides, Acetobacter, Aerobacter, Agrobacterium, Azotobacter, Spirilla, Serratia, Vibrio, Rhizobium, Chlamydia, Rickettsia, Treponema, and Fusobacterium.

[0153] "Gram positive bacteria" include cocci, nonsporulating rods, and sporulating rods. The genera of gram positive bacteria include, for example, *Actinomyces, Bacillus, Clostridium, Corynebacterium, Erysipelothrix, Lactobacillus, Listeria, Mycobacterium, Myxococcus, Nocardia, Staphylococcus, Streptococcus, and Streptomyces*.

[0154] The term "recombinant microorganism" and "recombinant host cell" are used interchangeably herein and refer to microorganisms that have been genetically modified to express or to overexpress endogenous enzymes, to express heterologous enzymes, such as those included in a vector, in an integration construct, or which have an alteration in expression of an endogenous gene. By "alteration" it is meant that the expression of the gene, or level of a RNA molecule or equivalent RNA molecules encoding one or more polypeptides or polypeptide subunits, or activity of one or more polypeptides or polypeptide subunits is up regulated or down regulated, such that expression, level, or activity is greater than or less than that observed in the absence of the alteration. For example, the term "alter" can mean "inhibit," but the use of the word "alter" is not limited to this definition. It is understood that the terms "recombinant microorganism" and "recombinant host cell" refer not only to the particular recombinant microorganism but to the progeny or potential progeny of such a microorganism. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

[0155] The term "expression" with respect to a gene sequence refers to transcription of the gene and, as appropriate, translation of the resulting mRNA transcript to a protein. Thus, as will be clear from the context, expression of a protein results from transcription and translation of the open reading frame sequence. The level of expression of a desired product in a host cell may be determined on the basis of either the amount of corresponding mRNA that is present in the cell, or the amount of the desired product encoded by the selected sequence. For example, mRNA transcribed from a selected sequence can be quantitated by qRT-PCR or by Northern hybridization (see Sambrook *et al*, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1989)). Protein encoded by a selected sequence can be quantitated by various methods, *e.g.*, by ELISA, by assaying for the

biological activity of the protein, or by employing assays that are independent of such activity, such as western blotting or radioimmunoassay, using antibodies that recognize and bind the protein. See Sambrook *etal*, 1989, *supra*.

[0156] The term "polynucleotide" is used herein interchangeably with the term "nucleic acid" and refers to an organic polymer composed of two or more monomers including nucleotides, nucleosides or analogs thereof, including but not limited to single stranded or double stranded, sense or antisense deoxyribonucleic acid (DNA) of any length and, where appropriate, single stranded or double stranded, sense or antisense ribonucleic acid (RNA) of any length, including siRNA. The term "nucleotide" refers to any of several compounds that consist of a ribose or deoxyribose sugar joined to a purine or a pyrimidine base and to a phosphate group, and that are the basic structural units of nucleic acids. The term "nucleoside" refers to a compound (as guanosine or adenosine) that consists of a purine or pyrimidine base combined with deoxyribose or ribose and is found especially in nucleic acids. The term "nucleotide analog" or "nucleoside analog" refers, respectively, to a nucleotide or nucleoside in which one or more individual atoms have been replaced with a different atom or with a different functional group. Accordingly, the term polynucleotide includes nucleic acids of any length, DNA, RNA, analogs and fragments thereof. A polynucleotide of three or more nucleotides is also called nucleotidic oligomer or oligonucleotide.

[0157] It is understood that the polynucleotides described herein include "genes" and that the nucleic acid molecules described herein include "vectors" or "plasmids." Accordingly, the term "gene", also called a "structural gene" refers to a polynucleotide that codes for a particular sequence of amino acids, which comprise all or part of one or more proteins or enzymes, and may include regulatory (non-transcribed) DNA sequences, such as promoter sequences, which determine for example the conditions under which the gene is expressed. The transcribed region of the gene may include untranslated regions, including introns, 5'-untranslated region (UTR), and 3'-UTR, as well as the coding sequence.

[0158] The term "enzyme" as used herein refers to any substance that catalyzes or promotes one or more chemical or biochemical reactions, which usually includes enzymes totally or partially composed of a polypeptide or polypeptides, but can include enzymes composed of a different molecule including polynucleotides.

[0159] As used herein, the term "non-naturally occurring," when used in reference to a microorganism organism or enzyme activity of the disclosure, is intended to mean that the

microorganism organism or enzyme has at least one genetic alteration not normally found in a naturally occurring strain of the referenced species, including wild-type strains of the referenced species. Genetic alterations include, for example, modifications introducing expressible nucleic acids encoding metabolic polypeptides, other nucleic acid additions, nucleic acid deletions and/or other functional disruption of the microorganism's genetic material. Such modifications include, for example, coding regions and functional fragments thereof, for heterologous, homologous, or both heterologous and homologous polypeptides for the referenced species. Additional modifications include, for example, non-coding regulator}' regions in which the modifications alter expression of a gene or operon. Exemplary non-naturally occurring microorganism or enzyme activity includes the hydroxylation activity described above.

[0160] The term "exogenous" as used herein with reference to various molecules, *e.g.*, polynucleotides, polypeptides, enzymes, etc., refers to molecules that are not normally or naturally found in and/or produced by a given yeast, bacterium, organism, microorganism, or cell in nature.

[0161] On the oilier hand, the term "endogenous" or "native" as used herein with reference to various molecules, *e.g.*, polynucleotides, polypeptides, enzymes, etc., refers to molecules that are normally or naturally found in and/or produced by a given yeast, bacterium, organism, microorganism, or cell in nature.

[0162] The term "an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid" as used herein refers to a source of saturated C₆-C₂₄ fatty acid originating from within the microorganism (endogenous), such as when a saturated C₆-C₂₄ fatty acid is produced or synthesized inside the microorganism, or originating from outside the microorganism (exogenous), such as when a saturated C₆-C₂₄ fatty acid is provided to the microorganism during the course of culturing or cultivating the microorganism in media in flasks or other containers.

[0163] The term "heterologous" as used herein in the context of a modified host cell refers to various molecules, *e.g.*, polynucleotides, polypeptides, enzymes, etc., wherein at least one of the following is true: (a) the molecule(s) is/are foreign ("exogenous") to (*i.e.*, not naturally-found in) the host cell; (b) the molecule(s) is/are naturally found in (*e.g.*, is "endogenous to") a given host microorganism or host cell but is either produced in an unnatural location or in an unnatural amount in the cell; and/or (c) the molecule(s) differ(s) in nucleotide or amino acid sequence from the endogenous nucleotide or amino acid sequence(s) such that the

molecule differing in nucleotide or amino acid sequence from the endogenous nucleotide or amino acid as found endogenously is produced in an unnatural (*e.g.*, greater than naturally found) amount in the cell.

[0164] As used herein, the term "homologous sequences" "homolog" "homologs" or "orthologs" refers to related sequences (nucleic or amino acid) that are functionally related to the referenced sequence. A functional relationship may be indicated in any one of a number of ways, including, but not limited to: (a) degree of sequence identity and/or (b) the same or similar biological function. Use of the term homolog in this disclosure refers to instances in which both (a) and (b) are indicated. The degree of sequence identity may vary, but in one embodiment, is at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, 50%, or 50% sequence identity when using standard sequence alignment programs known in the art (*e.g.*, Clustal Omega alignment using default parameters). Homology can be determined using software programs readily available in the art, such as those discussed in *Current Protocols in Molecular Biology* (F.M. Ausubel *et al.*, eds., 1987) Supplement 30, section 7.718, Table 7.71. Some alignment programs are MacVector (Oxford Molecular Ltd, Oxford, U.K.) and ALIGN Plus (Scientific and Educational Software, Pennsylvania). Other non-limiting alignment programs include Sequencher (Gene Codes, Ann Arbor, Michigan), AlignX, and Vector NTI (Invitrogen, Carlsbad, CA). Thus, a reference to a homolog in the present disclosure will be understood as referencing a related sequence with the same or similar biological function, and a high degree of sequence identity as described above.

[0165] The term "fatty acid" as used herein refers to a compound of structure R-COOH, wherein R is a C₆ to C₂₄ saturated, unsaturated, linear, branched or cyclic hydrocarbon and the carboxyl group is at position 1. In a particular embodiment, R is a C₆ to C₂₄ saturated or unsaturated linear hydrocarbon and the carboxyl group is at position 1.

[0166] The term "fatty alcohol" as used herein refers to an aliphatic alcohol having the formula R-OH, wherein R is a C₆ to C₂₄ saturated, unsaturated, linear, branched or cyclic hydrocarbon. In a particular embodiment, R is a C₆ to C₂₄ saturated or unsaturated linear hydrocarbon.

[0167] The term "fatty acyl-CoA" refers to a compound having the structure **R-(CO)-S-R₁**, wherein **R₁** is Coenzyme A, and the term "fatty acyl-ACP" refers to a compound having the structure **R-(CO)-S-R₁**, wherein **R₁** is an acyl carrier protein ACP.

[0168] The term "short chain" or "short-chain" refers to fatty alcohols, fatty aldehydes, and/or fatty acetates, including pheromones, fragrances, flavors, and polymer intermediates with carbon chain length shorter than or equal to C₁₈.

[0169] Introduction

[0170] The present disclosure addresses the need for novel technologies for the cost-efficient production of valuable products from low-cost feedstocks. Specifically, the present inventors have addressed this need with the development of recombinant microorganisms capable of producing a wide-range of unsaturated C₆-C₂₄ fatty alcohols, aldehydes, and acetates including synthetic insect pheromones, fragrances, flavors, and polymer intermediates from low-cost feedstocks. Thus, aspects of the disclosure are based on the inventors' discovery that recombinant microorganisms can be engineered in order to produce valuable products from low-cost feedstocks, which circumvents conventional synthetic methodologies to produce valuable products.

[0171] As discussed above, recombinant microorganisms can be engineered to synthesize mono- or poly-unsaturated C₆-C₂₄ fatty alcohols. Mono- or poly-unsaturated C₆-C₂₄ fatty alcohols synthesized as described herein can be further converted into the corresponding aldehydes or acetates. Thus, various embodiments of the present disclosure can be used to synthesize a variety of insect pheromones selected from fatty alcohols, aldehydes, and acetates. Additionally, embodiments described herein can also be used for the synthesis of fragrances, flavors, and polymer intermediates.

[0172] Engineering of the microbial hosts entail the expression of a non-native pheromone biosynthetic pathway which is comprised of but not limited to one or multiple fatty acyl desaturases, and fatty alcohol-forming or fatty aldehyde-forming reductases. Fatty acids produced by desaturation reactions can be stored intracellularly as triacylglycerides or reduced enzymatically by reductases to form fatty alcohols or aldehydes. Triacylglycerides containing unsaturated fatty acids can be extracted, esterified, and chemically reduced to produce unsaturated fatty alcohols. Fatty alcohols produced via the described pathways can be further converted into fatty aldehyde pheromones, and fatty acetate pheromones via subsequent chemical oxidation, and esterification methods, respectively. Methods of chemical oxidation and esterification are known in the arts. Fatty alcohols produced via the

described pheromone biosynthetic pathway can also be further converted into fatty aldehyde pheromones, and fatty acetate pheromones using enzymatic conversion such as alcohol dehydrogenases, and acetyltransferase, respectively. Similarly, fatty acyl-CoA or fatty acyl-ACP formed as intermediates in the pheromone biosynthetic pathway can be released as free fatty acids by native or heterologously derived thioesterases, to become substrates for synthesis of pheromones using metathesis.

[0173] Pheromones

[0174] As described above, embodiments of the disclosure provide for the synthesis of one or more insect pheromones using a recombinant microorganism. A pheromone is a volatile chemical compound that is secreted by a particular insect for the function of chemical communication within the species. That is, a pheromone is secreted or excreted chemical factor that triggers a social response in members of the same species. There are, *inter alia*, alarm pheromones, food trail pheromones, sex pheromones, aggregation pheromones, epideictic pheromones, releaser pheromones, primer pheromones, and territorial pheromones, that affect behavior or physiology.

[0175] Non-limiting examples of insect pheromones which can be synthesized using the recombinant microorganisms and methods disclosed herein include linear alcohols, aldehydes, and acetates listed in Table 1.

Table 1. C₆-C₂₀ Linear Pheromones

Name	Name
(E)-2-Decen-1-ol	(E,E)-10,12-Tetradecadien-1-ol
(E)-2-Decenyl acetate	(E,E)-10,12-Tetradecadienyl acetate
(E)-2-Decenal	(E,E)-10,12-Tetradecadienal
(Z)-2-Decen-1-ol	(E,Z)-10,12-Tetradecadienyl acetate
(Z)-2-Decenyl acetate	(Z,E)-10,12-Tetradecadienyl acetate
(Z)-2-Decenal	(Z,Z)-10,12-Tetradecadien-1-ol
(E)-3-Decen-1-ol	(Z,Z)-10,12-Tetradecadienyl acetate
(Z)-3-Decenyl acetate	(E,Z,Z)-3,8,11-Tetradecatrienyl acetate
(Z)-3-Decen-1-ol	(E)-8-Pentadecen-1-ol
(Z)-4-Decen-1-ol	(E)-8-Pentadecenyl acetate

Name	Name
(E)-4-Decenyl acetate	(Z)-8-Pentadecen-1-ol
(Z)-4-Decenyl acetate	(Z)-8-Pentadecenyl acetate
(Z)-4-Decenal	(Z)-9-Pentadecenyl acetate
(E)-5-Decen-1-ol	(E)-9-Pentadecenyl acetate
(E)-5-Decenyl acetate	(Z)-10-Pentadecenyl acetate
(Z)-5-Decen-1-ol	(Z)-10-Pentadecenal
(Z)-5-Decenyl acetate	(E)-12-Pentadecenyl acetate
(Z)-5-Decenal	(Z)-12-Pentadecenyl acetate
(E)-7-Decenyl acetate	(Z,Z)-8,9-Pentadecadien-1-ol
(Z)-7-Decenyl acetate	(Z,Z)-6,9-Pentadecadienyl acetate
(E)-8-Decen-1-ol	(Z,Z)-6,9-Pentadecadienal
(E,E)-2,4-Decadienal	(E, E)-8,10-Pentadecadienyl acetate
(E,Z)-2,4-Decadienal	(E,Z)-8,10-Pentadecadien-1-ol
(Z,Z)-2,4-Decadienal	(E,Z)-8,10-Pentadecadienyl acetate
(E,E)-3,5-Decadienyl acetate	(Z,E)-8,10-Pentadecadienyl acetate
(Z,E)-3,5-Decadienyl acetate	(Z,Z)-8,10-Pentadecadienyl acetate
(Z,Z)-4,7-Decadien-1-ol	(E,Z)-9,11-Pentadecadienal
(Z,Z)-4,7-Decadienyl acetate	(Z,Z)-9,11-Pentadecadienal
(E)-2-Undecenyl acetate	(Z)-3-Hexadecenyl acetate
(E)-2-Undecenal	(E)-5-Hexadecen-1-ol
(Z)-5-Undecenyl acetate	(E)-5-Hexadecenyl acetate
(Z)-7-Undecenyl acetate	(Z)-5-Hexadecen-1-ol
(Z)-8-Undecenyl acetate	(Z)-5-Hexadecenyl acetate
(Z)-9-Undecenyl acetate	(E)-6-Hexadecenyl acetate
(E)-2-Dodecenal	(E)-7-Hexadecen-1-ol

Name	Name
(Z)-3-Dodecen-1-ol	(E)-7-Hexadecenyl acetate
(E)-3-Dodecenyl acetate	(E)-7-Hexadecenal
(Z)-3-Dodecenyl acetate	(Z)-7-Hexadecen-1-ol
(E)-4-Dodecenyl acetate	(Z)-7-Hexadecenyl acetate
(E)-5-Dodecen-1-ol	(Z)-7-Hexadecenal
(E)-S-Dodecenyl acetate	(E)-S-Hexadecenyl acetate
(Z)-5-Dodecen-1-ol	(E)-9-Hexadecen-1-ol
(Z)-5-Dodecenyl acetate	(E)-9-Hexadecenyl acetate
(Z)-5-Dodecenal	(E)-9-Hexadecenal
(E)-6-Dodecen-1-ol	(Z)-9-Hexadecen-1-ol
(Z)-8-Dodecenyl acetate	(Z)-9-Hexadecenyl acetate
(E)-6-Dodecenal	(Z)-9-Hexadecenal
(E)-7-Dodecen-1-ol	(E)-10-Hexadecen-1-ol
(E)-7-Dodecenyl acetate	(E)-10-Hexadecenal
(E)-7-Dodecenal	(Z)-10-Hexadecenyl acetate
(Z)-7-Dodecen-1-ol	(Z)-10-Hexadecenal
(Z)-7-Dodecenyl acetate	(E)-11-Hexadecen-1-ol
(Z)-7-Dodecenal	(E)-11-Hexadecenyl acetate
(E)-8-Dodecen-1-ol	(E)-11-Hexadecenal
(E)-8-Dodecenyl acetate	(Z)-11-Hexadecen-1-ol
(E)-8-Dodecenal	(Z)-11-Hexadecenyl acetate
(Z)-8-Dodecen-1-ol	(Z)-11-Hexadecenal
(Z)-8-Dodecenyl acetate	(Z)-12-Hexadecenyl acetate
(E)-9-Dodecen-1-ol	(Z)-12-Hexadecenal
(E)-9-Dodecenyl acetate	(E)-14-Hexadecenal

Name	Name
(E)-9-Dodecenal	(Z)-14-Hexadecenyl acetate
(Z)-9-Dodecen-1-ol	(E,E)-1,3-Hexadecadien-1-ol
(Z)-9-Dodecenyl acetate	(E,Z)-4,6-Hexadecadien-1-ol
(Z)-9-Dodecenal	(E,Z)-4,6-Hexadecadienyl acetate
(E)-10-Dodecen-1-ol	(E,Z)-4,6-Hexadecadienal
(E)-10-Dodecenyl acetate	(E,Z)-6, 11-Hexadecadienyl acetate
(E)-10-Dodecenal	(E,Z)-6, 11-Hexadecadienal
(Z)-10-Dodecen-1-ol	(Z,Z)-7, 10-Hexadecadien-1-ol
(Z)-10-Dodecenyl acetate	(Z,Z)-7, 10-Hexadecadienyl acetate
(E,Z)-3,5-Dodecadienyl acetate	(Z,E)-7, 11-Hexadecadien-1-ol
(Z,E)-3,5-Dodecadienyl acetate	(Z,E)-7, 11-Hexadecadienyl acetate
(Z,Z)-3,8-Dodecadien-1-ol	(Z,E)-7, 11-Hexadecadienal
(E,E)-4,10-Dodecadienyl acetate	(Z,Z)-7, 11-Hexadecadien-1-ol
(E,E)-5,7-Dodecadien-1-ol	(Z,Z)-7, 11-Hexadecadienyl acetate
(E,E)-5,7-Dodecadienyl acetate	(Z,Z)-7, 11-Hexadecadienal
(E,Z)-5,7-Dodecadien-1-ol	(Z,Z)-8, 10-Hexadecadienyl acetate
(E,Z)-5,7-Dodecadienyl acetate	(E,Z)-8, 11-Hexadecadienal
(E,Z)-5,7-Dodecadienal	(E, E)-9, 11-Hexadecadienal
(Z, E)-5,7-Dodecadien-1-ol	(E,Z)-9, 11-Hexadecadienyl acetate
(Z,E)-5,7-Dodecadienyl acetate	(E,Z)-9, 11-Hexadecadienal
(Z,E)-5,7-Dodecadienal	(Z,E)-9, 11-Hexadecadienal
(Z,Z)-5,7-Dodecadienyl acetate	(Z,Z)-9, 11-Hexadecadienal
(Z,Z)-5,7-Dodecadienal	(E, E)-10, 12-Hexadecadien-1-ol
(E,E)-7,9-Dodecadienyl acetate	(E, E)-10, 12-Hexadecadienyl acetate
(E,Z)-7,9-Dodecadien-1-ol	(E, E)-10, 12-Hexadecadienal

Name	Name
(E,Z)-7,9-Dodecadienyl acetate	(E,Z)-10,12-Hexadecadien-1-ol
(E,Z)-7,9-Dodecadienal	(E,Z)-10,12-Hexadecadienyl acetate
(Z,E)-7,9-Dodecadien-1-ol	(E,Z)-10,12-Hexadecadienal
(Z,E)-7,9-Dodecadienyl acetate	(Z,E)-10,12-Hexadecadienyl acetate
(Z,Z)-7,9-Dodecadien-1-ol	(Z,E)-10,12-Hexadecadienal
(Z,Z)-7,9-Dodecadienyl acetate	(Z,Z)-10,12-Hexadecadienal
(E,E)-8,10-Dodecadien-1-ol	(E,E)-11,13-Hexadecadien-1-ol
(E,E)-8,10-Dodecadienyl acetate	(E,E)-11,13-Hexadecadienyl acetate
(E,E)-8,10-Dodecadienal	(E,E)-11,13-Hexadecadienal
(E,Z)-8,10-Dodecadien-1-ol	(E,Z)-11,13-Hexadecadien-1-ol
(E,Z)-8,10-Dodecadienyl acetate	(E,Z)-11,13-Hexadecadienyl acetate
(E,Z)-8,10-Dodecadienal	(E,Z)-11,13-Hexadecadienal
(Z,E)-8,10-Dodecadien-1-ol	(Z,E)-11,13-Hexadecadien-1-ol
(Z,E)-8,10-Dodecadienyl acetate	(Z,E)-11,13-Hexadecadienyl acetate
(Z,E)-8,10-Dodecadienal	(Z,E)-11,13-Hexadecadienal
(Z,Z)-8,10-Dodecadien-1-ol	(Z,Z)-11,13-Hexadecadien-1-ol
(Z,Z)-8,10-Dodecadienyl acetate	(Z,Z)-11,13-Hexadecadienyl acetate
(Z,E,E)-3,6,8-Dodecatrien-1-ol	(Z,Z)-11,13-Hexadecadienal
(Z,Z,E)-3,6,8-Dodecatrien-1-ol	(E,E)-10,14-Hexadecadienal
(E)-2-Tridecenyl acetate	(Z,E)-11,14-Hexadecadienyl acetate
(Z)-2-Tridecenyl acetate	(E,E,Z)-4,6,10-Hexadecatrien-1-ol
(E)-S-Tridecenyl acetate	(E,E,Z)-10-Hexadecatrienyl acetate
(E)-4-Tridecenyl acetate	(E,Z,Z)-4,6,10-Hexadecatrien-1-ol
(Z)-4-Tridecenyl acetate	(E,Z,Z)-4,6,10-Hexadecatrienyl acetate
(Z)-4-Tridecenal	(E,E,Z)-4,6,11-Hexadecatrienyl acetate

Name	Name
(E)-6-Tridecenyl acetate	(E, E,Z)-4,8, 11-Hexadecatrienal
(Z)-7-Tridecenyl acetate	(Z,Z, E)-7, 11, 13-Hexadecatrienal
(E)-8-Tridecenyl acetate	(E,E,E)-10,12,14-Hexadecatrienyl acetate
(Z)-8-Tridecenyl acetate	(E,E,E)-10,12,14-Hexadecatrienal
(E)-9-Tridecenyl acetate	(E, E,Z)-10,12,14-Hexadecatrienyl acetate
(Z)-9-Tridecenyl acetate	(E,E,Z)-10,12,14-Hexadecatrienal
(Z)-10-Tridecenyl acetate	(E, E,Z,Z)-4,6, 11, 13-Hexadecatetraenal
(E)-11-Tridecenyl acetate	(E)-2-Heptadecenal
(Z)-11-Tridecenyl acetate	(Z)-2-Heptadecenal
(E,Z)-4,7-Tridecadienyl acetate	(E)-8-Heptadecen-1-ol
(Z,Z)-4,7-Tridecadien-1-ol	(E)-8-Heptadecenyl acetate
(Z,Z)-4,7-Tridecadienyl acetate	(Z)-8-Heptadecen-1-ol
(E,Z)-5,9-Tridecadienyl acetate	(Z)-9-Heptadecenal
(Z,E)-5,9-Tridecadienyl acetate	(E)-10-Heptadecenyl acetate
(Z,Z)-5,9-Tridecadienyl acetate	(Z)-11-Heptadecen-1-ol
(Z,Z)-7,11-Tridecadienyl acetate	(Z)-11-Heptadecenyl acetate
(E,Z,Z)-4,7,10-Tridecatrienyl acetate	(E, E)-4,8-Heptadecadienyl acetate
(E)-3-Tetradecen-1-ol	(Z,Z)-8,10-Heptadecadien-1-ol
(E)-3-Tetradecenyl acetate	(Z,Z)-8, 11-Heptadecadienyl acetate
(Z)-3-Tetradecen-1-ol	(E)-2-Octadecenyl acetate
(Z)-3-Tetradecenyl acetate	(E)-2-Octadecenal
(E)-5-Tetradecen-1-ol	(Z)-2-Octadecenyl acetate
(E)-5-Tetradecenyl acetate	(Z)-2-Octadecenal
(E)-5-Tetradecenal	(E)-9-Octadecen-1-ol

Name	Name
(Z)-5-Tetradecen-1-ol	(E)-9-Octadecenyl acetate
(Z)-5-Tetradecenyl acetate	(E)-9-Octadecenal
(Z)-5-Tetradecenai	(Z)-9-Octadecen-1-ol
(E)-6-Tetradecenyl acetate	(Z)-9-Octadecenyl acetate
(Z)-6-Tetradecenyl acetate	(Z)-9-Octadecenal
(E)-7-Tetradecen-1-ol	(E)-11-Octadecen-1-ol
(E)-7-Tetradecenyl acetate	(E)-11-Octadecenal
(Z)-7-Tetradecen-1-ol	(Z)-11-Octadecen-1-ol
(Z)-7-Tetradecenyl acetate	(Z)-11-Octadecenyl acetate
(Z)-7-Tetradecenai	(Z)-11-Octadecenal
(E)-8-Tetradecenyl acetate	(E)-13-Octadecenyl acetate
(Z)-8-Tetradecen-1-ol	(E)-13-Octadecenai
(Z)-8-Tetradecenyl acetate	(Z)-13-Octadecen-1-ol
(Z)-8-Tetradecenal	(Z)-13-Octadecenyl acetate
(E)-9-Tetradecen-1-ol	(Z)-13-Octadecenal
(E)-9-Tetradecenyl acetate	(E)-14-Octadecenal
(Z)-9-Tetradecen-1-ol	(E,Z)-2,13-Octadecadien-1-ol
(Z)-9-Tetradecenyl acetate	(E,Z)-2,13-Octadecadienyl acetate
(Z)-9-Tetradecenal	(E,Z)-2,13-Octadecadienai
(E)-10-Tetradecenyl acetate	(Z,E)-2,13-Octadecadienyl acetate
(Z)-10-Tetradecenyl acetate	(Z,Z)-2,13-Octadecadien-1-ol
(E)-11-Tetradecen-1-ol	(Z,Z)-2,13-Octadecadienyl acetate
(E)-11-Tetradecenyl acetate	(E,E)-3,13-Octadecadienyl acetate
(E)-11-Tetradecenal	(E,Z)-3,13-Octadecadienyl acetate
(Z)-11-Tetradecen-1-ol	(E,Z)-3,13-Octadecadienal










Name	Name
(Z)-1 1-Tetradecenyl acetate	(Z, E)-3, 13-Octadecadienyl acetate
(Z)-1 1-Tetradecenai	(Z,Z)-3, 13-Octadecadienyl acetate
(E)-12-Tetradecenyl acetate	(Z,Z)-3, 13-Octadecadienai
(Z)-12-Tetradecenyl acetate	(E,E)-5,9-Octadecadien-1-oi
(E, E)-2,4-Tetradecadienal	(E,E)-5,9-Octadecadienyl acetate
(E,E)-3,5-Tetradecadienyl acetate	(E,E)-9,12-Octadecadien-1-ol
(E,Z)-3,5-Tetradecadienyl acetate	(Z,Z)-9, 12-Octadecadienyl acetate
(Z,E)-3,5-Tetradecadieny! acetate	(Z,Z)-9,12-Octadecadienal
(E,Z)-3,7-Tetradecadienyl acetate	(Z,Z)-1 1,13-Octadecadienal
(E,Z)-3,8-Tetradecadienyl acetate	(E, E)-1 1,14-Octadecadienal
(E,Z)-4,9-Tetradecadienyi acetate	(Z,Z)-1 3,15-Octadecadienal
(E,Z)-4,9-Tetradecadienal	(Z,Z,Z)-3,6,9-Octadecatrienyl acetate
(E,Z)-4, 10-Tetradecadienyl acetate	(E, E, E)-9, 12,15-Octadecatrien-1 -ol
(E,E)-5,8-Tetradecadiena!	(Z,Z,Z)-9, 12,15-Octadecatrienyi acetate
(Z,Z)-5,8-Tetradecadien-1-oi	(Z,Z,Z)-9, 12,15-Octadecatrienal
(Z,Z)-5,8-Tetradecadienyl acetate	
(Z,Z)-5,8~Tetradecadiena!	
(E, E)-8, 10-Tetradecadien- 1-ol	
(E, E)-8, 10-Tetradecadienyi acetate	
(E, E)-8, 10-Tetradecadienal	
(E,Z)-8, 10-Tetradecadienyl acetate	
(E,Z)-8, 10-Tetradecadienal	
(Z, E)-8, 10-Tetradecadien-1 -oi	
(Z, E)-8, 10-Tetradecadienyl acetate	
(Z,Z)-8, 10-Tetradecadienai	

Name	Name
(E,E)-9,11-Tetradecadienyl acetate	
(E,Z)-9,11-Tetradecadienyl acetate	
(Z,E)-9,11-Tetradecadien-1-ol	
(Z,E)-9,11-Tetradecadienyl acetate	
(Z,E)-9,11-Tetradecadienal	
(Z,Z)-9,11-Tetradecadien-1-ol	
(Z,Z)-9,11-Tetradecadienyl acetate	
(Z,Z)-9,11-Tetradecadienal	
(E,E)-9,12-Tetradecadienyl acetate	
(Z,E)-9,12-Tetradecadien-1-ol	
(Z,E)-9,12-Tetradecadienyl acetate	
(Z,E)-9,12-Tetradecadienal	
(Z,Z)-9,12-Tetradecadien-1-ol	
(Z,Z)-9,12-Tetradecadienyl acetate	

[0176] In some aspects, the pheromones synthesized as taught in this disclosure include at least one pheromone listed in Table 2a to modulate the behavior of an insect listed in Table 2a. In other aspects, non-limiting examples of insect pheromones which can be synthesized using the recombinant microorganisms and methods disclosed herein include alcohols, aldehydes, and acetates listed in Table 2a. However, the microorganisms described herein are not limited to the synthesis of C₆-C₂₀ pheromones listed in Table 1 and Table 2a. Rather, the disclosed microorganisms can also be utilized in the synthesis of various C₆-C₂₄ mono- or poly-unsaturated fatty alcohols, aldehydes, and acetates, including fragrances, flavors, and polymer intermediates.

Table 2a. Exemplary pheromones that can be synthesized according to methods described in the present disclosure.

Name	Structure	Example of Biological importance
(Z)-3-hexen-1-ol		See, Sugimoto <i>et al.</i> (2014)
(Z)-3-nonen-1-ol		West Indian Fruity Fly male sex pheromone
(Z)-5-decen-1-ol		
(Z)-5-decenyl acetate		<i>Agrotis segetum</i> sex pheromone component
(E)-5-decen-1-ol		<i>Anarsia lineatella</i> sex pheromone component
(E)-5-decenyl acetate		<i>Anarsia lineatella</i> sex pheromone component
(Z)-7-dodecen-1-ol		
(Z)-7-dodecenyl acetate		<i>Pseudoplusia includens</i> sex pheromone <i>Agrotis segetum</i> sex pheromone component
(E)-8-dodecen-1-ol		Citrus Fruit Moth sex pheromone
(E)-8-dodecenyl acetate		<i>Grapholitha molesta</i> , <i>Ecdytolopha aurantiana</i> sex pheromone component
(Z)-8-dodecen-1-ol		<i>Grapholitha molesta</i> , <i>Ecdytolopha aurantiana</i> sex pheromone component
(Z)-8-dodecenyl acetate		<i>Grapholitha molesta</i> sex pheromone component
(Z)-9-dodecen-1-ol		
(Z)-9-dodecenyl acetate		<i>Eupoecilia ambiguella</i> sex pheromone
(E,E)-8,10-dodecadien-1-ol		<i>Cydia pomonella</i>
(7E,9Z)-dodecadienyl acetate		<i>Lobesia botrana</i>
(Z)-9-tetradecen-1-ol		
(Z)-9-tetradecenyl acetate		<i>Pandemis pyrusana</i> , <i>Naranga aenescens</i> , <i>Agrotis segetum</i> sex pheromone component
(Z)-11-tetradecen-1-ol		
(Z)-11-tetradecenyl acetate		<i>Pandemis pyrusana</i> , <i>Choristoneura roseceana</i> sex pheromone component
(E)-11-tetradecen-1-ol		
(E)-11-tetradecenyl acetate		<i>Choristoneura roseceana</i> , <i>Crociodolomia pavonana</i> sex pheromone component
(Z)-7-hexadecen-1-ol		
(Z)-7-hexadecenol		<i>Diatraea considerata</i> sex pheromone component
(Z)-9-hexadecen-1-ol		
(Z)-9-hexadecenol		<i>Helicoverpa zea</i> , <i>Helicoverpa armigera</i> , <i>Heliothis virescens</i> sex pheromone component
(Z)-9-hexadecenyl acetate		<i>Naranga aenescens</i> sex pheromone component
(Z)-1 1-hexadecen-1-ol		

Name	Structure	Example of Biological importance
(Z)-1 1-hexadecenal		<i>Platyptilia carduidactylia</i> , <i>Heliothis virescens</i> sex pheromone <i>Helicoverpa zea</i> , <i>Helicoverpa armigera</i> , <i>Piutella xylostea</i> , <i>Diatraea considerata</i> , <i>Diatraea grandiosella</i> , <i>Diatraea saccharalis</i> , <i>Acrolepiopsis assectella</i> sex pheromone component
(Z)-1 1-hexadecenyl acetate		<i>Discestra trifolii</i> sex pheromone <i>Heliothis virescens</i> , <i>Piutella xylostea</i> , <i>Acrolepiopsis assectella</i> , <i>Crociodiomyia pavonana</i> , <i>Naranga aenescens</i> sex pheromone component
(Z,Z)-1 1,13-hexadecadienyl		<i>Amyeiosis transiteia</i>
(Z,Z)-1 1,13-hexadecadien-1-ol		<i>Amyeiosis transiteia</i>
(11Z,13E)-hexadecadien-1-ol		<i>Amyeiosis transiteia</i>
(9Z,11E)-hexadecadienyl		
(Z)-1 3-octadecen-1-ol		
(Z)-1 3-octadecenal		<i>Diatraea considerata</i> , <i>Diatraea grandiosella</i> sex pheromone component
(Z,Z,Z,Z)-3,6,9, 12,15-tricosapentaene		<i>Amyeiosis transiteia</i>

[0177] Most pheromones comprise a hydrocarbon skeleton with the terminal hydrogen substituted by a functional group (Ryan MF (2002). Insect **Chemoreception**. Fundamental and Applied. Kluwer Academic Publishers). Table 2b shows some common functional groups, along with their formulas, prefixes and suffixes. The presence of one or more double bonds, generated by the loss of hydrogens from adjacent carbons, determines the degree of **unsaturation** of the molecule and alters the designation of a hydrocarbon from **-ane** (no multiple bonds) to **-ene**. The presence of two and three double bonds is indicated by ending the name with **-diene** and **-triene**, respectively. The position of each double bond is represented by a numeral corresponding to that of the carbon from which it begins, with each carbon numbered from that attached to the functional group. The carbon to which the functional group is attached is designated -1-. Pheromones may have, but are **not** limited to, hydrocarbon chain lengths numbering 10 (deca-), 12 (dodeca-), 14 (tetradeca-), 16 (hexadeca-

), or 18 (**octadeca-**) carbons long. The presence of a double bond has another effect. It precludes rotation **of the** molecule by fixing it in one of two possible configurations, each representing **geometric** isomers that are different molecules. These are designated either *E* (from **the** German word *Enigegen*, opposite) or *Z* (*Zusammen*, together), when **the** carbon chains are connected on the opposite (*trans*) or same (*cis*) side, respectively, of the double bond.

Table 2b. Prefixes and suffixes for common functional groups

Functional group	Formula	Prefix	Suffix
Alcohol	-OH	Hydroxy-	-ol
Aldehyde	-CH=O	Formyl-	-al
Amine	-NH ₂	Amino-	-amine
Carboxylic acid	-COOH	Carboxy-	-oic acid
Ester	-COOR	R-oxy carbonyl-	-oate
Ketone	>C=O	Oxo-	-one

From Howse, PE, Stevens, IDR and Jones, OT (1998). Insect **pheromones** and their use in pest management. London: Chapman and **Hall**.

[0178] Pheromones described herein can be referred to using **IUPAC** nomenclature or various abbreviations or variations known to one skilled in the art. For example, **(11Z)-hexadecen-1-al**, can also be written as **Z-11-hexadecen-1-al**, **Z-11-hexadecenal**, or **Z-x-y:Al**, wherein x represents the position of the double bond and y represents **the** number of carbons **in** the hydrocarbon skeleton. Abbreviations used herein and known **to** those skilled in the art **to** identify functional groups on the hydrocarbon skeleton include "Al," indicating an aldehyde, "**OH**," indicating an alcohol, and "Ac," indicating an acetyl. Also, the number of carbons **in** the chain can be indicated using numerals rather than using the written name. Thus, as used herein, an unsaturated carbon chain comprised of sixteen carbons can be written as **hexadecene** or 16.

[0179] Similar abbreviation and derivations are used herein to describe **pheromone** precursors. For example, the fatty **acyl-CoA** precursors **of** **(11Z)-hexadecen-1-al** can be identified as **(HZ)-hexadecenyl-CoA** or **Z-11-16:Acyl-CoA**.

[0180] The present disclosure relates to the synthesis of mono- or poly-unsaturated C₆-C₂₄ fatty alcohols, aldehydes, and acetates using a recombinant microorganism comprised of one

or more heterologous enzymes, which catalyze substrate to product conversions for one or more steps in the synthesis process.

Desaturase

[0181] The present disclosure describes enzymes that desaturate fatty acyl substrates to corresponding unsaturated fatty acyl substrates.

[0182] In some embodiments, a desaturase is used to catalyze the conversion of a fatty acyl-CoA or acyl-ACP to a corresponding unsaturated fatty acyl-CoA or acyl-ACP. A desaturase is an enzyme that catalyzes the formation of a carbon-carbon double bond in a saturated fatty acid or fatty acid derivative, *e.g.*, fatty acyl-CoA or fatty acyl-ACP (collectively referred to herein as "fatty acyl"), by removing at least two hydrogen atoms to produce a corresponding unsaturated fatty acid/acyl. Desaturases are classified with respect to the ability of the enzyme to selectively catalyze double bond formation at a subterminal carbon relative to the methyl end of the fatty acid/acyl or a subterminal carbon relative to the carbonyl end of the fatty acid/acyl. Omega (ω) desaturases catalyze the formation of a carbon-carbon double bond at a fixed subterminal carbon relative to the methyl end of a fatty acid/acyl. For example, an ω^3 desaturase catalyzes the formation of a double bond between the third and fourth carbon relative to the methyl end of a fatty acid/acyl. Delta (Δ) desaturases catalyze the formation of a carbon-carbon double bond at a specific position relative to the carboxyl group of a fatty acid or the carbonyl group of a fatty acyl CoA. For example, a Δ^9 desaturase catalyzes the formation of a double bond between the C₉ and C₁₀ carbons with respect to the carboxyl end of the fatty acid or the carbonyl group of a fatty acyl CoA.

[0183] As used herein, a desaturase can be described with reference to the location in which the desaturase catalyzes the formation of a double bond and the resultant geometric configuration (*i.e.*, E/Z) of the unsaturated hydrocarbon. Accordingly, as used herein, a Z₉ desaturase refers to a Δ desaturase that catalyzes the formation of a double bond between the C₉ and C₁₀ carbons with respect to the carbonyl end of a fatty acid/acyl, thereby orienting two hydrocarbons on opposing sides of the carbon-carbon double bonds in the *cis* or Z configuration. Similarly, as used herein, a Z₁₁ desaturase refers to a Δ desaturase that catalyzes the formation of a double bond between the C₁₁ and C₁₂ carbons with respect to the carbonyl end of a fatty acid/acyl.

[0184] Desaturases have a conserved structural motif. This sequence motif of transmembrane desaturases is characterized by [HX3-4HX7-4 1(3 non-His)HX2-3(1 nonHis)HHX61-

189(40 non-His)HX2-3(1 non-His)HH]. The sequence motif of soluble desaturases is characterized by two occurrences of [D/EEXXHJ.

[0185] In some embodiments, the desaturase is a fatty acyl-CoA desaturase that catalyzes the formation of a double bond in a fatty acyl-CoA. In some such embodiments, the fatty acyl-CoA desaturase described herein is capable of utilizing a fatty acyl-CoA as a substrate that has a chain length of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 carbon atoms. Thus, the desaturase used in the recombinant microorganism can be selected based on the chain length of the substrate.

[0186] In some embodiments, the fatty acyl desaturase described herein is capable of catalyzing the formation of a double bond at a desired carbon relative to the terminal CoA on the unsaturated fatty acyl-CoA. Thus, in some embodiments, a desaturase can be selected for use in the recombinant microorganism which catalyzes double bond insertion at the 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 position with respect to the carbonyl group on a fatty acyl-CoA.

[0187] In some embodiments, the fatty acyl desaturase described herein is capable of catalyzing the formation of a double bond in a saturated fatty acyl-CoA such that the resultant unsaturated fatty acyl-CoA has a cis or trans (i.e., Z or E) geometric configuration.

[0188] In some embodiments, the desaturase is a fatty acyl-ACP desaturase that catalyzes the formation of a double bond in a fatty acyl-ACP. In some embodiments, the fatty acyl-ACP desaturase described herein is capable of utilizing a fatty acyl-CoA as a substrate that has a chain length of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 carbon atoms. Thus, the desaturase used in the recombinant microorganism can be selected based on the chain length of the substrate.

[0189] In some embodiments, the fatty acyl-ACP desaturase described herein is capable of catalyzing the formation of a double bond at a desired carbon relative to the terminal carbonyl on the unsaturated fatty acyl-ACP. Thus, in some embodiments, a desaturase can be selected for use in the recombinant microorganism which catalyzes double bond insertion at the 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 position with respect to the carbonyl group on a fatty acyl-ACP.

[0190] In some embodiments, the fatty acyl desaturase described herein is capable of catalyzing the formation of a double bond in a saturated fatty acyl-CoA such that the resultant unsaturated fatty acyl-ACP has a cis or trans (i.e., Z or E) geometric configuration.

[0191] In one embodiment, the fatty acyl desaturase is a Z11 desaturase. In some embodiments, a nucleic acid sequence encoding a Z11 desaturase from organisms of the

species *Agrotis segetum*, *Amyelois transitella*, *Argyrotaenia vehitiana*, *Choristoneura rosaceana*, *Lampronia capitella*, *Trichopliisia ni*, *Helicoverpa zea*, or *Thalassiosira pseudonana* is codon optimized. In some embodiments, the Z11 desaturase comprises a nucleotide sequence selected from SEQ ID NOs: 9, 18, 24 and 26 from *Trichopliisia ni*. In some embodiments, the Z11 desaturase comprises an amino acid sequence set forth in SEQ ID NO: 49 from *Tnchoplusia ni*. In other embodiments, the Z11 desaturase comprises a nucleotide sequence selected from SEQ ID NOs: 10 and 16 from *Agrotis segetum*. In some embodiments, the Z11 desaturase comprises an amino acid sequence set forth in SEQ ID NO: 53 from *Agrotis segetum*. In some embodiments, the Z11 desaturase comprises a nucleotide sequence selected from SEQ ID NOs: 11 and 23 from *Thalassiosira pseudonana*. In some embodiments, the Z11 desaturase comprises an amino acid sequence selected from SEQ ID NOs: 50 and 51 from *Thalassiosira pseudonana*. In certain embodiments, the Z11 desaturase comprises a nucleotide sequence selected from SEQ ID NOs: 12, 17 and 30 from *Amyelois transitella*. In some embodiments, the Z11 desaturase comprises an amino acid sequence set forth in SEQ ID NO: 52 from *Amyelois transitella*. In further embodiments, the Z11 desaturase comprises a nucleotide sequence selected from SEQ ID NOs: 13, 19, 25, 27 and 31 from *Helicoverpa zea*. In some embodiments, the Z11 desaturase comprises an amino acid sequence set forth in SEQ ID NO: 54 from *Helicoverpa zea*. In some embodiments, the Z11 desaturase comprises an amino acid sequence set forth in SEQ ID NO: 39 from *S. inferens*. In some embodiments, the Z11 desaturase comprises an amino acid sequence set forth in GenBank Accession nos. AF416738, AGH12217.1, AII21943.1, CAJ43430.2, AF441221, AAF81787.1, AF545481, AJ271414, AY362879, ABX71630.1 and NP001299594.1, Q9N9Z8, ABX71630.1 and AIM4022.1.1. In some embodiments, the Z11 desaturase comprises a chimeric polypeptide. In some embodiments, a complete or partial Z11 desaturase is fused to another polypeptide. In certain embodiments, the N-terminal native leader sequence of a Z11 desaturase is replaced by an oieosin leader sequence from another species. In certain embodiments, the Z11 desaturase comprises a nucleotide sequence selected from SEQ ID NOs: 15, 28 and 29. In some embodiments, the Z11 desaturase comprises an amino acid sequence selected from SEQ ID NOs: 61, 62, 63, 78, 79 and 80.

[0192] In one embodiment, the fatty acyl desaturase is a Z9 desaturase. In some embodiments, a nucleic acid sequence encoding a Z9 desaturase is codon optimized. In some embodiments, the Z9 desaturase comprises a nucleotide sequence set forth in SEQ ID NO: 20 from *Ostrinia furnacalis*. In some embodiments, the Z9 desaturase comprises an amino acid

sequence set forth in SEQ ID NO: 58 from *Ostrinia furnacalis*. In other embodiments, the Z9 desaturase comprises a nucleotide sequence set forth in SEQ ID NO: 21 from *Lampronia capitella*. In some embodiments, the Z9 desaturase comprises an amino acid sequence set forth in SEQ ID NO: 59 from *Lampronia capitella*. In some embodiments, the Z9 desaturase comprises a nucleotide sequence set forth in SEQ ID NO: 22 from *Helicoverpa zea*. In some embodiments, the Z9 desaturase comprises an amino acid sequence set forth in SEQ ID NO: 60 from *Helicoverpa zea*.

[0193] Thus, in some embodiments, the present disclosure teaches a recombinant microorganism comprising a Z11 or Z9 desaturase exhibiting at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, or 50% sequence identity with any one of SEQ ID Nos. selected from the group consisting of 39, 49, 50, 51, 52, 53, 54, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 78, 79, 80, 95, 97, 99, 101, 103, and 105.

[0194] Thus, in some embodiments, the present disclosure teaches a recombinant microorganism comprising a nucleic acid molecule encoding for a Z11 or Z9 desaturase, wherein said nucleic acid molecule exhibits at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, or 50% sequence identity with any one of SEQ ID Nos. selected from the group consisting of 9, 10, 11, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 68, 69, 70, 71, 94, 96, 98, 100, 102, and 104.

[0195] In some embodiments, the present disclosure teaches a recombinant microorganism comprising at least one nucleic acid molecule encoding a fatty acyl desaturase having at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, or 50% sequence identity to a fatty acyl desaturase selected from the group consisting of SEQ ID NOs: 39, 54, 60, 62, 78, 79, 80, 95, 97, 99, 101, 103, and 105 that catalyzes the conversion of a saturated C₆-C₂₄ fatty acyl-CoA to a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA.

Fatty Acyl Reductase

[0196] The present disclosure describes enzymes that reduce fatty acyl substrates to corresponding fatty alcohols or aldehydes.

[0197] In some embodiments, a fatty alcohol forming fatty acyl-reductase is used to catalyze the conversion of a fatty acyl-CoA to a corresponding fatty alcohol. In some embodiments, a fatty aldehyde forming fatty acyl-reductase is used to catalyze the conversion of a fatty acyl-ACP to a corresponding fatty aldehyde. A fatty acyl reductase is an enzyme that catalyzes the reduction of a fatty acyl-CoA to a corresponding fatty alcohol or the reduction of a fatty acyl-ACP to a corresponding fatty aldehyde. A fatty acyl-CoA and fatty' acyl-ACP has a structure of R-(CO)-S-R_i, wherein R is a C₆ to C₂₄ saturated, unsaturated, linear, branched or cyclic hydrocarbon, and R_i represents CoA or ACP. In a particular embodiment, R is a C₆ to C₂₄ saturated or unsaturated linear hydrocarbon. "CoA" is a non-protein acyl carrier group involved in the synthesis and oxidation of fatty acids. "ACP" is an acyl carrier protein, *i.e.*, a polypeptide or protein subunit, of fatty acid synthase used in the synthesis of fatty acids.

[0198] Thus, in some embodiments, the disclosure provides for a fatty alcohol forming fatty acyl-reductase which catalyzes the reduction of a fatty acyl-CoA to the corresponding fatty alcohol. For example, R-(CO)-S-CoA is converted to R-CH₂OH and CoA-SH when two molecules of NAD(P)H are oxidized to NAD(P)⁺. Accordingly, in some such embodiments, a recombinant microorganism described herein can include a heterologous fatty' alcohol forming fatty acyl-reductase, which catalyzes the reduction a fatty acyl-CoA to the corresponding fatty alcohol. In an exemplary embodiment, a recombinant microorganism disclosed herein includes at least one exogenous nucleic acid molecule encoding a fatty alcohol forming fatty-acyl reductase which catalyzes the conversion of a mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA into the corresponding mono- or poly-unsaturated C₆-C₂₄ fatty alcohol.

[0199] In other embodiments, the disclosure provides for a fatty aldehyde forming fatty acyl-reductase which catalyzes the reduction of a fatty acyl-ACP to the corresponding fatty-aldehyde. For example, R-(CO)-S-ACP is converted to R-(CO)-H and ACP-SH when one molecule of NAD(P)H is oxidized to NAD(P)⁺. In some such embodiments, a recombinant microorganism described herein can include a heterologous fatty aldehyde forming fatty acyl-reductase, which catalyzes the reduction a fatty acyl-ACP to the corresponding fatty aldehyde. In an exemplary embodiment, a recombinant microorganism disclosed herein includes at least one exogenous nucleic acid molecule encoding a fatty aldehyde forming

fatty-acyl] reductase which catalyzes the conversion of a mono- or poly-unsaturated C₆-C₂₄ fatty acyl-ACP into the corresponding mono- or poly-unsaturated C₆-C₂₄ fatty aldehyde.

[0200] In some insect species the respective alcohol-forming fatty acyl reductase (FAR) enzymes are activated via site specific dephosphorylation (Jurenka, R. & Rafaeli, A. Regulatory Role of PBAN in Sex Pheromone Biosynthesis of Heliothine Moths. Front. Endocrinol. (Lausanne). 2: 46 (2011); Gilbert, L. I. Insect Endocrinology. (Academic Press)). Without being bound by any one theory, phosphorylation of heterologously expressed FAR enzymes in yeast such as *Y. lipolytica* can lead to inactivation, and results in low fatty alcohol titers. In some embodiments, a bioinformatic approach can be used to predict phosphorylated residues within FAR. Alanine substitution of serine and threonine residues has been shown to abolish phosphorylation (Shi, S., Chen, Y., Siewers, V. & Nielsen, J. Improving Production of Malonyl Coenzyme A-Derived Metabolites by Abolishing Snf1-Dependent Regulation of Accl. mBio 5 (2014)). Thus, the impact of alanine substitutions to prevent phosphorylation of serine residues and its impact on fatty alcohol titers can be tested. In addition to alanine substitution, improvement of FAR activity can also be achieved by other amino acid substitutions.

[0201] In some embodiments, methods are provided to identify beneficial mutations of FAR based on selection and alteration of phosphorylation-sensitive residues upon its expression in a host microorganism. In a preferred embodiment, the host microorganism is yeast selected from the group consisting of *Yarrowia*, *Candida*, *Saccharomyces*, *Pichia*, *Hansenula*, and *Kluyveromyces*.

[0202] Other references for protein phosphorylation sites include: Blom, N., Gammeltoft, S. & Brunak, S. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J. Mol. Biol. 294, 1351-1362 (1999); Ingrell, C. R., Miller, M. L., Jensen, O. N. & Blom, N. NetPhosYeast: prediction of protein phosphorylation sites in yeast. Bioinforma. 23: 895-897 (2007); Miller, W. T. Tyrosine kinase signaling and the emergence of multicellularity. Biochim. Biophys. Acta 1823, 1053-1057 (2012), each of which is herein incorporated in its entirety.

[0203] In some embodiments, a nucleic acid sequence encoding a fatty-acyl reductase from organisms of the species *Agrotis segetum*, *Spodoptera exigua*, *Spodoptera littoralis*, *Euglena gracilis*, *Yponomeuta evonymellus* and *Helicoverpa armigera* is codon optimized. In some embodiments, the fatty acyl reductase comprises a nucleotide sequence set forth in SEQ ID NO: 1 from *Agrotis segetum*. In other embodiments, the fatty acyl reductase comprises a

nucleotide sequence set forth in SEQ ID NO: 2 from *Spodoptera littoralis*. In some embodiments, the fatty acyl reductase comprises a nucleotide sequence selected from SEQ ID NOs: 3, 32, 40, 72, 74, 76 and 81. In some embodiments, the fatty acyl reductase comprises an amino acid sequence set forth in SEQ ID NO: 55 from *Agrotis segetum*. In other embodiments, the fatty acyl reductase comprises an amino acid sequence set forth in SEQ ID NO: 56 from *Spodoptera littoralis*. In some embodiments, the fatty acyl reductase comprises an amino acid sequence selected from SEQ ID NOs: 41 and 57 from *Helicoverpa armigera*. In some embodiments, the fatty acyl reductase comprises an amino acid sequence selected from SEQ ID NOs: 73 and 82 from *Spodoptera exigua*. In some embodiments, the fatty acyl reductase comprises an amino acid sequence set forth in SEQ ID NO: 75 from *Euglena gracilis*. In some embodiments, the fatty acyl reductase comprises an amino acid sequence set forth in SEQ ID NO: 77 from *Yponomeuta evonymellus*.

[0204] In some embodiments, the production of unsaturated fatty alcohols in a recombinant microorganism comprises the expression of one or more mutant FARs. In certain embodiments, *Helicoverpa amigera* fatty acyl-CoA reductase (HaFAR) variants are provided which have increased enzymatic activity relative to enzymatic activity of a wild type *Helicoverpa amigera* fatty acyl-CoA reductase encoded by an amino acid sequence set forth in SEQ ID NO: 41. In some embodiments, the increased enzymatic activity is a net activity increase in amount of fatty alcohol produced relative to the amount of fatty alcohol produced by a wild type enzymatic activity of HaFAR encoded by an amino acid sequence set forth in SEQ ID NO: 41. In some embodiments, a wild type HaFAR comprises a nucleotide sequence set forth in SEQ ID NO: 90. In some embodiments, a variant of a wild type HaFAR encoded by an amino acid sequence set forth in SEQ ID NO: 41 comprises point mutations at the following positions: S60X, S195X, S298X, S378X, S394X, S418X, and S453X, wherein X comprises an amino acid selected from F, L, M, I, V, P, T, A, Y, K, H, N, Q, K, D, E, C, W and R. In some embodiments, a variant of a wild type HaFAR encoded by an amino acid sequence set forth in SEQ ID NO: 41 comprises a combination of point mutations selected from mutations at the following amino acid positions: S60X, S195X, S298X, S378X, S394X, S418X, and S453X, wherein X comprises an amino acid selected from F, L, M, I, V, P, T, A, Y, K, H, N, Q, K, D, E, C, W and R. In some embodiments, the fatty acyl reductase is a mutated fatty acyl reductase and comprises an amino acid sequence selected from SEQ ID NOs: 42-48. In some embodiments, the fatty acyl reductase is a mutated fatty acyl reductase and comprises a nucleotide sequence selected from SEQ ID NOs: 83-89.

[0205] Thus, in some embodiments, the present disclosure teaches a recombinant microorganism comprising a fatty acyl reductase exhibiting at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, or 50% sequence identity with any one of SEQ ID Nos. selected from the group consisting of, 41, 42, 43, 44, 45, 46, 47, 48, 55, 56, 57, 73, 75, 77, and 82.

[0206] Thus, in some embodiments, the present disclosure teaches a recombinant microorganism comprising a nucleic acid molecule encoding for a fatty acyl reductase, wherein said nucleic acid molecule exhibits at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, or 50% sequence identity with any one of SEQ ID Nos. selected from the group consisting of 1, 2, 3, 32, 37, 40, 72, 74, 76, 81, 83, 84, 85, 86, 87, 88, 89, and 90.

[0207] In some embodiments, the present disclosure teaches a recombinant microorganism comprising at least one nucleic acid molecule encoding a fatty acyl reductase having at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, or 50% sequence identity to a fatty acyl reductase selected from the group consisting of SEQ ID NOs: 41-48, 57, 73, 75 and 77 that catalyzes the conversion of the mono- or poly-unsaturated C_6 - C_{24} fatty acyl-CoA into the corresponding mono- or poly-unsaturated C_6 - C_{24} fatty alcohol.

Acyl-ACP Synthetase

[0208] The present disclosure describes enzymes that ligate a fatty acid to the corresponding fatty acyl-ACP.

[0209] In some embodiments, an acyl-ACP synthetase is used to catalyze the conversion of a fatty acid to a corresponding fatty acyl-ACP. An acyl-ACP synthetase is an enzyme capable of ligating a fatty acid to ACP to produce a fatty acid acyl-ACP. In some embodiments, an acyl-ACP synthetase can be used to catalyze the conversion of a fatty acid to a corresponding fatty acyl-ACP. In some embodiments, the acyl-ACP synthetase is a synthetase capable of utilizing a fatty acid as a substrate that has a chain length of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,

16, 17, 18, 19, 20, 21, 22, 23, or 24 carbon atoms. In one such embodiment, a recombinant microorganism described herein can include a heterologous acyl-ACP synthetase, which catalyzes the conversion of a fatty acid to a corresponding fatty acyl-ACP. In an exemplary embodiment, a recombinant microorganism disclosed herein includes at least one exogenous nucleic acid molecule which encodes an acyl-ACP synthetase that catalyzes the conversion of a saturated C_{6-C24} fatty acid to a corresponding saturated C_{6-C24} fatty acyl-ACP.

Fatty Acid Synthase Complex

[0210] The present disclosure describes enzymes that catalyze the elongation of a carbon chain in fatty acid.

[0211] In some embodiments, a fatty acid synthase complex is used to catalyze initiation and elongation of a carbon chain in a fatty acid. A "fatty acid synthase complex" refers to a group of enzymes that catalyzes the initiation and elongation of a carbon chain on a fatty acid. The ACP along with the enzymes in the fatty acid synthase (FAS) pathway control the length, degree of saturation, and branching of the fatty acids produced. The steps in this pathway are catalyzed by enzymes of the fatty acid biosynthesis (*fab*) and acetyl-CoA carboxylase (*acc*) gene families. Depending upon the desired product, one or more of these genes can be attenuated, expressed or over-expressed. In exemplary embodiments, one or more of these genes is over-expressed.

[0212] There are two principal classes of fatty acid synthases. Type I (FAS I) systems utilize a single large, multifunctional polypeptide and are common to both mammals and fungi (although the structural arrangement of fungal and mammalian synthases differ). The Type I FAS system is also found in the CMN group of bacteria (corynebacteria, mycobacteria, and nocardia). The Type II FAS (FAS II) is characterized by the use of discrete, monofunctional enzymes for fatty acid synthesis, and is found in archaea and bacteria.

[0213] The mechanism of FAS I and FAS II elongation and reduction is the substantially similar, as the domains of the FAS I multienzyme polypeptides and FAS II enzymes are largely conserved.

[0214] Fatty acids are synthesized by a series of decarboxylative Claisen condensation reactions from acetyl-CoA and malonyl-CoA. The steps in this pathway are catalyzed by enzymes of the fatty acid biosynthesis (*fab*) and acetyl-CoA carboxylase (*acc*) gene families. For a description of this pathway, see, *e.g.*, Heath *et al*, *Prog. Lipid Res.* 40:467, 2001, which is herein incorporated by reference in its entirety. Without being limited by theory, in bacteria, acetyl-CoA is carboxylated by acetyl-CoA carboxylase (Acc, a multi-

subunit enzyme encoded by four separate genes, accABCD), to form malonyl-CoA. In yeast, acetyl-CoA is carboxylated by the yeast equivalents of the acetyl-CoA carboxylase, encoded by ACC1 and ACC2. In bacteria, the malonate group is transferred to ACP by malonyl-CoA:ACP transacylase (FabD) to form malonyl-ACP. In yeast, a malonyl-palmitoyl transferase domain adds malonyl from malonyl-CoA to the ACP domain of the FAS complex. A condensation reaction then occurs, where malonyl-ACP merges with acyl-CoA, resulting in β -ketoacyl-ACP. In this manner, the hydrocarbon substrate is elongated by 2 carbons.

[0215] Following elongation, the β -keto group is reduced to the fully saturated carbon chain by the sequential action of a keto-reductase (KR), dehydratase (DH), and enol reductase (ER). The elongated fatty acid chain is carried between these active sites while attached covalently to the phosphopantetheine prosthetic group of ACP. First, the β -ketoacyl-ACP is reduced by NADPH to form β -hydroxyacyl-ACP. In bacteria, this step is catalyzed by β -ketoacyl-ACP reductase (FabG). The equivalent yeast reaction is catalyzed by the ketoreductase (KR) domain of FAS. β -hydroxyacyl-ACP is then dehydrated to form trans-2-enoyl-ACP, which is catalyzed by either β -hydroxyacyl-ACP dehydratase/isomerase (FabA) or β -hydroxyacyl-ACP dehydratase (FabZ) in bacteria or the dehydratase (DH) domain of FAS in yeast. NADPH-dependent trans-2-enoyl-ACP reductase I, II, or III (FabI, FabK, and FabL, respectively) in bacteria and the enol reductase (ER) domain of FAS in yeast reduces trans-2-enoyl-ACP to form acyl-ACP. Subsequent cycles are started by the condensation of malonyl-ACP with acyl-ACP by β -ketoacyl-ACP synthase I or β -ketoacyl-ACP synthase II (FabB and FabF, respectively, in bacteria or the β -ketoacyl synthase (KS) domain in yeast).

[0216] In some embodiments, a fatty acid synthase complex can be used to catalyze elongation of a fatty acyl-ACP to a corresponding fatty acyl-ACP with a two carbon elongation relative to the substrate.

Dehydrogenase

[0217] The present disclosure describes enzymes that catalyze the conversion of a fatty aldehyde to a fatty alcohol. In some embodiments, an alcohol dehydrogenase (ADH, Table 3 and Table 3a) is used to catalyze the conversion of a fatty aldehyde to a fatty alcohol. A number of ADHs identified from autotrophic organisms, *Pseudomonas fluorescens* NRRL B-1244 (Hou *et al.* 1983), *Pseudomonas butanovora* ATCC 43655 (Vangnai and Arp 2001), and *Acinetobacter sp.* strain M-1 (Tani *et al.* 2000), have shown to be active on short to medium-chain alkyl alcohols (C_2 to C_{14}). Additionally, commercially available ADHs from

Sigma, Horse liver ADH and Baker's yeast ADH have detectable activity for substrates with length C₁₀ and greater. The reported activities for the longer fatty alcohols may be impacted by the difficulties in solubilizing the substrates. For the yeast ADH from Sigma, little to no activity is observed for C₁₂ to C₁₄ aldehydes by (Tani *et al.* 2000), however, activity for C₁₂ and C₁₆ hydroxy -co-fatty acids has been observed (Lu *et al.* 2010). Recently, two ADHs were characterized from *Geobacillus thermodenitrificans* NG80-2, an organism that degrades C₁₅ to C₃₆ alkanes using the LadA hydroxylase. Activity was detected from methanol to 1-triacontanol (Go) for both ADHs, with 1-octanol being the preferred substrate for ADH2 and ethanol for ADH 1 (Liu *et al.* 2009).

[0218] The use of ADHs in whole-cell bioconversions has been mostly focused on the production of chiral alcohols from ketones (Ernst *et al.* 2005) (Schroer *et al.* 2007). Using the ADH from *Lactobacillus brevis* and coupled cofactor regeneration with isopropanol, Schroer *et al.* reported the production of 797 g of (R)-methyl-3 hydroxybutanoate from methyl acetoacetate, with a space time yield of 29 g/L/h (Schroer *et al.* 2007). Examples of aliphatic alcohol oxidation in whole-cell transformations have been reported with commercially obtained *S. cerevisiae* for the conversion of hexanol to hexanal (Presecki *et al.* 2012) and 2-heptanol to 2-heptanone (Cappaert and Larroche 2004).

Table 3. Exemplary alcohol dehydrogenase enzymes.

Organism	Gene Name	Accession No.
Bactrocera oleae (Olive fruit fly) (Dacus oleae)	ADH	Q9NAR7
Cupriavidus necator (Alcaligenes eutrophus) (Ralstonia eutropha)	adh	P14940
Drosophila adastola (Fruit fly) (Idiomya adastola)	Adh	Q00669
Drosophila affinisdisjuncta (Fruit fly) (Idiomya affinisdisjuncta)	Adh	P21518
Drosophila ambigua (Fruit fly)	Adh	P25139
Drosophila borealis (Fruit fly)	Adh	P48584
Drosophila differens (Fruit fly)	Adh	P22245
Drosophila equinoxialis (Fruit fly)	Adh	Q9NG42
Drosophila flavomontana (Fruit fly)	Adh	P48585

Organism	Gene Name	Accession No.
<i>Drosophila guanche</i> (Fruit fly)	Adh	Q09009
<i>Drosophila hawaiiensis</i> (Fruit fly)	Adh	P51549
<i>Drosophila heteroneura</i> (Fruit fly)	Adh	P21898
<i>Drosophila immigrans</i> (Fruit fly)	Adh	Q07588
<i>Drosophila insularis</i> (Fruit fly)	Adh	Q9NG40
<i>Drosophila lebanonensis</i> (Fruit fly) (<i>Scaptodrosophila lebanonensis</i>)	Adh	P10807
<i>Drosophila mauritiana</i> (Fruit fly)	Adh	P07162
<i>Drosophila madeirensis</i> (Fruit fly)	Adh	Q09010
<i>Drosophila mimica</i> (Fruit fly) (<i>Idiomvia mimica</i>)	Adh	Q00671
<i>Drosophila nigra</i> (Fruit fly) (<i>Idiomvia nigra</i>)	Adh	Q00672
<i>Drosophila orena</i> (Fruit fly)	Adh	P07159
<i>Drosophila pseudoobscura bogotana</i> (Fruit fly)	Adh	P84328
<i>Drosophila picticomis</i> (Fruit fly) (<i>Idiomvia picticornis</i>)	Adh	P23361
<i>Drosophila plamtibia</i> (Fruit fly)	Adh	P23277
<i>Drosophila paulistorum</i> (Fruit fly)	Adh	Q9U8S9
<i>Drosophila silvestris</i> (Fruit fly)	Adh	P23278
<i>Drosophila subobscura</i> (Fruit fly)	Adh	Q03384
<i>Drosophila teissieri</i> (Fruit fly)	Adh	P28484
<i>Drosophila tsacasi</i> (Fruit fly)	Adh	P51550
Fragaria ananassa (Strawberry)	ADH	PI7648
Malus domestica (Apple) (<i>Pyrus malus</i>)	ADH	P48977
<i>Scaptomyza albovittata</i> (Fruit fly)	Adh	P25988
<i>Scaptomyza crassifemur</i> (Fruit fly) (<i>Drosophila crassifemur</i>)	Adh	Q00670

Organism	Gene Name	Accession No.
<i>Sulfolobus</i> sp. (strain RC3)	adh	P50381
<i>Zaprionus tuberculatus</i> (Vinegar fly)	Adh	P51552
<i>Geobacillus stearothermophilus</i> (<i>Bacillus stearothermophilus</i>)	adh	P42327
<i>Drosophila mayaguana</i> (Fruit fly)	Adh, Adh2	P25721
<i>Drosophila melanogaster</i> (Fruit fly)	Adh, CG3481	P00334
<i>Drosophila pseudoobscura</i> (Fruit fly)	Adh, GA 17214	Q6LCE4
<i>Drosophila simulans</i> (Fruit fly)	Adh, GD23968	Q24641
<i>Drosophila yakuba</i> (Fruit fly)	Adh, GE19037	P26719
<i>Drosophila ananassae</i> (Fruit fly)	Adh, GF14888	Q50L96
<i>Drosophila erecta</i> (Fruit fly)	Adh, GG25120	P28483
<i>Drosophila grimshawi</i> (Fruit fly) (<i>Idiomya grimshawi</i>)	Adh, GH13025	P51551
<i>Drosophila willistoni</i> (Fruit fly)	Adh, GK 18290	Q05114
<i>Drosophila persimilis</i> (Fruit fly)	Adh, GL25993	P37473
<i>Drosophila sechellia</i> (Fruit fly)	Adh, GM 15656	Q9GN94
<i>Cupriavidus necator</i> (strain ATCC 17699 / H16 / DSM 428 / Stanier 337) (<i>Ralstonia eutropha</i>)	adh, HI6_A0757	Q0KDL6
<i>Mycobacterium tuberculosis</i> (strain CDC 1551 / Oshkosh)	adh, MT1581	P9WQC2
<i>Staphylococcus aureus</i> (strain MW2)	adh, MW0568	Q8NXU1
<i>Mycobacterium tuberculosis</i> (strain ATCC 25618 / H37Rv)	adh, Rv1530	P9WQC3
<i>Staphylococcus aureus</i> (strain N315)	adh, SA0562	Q7A742
<i>Staphylococcus aureus</i> (strain bovine RF122 / ET3-1)	adh, SAB0557	Q2YSX0
<i>Sulfolobus acidocaldarius</i> (strain ATCC 33909 / DSM 639 / JCM 8929 / NBRC 15157 / NCIMB	adh, Saci_2057	Q4J781

Organism	Gene Name	Accession No.
11770}		
<i>Staphylococcus aureus</i> (strain COL)	adh, SACOL0660	Q5HI63
<i>Staphylococcus aureus</i> (strain NCTC 8325)	adh, SAOUHSC_00608	Q2G0G1
<i>Staphylococcus aureus</i> (strain MRSA252)	adh, SAR0613	Q6GJ63
<i>Staphylococcus aureus</i> (strain MSSA476)	adh, SAS0573	Q6GBM4
<i>Staphylococcus aureus</i> (strain USA300)	adh, SAUSA300_0594	Q2FJ31
<i>Staphylococcus aureus</i> (strain Mu50 / ATCC 700699)	adh, SAV0605	Q99W07
<i>Staphylococcus epidermidis</i> (strain ATCC 12228)	adh, SE_0375	Q8CQ56
<i>Staphylococcus epidermidis</i> (strain ATCC 35984 / RP62A)	adh, SERP0257	Q5HRD6
<i>Sulfolobus solfatarius</i> (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2)	adh, SS02536	P39462
<i>Sulfolobus tokodaii</i> (strain DSM 16993 / JCM 10545 / NBRC 100140 / 7)	adh, STK_25770	Q96XE0
<i>Anas platyrhynchos</i> (Domestic duck) (<i>Anas boschas</i>)	ADH1	P30350
<i>Apteryx australis</i> (Brown kiwi)	ADH1	P49645
<i>Ceratitis capitata</i> (Mediterranean fruit fly) (<i>Tephritis capitata</i>)	ADH1	P48814
<i>Ceratitis cosyra</i> (Mango fruit fly) (<i>Trypeta cosyra</i>)	ADH1	Q70UN9
<i>Gallus</i> (Chicken)	ADH1	P23991
<i>Columba livia</i> (Domestic pigeon)	ADH1	P86883
<i>Coturnix japonica</i> (Japanese quail) (<i>Coturnix japonica</i>)	ADH1	P19631
<i>Drosophila hydei</i> (Fruit fly)	Adhl	P23236

Organism	Gene Name	Accession No.
Drosophila montana (Fruit fly)	Adhl	P48586
Drosophila mettleri (Fruit fly)	Adhl	P22246
Drosophila muileri (Fruit fly)	Adhl	P07161
Drosophila navojoa (Fruit fly)	Adhl	P12854
Geomys attwateri (Attwater's pocket gopher) (Geomys bursarius attwateri)	ADH1	Q9Z2M2
Geomys bursarius (Plains pocket gopher)	ADH1	Q64413
Geomys knoxjonesi (Knox Jones's pocket gopher)	ADH1	Q64415
Hordeum vulgare (Barley)	ADH1	P05336
Kluyveromyces marxianus (Yeast) (Candida kefir)	ADH1	Q07288
Zea mays (Maize)	ADH1	P00333
Mesocricetus auratus (Golden hamster)	ADH1	P86885
Pennisetum americanum (Pearl millet) (Pennisetum glaucum)	ADH1	P14219
Petunia hybrida (Petunia)	ADH1	P25141
Oryctolagus cuniculus (Rabbit)	ADH1	Q03505
Solanum tuberosum (Potato)	ADH1	P14673
Struthio camelus (Ostrich)	ADH1	P80338
Trifolium repens (Creeping white clover)	ADH1	P13603
Zea luxurians (Guatemalan teosinte) (Euchlaena luxurians)	ADH1	Q07264
Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast)	ADH1, ADC1 , YOL086C , O0947	P00330
Arabidopsis thaliana (Mouse-ear cress)	ADH1, ADH , Atlg77120 , F22K20.19	P06525
Schizosaccharomyces pombe (strain 972 / ATCC 24843) (Fission yeast)	adh1, adh, SPCC13B11.01	P00332

Organism	Gene Name	Accession No.
Drosophila laticola (Fruit fly)	Adhl, Adh-1	Q27404
Mus musculus (Mouse)	Adhl, Adh-1	P00329
Peromyscus maniculatus (North American deer mouse)	ADHL, ADH-1	P41680
Rattus norvegicus (Rat)	Adhl, Adh-1	P06757
Drosophila virilis (Fruit fly)	Adhl, Adh-1, GJ18208	B4M8Y0
Scheffersomyces stipitis (strain ATCC 58785 / CBS 6054 / NBRC 10063 / NRRL- Y-1 1545) (Yeast) (Pichia stipitis)	ADHL, ADH2, PICST __68558	000097
Aspergillus flavus (strain ATCC 200026 / FGSC A1120 / NRRL 3357 / JCM 12722 / SRRC 167)	adh1, AFLA __048690	P41747
Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987)	adh-1, B17C10.210, NCU01754	Q9P6C8
Candida albicans (Yeast)	ADHL, CAD	P43067
Oryza sativa subsp. japonica (Rice)	ADHL, DUPR1 1.3, Oslg02 10300 , LOC_Oslgl0480 , OsJ __032001	Q2R8Z5
Drosophila mojavensis (Fruit fly)	Adhl, Gil 7644	P09370
Kluyveromyces fragilis (strain ATCC 8585 / CBS 2359 / DSM 70799 / NBRC 1267 / NRRL Y-1 140 / WM37) (Yeast) (Candida sphaerica)	ADHL, KLLA0F21010g	P20369
Oryza sativa subsp. indica (Rice)	ADHL, Osl_034290	Q75ZX4
Pongo abelii (Sumatran orangutan) (Pongo pygmaeus abelii)	ADH1A	Q5RBP7
Homo sapiens (Human)	ADHL A, ADHL	P07327
Macaca mulatta (Rhesus macaque)	ADHL A, ADHL	P28469

Organism	Gene Name	Accession No.
Pan troglodytes (Chimpanzee)	ADH1B	Q5R1W2
Papio hamadryas (Hamadryas baboon)	ADH1B	P14139
Homo sapiens (Human)	ADH1B, ADH2	P00325
Homo sapiens (Human)	ADH1C, ADH3	P00326
Papio hamadryas (Hamadryas baboon)	ADH1C, ADH3	097959
Ceratitis capitata (Mediterranean fruit fly) (Tephritis capitata)	ADH2	P48815
Ceratitis cosyra (Mango fruit fly) (Trypeta cosyra)	ADH2	Q70UP5
Ceratitis rosa (Natal fruit fly) (Pterandras rosa)	ADH2	Q70UP6
Drosophila arizonae (Fruit fly)	Adh2	P27581
Drosophila buzzatii (Fruit fly)	Adh2	P25720
Drosophila hydei (Fruit fly)	Adh2	P23237
Drosophila montana (Fruit fly)	Adh2	P48587
Drosophila mulleri (Fruit fly)	Adh2	P07160
Drosophila wheeleri (Fruit fly)	Adh2	P24267
Entamoeba histolytica	ADH2	Q24803
Hordeum vulgare (Barley)	ADH2	P10847
Kluyveromyces marxianus (Yeast) (<i>Candida kefyr</i>)	ADH2	Q9P4C2
Zea mays (Maize)	ADH2	P04707
Oryza sativa subsp. indica (Rice)	ADH2	Q4R1E8
Solanum lycopersicum (Tomato) (Lycopersicon esculentum)	ADH2	P28032
Solanum tuberosum (Potato)	ADH2	P14674
Scheffersomyces stipitis (strain ATCC 58785 / CBS 6054 / NBRC 10063 / NRRL Y-1 1545) (Yeast) (Pichia stipitis)	ADH2, ADHL, PICST_27980	013309

Organism	Gene Name	Accession No.
<i>Arabidopsis thaliana</i> (Mouse-ear cress)	ADH2, ADH11, FDH1, At5g43940, MRH10.4	Q96533
<i>Saccharomyces cerevisiae</i> (strain ATCC 204508 / S288c) (Baker's yeast)	ADH2, ADR2, YMR303C, YM9952.05C	P00331
<i>Candida albicans</i> (strain SC5314 / ATCC MYA-2876) (Yeast)	ADH2, Ca41C10.04, Ca019.12579, Ca019.5113	094038
<i>Oryza sativa</i> subsp. <i>japonica</i> (Rice)	ADH2, DUPR11.L, Osllg0210500, LOC_Osllg10510	Q0ITW7
<i>Drosophila mojavensis</i> (Fruit fly)	Adh2, G117643	P09369
<i>Kluyveromyces lactis</i> (strain ATCC 8585 / CBS 2359 / DSM 70799 / NBRC 1267 / NRRL Y-140 / WM37) (Yeast) (<i>Candida sphaerica</i>)	ADH2, KLLA0F18260g	P49383
<i>Oryctolagus cuniculus</i> (Rabbit)	ADH2-1	046649
<i>Oryctolagus cuniculus</i> (Rabbit)	ADH2-2	046650
<i>Hordeum vulgare</i> (Barley)	ADH3	P10848
<i>Solanum tuberosum</i> (Potato)	ADH3	P14675
<i>Kluyveromyces lactis</i> (strain ATCC 8585 / CBS 2359 / DSM 70799 / NBRC 1267 / NRRL Y-140 / WM37) (Yeast) (<i>Candida sphaerica</i>)	ADH3, KLLA0B09064g	P49384
<i>Saccharomyces cerevisiae</i> (strain ATCC 204508 / S288c) (Baker's yeast)	ADH3, YMR083W, YM9582.08	P07246
<i>Homo sapiens</i> (Human)	ADH4	P08319
<i>Mus musculus</i> (Mouse)	Adh4	Q9QYY9
<i>Rattus norvegicus</i> (Rat)	Adh4	Q64563
<i>Struthio camelus</i> (Ostrich)	ADH4	P80468

Organism	Gene Name	Accession No.
<i>Kluyveromyces lactis</i> (strain ATCC 8585 / CBS 2359 / DSM 70799 / NBRC 1267 / NRRL Y-i 140 / WM37) (Yeast) (<i>Candida sphaerica</i>)	ADH4, KLLA0F13530g	P49385
<i>Schizosaccharomyces pombe</i> (strain 972 / ATCC 24843) (Fission yeast)	adh4, SPAC5H10.06c	Q09669
<i>Saccharomyces cerevisiae</i> (strain YJM789) (Baker's yeast)	ADH4, ZRG5, SCYJ818	A6ZTT5
<i>Saccharomyces cerevisiae</i> (strain ATCC 204508 / S288c) (Baker's yeast)	ADH4, ZRG5, YGL256W, NRC465	P10127
<i>Saccharomyces pastorianus</i> (Lager yeast) (<i>Saccharomyces cerevisiae</i> x <i>Saccharomyces eubayanus</i>)	ADH5	Q6XQ67
<i>Bos taurus</i> (Bovine)	ADH5	Q3ZC42
<i>Equus caballus</i> (Horse)	ADH5	P19854
<i>Mus musculus</i> (Mouse)	Adh5, Adh-2, Adh2	P28474
<i>Rattus norvegicus</i> (Rat)	Adh5, Adh-2, Adh2	P12711
<i>Qryctolagus cuniculus</i> (Rabbit)	ADH5, ADH3	019053
<i>Homo sapiens</i> (Human)	ADH5, ADHX, FDH	PI1766
<i>Dictyostelium discoideum</i> (Slime mold)	adb.5, DDB_G0281865	Q54TC2
<i>Saccharomyces cerevisiae</i> (strain ATCC 204508 / S288c) (Baker's yeast)	ADH5, YBR145W, YBR1122	P38113
<i>Homo sapiens</i> (Human)	ADH6	P28332
<i>Peromyscus maniculatus</i> (North American deer mouse)	ADH6	P41681
<i>Pongo abelii</i> (Sumatran orangutan) (<i>Pongo</i>)	ADH6	Q5R7Z8

Organism	Gene Name	Accession No.
pygmaeus abelii)		
<i>Rattus norvegicus</i> (Rat)	Adh6	Q5XI95
<i>Homo sapiens</i> (Human)	ADH7	P40394
<i>Rattus norvegicus</i> (Rat)	Adh7	P41682
<i>Mus musculus</i> (Mouse)	Adh7, Adh-3, Adh3	Q64437
<i>Mycobacterium tuberculosis</i> (strain CDC 1551 / Oshkosh)	adhA, MT1911	P9WQC0
Rhizobium meliloti (strain 1021) (<i>Ensifer meliloti</i>) (<i>Sinorhizobium meliloti</i>)	adhA, RA0704, SMal296	031186
<i>Mycobacterium tuberculosis</i> (strain ATCC 25618 / H37Rv)	adhA, Rv 1862	P9WQC1
<i>Zymomonas mobilis</i> subsp. <i>mobilis</i> (strain ATCC 31821 / ZM4 / CP4)	adhA, ZMO 1236	P20368
<i>Mycobacterium bovis</i> (strain ATCC BAA-935 / AF2 122/97)	adhB, Mb0784c	Q7U1B9
<i>Mycobacterium tuberculosis</i> (strain CDC 1551 / Oshkosh)	adhB, M10786	P9WQC6
<i>Mycobacterium tuberculosis</i> (strain ATCC 25618 / H37Rv)	adhB, Rv0761c, MTCY369.06C	P9WQC7
<i>Zymomonas mobilis</i> subsp. <i>mobilis</i> (strain ATCC 31821 / ZM4 / CP4)	adhB, ZMO 1596	P0DJA2
<i>Zymomonas mobilis</i> subsp. <i>mobilis</i> (strain ATCC 10988 / DSM 424 / LMG 404 / NCIMB 8938 / NRRL B-806 / ZM1)	adhB, Zmob_1 541	F8DVL8
<i>Mycobacterium tuberculosis</i> (strain CDC 1551 / Oshkosh)	adhD, MT3171	P9WQB8
<i>Mycobacterium tuberculosis</i> (strain ATCC 25618 / H37Rv)	adhD, Rv3086	P9WQB9
<i>Clostridium acetobutylicum</i> (strain ATCC 824 / DSM 792 / JCM 1419 / LMG 5710 / VKM B-	adliE, aad,	P33744

Organism	Gene Name	Accession No.
1787)	CA_P0162	
Escherichia coli (strain K12)	adhE , ana, b 1241 , JW1228	P0A9Q7
Escherichia coli 0157:H7	adhE , Z2016 , ECsl741	P0A9Q8
Rhodobacter sphaeroides (strain ATCC 17023 / 2.4.1 / NC1B 8253 / DSM 158)	adhI , RHOS4_11650, RSP_2576	P72324
Oryza sativa subsp. indica (Rice)	ADHIII , Osl_009236	A2XAZ3
Escherichia coli (strain K12)	adhP , yddN, b1478, JW1474	P39451
Geobacillus stearothermophilus (Bacillus stearothermophilus)	adhT	P12311
Emmericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) (Aspergillus nidulans)	alcA, AN8979	P08843
Emmericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) (Aspergillus nidulans)	alcA, AN3741	P54202
Emmericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) (Aspergillus nidulans)	alcC, adh3, AN2286	P07754
Arabidopsis thaliana (Mouse-ear cress)	Atlg22430, F12K8.22	Q9SK86
Arabidopsis thaliana (Mouse-ear cress)	Atlg22440 , F12K8.21	Q9SK87
Arabidopsis thaliana (Mouse-ear cress)	Atlg32780, F6N18.16	A1L4Y2
Arabidopsis thaliana (Mouse-ear cress)	Atlg64710, F130 11.3	Q8VZ49

Organism	Gene Name	Accession No.
Arabidopsis thaliana (Mouse-ear cress)	At4g22110, F1N20.210	Q0V7W6
Arabidopsis thaliana (Mouse-ear cress)	At5g24760, T4C12_30	Q8LEB2
Arabidopsis thaliana (Mouse-ear cress)	Ai5g42250, K5J14.5	Q9FH04
Zea mays (Maize)	FDH	P93629
Drosophila melanogaster (Fruit fly)	Fdh, gfd, ODH, CG6598	P46415
Bacillus subtilis (strain 168)	gbsB, BSU31050	P71017
Caenorhabditis elegans	H24K24.3	Q17335
Oryza sativa subsp. japonica (Rice)	Os02g08 15500, LOC_Os02g57040, OsJ_008550, P0643F09.4	QODWHI
Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)	Rv1895	007737
Caenorhabditis elegans	sodh-1, K12GIL3	Q17334
Caenorhabditis elegans	sodh-2, K12G11.4	G45687
Pseudomonas sp.	terPD	P33010
Escherichia coli (strain K12)	yiaY, b3589, JW5648	P37686
Moraxella sp. (strain TAE123)		P81786
Alligator mississippiensis (American alligator)		P80222
Catharantlius roseus (Madagascar periwinkle) (Vinca rosea)		P85440
Gadus morhua subsp. callarias (Baltic cod) (Gadus callarias)		P26325
Naja (Indian cobra)		P80512

Organism	Gene Name	Accession No.
Pisum sativum (Garden pea)		P12886
Pelophyiax perezii (Perez's frog) (Rana perezii)		P22797
Saara hardwickii (Indian spiny-tailed lizard) (Uromastix hardwickii)		P25405
Saara hardwickii (Indian spiny-tailed lizard) (Uromastix hardwickii)		P25406
Equus caballus (Horse)		P00327
Equus caballus (Horse)		P00328
Geobacillus stearothermophilus (Bacillus stearothermophilus)		P42328
Gadus morhua (Atlantic cod)		P81600
Gadus morhua (Atlantic cod)		P81601
Myxine glutinosa (Atlantic hagfish)		P80360
Octopus vulgaris (Common octopus)		P81431
Pisum sativum (Garden pea)		P80572
Saara hardwickii (Indian spiny-tailed lizard) (Uromastix hardwickii)		P80467
Scyliorhinus canicula (Small-spotted catshark) (Squalus canicula)		P86884
Sparas aurata (Gilt-head sea bream)		P79896

Table 3a. Additional Exemplar}' alcohol dehydrogenase enzymes

Organism	Accession No.
Helicoverpa armigera	A0A0F6Q2K7
Helicoverpa armigera	A0A0F6Q2W6
Helicoverpa armigera	AKD01723.1
Helicoverpa armigera	A0A0F6Q4H2

Organism	Accession No,
Helicoverpa armigera	A0A0F6Q1E8
Helicoverpa armigera	A0A0F6Q2K3
Helicoverpa armigera	A0A0F6Q4H7
Helicoverpa armigera	A0A0F6Q2J9
Helicoverpa armigera	A0A0F6Q0W0
Helicoverpa armigera	A0A0F6Q0V0
Helicoverpa armigera	A0A0F6Q1F1
Helicoverpa armigera	A0A0F6Q2X2
Helicoverpa armigera	A0A0F6Q412
Helicoverpa armigera	A0A0F6Q2X0
Helicoverpa assulta	A0A0F6Q2L9
Helicoverpa assulta	A0A0F6Q4K1
Helicoverpa assulta	A0A0F6Q4J7
Helicoverpa assulta	A0A0F6Q2Y5
Helicoverpa assulta	A0A0F6Q2Y1
Helicoverpa assulta	A0A0F6Q1G6
Helicoverpa assulta	A0A0F6Q2Y9
Helicoverpa assulta.	A0A0F6Q0X5
Helicoverpa assulta	A0A0F6Q2M3
Helicoverpa assulta	A0A0F6Q2L1
Helicoverpa assulta	A0A0F6Q1F9
Helicoverpa assulta	A0A0F6Q0W6
Helicoverpa assulta	A0A0F6Q1G9
Helicoverpa assulta	A0A0F6Q2L4
Helicoverpa assulta	A0A0F6Q2X6

Organism	Accession No,
Helico verpa assulta	A0A0F6Q1H3
Helicoverpa assulta	A0A0F6Q0X1
Bombyx mori	NP_001 188510.1
Aedes aegypti	XP_00 1655 103.1
Anopheles darlingi	ETN64 198.1
<i>Yarrowia lipolytica</i>	YALIOF09603g (FADH), YALIOD25 630g (ADH1), YALIOE17787g (ADH2), YALIOA16379g (ADH3), YALIOE15818g (ADH4), YALIOD02167g (ADH5), YALIOA15147g (ADH6), YALIOE07766g (ADH7)

[0219] In some embodiments, the present disclosure teaches a recombinant microorganism comprising a deletion, disruption, mutation, and or reduction in the activity of one or more endogenous (fatty) alcohol dehydrogenase selected from the group consisting of YALIOF09603g (FADH), YALIOD25630g (ADH1), YALIOE17787g (ADH2), YALIOA16379g (ADH3), YALIOE15818g (ADH4), YALIOD02167g (ADH5), YALIOA15147g (ADH6), YALIOE07766g (ADH7).

[0220] Thus, in some embodiments, the recombinant microorganism of the present disclosure will comprise deletions or other disruptions in endogenous genes encoding proteins exhibiting at least 100%, 99%, 98%, 97%, 95%, 94%, 93%, 92%, 91%, or 90% sequence identity with the proteins encoded by YALIOF09603g (FADH), YALIOD25630g (ADH1), YALIOE17787g (ADH2), YALIOA16379g (ADH3), YALIOE15818g (ADH4), YALIOD02167g (ADH5), YALIOA15147g (ADH6), and YALIOE07766g (ADH7).

[0221] Thus, in some embodiments, the recombinant microorganism of the present disclosure will comprise deletions in endogenous genes encoding proteins exhibiting at least 100%, 99%, 98%, 97%, 95%, 94%, 93%, 92%, 91%, or 90% sequence identity with uniprot database IDs Q6C297 (FADH), Q6C7T0 (ADH1), F2Z678 (ADH2), Q6CGT5 (ADH3), Q6C5R5 (ADH4), Q6CAT5 (ADH5), Q6CGX5 (ADH6), and Q6C7K3 (ADH7).

Alcohol Oxidase

[0222] The present disclosure describes enzymes **that** oxidize **fatty** alcohols **to** fatty-aldehydes.

[0223] In some embodiments, an alcohol oxidase (AOX) is used **to** catalyze the conversion of a fatty alcohol to a fatty aldehyde. Alcohol oxidases catalyze the conversion of alcohols **into** corresponding aldehydes (**or** ketones) **with** electron transfer via the use of molecular oxygen **to** form hydrogen peroxide as a by-product. AOX enzymes utilize flavin adenine dinucleotide (FAD) **as** an essential cofactor and regenerate with the help of oxygen in the reaction medium. Catalase enzymes may be coupled with the AOX to avoid accumulation of the hydrogen peroxide via catalytic conversion into water and oxygen.

[0224] Based on the substrate specificities, AOXs may be categorized into four groups: (a) short chain alcohol oxidase, (b) long chain alcohol oxidase, (c) aromatic alcohol oxidase, and (d) secondary alcohol oxidase (Goswami *et al.* 2013). Depending **on** the chain **length of the** desired substrate, some members **of these** four groups are better suited than others as candidates for evaluation.

[0225] Short chain alcohol oxidases (including but not limited **to** those **currently** classified as EC 1.1.3.13, Table 4) catalyze the oxidation of lower chain length alcohol substrates in the range of **C1-C8** carbons (van der Klei *et al.* 1991) (Ozimek *et al.* 2005). Aliphatic alcohol oxidases from methylotrophic yeasts such as *Candida boidinii* and *Komagataella pastoris* (formerly *Pichia pastoris*) catalyze the oxidation of **primary** alkanols to the corresponding aldehydes with a preference for **unbranched** short-chain aliphatic alcohols. The most broad substrate specificity is found for alcohol oxidase from the *Pichia pastoris* including **propargyl** alcohol, **2-chloroethanol**, **2-cyanoethanol** (Dienys *et al.* 2003). The major challenge encountered in alcohol oxidation is the high reactivity of the aldehyde product. Utilization of a two liquid phase system (water/solvent) can provide **in-situ** removal of the aldehyde product from the reaction phase before it is further converted to the acid. For example, **hexanal** production from hexanol using *Pichia pastoris* alcohol oxidase coupled **with** bovine liver catalase was achieved in a bi-phasic system by taking advantage **of** the presence of a stable alcohol oxidase **in** aqueous phase (Karra-Chaabouni *et al.* 2003). For example, alcohol oxidase from *Pichia pastoris* was able to oxidize aliphatic alcohols of C6 to C11 when used biphasic organic reaction system (Murray and Duff 1990). Methods for using alcohol oxidases **in** a biphasic system according to (Karra-Chaabouni *et al.* 2003) and (Murray and Duff 1990) are **incorporated** by reference in their entirety.

[0226] Long chain alcohol oxidases (including but not limited to those currently classified as EC 1.1.3.20; Table 5) include fatty alcohol oxidases, long chain fatty acid oxidases, and long chain fatty alcohol oxidases that oxidize alcohol substrates with carbon chain length of greater than six (Goswami *et al.* 2013). Banthorpe *et al.* reported a long chain alcohol oxidase purified from the leaves of *Tanacetum vulgare* that was able to oxidize saturated and unsaturated long chain alcohol substrates including hex-trans-2-en-1-ol and octan-1-ol (Banthorpe 1976) (Cardemil 1978). Other plant species, including *Simmondsia chinensis* (Moreau, R.A., Huang 1979), *Arahidopsis thaliana* (Cheng *et al.* 2004), and *Lotus japonicas* (Zhao *et al.* 2008) have also been reported as sources of long chain alcohol oxidases. Fatty alcohol oxidases are mostly reported from yeast species (Hommel and Ratledge 1990) (Vanhanen *et al.* 2000) (Hommel *et al.* 1994) (Kemp *et al.* 1990) and these enzymes play an important role in long chain fatty acid metabolism (Cheng *et al.* 2005). Fatty alcohol oxidases from yeast species that degrade and grow on long chain alkanes and fatty acid catalyze the oxidation of fatty alcohols. Fatty alcohol oxidase from *Candida tropicalis* has been isolated as microsomal cell fractions and characterized for a range of substrates (Eirich *et al.* 2004) (Kemp *et al.* 1988) (Kemp *et al.* 1991) (Mauersberger *et al.* 1992). Significant activity is observed for primary alcohols of length Cs to C₁₆ with reported KM in the 10-50 µM range (Eirich *et al.* 2004). Alcohol oxidases described may be used for the conversion of medium chain aliphatic alcohols to aldehydes as described, for example, for whole-cells *Candida hoidinii* (Gabelman and Luzio 1997), and *Pichia pastoris* (Duff and Murray 1988) (Murray and Duff 1990). Long chain alcohol oxidases from filamentous fungi were produced during growth on hydrocarbon substrates (Kumar and Goswami 2006) (Savitha and Ratledge 1991). The long chain fatty alcohol oxidase (LjFAOI) from *Lotus japonicas* has been heterologously expressed in *E. coli* and exhibited broad substrate specificity for alcohol oxidation including 1-dodecanol and 1-hexadecanol (Zhao *et al.* 2008).

Table 4. Alcohol oxidase enzymes capable of oxidizing short chain alcohols (EC 1.1.3.13)

Organism	Gene names	Accession No.
Komagataella pastoris (strain ATCC 76273 / CBS 7435 / CECT 11047 / NRRL Y-11430 / Wegner 21-1) (Yeast) (<i>Pichia pastoris</i>)	AOX1 PP7435_Chr4-0130	F2QY27
Komagataella pastoris (strain GS115 / ATCC 20864) (Yeast) (<i>Pichia pastoris</i>)	AOX1 PAS_chr4_0821	P04842

Organism	Gene names	Accession No.
Komagataella pastoris (strain ATCC 76273 / CBS 7435 / CECT 11047 / NRRL Y-1430 / Wegner 21-1) (Yeast) (Pichia pastoris)	AOX2 PP7435 __Chr4-0863	F2R038
Komagataella pastoris (strain GS115 / ATCC 20864) (Yeast) (Pichia pastoris)	AOX2 PAS_chr4_0152	C4R702
Candida boidinii (Yeast)	AOD1	Q00922
Pichia angusta (Yeast) (Hansenula polymorpha)	MOX	P04841
Thanatephoms cucumeris (strain AGI-IB / isolate 7/3/14) (Lettuce bottom rot fungus) (Rhizoctonia solani)	AOD1 BN14_10802	M5CC52
Thanatephoms cucumeris (strain AGI-IB / isolate 7/3/14) (Lettuce bottom rot fungus) (Rhizoctonia solani)	MOX BN14_12214	M5CF32
Thanatephoms cucumeris (strain AGI-IB / isolate 7/3/14) (Lettuce bottom rot fungus) (Rhizoctonia solani)	AOD1 BN14_10691	M5CAV1
Thanatephoms cucumeris (strain AGI-IB / isolate 7/3/14) (Lettuce bottom rot fungus) (Rhizoctonia solani)	AOD1 BN14_09479	M5C7F4
Thanatephoms cucumeris (strain AGI-IB / isolate 7/3/14) (Lettuce bottom rot fungus) (Rhizoctonia solani)	AOD1 BN14_10803	M5CB66
Thanatephoms cucumeris (strain AGI-IB / isolate 7/3/14) (Lettuce bottom rot fungus) (Rhizoctonia solani)	AOD1 BN14_09900	M5C9N9
Thanatephoms cucumeris (strain AGI-IB / isolate 7/3/14) (Lettuce bottom rot fungus) (Rhizoctonia solani)	AOD1 BN14_08302	M5C2L8
Thanatephoms cucumeris (strain AGI-IB / isolate 7/3/14) (Lettuce bottom rot fungus) (Rhizoctonia solani)	MOX BN14_09408	M5C784

Organism	Gene names	Accession No.
Thanatephorus cucumeris (strain AG1-IB / isolate 7/3/14) (Lettuce bottom rot fungus) (Rhizoctonia solani)	MOX BN14_09478	M5C8F8
Thanatephonis cucumeris (strain AG1-IB / isolate 7/3/14) (Lettuce bottom rot fungus) (Rhizoctonia solani)	AOD1 BN14_11356	M5CH40
Ogataea henricii	AOD1	A5LGF0
Candida methanosorbosa	AOD1	A5LGE5
Candida methanolovescens	AOD1	A5LGE4
Candida succiphila	AOD1	A5LGE6
Aspergillus niger (strain CBS 513.88 / FGSC A1513)	Anl5g02200	A2R501
Aspergillus niger (strain CBS 513.88 / FGSC A1513)	Anl8g05480	A2RB46
Moniliophthora perniciosa (Witches'-broom disease fungus) (Marasmius pernicius)		I7CMK2
Candida cariosilignicola	AOD1	A5LGE3
Candida pignaliae	AOD1	A5LGE1
Candida pignaliae	AOD2	A5LGE2
Candida sonorensis	AOD1	A5LGD9
Candida sonorensis	AOD2	A5LGE0
Pichia naganishii	AOD1	A5LGF2
Ogataea minuta	AOD1	A5LGF1
Ogataea philodendra	AOD1	A5LGF3
Ogataea wickerhamii	AOD1	A5LGE8
Kuraishia capsulate	AOD1	A5LGE7
Talaromyces stipitatus (strain ATCC 10500 / CBS 375.48 / QM 6759 / NRRL 1006)	TSTA_021940	B8MHF8

Organism	Gene names	Accession No.
(<i>Penicillium stipitatum</i>)		
<i>Talaromyces stipitatus</i> (strain ATCC 10500 / CBS 375.48 / QM 6759 / NRRL 1006) (<i>Penicillium stipitatum</i>)	TSTA_065150	B8LTH7
<i>Talaromyces stipitatus</i> (strain ATCC 10500 / CBS 375.48 / QM 6759 / NRRL 1006) (<i>Penicillium stipitatum</i>)	TSTA_065150	B8LTH8
<i>Talaromyces stipitatus</i> (strain ATCC 10500 / CBS 375.48 / QM 6759 / NRRL 1006) (<i>Penicillium stipitatum</i>)	TSTA_000410	B8MSB1
<i>Ogataea glucozyma</i>	AOD1	A5LGE9
<i>Ogataea parapolyomorpha</i> (strain DL-1 / ATCC 26012 / NRRL Y-7560) (Yeast) (<i>Hansenula polymorpha</i>)	HPODL_03886	W1QCJ3
<i>Gloeophyllum trabeum</i> (Brown rot fungus)	AOX	A8DPS4
<i>Pichia angusta</i> (Yeast) (<i>Hansenula polymorpha</i>)	mox1	A6PZG8
<i>Pichia trehalophila</i>	AOD1	A5LGF4
<i>Pichia angusta</i> (Yeast) (<i>Hansenula polymorpha</i>)	mox 1	A6PZG9
<i>Pichia angusta</i> (Yeast) (<i>Hansenula polymorpha</i>)	mox1	A6PZG7
<i>Ixodes scapularis</i> (Black-legged tick) (Deer tick)	IscWJSCWO 17898	B7PIZ7

Table 5. Alcohol oxidase enzymes capable of oxidizing long chain alcohols including fatty alcohols (EC 1.1.3.20)

Organism	Gene names	Accession No.
<i>Lotus japonicus</i> (<i>Lotus corniculatus</i> var. <i>japonicus</i>)	FAO1	B5WWZ8
<i>Arabidopsis thaliana</i> (Mouse-ear cress)	FAO1 At1g03990 F21M11.7	Q9ZWB9

Organism	Gene names	Accession No.
<i>Lotus japonicus</i> (<i>Lotus comiculatus</i> var. <i>japonicus</i>)	FA02	B5WWZ9
<i>Arabidopsis thaliana</i> (Mouse-ear cress)	FA03 At3g23410 MLM24.14 MLM24.23	Q9LW56
<i>Arabidopsis thaliana</i> (Mouse-ear cress)	FA04A At4g19380 T5K18.160	065709
<i>Arabidopsis thaliana</i> (Mouse-ear cress)	FA04B At4g28570 T5F17.20	Q94BP3
<i>Microbotryum violaceum</i> (strain p1A1 Lamole) (Anther smut fungus) (<i>Ustilago violacea</i>)	MVLG_06864	U5HIL4
<i>Ajellomyces dermatitidis</i> ATCC 26199	BDFG_03507	T5BNQ0
<i>Gibberella zeae</i> (strain PH-1 / ATCC MYA-4620 / FGSC 9075 / NRRL, 31084) (Wheat head blight fungus) (<i>Fusarium graminearum</i>)	FG06918.1 FGSG_06918	I1RS14
<i>Pichia sorbitophila</i> (strain ATCC MYA-4447 / BCRC 22081 / CBS 7064 / NBRC 10061 / NRRL Y-12695) (Hybrid yeast)	PisoO_004410 GNLVR501_PISO0K16268g GNLVR501_PISO0L16269g	G8Y5E1
<i>Emmericia nidulans</i> (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) (<i>Aspergillus nidulans</i>)	AN0623.2 AN1A_00623	Q5BFQ7
<i>Pyrenophora tritici-repentis</i> (strain Pt-1C-BFP) (Wheat tan spot fungus) (<i>Drechslera tritici-repentis</i>)	PTRG_10154	B2WJW5
<i>Paracoccidioides lutzii</i> (strain ATCC MYA-826 / PbOI) (<i>Paracoccidioides brasiliensis</i>)	PAAG_09117	C1HEC6
<i>Candida parapsilosis</i> (strain CDC 317 / ATCC MYA-4646) (Yeast) (<i>Monilia parapsilosis</i>)	CPAR2_204420	G8BG15
<i>Pseudozyma brasiliensis</i> (strain GHG001) (Yeast)	PSEUBRA_SCAF2g03010	V5GPS6

Organism	Gene names	Accession No.
<i>Candida parapsilosis</i> (strain CDC 317 / ATCC MYA-4646) (Yeast) (<i>Monilia parapsilosis</i>)	CPAR2_204430	G8BG16
<i>Sclerotinia borealis</i> F-4157	SBOR_5750	W9CDE2
<i>Sordaria macrospora</i> (strain ATCC MYA-333 / DSM 997 / K(L3346) / K-hell)	SMAC_06361	F7W6K4
<i>Sordaria macrospora</i> (strain ATCC MYA-333 / DSM 997 / K(L3346) / K-hell)	SMAC_01933	F7VSA1
<i>Meyerozyma guilliermondii</i> (strain ATCC 6260 / CBS 566 / DSM 6381 / K(M 1539 / NBRC 10279 / NRRL Y-324) (Yeast) (<i>Candida guilliermondii</i>)	PGUG_03467	A5DJL6
<i>Trichophyton rubrum</i> CBS 202.88	HI07_00669	A0A023ATC5
<i>Arthrobotrys oligospora</i> (strain ATCC 24927 / CBS 115.81 / DSM 1491) (Nematode-trapping fungus) (<i>Didymozophaga oligospora</i>)	AOL_s00097g516	G1XJI9
<i>Scheffersomyces stipitis</i> (strain ATCC 58785 / CBS 6054 / NBRC 10063 / NRRL Y-1 1545) (Yeast) (<i>Pichia stipitis</i>)	FAOI PICST_90828	A3LYX9
<i>Scheffersomyces stipitis</i> (strain ATCC 58785 / CBS 6054 / NBRC 10063 / NRRL Y-1 1545) (Yeast) (<i>Pichia stipitis</i>)	FA02 PICST_32359	A3LW61
<i>Aspergillus oryzae</i> (strain 3.042) (Yellow koji mold)	Ao3042_09114	I8TL25
<i>Fusarium oxysporum</i> (strain Fo5176) (<i>Fusarium vascular wilt</i>)	FOXB_17532	F9GFU8
<i>Rhizopus delemar</i> (strain RA 99-880 / ATCC MYA-4621 / FGSC 9543 / NRRL 43880) (<i>Mucormycosis agent</i>) (<i>Rhizopus arrhizus</i> var. <i>delemar</i>)	RO3G_08271	I1C536

Organism	Gene names	Accession No.
Rhizopus delemar (strain RA 99-880 / ATCC MYA-4621 / FGSC 9543 / NRRL 43880) (Mucormycosis agent) (Rhizopus arrhizus var. delemar)	R03G_00154	I1BGX0
Fusarium oxysporum (strain Fo5176) (Fusarium vascular wilt)	FOXB_07532	F9FMA2
Penicillium roqueforti	PROQFM1 64_S02g00 1772	W6QPY1
Aspergillus clavatus (strain ATCC 1007 / CBS 513.65 / DSM 816 / NCTC 3887 / NRRL 1)	ACLA_018400	A1CNB5
Arthroderma otae (strain ATCC MYA-4605 / CBS 113480) (Microsporum canis)	MCYG_08732	C5G1B0
Trichophyton tonsurans (strain CBS 112818) (Scalp ringworm fungus)	TESG_07214	F2S8I2
Colletotrichum higginsianum (strain IMI 349063) (Crucifer anthracnose fungus)	CH063_13441	H1VUE7
Ajellomyces capsulatus (strain H143) (Darling's disease fungus) (Histoplasma capsulation)	HCDG_07658	C6HN77
Trichophyton rubrum (strain ATCC MYA-4607 / CBS 118892) (Athlete's foot fungus)	TERG_08235	F2T096
Cochliobolus heterostrophus (strain C5 / ATCC 48332 / race O) (Southern corn leaf blight fungus) (Bipolaris maydis)	COCHEDRAFT_1201414	M2UMT9
Candida orthopsilosis (strain 90-125) (Yeast)	CORT_0D04510	H8X643
Candida orthopsilosis (strain 90-125) (Yeast)	CORT_0D04520	H8X644
Candida orthopsilosis (strain 90-125) (Yeast)	CORT_0D04530	H8X645

Organism	Gene names	Accession No.
<i>Pseudozyma aphidis</i> DSM 70725	PaG_03027	W3VP49
<i>Coccidioides posadasii</i> (strain C735) (Valley fever fungus)	CPC735_000380	C5P005
<i>Magnaporthe oryzae</i> (strain PIS 1) (Rice blast fungus) (<i>Pyricularia oryzae</i>)	OOW_P131scaffold01214g15	L7IZ92
<i>Neurospora tetrasperma</i> (strain FGSC 2508 / ATCC MYA-4615 / P0657)	NEUTE1DRAFT_82541	F8MKD1
<i>Hypocrea virens</i> (strain Gv29-8 / FGSC 10586) (<i>Gliocladium virens</i>) (<i>Trichoderma virens</i>)	TRIVIDRAFT__54537	G9MMY7
<i>Hypocrea virens</i> (strain Gv29-8 / FGSC 10586) (<i>Gliocladium virens</i>) (<i>Trichoderma virens</i>)	TRIVIDRAFT__53801	G9MT89
<i>Aspergillus niger</i> (strain CBS 513.88 / FGSC A1513)	An01g09620	A2Q9Z3
<i>Verticillium dahliae</i> (strain VdLs.17 / ATCC MYA-4575 / FGSC 10137) (<i>Verticillium wilt</i>)	VDAG_05780	G2X6J8
<i>Ustilago maydis</i> (strain 521 / FGSC 9021) (Corn smut fungus)	UM02023.1	Q4PCZ0
<i>Fusarium oxysporum</i> f. sp. <i>lycopersici</i> MN25	FOWG_13006	W9LNI9
<i>Fusarium oxysporum</i> f. sp. <i>lycopersici</i> MN25	FQWG__02542	W9N9Z1
<i>Candida tropicalis</i> (Yeast)	FAOI	Q6Q1R6
<i>Magnaporthe oryzae</i> (strain 70-15 / ATCC MYA-4617 / FGSC 8958) (Rice blast fungus) (<i>Pyricularia oryzae</i>)	MGG_11317	G4MVK1
<i>Candida tropicalis</i> (Yeast)	faat	Q9P8D9
<i>Candida tropicalis</i> (Yeast)	FA02a	Q6QIR5

Organism	Gene names	Accession No.
Phaeosphaeria nodorum (strain SN15 / ATCC MYA-4574 / FGSC 10173) (Glume blotch fungus) (Septoria nodorum)	SNOG_02371	Q0V0U3
Candida tropicalis (Yeast)	FA02b	Q6QIR4
Pestalotiopsis fici W106-1	PFICI_11209	W3WU04
Magnaporthe oryzae (strain Y34) (Rice blast fungus) (Pyricularia oryzae)	OOU_Y34scaffold00240g5_7	L7IFT5
Pseudogymnoascus destructans (strain ATCC MYA-4855 / 20631-21) (Bat white-nose syndrome fungus) (Geomyces destructans)	GMDG_01756	L8G0G6
Pseudogymnoascus destructans (strain ATCC MYA-4855 / 20631-21) (Bat white-nose syndrome fungus) (Geomyces destructans)	GMDG_04950	L8GCY2
Mycosphaerella fijiensis (strain CIRAD86) (Black leaf streak disease fungus) (Pseudocercospora fijiensis)	MYCFIDRAFT_52380	M2Z831
Bipolaris oryzae ATCC 44560	COCMIDRAFT_84580	W7A018
Cladophialophora psammophila CBS 110553	AIO5_08147	W9WTM9
Fusarium oxysporum f. sp. melonis 26406	FOMG_05173	X0AEE6
Fusarium oxysporum f. sp. melonis 26406	FOMG_17829	W9ZBB7
Cyphellophora europaea CBS 101466	HMPREF1541_02174	W2S2S5
Aspergillus kawachii (strain NBRC 4308) (White koji mold) (Aspergillus awamori var. kawachi)	AKAW_00147	G7X626
Aspergillus terreus (strain NIH 2624 / FGSC A1156)	ATEG_05086	Q0CMJ8

Organism	Gene names	Accession No.
<i>Coccidioides immitis</i> (strain RS) (Valley fever fungus)	CIMG_02987	J3KAI8
<i>Ajellomyces dermatitidis</i> (strain ER-3 / ATCC MYA-2586) (<i>Blastomyces dermatitidis</i>)	BDCG_04701	C5GLS5
<i>Fusarium oxysporum</i> f. sp. cubense (strain race 1) (Panama disease fungus)	FGC1_g10013865	N4U732
<i>Rhodotorula glutinis</i> (strain ATCC 204091 / IIP 30 / MTCC 1151) (Yeast)	RIG_00643	G0SVU8
<i>Aspergillus niger</i> (strain ATCC 1015 / CBS 113.46 / FGSC A1144 / LSHB Ac4 / NCTC 3858a / NRRL 328 / USDA 3528.7)	ASPNI DRAFT_35778	G3XTM6
<i>Candida cloacae</i>	fao1	Q9P8D8
<i>Candida cloacae</i>	fao2	Q9P8D7
<i>Fusarium oxysporum</i> f. sp. cubense (strain race 1) (Panama disease fungus)	FOC1_g10006358	N4TUH3
<i>Candida albicans</i> (strain SC5314 / ATCC MYA-2876) (Yeast)	FAO1_Ca019.13562 orf19.13562	Q59RS8
<i>Candida albicans</i> (strain SC5314 / ATCC MYA-2876) (Yeast)	FAO1_Ca019.6143 orf19.6143	Q59RP0
<i>Chaetomium thermophilum</i> (strain DSM 1495 / CBS 144.50 / IMI 039719)	CTHT_0018560	G0S2U9
<i>Mucor circinelloides</i> f. <i>circinelloides</i> (strain 1006PhL) (Mucormycosis agent) (<i>Calypotromyces circinelloides</i>)	HMPREF 1544_05296	S2JDN0
<i>Mucor circinelloides</i> f. <i>circinelloides</i> (strain 1006PhL) (Mucormycosis agent) (<i>Calypotromyces circinelloides</i>)	HMPREF 1544_05295	S2JYP5
<i>Mucor circinelloides</i> f. <i>circinelloides</i> (strain 1006PhL) (Mucormycosis agent) (<i>Calypotromyces circinelloides</i>)	HMPREF 1544_06348	S2JVK9

Organism	Gene names	Accession No.
<i>Botryotinia fuckeliana</i> (strain BcDWI) (Noble rot fungus) (<i>Botrytis cinerea</i>)	BcDWI_6807	M7UD26
<i>Podospora anserina</i> (strain S / ATCC MYA-4624 / DSM 980 / FGSC 10383) (<i>Pleurage anserina</i>)	PODANS_5_13040	B2AFD8
<i>Neosartorya fumigata</i> (strain ATCC MYA-4609 / Af293 / CBS 101355 / FGSC A1100) (<i>Aspergillus fumigatus</i>)	AFUA_1G171_10	Q4WR91
<i>Fusarium oxysporum</i> f. sp. vasinfectum 25433	FOTG_00686	X0MEE6
<i>Fusarium oxysporum</i> f. sp. vasinfectum 25433	FOTG_12485	X0LE98
<i>Trichophyton interdigitale</i> H6	H101_06625	A0A022U717
<i>Beauveria bassiana</i> (strain ARSEF 2860) (White muscardine disease fungus) (<i>Tritirachium shioetae</i>)	BBA_04100	J4UNY3
<i>Fusarium oxysporum</i> f. sp. radicis-lycopersici 26381	FOCG_00843	X0GQ62
<i>Fusarium oxysporum</i> f. sp. radicis-lycopersici 26381	FOCG_15170	X0F4T1
<i>Neurospora tetrasperma</i> (strain FGSC 2509 / P0656)	NEUTE2DRAFT_88670	G4UNN6
<i>Pseudozyma hubeiensis</i> (strain SY62) (Yeast)	PHSY_000086	R9NVU1
<i>Lodderomyces elongisporus</i> (strain ATCC 11503 / CBS 2605 / JCM 1781 / NBRC 1676 / NRRL YB-4239) (Yeas!) (<i>Saccharomyces elongisporus</i>)	LELG_03289	A5E102
<i>Malassezia globosa</i> (strain ATCC MYA-4612 / CBS 7966) (Dandruff-associated fungus)	MGL_3855	A8QAY8
<i>Byssoschlamys spectabilis</i> (strain No. 5 /	PVAR5_7014	V5GBL6

Organism	Gene names	Accession No.
NBRC 109023) (<i>Paecilomyces variotii</i>)		
<i>Ajellomyces capsulatus</i> (strain H88) (Darling's disease fungus) (<i>Histoplasma capsulatum</i>)	HCEG_03274	F0UF47
<i>Trichosporon asahii</i> var. <i>asahii</i> (strain ATCC 90039 / CBS 2479 / JCM 2466 / KCTC 7840 / NCYC 2677 / UAMH 7654) (Yeast)	A1Q1_03669	J6FBP4
<i>Penicillium oxalicum</i> (strain 114-2 / CGMCC 5302) (<i>Penicillium decumbens</i>)	PDE_00027	S7Z8U8
<i>Fusarium oxysporum</i> f. sp. <i>conglutinans</i> race 2 54008	FOPG_02304	X0IBE3
<i>Fusarium oxysporum</i> f. sp. <i>conglutinans</i> race 2 54008	FOPG_13066	X0H540
<i>Fusarium oxysporum</i> f. sp. <i>raphani</i> 54005	FOQG_00704	X0D1G8
<i>Fusarium oxysporum</i> f. sp. <i>raphani</i> 54005	FOQG_10402	X0C482
<i>Metarhizium acridum</i> (strain CQMa 102)	MAC_03115	E9DZR7
<i>Arthroderma benhamiae</i> (strain ATCC MYA-4681 / CBS 112371) (<i>Trichophyton mentagrophytes</i>)	ARB_02250	D4B1C1
<i>Fusarium oxysporum</i> f. sp. <i>cubense</i> tropical race 4 54006	FOIG_12161	X0JFI6
<i>Fusarium oxysporum</i> f. sp. <i>cubense</i> tropical race 4 54006	FOIG_12751	X0JDU5
<i>Cochliobolus heterostrophus</i> (strain C4 / ATCC 48331 / race T) (Southern corn leaf blight fungus) (<i>Bipolaris maydis</i>)	COCC4DRAFT_52836	N4WZZ0
<i>Trichosporon asahii</i> var. <i>asahii</i> (strain	A1Q2_00631	K1VZW1

Organism	Gene names	Accession No.
CBS 8904) (Yeast)		
Mycosphaerella graminicola (strain CBS 115943 / IP0323) (Speckled leaf blotch fungus) (Septoria tritici)	MYCGRDRAFT_37086	F9X375
Botryotinia fiickehana (strain T4) (Noble rot fungus) (Botrytis cinerea)	BofuT4_P072020.1	G2XQ18
Metarhizium anisopliae (strain ARSEF 23 / ATCC MYA-3075)	MAA_05783	E9F0I4
Cladophialophoracamonii CBS 160.54	G647_05801	V9DAR1
Coccidioides posadasii (strain RMSCC 757 / Silveira) (Valley fever fungus)	CPSG_09174	E9DH75
Rhodosporidium toruloides (strain NP11) (Yeast) (Rhodotorula gracilis)	RHTO_06879	M7X159
Puccinia graminis f. sp. tritici (strain CRL 75-36-700-3 / race SCCL) (Black stem rust fungus)	PGTG_10521	E3KIL8
Trichophyton rubrum CBS 288.86	H103_00624	A0A022WG28
Colletotrichum fioriniae PJ7	CFIO01_08202	A0A010RKZ4
Trichophyton rubrum CBS 289.86	H104_00611	A0A022XB46
Cladophialophora yegresii CBS 114405	AIO7_02579	W9WC55
Colletotrichum orbiculare (strain 104-T / ATCC 96160 / CBS 514.97 / LARS 414 / MAFF 240422) (Cucumber anthracnose fungus) (Colletotrichum lagenarium)	Cob_10151	N4VFP3
Drechslerella stenobrocha 248	DRE_03459	W7IDL6
Neosartorya fumigata (strain CEA10 / CBS 144.89 / FGSC A 1163) (Aspergillus fumigatus)	AFUB_016500	B0XP90
Thielavia terrestris (strain ATCC 38088 / NRRL 8126) (Acremonium	THIE_2117674	G2R8H9

Organism	Gene names	Accession No.
alabamense)		
Gibberellafujikuroi (strain CBS 195.34 / IMI 58289 / NRRL A-683 1) (Bakanae and foot rot disease fungus) (Fusarium fujikuroi)	FFUJ_02948	S0DZP7
Gibberellafujikuroi (strain CBS 195.34 / IMI 58289 / NRRL A-683 1) (Bakanae and foot rot disease fungus) (Fusarium fujikuroi)	FFUJ_12030	S0EMC6
Aspergillus flaws (strain ATCC 200026 / FGSC A1120 / NRRL 3357 / JCM 12722 / SRRC 167)	AFLA_109870	B8N941
Togninia minima (strain UCR-PA7) (Esca disease fungus) (Phaeoacremonium aleophilum)	UCRPA7_1719	R8BTZ6
Ajellomyces dermatitidis (strain ATCC 18188 / CBS 674.68) (Blastomyces dermatitidis)	BDDG_09783	F2TUC0
Macrophoma phaseolina (strain MS6) (Charcoal rot fungus)	MPH_10582	K2RHA5
Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987)	NCU08977	Q7S2Z2
Neosartorya fischeri (strain ATCC 1020 / DSM 3700 / FGSC A1164 / NRRL 181) (Aspergillus fischerianus)	NFIA_008260	A1D156
Fusarium pseudograminearum (strain CS3096) (Wheat and barley crown-rot fungus)	FPSE_11742	K3U9J5
Spathaspora passalidarum (strain NRRL Y-27907 / 11-Y1)	SPAPADRAFT_54193	G3AJP0
Spathaspora passalidarum (strain NRRL Y-27907 / 11-Y1)	SPAPADRAFT_67198	G3ANX7

Organism	Gene names	Accession No.
Trichophyton verrucosum (strain HKJ 0517)	TRV_07960	D4DL86
Arthroderma gypsenm (strain ATCC MYA-4604 / CBS 118893) (Microsporum gypseum)	MGYG_07264	E4V2J0
Hypocrea jecorina (strain QM6a) (Trichoderma reesei)	TRIREDRAFT_43893	G0R7P8
Trichophyton rubrum MR 1448	H110_00629	A0A022Z1G4
Aspergillus ruber CBS 135680	EURHEDRAFT_5 12 125	A0A017SPR0
Glarea lozoyensis (strain ATCC 20868 / MF5171)	GLAREA_04397	S3D6C1
Setosphaeria turcica (strain 28A) (Northern leaf blight fungus) (Exserohilum turcicum)	SETTUDRAFT_20639	R0K6H8
Paracoccidioides brasiliensis (strain Pbl8)	PADG_06552	C1GH16
Fusarium oxysporum Fo47	FOZG_13577	W9JPG9
Fusarium oxysporum Fo47	FOZG_05344	W9KPH3
Trichophyton rubrum MR1459	H113_00628	A0A022ZY09
Penicillium marneffei (strain ATCC 18224 / CBS 334.59 / QM 7333)	PMAA_075740	B6QBY3
Sphaerulina musiva (strain SO2202) (Poplar stem canker fungus) (Septoria musiva)	SEPMUDRAFT_154026	M3DAK6
Gibberella moniliformis (strain M3125 / FGSC 7600) (Maize ear and stalk rot fungus) (Fusarium verticillioides)	FVEG_10526	W7N4P8
Gibberella moniliformis (strain M3125 / FGSC 7600) (Maize ear and stalk rot fungus) (Fusarium verticillioides)	FVEG_08281	W7MVR9
Pseudozyma antarctica (strain T-34)	PANT_22d00298	M9MGF2

Organism	Gene names	Accession No.
(Yeast) (<i>Candida antartica</i>)		
<i>Paracoccidioides brasiliensis</i> (strain Pb03)	PABG_07795	C0SJD4
<i>Rhizophagus irregularis</i> (strain DAOM 181602 / DAOM 197198 / MUCL 43194) (Arbuscular mycorrhizal fungus) (<i>Glomus intraradices</i>)	GLOINDRAFT_82554	U9TF61
<i>Penicillium chrysogenum</i> (strain ATCC 28089 / DSM 1075 / Wisconsin 54-1255) (<i>Penicillium notatum</i>)	Pc21g23700 PCH_Pc21g23700	B6HJ58
<i>Baudoinia compniacensis</i> (strain UAMH 10762) (Angels' share fungus)	BAUCODRAFT_274597	M2M6Z5
<i>Hypocrea atroviridis</i> (strain ATCC 20476 / IMI 206040) (<i>Trichoderma atroviride</i>)	TRIATDRAFT_280929	G9NJ32
<i>Colletotrichum gloeosporioides</i> (strain Cg-14) (Anthracnose fungus) (<i>Glomerella cingulata</i>)	CGLO_06642	T0LPH0
<i>Cordyceps militaris</i> (strain CMOI) (Caterpillar fungus)	CCM_02665	G3JB34
<i>Pyronema omphalodes</i> (strain CBS 100304) (<i>Pyronema confluens</i>)	PCON_13062	U4LKE9
<i>Colletotrichum graminicola</i> (strain M1.001 / M2 / FGSC 10212) (Maize anthracnose fungus) (<i>Glomerella graminicola</i>)	GLRG_08499	E3QR67
<i>Glarea lozoyensis</i> (strain ATCC 74030 / MF5533)	M7I_2117	H0EHX4
<i>Fusarium oxysporum</i> f. sp. <i>cubense</i> (strain race 4) (Panama disease fungus)	FOC4_g 10002493	N1S969
<i>Fusarium oxysporum</i> f. sp. <i>cubense</i> (strain race 4) (Panama disease fungus)	FGC4_g 10011461	N1RT80

Organism	Gene names	Accession No.
<i>Cochliobolus sativus</i> (strain ND90Pr / ATCC 201652} (Common root rot and spot blotch fungus) (<i>Bipolaris sorokiniana</i>)	COCSADRAFT__295770	M2TBE4
<i>Mixia osmundae</i> (strain CBS 9802 / IAM 14324 / JCM 22182 / KY 12970)	Mo05571 E5Q_05571	G7E7S3
<i>Mycosphaerellapini</i> (strain NZE10 / CBS 128990) (Red band needle blight fungus) (<i>Dothiostroma septosporum</i>)	DOTSEDRAFT__6965 1	N1PXR0
<i>Grossmannia clavigera</i> (strain kwl407 / UAMH 11150) (Blue stain fungus) (<i>Graphiociadiella clavigera</i>)	CMQ_1113	F0XC64
<i>Fusarium oxysporum</i> FOSC 3-a	FOYG__03004	W9IUE5
<i>Fusarium oxysporum</i> FOSC 3-a	FOYG_16040	W9HNP0
<i>Fusarium oxysporum</i> FOSC 3-a	FOYG__17058	W9HB31
<i>Nectria haematococca</i> (strain 77-13-4 / ATCC MYA-4622 / FGSC 9596 / MPVI) (<i>Fusarium solani</i> subsp. <i>pisi</i>)	NECHADRAFT_37686	C7YQL1
<i>Nectria haematococca</i> (strain 77-13-4 / ATCC MYA-4622 / FGSC 9596 / MPVI) (<i>Fusarium solani</i> subsp. <i>pisi</i>)	NECHADRAFT__77262	C7ZJ10
<i>Tuber melanosporum</i> (strain Mel28) (Perigord black truffle)	GSTUM_000 10376001	D5GLS0
<i>Ajellomyces dermatitidis</i> (strain SLH14081) (<i>Blastomyces dermatitidis</i>)	BDBG__07633	C5JYI9
<i>Chaetomium globosum</i> (strain ATCC 6205 / CBS 148.51 / DSM 1962 / NBRC 6347 / NRRL 1970) (Soil fungus)	CHGG__09885	Q2GQ69
<i>Candida tenuis</i> (strain ATCC 10573 / BCRC 21748 / CBS 615 / JCM 9827 / NBRC 10315 / NRRL Y-1498 / VKM Y-70) (Yeast)	CANTEDRAFT_108652	G3B9Z1

Organism	Gene names	Accession No.
Trichophyton rubrum CBS 100081	H102_00622	A0A022VKY4
Pyrenophora teres f. <i>teres</i> (strain 0-1) (Barley net blotch fungus) (Drechslera <i>teres</i> f. <i>teres</i>)	PTT_09421	E3RLZ3
Colletotrichum gloeosporioides (strain Naragc5) (Anthraco se fungus) (Glomerella cingulata)	CGGC5_4608	L2GB29
Gibberella zeae (Wheat head blight fungus) (Fusarium graminearum)	FG05_06918	A0A016PCS4
Trichophyton soudanense CBS 452.61	H105_00612	A0A022Y6A6
<i>Sclerotinia sclerotium</i> (strain ATCC 18683 / 1980 / Ss-1) (White mold) (Whetzelinia sclerotium)	SS1G_07437	A7EQ37
<i>Fusarium oxysporum</i> f. sp. <i>lisi</i> HDV247	FOVG_14401	W9NWU8
<i>Fusarium oxysporum</i> f. sp. <i>lisi</i> HDV247	FOVG_02874	W9Q5V3
<i>Ustilago hordei</i> (strain Uh4875-4) (Barley covered smut fungus)	UHQR_03009	12G1Z4
Sporisorium reilianum (strain SRZ2) (Maize head smut fungus)	si-12985	E6ZYF7
<i>Bipolaris zeicola</i> 26-R-13	CQCCADRAFT_81154	W6Y1P8
<i>Meiampsora larici-populina</i> (strain 98AG31 / pathotype 3-4-7) (Poplar leaf rust fungus)	MELLADRAFT_78490	F4RUZ8
<i>Fusarium oxysporum</i> f. sp. <i>lycopersici</i> (strain 4287 / CBS 123668 / FGSC 9935 /NRRL 34936) (<i>Fusarium</i> vascular wilt of tomato)	FOXG_01901	J9MG95
<i>Fusarium oxysporum</i> f. sp. <i>lycopersici</i> (strain 4287 / CBS 123668 / FGSC 9935 /NRRL 34936) (<i>Fusarium</i> vascular wilt of tomato)	FOXGJ1941	J9N9S4
<i>Bipolaris victoriae</i> FI3	COCVIDRAFT_39053	W7EMJ8

Organism	Gene names	Accession No.
<i>Debaryomyces hansenii</i> (strain ATCC 36239 / CBS 767 / JCM 1990 / NBRC 0083 / IGC 2968) (Yeast) (<i>Torulaspora hansenii</i>)	DEHA2E04268g	Q6BQL4
<i>Clavispora lusitaniae</i> (strain ATCC 42720) (Yeast) (<i>Candida lusitaniae</i>)	CLUG_01505	C4XZX3
<i>Candida albicans</i> (strain WO-1) (Yeast)	CAWG_02023	C4YME4
<i>Trichophyton rubrum</i> MR850	H100_00625	A0A022U0Q2
<i>Candida dubliniensis</i> (strain CD36 / ATCC MYA-646 / CBS 7987 / NCPF 3949 / NRRL Y-17841) (Yeast)	CD36_32890	B9WMC7
<i>Starmerella bombicola</i>	AOX1	A0A024FB95
<i>Thielavia heterothallica</i> (strain ATCC 42464 / BCRC 31852 / DSM 1799) (<i>Myceliophthora thermophila</i>)	MYCTH_10759	G2QJL7
<i>Claviceps purpurea</i> (strain 20.1) (Ergot fungus) (<i>Sphacelia segetum</i>)	CPUR_07614	M1WFI4
<i>Aspergillus oryzae</i> (strain ATCC 42149 / RIB 40) (Yellow koji mold)	AO090023000571	Q2UH61
<i>Dictyostelium discoideum</i> (Slime mold)	DDB_0184181 DDB_G0292042	Q54DT6
<i>Triticum urartu</i> (Red wild einkorn) (<i>Crithodium urartu</i>)	TRIUR3_22733	M7YME5
<i>Solarium tuberosum</i> (Potato)	PGSC0003DMG4000 172 11	M1BG07
<i>Oryza sativa</i> subsp. <i>japonica</i> (Rice)	OSJNBb0044B19.5 LOC_Os10g33540	Q8W5P8
<i>Oryza sativa</i> subsp. <i>japonica</i> (Rice)	OJ1234_B11.20 Os02g0621800	Q6K9N5
<i>Oryza sativa</i> subsp. <i>japonica</i> (Rice)	OSJNBa0001K12.5 LOC_Os10g33520	Q8W5P3
<i>Zea mays</i> (Maize)	ZEAMMB73_809149	C0P3J6

Organism	Gene names	Accession No.
Citrus Clementina	CICLE_vl00111 11mg	V4S9P4
Citrus Clementina	CICLE_vl0018992mg	V4U4C9
Citrus Clementina	CICLE_v 1000440 5mg	V4S9D3
Citrus Clementina	CICLE_vl0004403mg	V4RZZ6
Morus notabilis	L484_011703	W9RIK0
Morus notabilis	L484_005930	W9RET7
Medicago truncatula (Barrel medic) (Medicago tribuloides)	MTR_lg075650	G714U3
Arabidopsis thaliana (Mouse-ear cress)		Q8LDP0
Medicago truncatula (Barrel medic) (Medicago tribuloides)	MTR_4g081080	G7JF07
Simmondsia chinensis (Jojoba) (Buxus chinensis)		L7VfV2
Prunus persica (Peach) (Amygdalus persica)	PRUPE_ppa018458mg	M5VXL1
Aphanomyces astaci	H257_0741 1	W4GI89
Aphanomyces astaci	H257_07412	W4GI44
Aphanomyces astaci	H257_0741 1	W4GKE3
Aphanomyces astaci	H257_07411	W4GK29
Aphanomyces astaci	H257_0741 1	W4GJ79
Aphanomyces astaci	H257_0741 1	W4GI38
Phaeodactylum tricornutum (strain CCAP 1055/1)	PHATRDRAFT_48204	B7G6C1
Hordeum vulgare var. distichum (Two-rowed barley)		F2E4R4
Hordeum vulgare var. distichum (Two-rowed barley)		F2DZG1

Organism	Gene names	Accession No.
<i>Hordeum vulgare</i> var. <i>distichum</i> (Two-rowed barley)		M0YPG7
<i>Hordeum vulgare</i> var. <i>distichum</i> (Two-rowed barley)		M0YPG6
<i>Hordeum vulgare</i> var. <i>distichum</i> (Two-rowed barley)		F2CUIY4
<i>Ricinus communis</i> (Castor bean)	RCOM_0867830	B9S1S3
<i>Brassicarapa</i> subsp. <i>pekinensis</i> (Chinese cabbage) (<i>Brassica pekinensis</i>)	BRAO14947	M4DEM5
<i>Ricinus communis</i> (Castor bean)	RCOM_0258730	B9SV13
<i>Brassica rapa</i> subsp. <i>pekinensis</i> (Chinese cabbage) (<i>Brassica pekinensis</i>)	BRA001912	M4CCI2
<i>Brassica rapa</i> subsp. <i>pekinensis</i> (Chinese cabbage) (<i>Brassica pekinensis</i>)	BRAO12548	M4D7T8
<i>Brassicarapa</i> subsp. <i>pekinensis</i> (Chinese cabbage) (<i>Brassica pekinensis</i>)	BRA024190	M4E5Y6
<i>Brassicarapa</i> subsp. <i>pekinensis</i> (Chinese cabbage) (<i>Brassica pekinensis</i>)	BRAO15283	M4DFL0
<i>Ricinus communis</i> (Castor bean)	RCOM_1168730	B9SS54
<i>Zea mays</i> (Maize)		C4J691
<i>Oryza glaberrima</i> (African rice)		11P2B7
<i>Zea mays</i> (Maize)		B6SXM3
<i>Zea mays</i> (Maize)		C0HFU4
<i>Aegilops tauschii</i> (Tausch's goatgrass) (<i>Aegilops squarrosa</i>)	F775_19577	R7W4J3
<i>Solanum habrochaites</i> (Wild tomato) (<i>Lycopersicon hirsutum</i>)		R9R6T0
<i>Physcomitrella patens</i> subsp. <i>patens</i> (Moss)	PHYPADRAFTJ 24285	A9S535

Organism	Gene names	Accession No.
<i>Physcomitrella patens</i> subsp. <i>patens</i> (Moss)	PHYPADRAFT __113581	A9RG13
<i>Physcomitrella patens</i> subsp. <i>patens</i> (Moss)	PHYPADRAFT _182504	A9S9A5
<i>Solanum pennellii</i> (Tomato) (<i>Lycopersicon pennellii</i>)		R9R6Q1
<i>Vitis vinifera</i> (Grape)	VTT_02s0087g00630	F6HJ27
<i>Vitis vinifera</i> (Grape)	VIT_07s0005g03780	F6HZM3
<i>Vitis vinifera</i> (Grape)	VIT_05s0049g01400	F6H8T4
<i>Vitis vinifera</i> (Grape)	VraSVJ 19349	A5AH38
<i>Capsella rubella</i>	CARUB __v10013046mg	R0HIT3
<i>Capsella rubella</i>	CARUB_vl 00042 12mg	R0GUX4
<i>Capsella rubella</i>	CARUB_vl0004208mg	R0F3X6
<i>Capsella rubella</i>	CARUB _v 1001 245 3mg	R0ILD0
<i>Capsella rubella</i>	CARUB_v l0004208mg	R0GUX1
<i>Eutrema salsugineum</i> (Saltwater cress) (<i>Sisymbrium salsugineum</i>)	EUTSA_vl0024496mg	V4MD54
<i>Eutrema salsugineum</i> (Saltwater cress) (<i>Sisymbrium salsugineum</i>)	EUTSA __v 10020 141 mg	V4NM59
<i>Eutrema salsugineum</i> (Saltwater cress) (<i>Sisymbrium salsugineum</i>)	EUTSA_vl0024496mg	V4LUR9
<i>Eutrema salsugineum</i> (Saltwater cress) (<i>Sisymbrium salsugineum</i>)	EUTSA_v l0024528mg	V4P767
<i>Eutrema salsugineum</i> (Saltwater cress) (<i>Sisymbrium salsugineum</i>)	EUTSA __v 100068 82mg	V4L2P6
<i>Selaginella moellendorffii</i> (Spikemoss)	SELMODRAFT_87684	D8R6Z6
<i>Selaginella moellendorffii</i> (Spikemoss)	SELMODRAFT _87621	D8R6Z5
<i>Selaginella moellendorffii</i> (Spikemoss)	SELMODRAFT_74601	D8QN81

Organism	Gene names	Accession No.
Selaginella moellendorffii (Spikemoss)	SELMODRAFT_7353 1	D8QN82
Sorghum bicolor (Sorghum) (Sorghum vulgare)	Sb04g026390 SORBIDRAFT_04g0263 90	C5XXS4
Sorghum bicolor (Sorghum) (Sorghum vulgare)	Sb04g026370 SORBIDRAFT_04g026370	C5XXS1
Sorghum bicolor (Sorghum) (Sorghum vulgare)	SbOl gO 19470 SORBIDRAFT_01g019470	C5WYH6
Sorghum bicolor (Sorghum) (Sorghum vulgare)	SbOl gO 19480 SORBIDRAFT_01g019480	C5WYH7
Sorghum bicolor (Sorghum) (Sorghum vulgare)	SbOl gO 19460 SORBIDRAFT_01g019460	C5WYH5
Solanum pimpinellifolium (Currant tomato) (Lycopersicon pimpinellifolium)		R9R6J2
Phaseolus vulgaris (Kidney bean) (French bean)	PHAVU_007G124200g	V7BGM7
Phaseolus vulgaris (Kidney bean) (French bean)	PHAVU_011G136600g	V7AI35
Phaseolus vulgaris (Kidney bean) (French bean)	PHAVU_001G162800g	V7D063
Solanum tuberosum (Potato)	PGSC0003DMG400024294	M1C923
Solanum tuberosum (Potato)	PGSC0003DMG4000 18458	M1BKV4
Solanum tuberosum (Potato)	PGSC0003DMG4000 18458	M1BKV3
Glycine max (Soybean) (Glycine hispida)		K7LK61
Glycine max (Soybean) (Glycine hispida)		K7KXQ9
Populus trichocarpa (Western balsam poplar) (Populus baisamifera subsp. trichocarpa)	PGPTR_0008s16920g	B9HKS3

Organism	Gene names	Accession No.
<i>Picea sitchensis</i> (Sitka spruce) (<i>Pinus sitchensis</i>)		B8LQ84
<i>Populus trichocarpa</i> (Western balsam poplar) (<i>Populus balsamifera</i> subsp. <i>trichocarpa</i>)	POPTR_0004s24310g	U5GKQ5
<i>Populus trichocarpa</i> (Western balsam poplar) (<i>Populus balsamifera</i> subsp. <i>trichocarpa</i>)	POPTR_0010s07980g	B9HSG9
<i>Glycine max</i> (Soybean) (<i>Glycine hispida</i>)		I1N9S7
<i>Glycine max</i> (Soybean) (<i>Glycine hispida</i>)		I1LSK5
<i>Setaria italica</i> (Foxtail millet) (<i>Panicum italicum</i>)	Si034362m.g	K4A658
<i>Solanum lycopersicum</i> (Tomato) (<i>Lycopersicon esculentum</i>)	Solyc09g072610.2	K4CUT7
<i>Setaria italica</i> (Foxtail millet) (<i>Panicum italicum</i>)	Si016380m.g	K3YQ38
<i>Solanum lycopersicum</i> (Tomato) (<i>Lycopersicon esculentum</i>)		R9R6I9
<i>Solanum lycopersicum</i> (Tomato) (<i>Lycopersicon esculentum</i>)	Solyc09g090350.2	K4CW61
<i>Solanum lycopersicum</i> (Tomato) (<i>Lycopersicon esculentum</i>)	Solyc08g005630.2	K4CI54
<i>Solanum lycopersicum</i> (Tomato) (<i>Lycopersicon esculentum</i>)	Solyc08g075240.2	K4CMP1
<i>Setaria italica</i> (Foxtail millet) (<i>Panicum italicum</i>)	Si034359m.g	K4A655
<i>Setaria italica</i> (Foxtail millet) (<i>Panicum italicum</i>)	Si034354m.g	K4A650
<i>Mimulus guttatus</i> (Spotted monkey flower) (<i>Yellow monkey flower</i>)	MIMGU_1r1gv la00 1896mg	A0A022PU07

Organism	Gene names	Accession No.
Mimulus guttatus (Spotted monkey flower) (Yellow monkey flower)	MIMGU__mgv 1a022390mg	A0A022RAV4
Mimulus guttatus (Spotted monkey flower) (Yellow monkey flower)	MIMGU__mgv 1a001868mg	A0A022S2E6
Mimulus guttatus (Spotted monkey flower) (Yellow monkey flower)	MIMGU__mgv 1a001883mg	A0A022S275
Mimulus guttatus (Spotted monkey flower) (Yellow monkey flower)	MIMGU__mgv 1a001761mg	A0A022QJNF0
Musa acuminata subsp. malaccensis (Wild banana) (Musa malaccensis)		M0SNA8
Musa acuminata subsp. malaccensis (Wild banana) (Musa malaccensis)		M0RUT7
Musa acuminata subsp. malaccensis (Wild banana) (Musa malaccensis)		M0RUK3
Saprolegnia diclina VS20	SDRG__10901	T0RG89
Brachypodium distachyon (Purple false brome) (Trachynia distachya)	BRADI3G49085	11IBP7
Brachypodium distachyon (Purple false brome) (Trachynia distachya)	BRADI3G28677	11I4N2
Brachypodium distachyon (Purple false brome) (Trachynia distachya)	BRADI3G28657	11I4N0
Oryza sativa subsp. indica (Rice)	Osl_34012	B8BHG0
Oryza sativa subsp. indica (Rice)	Osl__08118	B8AFT8
Oryza sativa subsp. indica (Rice)	Osl__34008	A2Z8H1
Oryza sativa subsp. indica (Rice)	Osl_34014	B8BHG1
Oryza sativa subsp. japonica (Rice)	LOC_Osl0g33460	Q7XDG3
Oryza sativa subsp. japonica (Rice)	Osl0g0474800	Q0IX12
Oryza sativa subsp. japonica (Rice)	Osl0g0474966	C7J7R1
Oryza sativa subsp. japonica (Rice)	OSJNBa0001K12.13	Q8W5N7

Organism	Gene names	Accession No.
Oryza sativa subsp. japonica (Rice)	OsJ_31873	B9G683
Oryza sativa subsp. japonica (Rice)	OsJ_31875	B9G684
Oryza sativa subsp. japonica (Rice)	OSJNBa0001K12.3	Q8W5P5
Arabidopsis lyrata subsp. lyrata (Lyre-leaved rock-cress)	ARALYDRAFT_4703 76	D7KDA3
Arabidopsis lyrata subsp. lyrata (Lyre-leaved rock-cress)	ARALYDRAFT_47 9855	D7L3B6
Arabidopsis lyrata subsp. lyrata (Lyre-leaved rock-cress)	ARALYDRAFT_49 1906	D7MDA9
Arabidopsis lyrata subsp. lyrata (Lyre-leaved rock-cress)	ARALYDRAFT_9 14728	D7MGS9

[0227] In some embodiments, the present disclosure teaches a recombinant microorganism comprising a deletion, disruption, mutation, and or reduction in the activity of one or more endogenous a (fatty) alcohol oxidase YALI0B14014g (FAOI).

[0228] Thus, in some embodiments, the recombinant microorganism of the present disclosure will comprise deletions or other disruptions in endogenous genes encoding proteins exhibiting at least 100%, 99%, 98%, 97%, 95%, 94%, 93%, 92%, 91%, or 90% sequence identity with the proteins encoded by a (fatty) alcohol oxidase YALI0B14014g (FAOI)

[0229] Thus, in some embodiments, the recombinant microorganism of the present disclosure will comprise deletions in endogenous genes encoding proteins exhibiting at least 100%, 99%, 98%, 97%, 95%, 94%, 93%, 92%, 91%, or 90% sequence identity with uniprot database IDs Q6CEP8 (FAOI).

Acetyl Transferase

[0230] The present disclosure describes enzymes that convert alcohols to fatty acetates.

[0231] In some embodiments, an acetyl transferase is used to catalyze the conversion of a fatty alcohol to a fatty acetate. An acetyl transferase is an enzyme that has the ability to produce an acetate ester by transferring the acetyl group from acetyl-CoA to an alcohol. In some embodiments, the acetyl transferase may have an EC number of 2.3.1.84.

[0232] The acetyl transferase, or the nucleic acid sequence that encodes it, can be isolated from various organisms, including but not limited to, organisms of the species *Candida glabrata*, *Saccharomyces cerevisiae*, *Danaiis plexippus*, *Heliotis virescens*, *Bomhyx mori*, *Agrotis ipsilon*, *Agrotis segetum*, *Euonymus alatiis*, *Homo sapiens*, *Lachancea thermotolerans* and *Yarrowia lipolytica*. In exemplary embodiments, the acetyl transferase comprises a sequence selected from GenBank Accession Nos. AY242066, AY242065, AY242064, AY242063, AY242G62, EHJ65205, ACX53812, NP_001 182381, EHJ65977, EHJ68573, KJ579226, GU594061, KTA99184.1, AIN34693.1, AY605053, XP_002552712.1, XP_503024.1, and XP_505595.1, and XP_505513.1. Exemplary acetyl transferase enzymes are listed in Table 5d. Additional exemplary acetyl transferase peptides may be found in US2010/0199548, which is herein incorporated by reference.

Table 5d. Exemplary acetyl transferase enzymes

<i>Organism</i>	<i>Enzyme ID</i>
<i>Candida glabrata</i>	KTA99184.1
<i>Agrotis segetum</i>	AIN34693.1
<i>Homo sapiens</i>	AY605053
<i>Lachancea thermotolerans</i>	XP_002552712.1
<i>Yarrowia lipolytica</i>	XP_503024.1
<i>Yarrowia lipolytica</i>	XP_505595.1
<i>Yarrowia lipolytica</i>	XP_505513.1

Fatty acyl-ACP thioesterase

[0233] Acyl-ACP thioesterase releases free fatty acids from Acyl-ACPs, synthesized from de novo fatty acid biosynthesis. The reaction terminates fatty acid biosynthesis. In plants, fatty acid biosynthesis occurs in the plastid and thus requires plastid-localized acyl-ACP thioesterases. The main products of acyl-ACP thioesterase are oleate (C18:0) and to a lesser extent palmitate (C16:0) in the vegetative tissues of all plants. The released free fatty acids are re-esterified to coenzyme A in the plastid envelope and exported out of plastid.

[0234] There are two isoforms of acyl-ACP thioesterase, FatA and FatB. Substrate specificity of these isoforms determines the chain length and level of saturated fatty acids in plants. The

highest activity of FatA is with C18:1-ACP. FatA has very low activities towards other acyl-ACPs when compared with C18:1-ACP. FatB has highest activity with C16:0-ACP. It also has significant high activity with C18:1-ACP, followed by C18:0-ACP and C16:1-ACP. Kinetics studies of FatA and FatB indicate that their substrate specificities with different acyl-ACPs came from the K_{cat} values, rather than from K_m . K_m values of the two isoforms with different substrates are similar, in the micromolar order. Domain swapping of FatA and FatB indicates the N-terminus of the isoforms determines their substrate specificities (Salas JJ and Ohlrogge JB (2002) Characterization of substrate specificity of plant FatA and FatB acyl-ACP thioesterases. *Arch Biochem Biophys* 403(1): 25-34). For those plants which predominantly accumulate medium-chain length saturated fatty acids in seeds, they evolved with specialized FatB and/or FatA thioesterases (Voelker T and Kinney AJ (2001) Variations in the biosynthesis of seed-storage lipids. *Annu Rev Plant Physiol Plant Mol Biol* 52: 335-361). For example, laurate (12:0) is the predominant seed oil in coconut. Correspondingly, the medium-chain specific acyl-ACP thioesterase activity was detected in coconut seeds.

[0235] In some embodiments, the present disclosure teaches a recombinant microorganism comprising a deletion, disruption, mutation, and or reduction in the activity of YALI0E16016g (FATI).

[0236] Thus, in some embodiments, the recombinant microorganism of the present disclosure will comprise deletions or other disruptions in endogenous genes encoding proteins exhibiting at least 100%, 99%, 98%, 97%, 95%, 94%, 93%, 92%, 91%, or 90% sequence identity with the protein encoded by YALI0E16016g (FATI).

[0237] Thus, in some embodiments, the recombinant microorganism of the present disclosure will comprise deletions in endogenous genes encoding proteins exhibiting at least 100%, 99%, 98%, 97%, 95%, 94%, 93%, 92%, 91%, or 90% sequence identity with uniprot database ID Q6C5Q8 (FAG1).

Acyl-CoA oxidase

[0238] Acyl-CoA oxidase (ACO) acts on CoA derivatives of fatty acids with chain lengths from 8 to 18. They are flavoenzymes containing one noncovalently bound FAD per subunit and belong to the same superfamily as mitochondrial acyl-CoA dehydrogenases. Like mitochondrial fatty acyl-CoA dehydrogenases, peroxisomal acyl-CoA oxidases catalyze the initial and rate-determining step of the peroxisomal fatty acid β -oxidation pathway, i.e. α,β -dehydrogenation of acyl-CoA, yielding trans-2-enoyl-CoA in the reductive half-reaction. In

the oxidative half-reaction of peroxisomal acyl-CoA oxidase, the reduced FAD is reoxidized by molecular oxygen, producing hydrogen peroxide.

[0239] Acyl-CoA oxidase is a homodimer and the polypeptide chain of the subunit is folded into the N-terminal alpha-domain, beta-domain, and C-terminal alpha-domain. Functional differences between the peroxisomal acyl-CoA oxidases and the mitochondrial acyl-CoA dehydrogenases are attributed to structural differences in the FAD environments.

[0240] In some embodiments, recombinant microorganisms and methods are provided for the production of short chain fatty alcohols, fatty aldehydes and/or fatty acetates. In certain embodiments, the short chain fatty alcohols, fatty aldehydes and/or fatty acetates have carbon chain length shorter than or equal to C16. In some embodiments, the short chain fatty alcohols, fatty aldehydes and/or fatty acetates are produced from long chain fatty acids. In some preferred embodiments of methods to produce short chain pheromones, select enzymes capable of shortening fatty acyl-CoAs in the pheromone biosynthetic pathway are co-expressed with pheromone biosynthetic pathway enzymes. Examples of suitable chain shortening enzymes include FAD-dependent acyl-CoA oxidase. In the case of fatty acid molecules with an even number of carbons, chain shortening enzymes produce a molecule of acetyl-CoA, and a fatty acyl-CoA shortened by two carbons. Fatty acid molecules with an odd number of carbons are oxidized in a similar fashion producing acetyl-CoA molecules during every round of oxidation until the chain-length is reduced to 5 carbons. In the final cycle of oxidation, this 5-carbon acyl-CoA is oxidized to produce acetyl-CoA and propionyl-CoA.

[0241] It is known that acyl-CoA oxidases exhibit varying specificity towards substrates with different chain-length (Figure 40). Therefore, controlling the degree of fatty acyl-CoA truncation relies on engineering or selecting the appropriate enzyme variant. Examples of acyl-CoA oxidases that are suitable for this purpose are listed in Table 5a.

[0242] In a further embodiment, the disclosure provides a recombinant microorganism capable of producing a mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol from an endogenous or exogenous source of saturated C_6 - C_{24} fatty acid, wherein the recombinant microorganism comprises: (a) at least one exogenous nucleic acid molecule encoding a fatty acyl desaturase that catalyzes the conversion of a saturated C_6 - C_{24} fatty acyl-CoA to a corresponding mono- or poly-unsaturated C_6 - C_{24} fatty acyl-CoA; (b) at least one exogenous nucleic acid molecule encoding an acyl-CoA oxidase that catalyzes the conversion of the mono- or poly-unsaturated C_6 - C_{24} fatty acyl-CoA from (a) into a mono- or poly-unsaturated $\leq C_{18}$ fatty acyl-CoA after

one or more successive cycle of acyl-CoA oxidase activity, with a given cycle producing a mono- or poly-unsaturated C_4-C_{22} fatty acyl-CoA intermediate with a two carbon truncation relative to a starting mono- or poly-unsaturated C_6-C_{24} fatty acyl-CoA substrate in that cycle; and (c) at least one exogenous nucleic acid molecule encoding a fatty alcohol forming fatty acyl reductase that catalyzes the conversion of the mono- or poly-unsaturated $\leq C_{18}$ fatty acyl-CoA from (fa) into the corresponding mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol. In some embodiments, the fatty acyl desaturase is selected from an *Argyrotaenia velutinana*, *Spodoptera litura*, *Sesamia inferens*, *Manduca sexta*, *Ostrinia nubilalis*, *Helicoverpa zea*, *Chorisloneura rosacearia*, *Drosophila melanogaster*, *Spodoptera littoralis*, *Lampronia capitella*, *Amyelois transitella*, *Trichoplusia ni*, *Agrotis segetum*, *Ostrinia furnicalis*, and *Thalassiosira pseudomonas* derived fatty acyl desaturase. In some embodiments, the fatty acyl desaturase has at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, 50%, or 50% sequence identity to a fatty acyl desaturase selected from the group consisting of: SEQ ID NOs: 39, 49-54, 58-63, 78-80 and GenBank Accession nos. AF4I6738, AGH12217.1, AII21943.I, CAJ43430.2, AF441221, AAF81787.1, AF545481, AJ271414, AY362879, ABX71630.1, NP001299594.1, Q9N9Z8, ABX71630.1 and AIM4022 1.1. In some embodiments, the acyl-CoA oxidase is selected from Table 5a. In other embodiments, the fatty alcohol forming fatty acyl reductase is selected from an *Agrotis segetum*, *Spodoptera exigna*, *Spodoptera littoralis*, *Euglena gracilis*, *Yponomeuta evonymellus* and *Helicoverpa armigera* derived fatty alcohol forming fatty acyl reductase. In further embodiments, the fatty alcohol forming fatty acyl reductase has at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, 50%, or 50% sequence identity to a fatty alcohol forming fatty acyl reductase selected from the group consisting of: SEQ ID NOs: 1-3, 32, 41-48, 55-57, 73, 75, 77 and 82. In some embodiments, the recombinant microorganism is a yeast selected from the group consisting of *Yarrowia lipolytica*, *Saccharomyces cerevisiae*, *Candida albicans*, *Candida tropicalis* and *Candida viswanathii*.

[0243] In some preferred embodiments of methods to produce fatty alcohols, fatty aldehydes and/or fatty acetates, one or more genes of the microbial host encoding acyl-CoA oxidases

are deleted or down-regulated to eliminate or reduce the truncation of desired fatty acyl-CoAs beyond a desired chain-length. Such deletion or down-regulation targets include but are not limited to *Y. lipofytica* POX1(YALI0E32835g), *Y. lipofytica* POX2(YALI0F10857g), *Y. lipofytica* POX3(YALI0D24750g), *Y. lipofytica* POX4(YALI0E27654g), *Y. lipofytica* POX5(YALI0C23859g), *Y. lipofytica* POX6(YALI0E06567g); *S. cerevisiae* POXKYGL205W); *Candida* POX2 (Ca019.1655, Ca019.9224, CTRG_02374, M18259), *Candida* POX4 (Ca019.1652, Ca019.9221, CTRG_02377, M12160), and *Candida* POX5 (Ca019.5723, Ca019.13146, CTRG_02721, M12161).

[0244] In some embodiments, the present disclosure teaches a recombinant microorganism comprising a deletion, disruption, mutation, and or reduction in the activity of one or more acyl-CoA oxidases selected from the group consisting of POX1(YALI0E32835g), *Y. lipofytica* POX2(YALI0F10857g), *Y. lipofytica* POX3(YALI0D24750g), *Y. lipofytica* POX4(YALI0E27654g), *Y. lipofytica* POX5(YALI0C23859g), *Y. lipofytica* POX6(YALI0E06567g).

[0245] Thus, in some embodiments, the recombinant microorganism of the present disclosure will comprise deletions or other disruptions in endogenous genes encoding proteins exhibiting at least 100%, 99%, 98%, 97%, 95%, 94%, 93%, 92%, 91%, or 90% sequence identity with the proteins encoded by POX1 (YALI0E32835g), *Y. lipofytica* POX2 (YALI0F10857g), *Y. lipofytica* POX3 (YALI0D24750g), *Y. lipofytica* POX4 (YALI0E27654g), *Y. lipofytica* POX5 (YALI0C23859g), *Y. lipofytica* POX6 (YALI0E06567g).

[0246] Thus, in some embodiments, the recombinant microorganism of the present disclosure will comprise deletions in endogenous genes encoding proteins exhibiting at least 100%, 99%, 98%, 97%, 95%, 94%, 93%, 92%, 91%, or 90% sequence identity with uniprot database ID P0X1(074934), *Y. lipofytica* POX2 (074935), *Y. lipofytica* POX3 (074936), *Y. lipofytica* POX4 (F2Z627), *Y. lipofytica* POX5 (F2Z630), *Y. lipofytica* POX6 (Q6C6T0).

[0247] In some embodiments, a recombinant microorganism capable of producing a mono- or poly-unsaturated \leq Cis fatty alcohol, fatty aldehyde and/or fatty acetate from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid is provided, wherein the recombinant microorganism expresses one or more acyl-CoA oxidase enzymes, and wherein the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the activity of one or more endogenous acyl-CoA oxidase enzymes. In some embodiments, the one or more acyl-CoA oxidase enzymes being expressed are different from the one or more

endogenous acyl-CoA oxidase enzymes being deleted or downregulated. In some embodiments, the recombinant microorganism further expresses pheromone biosynthetic pathway enzymes. In further embodiments, the pheromone biosynthetic pathway enzymes comprise one or more fatty acyl desaturase and/or fatty acyl conjugase. In yet further embodiments, the pheromone biosynthetic pathway enzymes comprise one or more fatty alcohol forming fatty acyl reductase. In some embodiments, the one or more acyl-CoA oxidase enzymes that are expressed are selected from Table 5a. In other embodiments, the one or more acyl-CoA oxidase enzymes that are expressed regulate chain length of the mono- or poly-unsaturated \leq Cis fatty alcohol, fatty aldehyde and/or fatty acetate. In some embodiments, the one or more endogenous acyl-CoA oxidase enzymes that are deleted, disrupted, mutated, or downregulated are selected from *Y. lipolytica* POX1(YALI0E32835g), *Y. lipolytica* POX2(YALI0F10857g), *Y. lipolytica* POX3(YALI0D24750g), *Y. lipolytica* POX4(YALI0E27654g), *Y. lipolytica* POX5(YALI0C23859g), *Y. lipolytica* POX6(YALI0E06567g); *S. cerevisiae* POX1(YGL205W); *Candida* POX2 (Ca019.1655, Ca019.9224, CTRG_02374, M18259), *Candida* POX4 (Ca019.1652, Ca019.9221, CTRG_02377, M12160), and *Candida* POX5 (Ca019.5723, Ca019.13146, CTRG_G2721, M12161). In other embodiments, the one or more endogenous acyl-CoA oxidase enzymes that are deleted, disrupted, mutated, or downregulated control chain length of the mono- or poly-unsaturated \leq Cis fatty alcohol, fatty aldehyde and/or fatty acetate.

[0248] In some embodiments, a method of producing a mono- or poly-unsaturated \leq Cis fatty alcohol, fatty aldehyde and/or fatty acetate from an endogenous or exogenous source of saturated C6-C24 fatty acid are provided, wherein the method comprises introducing into or expressing in a recombinant microorganism at least one endogenous or exogenous nucleic acid molecule encoding an acyl-CoA oxidase and introducing a deletion, insertion, or loss of function mutation in one or more gene encoding an acyl-CoA oxidase, wherein the at least one endogenous or exogenous nucleic acid molecule encoding an acyl-CoA oxidase being introduced or expressed is different from the one or more gene encoding an acyl-CoA oxidase being deleted or downregulated. In some embodiments, the method further comprises introducing into or expressing in the recombinant microorganism at least one endogenous or exogenous nucleic acid molecule encoding a fatty acyl desaturase and/or fatty acyl conjugase. In further embodiments, the method further comprises introducing into or expressing in the recombinant microorganism at least one endogenous or exogenous nucleic acid molecule encoding a fatty alcohol forming fatty acyl reductase. In some embodiments, the least one

endogenous or exogenous nucleic acid molecule encodes an acyl-CoA oxidase selected from Table 5a. In other embodiments, the least one endogenous or exogenous nucleic acid molecule encodes an acyl-CoA oxidase that regulates chain length of the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol, fatty aldehyde and/or fatty acetate. In some embodiments, the one or more gene being deleted or downregulated encodes an acyl-CoA oxidase selected from *Y. lipolytica* POX1(YALI0E32835g), *Y. lipolytica* POX2(YAL10F10857g), *Y. lipolytica* POX3(YALI0D24750g), *Y. lipolytica* POX4(YALI0E27654g), *Y. lipolytica* POX5(YALT0C23859g), *Y. lipolytica* POX6(YALI0E06567g); *S. cerevisiae* POX1(YGL205W); *Candida* POX2 (Ca019.1655, Ca019.9224, CTRG_02374, M18259), *Candida* POX4 (Ca019.1652, Ca019.9221, CTRG_02377, M12160), and *Candida* POX5 (Ca019.5723, Ca019.13146, CTRG_02721, M12161). In other embodiments, the one or more gene being deleted or downregulated encodes an acyl-CoA oxidase that regulates chain length of the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol, fatty aldehyde and/or fatty acetate.

Table 5a. Exemplary acyl-CoA oxidases

Accession No.	Source Organism
P07872	<i>Rattus norvegicus</i>
A0A178WDE4	<i>Arabidopsis thaliana</i>
P0CZ23	<i>Arabidopsis thaliana</i>
D7KG20	<i>Arabidopsis lyrata</i>
R019Z2	<i>Capsella rubella</i>
V4KEW0	<i>Eutrema salsugineum</i>
M4DG68	<i>Brassica rapa</i>
A0A078IZG1	<i>Brassica napus</i>
A0A087HLF0	<i>Arabis alpina</i>
A0A0D3C825	<i>Brassica oleracea</i>
A0A078FAW4	<i>Brassica napus</i>
A0A178W833	<i>Arabidopsis thaliana</i>
Q9LMI7	<i>Arabidopsis thaliana</i>

Accession No.	Source Organism
D7KG21	<i>Arabidopsis lyrata</i>
A0A0D3C827	<i>Brassica oleracea</i>
M4DG69	<i>Brassica rapa</i>
A0A078J4V6	<i>Brassica napus</i>
A0A078FAY6	<i>Brassica napus</i>
V4KY71	<i>Eutrema saisugineum</i>
A0A061E5C2	<i>Theobroma cacao</i>
A0A061E4K0	<i>Theobroma cacao</i>
M1APIS	<i>Solanum tuberosum</i>
J7KB16	<i>Prunus persica</i>
K4CXY8	<i>Solanum lycopersicum</i>
V4W234	<i>Citrus Clementina</i>
G8XNW7	<i>Morus domestica</i>
F6H4X3	<i>Vitis vinifera</i>
A0A068V5Q3	<i>Coffea canephora</i>
M1APJ6	<i>Solanum tuberosum</i>
A0A067KHP0	<i>Jatropha curcas</i>
A0A0D2PZG8	<i>Gossypium raimondii</i>
B9IQS0	<i>Populus trichocarpa</i>
W9RG01	<i>Morus notabilis</i>
A0A0S3SB10	<i>Vigna angularis</i> var. <i>angularis</i>
A0A0L9V573	<i>Phaseolus angularis</i>
A0A0B0PPT6	<i>Gossypium arboreum</i>
A0A0D2T164	<i>Gossypium raimondii</i>
I1KEV4	<i>Glycine max</i>

Accession No.	Source Organism
11LS94	<i>Glycine max</i>
G7JUZ2	<i>Medicago truncatula</i>
U5FVP5	<i>Populus trichocarpa</i>
V7AGL5	<i>Phaseolus vulgaris</i>
A0A059A0G8	<i>Eucalyptus grandis</i>
A0A059A0N3	<i>Eucalyptus grandis</i>
A0A166AUM6	<i>Daucus carota suhsp. sativus</i>
A0A061EB81	<i>Theobroma cacao</i>
A0A0A0LQY1	<i>Cucumis sativus</i>
A0A022QRB0	<i>Erythranthe guttata</i>
A0A0S3SB01	<i>Vigna angustata var. annularis</i>
A0A0D2Q6S9	<i>Gossypium raimondii</i>
B9SGN6	<i>Ricinus communis</i>
A0A0B2PER8	<i>Glycine soja</i>
A0A0B0NGI2	<i>Gossypium arboreum</i>
A0A0D2SKF2	<i>Gossypium raimondii</i>
A0A0B0NRR7	<i>Gossypium arboreum</i>
A0A0J8EFZ4	<i>Beta vulgaris suhsp. vulgaris</i>
A0A0J8BLD2	<i>Beta vulgaris suhsp. vulgaris</i>
M4DG71	<i>Brassica rapa</i>
W1Q1 11	<i>Amphorella trichopoda</i>
M0S864	<i>Musa acuminata</i>
A0A166ABS1	<i>Daucus carota suhsp. sativus</i>
A0A1D6CA75	<i>Triticum aestivum</i>
A0A0A9CN11	<i>Arundo donax</i>

Accession No.	Source Organism
A0A1D6CKJ3	<i>Triticum aestivum</i>
A0A164VV703	<i>Daucus carota subsp. sativus</i>
A0A1D1YDC5	<i>Anihurium amnicola</i>
I1Q2B7	<i>Oryza glaberrima</i>
A0A0D9WQH3	<i>Leersia perrieri</i>
Q69XR7	<i>Oryza sativa subsp. japonica</i>
A0A1D6CA73	<i>Triticum aestivum</i>
AGAGE0A9E1	<i>Oryza glurmpatula</i>
A0A199W504	<i>Ananas comosus</i>
A0A0E0HQR9	<i>Oryza nivara</i>
M0T4I4	<i>Musa acuminata subsp. malacc.</i>
C0PTG5	<i>Picea sitchensis</i>
I1I3F1	<i>Brachypodium distachyon</i>
K3XV57	<i>Setaria italica</i>
A0A0D3GGF4	<i>Oryza harthii</i>
A2YCR4	<i>Oryza sativa subsp. mdica</i>
A0A0K9RYF5	<i>Spinacia oleracea</i>
A0A0D3GGF3	<i>Oryza harthii</i>
A0A0D3GGF2	<i>Oryza bartkii</i>
A0A0E0HQR8	<i>Oryza nivara</i>
A0A1D6CA72	<i>Triticum aestivum</i>
A3BBK8	<i>Oryza sativa subsp. japonica</i>
A0A199V6E4	<i>Ananas comosus</i>
C5XPR4	<i>Sorghum bicolor</i>
A0A0E0PXN1	<i>Oryza rufipogon</i>

Accession No.	Source Organism
B6U7U8	<i>Zea mays</i>
A0A1D6N7A4	<i>Zea mays</i>
A0A0E0E1N7	<i>Oryza rneridionalis</i>
A0A0K9NPK9	<i>Zostera marina</i>
A0A059Q1I9	<i>Saccharum hybrid cultivar R570</i>
J3MDZ2	<i>Oryza hrachyantha</i>
A0A0K9RYH2	<i>Spinacia oleracea</i>
A0A103Y1T3	<i>Cynara cardunculus</i>
A0A0E0PXN2	<i>Oryza ruflpogon</i>
A9RZ70	<i>Physcomitrella patens</i>
D8TES8	<i>Selaginella moellendorffii</i>
D8SQF1	<i>Selaginella moellendorffii</i>
M5X7E6	<i>Primus persica</i>
A9T150	<i>Physcomitrella patens</i>
A0A176WTU5	<i>Marchantia polymorpha</i>
A0A0D2QZ34	<i>Gossypium raimondii</i>
A0A1D6N7A2	<i>Zea mays</i>
A0A1D1Z3C0	<i>Anthurium amnicola</i>
A0A067DSI1	<i>Citrus sinensis</i>
A0A1D6CA74	<i>Triticum aestivum</i>
M8CMI0	<i>Aegilops tauschii</i>
A0A0S3SB72	<i>Vigna angularis var. angularis</i>
M0UX36	<i>Hordeiim vulgare subsp. vulgare</i>
A0A1D6CA76	<i>Triticum aestivum</i>
A0A151SDZ7	<i>Cajanus cajan</i>

Accession No.	Source Organism
Q9LNB8	<i>Arabidopsis thaliana</i>
A0A1D6CKJ4	<i>Triticum aestivum</i>
F2EGJ0	<i>Hordeum vulgare subsp. vulgare</i>
A0A0D2U3V1	<i>Gossypium raimondii</i>
M0UX35	<i>Hordeum vulgare subsp. vulgare</i>
M2Y3U7	<i>Galdieria sulphuraria</i>
S8CGJ3	<i>Genlisea aurea</i>
A0A0E0HQS2	<i>Oryza nivara</i>
A0A199VU62	<i>Ananas comosus</i>
M2WTY9	<i>Galdieria sulphuraria</i>
A0A1D6N7A3	<i>Zea mays</i>
A0A0E0HQS0	<i>Oryza nivara</i>
A0A1E5VL23	<i>Dichanthelium oligosanthes</i>
R7Q711	<i>Chondrus crispus</i>
S0F2R6	<i>Chondrus crispus</i>
S0F2T2	<i>Chondrus crispus</i>
A0A0E0HQS1	<i>Oryza nivara</i>
D3BSZ9	<i>Polysphondylium pallidum</i>
A0A0D2WJ11	<i>Capsaspora owczarzaki strai.</i>
R7QDC3	<i>Chondrus crispus</i>
M1VCW4	<i>Cyanidioschyzon merolae str.</i>
F1A2F0	<i>Dictyostelium purpureum</i>
F4PI57	<i>Dictyostelium fasciculatum</i>
Q54111	<i>Dictyostelium discoideum</i>
A0A0E0LBG6	<i>Oryza punctata</i>

Accession No.	Source Organism
A0A151ZKZ0	<i>Dictyostelium lacteum</i>
M1BZ65	<i>Solanum tuberosum</i>
H8MFT9	<i>Corallococcus coralloides s.</i>
F8CEB4	<i>Myxococcus fulvus</i>
A0A0H4WJP1	<i>Myxococcus hansupus</i>
Q1CYG7	<i>Myxococcus xcmthus</i>
F1A3A8	<i>Dictyostelium purpureum</i>
L7UK64	<i>Myxococcus stipitatus</i>
A0A0F7BPX0	<i>Myxococcus fulvus 124B02</i>
A0A0G4J3N5	<i>Plasmodiophora brassicae</i>
D5H9X3	<i>Salinibacter ruber strain M8</i>
Q2S1W1	<i>Salinibacter ruber strain D.</i>
A0A085WN59	<i>Hyalangium minutum</i>
A0A0G2ZRH9	<i>Archangium gephyra</i>
A0A0S8HAC5	<i>Gemmatimonas sp. SM23_52</i>
A0A177Q5I1	<i>Vernicomicrobia bacterium SC</i>
D8TVM2	<i>Volvox carteri f. nagariensis</i>
A0A084SWJ9	<i>Cystobacter violaceus Cb vi76</i>
Q096A6	<i>Stigmaiella aurantiaca stra.</i>
R7QMZ0	<i>Chondrus crispus</i>
A0A0G4J5Q9	<i>Plasmodiophora brassicae</i>
A0A0Q9RNC6	<i>Nocardioides sp. Soil797</i>
A0A010YG34	<i>Cryptosporangium arzum DSM 4</i>
A0A098BJC6	<i>Putative Rhodococcus ruber</i>
A0A059ML28	<i>Rhodococcus aetherivorans</i>

Accession No.	Source Organism
N1M744	<i>Rhodococciis sp. EsD8</i>
W3ZXB8	<i>Rhodococciis rhodochrous ATCC</i>
A0A0A9CKJ6	<i>2 Arundo donax</i>
F4PQH3	<i>Dictyostelium fasciculatiim</i>
T0Z1P9	<i>Coccomyxa suhellipsoidea si.</i>
A0A076ESS0	<i>Rhodococciis opacus</i>
D3BKV2	<i>Polysphondylium pallidum</i>
X0Q4M3	<i>Putative Rhodococciis wratislaviensis</i>
A0A1D6BHN7	<i>Tnticiim aestivum</i>
C1AZ37	<i>Putative Rhodococciis opacus strain B4</i>
M7ZG40	<i>Triticum urartii</i>
W8HEJ3	<i>Rhodococciis opacus PD630</i>
A0A135GJ74	<i>Rhodococciis sp. SC4</i>
A0A149ZW75	<i>Rhodococcus sp. LB1</i>
Q0SF32	<i>Rhodococcus jostii strain R.</i>
J2JJ09	<i>Rhodococcus sp. JVH1</i>
K8XW36	<i>Rhodococciis opacus M213</i>
A0A152A546	<i>Dictyostelium lacleum</i>
A0A0Q8ZY28	<i>Flavobacterium sp. Root901</i>
L2TJT8	<i>Rhodococcus wratislaviensis</i>
T0WB64	<i>Rhodococcus imtechensis</i>
A0A1B1KC92	<i>Rhodococcus opacus</i>
I3C521	<i>Joostella marina DSM 19592</i>
A0A0F6W8X8	<i>Sandaracinus amylolyticiis</i>
I3Z8X9	<i>Belliella baltica strain DS</i>

Accession No.	Source Organism
A0A0J6W3K0	<i>Mycobacterium obuense</i>
A0A0Q7GA13	<i>Fiavobacterium</i> sp. Root420
D3BUR8	<i>Polysphondylium pallidum</i>
A0A098SD35	<i>Phaeodactylibacter xiamenensis</i>
A0A0D1LF86	<i>Mycobacterium llutzerense</i>
A0A0Q5QHB8	<i>Williamsia</i> sp. Leaf354
A0A139VJG5	<i>Mycobacterium phlei</i> DSM 4323
F4PMW9	<i>Dictyostelium fasciculatum</i>
A0A180ERQ3	<i>Lewinella</i> sp. 4G2
Q8MMS1	<i>Dictyostelium discoideum</i>
A0A101CR99	<i>Fiavobacteriaceae</i> bacterium
A0A0Q9TDE2	<i>Nocardioides</i> sp. Soil805
A0A0Q9DX23	<i>Fiavobacterium</i> sp. Root935
A0A0C1XE41	<i>Hassallia byssoidea</i> VB5121 70
A0A0J6W7K0	<i>Mycobacterium chubuense</i>
A0A0H4PGA5	<i>Cyclobacterium amurskyense</i>
A0A1B1WLB8	<i>Mycobacterium</i> sp. djl-10
A0A0Q8NET9	<i>Fiavobacterium</i> sp. Root 186
A0A0J6ZGS8	<i>Mycobacterium chlorophenolicum</i>
A0A085ZIW1	<i>Fiavobacterium reichenbachii</i>
J3BZ97	<i>Fiavobacterium</i> sp. strain C.
A0A066WRY7	<i>Flavohactermm seoulense</i>
K2PYQ1	<i>Galbibacter marinus</i>
A0A0G4IN41	<i>Plasmodiophora brassicae</i>
A0A1B5ZW29	<i>Arenibacter</i> sp. C-2/

Accession No.	Source Organism
A0A1B9DW83	<i>Flavobacterium piscis</i>
A0A099CMP1	<i>Mycobacterium rufum</i>
A0A1B2U6C7	<i>Flavobacterium johnsoniae</i>
A0A0M8YPK7	<i>Saccharothrix sp. NRRL B-16348</i>
A0A0T1WAX5	<i>Mycobacterium sp. Root 135</i>
K0VAQ4	<i>Mycobacterium vaccae</i>
A0A0Q9JG60	<i>Mycobacterium sp. Soil538</i>
A0A0M0TLE5	<i>Flavobacterium sp. VMW</i>
A0A151ZK81	<i>Diciyostelium lacteum</i>
K6WMK4	<i>Putative Gordonia rhizosphaera NBRC 16</i>
L8GZJ4	<i>Acanthamoeba castellanii</i>
I4BLB8	<i>Mycobacterium chubuense</i>
H0RLL0	<i>Putative Gordonia polyisoprenivorans</i>
A0A0C1LEQ5	<i>Prauserella sp. Am3</i>
A0A1E4NXS4	<i>Pseudonocardia sp. SCN 73-27</i>
A0A1A1YGK6	<i>Mycobacterium sp. ACS4331</i>
A0A0G3ILT8	<i>Mycobacterium sp. EPa45</i>
G7GR35	<i>Putative Gordonia amarae NBRC 15530</i>
A0A1A2LUF7	<i>Mycobacterium sp. El 36</i>
A0A1A3GTN2	<i>Mycobacterium mucogenicum</i>
A0A1A0RZ49	<i>Mycobacterium sp. 852002-519..</i>
A0A101 AHKO	<i>Mycobacterium sp. IS-1496</i>
A0A126YBZ9	<i>Streptomyces alhiis</i>
A0A0X3WJ69	<i>Streptomyces griseus subsp.</i>
A0A1C4KUQ6	<i>Streptomyces sp. BvitLS-983</i>

Accession No.	Source Organism
A0A1C4T5K2	<i>Streptomyces sp. OspMP-M43</i>
A0A1A3C0V1	<i>Mycobacterium sp. E740</i>
A0A0G4IKE4	<i>Plasmodiophora brassicae</i>
K1VUE5	<i>Streptomyces sp. SMS</i>
D6B5U8	<i>Streptomyces albus J1074</i>
A0A1C4NBH5	<i>Streptomyces sp. ScaeMP-6 W</i>
A0A1C4Q3W7	<i>Streptomyces sp. IgraMP-1</i>
R7WSQ4	<i>Rhodococciis rhodnii LMG 5362</i>
A0A0K2YP95	<i>Rhodococciis sp. RD6.2</i>
XP_011566937	<i>Plutella xylostella</i> peroxisomal acyl-coenzyme A oxidase 1-like
XP_011568279	<i>Plutella xylostella</i> probable peroxisomal acyl-coenzyme A oxidase 1
XP_011568389.1	<i>Plutella xylostella</i> probable peroxisomal acyl-coenzyme A oxidase 1
XP_011554180.1	<i>Plutella xylostella</i> probable peroxisomal acyl-coenzyme A oxidase I
XP_011549583.1	<i>Plutella xylostella</i> probable peroxisomal acyl-coenzyme A oxidase 3
XP_011548846.1	<i>Plutella xylostella</i> probable peroxisomal acyl-coenzyme A oxidase 3
AAP37772	<i>A. thaliana</i> Acyl-CoA oxidase - 3 (ACX3)
XP_011548846.1	<i>plutella xylostella dhmjvxl core 32_85_1 protein XP_011548846.1</i> predicted peroxisomal acyl-coenzyme A oxidase 3

Acyl transferases

[0249] In some embodiments, recombinant microorganisms and methods are provided for the production of short chain fatty alcohols, fatty aldehydes and/or fatty acetates. In certain embodiments, the short chain fatty alcohols, fatty aldehydes and/or fatty acetates have carbon

chain length shorter than or equal to C18. In some preferred embodiments of methods to produce short chain pheromones, select enzymes which prefer to store short-chain fatty acyl-CoAs are co-expressed with one or more fatty acyl desaturase. Such suitable acyltransferase enzymes are exemplified by heterologous or engineered glycerol-3-phosphate acyl transferases (GPATs), lysophosphatidic acid acyltransferases (LPAATs), glycerolphospholipid acyltransferase (GPLATs) and/or diacylglycerol acyltransferases (DGATs). Examples of acyl transferases that are suitable for this purpose are listed in Table 5b.

[0250] In some preferred embodiments of methods to produce fatty alcohols, fatty aldehydes and/or fatty acetates, one or more genes of the microbial host encoding glycerol-3-phosphate acyl transferases (GPATs), lysophosphatidic acid acyltransferases (LPAATs), glycerolphospholipid acyltransferase (GPLATs) and/or diacylglycerol acyltransferases (DGATs) are deleted or downregulated, and replaced with one or more GPATs, LPAATs, GPLATs, or DGATs which prefer to store short-chain fatty acyl-CoAs. Such deletion or downregulation targets include but are not limited to *Y. Upofytica* YAL10C00209g, *Y. lipolytica* YAL10E18964g, *Y. Upofytica* YAL10F19514g, *Y. Upofytica* *Y. Upofytica* YAL10C14014g, *Y. Upofytica* YAL10E16797g, *Y. Upofytica* YAL10E32769g, *Y. Upofytica* YAL10D07986g, *S. cerevisiae* YBLO11w, *S. cerevisiae* YDL052c, *S. cerevisiae* YOR175C, *S. cerevisiae* YPR139C, *S. cerevisiae* YNROOSw, *S. cerevisiae* Y(R)245c, *Candida* I503_02577, *Candida* CTRG_02630, *Candida* CaO19.250, *Candida* Ca019.7881, *Candida* CTRG_02437, *Candida* Ca019.1881, *Candida* Ca019.9437, *Candida* CTRG_01687, *Candida* CaO19.1043, *Candida* Ca019.8645, *Candida* CTRG_04750, *Candida* Ca019.13439, *Candida* CTRG_04390, *Candida* Ca019.6941, *Candida* CaO19.14203, and *Candida* CTRG_06209. In other embodiments, the acyltransferase is inserted at the AXP Acid extracellular protease locus (YAL10B05654g).

[0251] Thus, in some embodiments, the present disclosure teaches a recombinant microorganism comprising an acyltransferase exhibiting at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, or 50% sequence identity with any one of SEQ ID Nos. selected from the group consisting of 92.

[0252] Thus, in some embodiments, the present disclosure teaches a recombinant microorganism comprising a nucleic acid molecule encoding for an acyltransferase, wherein

said nucleic acid molecule exhibits at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, or 50% sequence identity with any one of SEQ ID Nos. selected from the group consisting of 91.

[0253] In some embodiments, the present disclosure teaches a recombinant microorganism comprising at least one nucleic acid molecule encoding an acyltransferase having at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61%, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, or 50% sequence identity to an acyltransferase selected from the group consisting of SEQ ID NO: 92.

[0254] In some embodiments, the present disclosure teaches a recombinant microorganism comprising a deletion, disruption, mutation, and or reduction in the activity of one or more acyltransferases selected from the group consisting of YALI0E32791g (DGA1) and/or YALI0D07986g (DGA2).

[0255] Thus, in some embodiments, the recombinant microorganism of the present disclosure will comprise deletions or other disruptions in endogenous genes encoding proteins exhibiting at least 100%, 99%, 98%, 97%, 95%, 94%, 93%, 92%, 91%, or 90% sequence identity with the proteins encoded by YALI0E32791g (DGA1) and YALI0D07986g (DGA2).

[0256] Thus, in some embodiments, the recombinant microorganism of the present disclosure will comprise deletions in endogenous genes encoding proteins exhibiting at least 100%, 99%, 98%, 97%, 95%, 94%, 93%, 92%, 91%, or 90% sequence identity with uniprot database ID Q6C3R1 (DGA1) and/or Q6C9V5 (DGA2).

Glycerol-3-phosphate acyltransferase (GPAT)

[0257] The present disclosure describes enzymes that catalyze the acylation reaction at the sn-1 position of glycerol 3-phosphate shown as follows:

[0258] a long-chain acyl-CoA + sn-glycerol 3-phosphate → a 1-acyl-sn-glycerol 3-phosphate + coenzyme A.

[0259] Glycerol-3-phosphate acyltransferase (GPAT) catalyzes the acylation reaction at the sn-1 position of glycerol 3-phosphate. The plant cell contains three types of GPAT, which are located in the chloroplasts, mitochondria and cytoplasm. The enzyme in chloroplasts is soluble and uses acyl-(acyl-carrier protein) as the acyl donor, whereas the enzymes in the

mitochondria and the cytoplasm are bound to membranes and use acyl-CoA as the acyl donor (Nishida I et al. (1993) The gene and the RNA for the precursor to the plastid-located glycerol-3-phosphate acyltransferase of *Arabidopsis thaliana*. *Plant Mol Biol.* 21(2): 267-77; Murata N and Tasaka Y (1997) Glycerol-3-phosphate acyltransferase in plants. *Biochim Biophys Acta.* 1348(1-2): 10-16).

[0260] Eight GPAT genes have been identified in *Arabidopsis* (Zheng Z et al. (2003) *Arabidopsis* AtGPAT1, a member of the membrane-bound glycerol-3-phosphate acyltransferase gene family, is essential for tapetum differentiation and male fertility. *Plant Cell* 15(8): 1872-87). GPAT1 was shown to encode a mitochondrial enzyme (Zheng et al. 2003). GPAT4, GPAT5 and GPAT8 were shown to be essential for cutin biosynthesis (Beisson F et al. (2007) The acyltransferase GPAT5 is required for the synthesis of suberin in seed coat and root of *Arabidopsis*. *Plant Cell* 19(1): 351-368; Li, Y et al. (2007) Identification of acyltransferases required for cutin biosynthesis and production of cutin with suberin-like monomers. *Proc Natl Acad Sci USA* 104(46): 18339-18344). GPAT2, GPAT3, GPAT6 and GPAT7 have not been characterized yet.

[0261] The cytoplasmic GPAT is responsible for the synthesis of triacylglycerol and non-chloroplast membrane phospholipids. It is expected to have a substrate preference for palmitate (C16:0) and oleate (C18:1) since these two fatty acids are the most common ones found at the sn-1 position of plant triacylglycerols. The cytoplasmic GPAT was partially purified from avocado (Eccleston VS and Harwood JL (1995) Solubilisation, partial purification and properties of acyl-CoA: glycerol-3-phosphate acyltransferase from avocado (*Persea americana*) fruit mesocarp. *Biochim Biophys Acta* 1257(1): 1-10).

[0262] Membrane-bound glycerol-3-phosphate acyltransferase (PlsB) from *E. coli* catalyzes the first committed step in phospholipid biosynthesis and is thought to function in close proximity to the succeeding enzyme 1-acylglycerol-3-phosphate O-acyltransferase (PlsC) (Kessels JM et al. (1983) Facilitated utilization of endogenously synthesized lysophosphatidic acid by 1-acylglycerophosphate acyltransferase from *Escherichia coli*. *Biochim Biophys Acta* 753(2): 227-235). It is specific for acylation at position 1 of sn-glycerol 3-phosphate and can utilize either fatty acyl-acyl carrier protein (acyl-ACP) or fatty acyl-coenzyme A (acyl-CoA) thioesters as acyl donors to form a 1-acyl-sn-glycerol 3-phosphate. Fatty acids that are endogenously synthesized are attached to ACP and exogenously added fatty acids are attached to CoA. In *E. coli* phospholipids, the sn 1 position is occupied mainly by either palmitate, or cis-vaccenate, whereas the sn 2 position is

predominantly palmitoleate, or cis-vaccenate. This is thought to result from the substrate preferences of the PlsB and PlsC enzymes.

[0263] The *plsB* gene has been shown to be regulated by stress response regulators such as RNA polymerase, sigma 24 (sigma E) factor and ppGpp (Wahl A et al. (2011) Antagonistic regulation of *dgkA* and *plsB* genes of phospholipid synthesis by multiple stress responses in *Escherichia coli*. *Mol Microbiol* 80(5): 1260-75. PlsB is part of a protein network for phospholipid synthesis and interacts with a holo-[acyl-carrier protein] (ACP), esterase/thioesterase (YbgC) and phosphatidylserine synthase (PssA) to form a complex at the cytoplasmic side of the inner membrane.

[0264] *plsB* is essential for growth (Baba T et al. (2006) Construction of *Escherichia coli* K-12 in-frame, single-gene knockout mutants: the Keio collection. *Mol Syst Biol.* 2:2006-2008; Yoshimura M et al. (2007) Involvement of the YneS/YgiH and PlsX proteins in phospholipid biosynthesis in both *Bacillus subtilis* and *Escherichia coli*. *BMC Microbiol* 7: 69).

[0265] Site-directed mutagenesis and chemical modification studies have demonstrated catalytically important amino acid residues in PlsB, including an invariant histidine residue that is essential for catalysis (Lewin TM et al. (1999) Analysis of amino acid motifs diagnostic for the sn-glycerol-3-phosphate acyltransferase reaction. *Biochemistry* 38(18): 5764-5771). Genetic studies have identified the *plsB* locus as involved in the formation of multidrug tolerant persister cells.

[0266] The properties of the *E. coli* B enzyme were studied in earlier work (Kito M et al. (1972) Inhibition of L-glycerol 3-phosphate acyltransferase from *Escherichia coli* by cis-9, 10-methylenehexadecanoic acid. *J Biochem* 71(1): 99-105; Okuyama H and Wakil SJ (1973) Positional specificities of acyl coenzyme A: glycerophosphate and acyl coenzyme A: monoacylglycerophosphate acyltransferases in *Escherichia coli*. *J Biol Chem* 248(14): 5197-5205; Kito M. et al. (1978) Function of phospholipids on the regulatory properties of solubilized and membrane-bound sn-glycerol-3-phosphate acyltransferase of *Escherichia coli*. *Biochim Biophys Acta* 529(2): 237-249).

[0267] A glycerol-3-phosphate/dihydroxyacetone phosphate dual substrate-specific sn-1 acyltransferase is located in lipid particles and the ER and is involved in the stepwise acylation of glycerol-3-phosphate and dihydroxy acetone in lipid biosynthesis. The most conserved motifs and functionally relevant residues are oriented towards the ER lumen.

[0268] A gene (SCT1) encoding a dual glycerol-3-phosphate O-acyltransferase (GATVdihydroxyacetone phosphate acyltransferase (DHAT) was identified, cloned and

biochemically characterized from *Saccharomyces cerevisiae*. In the yeast Δ gpt1 mutant which exhibits very low GAT/DHAT activity, the overexpression of SCT1 through a plasmid vector showed increased GAT/DHAT activity underlining the proposed molecular function as glycerol-3-phosphate O-acyltransferase/ dihydroxyacetone phosphate acyltransferase. The GAT/DHAT activity towards acyl-donors was highest with palmitoleoyl-CoA followed by palmitoyl-CoA, oleoyl-CoA and stearoyl-CoA. The SCT1p was localized to membranes in the cytosol, most probably to the endoplasmic reticulum. In vivo studies of Asct1 mutants did reveal an impact on all four phospholipids but the observed decrease of 16:0 fatty acids in the phosphatidylethanolamine class was balanced out by an increase in other fatty acids, particularly 18:0 molecular species. The null mutants of SCT1 and GPT2 were synthetically lethal in yeast (Zheng Z and Zou J (2001) The initial step of the glycerolipid pathway: identification of glycerol 3-phosphate/dihydroxy acetone phosphate dual substrate acyltransferases in *Saccharomyces cerevisiae*. J Biol Chem 276(45): 417104-41716).

[0269] The gene (GPT2) encoding a dual glycerol-3-phosphate O-acyltransferase (GAT)/dihydroxyacetone phosphate acyltransferase (DHAT) from *Saccharomyces cerevisiae* was identified, cloned and biochemically characterized. GPT2 was recombinantly expressed in *E. coli* in the Δ p1sB background devoid of GAT/DHAT activity and showed an increased GAT activity but could not rescue the mutant probably because of the incorrect embedding of GPT2 in the membrane. In the yeast Δ gpt1 mutant which exhibits very low GAT/DHAT activity, the overexpression of GPT2 from a plasmid vector showed increased GAT/DHAT activity, underlining the proposed molecular function as glycerol-3-phosphate O-acyltransferase/ dihydroxyacetone phosphate acyltransferase. The GAT/DHAT activity towards acyl-donors was highest with oleoyl-CoA followed by palmitoleoyl-CoA, palmitoyl-CoA and stearoyl-CoA.

[0270] The GPT2p was localized to membranes in the cytosol. *In vivo* studies of Δ gpt2 mutants did not reveal any significant impact on the total fatty acid profile but a decrease of 16:1 fatty acids in the phosphatidylethanolamine class was observed which was compensated by an increase in 16:0 and 18:1 molecular species. Analysis of a known yeast mutant TTA1 deficient in GAT activity showed that the TTA1 GPT2 gene had a missense mutation with one nucleotide change in the conserved motif III for acyltransferases. The null mutants of SCT1 and GPT2 were synthetically lethal in yeast (Zheng and Zou 2001).

[0271] In some embodiments, the glycerol-3-phosphate acyltransferase is a GPAT from *Arabidopsis thaliana* (At1g02390). In some embodiments, the glycerol-3-phosphate

acyltransferase is PlsB from *E. coli* (Gene ID EG10740). In some embodiments, the glycerol-3-phosphate acyltransferase is the dual glycerol-3-phosphate O-acyltransferase (GAT)/dihydroxyacetone phosphate acyltransferase (DHAT) SCT1 from *S. cerevisiae* (YBLO11w). In some embodiments, the glycerol-3-phosphate acyltransferase is YALI0C00209g from *Yarrowia lipolytica*. In some embodiments, the glycerol-3-phosphate acyltransferase is l503_02577 from *Candida albicans*. In some embodiments, the glycerol-3-phosphate acyltransferase is CTRG_02630 from *Candida tropicalis*. In some embodiments, the glycerol-3-phosphate acyltransferase is the dual glycerol-3-phosphate O-acyltransferase (GAT)/dihydroxyacetone phosphate acyltransferase (DHAT) GPT2 from *S. cerevisiae* (YKR067w). In some embodiments, the glycerol-3-phosphate acyltransferase is CaO 19.5815 from *Candida albicans*. In some embodiments, the glycerol-3-phosphate acyltransferase is CaO 19.13237 from *Candida albicans*. In some embodiments, the glycerol-3-phosphate acyltransferase is CTRG_02630 from *Candida tropicalis*.

Lysophosphatidic acid acyltransferase (LPAAT)

[0272] The present disclosure describes enzymes that catalyze acylation of the sn-2 position of sn-glycerol.

[0273] Membrane-bound 1-acylglycerol-3-phosphate O-acyltransferase encoded by gene plsC catalyzes the second step in phospholipid biosynthesis and is thought to function in close proximity to the preceding enzyme glycerol-3-phosphate acyltransferase encoded by gene plsB (Kessels JM et al. 1983). It is specific for acylation at the sn-2 position of a 1-acyl-sn-glycerol 3-phosphate and can utilize either acyl-acyl carrier protein (acyl-ACP), or acyl-coenzyme A (acyl-CoA) as the fatty acyl donor to form a 1,2-diacyl-sn-glycerol 3-phosphate (a phosphatidate, a phosphatidic acid). Fatty acids that are endogenously synthesized are attached to ACP and exogenously added fatty acids are attached to CoA (Greenway DL and Silbert DF (1983) Altered acyltransferase activity in *Escherichia coli* associated with mutations in acyl coenzyme A synthetase. J Biol Chem 258(21): 13034-13042). In *E. coli* phospholipids at the sn 1 position is occupied mainly by either palmitate, or cis-vaccenate, whereas the sn 2 position is predominantly palmitoleate, or cis-vaccenate. This is thought to result from the substrate preferences of the PlsB and PlsC enzymes (Rock CO et al. (1981) Phospholipid synthesis in *Escherichia coli*. Characteristics of fatty acid transfer from acyl-acyl carrier protein to sn-glycerol 3-phosphate. J Biol Chem 256(2): 736-742; Goetz SE and Cronan JE (1980) The positional distribution of fatty acids in *Escherichia coli* phospholipids is not regulated by sn-glycerol 3-phosphate levels. J Bacteriol 144(1): 462-464).

[0274] Site directed mutagenesis studies showed that changing threonine-22 to alanine or leucine resulted in changes in acyl-CoA substrate specificity (Morand LZ et al. (1998) Alteration of the fatty acid substrate specificity of lysophosphatidate acyltransferase by site-directed mutagenesis. *Biochem Biophys Res Commun* 244(1): 79-84).

[0275] In an engineered strain of *E. coli*, overexpression of PlsC and GalU resulted in increased production of glycoacylglycerolipids (Mora-Buyé N et al. (2012). An engineered *E. coli* strain for the production of glycoacylglycerolipids. *Metab Eng* 14(5): 551-559).

[0276] The *plsC* gene of *Streptococcus pneumoniae* encodes a 1-acylglycerol-3-phosphate acyltransferase homologous to the *E. coli* enzyme. The gene was cloned and expressed in *E. coli*, and membranes expressing it were shown to catalyze the predicted function (Lu YJ et al. (2006) Acyl-phosphates initiate membrane phospholipid synthesis in Gram-positive pathogens. *Mol Cell* 23(5): 765-772).

[0277] Plant lysophosphatidate acyltransferase (LPAAT) catalyzes acylation of the sn-2 position of triacylglycerol. The substrate specificity of LPAAT in a given plant species generally determines what fatty acid species are incorporated at the sn-2 position. LPAAT has been cloned from maize and meadow foam. There are two LPAAT genes in meadow foam, whereas only one in maize. The enzyme activity of both LAT1 and LAT2 in meadow foam was confirmed by *in vitro* assay. In addition, LAT2 was shown to functionally complement the *E. coli* LPAAT deficient strain (Brown AP et al. (2002) Limnanthes douglasii lysophosphatidic acid acyltransferases: immunological quantification, acyl selectivity and functional replacement of the *Escherichia coli* *plsC* gene. *Biochem J* 364(Pt 3):795-805).

[0278] LAT1 is a highly selective acyltransferase that only uses 18:1-CoA as a substrate. LAT2 is less selective. The highest activity was shown towards 22:1-CoA, followed by 16:0- and 18:1-CoA. The substrate specificities of LAT1 and LAT2 are consistent with their proposed roles, for LAT1 in membrane lipid biosynthesis and LAT2 in storage lipid biosynthesis. Plant cell membranes predominantly contain C16 and C18 unsaturated fatty acids, whereas storage lipids contain a wide range of fatty acids including saturated fatty acids and very long-chain unsaturated fatty acids. The protein level of LAT1 and LAT2 in different plant tissues was detected by antibodies. LAT1 is present in both leaves and developing seeds, whereas LAT2 is only detected in developing seeds. This again is consistent with their proposed roles. The role of LAT2 in triacylglycerol biosynthesis was further shown by transformation of LAT2 in oil seed rape which does not normally contain

22:1-CoA at the sn-2 position. The transformation of the meadow foam LAT2 inserted 22:1-CoA at the sn-2 position (Lassner MW et al. (1995) Lysophosphatidic acid acyltransferase from meadowfoam mediates insertion of erucic acid at the sn-2 position of triacylglycerol in transgenic rapeseed oil. *Plant Physiol* 109(4): 1389-1394).

[0279] Utilizing viable mutant *Saccharomyces cerevisiae* strains lacking sphingolipid biosynthesis, the gene *SLC1* was isolated and demonstrated to encode an acyl-CoA:lysophosphatidate acyltransferase. Sequence homology with the PLSC protein of *E. coli* which is classified as 1-acyl-sn-glycerol-3-phosphate acyltransferase indicated a similar function. This presumed molecular function of *SLC1p* was corroborated by the ability to rescue the *ApisC* mutant of *E. coli*. It could be shown that a single nucleotide alteration changing an L-glutamine to an L-leucine at position 131 transformed the substrate preference from C16 and C18 fatty acids to C26 fatty acids which was reflected in vivo in the corresponding fatty acid composition of wild type (*SLC1*) versus mutant (*SLC1-1*) (Nagiec MM et al. (1993) A suppressor gene that enables *Saccharomyces cerevisiae* to grow without making sphingolipids encodes a protein that resembles an *Escherichia coli* fatty acyltransferase. *J Biol Chem* 268(29): 22156-22163).

[0280] *In vitro* assays with the recombinantly expressed and purified *SLC1p* in *E. coli* revealed a substrate preference towards lyso-phosphatidate and oleoyl-CoA but also accepted 1-palmitoylglycerol 3-phosphate and 1-stearoyl-sn-glycerol 3-phosphate. In vivo studies of mutants such as *Asic1*, *Aslc4* (another potential acyl-CoA:phosphatidyl acyltransferase) and double mutants of *Asic1Aslc4* bearing a plasmid with either the *SLC1* or *SLC4* gene referred to as 2.*ASLC1* (or 2.*ASLC4*) showed that *SLC1* promoted the biosyntheses of phosphatidate and also phosphatidylinositol and diacylglycerol. It was suggested that *SLC1* is involved in phospholipid remodeling by exchanging fatty acids on glycerophospholipids *in vivo* (Benghezal M et al. (2007) *SLC1* and *SLC4* encode partially redundant acyl-coenzyme A 1-acylglycerol-3-phosphate O-acyltransferases of budding yeast. *J Biol Chem* 282(42): 30845-30855).

[0281] Screening the yeast genome with candidate open reading frames (ORFs) of known acyltransferase enzymes and testing the associated deletion strains, the gene encoding an acyl-CoA dependent lyso-phospholipid acyltransferase (*ALE1*) was identified. In the *Aale1* strain a dramatic decrease of lyso-phosphatidylethanolamine acyltransferase (*LPEAT*) activity was observed but it could also be demonstrated that *ALE1p* may provide redundant lyso-phosphatidate acyltransferase (*LPAAT*) activity when the main *LPAAT* in

Saccharomyces cerevisiae, i.e. SLCip, is absent or rendered inactive. ALElp preferably attaches unsaturated acyl chains of varying length to the sn-2 position of lyso-phospholipids. The enzyme was localized to both microsomal and mitochondrial membranes utilizing high purity cell fractionation. It has been proposed that ALEi may be the major LPEAT in the exogenous lysolipid metabolism (ELM) pathway in yeast but it is also required for efficient functioning of the endogenous Kennedy pathway (Riekhof WR et al. (2007) Identification and characterization of the major lysophosphatidylethanolamine acyltransferase in *Saccharomyces cerevisiae*. J Biol Chem 282(39): 28344-28352).

[0282] In a simultaneous study, LPT1 (synonymous to ALEI) was identified by applying a synthetic genetic array analysis and shown to have lyso-phospholipid acyltransferase activity. In this study the best substrate for LPT1 (=ALE1) was lyso-phosphatidylcholine, hence acting as a lyso-phosphatidylcholine acyltransferase (LPCAT) and the residual activity as LPAAT reported earlier was also demonstrated utilizing single Aipt1 and double Ascl1Δipt1 mutants, the latter being inviable. The ratio of incorporating oleate into phosphatidylcholine was determined as 70% towards the de novo synthesis and 30% towards remodeling (Jain S et al. (2007) Identification of a novel lysophospholipid acyltransferase in *Saccharomyces cerevisiae*. J Biol Chem 282(42): 30562-30569).

[0283] The molecular function of ALEI (also referred to as LCA1 or SLC4) as a lyso-phosphatidylcholine acyltransferase (LPCAT) was corroborated in another simultaneous study monitoring the incorporation of radioactive labeled lyso-phosphatidylcholine and/or palmitoyl-CoA into phosphatidylcholine (PC). The study confirmed that ALElp (=LCAlp in this study) was accepting a variety of acyl-donors but showed highest activity as LPCAT regardless of the acyl-chain of lyso-phosphatidylcholine species (16:0 or 18:1). In addition, a high sensitivity towards Zn²⁺ was observed which was inhibitory at concentrations above 0.1 mM and activating at lower concentrations (10 to 25 μM). The high PC turnover-rate measured for ALElp (=LCAlp) emphasized the enzyme as a key catalyst involved in the re-acylation of PC (Chen Q et al. (2007) The yeast acylglycerol acyltransferase LCA1 is a key component of Lands cycle for phosphatidylcholine turnover." FEBS Lett 581(28): 5511-5516).

[0284] The search for genes causing aberrations in the formation of lipid droplets (LD) in *Saccharomyces cerevisiae* identified the gene LOA1 (formerly VPS66) encoding for an acyl-CoA dependent lysophosphatidate acyltransferase. The in vivo molecular function of LOA1p was determined using the comparison of the lipidome of wild type and Aloa1 yeast strains.

The analysis showed that in the LOA1 deficient mutant ($\Delta loal$) the percentage of oleate containing phosphatidate molecular species was considerably reduced and the content of triacylglycerols (TGA) was lowered by 20 percent. The protein was recombinantly expressed in *E. coli* and partially purified by obtaining the highly enriched lipid droplet fraction and by affinity chromatography with LOAlp still attached to the matrix beads. The purified LOAlp was characterized in in vitro assays demonstrating that LOAlp was specific for lysophosphatidate and oleoyl-CoA, thus acting as a oleoyl-CoA: lysophosphatidate acyltransferase in yeast. Based upon the results, LOAlp was proposed to be significantly involved in channeling excess oleate - containing phosphatidate species into TAG biosynthesis and the proper development of lipid droplets (LD's). Utilizing a genomic-tagging construct, subcellular fractionation, immunohistochemistry and fluorescence microscopy LOA1 could be localized to both endoplasmic reticulum (ER) and lipid droplets (LD's) (Ayciriex S et al. (2012) YPR139c/LOA1 encodes a novel lysophosphatidic acid acyltransferase associated with lipid droplets and involved in TAG homeostasis. Mol Biol Cell 23(2): 233-246).

[0285] In some embodiments, the lysophosphatidic acid acyltransferase is plsC from *E. coli* (MetaCyc Accession ID EG11377). In other embodiments, the lysophosphatidic acid acyltransferase is plsC from *S. pneumoniae* (MetaCyc Accession ID G-10763). In some embodiments, the lysophosphatidic acid acyltransferase is LAT1 from *Limnanthes douglasii*. In some embodiments, the lysophosphatidic acid acyltransferase is LAT2 from *Limnanthes douglasii* (MetaCyc Accession ID G-9398). In some embodiments, the lysophosphatidic acid acyltransferase is SLC1 from *Saccharomyces cerevisiae* (YDL052c). In some embodiments, the lysophosphatidic acid acyltransferase is YALI0E18964g from *Yarrowia lipolytica*. In some embodiments, the lysophosphatidic acid acyltransferase is CaO 19.250 from *Candida albicans*. In some embodiments, the lysophosphatidic acid acyltransferase is Ca019.7881 from *Candida albicans*. In some embodiments, the lysophosphatidic acid acyltransferase is CTRG_02437 from *Candida tropicalis*. In some embodiments, the lysophosphatidic acid acyltransferase is ALE1 from *Saccharomyces cerevisiae* (YOR175C). In some embodiments, the lysophosphatidic acid acyltransferase is YALI0F19514g from *Yarrowia lipolytica*. In some embodiments, the lysophosphatidic acid acyltransferase is CaO 19.1881 from *Candida albicans*. In some embodiments, the lysophosphatidic acid acyltransferase is Ca019.9437 from *Candida albicans*. In some embodiments, the lysophosphatidic acid acyltransferase is CTRG_01687 from *Candida tropicalis*. In some embodiments, the lysophosphatidic acid

acyltransferase is LOA1 from *Saccharomyces cerevisiae* (YPR139C). In some embodiments, the lysophosphatidic acid acyltransferase is YALI0C14014g from *Yarrowia lipolytica*. In some embodiments, the lysophosphatidic acid acyltransferase is CaO19.1043 from *Candida albicans*. In some embodiments, the lysophosphatidic acid acyltransferase is CaO19.8645 from *Candida albicans*. In some embodiments, the lysophosphatidic acid acyltransferase is CTRG_04750 from *Candida tropicalis*.

Glycerolphospholipid acyltransferase (GPLAT)

[0286] The present disclosure describes enzymes that catalyze the following reaction:

[0287] 1-alkyl-sn-glycero-3-phosphoethanolamine + a 2-acyl-1-alkyl-sn-glycero-3-phosphocholine \rightarrow an 0-1-alkyl-2-acyl-sn-glycero-3-phosphoethanolamine + a 1-alkyl-2-lyso-sn-glycero-3-phosphocholine

[0288] GPLAT enzymes catalyze the transfer of fatty acids from intact choline- or ethanolamine-containing glycerolphospholipids to the sn-2 position of a lyso-glycerolphospholipid. The organyl group on sn-1 of the donor or acceptor molecule can be alkyl, acyl or alk-1-enyl. The term 'radyl' has sometimes been used to refer to such substituting groups. The enzyme requires Coenzyme A and does not favor the transfer of polyunsaturated acyl groups.

Diacylglycerol acyltransferase (DGAT)

[0289] The present disclosure describes enzymes that add an acyl group to the sn-3 position of diacylglycerol (DAG) to form triacylglycerol (TAG).

[0290] Diacylglycerol acyltransferase (DGAT) catalyzes the only unique reaction in triacylglycerol biosynthesis. It adds an acyl group to the sn-3 position of diacylglycerol (DAG) and forms triacylglycerol (TAG), shown as follows:

[0291] an acyl-CoA + a 1,2-diacyl-sn-glycerol \rightarrow a triacyl-sn-glycerol + coenzyme A.

[0292] DGAT accepts a broad range of acyl-CoA as acyl donor including C18:1, C18:2, and C20:1 acyl-CoA as demonstrated for the *Arabidopsis* DGAT (Jako C et al. (2001) Seed-specific over-expression of an *Arabidopsis* cDNA encoding a diacylglycerol acyltransferase enhances seed oil content and seed weight. Plant Physiol 126(2): 861-874). Expressing the *Arabidopsis* cDNA of DGAT in an insect cell culture and in yeast, as well as over-expressing the cDNA in wild type *Arabidopsis*, demonstrated the DGAT activity in transferring an acyl group to the sn-3 position of DAG (Hobbs DH et al. (1999) Cloning of a cDNA encoding diacylglycerol acyltransferase from *Arabidopsis thaliana* and its functional expression. FEBS Lett 452(3): 145-149; Zou J et al. (1999) The *Arabidopsis thaliana* TAG1 mutant has a

mutation in a diacylglycerol acyltransferase gene. Plant J 19(6): 645-653). Over-expression of the *Arabidopsis* cDNA in wild type *Arabidopsis* increased oil deposition in seeds and this increase is correlated to the increased mRNA expression level of DGAT. This indicates that DGAT is a regulatory point of the triacylglycerol biosynthesis pathway.

[0293] The gene encoding the bifunctional acyl-CoA:acylglycerol acyltransferase (DGAT) has been identified in *Saccharomyces cerevisiae* as a major contributor to triacylglycerol biosynthesis (Sandager L et al. (2002.) Storage lipid synthesis is non-essential in yeast. J Biol Chem 277(8): 6478-6482). The gene (DGA1) belongs in the DGAT2 family which members are characterized as acyl-CoA dependent acyltransferases (Lardizabai KD et al. (2001) DGAT2 is a new diacylglycerol acyltransferase gene family: purification, cloning, and expression in insect cells of two polypeptides from *Mortierella ramanniana* with diacylglycerol acyltransferase activity." J Biol Chem 276(42): 38862-38869). It has been demonstrated that DGA1p is the only acyl-CoA dependent acyltransferase catalyzing the esterification of diacylglycerol (DAG) to triacylglycerol (TAG) in the yeast genome. This has been shown in deletion mutants of DGA1 (Adgal) and in combination with the deletion of the other diacylglycerol acyltransferase of importance in yeast, i.e. LRO1 which esterifies DAG utilizing a phospholipid acyl donor (Alro1). In the Adgal Alro1 double mutant almost all of the diacylglycerol acyltransferase has been lost and TAG synthesis was abolished. A plasmid carrying the DGA1 gene could rescue the TAG synthetic deficiency in the mutant indicating that *in vivo* DGA1 was prominently involved in the TAG biosynthetic route (Sorger D, Daum G (2002). Synthesis of triacylglycerols by the acyl-coenzyme A:diacylglycerol acyltransferase Dgalp in lipid particles of the yeast *Saccharomyces cerevisiae*. J Bacteriol 184(2): 519-524; Oeikers P et al. (2002) The DGA1 gene determines a second triglyceride synthetic pathway in yeast. J Biol Chem 277(11): 8877-8881). In vitro a preference of DGA1p towards oleoyl-CoA and palmitoyl-CoA was observed which is inverted for the phospholipid dependent acyltransferase LRO1p (Oeikers et al. 2002).

[0294] In addition, the function of DGA1p as an acyl-CoA dependent monoacylglycerol acyltransferase (MGAT) was demonstrated in vivo utilizing Adgal mutants which had lost more than 60% of the MGAT activity. The in vitro MGAT activity of DGA1 was shown by the oleoyl-CoA dependent esterification of 2-oleoylglycerol yielding 1,2-dioleoylglycerol in the process (Heier C et al. (2010) Identification of Yju3p as functional orthologue of mammalian monoglyceride lipase in the yeast *Saccharomyces cerevisiae*. Biochim Biophys Acta 1801(9): 1063-1071).

[0295] More insights into the functional importance and topological orientation of sequence motifs in the primary sequence of DGA1p has been gained by in silico analyses, site-directed mutagenesis of signature motifs and deletion mutations of the C- and N-termini. It could be demonstrated that besides the signature motifs found in other DGAT2 family members *Saccharomyces* possesses a unique hydrophilic stretch which was shown to significantly modulate enzyme activity. Also, the histidine residue 195 in the second of the four determined transmembrane domains was proven to be essential for enzyme activity. The topology of DGA1 revealed that both C- and N-termini face the cytoplasm and that the C-terminus was more important for DGA1 activity than the N-terminus (Liu Q et al. (2011) Functional and topological analysis of yeast acyl-CoA:diacylglycerol acyltransferase 2, an endoplasmic reticulum enzyme essential for triacylglycerol biosynthesis. *J Biol Chem* 286(15): 13115-13126).

[0296] Using highly purified cell fragments and immunoblotting, Sorger et al. (2002) and Liu et al. (2011) demonstrated that DGA1 was localized to lipid droplets and microsomal membranes, most probably the endoplasmic reticulum.

[0297] *Acinetobacter* sp. ADPI expresses a bifunctional enzyme that exhibits both wax ester synthase (WS) and acyl-CoA:diacylglycerol acyltransferase (DGAT) activities (Kalscheuer R and Steinbüchel A (2003) A novel bifunctional wax ester synthase/acyl-CoA:diacylglycerol acyltransferase mediates wax ester and triacylglycerol biosynthesis in *Acinetobacter calcoaceticus* ADPI. *J Biol Chem* 278(10): 8075-8082). This homodimer catalyzes the final steps in TAG and WE biosynthesis (Stoveken T et al. (2005) The wax ester synthase/acyl coenzyme A:diacylglycerol acyltransferase from *Acinetobacter* sp. strain ADPI: characterization of a novel type of acyltransferase. *J Bacteriol* 187(4): 1369-1376). It mediates both oxo ester and thio ester bond formation and has a broad substrate range, accepting medium chain fatty alcohols and acyl-CoA esters as well as monoacylglycerols (MAGs) (Uthoff S et al. (2005) Thio wax ester biosynthesis utilizing the unspecific bifunctional wax ester synthase/acyl coenzyme A:diacylglycerol acyltransferase of *Acinetobacter* sp. strain ADPI. *Appl Environ Microbiol* 71(2): 790-796).

[0298] In some embodiments, the diacylglycerol acyltransferase is TAG1 from *Arabidopsis thaliana* (Gene ID AT2G19450). In some embodiments, the diacylglycerol acyltransferase is DGA1 from *S. cerevisiae* (YQR245c). In some embodiments, the diacylglycerol acyltransferase is atfA from *Acinetobacter* sp. ADPI (MetaCyc Accession ID ACIAD0832). In some embodiments, the diacylglycerol acyltransferase is YALI0E32769g from *Yarrowia*

lipofytica. In some embodiments, the diacylglycerol acyltransferase is Ca019.6941 from *Candida albicans*. In some embodiments, the diacylglycerol acyltransferase is CaO19.14203 from *Candida albicans*. In some embodiments, the diacylglycerol acyltransferase is CTRG_06209 from *Candida tropicalis*.

[0299] Phospholipid: diacylglycerol acyltransferase (PDAT) catalyzes the following reaction: a phosphatidylcholine + a 1,2-diacyl-sn-glycerol \rightarrow a triacyl-sn-glycerol + a 1-acyl-sn-glycero-3-phosphocholine.

[0300] The *Arabidopsis* PDAT can use different phospholipids as acyl donor, with acyl groups of 10-22 carbon chain length at either sn- positions (Stahl U et al. (2004) Cloning and functional characterization of a phospholipid:diacylglycerol acyltransferase from *Arabidopsis*. Plant Physiol 135(3): 1324-1335). Acyl group at the sn-2 position of phosphatidylcholine is however used three times greater than at the sn-1 position. The highest activity is with acyl groups having multiple double bonds, epoxy or hydroxy groups. Among the tested, the enzyme activity was highest with ricinoleoyl. 18:0- and 22:1-acyl groups gave the lowest enzyme activity. Among different phospholipid species, higher activity is with phosphatidylethanolamine than with phosphatidate or phosphatidylcholine.

[0301] A PDAT activity was detected in castor bean seed microsome fraction. Radio-labeled ricinoleoyl and vernoloyl groups are effectively transferred from phosphatidylcholine to DAG forming triacylglycerol (Dahlqvist A et al. (2000) Phospholipid: diacylglycerol acyltransferase: an enzyme that catalyzes the acyl-CoA-independent formation of triacylglycerol in yeast and plants. Proc Natl Acad Sci USA 97(12): 6487-6492).

[0302] In other embodiments, the diacylglycerol acyltransferase is a phospholipid: diacylglycerol acyltransferase (PDAT). In some embodiments, the PDAT is from *Arabidopsis thaliana* (Gene ID AT5G13640). In some embodiments, the PDAT is from *Ricinus communis*. In some embodiments, the PDAT is LROI from *Saccharomyces cerevisiae* (YNR008w). In some embodiments, the PDAT is YALI0E16797g from *Yarrowia lipolytica*. In some embodiments, the PDAT is Ca019.13439 from *Candida albicans*. In some embodiments, the PDAT is CTRG_04390 from *Candida tropicalis*.

[0303] In some embodiments, a recombinant microorganism capable of producing a mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol, fatty aldehyde and/or fatty acetate from an endogenous or exogenous source of saturated C_6 - C_{24} fatty acid is provided, wherein the recombinant microorganism expresses one or more acyltransferase enzymes, and wherein the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the

activity of one or more endogenous acyltransferase enzymes. In some embodiments, the one or more acyltransferase enzymes being expressed are different from the one or more endogenous acyltransferase enzymes being deleted or downregulated. In some embodiments, the one or more endogenous or exogenous acyltransferase enzymes comprise glycerol-3-phosphate acyl transferases (GPATs), lysophosphatidic acid acyltransferases (LPAATs), glycerolphospholipid acyltransferase (GPLATs) and/or diacylglycerol acyltransferases (DGATs). In some embodiments, the one or more acyltransferase enzymes being expressed prefer to store short-chain fatty acyl-CoAs. In other embodiments, the one or more acyltransferase enzymes being expressed are selected from Table 5b. In some embodiments, the one or more endogenous acyltransferase enzymes being deleted or downregulated are selected from *Y. lipofytica* YALI0C00209g, *Y. lipofytica* YALT0E18964g, *Y. lipolytica* YALI0F19514g, *Y. lipolytica* YALI0C14014g, *Y. lipolytica* YALI0E16797g, *Y. lipolytica* YALI0E32769g, *Y. lipofytica* YALI0D07986g, *S. cerevisiae* YBL0llw, *S. cerevisiae* YDL052c, *S. cerevisiae* YOR175C, *S. cerevisiae* YPR139C, *S. cerevisiae* YNR008w, *S. cerevisiae* YOR245c, *Candida* T503_02577, *Candida* CTRG_02630, *Candida* CaO19.250, *Candida* Ca019.7881, *Candida* CTRG__02437, *Candida* Ca019.1881, *Candida* Ca019.9437, *Candida* CTRG__01687, *Candida* CaO19.1043, *Candida* Ca019.8645, *Candida* CTRG_04750, *Candida* CaO19.13439, *Candida* CTRG_04390, *Candida* Ca019.6941, *Candida* CaO19.14203, and *Candida* CTRG__06209. In some embodiments, the recombinant microorganism further expresses pheromone biosynthetic pathway enzymes. In further embodiments, the pheromone biosynthetic pathway enzymes comprise one or more fatty acyl desaturase and/or fatty acyl conjugase. In yet further embodiments, the pheromone biosynthetic pathway enzymes comprise one or more fatty alcohol forming fatty acyl reductase.

[0304] In some embodiments, a method of producing a mono- or poly-unsaturated \leq C₁₈ fatty alcohol, fatty aldehyde and/or fatty acetate from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid are provided, wherein the method comprises introducing into or expressing in a recombinant microorganism at least one endogenous or exogenous nucleic acid molecule encoding an acyltransferase and introducing a deletion, insertion, or loss of function mutation in one or more gene encoding an acyltransferase, wherein the at least one endogenous or exogenous nucleic acid molecule encoding an acyltransferase being introduced or expressed is different from the one or more gene encoding an acyltransferase being deleted or downregulated. In some embodiments, the at least one endogenous or

exogenous nucleic acid molecule encoding an acyltransferase being introduced or expressed or the one or more gene encoding an acyltransferase being deleted or downregulated comprise glycerol-3-phosphate acyl transferases (GPATs), lysophosphatidic acid acyltransferases (LPAATs), glycerolphospholipid acyltransferase (GPLATs) and/or diacylglycerol acyltransferases (DGATs). In some embodiments, the at least one endogenous or exogenous nucleic acid molecule encodes an acyltransferase that prefers to store short-chain fatty acyl-CoAs. In some embodiments, the at least one endogenous or exogenous nucleic acid molecule encodes an acyltransferase selected from Table 5b. In some embodiments, the one or more endogenous acyltransferase enzymes being deleted or downregulated are selected from *Y. lipolytica* YALI0C00209g, *Y. lipolytica* YALIOE18964g, *Y. lipolytica* YALT0F19514g, *Y. lipolytica* YAU0CA4014g, *Y. lipolytica* YALIOE16797g, *Y. lipolytica* YALIOE32769g, *Y. lipolytica* YALIOD07986g, *S. cerevisiae* YBL011w, *S. cerevisiae* YDL052c, *S. cerevisiae* YOR175C, *S. cerevisiae* YPR139C, *S. cerevisiae* YNROOSw, *S. cerevisiae* YOR245c, *Candida* I503_02577, *Candida* CTRG_02630, *Candida* CaO19.250, *Candida* CaO19.7881, *Candida* CTRG_02437, *Candida* CaO19.1881, *Candida* CaO19.9437, *Candida* CTRG_01687, *Candida* CaO19.1043, *Candida* CaO19.8645, *Candida* CTRG_04750, *Candida* CaO19.13439, *Candida* CTRG_04390, *Candida* CaO19.6941, *Candida* CaO19.14203, and *Candida* CTRG_06209. In some embodiments, the method further comprises introducing into or expressing in the recombinant microorganism at least one endogenous or exogenous nucleic acid molecule encoding a fatty acyl desaturase and/or fatty acyl conjugase. In further embodiments, the method further comprises introducing into or expressing in the recombinant microorganism at least one endogenous or exogenous nucleic acid molecule encoding a fatty alcohol forming fatty acyl reductase.

Table 5b, Exemplary acyltransferases

Accession No.	Source Organism
AAL49962.1	<i>Bos taurus</i>
BAC43739.1	<i>Rattus norvegicus</i>
AAH89846.1	<i>Rattus norvegicus</i>
F6TMU0	<i>Equus caballus</i>
F6PXX7	<i>Equus caballus</i>

Accession No.	Source Organism
F7B020	<i>Equus caballus</i>
ALT83519.1	<i>Macadamia tetraphylla</i>
ANN46862.1	<i>Cuphea avigera</i>
ANN46863.1	<i>Cuphea avigera</i>
ANN46864.1	<i>Cuphea avigera</i>
ANN46865.1	<i>Cuphea avigera</i>
AAC49 119.1	<i>Cocos nucifera</i>
JAT48335.1	<i>Anthurium amnicola</i>
XP__008793203.1	<i>Phoenix dactylifera</i>
XP__008806896.1	<i>Phoenix dactylifera</i>
XP__008806740.1	<i>Phoenix dactylifera</i>
XP__010908895.1	<i>Elaeis guineensis</i>
XP__010908896.1	<i>Elaeis guineensis</i>
Q96UY2	<i>Umbelopsis ramanniana</i>
A0A077WEU5	<i>Lichtheimia ramosa</i>
A0A068SDP4	<i>Lichtheimia corymbifera</i> JMRC
A0A068RXA2	<i>Lichtheimia corymbifera</i> JMRC
A0A197JCE2	<i>Mortierelia elongata</i> AG-77
A0A1C7N060	<i>Choanephora cucurbitarum</i>
I1BLC3	<i>Rhizopus delemar</i>
A0A1C7NC56	<i>Choanephora cucurbitarum</i>
A0A077X3B5	<i>Lichtheimia ramosa</i>
Q96UY1	<i>Umbelopsis ramanniana</i>
A0A077WVD4	<i>Lichtheimia ramosa</i>
A0A163K8G3	<i>Absidia glauca</i>

Accession No.	Source Organism
S2J8P3	<i>Mucor circineHoides</i>
A0A168J818	<i>Mucor circineHoides</i>
A0A0C9MR10	<i>Mucor arnbiguus</i>
A0A162PN39	<i>Phycomyces hlakesleeanus</i>
A0A167QXD0	<i>Phycomyces hlakesleeanus</i>
A0A0C9M4C3	<i>Mucor arnbiguus</i>
A0A0B7NDT1	<i>Parasitella parasitica</i>
A0A015LM78	<i>Rhizophagus irregularis</i>
A0A0B7NHQ3	<i>Parasitella parasi iica</i>
A0A0A1NVK5	<i>Rhizopus microsporias</i>
A0A0A1P436	<i>Rhizopus microsporia</i>
A0A0D7BI48	<i>Cylindrohasidium torrendii</i>
A0A1B9HZT8	<i>Kwoniella pini</i>
A0A1D1XN50	<i>Anthurium amnicola</i>
A0A1B9ILF0	<i>Kwoniella mangroviensis</i>
S2JU94	<i>Mucor circineHoides</i>
A0A1B9GCB0	<i>Kwoniella bestiolae CBS 101 1S</i>
A0A068RKT0	<i>Lichtheimia corymhifera</i>
Q5KFU4	<i>Cryptococcus neoformans</i>
Q55QC2	<i>Cryptococcus neoformans</i>
U5GY58	<i>Microhotryum lychnidis</i>
A0A197KA94	<i>Mortierella elongata AG-77</i>
A0A088FR92	<i>Rhodotorula dihovata</i>
A0A194SBY3	<i>Rhodotorula grammis</i>
E6R8N8	<i>Cryptococcus gattii</i>

Accession No.	Source Organism
M7WKS9	<i>Rhodosporidium toruioides</i>
A0A191UMW0	<i>Rhodosporidium toruioides</i>
C6KZS6	<i>Rhodosporidium toruioides</i>
J9VS50	<i>Cryptococcus neoformans</i>
A0A109FM23	<i>Rhodotorula sp. JG-lb</i>
I4YE91	<i>Wallemia mellicola</i>
A0A066WAJ3	<i>Tilletiaria anomala UBC 951</i>
A0A151VHJ4	<i>Hypsizygus marmoreus</i>
A0A168LDJ3	<i>Absidia glauca</i>
A0A0A1ULK8	<i>Rhizoctonia solani AG-3 RhslAP</i>
A0A074RWU7	<i>Rhizocionia solani 123E</i>
A0A0K6FWT6	<i>Rhizoctonia solani</i>
R9AL76	<i>Wallemia ichthyophaga</i>
E6ZMU5	<i>Sporisorium reilianum</i>
A0A0K3CJX4	<i>Rhodosporidium toruioides</i>
A0A162Y103	<i>Phycomyces blakesleeanus</i>
A0A0B7FYU9	<i>Thanatephorus cucumeris</i>
A0A1A5ZUI2	<i>Kwoniella dejecticola</i>
A0A1B9GXE9	<i>Kwoniella heveanensis BCC8398</i>
V5E1P7	<i>Kalmanozyma brasiliensis</i>
A0A127ZHG0	<i>Sporisorium scitamineum</i>
M5FTN9	<i>Dacryopinax primogenitus</i>
A0A166HX72	<i>Sistotremastrum suecicum</i>
A0A067QH80	<i>Jaapia argillacea MUCL 33604</i>
A0A165PFB6	<i>Neolentinus lepideus</i>

Accession No.	Source Organism
G7DXE4	<i>Mixia osmundae</i>
A0A165KJK5	<i>Exidia glandulosa</i> HHB 12029
A0A0F7TLQ7	<i>Penicillium brasiUariiim</i>
S8FI87	<i>Fomitopsis pinicola</i>
S7ZL04	<i>Penicillium oxalicum</i>
I2FMX3	<i>Ustilago hordei</i>
F8P370	<i>Serpula lactymans</i>
V2WTH2	<i>Moniliophthora roreri</i>
S7Q9H4	<i>Gloeophyllum trabeum</i>
W3VTZ4	<i>Pseudozyrna aphidis</i>
B8M0V7	<i>Talaromyces stipilatus</i>
A0A0D7B6H5	<i>Cylindrohasidiium torrendii</i>
R7SCW4	<i>Tremella mesenterial</i>
A0A093UWD0	<i>Talaromyces marneffeii</i> PML
B6Q8Q9	<i>Talaromyces marneffeii</i>
A0A093VC12	<i>Talaromyces marneffeii</i> PML
A0A167SF58	<i>Caicocera viscosa</i> Ti/F'C12733
A0A180GQ68	<i>Puccinia iriticina</i>
E3KWZ5	<i>Piuccinia graminis</i> f. sp.
F4S978	<i>Melampsora larici-popu</i> Una
A0A0U5GN87	<i>Aspergillus calidoustus</i>
W9WBT1	<i>Cladopkialophora yegresii</i>
A0A0D2A9G0	<i>Verrucosis gallopava</i>
S3DKQ1	<i>Glarea lozoyensis</i>
A0A167S691	<i>Penicillium chrysogenum</i>

Accession No.	Source Organism
A0A0C3G1P8	<i>Piloderma croceum</i> F 1598
A0A117NM34	<i>Penicillium freii</i>
A0A0M8NPT1	<i>Penicillium nordicum</i>
M2R3J5	<i>Ceriporiopsis siibvermispora</i>
A0A1E3JS60	<i>Cryptococcus depauperatus</i>
V9DJY4	<i>Cladophialophora carrionii</i>
A0A1C1D128	<i>Cladophialophora carrionii</i>
A0A194XRZ1	<i>Phialocephala scopiformis</i>
A0A135LQY4	<i>Penicillium patulum</i>
F2S034	<i>Trichophyton tonsurans</i>
A0A059J710	<i>Trichophyton interdigitale</i>
R7YTC1	<i>Coniosporium apollinis</i>
A0A0G4PR1 1	<i>Penicillium camemberti</i> FM 013
F2SHG6	<i>Trichophyton rubrum</i>
A0A022VWY8	<i>Trichophyton rubrum</i> . CBS 288.86
A0A178F1Q9	<i>Trichophyton rubrum</i>
A0A022XM67	<i>Trichophyton soudanense</i>
F2PHM1	<i>Trichophyton equinum</i>
A0A178FDV0	<i>Trichophyton violaceum</i>
A0A0F8UUV5	<i>Aspergillus ochraceoroseus</i>
A0A0F8XD12	<i>Aspergillus rambelii</i>
D8Q1Z6	<i>Schizophyllum commune</i>
A0A0L0VQ99	<i>Puccinia striiformis</i>
W6QE33	<i>Penicillium roqueforti</i>
A0A0J0XU39	<i>Cutaneotrichosporon</i>

Accession No.	Source Organism
K2R1Y7	<i>Macrophomina phaseolma</i>
A0A1B9HIE8	<i>Kwoniella heveanensis</i> CBS 569
A0A0A2KLE4	<i>Peniciilium ilalicum</i>
A0A177FP94	<i>Fonsecaea monophora</i>
Q0CU51	<i>Aspergillus terreus</i>
A0A0D2C195	<i>Exophiala spinifera</i>
K9GS70	<i>Peniciilium digitatum</i>
K9H4T7	<i>Peniciilium digitatum</i>
A0A0A2IRX2	<i>Peniciilium expansum</i>
A0A165XA55	<i>Fibulorhizoctonici</i> sp.
A0A1E3HS30	<i>Cryptococcus clepauperatus</i>
R0JHT6	<i>Setosphaeria turcica</i>
W6XT38	<i>Bipolaris zeicola</i> 26-R-l 3
K1WNS8	<i>Marssonina brunneaf.</i> sp.
A0A077R6Q5	<i>Melanopsichium pennsylvanicum.</i>
A0A0G2F2K4	<i>Phaeomoniella chlamydospora</i>
M2UB23	<i>Cochliobolus heterosirophus</i>
N4WZB4	<i>Cochliobolus heterosirophus</i>
A0A0D2ECJ4	<i>Caproriia semi-imrnersa</i>
K5ULK6	<i>Phanerochaete carnosa</i>
A0A081CNS6	<i>Pseudozyma antarctica</i>
W7E3D1	<i>Bipolaris victoriae</i> FI3
A0A0D1YAT0	<i>Exophiala sideris</i>
V5FVB4	<i>Byssochlamys speciabilis</i>
A0A150V2J4	<i>Acidomyces richmondensis</i> BFW

Accession No.	Source Organism
A0A0D2P224	<i>Hypholoma sublateritium</i>
C5FY83	<i>Arlhroderma otae</i>
A0A0E9NND3	<i>Sailoella complicates</i>
A0A163JY17	<i>Ahsidia glauca</i>
M2SYN8	<i>Cochliobolus sativus</i>
A0A0D2A9Y8	<i>Exophiala oligospernia</i>
B2WFQ5	<i>Pyrenophora tritici</i>
A0A178Z686	<i>Fonsecaea erecta</i>
R1GYF1	<i>Botryosphaeria parva</i>
A0A0D2AM77	<i>Cladophialophora imnnmda</i>
A0A067TPJ7	<i>Galerina rnarginaia CBS 339.88</i>
A0A0G2DT71	<i>Dip!odia seriata</i>
A0A0S6XG57	fungal sp. No. 11243
A1CD57	<i>Aspergillus clavatus strain</i>
W6ZE59	<i>Bipolaris oryzae ATCC 44560</i>
W9X299	<i>Cladophialophora psammophila</i>
A0A0L1HS74	<i>Stemphylium lycopersici</i>
E3RYE6	<i>Pyrenophora teres</i>
A0A178C491	<i>Fonsecaea multimorphosa</i>
A0A0D2JW30	<i>Fonsecaea multimorphosa</i>
A0A100ISZ7	<i>Aspergillus niger</i>
G7XRR4	<i>Aspergillus kawachii</i>
E4ZGH1	<i>Leptosphaeria macuians</i>
A0A0C3AU69	<i>Serendipita vermifera</i>
A0A0U1M481	<i>Talaromyces islandiciis</i>

Accession No.	Source Organism
A0A179UDB8	<i>Ajellomyces dermatitidis</i>
A0A177DML0	<i>Alternaria allemla</i>
A0A074XTA2	<i>Aureobasidium namibiae</i>
R8BK00	<i>Togninia minima</i>
A0A178E1M9	<i>Pyrenochaeta sp. DS3sA Y3a</i>
A0A074XCF2	<i>Aureobasidium puHulans</i>
A0A178CVL7	<i>Fonsecaea nubica</i>
J4H349	<i>Fmbroporia radiculosa</i>
F2T2H3	<i>Ajellomyces dermatitidis</i>
T5C9R0	<i>Blastomyces dermatitidis</i>
C5GGF5	<i>Ajellomyces dermatitidis</i>
F8Q4F5	<i>Serpula lacrymans</i>
A0A074YHW3	<i>Aureobasidium subglaciale</i>
A0A0D2E953	<i>Exophiala xenohiotica</i>
A0A0D2ETM7	<i>Exophiala xenohiotica</i>
A0A163ADJ9	<i>Didymella rabiei</i>
U7PLY5	<i>Sporoihris schenckii</i>
A0A0F2MF45	<i>Sporothrix schenckii 1099-18</i>
A0A0C2J820	<i>Sporothrix brasiliensis 5110</i>
A0A1E3B843	<i>Aspergillus cristaius</i>
A0A0L6WTD3	<i>Termitomyces sp. J132</i>
G2YTS7	<i>Botryotinia fuckeliana</i>
W9XGA9	<i>Capronia epimyces CBS 606.96</i>
A0A0F4YS69	<i>Rasamsoma emersonii</i>
M9LWR9	<i>Pseudozyma antarctica</i>

Accession No.	Source Organism
A0A074WDM7	<i>Aureobasidium melanogenum</i>
M3CBZ0	<i>Sphaerulina musiva</i>
A0A0C7C2J7	<i>Rhizopus microsporias</i>
W9YU83	<i>Capronia coronata</i> CBS 617.96
T8IUH8	<i>Aspergillus oryzae</i>
A0A139HZI0	<i>Pseudocercospora musae</i>
E9DGY4	<i>Coccidioides posadasu</i>
A0A0J6F9P8	<i>Coccidioides posadasii</i>
H6BM52	<i>Exophiala dermatitidis</i>
Q2UDX3	<i>Aspergillus oryzae</i>
M3ASJ4	<i>Pseudocercospora fijiensis</i>
A0A177BZU0	<i>Paraphaeosphaeria sporulosa</i>
A0A017S910	<i>Aspergillus ruber</i> CBS 135680
A0A175WF2	<i>Madurella mycetomatis</i>
A0A0J8UWI6	<i>Coccidioides immitis</i>
A0A0J6YFS7	<i>Coccidioides immitis</i> RMSCC
J3K3F7	<i>Coccidioides immitis</i>
A0A0D2FX82	<i>Rhinocladiella rnackenziei</i>
A0A072PSS5	<i>Exophiala aquamarina</i>
A0A0A1MWE2	<i>Rhizopus microsporus</i>
W2RSU8	<i>Cypheilophora europaea</i>
C0S1D5	<i>Paracoccidioides brasiliensis</i>
C1G9R2	<i>Paracoccidioides brasiliensis</i>
A0A1D2JGH6	<i>Paracoccidioides brasiliensis</i>
A0A166PXN0	<i>Cordyceps brongniartii</i>

Accession No.	Source Organism
Q54GC1	<i>Dictyostelium discoideum</i>
A0A0H1B9A9	<i>Emmonsia parva</i> UAMH 139
R4XEF3	<i>Taphria deformans</i>
D3B2U8	<i>Polysphondylium pallidum</i>
U1HHT8	<i>Endocarpon pusillum</i>
A0A1E3JYY5	<i>Tsuckiyaea wingfieldii</i>
A0A0C3JN41	<i>Pisolithus tinctorius</i> Marx. 270
B6HF05	<i>Penicillium nibens</i>
A0A060S368	<i>Pycnoporus cinnabarinus</i>
K5W449	<i>Agaricus bisporus</i>
B0CTA0	<i>Laccaria bicolor</i>
F0XD96	<i>Grosmannia clavigera</i>
A0A165EP91	<i>Calocera cornea</i> HHB12733

Acylglycerol lipases and sterol esterases

[0305] In some embodiments, recombinant microorganisms and methods are provided for the production of short chain fatty alcohols, fatty aldehydes and/or fatty acetates. In certain embodiments, the short chain fatty alcohols, fatty aldehydes and/or fatty acetates have carbon chain length shorter than or equal to C18. In some preferred embodiments of methods to produce short chain pheromones, select enzymes which prefer to hydrolyze ester bonds of long-chain acylglycerols are co-expressed with one or more fatty acyl desaturases. Such suitable enzymes are exemplified by heterologous or engineered acylglycerol lipases. Examples of acylglycerol lipases that are suitable for this purpose are listed in Table 5c.

[0306] In some preferred embodiments of methods to produce fatty alcohols, fatty aldehydes and/or fatty acetates, one or more genes of the microbial host encoding acylglycerol lipases (mono-, di-, or triacylglycerol lipases) and sterol ester esterases are deleted or downregulated and replaced with one or more acylglycerol lipases which prefer long chain acylglycerol substrates. Such deletion or down-regulation targets include, but are not limited to *Y.*

lipofytica YALIOE32035g, *Y. lipolytica* YALIOD17534g, *Y. hpolytica* YALIOFIOOIOg, *Y. hpofytica* YALIOC14520g, *Y. hpolytica* YALIOE00528g, *S. cerevisiae* YKL140w, *S. cerevisiae* YMR313c, *S. cerevisiae* YKR089c, *S. cerevisiae* YOR081c, *S. cerevisiae* YKL094W, *S. cerevisiae* YLL012W, *S. cerevisiae* YLR020C, *Candida* CaO19.2050, *Candida* CaO19.9598, *Candida* CTRG_01138, *Candida* W5Q_03398, *Candida* CTRG_00057, *Candida* Ca019.5426, *Candida* Ca019.12881, *Candida* CTRG_06185, *Candida* Ca019.4864, *Candida* Ca019.12328, *Candida* CTRG_03360, *Candida* CaO19.6501, *Candida* Ca019.13854, *Candida* CTRG_05049, *Candida* Ca019.1887, *Candida* Ca019.9443, *Candida* CTRG_01683, and *Candida* CTRG_04630.

[0307] Carboxylic ester hydrolases (EC 3.1.1) are a large class of enzymes catalyzing the hydrolysis or synthesis of ester bonds. They have been described in all life domains, prokaryotic and eukaryotic. Most of them belong to the α/β -hydrolase superfamily and have a conserved "catalytic triad" formed by His, an acidic amino acid and a Ser residue that is located in a highly conserved GX SXG sequence. During hydrolysis, the catalytic Ser will start the nucleophilic attack of the substrate helped by the other two residues from the triad, which are in close spatial vicinity. These are presumed to facilitate the hydrolysis of esters by a mechanism similar to that of chymotrypsin-like serine proteases. Another characteristic feature is the presence of an amino acidic region whose sequence is not as conserved as that of the catalytic triad, the oxyanion hole, which serves to stabilize a transition state generated during catalysis. In addition, these enzymes generally do not require cofactors. Acylglycerol lipases and sterol esterases belong to the carboxylic ester hydrolase family.

[0308] An acylglycerol lipase enzyme catalyzes a chemical reaction that uses water molecules to break the glycerol monoesters of long-chain fatty acids. The systematic name of this enzyme class is glycerol-ester acylhydrolase. Other names in common use include monoacylglycerol lipase, monoacylglycerolipase, monoglyceride lipase, monoglyceride hydrolase, fatty acyl monoester lipase, monoacylglycerol hydrolase, monoglyceridylipase, and monoglyceridase. This enzyme participates in glycerolipid metabolism.

[0309] A sterol esterase enzyme catalyzes the chemical reaction:

[0310] $\text{steryl ester} + \text{H}_2\text{O} \rightleftharpoons \text{sterol} + \text{fatty acid}$

[0311] Thus, the two substrates of this enzyme are steryl ester and H₂O, whereas its two products are sterol and fatty acid.

[0312] The systematic name of this enzyme class is steryl-ester acylhydrolase. Other names in common use include cholesterol esterase, cholesteryl ester synthase, triterpenol esterase,

cholesteryl esterase, cholesteryl ester hydrolase, sterol ester hydrolase, cholesterol ester hydrolase, cholesterase, and acylcholesterol lipase. This enzyme participates in bile acid biosynthesis. Sterol esterases are widespread in nature and have been identified from mammals' tissues such as the pancreas, intestinal mucosa, liver, placenta, aorta, and brain, to filamentous fungi, yeast, and bacteria.

[0313] In terms of substrate specificity, many sterol esterases are able to catalyze the hydrolysis or synthesis of a rather broad range of other substrates containing ester linkages, such as acylglycerols, aryl esters, and in some cases alcohol esters, cinnamyl esters, xanthophyll esters, or synthetic polymers.

[0314] In some embodiments, a recombinant microorganism capable of producing a mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol, fatty aldehyde and/or fatty acetate from an endogenous or exogenous source of saturated C_6 - C_{24} fatty acid is provided, wherein the recombinant microorganism expresses one or more acylglycerol lipase and/or sterol ester esterase enzymes, and wherein the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the activity of one or more endogenous acylglycerol lipase and/or sterol ester esterase enzymes. In some embodiments, the one or more acylglycerol lipase and/or sterol ester esterase enzymes being expressed are different from the one or more endogenous acylglycerol lipase and/or sterol ester esterase enzymes being deleted or downregulated. In some embodiments, the one or more endogenous or exogenous acylglycerol lipase and/or sterol ester esterase enzymes being expressed prefer to hydrolyze ester bonds of long-chain acylglycerols. In other embodiments, the one or more acylglycerol lipase and/or sterol ester esterase enzymes being expressed are selected from Table 5c. In some embodiments, the one or more endogenous acylglycerol lipase and/or sterol ester esterase enzymes being deleted or downregulated are selected from *Y. lipolytica* YALIOE32035g, *Y. lipolytica* YALIOD17534g, *Y. lipolytica* YALIOFIOO10g, *Y. lipolytica* YALIOC14520g, *Y. lipolytica* YALIOE00528g, *S. cerevisiae* YKL140w, *S. cerevisiae* YMR313c, *S. cerevisiae* YKR089c, *S. cerevisiae* YORGS1c, *S. cerevisiae* YKL094W, *S. cerevisiae* YLL012W, *S. cerevisiae* YLR020C, *Candida* CaO19.2050, *Candida* CaO19.9598, *Candida* CTRG_01138, *Candida* W5Q_03398, *Candida* CTRG_00057, *Candida* CaO19.5426, *Candida* CaO19.12881, *Candida* CTRG_06185, *Candida* CaO19.4864, *Candida* CaO19.12328, *Candida* CTRG_0336G, *Candida* CaO19.6501, *Candida* CaO19.13854, *Candida* CTRG_05049, *Candida* CaO19.1887, *Candida* CaO19.9443, *Candida* CTRG_01683, and *Candida* CTRG_04630. In some embodiments, the recombinant

microorganism further expresses pheromone biosynthetic pathway enzymes. In further embodiments, the pheromone biosynthetic pathway enzymes comprise one or more fatty acyl desaturase and/or fatty acyl conjugase. In yet further embodiments, the pheromone biosynthetic pathway enzymes comprise one or more fatty alcohol forming fatty acyl reductase.

[0315] In some embodiments, a method of producing a mono- or poly-unsaturated \leq Cis fatty alcohol, fatty aldehyde and/or fatty acetate from an endogenous or exogenous source of saturated C6-C24 fatty acyl-CoA are provided, wherein the method comprises introducing into or expressing in a recombinant microorganism at least one endogenous or exogenous nucleic acid molecule encoding an acylglycerol lipase or sterol ester esterase and introducing a deletion, insertion, or loss of function mutation in one or more gene encoding an acylglycerol lipase or sterol ester esterase, wherein the at least one endogenous or exogenous nucleic acid molecule encoding an acylglycerol lipase or sterol ester esterase being introduced or expressed is different from the one or more gene encoding an acylglycerol lipase or sterol ester esterase being deleted or downregulated. In some embodiments, the at least one endogenous or exogenous nucleic acid molecule encoding an acylglycerol lipase or sterol ester esterase being introduced or expressed prefers to hydrolyze ester bonds of long-chain acylglycerols. In some embodiments, the at least one endogenous or exogenous nucleic acid molecule encoding an acylglycerol lipase or sterol ester esterase being introduced or expressed is selected from Table Sc. In some embodiments, the one or more gene being deleted or downregulated encodes an acylglycerol lipase or sterol ester esterase selected from *Y. lipofytica* YALI0E32035g, *Y. lipofytica* YALI0D17534g, *Y. lipolytica* YALIOF10010g, *Y. lipofytica* YALI0C14520g, *Y. lipofytica* YALI0E00528g, *S. cerevisiae* YKL140w, *S. cerevisiae* YMR313c, *S. cerevisiae* YKR089c, *S. cerevisiae* YOROSlc, *S. cerevisiae* YKL094W, *S. cerevisiae* YLL012W, *S. cerevisiae* YLR020C, *Candida* CaO19.2050, *Candida* CaO19.9598, *Candida* CTRG_01138, *Candida* W5Q_03398, *Candida* CTRG_00057, *Candida* CaO19.5426, *Candida* Ca019.12881, *Candida* CTRG_06185, *Candida* Ca019.4864, *Candida* Ca019.12328, *Candida* CTRG_03360, *Candida* CaO19.6501, *Candida* Ca019.13854, *Candida* CTRG_05049, *Candida* Ca019.1887, *Candida* Ca019.9443, *Candida* CTRG_01683, and *Candida* CTRG_04630. In some embodiments, the method further comprises introducing into or expressing in the recombinant microorganism at least one endogenous or exogenous nucleic acid molecule encoding a fatty acyl desaturase and/or fatty acyl conjugase. In further embodiments, the

method further comprises introducing into or expressing in the recombinant microorganism at least one endogenous or exogenous nucleic acid molecule encoding a fatty alcohol forming fatty acyl reductase.

Table Sc. Exemplary acviglycerol lipases

Accession No.	Source Organism
EAY76846.1	<i>Oryza sativa</i>
OEL29276.1	<i>Dichanthelium oligosanthes</i>
ONM35522.1	<i>Zea mays</i>
AFW56472.1	<i>Zea mays</i>
AFW60230.1	<i>Zea mays</i>
ACG33769.1	<i>Zea mays</i>
ACG30143.1	<i>Zea mays</i>
ACG39100.1	<i>Zea mays</i>
ACG48810.1	<i>Zea mays</i>
KQK11040.1	<i>Brachypodium distachyon</i>
CAA64004.1	<i>Saccharomyces cerevisiae</i>
CAA81640.1	<i>Saccharomyces cerevisiae</i>
CAG78037.1	<i>Yarrowia lipolytica</i>
EEF47288.1	<i>Ricinus communis</i>
EEF45491.1	<i>Ricinus communis</i>
EEF52390.1	<i>Ricinus communis</i>
EEF38788.1	<i>Ricinus communis</i>
EEF38789.1	<i>Ricinus communis</i>
EEF28563.1	<i>Ricinus communis</i>
EEF46013.1	<i>Ricinus communis</i>
AFQ93681.1	<i>Ricinus communis</i>

Accession No.	Source Organism
EEF45592.1	<i>Ricinus communis</i>
EEF43592.1	<i>Ricinus communis</i>
EEF50924.1	<i>Ricinus communis</i>
EEF33440.1	<i>Ricinus communis</i>

Expression of Toxic Proteins or Polypeptides

[0316] The present disclosure describes a toxic protein, peptide, or small molecule that can be encoded by a recombinant microorganism. In some embodiments, the toxic protein, peptide, or small molecule is biosynthetically produced along with an insect pheromone.

[0317] In some embodiments, the recombinant microorganism expresses one or more nucleic acid molecules encoding a protein or polypeptide which is toxic to an insect. In some embodiments, the toxic protein or polypeptide is from an entomopathogenic organism. In some embodiments, the entomopathogenic organism is selected from *Bacillus thuringiensis*, *Pseudomonas aeruginosa*, and *Serratia marcescens*. In a particular embodiment, the nucleic acid molecule encodes a *Bacillus thuringiensis* toxin.

[0318] In some embodiments, a recombinant microorganism is engineered to express a metabolic pathway which, when expressed, produces a small molecule that is toxic to an insect.

[0319] In exemplary embodiments, an insect pheromone produced by a recombinant microorganism described herein may be used to attract a pest insect, and subsequently, the pest insect is eradicated with a toxic substance, such as a toxic protein, peptide, or small molecule, which has been co-produced by a recombinant microorganism described herein.

[0320] Biosynthesis of Pheromones Using a Recombinant Microorganism

[0321] As discussed above, in a first aspect, the present disclosure relates to a recombinant microorganism capable of producing a mono- or poly-unsaturated C₆-C₂₄ fatty alcohol from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acyl-CoA. An illustrative embodiment of the first aspect is shown in Figure 1. The blue lines designate biochemical pathways used to produce a saturated acyl-CoA, which acts as a substrate for unsaturated fatty-acyl CoA conversion. The substrate to unsaturated fatty acyl-CoA conversion can be performed by endogenous or exogenous enzymes in a host. Green lines indicate conversions

catalyzed by an exogenous nucleic acid molecule encoding for an enzyme. Accordingly, in some embodiments, the conversion of a saturated fatty acyl-CoA to a mono- or poly-unsaturated fatty acyl-CoA is catalyzed by at least one desaturase, which is encoded by an exogenous nucleic acid molecule. In further embodiments, the conversion of the mono- or poly-unsaturated fatty acyl-CoA to a mono- or poly-unsaturated fatty alcohol is catalyzed by at least one reductase, which is encoded by an exogenous nucleic acid molecule. The dashed grey lines indicate downstream steps for the synthesis of pheromones, fragrances, flavors, and polymer intermediates, such as using an alcohol oxidase or oxidant to produce a mono- or poly-unsaturated fatty aldehyde, and an acetyl transferase or a chemical such as acetylchloride to produce a mono- or poly-unsaturated fatty acetate. The red crosses indicate deleted or down regulated pathways native to the host, which increase flux towards the engineered pathway.

[0322] Accordingly, in one embodiment, the recombinant microorganism expresses: (a) at least one exogenous nucleic acid molecule encoding a fatty acyl desaturase that catalyzes the conversion of a saturated C_6-C_{24} fatty acyl-CoA to a corresponding mono- or poly-unsaturated C_6-C_{24} fatty acyl-CoA; and (b) at least one exogenous nucleic acid molecule encoding a fatty alcohol forming fatty-acyl reductase that catalyzes the conversion of the mono- or poly-unsaturated C_6-C_{24} fatty acyl-CoA from (a) into the corresponding mono- or poly-unsaturated C_6-C_{24} fatty alcohol. In some embodiments, the saturated C_6-C_{24} fatty acyl-CoA can be produced using endogenous enzymes in the host microorganism. In other embodiments, the saturated C_6-C_{24} fatty acyl-CoA can be produced using one or more exogenous enzymes in the host microorganism.

[0323] As described above, a fatty acyl desaturase catalyzes the desaturation of the hydrocarbon chain on, *e.g.*, a saturated fatty acyl-CoA molecule to generate a corresponding unsaturated fatty acyl CoA molecule. In some embodiments, an exogenous fatty acyl desaturase can be selected and expressed in a recombinant microorganism to catalyze the formation of at least one double bond in fatty acyl-CoA molecule having from 6 to 24 carbons in the hydrocarbon chain. Accordingly, in some embodiments, the fatty-acyl desaturase is a desaturase capable of utilizing a fatty acyl-CoA as a substrate that has a chain length of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 carbon atoms.

[0324] An exogenous fatty acyl desaturase described herein can be selected to catalyze the desaturation at a desired position on the hydrocarbon chain. Accordingly, in some embodiments, the fatty-acyl desaturase is capable of generating a double bond at position C5,

C6, C7, C8, C9, C10, C11, C12, or C13, in the fatty acid or its derivatives, such as, for example, fatty acid CoA esters.

[0325] One or more than one fatty acyl-CoA desaturase can be expressed in the host to catalyze desaturation at multiple positions on the hydrocarbon chain. In some embodiments, the fatty acyl-CoA desaturase is heterologous to the host microorganism. Accordingly, various embodiments provide for recombinant microorganism comprised of at least one exogenous nucleic acid molecule, which encodes a fatty acyl desaturase that catalyzes the conversion of a saturated C₆-C₂₄ fatty acyl-CoA to a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA.

[0326] In one exemplary embodiment, the fatty-acyl desaturase is a Z11 desaturase. The Z11 fatty-acyl desaturase catalyze double bond formation between the 11th and 12th carbons in the substrate relative to the carbonyl group. In various embodiments described herein, the Z11 desaturase, or the nucleic acid sequence that encodes it, can be isolated from organisms of the species *Agrotis segetum*, *Amyelois transitella*, *Argyrotaenia velutiana*, *Ckoristoneura rosaceana*, *Lampronia capitella*, *Trichoplusia ni*, *Helicoverpa zea*, or *Thalassiosira pseudonana*. Further Z11-desaturases, or the nucleic acid sequences encoding them, can be isolated from *Bombyx mori*, *Manduca sexta*, *Diatraea grandiosella*, *Earias insulana*, *Earias vittella*, *Piutelia xylostella*, *Bombyx mori* or *Diaphania ni*Udalis. In exemplary embodiments, the Z11 desaturase comprises a sequence selected from GenBank Accession Nos. JX679209, JX964774, AF416738, AF545481, EU152335, AAD03775, AAF81787, and AY493438. In some embodiments, a nucleic acid sequence encoding a Z11 desaturase from organisms of the species *Agrotis segetum*, *Amyelois transitella*, *Argyrotaenia velutiana*, *Ckoristoneura rosaceana*, *Lampronia capitella*, *Trichoplusia ni*, *Helicoverpa zea*, or *Thalassiosira pseudonana* is codon optimized. In some embodiments, the Z11 desaturase comprises a sequence selected from SEQ ID NOs: 9, 18, 24 and 26 from *Trichoplusia ni*. In some embodiments, the Z11 desaturase comprises an amino acid sequence set forth in SEQ ID NO: 49 from *Trichoplusia ni*. In other embodiments, the Z11 desaturase comprises a sequence selected from SEQ ID NOs: 10 and 16 from *Agrotis segetum*. In some embodiments, the Z11 desaturase comprises an amino acid sequence set forth in SEQ ID NO: 53 from *Agrotis segetum*. In some embodiments, the Z11 desaturase comprises a sequence selected from SEQ ID NOs: 11 and 23 from *Thalassiosira pseudonana*. In some embodiments, the Z11 desaturase comprises an amino acid sequence selected from SEQ ID NOs: 50 and 51 from *Thalassiosira pseudonana*. In certain embodiments, the Z11 desaturase comprises a sequence

selected from SEQ ID NOs: 12, 17 and 30 from *Amyelois tramitella*. In some embodiments, the Z11 desaturase comprises an amino acid sequence set forth in SEQ ID NO: 52 from *Amyelois tramitella*. In further embodiments, the Z11 desaturase comprises a sequence selected from SEQ ID NOs: 13, 19, 25, 27 and 31 from *Helicoverpa zea*. In some embodiments, the Z11 desaturase comprises an amino acid sequence set forth in SEQ ID NO: 54 from *Helicoverpa zea*. In some embodiments, the Z11 desaturase comprises an amino acid sequence set forth in SEQ ID NO: 39 from *S. inferens*. In some embodiments, the Z11 desaturase comprises an amino acid sequence set forth in GenBank Accession nos. AF416738, AGH12217.1, AF21943.1, CAJ43430.2, AF441221, AAF81787.1, AF545481, AJ271414, AY362879, ABX71630.1, NP001299594.1, Q9N9Z8, ABX71630.1 and AIM40221.1. In some embodiments, the Z11 desaturase comprises a chimeric polypeptide. In some embodiments, a complete or partial Z11 desaturase is fused to another polypeptide. In certain embodiments, the N-terminal native leader sequence of a Z11 desaturase is replaced by an oleosin leader sequence from another species. In certain embodiments, the Z11 desaturase comprises a sequence selected from SEQ ID NOs: 15, 28 and 29. In some embodiments, the Z11 desaturase comprises an amino acid sequence selected from SEQ ID NOs: 61, 62, 63, 78, 79 and 80.

[0327] In certain embodiments, the Z11 desaturase catalyzes the conversion of a fatty acyl-CoA into a mono- or poly-unsaturated product selected from Z11-13:Acyl-CoA, Ell-13:Acyl-CoA, (Z,Z)-7,11-13:Acyl-CoA, Z11-14:Acyl-CoA, Ell-14:Acyl-CoA, (E,E)-9,11-14:Acyl-CoA, (E,Z)-9,11-14:Acyl-CoA, (Z,E)-9,11-14:Acyl-CoA, (Z,Z)-9,11-14:Acyl-CoA, (E,Z)-9,11-15:Acyl-CoA, (Z,Z)-9,11-15:Acyl-CoA, Z11-16:Acyl-CoA, Ell-16:Acyl-CoA, (E,Z)-6,11-16:Acyl-CoA, (E,Z)-7,11-16:Acyl-CoA, (E,Z)-8,11-16:Acyl-CoA, (E,E)-9,11-16:Acyl-CoA, (E,Z)-9,11-16:Acyl-CoA, (Z,E)-9,11-16:Acyl-CoA, (Z,Z)-9,11-16:Acyl-CoA, (E,E)-11,13-16:Acyl-CoA, (E,Z)-11,13-16:Acyl-CoA, (Z,E)-11,13-16:Acyl-CoA, (Z,Z)-11,13-16:Acyl-CoA, (Z,E)-11,14-16:Acyl-CoA, (E,E,Z)-4,6,11-16:Acyl-CoA, (Z,Z,E)-7,11,13-16:Acyl-CoA, (E,E,Z,Z)-4,6,11,13-16:Acyl-CoA, Z11-17:Acyl-CoA, (Z,Z)-8,11-17:Acyl-CoA, Z11-18:Acyl-CoA, Ell-18:Acyl-CoA, (Z,Z)-11,13-18:Acyl-CoA, (E,E)-11,14-18:Acyl-CoA, or combinations thereof.

[0328] In another exemplary embodiment, the fatty-acyl desaturase is a Z9 desaturase. The Z9 fatty-acyl desaturase catalyzes double bond formation between the 9th and 10th carbons in the substrate relative to the carbonyl group. In various embodiments described herein, the Z9 desaturase, or the nucleic acid sequence that encodes it, can be isolated from organisms of the

species *Ostrinia fiirnacalis*, *Ostrinia nohilalis*, *Choristoneura rosaceana*, *Lampronia capitella*, *Hehcoverpa assulta*, or *Helicoverpa zea*. In exemplary- embodiments, the Z9 desaturase comprises a sequence selected from GenBank Accession Nos. AY057862, AF243047, AF518017, EU152332, AF482906, and AAF81788. In some embodiments, a nucleic acid sequence encoding a Z9 desaturase is codon optimized. In some embodiments, the Z9 desaturase comprises a nucleotide sequence set forth in SEQ ID NO: 20 from *Ostrinia fiirnacalis*. In some embodiments, the Z9 desaturase comprises an amino acid sequence set forth in SEQ ID NO: 58 from *Ostriniafiirnacalis*. In other embodiments, the Z9 desaturase comprises a nucleotide sequence set forth in SEQ ID NO: 21 from *Lampronia capitella*. In some embodiments, the Z9 desaturase comprises an amino acid sequence set forth in SEQ ID NO: 59 from *Lampronia capitella*. In some embodiments, the Z9 desaturase comprises a nucleotide sequence set forth in SEQ ID NO: 22 from *Helicoverpa zea*. In some embodiments, the Z9 desaturase comprises an amino acid sequence set forth in SEQ ID NO: 60 from *Helicoverpa zea*.

[0329] In certain embodiments, the Z9 desaturase catalyzes the conversion of a fatty acyl-CoA into a monounsaturated or polyunsaturated product selected from Z9-11:Acyl-CoA, Z9-12:Acyl-CoA, E9-12:Acyl-CoA, (E,E)-7,9-12:Acyl-CoA, (E,Z)-7,9-12:Acyl-CoA, (Z,E)-7,9-12:Acyl-CoA, (Z,Z)-7,9-12:Acyl-CoA, Z9-13:Acyl-CoA, E9-13:Acyl-CoA, (E,Z)-5,9-13:Acyl-CoA, (Z,E)-5,9-13:Acyl-CoA, (Z,Z)-5,9-13:Acyl-CoA, Z9-14:Acyl-CoA, E9-14:Acyl-CoA, (E,Z)-4,9-14:Acyl-CoA, (E,E)-9,11-14:Acyl-CoA, (E,Z)-9,11-14:Acyl-CoA, (Z,E)-9,11-14:Acyl-CoA, (Z,Z)-9,11-14:Acyl-CoA, (E,E)-9,12-14:Acyl-CoA, (Z,E)-9,12-14:Acyl-CoA, (Z,Z)-9,12-14:Acyl-CoA, Z9-15:Acyl-CoA, E9-15:Acyl-CoA, (Z,Z)-6,9-15:Acyl-CoA, Z9-16:Acyl-CoA, E9-16:Acyl-CoA, (E,E)-9,11-16:Acyl-CoA, (E,Z)-9,11-16:Acyl-CoA, (Z,E)-9,11-16:Acyl-CoA, (Z,Z)-9,11-16:Acyl-CoA, Z9-17:Acyl-CoA, E9-18:Acyl-CoA, Z9-18:Acyl-CoA, (E,E)-5,9-18:Acyl-CoA, (E,E)-9,12-18:Acyl-CoA, (Z,Z)-9,12-18:Acyl-CoA, (Z,Z,Z)-3,6,9-18:Acyl-CoA, (E,E,E)-9,12,15-18:Acyl-CoA, (Z,Z,Z)-9,12,15-18:Acyl-CoA, or combinations thereof.

[0330] Desaturation of a saturated C_{6-C24} fatty acyl-CoA can proceed through a plurality of reactions to produce a poly-unsaturated G_{5-C24} fatty acyl-CoA. In some embodiments, the recombinant microorganism may express a bifunctional desaturase capable of catalyzing the formation at least two double bonds. In some embodiments, the recombinant microorganism may express more than one exogenous nucleic acid molecule encoding more than one fatty-acyl desaturase that catalyzes the conversion of a saturated C_{6-C24} fatty acyl-CoA to a

corresponding poly-unsaturated C₆-C₂₄ fatty acyl-CoA. For example, the recombinant microorganism may express an exogenous nucleic acid molecule encoding a Z11 desaturase and another exogenous nucleic acid molecule encoding a Z9 desaturase. Thus, the resultant poly-unsaturated fatty acyl-CoA would have a double bond between the 9th and 10th carbon and another double bond between the 11th and 12th carbon.

[0331] In some embodiments, the recombinant microorganism may express a fatty-acyl conjugase that acts independently or together with a fatty-acyl desaturase to catalyze the conversion of a saturated or monounsaturated fatty acyl-CoA to a conjugated polyunsaturated fatty acyl-CoA.

[0332] In one embodiment, the disclosure provides a recombinant microorganism capable of producing a polyunsaturated C₆-C₂₄ fatty alcohol from an endogenous or exogenous source of saturated or monounsaturated C₆-C₂₄ fatty acyl-CoA, wherein the recombinant microorganism expresses: (a) at least one exogenous nucleic acid molecule encoding a fatty acyl conjugase that catalyzes the conversion of a saturated or monounsaturated C₆-C₂₄ fatty acyl-CoA to a corresponding polyunsaturated C₆-C₂₄ fatty acyl-CoA; and (b) at least one exogenous nucleic acid molecule encoding a fatty alcohol forming fatty-acyl reductase that catalyzes the conversion of the polyunsaturated C₆-C₂₄ fatty acyl-CoA from (a) into the corresponding polyunsaturated C₆-C₂₄ fatty alcohol.

[0333] In another embodiment, the recombinant microorganism expresses at least two exogenous nucleic acid molecules encoding fatty-acyl conjugases that catalyze the conversion of a saturated or monounsaturated C₆-C₂₄ fatty acyl-CoA to a corresponding polyunsaturated C₆-C₂₄ fatty acyl-CoA.

[0334] In a further embodiment, the disclosure provides a recombinant microorganism capable of producing a polyunsaturated C₆-C₂₄ fatty alcohol from an endogenous or exogenous source of saturated or monounsaturated C₆-C₂₄ fatty acyl-CoA, wherein the recombinant microorganism expresses: (a) at least one exogenous nucleic acid molecule encoding a fatty-acyl desaturase and at least one exogenous nucleic acid molecule encoding a fatty acyl conjugase that catalyze the conversion of a saturated or monounsaturated C₆-C₂₄ fatty acyl-CoA to a corresponding polyunsaturated C₆-C₂₄ fatty acyl-CoA; and (b) at least one exogenous nucleic acid molecule encoding a fatty alcohol forming fatty-acyl reductase that catalyzes the conversion of the polyunsaturated C₆-C₂₄ fatty acyl-CoA from (a) into the corresponding polyunsaturated C₆-C₂₄ fatty alcohol.

[0335] In another embodiment, the recombinant microorganism expresses at least two exogenous nucleic acid molecules encoding fatty-acyl desaturases and at least two exogenous nucleic acid molecules encoding fatty-acyl conjugases that catalyze the conversion of a saturated or monounsaturated C₆-C₂₄ fatty acyl-CoA to a corresponding polyunsaturated C₆-C₂₄ fatty acyl-CoA.

[0336] In yet a further embodiment, the fatty-acyl conjugase is a conjugase capable of utilizing a fatty acyl-CoA as a substrate that has a chain length of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 carbon atoms.

[0337] In certain embodiments, the conjugase, or the nucleic acid sequence that encodes it, can be isolated from organisms of the species *Cydia pomonella*, *Cydia nigricana*, *Lohesia botrana*, *Myelois cribrilella*, *Plodia interpunctella*, *Dendrolimus punctatus*, *Lampronia capitella*, *Spodoptera litura*, *Amyelois trarisitella*, *Manduca sexta*, *Bombyx mori*, *Calendula officinalis*, *Trichosanihes hrilowii*, *Punica granatum*, *Momordica charantia*, *Impatiens balsamina*, and *Epiphyas postvittana*. In exemplar embodiments, the conjugase comprises a sequence selected from GenBank Accession No. or Uniprot database: A0A059TBF5, A0A0M3L9E8, A0A0M3L9S4, A0A0M3LAH8, A0A0M3LAS8, A0A0M3LAH8, B6CBS4, XP_013183656.1, XP_004923568.2, ALA65425.1, NP_001296494.1, NP_001274330.1, Q4A181, Q75PL7, Q9FPP8, AY178444, AY178446, AF182521, AF182520, Q95UJ3.

[0338] As described above, a fatty acyl reductase catalyzes the reduction of a carbonyl group, e.g., on an unsaturated fatty acyl-CoA molecule to generate a corresponding unsaturated fatty acid molecule. In some embodiments, the fatty alcohol forming fatty acyl CoA reductase is heterologous to the microorganism. Accordingly, various embodiments provide for recombinant microorganism comprised of at least one exogenous nucleic acid molecule, which encodes a fatty alcohol forming fatty acyl reductase that catalyzes the reduction of a carbonyl group on an unsaturated fatty acyl-CoA molecule to generate a corresponding unsaturated fatty acid molecule.

[0339] In some embodiments, the fatty acyl reductase is from an organism of the species *Agrotis segetum*, *Spodoptera exigua*, *Spodoptera Uttoralis*, *Euglena gracilis*, *Yponomeuta evonymellus* and *Helicoverpa armigera*. In some embodiments, a nucleic acid sequence encoding a fatty-acyl reductase is codon optimized. In some embodiments, the fatty acyl reductase comprises a sequence set forth in SEQ ID NO: 1 from *Agrotis segetum*. In some embodiments, the fatty acyl reductase comprises an amino acid sequence set forth in SEQ ID

NO: 55 from *Agrotis segetum*. In other embodiments, the fatty acyl reductase comprises a sequence set forth in SEQ ID NO: 2 from *Spodoptera httoralis*. In other embodiments, the fatty acyl reductase comprises an amino acid sequence set forth in SEQ ID NO: 56 from *Spodoptera Httoralis*. In some embodiments, the fatty acyl reductase comprises a sequence selected from SEQ ID NOs: 3, 32, 40, 72, 74, 76 and 81. In some embodiments, the fatty acyl reductase comprises an amino acid sequence set forth in SEQ ID NO: 55 from *Agrotis segetum*. In other embodiments, the fatty acyl reductase comprises an amino acid sequence set forth in SEQ ID NO: 56 from *Spodoptera Httoralis*. In some embodiments, the fatty acyl reductase comprises an amino acid sequence selected from SEQ ID NOs: 41 and 57 from *Helicoverpa armigera*. In some embodiments, the fatty acyl reductase comprises an amino acid sequence selected from SEQ ID NOs: 73 and 82 from *Spodoptera exigua*. In some embodiments, the fatty acyl reductase comprises an amino acid sequence set forth in SEQ ID NO: 75 from *Euglena gracilis*. In some embodiments, the fatty acyl reductase comprises an amino acid sequence set forth in SEQ ID NO: 77 from *Yponomeuta evonymellus*.

[0340] In some embodiments, the production of unsaturated fatty alcohols in a recombinant microorganism comprises the expression of one or more mutant FARs. In certain embodiments, *Helicoverpa amigera* fatty acyl-CoA reductase (HaFAR) variants are provided which show a net increase in fatty alcohol produced compared to the wild type *Helicoverpa amigera* fatty acyl-CoA reductase encoded by an amino acid sequence set forth in SEQ ID NO: 41. In some embodiments, the increased enzymatic activity is a net activity increase in amount of fatty alcohol produced relative to the amount of fatty alcohol produced by a wild type enzymatic activity of HaFAR encoded by an amino acid sequence set forth in SEQ ID NO: 41. In some embodiments, a wild type HaFAR comprises a nucleotide sequence set forth in SEQ ID NO: 90. In some embodiments, a variant of a wild type HaFAR encoded by an amino acid sequence set forth in SEQ ID NO: 41 comprises point mutations at the following positions: S60X, S195X, S298X, S378X, S394X, S418X, and S453X, wherein X comprises the amino acids F, L, M, I, V, P, T, A, Y, K, H, N, Q, K, D, E, C, W, R. In some embodiments, a variant of a wild type HaFAR encoded by an amino acid sequence set forth in SEQ ID NO: 41 comprises a combination of point mutations selected from mutations at the following amino acid positions: S60X, S195X, S298X, S378X, S394X, S418X, and S453X, wherein X comprises the amino acids F, L, M, I, V, P, T, A, Y, K, H, N, Q, K, D, E, C, W, R. In some embodiments, the fatty acyl reductase is a mutated fatty acyl reductase and

comprises an amino acid sequence selected from SEQ ID NOs: 42-48. In some embodiments, the fatty acyl reductase is a mutated fatty acyl reductase and comprises nucleotide sequence selected from SEQ ID NOs: 83-89.

[0341] In exemplary embodiments, the fatty-acyl reductase catalyzes the conversion of a mono- or poly-unsaturated fatty acyl-CoA into a fatty alcohol product selected from (Z)-3-hexenol, (Z)-3-nonenol, (Z)-5-decenol, (E)-5-decenol, (Z)-7-dodecenol, (E)-S-dodecenol, (Z)-8-dodecenol, (Z)-9-dodecenol, (Z)-9-tetradecenol, (Z)-9-hexadecenol, (Z)-11-tetradecenol, (Z)-7-hexadecenol, (Z)-11-hexadecenol, (E)-11-tetradecenol, or (Z,Z)-11,13-hexadecadienol, (11Z,13E)-hexadecadienol, (E,E)-8,10-dodecadienol, (E,Z)-7,9-dodecadienol, (Z)-13-octadecenol, or combinations thereof.

[0342] In some embodiments, a recombinant microorganism described herein can include a plurality of fatty acyl reductases. Accordingly, in such embodiments, the recombinant microorganism expresses at least two exogenous nucleic acid molecules, which encode fatty-acyl reductases that catalyze the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA into the corresponding mono- or poly-unsaturated C₆-C₂₄ fatty alcohol.

[0343] In a further embodiment, the disclosure provides a recombinant microorganism capable of producing a mono- or poly-unsaturated \leq Cis fatty alcohol from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid, wherein the recombinant microorganism comprises: (a) at least one exogenous nucleic acid molecule encoding a fatty acyl desaturase that catalyzes the conversion of a saturated C₆-C₂₄ fatty acyl-CoA to a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA; (b) at least one exogenous nucleic acid molecule encoding an acyl-CoA oxidase that catalyzes the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA from (a) into a mono- or poly-unsaturated \leq Cis fatty acyl-CoA after one or more successive cycle of acyl-CoA oxidase activity, with a given cycle producing a mono- or poly-unsaturated C₄-C₂₂ fatty acyl-CoA intermediate with a two carbon truncation relative to a starting mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA substrate in that cycle; and (c) at least one exogenous nucleic acid molecule encoding a fatty alcohol forming fatty acyl reductase that catalyzes the conversion of the mono- or poly-unsaturated \leq C₁₈ fatty acyl-CoA from (b) into the corresponding mono- or poly-unsaturated \leq C₁₈ fatty alcohol. In some embodiments, the fatty acyl desaturase is selected from an *Argyrotaenia velutinana*, *Spodoptera litura*, *Sesamia inferens*, *Manduca sexta*, *Ostrinia nubilalis*, *Helicoverpa zea*, *Choristoneura rosaceana*, *Drosophila melanogaster*, *Spodoptera littoralis*, *Lampronia capitella*, *Amyelois transiteila*, *Trichoplusia ni*, *Agrotis segetum*, *Ostrinia furnicalis*, and

Thalassiosira pseudonana derived fatty acyl desaturase. In some embodiments, the fatty acyl desaturase has 95% sequence identity to a fatty acyl desaturase selected from the group consisting of: SEQ ID NOs: 39, 49-54, 58-63, 78-80 and GenBank Accession nos. AF416738, AGH12217.1, AΠ21943.1, CAJ43430.2, AF441221, AAF81787.1, AF545481, AJ271414, AY362879, ABX71630.1, NP001299594.1, Q9N9Z8, ABX71630.1 and AIM40221.1. In some embodiments, the acyl-CoA oxidase is selected from Table 5a. In other embodiments, the fatty alcohol forming fatty acyl reductase is selected from an *Agrotis segetum*, *Spodoptera exigia*, *Spodoptera littoralis*, *Euglena gracilis*, *Yponomeuta evonymellus* and *Helicoverpa armigera* derived fatty alcohol forming fatty acyl reductase. In further embodiments, the fatty alcohol forming fatty acyl reductase has 95% sequence identity to a fatty alcohol forming fatty acyl reductase selected from the group consisting of SEQ ID NOs: 1-3, 32, 41-48, 55-57, 73, 75, 77 and 82. In some embodiments, the recombinant microorganism is a yeast selected from the group consisting of *Yarrowia lipolytica*, *Saccharomyces cerevisiae*, *Candida albicans*, *Candida tropicalis* and *Candida viswanathii*.

[0344] In some embodiments, the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an acyltransferase that preferably stores \leq Cis fatty acyl-CoA. In some embodiments, the acyltransferase is selected from the group consisting of glycerol-3-phosphate acyl transferase (GPAT), Ivsophosphatidic acid acyltransferase (LPAAT), glycerolphospholipid acyltransferase (GPLAT) and diacylglycerol acyltransferases (DGAT). In some preferred embodiments, the acyltransferase is selected from Table 5b.

[0345] In some embodiments, the coexpression of a wax esterase would allow the storage of fatty alcohols and fatty acids in a 1: 1 ratio. In combination with TAG storage that could lead to interesting ratios of TAG and fatty alcohols which could subsequently be used for different product streams. Examples for waxester synthases: Homo sapiens AWAT2 (XM_011530876.2), Mus musculus (AAT68766.1) Euglena gracilis WS (ADI60058.1), Euglena gracilis WSD2 (BAV82975.1), Euglena gracilis WSD5 (BAV82978.1).

[0346] In some embodiments, the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an acylglycerol lipase that preferably hydrolyzes ester bonds of >C16, of >C14, of >C12 or of >C10 acylglycerol substrates. In some embodiments, the acylglycerol lipase is selected from Table 5e.

[0347] In some embodiments, the recombinant microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous enzymes that catalyzes a reaction in a pathway that competes with the biosynthesis pathway for the production of a mono- or poly-unsaturated \leq C₁₈ fatty alcohol. In further embodiments, the recombinant microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous enzyme selected from: (i) one or more acyl-CoA oxidase; (ii) one or more acyltransferase; (iii) one or more acylglycerol lipase and/or sterol ester esterase; (iv) one or more (fatty) alcohol dehydrogenase; (v) one or more (fatty) alcohol oxidase; and (vi) one or more cytochrome P450 monooxygenase.

[0348] In some preferred embodiments, one or more genes of the microbial host encoding acyl-CoA oxidases are deleted or down-regulated to eliminate or reduce the truncation of desired fatty acyl-CoAs beyond a desired chain-length. In some embodiments, the recombinant microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous acyl-CoA oxidase enzyme selected from the group consisting of *Y. lipolytica* POX1 (YALI0E32835g), *Y. lipolytica* POX2 (YALI0F10857g), *Y. lipolytica* POX3 fYALI0D24750gj, *Y. lipolytica* POX4 (YALI0E27654g), *Y. lipolytica* POX5 (YALI0C23859g), *Y. lipolytica* POX6 (YALI0E06567g); *S. cerevisiae* POX1 (YGL205W); *Candida* POX2 (Ca019.1655, Ca019.9224, CTRG_02374, M18259), *Candida* POX4 (Ca019.1652, Ca019.9221, CTRG_02377, M12160), and *Candida* POX5 (Ca019.5723, Ca019.13146, CTRG_02721, M12161).

[0349] In some embodiments, a recombinant microorganism capable of producing a mono- or poly-unsaturated C₆-C₂₄ fatty alcohol, fatty aldehyde and/or fatty acetate from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid is provided, wherein the recombinant microorganism expresses one or more acyl-CoA oxidase enzymes, and wherein the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the activity of one or more endogenous acyl-CoA oxidase enzymes. In some embodiments, the one or more acyl-CoA oxidase enzymes being expressed are different from the one or more endogenous acyl-CoA oxidase enzymes being deleted or downregulated. In other embodiments, the one or more acyl-CoA oxidase enzymes that are expressed regulate chain length of the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol, fatty aldehyde and/or fatty acetate. In other embodiments, the one or more acyl-CoA oxidase enzymes being expressed are selected from Table 5a.

[0350] In some embodiments, the recombinant microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous acyltransferase enzyme selected from the group consisting of *Y. lipolytica* YALI0C00209g, *Y. lipolytica* YALI0E18964g, *Y. lipolytica* YALI0F19514g, *Y. lipolytica* YALTOC14014g, *Y. lipolytica* YALI0E16797g, *Y. lipolytica* YALI0E32769g, and *Y. lipolytica* YALI0D07986g, *S. cerevisiae* YBLO1lw, *S. cerevisiae* YDL052c, *S. cerevisiae* YORI75C, *S. cerevisiae* YPR139C, *S. cerevisiae* YNR008w, and *S. cerevisiae* YOR245c, and *Candida* I503_02577, *Candida* CTRG_02630, *Candida* CaO 19.250, *Candida* CaO 19.7881, *Candida* CTRG_02437, *Candida* Ca019.1881, *Candida* CaO 19.9437, *Candida* CTRG_01687, *Candida* CaO19.1043, *Candida* Ca019.8645, *Candida* CTRG_04750, *Candida* Ca019.13439, *Candida* CTRG_04390, *Candida* CaO 19.6941, *Candida* CaO 19.14203, and *Candida* CTRG_06209.

[0351] In some embodiments, a recombinant microorganism capable of producing a mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol, fatty aldehyde and/or fatty acetate from an endogenous or exogenous source of saturated C_6 - C_{24} fatty acid is provided, wherein the recombinant microorganism expresses one or more acyltransferase enzymes, and wherein the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the activity of one or more endogenous acyltransferase enzymes. In some preferred embodiments, one or more genes of the microbial host encoding GPATs, LPAATs, GPLATs and/or DGATs are deleted or downregulated, and replaced with one or more GPATs, LPAATs, GPLATs, or DGATs which prefer to store short-chain fatty acyl-CoAs. In some embodiments, the one or more acyltransferase enzymes being expressed are different from the one or more endogenous acyltransferase enzymes being deleted or downregulated. In other embodiments, the one or more acyltransferase enzymes being expressed are selected from Table 5b.

[0352] In some preferred embodiments, one or more genes of the microbial host encoding acylglycerol lipases (mono-, di-, or triacylglycerol lipases) and sterol ester esterases are deleted or downregulated and replaced with one or more acylglycerol lipases which prefer long chain acylglycerol substrates. In some embodiments, the recombinant microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous acylglycerol lipase and/or sterol ester esterase enzyme selected from the group consisting of *Y. lipolytica* YALI0E32035g, *Y. lipolytica* YALI0D17534g, *Y. lipolytica* YALIOF10010g, *Y. lipolytica* YALI0C14520g, and *Y. lipolytica* YALI0E00528g, *S. cerevisiae* YKLMOW, *S. cerevisiae* YMR313c, *S. cerevisiae* YKR089c, *S. cerevisiae*

YOR081c, *S. cerevisiae* YKL094W, *S. cerevisiae* YLL012W, and *S. cerevisiae* YLR020C, and *Candida* CaO19.2050, *Candida* CaQ19.9598, *Candida* CTRG_01138, *Candida* W5Q_03398, *Candida* CTRG_00057, *Candida* CaO19.5426, *Candida* Ca019.12881, *Candida* CTRG_06185, *Candida* CaO19.4864, *Candida* CaO19.12328, *Candida* CTRG_03360, *Candida* CaO19.6501, *Candida* Ca019.13854, *Candida* CTRG_05049, *Candida* Ca019.1887, *Candida* Ca019.9443, *Candida* CTRG_01683, and *Candida* CTRG_04630.

[0353] In some embodiments, the recombinant microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous cytochrome P450 monooxygenases selected from the group consisting of *Y. lipolytica* YALI0E25982g (ALK1), *Y. lipolytica* YALI0F01320g (ALK2), *Y. lipolytica* YALI0E23474g (ALK3), *Y. lipolytica* YALI0B13816g (ALK4), *Y. lipolytica* YALI0B13838g (ALK5), *Y. lipolytica* YALI0B01848g (ALK6), *Y. lipolytica* YALIOA15488g (ALK7), *Y. lipolytica* YALIOC12122g (ALK8), *Y. lipolytica* YALIOB06248g (ALK9), *Y. lipolytica* YALI0B20702g (ALK10), *Y. lipolytica* YALIOCK054g (ALK11) and *Y. lipolytica* YALIOA20130g (ALK12).

[0354] In some embodiments, a recombinant microorganism capable of producing a mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol, fatty aldehyde and/or fatty acetate from an endogenous or exogenous source of saturated C_6 - C_{24} fatty acid is provided, wherein the recombinant microorganism expresses one or more acylglycerol lipase and/or sterol ester esterase enzymes, and wherein the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the activity of one or more endogenous acylglycerol lipase and/or sterol ester esterase enzymes. In some embodiments, the one or more acylglycerol lipase and/or sterol ester esterase enzymes being expressed are different from the one or more endogenous acylglycerol lipase and/or sterol ester esterase enzymes being deleted or downregulated. In some embodiments, the one or more endogenous or exogenous acylglycerol lipase and/or sterol ester esterase enzymes being expressed prefer to hydrolyze ester bonds of long-chain acylglycerols. In other embodiments, the one or more acylglycerol lipase and/or sterol ester esterase enzymes being expressed are selected from Table 5c.

[0355] In some embodiments, the fatty acyl desaturase catalyzes the conversion of a fatty acyl-CoA into a mono- or poly-unsaturated intermediate selected from E5-10:Acyl-CoA, E7-12:Acyl-CoA, E9-14:Acyl-CoA, E11-16:Acyl-CoA, E13-18:Acyl-CoA, Z7-12:Acyl-CoA, Z9-14:Acyl-CoA, Z11-16:Acyl-CoA, Z13-18:Acyl-CoA, Z8-12:Acyl-CoA, Z10-14:Acyl-

CoA, Z12-16:Acyl-CoA, Z14-18:Acyl-CoA, Z7-10:Acyl-coA, Z9-12:Acyl-CoA, Z11-14:Acyl-CoA, Z13-16:Acyl-CoA, Z15-18:Acyl-CoA, E7-10:Acyl-CoA, E9-12:Acyl-CoA, E11-14:Acyl-CoA, E13-16:Acyl-CoA, E15-18:Acyl-CoA, E5Z7-12:Acyl-CoA, E7Z9-12:Acyl-CoA, E9Z11-14:Acyl-CoA, E11Z13-16:Acyl-CoA, E13Z15-18:Acyl-CoA, E6E8-10:Acyl-CoA, E8E10-12:Acyl-CoA, E10E12-14:Acyl-CoA, E12E14-16:Acyl-CoA, Z5E8-10:Acyl-CoA, Z7E10-12:Acyl-CoA, Z9E12-14:Acyl-CoA, Z11E14-16:Acyl-CoA, Z13E16-18:Acyl-CoA, Z3-10:Acyl-CoA, Z5-12:Acyl-CoA, Z7-14:Acyl-CoA, Z9-16:Acyl-CoA, Z11-18:Acyl-CoA, Z3Z5-10:Acyl-CoA, Z5Z7-12:Acyl-CoA, Z7Z9-14:Acyl-CoA, Z9Z11-16:Acyl-CoA, Z11Z13-16:Acyl-CoA, and Z13Z15-18:Acyl-CoA. In further embodiments, the mono- or poly-unsaturated \leq Cis fatty alcohol is selected from the group consisting of E5-10:OH, Z8-12:OH, Z9-12:OH, Z11-14:OH, Z11-16:OH, E11-14:OH, E8E10-12:OH, E7Z9-12:OH, Z11Z13-16OH, Z9-14:OH, Z9-16:OH, and Z13-18:OH.

[0356] In some embodiments, the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an aldehyde forming fatty acyl-CoA reductase capable of catalyzing the conversion of the mono- or poly-unsaturated \leq Cis fatty alcohol into a corresponding \leq Cis fatty aldehyde. In some preferred embodiments, the aldehyde forming fatty acyl-CoA reductase is selected from the group consisting of *Acineobacter calcoaceticus* A0A1C4HN78, *A. calcoaceticus* N9DA85, *A. calcoaceticus* R8XW24, *A. calcoaceticus* A0A1A0GGM5, *A. calcoaceticus* A0A117N158, and *Nosioc punctiforme* YP_001865324. In some embodiments, the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase or an alcohol dehydrogenase capable of catalyzing the conversion of the mono- or poly-unsaturated \leq Cis fatty alcohol into a corresponding \leq Cis fatty aldehyde. In some preferred embodiments, the \leq Cis fatty aldehyde is selected from the group consisting of Z9-16:Ald, Z11-16:Ald, Z11-13-16:Ald, and Z13-18:Ald.

[0357] In some embodiments, the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated \leq Cis fatty alcohol into a corresponding \leq Cis fatty acetate. In some embodiments, the acetyl transferase is selected from Table 5d. In some preferred embodiments, the \leq C18 fatty acetate is selected from the group consisting of E5-10:Ac, Z7-12:Ac, Z8-12:Ac, Z9-12:Ac, E7Z9-12:Ac, Z9-14:Ac, Z9E12-14:Ac, Z11-14:Ac, E11-14:Ac, Z9-16:Ac, and Z11-16:Ac.

[0358] In some embodiments, the recombinant microorganism further comprises: at least one endogenous or exogenous nucleic acid molecule encoding an enzyme selected from an alcohol oxidase, an alcohol dehydrogenase, and an aldehyde forming fatty acyl-CoA reductase capable of catalyzing the conversion of the mono- or poly-unsaturated \leq C₁₈ fatty alcohol into a corresponding \leq C₁₈ fatty aldehyde; and at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated \leq C₁₈ fatty alcohol into a corresponding \leq C₁₈ fatty acetate. In some preferred embodiments, the mono- or poly-unsaturated \leq C₁₈ fatty aldehyde and \leq C₁₈ fatty acetate is selected from the group consisting of E5-10:Ac, Z7-12:Ac, Z8-12:Ac, Z9-12:Ac, E7Z9-12:Ac, Z9-14:Ac, Z9E12-14:Ac, E11-14:Ac, Z1M4:Ac, Z11-16:Ac, Z9-16:Ac, Z9-16:Ald, Z11-16:Ald, Z12-13-16:Ald, and Z13-18:Ald.

[0359] In a further embodiment, the disclosure provides a recombinant *Yarrowia lipolytica* microorganism capable of producing a mono- or poly-unsaturated C₆-C₂₄ fatty alcohol from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid, wherein the recombinant *Yarrowia lipolytica* microorganism comprises: (a) at least one nucleic acid molecule encoding a fatty acyl desaturase having 95% sequence identity to a fatty acyl desaturase selected from the group consisting of SEQ ID NOs: 54, 60, 62, 78, 79, 80, 95, 97, 99, 101, 103, and 105 that catalyzes the conversion of a saturated C₆-C₂₄ fatty acyl-CoA to a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA; and (b) at least one nucleic acid molecule encoding a fatty alcohol forming fatty acyl reductase having 95% sequence identity to a fatty alcohol forming fatty acyl reductase selected from the group consisting of SEQ ID NOs: 41-48, 57, 73, 75 and 77 that catalyzes the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA from (a) into the corresponding mono- or poly-unsaturated C₆-C₂₄ fatty alcohol.

[0360] In some embodiments, the recombinant *Yarrowia lipolytica* microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous enzymes that catalyzes a reaction in a pathway that competes with the biosynthesis pathway for the production of a mono- or poly-unsaturated C₆-C₂₄ fatty alcohol. In some preferred embodiments, the recombinant *Yarrowia lipolytica* microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous enzyme selected from the following: (i) one or more acyl-CoA oxidase selected from the group consisting of YALI0E32835g (PGX1), YALI0F10857g (PGX2), YALI0D24750g (POX3), YALI0E27654g (POX4), YALI0C23859g (POX5),

YALI0E06567g (POX6); (ii) one or more (fatty) alcohol dehydrogenase selected from the group consisting of YAL10F09603g (FADH), YALI0D25630g (ADH1), YALI0E17787g (ADH2), YALI0A16379g (ADH3), YALI0E158 18g (ADH4), YALI0D02 167g (ADH5), YALI0A15 147g (ADH6), YALI0E07766g (ADH7); (iii) a (fatty) alcohol oxidase YALI0B 14014g (FAO1); (iv) one or more cytochrome P450 enzyme selected from the group consisting of YALI0E25982g (ALK1), YALI0F0 1320g (ALK2), YALI0E23474g (ALK3), YALI0B 13816g (ALK4), YALI0B 13838g (ALK5), YALI0B0 1848g (ALK6), YALI0A 15488g (ALK7), (YALI0C 12 122g (ALK8), YALI0B06248g (ALK9), YALI0B20702g (ALK10), YALI0C 10054g (ALK11) and YALI0A20130g (ALK12); and (v) one or more diacylglycerol acyltransferase selected from the group consisting of YALI0E32791g (DGA1) and YALI0D07986g (DGA2). In other preferred embodiments, the recombinant *Yarrowia lipolytica* microorganism comprises a deletion of one or more endogenous enzyme selected from the following: (i) one or more acyl-CoA oxidase selected from the group consisting of YALI0E32835g (POX1), YALI0F10857g (POX2), YALI0D24750g (POX3), YALI0E27654g (POX4), YALI0C23859g (POX5), YALI0E06567g (POX6); (ii) one or more (fatty) alcohol dehydrogenase selected from the group consisting of YAL10F09603g (FADH), YALI0D25630g (ADH1), YALI0E17787g (ADH2), YALI0A16379g (ADH3), YALI0E158 18g (ADH4), YALI0D02 167g (ADH5), YALI0A15 147g (ADH6), YALI0E07766g (ADH7); (iii) a (fatty) alcohol oxidase YALI0B 14014g (FAO1); (iv) one or more cytochrome P450 enzyme selected from the group consisting of YALI0E25982g (ALK1), YALI0F0 1320g (ALK2), YALI0E23474g (ALK3), YALI0B 13816g (ALK4), YALI0B 13838g (ALK5), YALI0B0 1848g (ALK6), YALI0A 15488g (ALK7), (YALI0C12 122g (ALK8), YALI0B06248g (ALK9), YALI0B20702g (ALK10), YALI0C 10054g (ALK11) and YALI0A20130g (ALK12); and (v) one or more diacylglycerol acyltransferase selected from the group consisting of YALI0E32791g (DGA1) and YALI0D07986g (DGA2).

[0361] In some embodiments, the fatty acyl desaturase catalyzes the conversion of a saturated fatty acyl-CoA into a mono- or poly-unsaturated intermediate selected from Z9-14:Acyl-CoA, Z11-14:Acyl-CoA, E11-14:Acyl-CoA, Z9-16:Acyl-CoA, and Δ¹¹-16:Acyl-CoA. In other embodiments, the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol is selected from the group consisting of Z9-14:OH, Z11-14:OH, E11-14:OH, Z9-16:OH, Z11-16:OH, Z11-13-16:OH, and Δ¹¹-18:OH.

[0362] In some embodiments, the recombinant *Yarrowia lipolytica* microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase or an alcohol dehydrogenase capable of catalyzing the conversion of the mono- or poly-unsaturated C6-C24 fatty alcohol into a corresponding C6-C24 fatty aldehyde. In some embodiments, the alcohol dehydrogenase is selected from Table 3a. In some embodiments, the C6-C24 fatty aldehyde is selected from the group consisting of Z9-14:Ald, Z11-14:A3d, E11-14:Ald, Z9-16:Ald, Z11-16:Ald, Z11Z13-16:Ald and Z13-18:Ald.

[0363] In some embodiments, the recombinant *Yarrowia lipolytica* microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated C6-C24 fatty alcohol into a corresponding C6-C24 fatty acetate. In some embodiments, the acetyl transferase is selected from Table 5d. In some embodiments, the C6-C24 fatty acetate is selected from the group consisting of Z9-14:Ac, Z11-14:Ac, E11-14:Ac, Z9-16:Ac, Z11-16:Ac, Z11Z13-16:Ac, and Z13-18:Ac.

[0364] In some embodiments, the recombinant *Yarrowia lipolytica* microorganism further comprises: at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase or an alcohol dehydrogenase capable of catalyzing the conversion of the mono- or poly-unsaturated C6-C24 fatty alcohol into a corresponding C6-C24 fatty aldehyde; and at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated C6-C24 fatty alcohol into a corresponding C6-C24 fatty acetate. In some embodiments, the mono- or poly-unsaturated C6-C24 fatty aldehyde and C6-C24 fatty acetate is selected from the group consisting of Z9-14:Ac, Z11-14:Ac, E11-14:Ac, Z9-16:Ac, Z11Z13-16:Ac, Z13-18:Ac, Z9-14:Ald, Z11-14:Ald, E11-14:Ald, Z9-16:Ald, Z11-16:Ald, Z11Z13-16:Ald and Z13-18:Ald.

[0365] In some embodiments, the fatty acyl desaturase does not comprise a fatty acyl desaturase comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 64, 65, 66 and 67. In other embodiments, the fatty acyl desaturase does not comprise a fatty acyl desaturase selected from an *Amyelois trcmsitella*, *Spodoptera littoralis*, *Agrotis segetum*, or *Trichoplusia ni* derived desaturase.

[0366] In some embodiments, the disclosure provides a method of engineering a *Yarrowia lipolytica* microorganism that is capable of producing a mono- or poly-unsaturated C6-C24 fatty alcohol from an endogenous or exogenous source of saturated C6-C24 fatty acid, wherein the method comprises introducing into the *Yarrowia lipolytica* microorganism the following:

(a) at least one nucleic acid molecule encoding a fatty acyl desaturase having 95% sequence identity to a fatty acyl desaturase selected from the group consisting of SEQ ID NOs: 39, 54, 60, 62, 78, 79, 80, 95, 97, 99, 101, 103, and 105 that catalyzes the conversion of a saturated C₆-C₂₄ fatty acyl-CoA to a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA; and (b) at least one nucleic acid molecule encoding a fatty alcohol forming fatty acyl reductase having 95% sequence identity to a fatty alcohol forming fatty acyl reductase selected from the group consisting of SEQ ID NOs: 41-48, 57, 73, 75 and 77 that catalyzes the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA from (a) into the corresponding mono- or poly-unsaturated C₆-C₂₄ fatty alcohol. In some embodiments, the microorganism is MATA ura3-302::SUC2 Δ*poxI* Δ*pox2* Δ*pox3* Δ*pox4* Δ*pox5* Δ*pox6* Δ*adh1* Δ*adh2* Δ*adh3* Δ*adh4* Δ*adh5* Δ*adh6* Δ*adh7* Δ*faol*::URA3.

[0367] In some embodiments, the disclosure provides a method of producing a mono- or poly-unsaturated C₆-C₂₄ fatty alcohol, fatty aldehyde or fatty acetate from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid, comprising: cultivating a recombinant microorganism described herein in a culture medium containing a feedstock that provides a carbon source adequate for the production of the mono- or poly-unsaturated C₆-C₂₄ fatty-alcohol, fatty aldehyde or fatty acetate. In some embodiments, the method further comprises a step of recovering the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol, fatty aldehyde or fatty acetate. In further embodiments, the recovery step comprises distillation. In yet further embodiments, the recovery step comprises membrane-based separation.

[0368] In some embodiments, the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol is converted into a corresponding C₆-C₂₄ fatty aldehyde using chemical methods. In further embodiments, the chemical methods are selected from TEMPO-bleach, TEMPO-copper-air, TEMPQ-PM(QAc)₂, Swern oxidation and noble metal-air. In some embodiments, the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol is converted into a corresponding C₆-C₂₄ fatty acetate using chemical methods. In further embodiments, the chemical methods utilize a chemical agent selected from the group consisting of acetyl chloride, acetic anhydride, butyryl chloride, butyric anhydride, propanoyl chloride and propionic anhydride in the presence of 4-*N*, *N*-dimethylaminopyridine (DMAP) or sodium acetate to esterify the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol to the corresponding C₆-C₂₄ fatty acetate.

[0369] As discussed above, in a second aspect, the application relates to a recombinant microorganism capable of producing an unsaturated C₆-C₂₄ fatty alcohol from an endogenous or exogenous source of C₆-C₂₄ fatty acid. An illustrative embodiment of the second aspect is

shown in **Figure 2**. The blue lines designate biochemical pathways endogenous to the host, *e.g.*, pathways for converting an **n-alkane**, fatty alcohol, or fatty aldehyde to a fatty acid, or the conversion of a fatty acid to fatty-acyl-CoA, acetyl-CoA, or **dicarboxylic** acid. The substrate to unsaturated fatty acid conversion can be performed by endogenous or exogenous enzymes in a host. Yellow lines indicate conversions catalyzed by an exogenous nucleic acid molecule encoding for an enzyme. Accordingly, **in** some embodiments, the conversion **of** a saturated fatty acid to a saturated fatty **acyl-ACP** can be catalyzed by **at** least one saturated fatty acyl-ACP synthetase, wherein the fatty acyl-ACP synthetase is encoded by an exogenous nucleic acid molecule. In further embodiments, the conversion **of** the saturated fatty acyl-ACP to a mono- or poly-unsaturated fatty acyl-ACP can be catalyzed by at least one fatty acyl-ACP **desaturase**, wherein the **fatty** acyl-ACP desaturase is encoded by an exogenous nucleic acid molecule. In still further embodiments, the mono- or **poly-unsaturated** fatty acyl-ACP can be elongated by at least 2 carbons relative using a fatty acid synthase complex and a carbon source, *e.g.*, **malonyl-ACP**. **In** one such embodiment, **the** conversion of the mono- or poly-unsaturated fatty acyl-ACP **to** a corresponding two carbon elongated mono- or poly-unsaturated fatty acyl-ACP can be catalyzed by at least one fatty acid synthase complex, wherein the fatty acid synthase complex is encoded by one or more exogenous nucleic acid molecules. In yet further embodiments, the conversion of **the** elongated mono- or poly-unsaturated fatty acyl-ACP to a mono- or poly-unsaturated fatty aldehyde can be catalyzed by a fatty aldehyde **forming** fatty **acyl** reductase, wherein the fatty aldehyde forming fatty acyl reductase is encoded by an exogenous nucleic acid molecule. In some embodiments, the mono- or poly-unsaturated **fatty** aldehyde can be converted **to** a corresponding mono- or poly-unsaturated fatty alcohol, wherein the substrate **to** product conversion is catalyzed by a dehydrogenase, wherein the dehydrogenase is encoded by an endogenous or exogenous nucleic acid molecule. The dashed lines indicate downstream steps **of the** disclosure, such as utilizing an acetyl transferase or metathesis, or subsequent chemical transformations **to** produce **functionalized pheromones**. The red crosses indicate deleted **or** down regulated pathways native to the host, which increase flux towards **the** engineered pathway.

[0370] In one embodiment, the recombinant microorganism expresses (a): at least one exogenous nucleic acid molecule encoding an acyl-ACP synthetase that catalyzes the conversion of a C₆-C₂₄ **fatty** acid to a corresponding saturated C₈-C₂₄ fatty acyl-ACP; (b) at least one exogenous nucleic acid molecule encoding a **fatty-acyl-ACP** desaturase that

catalyzes the conversion of a saturated C₆-C₂₄ fatty acyl-ACP to a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty acyl-ACP; (c) one or more endogenous or exogenous nucleic acid molecules encoding a fatty acid synthase complex that catalyzes the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty acyl-ACP from (b) to a corresponding mono- or poly-unsaturated **C6-C24** fatty acyl-ACP with a two carbon elongation relative to the product of (b); (d): at least one exogenous nucleic acid molecule encoding a fatty aldehyde forming fatty-acyl reductase that catalyzes the conversion of the mono- or poly-unsaturated **C6-C24** fatty acyl-ACP from (c) into a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty aldehyde; and (e) at least one endogenous or exogenous nucleic acid molecule encoding a dehydrogenase that catalyzes the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty aldehyde C₆-C₂₄ from (d) into a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty alcohol. In some embodiments, the C₆-C₂₄ fatty acid can be produced using endogenous enzymes in the host microorganism. In other embodiments, the saturated G₅-C₂₄ fatty acid can be produced by one or more exogenous enzymes in the host microorganism.

[0371] In some embodiments, the recombinant microorganism disclosed herein includes an acyl-ACP synthetase to catalyze the conversion of a C₆-C₂₄ fatty acid to a corresponding saturated C₆-C₂₄ fatty acyl-ACP. In some embodiments the acyl-ACP synthetase is a synthetase capable of utilizing a fatty acid as a substrate that has a chain length of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 carbon atoms. In exemplary embodiments, the recombinant microorganism can include a heterologous the acyl-ACP synthetase from an organism of the species *Vibrio han'eyi*, *Rhodotorula ghitisinis*, or *Yarrowia lipolytica*.

[0372] In some embodiments, the recombinant microorganism includes a fatty acyl-ACP desaturase. In some embodiments, the fatty acyl-ACP desaturase is a soluble desaturase. In other embodiments, the fatty-acyl-ACP desaturase is from an organism of the species *Pelargonium hortorum*, *Asclepias syriaca*, or *Uncaria tomentosa*.

[0373] In some embodiments, the recombinant microorganism includes a fatty acid synthase complex. In some embodiments, the one or more nucleic acid molecules encoding the fatty acid synthase complex are endogenous nucleic acid molecules. In other embodiments, the one or more nucleic acid molecules encoding a fatty acid synthase complex are exogenous nucleic acid molecules.

[0374] In some embodiments, the recombinant microorganism disclosed herein includes a fatty aldehyde forming fatty-acyl reductase which catalyzes the conversion of a **C6-C24** fatty

acyl-ACP to the corresponding C₆-C₂₄ fatty aldehyde. In exemplary embodiments, the fatty aldehyde forming fatty-acyl reductase is from an organism of the species *Pelargonium hortorum*, *Asclepias syriaca*, and *Uncaria tomentosa*. In some embodiments, the recombinant microorganism includes a dehydrogenase to convert the unsaturated fatty aldehyde to a corresponding unsaturated fatty alcohol. In some embodiments, the nucleic acid molecule encoding the dehydrogenase is endogenous to the recombinant microorganism. In other embodiments, the nucleic acid molecule encoding a dehydrogenase is exogenous to the recombinant microorganism. In exemplary embodiments, the endogenous or exogenous nucleic acid molecule encoding a dehydrogenase is isolated from organisms of the species *Saccharomyces cerevisiae*, *Escherichia coli*, *Yarrowia lipolytica*, or *Candida tropicalis*.

[0375] As discussed above, in a third aspect, the application relates to a recombinant microorganism capable of producing an unsaturated C₆-C₂₄ fatty alcohol from an endogenous or exogenous source of C₆-C₂₄ fatty acid. An illustrative embodiment of the second aspect is shown in Figure 3. The blue lines designate biochemical pathways endogenous to the host, e.g., pathways for converting an n-alkane, fatty alcohol, or fatty aldehyde to a fatty acid, or the conversion of a fatty acid to fatty-acyl-CoA, acetyl-CoA, or dicarboxylic acid. The substrate to unsaturated fatty acid conversion can be performed by endogenous or exogenous enzymes in a host. Yellow lines indicate conversions catalyzed by an exogenous nucleic acid molecule encoding for an enzyme. Accordingly, in some embodiments, the conversion of a saturated fatty acid to a saturated fatty acyl-ACP can be catalyzed by at least one saturated fatty acyl-ACP synthetase, wherein the fatty acyl-ACP synthetase is encoded by an exogenous nucleic acid molecule. The non-native saturated fatty acyl-ACP thioesters create a substrate suitable for desaturation and distinct from CoA-thioesters used for beta-oxidation or fatty acid elongation. In further embodiments, the conversion of the saturated fatty acyl-ACP to a mono- or poly-unsaturated fatty acyl-ACP can be catalyzed by at least one fatty acyl-ACP desaturase, wherein the fatty acyl-ACP desaturase is encoded by an exogenous nucleic acid molecule. In still further embodiments, the mono- or poly-unsaturated fatty acyl-ACP can be converted to a corresponding mono- or poly-unsaturated fatty acid by a fatty-acyl-ACP thioesterase. In a particular embodiment, soluble fatty acyl-ACP thioesterases can be used to release free fatty acids for reactivation to a CoA thioester. Fatty acyl-ACP thioesterases including Q41635, Q39473, P05521.2, AEM72519, AEM72520, AEM72521, AEM72523, AAC49784, CAB60830, EER87824, EER96252, ABN54268, AA077182, CAH09236, ACL08376, and homologs thereof may be used. In an additional embodiment,

the mono- or poly-unsaturated fatty acyl-CoA can be elongated by at least 2 carbons relative using an elongase and a carbon source, *e.g.*, malonyl-ACP. In yet further embodiments, the conversion of the elongated mono- or poly-unsaturated fatty acyl-CoA to a mono- or poly-unsaturated fatty alcohol can be catalyzed by a fatty alcohol forming fatty acyl reductase, wherein the fatty alcohol forming fatty acyl reductase is encoded by an exogenous nucleic acid molecule. The dashed lines indicate downstream steps of the disclosure, such as utilizing an acetyl transferase or metathesis, or subsequent chemical transformations to produce functionalized pheromones. The red crosses indicate deleted or down regulated pathways native to the host, which increase flux towards the engineered pathway.

[0376] The fatty alcohols produced as taught herein can be further converted to produce downstream products such as insect pheromones, fragrances, flavors, and polymer intermediates, which utilize aldehydes or acetate functional groups. Thus, in some embodiments, the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase or an alcohol dehydrogenase, wherein the alcohol oxidase or alcohol dehydrogenase is capable of catalyzing the conversion of a C₆-C₂₄ fatty alcohol into a corresponding C₆-C₂₄ fatty aldehyde. In other embodiments, the recombinant microorganism can further comprise at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of a C₆-C₂₄ fatty alcohol into a corresponding C₆-C₂₄ fatty acetate. In certain embodiments, the acetyl transferase, or the nucleic acid sequence that encodes it, can be isolated from organisms of the species *Candida glabrata*, *Saccharomyces cerevisiae*, *Danaus plexippus*, *Heliotis virescens*, *Bombyx mori*, *Agrotis ipsilon*, *Agrotis segetum*, *Euonymus alatus*, *Homo sapiens*, *Lacharicea thermotolerans* and *Yarrowia lipolytica*. In exemplary embodiments, the acetyl transferase comprises a sequence selected from GenBank Accession Nos. AY242066, AY242065, AY242064, AY242063, AY242062, EHJ65205, ACX53812, NP_001182381, EHJ65977, EHJ68573, KJ579226, GU594061, KTA99184.1, AIN34693.1, AY605053, XP_002552712.1, XP_0503024.1, and XP_0505595.1.

Recombinant Microorganism

[0377] The disclosure provides microorganisms that can be engineered to express various exogenous enzymes.

[0378] In various embodiments described herein, the recombinant microorganism is a eukaryotic microorganism. In some embodiments, the eukaryotic microorganism is a yeast. In exemplary embodiments, the yeast is a member of a genus selected from the group consisting

of *Yarrowia*, *Candida*, *Saccharomyces*, *Pichia*, *Hansenula*, *Kluyveromyces*, *Issatchenkia*, *Zygosaccharomyces*, *Debaryomyces*, *Schizosaccharomyces*, *Pachysolen*, *Cryptococcus*, *Trichosporon*, *Rhodotorula*, and *Myxozyma*.

[0379] The present inventors have discovered that oleaginous yeast, such as *Candida* and *Yarrowia*, have a surprisingly high tolerance to the C₆-C₂₄ fatty alcohol substrates and products. Accordingly, in one such exemplary embodiment, the recombinant microorganism of the invention is an oleaginous yeast. In further embodiments, the oleaginous yeast is a member of a genus selected from the group consisting of *Yarrowia*, *Candida*, *Rhodotorula*, *Rhodospiridium*, *Cryptococcus*, *Trichosporon*, and *Lipomyces*. In even further embodiments, the oleaginous yeast is a member of a species selected from *Yarrowia* *hpolytica*, *Candida* *tropicalis*, *Rhodospiridium* *toruloid.es*, *Lipomyces* *starkey*, *L. lipoferus*, *C. revkaii*, *C. pulcherrima*, *C. utilis*, *Rhodotorula* *rubra*, *Trichosporon* *pullans*, *T. cutaneum*, *Cryptococcus* *curvatus*, *R. glutinis*, and *R. graminis*.

[0380] In some embodiments, the recombinant microorganism is a prokaryotic microorganism. In exemplary embodiments, the prokaryotic microorganism is a member of a genus selected from the group consisting of *Escherichia*, *Clostridium*, *Zytnomonas*, *Salmonella*, *Rhodococcus*, *Pseudomonas*, *Bacillus*, *Lactobacillus*, *Enterococcus*, *Alcaligenes*, *Klebsiella*, *Paenibacillus*, *Arthrobacter*, *Corynebacterium*, and *Brevibacterium*.

[0381] In some embodiments, the recombinant microorganism is used to produce a mono- or poly-unsaturated C₆-C₂₄ fatty alcohol, aldehyde, or acetate disclosed herein.

[0382] Accordingly, in another aspect, the present inventions provide a method of producing a mono- or poly-unsaturated C₆-C₂₄ fatty alcohol, aldehyde, or acetate using a recombinant microorganism described herein. In one embodiment, the method comprises cultivating the recombinant microorganism in a culture medium containing a feedstock providing a carbon source until the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol, aldehyde, or acetate is produced. In some embodiments, the method comprises cultivating the recombinant microorganism described herein in a culture medium containing a feedstock that provides a carbon source adequate for the production of a mono- or poly-unsaturated ≤ C₁₈ fatty alcohol, fatty aldehyde or fatty acetate. In a further embodiment, the mono- or poly-unsaturated ≤ C₁₈ fatty alcohol, aldehyde, or acetate is recovered. Recovery can be by methods known in the art, such as distillation, membrane-based separation gas stripping, solvent extraction, and expanded bed adsorption.

[0383] In some embodiments, the feedstock comprises a carbon source. In various embodiments described herein, the carbon source may be selected from sugars, glycerol, alcohols, organic acids, alkanes, fatty acids, lignocellulose, proteins, carbon dioxide, and carbon monoxide. In a further embodiment, the sugar is selected from the group consisting of glucose, fructose, and sucrose.

[0384] Methods of engineering microorganisms that are capable of producing mono- or poly-unsaturated C₆-C₂₄ fatty alcohols, fatty aldehydes and/or fatty acetates

[0385] In one aspect, the present disclosure provides a method of engineering a microorganism that is capable of producing a mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid, wherein the method comprises introducing into a microorganism the following: (a) at least one exogenous nucleic acid molecule encoding a fatty acyl desaturase that catalyzes the conversion of a saturated C₆-C₂₄ fatty acyl-CoA to a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA; (b) at least one exogenous nucleic acid molecule encoding an acyl-CoA oxidase that catalyzes the conversion of the mono- or poly-unsaturated C₀-C₂₄ fatty acyl-CoA from (a) into a mono- or poly-unsaturated $\leq C_{18}$ fatty acyl-CoA after one or more successive cycle of acyl-CoA oxidase activity, with a given cycle producing a mono- or poly-unsaturated C₄-C₂₂ fatty acyl-CoA intermediate with a two carbon truncation relative to a starting mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA substrate in that cycle; and (c) at least one exogenous nucleic acid molecule encoding a fatty alcohol forming fatty acyl reductase that catalyzes the conversion of the mono- or poly-unsaturated $\leq C_{18}$ fatty acyl-CoA from (b) into the corresponding mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol. In some embodiments, the microorganism is MATA ura3-302::SUC2 $\Delta pox1$ $\Delta pox2$ $\Delta pox3$ $\Delta pox4$ $\Delta pox5$ $\Delta pox6$ $\Delta fadL$ $\Delta adh1$ $\Delta adh2$ $\Delta adh3$ $\Delta adh4$ $\Delta adh5$ $\Delta adh6$ $\Delta adh7$ $\Delta fao1$::URA3.

[0386] In some embodiments, the fatty acyl desaturase is selected from an *Argyrotaenia velutinana*, *Spodoptera litura*, *Sesamia inferens*, *Manduca sexta*, *Ostrinia nubilalis*, *Helicoverpa zea*, *Choristoneura rosaceana*, *Drosophila melanogaster*, *Spodoptera littoralis*, *Lampronia capitella*, *Amyelois transitella*, *Trichoplusia ni*, *Agrotis segetum*, *Ostrinia fumicalis*, and *Thaiaassiosira pseudonana* derived fatty acyl desaturase. In some preferred embodiments, the fatty acyl desaturase has 95% sequence identity to a fatty acyl desaturase selected from the group consisting of: SEQ ID NOs: 39, 49-54, 58-63, 78-80 and GenBank Accession nos. AF416738, AGH12217.1, AII21943.1, CAJ43430.2, AF441221, AAF81787.1, AF545481, AJ271414, AY362879, ABX71630.1 and NP001299594.1,

Q9N9Z8, ABX71630.1 and AIM40221.1. In further embodiments, the acyl-CoA oxidase is selected from Table 5a. In yet further embodiments, the fatty alcohol forming fatty acyl reductase is selected from an *Agrotis segetum*, *Spodoptera exigua*, *Spodoptera littoralis*, *Euglena gracilis*, *Yponomeuta evonymellus* and *Helicoverpa armigera* derived fatty alcohol forming fatty acyl reductase. In further embodiments, the fatty alcohol forming fatty acyl reductase has 90% sequence identity to a fatty alcohol forming fatty acyl reductase selected from the group consisting of: SEQ ID NOs: 1-3, 32, 41-48, 55-57, 73, 75, 77 and 82. In some embodiments, the recombinant microorganism is a yeast selected from the group consisting of *Yarrowia lipolytica*, *Saccharomyces cerevisiae*, *Candida albicans*, *Candida tropicalis* and *Candida viswanathii*.

[0387] In some embodiments, the fatty acyl desaturase catalyzes the conversion of a fatty acyl-CoA into a mono- or poly-unsaturated intermediate selected from E5-10:Acyl-CoA, E7-12:Acyl-CoA, E9-14:Acyl-CoA, E11-16:Acyl-CoA, E13-18:Acyl-CoA, Z7-12:Acyl-CoA, Z9-14:Acyl-CoA, Z11-16:Acyl-CoA, Z13-18:Acyl-CoA, Z8-12:Acyl-CoA, Z10-14:Acyl-CoA, Z12-16:Acyl-CoA, Z14-18:Acyl-CoA, Z7-10:Acyl-CoA, Z9-12:Acyl-CoA, Z11-14:Acyl-CoA, Z13-16:Acyl-CoA, Z15-18:Acyl-CoA, E7-10:Acyl-CoA, E9-12:Acyl-CoA, E11-14:Acyl-CoA, E13-16:Acyl-CoA, E15-18:Acyl-CoA, E5Z7-12:Acyl-CoA, E7Z9-12:Acyl-CoA, E9Z11-14:Acyl-CoA, E11Z13-16:Acyl-CoA, E13Z15-18:Acyl-CoA, E6E8-10:Acyl-CoA, E8E10-12:Acyl-CoA, E10E12-14:Acyl-CoA, E12E14-16:Acyl-CoA, Z5E8-10:Acyl-CoA, Z7E10-12:Acyl-CoA, Z9E12-14:Acyl-CoA, Z11E14-16:Acyl-CoA, Z13E16-18:Acyl-CoA, Z3-10:Acyl-CoA, Z5-12:Acyl-CoA, Z7-14:Acyl-CoA, Z9-16:Acyl-CoA, Z11-18:Acyl-CoA, Z3Z5-10:Acyl-CoA, Z5Z7-12:Acyl-CoA, Z7Z9-14:Acyl-CoA, Z9Z11-16:Acyl-CoA, Z11Z13-16:Acyl-CoA, and Z13Z15-18:Acyl-CoA. In further embodiments, the mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol is selected from the group consisting of E5-10:OH, Z8-12:OH, Z9-12:OH, Z11-14:OH, Z11-16:OH, E11-14:OH, E8E10-12:OH, E7Z9-12:OH, Z11Z13-16OH, Z9-14:OH, Z9-16:OH, and Z13-18:OH.

[0388] In some embodiments, the method further comprises introducing into the microorganism at least one endogenous or exogenous nucleic acid molecule encoding an acyltransferase that preferably stores $\leq C_{18}$ fatty acyl-CoA. In some embodiments, the acyltransferase is selected from the group consisting of glycerol-3-phosphate acyl transferase (GPAT), lysophosphatidic acid acyltransferase (LPAAT), glycerophospholipid acyltransferase (GPLAT) and diacylglycerol acyltransferases (DGAT). In some preferred embodiments, the acyltransferase is selected from Table 5b.

[0389] In some embodiments, the method further comprises introducing into the microorganism at least one endogenous or exogenous nucleic acid molecule encoding an acylglycerol lipase that preferably hydrolyzes ester bonds of >C16, of >C14, of >C12 or of >C10 acylglycerol substrates. In some embodiments, the acylglycerol lipase is selected from Table 5c.

[0390] In some embodiments, the method further comprises introducing into the microorganism one or more modifications comprising a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous enzyme that catalyzes a reaction in a pathway that competes with the biosynthesis pathway for the production of a mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol. In further embodiments, the recombinant microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous enzyme selected from: (i) one or more acyl-CoA oxidase; (ii) one or more acyltransferase; (iii) one or more acylglycerol lipase and/or sterol ester esterase; (iv) one or more (fatty) alcohol dehydrogenase; (v) one or more (fatty) alcohol oxidase; and (vi) one or more cytochrome P450 monooxygenase.

[0391] In some embodiments, the method further comprises introducing into the microorganism one or more modifications comprising a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous acyl-CoA oxidase enzyme selected from the group consisting of *γ. lipolytica* POX1(YALI0E32835g), *γ. lipolytica* POX2(YALI0F10857g), *Y. lipolytica* POX3(YALI0D24750g), *Y. lipolytica* POX4(YALI0E27654g), *Y. lipolytica* POX5(YALI0C23859g), *Y. lipolytica* POX6(YALT0E06567g); *S. cerevisiae* POX1(YGL205W); *Candida* POX2 (Ca019.1655, Ca019.9224, CTRG_02374, M18259), *Candida* POX4 (Ca019.1652, Ca019.9221, CTRG_02377, M12160), and *Candida* POX5 (Ca019.5723, Ca019.13146, CTRG_02721, M12161).

[0392] In some embodiments, the method further comprises introducing into the microorganism one or more modifications comprising a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous acyltransferase enzyme selected from the group consisting of *γ. lipolytica* YALI0C00209g, *γ. lipolytica* YALI0E18964g, *γ. lipolytica* YALI0F19514g, *γ. lipolytica* YALI0C14014g, *γ. lipolytica* YALI0E16797g, *γ. lipolytica* YALI0E32769g, and *γ. lipolytica* YALI0D07986g, *S. cerevisiae* YBL011w, *S. cerevisiae* YDL052c, *S. cerevisiae* YOR175C, *S. cerevisiae* YPR139C, *S. cerevisiae* YNR008w, and *S. cerevisiae* YOR245c, and *Candida* I503_02577, *Candida* CTRG_02630, *Candida*

CaO 19.250, *Candida* Ca019.788 1, *Candida* CTRG_02437, *Candida* Ca0 19.188 1, *Candida* Ca0 19.9437, *Candida* CTRG_01687, *Candida* CaO 19.1043, *Candida* Ca0 19.8645, *Candida* CTRG_04750, *Candida* CaO 19.13439, *Candida* CTRG_04390, *Candida* Ca0 19.694 1, *Candida* Ca0 19.14203, and *Candida* CTRG_06209.

[0393] In some embodiments, the method further comprises introducing into the microorganism one or more modifications comprising a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous acylglycerol lipase and/or sterol ester esterase enzyme selected from the group consisting of *Y. lipolytica* YALI0E32035g, *Y. lipolytica* YALI0D 17534g, *Y. lipolytica* YALI0F 100 10g, *Y. lipolytica* YALI0C 14520g, and *Y. lipolytica* YALI0E00528g, *S. cerevisiae* YKL140w, *S. cerevisiae* YMR3 13c, *S. cerevisiae* YKR089c, *S. cerevisiae* YOROS 1c, *S. cerevisiae* YKL094W, *S. cerevisiae* YLL0 12W, and *S. cerevisiae* YLR02QC, and *Candida* CaO 19.2050, *Candida* CaO 19.9598, *Candida* CTRG_01138, *Candida* W5Q_03398, *Candida* CTRG_00057, *Candida* Ca0 19.5426, *Candida* Ca0 19.1288 1, *Candida* CTRG_06 185, *Candida* Ca0 19.4864, *Candida* Ca0 19.12328, *Candida* CTRG_03360, *Candida* CaO 19.650 1, *Candida* Ca0 19.13854, *Candida* CTRG_05049, *Candida* Ca() 19.1887, *Candida* Ca0 19.9443, *Candida* CTRG_01683, and *Candida* CTRG_04630.

[0394] In some embodiments, the method further comprises introducing into the microorganism one or more modifications comprising a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous cytochrome P450 monooxygenases selected from the group consisting of *Y. lipolytica* YALI0E25982g (ALK 1), *Y. lipolytica* YALI0F0 1320g (ALK2), *Y. lipolytica* YALI0E23 474g (ALK3), *Y. lipolytica* YALI0B 13816g (ALK4), *Y. lipolytica* YALI0B 13838g (ALK5), *Y. lipolytica* YALI0B0 1848g (ALK6), *Y. lipolytica* YALI0A15488g (ALK7), *Y. lipolytica* YALI0C12122g (ALK8), *Y. lipolytica* YALK)B06248g (ALK9), *Y. lipolytica* YALI0B20702g (ALK10), *Y. lipolytica* YALI0C10054g (ALK11) and *Y. lipolytica* YALI0A20 130g (ALK12).

[0395] In some embodiments, the method further comprises introducing into the microorganism at least one endogenous or exogenous nucleic acid molecule encoding an aldehyde forming fatty acyl-CoA reductase capable of catalyzing the conversion of the mono- or poly-unsaturated $\leq C_{15}$ fatty alcohol into a corresponding $\leq C_{15}$ fatty aldehyde. In some preferred embodiments, the aldehyde forming fatty acyl-CoA reductase is selected from the group consisting of *Acinetobacter calcoaceticus* A0A1C4HN78, *A. calcoaceticus* N9DA85, *A. calcoaceticus* R8XW24, *A. calcoaceticus* A0A1A0GGM5, *A. calcoaceticus*

A0A1 17N 158, and *Nostoc punctiforme* YP_001 865324. In some embodiments, the method further comprises introducing into the microorganism at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase or an alcohol dehydrogenase capable of catalyzing the conversion of the mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol into a corresponding $\leq C_{18}$ fatty aldehyde. In some preferred embodiments, the $\leq C_{18}$ fatty aldehyde is selected from the group consisting of Z9-16:Ald, Z11-16:Ald, Z11Z13-16:Ald, and Z13-18:Ald.

[0396] In some embodiments, the method further comprises introducing into the microorganism at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol into a corresponding $\leq C_{18}$ fatty acetate. In some embodiments, the acetyl transferase is selected from Table 5d. In some preferred embodiments, the $\leq C_{18}$ fatty acetate is selected from the group consisting of E5-10:Ac, Z7-12:Ac, Z8-12:Ac, Z9-12:Ac, E7Z9-12:Ac, Z9-14:Ac, Z9E12-14:Ac, Z11-14:Ac, E11-14:Ac, Z9-16:Ac, and Z11-16:Ac.

[0397] In some embodiments, the method further comprises introducing into the microorganism: at least one endogenous or exogenous nucleic acid molecule encoding an enzyme selected from an alcohol oxidase, an alcohol dehydrogenase, and an aldehyde forming fatty acyl-CoA reductase capable of catalyzing the conversion of the mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol into a corresponding $\leq C_{18}$ fatty aldehyde; and at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol into a corresponding $\leq C_{18}$ fatty acetate. In some preferred embodiments, the mono- or poly-unsaturated $\leq C_{18}$ fatty aldehyde and $\leq C_{18}$ fatty acetate is selected from the group consisting of E5-10:Ac, Z7-12:Ac, Z8-12:Ac, Z9-12:Ac, E7Z9-12:Ac, Z9-14:Ac, Z9E12-14:Ac, E11-14:Ac, Z11-14:Ac, Z11-16:Ac, Z9-16:Ac, Z9-16:Ald, Z11-16:Ald, Z11Z13-16:Ald, and Z13-18:Ald.

[0398] In some embodiments, the disclosure provides a method of producing a mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol, fatty aldehyde or fatty acetate from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid, comprising: cultivating a recombinant microorganism described herein in a culture medium containing a feedstock that provides a carbon source adequate for the production of the mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol, fatty aldehyde or fatty acetate. In some embodiments, the method further comprises a step of recovering the mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol, fatty aldehyde or fatty

acetate. In further embodiments, the recovery step comprises distillation. In yet further embodiments, the recovery step comprises membrane-based separation.

[0399] In some embodiments, the mono- or poly-unsaturated \leq Cis fatty alcohol is converted into a corresponding \leq Cis fatty aldehyde using chemical methods. In further embodiments, the chemical methods are selected from TEMPO-bleach, TEMPO-copper-air, TEMPO-PhI(OAc)₂, Swern oxidation and noble metal-air. In some embodiments, the mono- or poly-unsaturated \leq Cis fatty alcohol is converted into a corresponding \leq Cis fatty acetate using chemical methods. In further embodiments, the chemical methods utilize a chemical agent selected from the group consisting of acetyl chloride, acetic anhydride, butyryl chloride, butyric anhydride, propanoyl chloride and propionic anhydride in the presence of 4-*N*, *N*-dimethylaminopyridine (DMAP) or sodium acetate to esterify the mono- or poly-unsaturated \leq Cis fatty alcohol to the corresponding \leq Cis fatty acetate.

[0400] In another aspect, the present disclosure provides methods of engineering a *Yarrowia lipolytica* microorganism capable of producing a mono- or poly-unsaturated C₆-C₂₄ fatty alcohol from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid, wherein the recombinant *Yarrowia lipolytica* microorganism comprises: (a) at least one nucleic acid molecule encoding a fatty acyl desaturase having 95% sequence identity to a fatty acyl desaturase selected from the group consisting of SEQ ID NOs: 54, 60, 62, 78, 79, 80, 95, 97, 99, 101, 103, and 105 that catalyzes the conversion of a saturated C₆-C₂₄ fatty acyl-CoA to a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA; and (b) at least one nucleic acid molecule encoding a fatty alcohol forming fatty acyl reductase having 95% sequence identity to a fatty alcohol forming fatty acyl reductase selected from the group consisting of SEQ ID NOs: 41-48, 57, 73, 75 and 77 that catalyzes the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA from (a) into the corresponding mono- or poly-unsaturated C₆-C₂₄ fatty alcohol.

[0401] In some embodiments, the method further comprises introducing into the *Yarrowia lipolytica* microorganism one or more modifications comprising a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous enzymes that catalyzes a reaction in a pathway that competes with the biosynthesis pathway for the production of a mono- or poly-unsaturated C₆-C₂₄ fatty alcohol. In some preferred embodiments, the recombinant *Yarrowia lipolytica* microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous enzyme selected from the following: (i) one or more acyl-CoA oxidase selected from the group

consisting of **YALI0E32835g** (POX1), **YALT0F10857g** (POX2), **YALI0D24750g** (POX3), **YALI0E27654g** (POX4), **YALI0C23859g** (POX5), **YALI0E06567g** (POX6); (ii) one or more (fatty) alcohol dehydrogenase selected from the group consisting of **YALI0F09603g** (FADH), **YALI0D25630g** (ADH1), **YALI0E17787g** (ADH2), **YALI0A16379g** (ADH3), **YALI0E15818g** (ADH4), **YALI0D02167g** (ADH5), **YALI0A15147g** (ADH6), **YALI0E07766g** (ADH7); (iii) a (fatty) alcohol oxidase **YALI0B14014g** (FAO1); (iv) one or more cytochrome P450 enzyme selected from the group consisting of **YALI0E25982g** (ALK1), **YALI0F01320g** (ALK2), **YALT0E23474g** (ALK3), **YALI0B13816g** (ALK4), **YALI0B13838g** (ALK5), **YALI0B01848g** (ALK6), **YALI0A15488g** (ALK7), **(YALI0C12122g (ALK8), YALI0B06248g (ALK9), YALI0B20702g (ALK10), YALI0C10054g (ALK11) and YALI0A20130g (ALK12))**; and (v) one or more diacylglycerol acyltransferase selected from the group consisting of **YALI0E32791g** (DGA1) and **YALI0D07986g** (DGA2). In other preferred embodiments, the recombinant *Yarrowia lipolytica* microorganism comprises a deletion of one or more endogenous enzyme selected from the following: (i) one or more acyl-CoA oxidase selected from the group consisting of **YALI0E32835g** (POX1), **YALI0F10857g** (POX2), **YALI0D24750g** (POX3), **YALI0E27654g** (POX4), **YALI0C23859g** (POX5), **YALI0E06567g** (POX6); (ii) one or more (fatty) alcohol dehydrogenase selected from the group consisting of **YALI0F09603g** (FADH), **YALI0D25630g** (ADH1), **YALI0E17787g** (ADH2), **YALI0A16379g** (ADH3), **YALI0E15818g** (ADH4), **YALI0D02167g** (ADH5), **YALI0A15147g** (ADH6), **YALI0E07766g** (ADH7); (iii) a (fatty) alcohol oxidase **YALI0B14014g** (FAO1); (iv) one or more cytochrome P450 enzyme selected from the group consisting of **YALI0E25982g** (ALK1), **YALI0F01320g** (ALK2), **YALI0E23474g** (ALK3), **YALI0B13816g** (ALK4), **YALI0B13838g** (ALK5), **YALI0B01848g** (ALK6), **YALI0A15488g** (ALK7), **(YALI0C12122g (ALK8), YALI0B06248g (ALK9), YALI0B20702g (ALK10), YALT0C10054g (ALK11) and YALI0A20130g (ALK12))**; and (v) one or more diacylglycerol acyltransferase selected from the group consisting of **YALI0E32791g** (DGA1) and **YALI0D07986g** (DGA2).

[0402] In some embodiments, the **fatty acyl desaturase** catalyzes the conversion of a saturated fatty **acyl-CoA** into a mono- or poly-unsaturated intermediate selected from **Z9-14:Acyl-CoA**, **Z11-14:Acyl-CoA**, **E11-14:Acyl-CoA**, **Z9-16:Acyl-CoA**, and **Z11-16:Acyl-CoA**. In other embodiments, the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol is selected

from the group consisting of Z9-14:OH, Z11-14:OH, E11-14:OH, Z9-16:OH, Z11-16:OH, Z11Z13-16:OH, and Z13-18:OH.

[0403] In some embodiments, the method further comprises introducing into the *Yarrowia lipofytica* microorganism at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase or an alcohol dehydrogenase capable of catalyzing the conversion of the mono- or poly-unsaturated C6-C24 fatty alcohol into a corresponding C6-C24 fatty aldehyde. In some embodiments, the alcohol dehydrogenase is selected from Table 3a. In some embodiments, the C6-C24 fatty aldehyde is selected from the group consisting of Z9-14:Ald, Z11-14:Ald, E11-14:Ald, Z9-16:Ald, Z11-16:Ald, Z11Z13-16:Ald and Z13-18:Ald.

[0404] In some embodiments, the method further comprises introducing into the *Yarrowia lipofytica* microorganism at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated C6-C24 fatty alcohol into a corresponding C6-C24 fatty acetate. In some embodiments, the acetyl transferase is selected from Table Sd. In some embodiments, the C6-C24 fatty acetate is selected from the group consisting of Z9-14:Ac, Z11-14:Ac, E11-14:Ac, Z9-16:Ac, Z11-16:Ac, Z11Z13-16:Ac, and Z13-18:Ac.

[0405] In some embodiments, the method further comprises introducing into the *Yarrowia lipofytica* microorganism: at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase or an alcohol dehydrogenase capable of catalyzing the conversion of the mono- or poly-unsaturated C6-C24 fatty alcohol into a corresponding C6-C24 fatty aldehyde; and at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated C6-C24 fatty alcohol into a corresponding C6-C24 fatty acetate. In some embodiments, the mono- or poly-unsaturated C6-C24 fatty aldehyde and C6-C24 fatty acetate is selected from the group consisting of Z9-14:Ac, Z11-14:Ac, E11-14:Ac, Z9-16:Ac, Z11-16:Ac, Z11Z13-16:Ac, Z13-18:Ac, Z9-14:Ald, Z11-14:Ald, E11-14:Ald, Z9-16:Ald, Z11-16:Ald, Z11Z13-16:Ald and Z13-18:Ald.

[0406] In some embodiments, the fatty acyl desaturase does not comprise a fatty acyl desaturase comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 64, 65, 66 and 67. In other embodiments, the fatty acyl desaturase does not comprise a fatty acyl desaturase selected from an *Amyeloides transitella*, *Spodoptera littoralis*, *Agrotis segetum*, or *Trichoplusia ni* derived desaturase.

[0407] In some embodiments, the disclosure provides a method of producing a mono- or poly-unsaturated C₆-C₂₄ fatty alcohol, fatty aldehyde or fatty acetate from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid, comprising: cultivating a recombinant microorganism described herein in a culture medium containing a feedstock that provides a carbon source adequate for the production of the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol, fatty aldehyde or fatty acetate. In some embodiments, the method further comprises a step of recovering the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol, fatty aldehyde or fatty acetate. In further embodiments, the recovery step comprises distillation. In yet further embodiments, the recovery step comprises membrane-based separation.

[0408] In some embodiments, the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol is converted into a corresponding C₆-C₂₄ fatty aldehyde using chemical methods. In further embodiments, the chemical methods are selected from TEMPO-bleach, TEMPO-copper-air, TEMPO-PhI(OAc)₂, Swern oxidation and noble metal-air. In some embodiments, the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol is converted into a corresponding C₆-C₂₄ fatty acetate using chemical methods. In further embodiments, the chemical methods utilize a chemical agent selected from the group consisting of acetyl chloride, acetic anhydride, butyryl chloride, butyric anhydride, propanoyl chloride and propionic anhydride in the presence of 4-*N,N*-dimethylaminopyridine (DMAP) or sodium acetate to esterify the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol to the corresponding C₆-C₂₄ fatty acetate.

Enzyme Engineering

[0409] The enzymes in the recombinant microorganism can be engineered to improve one or more aspects of the substrate to product conversion. Non-limiting examples of enzymes that can be further engineered for use in methods of the disclosure include a desaturase (*e.g.*, a fatty acyl-CoA desaturase or fatty acyl-ACP desaturase), a fatty alcohol forming fatty acyl reductase, an acyl-ACP synthetase, a fatty acid synthetase, a fatty acid synthase complex, an acetyl transferase, dehydrogenase, and an alcohol oxidase, and combinations thereof. These enzymes can be engineered for improved catalytic activity, improved selectivity, improved stability, improved tolerance to various fermentations conditions (temperature, pH, etc.), or improved tolerance to various metabolic substrates, products, by-products, intermediates, etc.

[0410] Desaturase enzymes can be engineered for improved catalytic activity in the desaturation of an unsaturated substrate, for improved hydrocarbon selectivity, for improved selectivity of a Z product over an E product, or an E product over a Z product. For example,

the Z9 fatty-acyl desaturase can be engineered to improve the yield in the substrate to product conversion of a saturated fatty acyl-CoA to the corresponding unsaturated fatty acyl-CoA, and, in addition or in the alternative, to improve selectivity of the desaturation at the 9 position to produce a corresponding Z-9 fatty acyl-CoA. In further non-limiting examples, the fatty acyl-ACP synthetase can be engineered for improved ACP ligation activity; a fatty acid synthase complex enzyme can be engineered for improved catalytic activity of elongation of a fatty acid substrate; a fatty alcohol forming fatty acyl-reductase can be engineered for improved catalytic activity in the reduction of a fatty acyl-CoA to a corresponding fatty alcohol; a fatty aldehyde forming fatty acyl-reductase can be engineered for improved catalytic activity in the reduction of a fatty acyl-ACP to a corresponding fatty aldehyde; a dehydrogenase can be engineered for improved catalytic activity in the conversion of a fatty acyl-ACP to a corresponding fatty alcohol; an alcohol oxidase can be engineered for improved catalytic activity in the conversion of a fatty alcohol into a corresponding fatty aldehyde; and an acetyl transferase can be engineered for improved catalytic activity in the conversion of a fatty alcohol into a corresponding fatty acetate.

[0411] The term "improved catalytic activity" as used herein with respect to a particular enzymatic activity refers to a higher level of enzymatic activity than that measured relative to a comparable non-engineered enzyme, such as a non-engineered desaturase (e.g. fatty acyl-CoA desaturase or fatty acyl-ACP desaturase), fatty alcohol or aldehyde forming fatty-acyl reductase, acyl-ACP synthetase, fatty acid synthetase, fatty acid synthase complex, acyl transferase, dehydrogenase, or an alcohol oxidase enzyme. For example, overexpression of a specific enzyme can lead to an increased level of activity in the cells for that enzyme. Mutations can be introduced into a desaturase (e.g. fatty acyl-CoA desaturase or fatty acyl-ACP desaturase), a fatty alcohol or aldehyde forming fatty-acyl reductase, a acyl-ACP synthetase, a fatty acid synthetase, a fatty acid synthase complex, a acyl transferase, a dehydrogenase, or an alcohol oxidase enzyme resulting in engineered enzymes with improved catalytic activity. Methods to increase enzymatic activity are known to those skilled in the art. Such techniques can include increasing the expression of the enzyme by increasing plasmid copy number and/or use of a stronger promoter and/or use of activating riboswitches, introduction of mutations to relieve negative regulation of the enzyme, introduction of specific mutations to increase specific activity and/or decrease the K_M for the substrate, or by directed evolution. See, e.g., *Methods in Molecular Biology* (vol. 231), ed. Arnold and Georgiou, Humana Press (2003).

Metabolic Engineering - Enzyme **Overexpression** and gene deletion/downregulation for Increased Pathway Flux

[0412] In various embodiments described herein, the exogenous and endogenous enzymes in the recombinant microorganism participating in the biosynthesis pathways described herein may be overexpressed.

[0413] The terms "overexpressed" or "overexpression" refers to an elevated level (*e.g.*, aberrant level) of mRNAs encoding for a protein(s), and/or to elevated levels of protein(s) in cells as compared to similar corresponding unmodified cells expressing basal levels of mRNAs or having basal levels of proteins. In particular embodiments, miRNA(s) or protein(s) may be overexpressed by at least 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 8-fold, 10-fold, 12-fold, 15-fold or more in microorganisms engineered to exhibit increased gene mRNA, protein, and/or activity.

[0414] In some embodiments, a recombinant microorganism of the disclosure is generated from a host that contains the enzymatic capability to synthesize a substrate fatty acid. In this specific embodiment it can be useful to increase the synthesis or accumulation of a fatty acid to, for example, increase the amount of fatty acid available to an engineered fatty alcohol production pathway.

[0415] In some embodiments, it may be useful to increase the expression of endogenous or exogenous enzymes involved in the fatty alcohol, aldehyde, or acetate production pathway to increase flux from the fatty acid to the fatty alcohol, aldehyde, or acetate, thereby resulting in increased synthesis or accumulation of the fatty alcohol, aldehyde, or acetate.

[0416] In some embodiments, it may be useful to increase the expression of endogenous or exogenous enzymes to increase intracellular levels of a coenzyme. In one embodiment, the coenzyme is NADH. In another embodiment, the coenzyme is NADPH. In one embodiment, the expression of proteins in the pentose phosphate pathway is increased to increase the intracellular levels of NADPH. The pentose phosphate pathway is an important catabolic pathway for supplying reduction equivalents and an important anabolic pathway for biosynthesis reactions. In one embodiment, a glucose-6-phosphate dehydrogenase that converts glucose-6-phosphate to 6-phospho D-glucono-1,5-lactone is overexpressed. In some embodiments, the glucose-6-phosphate dehydrogenase is ZWF1 from yeast. In another embodiment, the glucose-6-phosphate dehydrogenase is ZWF1 (YNL241C) from *Saccharomyces cerevisiae*. In one embodiment, a glucose-6-phosphate-1-dehydrogenase that converts D-glucopyranose-6-phosphate to 6-phospho D-glucono-1,5-lactone is

overexpressed. In another embodiment, the glucose-6-phosphate-1-dehydrogenase is zwf from bacteria. In certain embodiments, the glucose-6-phosphate-1-dehydrogenase is zwf (NP_416366) from *E. coli*. In one embodiment, a 6-phosphogluconolactonase that converts 6-phospho D-glucono-1,5-lactone to D-gluconate 6-phosphate is overexpressed. In some embodiments, the 6-phosphogluconolactonase is SOL3 of yeast. In certain embodiments, the 6-phosphogluconolactonase is SOL3 (NP_012033) of *Saccharomyces cerevisiae*. In some embodiments, the 6-phosphogluconolactonase is SOL4 of yeast. In certain embodiments, the 6-phosphogluconolactonase is SOL4 (NP_011764) of *Saccharomyces cerevisiae*. In some embodiments, the 6-phosphogluconolactonase is pgl of bacteria. In certain embodiments, the 6-phosphogluconolactonase is pgl (NP_415288) of *E. coli*. In one embodiment, a 6-phosphogluconate dehydrogenase that converts D-gluconate 6-phosphate to D-ribulose 5-phosphate is overexpressed. In some embodiments, the 6-phosphogluconate dehydrogenase is GND1 from yeast. In certain embodiments, the 6-phosphogluconate dehydrogenase is GND1 (YHR183W) from *Saccharomyces cerevisiae*. In some embodiments, the 6-phosphogluconate dehydrogenase is GND2 from yeast. In certain embodiments, the 6-phosphogluconate dehydrogenase is GND2 (YGR256W) from *Saccharomyces cerevisiae*. In some embodiments, the 6-phosphogluconate dehydrogenase is gnd from bacteria. In certain embodiments, the 6-phosphogluconate dehydrogenase is gnd (NP_416533) from *E. coli*. In one embodiment, a transaldolase that interconverts D-glyceraldehyde 3-phosphate and D-sedoheptulose 7-phosphate to β -D-fructofuranose 6-phosphate and D-erythrose 4-phosphate is overexpressed. In some embodiments, the transaldolase is TAL1 of yeast. In certain embodiments, the transaldolase is TAL1 (NP_013458) of *Saccharomyces cerevisiae*. In some embodiments, the transaldolase is NQMI of yeast. In certain embodiments, the transaldolase is NQMI (NP_011557) of *Saccharomyces cerevisiae*. In some embodiments, the transaldolase is tal of bacteria. In certain embodiments, the transaldolase is talB (NP_414549) of *E. coli*. In certain embodiments, the transaldolase is talA (NP_416959) of *E. coli*. In one embodiment, a transketolase that interconverts D-erythrose 4-phosphate and D-xylulose 5-phosphate to β -D-fructofuranose 6-phosphate and D-glyceraldehyde 3-phosphate and/or interconverts D-sedoheptulose 7-phosphate and D-glyceraldehyde 3-phosphate to D-ribose 5-phosphate and D-xylulose 5-phosphate is overexpressed. In some embodiments, the transketolase is TKL1 of yeast. In certain embodiments, the transketolase is TKL1 (NP_015399) of *Saccharomyces cerevisiae*. In some embodiments, the transketolase is TKL2 of yeast. In some embodiments, the transketolase is TKL2 (NP_009675) of *Saccharomyces*

cerevisiae. In some embodiments, the transketolase is tkt of bacteria. In certain embodiments, the transketolase is tktA (YP_026188) of *E. coli*. In certain embodiments, the transketolase is tktB (NP_416960) of *E. coli*. In one embodiment, a ribose-5-phosphate ketol-isomerase that interconverts D-ribose 5-phosphate and D-ribulose 5-phosphate is overexpressed. In some embodiments, the ribose-5-phosphate ketol-isomerase is RKI1 of yeast. In certain embodiments, the ribose-5-phosphate ketol-isomerase is RKI1 (NP_014738) of *Saccharomyces cerevisiae*. In some embodiments, the ribose-5-phosphate isomerase is rpi of bacteria. In certain embodiments, the ribose-5-phosphate isomerase is rpiA (NP_417389) of *E. coli*. In certain embodiments, the ribose-5-phosphate isomerase is rpiB (NP_418514) of *E. coli*. In one embodiment, a D-ribulose-5-phosphate 3-epimerase that interconverts D-ribulose 5-phosphate and D-xylulose 5-phosphate is overexpressed. In some embodiments, the D-ribulose-5-phosphate 3-epimerase is RPE1 of yeast. In certain embodiments, the D-ribulose-5-phosphate 3-epimerase is RPE1 (NP_012414) of *Saccharomyces cerevisiae*. In some embodiments, the D-ribulose-5-phosphate 3-epimerase is rpe of bacteria. In certain embodiments, the D-ribulose-5-phosphate 3-epimerase is rpe (NP_417845) of *E. coli*.

[0417] In one embodiment, the expression of an NADP⁺-dependent isocitrate dehydrogenase is increased to increase intracellular levels of a coenzyme. In one embodiment, an NADP⁺-dependent isocitrate dehydrogenase oxidizes D-threo-isocitrate to 2-oxoglutarate with concomitant generation of NADPH. In another embodiment, an NADP⁺-dependent isocitrate dehydrogenase oxidizes D-threo-isocitrate to 2-oxalosuccinate with concomitant generation of NADPH. In some embodiments, the NADP⁺-dependent isocitrate dehydrogenase is IDP from yeast. In certain embodiments, the NADP⁺-dependent isocitrate dehydrogenase is IDP2 (YLR174W) from *Saccharomyces cerevisiae*. In some embodiments, the NADP⁺-dependent isocitrate dehydrogenase is icd from bacteria. In certain embodiments, the NADP⁺-dependent isocitrate dehydrogenase is icd (NP_415654) from *E. coli*.

[0418] In some embodiments, the expression of a malic enzyme that decarboxylates malate to pyruvate with concomitant generation of NADH or NADPH is increased to increase intracellular levels of a coenzyme. In one embodiment, the malic enzyme is NAD⁺-dependent. In another embodiment, the malic enzyme is NADP⁺-dependent. In one embodiment, the malic enzyme is an NAD⁺-dependent malate dehydrogenase from bacteria. In some embodiments, the NAD⁺-dependent malate dehydrogenase is maeA (NP_415996) from *E. coli*. In some embodiments, the NAD⁺-dependent malate dehydrogenase is maeE (CAQ68I 19) from *Lactobacillus casei*. In another embodiment, the malic enzyme is a

mitochondrial NAD⁺ dependent malate dehydrogenase from yeast. In some embodiments, the NAD⁺ dependent malate dehydrogenase is MAE1 (YKL029C) from *S. cerevisiae*. In another embodiment, the malic enzyme is a mitochondrial NAD⁺ dependent malate dehydrogenase from a parasitic nematode. In some embodiments, the NAD⁺ dependent malate dehydrogenase is M81055 from *Ascaris suum*. In one embodiment, the malic enzyme is an NADP⁺ dependent malate dehydrogenase from bacteria. In some embodiments, the NADP⁺ dependent malate dehydrogenase is maeB (NP_416958) from *E. coli*. In one embodiment, the malic enzyme is an NADP⁺ dependent malate dehydrogenase from com. In some embodiments, the NADP⁺ dependent malate dehydrogenase is mel from *Zea mays*.

[0419] In some embodiments, the expression of an aldehyde dehydrogenase that oxidizes an aldehyde to a carboxylic acid with concomitant generation of NADH or NADPH is increased to increase intracellular levels of a coenzyme. In one embodiment, the aldehyde dehydrogenase is NAD⁺ dependent. In another embodiment, the aldehyde dehydrogenase is NADP⁺ dependent. In one embodiment, the aldehyde dehydrogenase is an NAD⁺ dependent aldehyde dehydrogenase from bacteria. In some embodiments, the NAD⁺ dependent aldehyde dehydrogenase is aldA (NP_415933) from *E. coli*. In another embodiment, the aldehyde dehydrogenase is a cytosolic NADP⁺ dependent aldehyde dehydrogenase from yeast. In some embodiments, the NADP⁺ dependent aldehyde dehydrogenase is ALD6 (YPL061W) from *S. cerevisiae*. In another embodiment, the aldehyde dehydrogenase is a cytosolic NADP⁺ dependent aldehyde dehydrogenase from bacteria. In some embodiments, the NADP⁺ dependent aldehyde dehydrogenase is aldB (NP_418045) from *E. coli*.

[0420] In one embodiment, overexpression of an enzyme to increase intracellular levels of a coenzyme comprises coupling supplementation of a co-substrate and overexpression of the enzyme. In one embodiment, the overexpression of an enzyme coupled with supplementation of a co-substrate of that enzyme increase flux through a biochemical pathway. In one embodiment, an NAD⁺ or NADP⁺ dependent alcohol dehydrogenase is expressed with a co-substrate. In certain embodiments, an alcohol dehydrogenase is expressed with an isopropanol co-substrate. In one embodiment, an NAD⁺ or NADP⁺ dependent glucose dehydrogenase is expressed with a co-substrate. In certain embodiments, a glucose dehydrogenase is expressed with a glucose co-substrate.

[0421] In one embodiment, the expression of a transhydrogenase is increased to interconvert NADH and NADPH. In some embodiments, the transhydrogenase is a pyridine nucleotide transhydrogenase. In some embodiments, the pyridine nucleotide transhydrogenase is from

bacteria. In certain embodiments, the pyridine nucleotide transhydrogenase is pntAB (beta subunit: NP_416119; alpha subunit: NP_416120) from *E. coli*. In some embodiments, the pyridine nucleotide transhydrogenase is from human. In certain embodiments, the pyridine nucleotide transhydrogenase is NNT (NP_036475) from *Homo sapiens*. In certain embodiments, the pyridine nucleotide transhydrogenase is from *Solatum tuberosum*. In certain embodiments, the pyridine nucleotide transhydrogenase is from *Spinacea oleracea*.

[0422] In some embodiments, it may be useful to increase the expression of endogenous or exogenous proteins to induce endoplasmic reticulum (ER) membrane proliferation. In some embodiments, the induction of endoplasmic reticulum membrane proliferation can improve production of fatty alcohols, aldehydes, or acetates. In one embodiment, the expression of an inactivated HMG-CoA reductase (hydroxymethylglutaryl-CoA reductase) containing one or more ER facing loops is increased. In certain embodiments, the one or more loops is between transmembrane domains 6 and 7 of an inactivated HMG-CoA reductase. In some embodiments, the inactivated HMG-CoA reductase comprises an inactivated protein or chimera which codes for the first 500 amino acids or a subsequence of the first 500 amino acids of *Yarrowia lipolytica* YALI0E04807p. In other embodiments, the inactivated HMG-CoA reductase comprises an inactivated protein or chimera which codes for the first 522 amino acids or a subsequence of the first 522 amino acids of HMG1 from *Saccharomyces cerevisiae* (NP_013636.1). In other embodiments, the inactivated HMG-CoA reductase comprises an inactivated protein or chimera which codes for the first 522 amino acids or a subsequence of the first 522 amino acids of HMG2 from *Saccharomyces cerevisiae* (NP_013555.1). In some embodiments, the expression of one or more regulatory proteins is increased to improve production of fatty alcohols, aldehydes, or acetates. In certain embodiments, the regulatory protein comprises HAC1 transcription factor from *Saccharomyces cerevisiae* (NP_116622.1). In certain embodiments, the regulatory protein comprises HAC1 transcription factor from *Yarrowia lipolytica* (YALI0B12716p).

[0423] Increased synthesis or accumulation can be accomplished by, for example, overexpression of nucleic acids encoding one or more of the above-described fatty alcohol pathway enzymes. Overexpression of a fatty alcohol pathway enzyme or enzymes can occur, for example, through increased expression of an endogenous gene or genes, or through the expression, or increased expression, of an exogenous gene or genes. Therefore, naturally occurring organisms can be readily modified to generate non-natural, fatty alcohol producing microorganisms through overexpression of one or more nucleic acid molecules encoding a

fatty alcohol biosynthetic pathway enzyme. In addition, a non-naturally occurring organism can be generated by mutagenesis of an endogenous gene that results in an increase in activity of an enzyme in the fatty alcohol biosynthetic pathways.

[0424] Equipped with the present disclosure, the skilled artisan will be able to readily construct the recombinant microorganisms described herein, as the recombinant microorganisms of the disclosure can be constructed using methods well known in the art as exemplified above to exogenously express at least one nucleic acid encoding a fatty alcohol pathway enzyme in sufficient amounts to produce a fatty alcohol.

[0425] Methods for constructing and testing the expression levels of a non-naturally occurring fatty alcohol-producing host can be performed, for example, by recombinant and detection methods well known in the art. Such methods can be found described in, for example, Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Third Ed., Cold Spring Harbor Laboratory, New York (2001); Ausubo et al., *Current Protocols in Molecular Biology*, John Wiley and Sons, Baltimore, Md. (1999).

[0426] A variety of mechanisms known in the art can be used to express, or overexpress, exogenous or endogenous genes. For example, an expression vector or vectors can be constructed to harbor one or more fatty alcohol biosynthetic pathway enzyme encoding nucleic acids as exemplified herein operably linked to expression control sequences functional in the host organism. Expression vectors applicable for use in the microbial host organisms of the invention include, for example, plasmids, phage vectors, viral vectors, episomes and artificial chromosomes, including vectors and selection sequences or markers operable for stable integration into a host chromosome.

[0427] Selectable marker genes also can be included that, for example, provide resistance to antibiotics or toxins, complement auxotrophic deficiencies, or supply critical nutrients not in the culture media. In some embodiments, the present disclosure teaches the use of the bla (bacterial ampR resistance marker). In some embodiments, the present disclosure teaches use of the URA3 marker. In some embodiments, the present disclosure teaches microorganisms comprising the SUC2 gene to permit fermentation in sucrose media.

[0428] Expression control sequences can include constitutive and inducible promoters, transcription enhancers, transcription terminators, and the like which are well known in the art. When two or more exogenous encoding nucleic acids are to be co-expressed, both nucleic acids can be inserted, for example, into a single expression vector or in separate expression vectors. For single vector expression, the encoding nucleic acids can be operationally linked

to one common expression control sequence or linked to different expression control sequences, such as one inducible promoter and one constitutive promoter. The transformation of exogenous nucleic acid sequences involved in a metabolic or synthetic pathway can be confirmed using methods well known in the art.

[0429] Expression control sequences are known in the art and include, for example, promoters, enhancers, polyadenylation signals, transcription terminators, internal ribosome entry sites (IRES), and the like, that provide for the expression of the polynucleotide sequence in a host cell. Expression control sequences interact specifically with cellular proteins involved in transcription (Maniatis et al., *Science*, 236: 1237-1245 (1987)). Exemplary expression control sequences are described in, for example, Goeddel, *Gene-Expression Technology: Methods in Enzymology*, Vol. 185, Academic Press, San Diego, Calif. (1990).

[0430] In various embodiments, an expression control sequence may be operably linked to a polynucleotide sequence. By "operably linked" is meant that a polynucleotide sequence and an expression control sequence(s) are connected in such a way as to permit gene expression when the appropriate molecules (e.g., transcriptional activator proteins) are bound to the expression control sequence(s). Operably linked promoters are located upstream of the selected polynucleotide sequence in terms of the direction of transcription and translation. Operably linked enhancers can be located upstream, within, or downstream of the selected polynucleotide.

[0431] In some embodiments, the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the activity of one or more endogenous enzymes that catalyzes a reaction in a pathway that competes with the biosynthesis pathway for the production of a mono- or poly-unsaturated C_{6-C24} fatty alcohol, aldehyde, or acetate.

[0432] In some embodiments, the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the activity of one or more endogenous enzymes that catalyzes the conversion of a fatty acid into a ω -hydroxyfatty acid. In some such embodiments, the enzymes that catalyze the conversion of a fatty acid into a ω -hydroxyfatty acid are selected from the group consisting of XP_504406, XP_504857, XP_504311, XPJ500855, XP_500856, XP_500402, XP_500097, XP_501748, XP_500560, XP_501148, XP_501667, XP_500273, BAA02041, CAA39366, CAA39367, BAA02210, BAA02211, BAA02212, BAA02213, BAA02214, AA073952, AA073953, AA073954, AA073955, AA073956, AA073958, AA073959, AAO73960, AA073961, AA073957, XP_002546278,

BAM49649, AAB80867, AAB 17462, ADL27534, AAU24352, AAA87602, CAA34612, ABM1770L, AAA25760, CABS 1047, AAC82967, WP__011027348, or homologs thereof.

[0433] In some embodiments, the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the activity of one or more endogenous cytochrome P450 monooxygenases selected from the group consisting of *Y. lipolytica* YALI0E25982g (ALK1), *Y. lipolytica* YALI0F01320g (ALK2), *Y. lipolytica* YALI0E23474g (ALK3), *Y. lipolytica* YAU0B13816g (ALK4), *Y. lipolytica* YALI0B13838g (ALK5), *Y. lipolytica* YALI0B01848g (ALK6), *Y. lipolytica* YALX0AL5488g (ALK7), *Y. lipolytica* YALI0C12122g (ALK8), *Y. lipolytica* YALI0B06248g (ALK9), *Y. lipolytica* YALI0B20702g (ALK10), *Y. lipolytica* YALI0C10054g (ALK11) and *Y. lipolytica* YALI0A20130g (ALK12).

[0434] In other embodiments, the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the activity of one or more endogenous enzymes that catalyzes the conversion of a fatty acyl-CoA into α,β -enoyl-CoA. In some such embodiments, the enzymes that catalyze the conversion of a fatty acyl-CoA into α,β -enoyl-CoA are selected from the group consisting of CAA04659, CAA04660, CAA04661, CAA04662, CAA04663, CAG79214, AAA34322, AAA34361, AAA34363, CAA2990L, BAA0476L, AAA34891, AAB08643, CAB 15271, BAN55749, CAC44516, ADK16968, AEI37634, WP_000973047, WPJ325433422, WP_035 184107, WP__026484842, CEL80920, WP__0268 18657, WP__005293707, WP__005883960, or homologs thereof.

[0435] In some embodiments, one or more genes of the microbial host encoding acyl-CoA oxidases are deleted or down-regulated to eliminate or reduce the truncation of desired fatty acyl-CoAs beyond a desired chain-length. Such deletion or down-regulation targets include but are not limited to *Y. lipolytica* POX1(YALI0E32835g), *Y. lipolytica* POX2(YALI0F10857g), *Y. lipolytica* POX3(YALI0D24750g), *Y. lipolytica* POX4(YALI0E27654g), *Y. lipolytica* POX5(YALI0C23859g), *Y. lipolytica* POX6(YALI0E06567g); *S. cerevisiae* PCX1(YGL205W); *Candida* POX2 (Ca019.1655, Ca019.9224, CTRG__02374, MI8259), *Candida* POX4 (Ca019.1652, Ca019.9221, CTRG_02377, M12160), and *Candida* POX5 (Ca0 19.5723, Ca0 19.13146, CTRG_02721, M12161).

[0436] In some embodiments, the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the activity of one or more proteins involved in peroxisome biogenesis. In such embodiments, the one or more proteins involved in peroxisome

biogenesis are selected from the group consisting of XP_505754, XP_5Q1986, XP_501311, XP_504845, XP_503326, XP_504029, XP_002549868, XP_002547156, XP_002545227, XP_002547350, XP_002546990, EIW11539, EIW08094, EIW11472, EIW09743, EIW0828, or homologs thereof.

[0437] In some embodiments, the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the activity of one or more endogenous enzymes that catalyzes a reaction in a pathway that competes with the biosynthesis pathway for one or more unsaturated fatty acyl-CoA intermediates. In one embodiment, the one or more endogenous enzymes comprise one or more diacylglycerol acyltransferases. In the context of a recombinant yeast microorganism, the recombinant yeast microorganism is engineered to delete, disrupt, mutate, and/or reduce the activity of one or more diacylglycerol acyltransferases selected from the group consisting of YALI0E32769g, YALI0D07986g and CTRG_06209, or homolog thereof. In another embodiment, the one or more endogenous enzymes comprise one or more glycerolphospholipid acyltransferases. In the context of a recombinant yeast microorganism, the recombinant yeast microorganism is engineered to delete, disrupt, mutate, and/or reduce the activity of one or more glycerolphospholipid acyltransferases selected from the group consisting of YALIOE16797g and CTG_04390, or homolog thereof. In another embodiment, the one or more endogenous enzymes comprise one or more acyl-CoA/sterol acyltransferases. In the context of a recombinant yeast microorganism, the recombinant yeast microorganism is engineered to delete, disrupt, mutate, and/or reduce the activity of one or more acyl-CoA/sterol acyltransferases selected from the group consisting of YALIOF06578g, CTRG_01764 and CTRG_01765, or homolog thereof.

[0438] In some embodiments, one or more genes of the microbial host encoding glycerol-3-phosphate acyl transferases (GPATs), lysophosphatidic acid acyltransferases (LPAATs), glycerolphospholipid acyltransferase (GPLAT's) and/or diacylglycerol acyltransferases (DGATs) are deleted or downregulated, and replaced with one or more GPATs, LPAATs, GPLATs, or DGATs which prefer to store short-chain fatty acyl-CoAs. Such deletion or downregulation targets include but are not limited to *Y. lipolytica* YALIO00209g, *Y. lipolytica* YALIOE18964g, *Y. lipolytica* YALIOF19514g, *Y. lipolytica* YALIO0C14014g, *Y. lipolytica* YALIOE16797g, *Y. lipolytica* YALIOE32769g, *Y. lipolytica* YALI0D07986g, *S. cerevisiae* YBL011w, *S. cerevisiae* YDL052c, *S. cerevisiae* YOR175C, *S. cerevisiae* YPR139C, *S. cerevisiae* YNR008w, *S. cerevisiae* YQR245c, *Candida* I503_02577, *Candida* CTRG_02630, *Candida* CaO19.250, *Candida* Ca019.7881, *Candida*

CTRG_02437, *Candida* Ca019.1881, *Candida* Ca019.9437, *Candida* CTRG_01687, *Candida* Ca019.1043, *Candida* Ca019.8645, *Candida* CTRG_04750, *Candida* Ca019.13439, *Candida* CTRG_04390, *Candida* Ca019.6941, *Candida* Ca019.14203, and *Candida* CTRG_06209.

[0439] In some preferred embodiments, one or more genes of the microbial host encoding acylglycerol lipases (mono-, di-, or triacylglycerol lipases) and sterol ester esterases are deleted or downregulated and replaced with one or more acylglycerol lipases which prefer long chain acylglycerol substrates. In some embodiments, the one or more endogenous acylglycerol lipase and/or sterol ester esterase enzymes being deleted or downregulated are selected from *Y. lipolytica* YALIOE32035g, *Y. lipolytica* YAL10D17534g, *Y. lipolytica* YALIOFIOOIOg, *Y. lipolytica* YALT0C14520g, *Y. lipolytica* YALIOE00528g, *S. cerevisiae* YKL140w, *S. cerevisiae* YMR313c, *S. cerevisiae* YKR089c, *S. cerevisiae* YOR081c, *S. cerevisiae* YKL094W, *S. cerevisiae* YLL012W, *S. cerevisiae* YLR020C, *Candida* Ca019.2050, *Candida* Ca019.9598, *Candida* CTRG_01138, *Candida* W5Q_03398, *Candida* CTRG_00057, *Candida* Ca019.5426, *Candida* Ca019.12881, *Candida* CTRG_06185, *Candida* Ca019.4864, *Candida* Ca019.12328, *Candida* CTRG_03360, *Candida* Ca019.6501, *Candida* Ca019.13854, *Candida* CTRG_05049, *Candida* Ca019.1887, *Candida* Ca019.9443, *Candida* CTRG_01683, and *Candida* CTRG_04630.

[0440] In another embodiment, the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the activity of one or more endogenous enzymes that catalyzes a reaction in a pathway that oxidizes fatty aldehyde intermediates. In one embodiment, the one or more endogenous enzymes comprise one or more fatty aldehyde dehydrogenases. In the context of a recombinant yeast microorganism, the recombinant yeast microorganism is engineered to delete, disrupt, mutate, and/or reduce the activity of one or more fatty aldehyde dehydrogenases selected from the group consisting of YALIOA17875g, YALIOE15400g, YALIOB01298g, YALIOF23793g, CTRG_05010 and CTRG_04471, or homolog thereof.

[0441] In another embodiment, the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the activity of one or more endogenous enzymes that catalyzes a reaction in a pathway that consumes fatty acetate products. In one embodiment, the one or more endogenous enzymes comprise one or more sterol esterases. In the context of a recombinant yeast microorganism, the recombinant yeast microorganism is engineered to delete, disrupt, mutate, and/or reduce the activity of one or more sterol esterases selected from the group consisting of YALIOE32035g, YALIOE00528g, CTRG_01138, CTRG_01683

and CTRG_04630, or homolog thereof. In another embodiment, the one or more endogenous enzymes comprise one or more triacylglycerol lipases. In the context of a recombinant yeast microorganism, the recombinant yeast microorganism is engineered to delete, disrupt, mutate, and/or reduce the activity of one or more triacylglycerol lipases selected from the group consisting of YALI0D17534g, YALIOFIOOI0g, CTRG_00057 and CTRG_06185, or homolog thereof. In another embodiment, the one or more endogenous enzymes comprise one or more monoacylglycerol lipases. In the context of a recombinant yeast microorganism, the recombinant yeast microorganism is engineered to delete, disrupt, mutate, and/or reduce the activity of one or more monoacylglycerol lipases selected from the group consisting of YALiOCI4520g, CTRG_03360 and CTRG_05049, or homolog thereof. In another embodiment, the one or more endogenous enzymes comprise one or more extracellular lipases. In the context of a recombinant yeast microorganism, the recombinant yeast microorganism is engineered to delete, disrupt, mutate, and/or reduce the activity of one or more extracellular lipases selected from the group consisting of YALI0A20350g, YALI0D19184g, YALI0B09361g, CTRG_05930, CTRG_04188, CTRG_02799, CTRG_03052 and CTRG_03885, or homolog thereof.

[0442] In some embodiments, the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the activity of one or more endogenous enzymes that (1) break down fatty acids in the course of beta-oxidation and/or (2) oxidize co-hydroxy fatty acids to fatty acid aldehyde or to dicarboxylic acid in the course of ω -oxidation. In some embodiments, the recombinant microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of: (i) one or more endogenous acyl-CoA oxidase selected from the group consisting of YALI0E32835g (POX1), YALI0F10857g (POX2), YALI0D24750g (POX3), YALI0E27654g (POX4), YAL10C23859g (POX5), YALI0E06567g (POX6); (ii) one or more endogenous (fatty) alcohol dehydrogenase selected from the group consisting of YALI0F09603g (FADH), YALI0D25630g (ADH1), YALI0E17787g (ADH2), YALI0A16379g (ADH3), YALI0E15818g (ADH4), YALI0D02167g (ADH5), YALI0A15147g (ADH6), YAL10E07766g (ADH7); and (iii) an endogenous (fatty) alcohol oxidase YALI0B14014g (FAOI).

[0443] In some embodiments, the *Y. lipolytica* microorganism into which biosynthesis pathways for the production of C₆-C₂₄ fatty alcohol, fatty aldehyde and/or fatty acetate are introduced is H222 Δ P Δ A AF AURA3. Δ P denotes deletion of the acyl-CoA oxidase genes (POX 1-6) in *Y. lipolytica*. Δ A denotes deletion of the (fatty) alcohol dehydrogenase genes

(FADH, ADH 1-7) in *Y. lipolytica*. AF denotes deletion of the (fatty) alcohol oxidase gene (FAO1) in *Y. lipolytica*. AURA3 denotes deletion of the URA3 gene in *Y. lipolytica*, rendering the yeast a uracil auxotroph. In some embodiments, the *Y. lipolytica* microorganism into which biosynthesis pathways for the production of C₆-C₂₄ fatty alcohol, fatty aldehyde and/or fatty acetate are introduced is H222 ΔP ΔA AF. In some embodiments, the *Y. lipolytica* microorganism into which biosynthesis pathways for the production of C₆-C₂₄ fatty alcohol, fatty aldehyde and/or fatty acetate are introduced is MATA ura3-302::SUC2 Δpox1 Apox2 Apox3 Apox4 Apox5 Apox6 Afadh Aadhl Aadh2 Aadh3 Aadh4 Aadh5 Aadh6 Aadh7 Afaol::URA3.

[0444] A wild type isolate of the yeast *Y. lipolytica*, preferably of the strain H222, can be used as the starting strain for the construction of strains according to the disclosure. The strain H222 was deposited on 29.04.2013 at the DSMZ (Deutsche Sammlung für Mikroorganismen und Zellkulturen GmbH, D-38142 Braunschweig) under the number DSM 27185 according to the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. A selection marker is required for the use of a strain for further genetic processing. This selection marker can be introduced into the strain in a manner known *per se*, e.g. in the form of the uracil auxotroph. Alternatively, already known uracil auxotrophic strains can be used, preferably the strain H222-S4 (Mauersberger S, Wang HJ, Gaillardin C, Barth G & Nicaud JM (2001) J Bacteriol 183: 5102-5109). The respective deletion cassette (e.g. POX 1-6, FADH, ADH 1-7, FAO1) is obtained by PCR or restriction and transformed into *Y. lipolytica* H222-S4, which can be produced from *Y. lipolytica* H222 (Mauersberger et al. (2001)), according to Barth and Gaillardin (Barth G & Gaillardin C (1996) *Yarrowia lipolytica*. Springer-Verlag, Berlin, Heidelberg, New York). The creation of H222 ΔP ΔA AF AURA3 is described in WO 2015/086684, which is herein incorporated by reference in its entirety. *Y. lipolytica* strain H222 ΔP ΔA AF AURA3 is used as the starting microorganism for introduction of desaturases and reductases in the present disclosure (see, for example, Examples 7, 9 and 10).

[0445] In another embodiment, the recombinant microorganism is manipulated to delete, disrupt, mutate, and/or reduce the activity of one or more endogenous reductase or desaturase enzymes that interferes with the unsaturated C₆-C₂₄ fatty alcohol, aldehyde, or acetate, *i.e.*, catalyzes the conversion of a pathway substrate or product into an unwanted by-product.

Chemical Conversion of Product from Microorganism Synthesis

[0446] The present disclosure describes chemical conversions that can be used to convert a product synthesized by recombinant microorganism into a down-stream product.

[0447] In some embodiments, an unsaturated fatty alcohol, aldehyde, acetate, or carboxylic acid produced by a microorganism can undergo subsequent chemical conversion to produce a pheromone, fragrance, flavor, polymer, or polymer intermediate. Non-limiting examples of chemical transformations include esterification, metathesis, and polymerization.

[0448] Unsaturated fatty carboxylic acids can be esterified by methods known in the art. For example, Fischer esterification can be used to convert a fatty carboxylic acid to a corresponding fatty ester. See, e.g., Komura, K. et al., *Synthesis* 2008. 3407-3410.

[0449] Elongation of the carbon chain can be performed by known methods to convert an unsaturated fatty alcohol into an elongated derivative thereof. Olefin metathesis catalysts can be performed to increase the number of carbons on the fatty carbon chain and impart Z or E stereochemistry on the corresponding unsaturated product.

[0450] In some embodiments, the metathesis catalyst is a tungsten metathesis catalyst, a molybdenum metathesis catalyst, or a ruthenium metathesis catalyst. In certain embodiments, the metathesis catalyst is a tungsten catalyst or a molybdenum catalyst. The catalysts employed in the present invention generally employ metals which can mediate a particular desired chemical reaction. In general, any transition metal (e.g., having d electrons) can be used to form the catalyst, e.g., a metal selected from one of Groups 3-12 of the periodic table or from the lanthanide series. In some embodiments, the metal is selected from Groups 3-8, or, in some cases, from Groups 4-7. In some embodiments, the metal is selected from Group 6. The term "Group 6" refers to the transition metal group comprising chromium, molybdenum, and tungsten. Additionally, the present invention may also include the formation of heterogeneous catalysts containing forms of these elements (e.g., by immobilizing a metal complex on an insoluble substrate, for example, silica).

[0451] In general, any metathesis catalyst stable under the reaction conditions and nonreactive with functional groups on the fatty substrate (e.g., alcohol, ester, carboxylic acid, aldehyde, or acetate) can be used with the present disclosure. Such catalysts are, for example, those described by Grubbs (Grubbs, R.H., "Synthesis of large and small molecules using olefin metathesis catalysts." *PMSE Prepr.*, 2012), herein incorporated by reference in its entirety. Depending on the desired isomer of the olefin, a cis-selective metathesis catalyst may be used, for example one of those described by Shahane *et al* (Shahane, S., *et al ChemCatChem*, 2013. 5(12): p. 3436-3459), herein incorporated by reference in its entirety.

Catalysts exhibiting cis-selectivity have been described previously (Khan, R.K., *et al. J. Am. Chem. Soc.* 2013. 135(28): p. 10258-61; Hartung, J. *et al. J. Am. Chem. Soc.* 2013. 135(28): p. 10183-5.; Rosebrugh, L.E., *et al. J. Am. Chem. Soc.*, 2013. 135(4): p. 1276-9.; Marx, V.M., *et al. J. Am. Chem. Soc.*, 2013. 135(1): p. 94-7.; Herbert, M.B., *et al. Angew. Chem. Int. Ed. Engl.*, 2013. 52(1): p. 310-4; Keitz, B.K., *et al. J. Am. Chem. Soc.*, 2012. 134(4): p. 2040-3.; Keitz, B.K., *et al. J. Am. Chem. Soc.*, 2012. 134(1): p. 693-9.; Endo, K. *et al. J. Am. Chem. Soc.*, 2011. 133(22): p. 8525-7).

[0452] Additional Z-selective catalysts are described in (Cannon and Grubbs 2013; Bronner *et al.* 2014; Hartung *et al.* 2014; Pnisko *et al.* 2014; Quigley and Grubbs 2014) and are herein incorporated by reference in their entirety. Due to their excellent stability and functional group tolerance, in some embodiments metathesis catalysts include, but are not limited to, neutral ruthenium or osmium metal carbene complexes that possess metal centers that are formally in the +2 oxidation state, have an electron count of 16, are penta-coordinated, and are of the general formula $LLA A'M=CRbRc$ or $LL'AA'M=(C=n)CRbRc$ (Pederson and Grubbs 2002); wherein

[0453] M is ruthenium or osmium;

[0454] L and L' are each independently any neutral electron donor ligand and selected from phosphine, sulfonated phosphine, phosphite, phosphinite, phosphonite, arsine, stibnite, ether, amine, amide, imine, sulfoxide, carboxyl, nitrosyl, pyridine, thioether, or heterocyclic carbenes; and

[0455] A and A' are anionic ligands independently selected from halogen, hydrogen, C1-C20 alkyl, aryl, C1-C20 alkoxide, aryloxy, C2-C20 alkoxy, arylalkoxy, C1-C20 carboxylate, arylsulfonate, C1-C20 alkylsulfonate, C1-C20 alkylsulfinate; each ligand optionally being substituted with C1-C5 alkyl, halogen, C1-C5 alkoxy; or with a phenyl group that is optionally substituted with halogen, C1-C5 alkyl, or C1-C5 alkoxy; and A and A' together may optionally comprise a bidentate ligand; and

[0456] Rb and Rc are independently selected from hydrogen, C1-C20 alkyl, aryl, C1-C20 carboxylate, C1-C20 alkoxy, aryloxy, C1-C20 alkoxy, C1-C20 alkoxy, C1-C20 alkylthio, C1-C20 alkylsulfonate and C1-C20 alkylsulfinate, each of Rb and Rc optionally substituted with C1-C5 alkyl, halogen, C1-C5 alkoxy or with a phenyl group that is optionally substituted with halogen, C1-C5 alkyl, or C1-C5 alkoxy.

[0457] Other metathesis catalysts such as "well defined catalysts" can also be used. Such catalysts include, but are not limited to, Schrock's molybdenum metathesis catalyst, 2,6-

diisopropylphenylimido neophylidenemolybdenum (VI) bis(hexafluoro-t-butoxide), described by Grabbs *et al.* (*Tetrahedron* 1998, 54: 4413-4450) and Basset's tungsten metathesis catalyst described by Couturier, J. L. *et al.* (*Angew. Chem. Int. Ed. Engl.* 1992, 31: 628).

[0458] Catalysts useful in the methods of the disclosure also include those described by U.S. Patent NO. 9,776,179, Peryshkov, *et al.* *J. Am. Chem. Soc.* 2011, 133: 20754-20757; Wang, *et al.* *Angewandte Chemie*, 2013, 52: 1939-1943; Yu, *et al.* *J. Am. Chem. Soc.*, 2012, 134: 2788-2799; Halford. *Chem. Eng. News*. 2011, 89 (45): 11; Yu, *et al.* *Nature*, 2011, 479: 88-93; Lee. *Nature*, 2011, 471: 452-453; Meek, *et al.* *Nature*, 2011: 471, 461-466; Flook, *et al.* *J. Am. Chem. Soc.* 2011, 133: 1784-1786; Zhao, *et al.* *Org Lett.*, 2011, 13(4): 784-787; Ondi, *et al.* "High activity, stabilized formulations, efficient synthesis and industrial use of Mo- and W-based metathesis catalysts" *XiMo Technology Updates*, 2015: http://www.ximo-inc.com/files/xmio/uploads/download/Summary_3.11.15.pdf; Schrock, *et al.* *Macromolecules*, 2010: 43, 7515-7522; Peryshkov, *et al.* *Organometallics* 2013: 32, 5256-5259; Gerber, *et al.* *Organometallics* 2013: 32, 5573-5580; Marinescu, *et al.* *Organometallics* 2012: 31, 6336-6343; Wang, *et al.* *Angew. Chem. Int. Ed.* 2013: 52, 1939 - 1943; Wang, *et al.* *Chem. Eur. J.* 2013: 19, 2726-2740; and Townsend *et al.* *J. Am. Chem. Soc.* 2012: 134, 11334-11337.

[0459] Catalysts useful in the methods of the disclosure also include those described in International Pub. No. WO 2014/155185; International Pub. No. WO 2014/172534; U.S. Pat. Appl. Pub. No. 2014/0330018; international Pub. No. WO 2015/003815; and International Pub. No. WO 2015/003814.

[0460] Catalysts useful in the methods of the disclosure also include those described in U.S. Pat. No. 4,231,947; U.S. Pat. No. 4,245,131; U.S. Pat. No. 4,427,595; U.S. Pat. No. 4,681,956; U.S. Pat. No. 4,727,215; international Pub. No. WO 1991/009825; U.S. Pat. No. 5,087,10; U.S. Pat. No. 5,142,073; U.S. Pat. No. 5,146,033; International Pub. No. WO 1992/019631; U.S. Pat. No. 6,121,473; U.S. Pat. No. 6,346,652; U.S. Pat. No. 8,987,531; U.S. Pat. Appl. Pub. No. 2008/0119678; International Pub. No. WO 2008/066754; International Pub. No. WO 2009/094201; U.S. Pat. Appl. Pub. No. 2011/0015430; U.S. Pat. Appl. Pub. No. 2011/0065915; U.S. Pat. Appl. Pub. No. 2011/0077421; International Pub. No. WO 2011/040963; International Pub. No. WO 2011/097642; U.S. Pat. Appl. Pub. No. 2011/0237815; U.S. Pat. Appl. Pub. No. 2012/0302710; International Pub. No. WO 2012/167171; U.S. Pat. Appl. Pub. No. 2012/0323000; U.S. Pat. Appl. Pub. No.

2013/0116434; International Pub. No. WO 2013/070725; U.S. Pat. Appl. Pub. No. 2013/0274482; U.S. Pat. Appl. Pub. No. 2013/0281706; International Pub. No. WO 2014/139679; International Pub. No. WO 2014/169014; U.S. Pat. Appl. Pub. No. 2014/0330018; and U.S. Pat. Appl. Pub. No. 2014/0378637.

[0461] Catalysts useful in the methods of the disclosure also include those described in International Pub. No. WO 2007/075427; U.S. Pat. Appl. Pub. No. 2007/0282148; International Pub. No. WO 2009/126831; International Pub. No. WO 2011/069134; U.S. Pat. Appl. Pub. No. 2012/0123133; U.S. Pat. Appl. Pub. No. 2013/0261312; U.S. Pat. Appl. Pub. No. 2013/0296511; International Pub. No. WO 2014/134333; and U.S. Pat. Appl. Pub. No. 2015/0018557.

[0462] Catalysts useful in the methods of the disclosure also include those described in U.S. Pat. Appl. Pub. No. 2008/0009598; U.S. Pat. Appl. Pub. No. 2008/0207911; U.S. Pat. Appl. Pub. No. 2008/0275247; U.S. Pat. Appl. Pub. No. 2011/0040099; U.S. Pat. Appl. Pub. No. 2011/0282068; and U.S. Pat. Appl. Pub. No. 2015/0038723.

[0463] Catalysts useful in the methods of the disclosure include those described in International Pub. No. WO 2007/140954; U.S. Pat. Appl. Pub. No. 2008/0221345; International Pub. No. WO 2010/037550; U.S. Pat. Appl. Pub. No. 2010/0087644; U.S. Pat. Appl. Pub. No. 2010/0113795; U.S. Pat. Appl. Pub. No. 2010/0174068; International Pub. No. WO 2011/091980; International Pub. No. WO 2012/168183; U.S. Pat. Appl. Pub. No. 2013/0079515; U.S. Pat. Appl. Pub. No. 2013/0144060; U.S. Pat. Appl. Pub. No. 2013/0211096; International Pub. No. WO 2013/135776; International Pub. No. WO 2014/001291; International Pub. No. WO 2014/067767; U.S. Pat. Appl. Pub. No. 2014/0171607; and U.S. Pat. Appl. Pub. No. 2015/0045558.

[0464] The catalyst is typically provided in the reaction mixture in a sub-stoichiometric amount (*e.g.*, catalytic amount). In certain embodiments, that amount is in the range of about 0.001 to about 50 mol % with respect to the limiting reagent of the chemical reaction, depending upon which reagent is in stoichiometric excess. In some embodiments, the catalyst is present in less than or equal to about 40 mol % relative to the limiting reagent. In some embodiments, the catalyst is present in less than or equal to about 30 mol % relative to the limiting reagent. In some embodiments, the catalyst is present in less than about 20 mol %, less than about 10 mol %, less than about 5 mol %, less than about 2.5 mol %, less than about 1 mol %, less than about 0.5 mol %, less than about 0.1 mol %, less than about 0.015 mol %, less than about 0.01 mol %, less than about 0.0015 mol %, or less, relative to the limiting

reagent. In some embodiments, the catalyst is present in the range of about 2.5 mol % to about 5 mol %, relative to the limiting reagent. In some embodiments, the reaction mixture contains about 0.5 mol% catalyst. In the case where the molecular formula of the catalyst complex includes more than one metal, the amount of the catalyst complex used in the reaction may be adjusted accordingly.

[0465] In some cases, the methods described herein can be performed in the absence of solvent (*e.g.*, neat). In some cases, the methods can include the use of one or more solvents. Examples of solvents that may be suitable for use in the disclosure include, but are not limited to, benzene, p-cresol, toluene, xylene, diethyl ether, glycol, diethyl ether, petroleum ether, hexane, cyclohexane, pentane, methylene chloride, chloroform, carbon tetrachloride, dioxane, tetrahydrofuran (THF), dimethyl sulfoxide, dimethylformamide, hexamethylphosphoric triamide, ethyl acetate, pyridine, triethylamine, picoline, and the like, as well as mixtures thereof. In some embodiments, the solvent is selected from benzene, toluene, pentane, methylene chloride, and THF. In certain embodiments, the solvent is benzene.

[0466] In some embodiments, the method is performed under reduced pressure. This may be advantageous in cases where a volatile byproduct, such as ethylene, may be produced during the course of the metathesis reaction. For example, removal of the ethylene byproduct from the reaction vessel may advantageously shift the equilibrium of the metathesis reaction towards formation of the desired product. In some embodiments, the method is performed at a pressure of about less than 760 torr. In some embodiments, the method is performed at a pressure of about less than 700 torr. In some embodiments, the method is performed at a pressure of about less than 650 torr. In some embodiments, the method is performed at a pressure of about less than 600 torr. In some embodiments, the method is performed at a pressure of about less than 550 torr. In some embodiments, the method is performed at a pressure of about less than 500 torr. In some embodiments, the method is performed at a pressure of about less than 450 torr. In some embodiments, the method is performed at a pressure of about less than 400 torr. In some embodiments, the method is performed at a pressure of about less than 350 torr. In some embodiments, the method is performed at a pressure of about less than 300 torr. In some embodiments, the method is performed at a pressure of about less than 250 torr. In some embodiments, the method is performed at a pressure of about less than 200 torr. In some embodiments, the method is performed at a pressure of about less than 150 torr. In some embodiments, the method is performed at a pressure of about less than 100 torr. In some embodiments, the method is performed at a

pressure of about less than 90 torr. In some embodiments, the method is performed at a pressure of about less than 80 torr. In some embodiments, the method is performed at a pressure of about less than 70 torr. In some embodiments, the method is performed at a pressure of about less than 60 torr. In some embodiments, the method is performed at a pressure of about less than 50 torr. In some embodiments, the method is performed at a pressure of about less than 40 torr. In some embodiments, the method is performed at a pressure of about less than 30 torr. In some embodiments, the method is performed at a pressure of about less than 20 torr. In some embodiments, the method is performed at a pressure of about 20 torr. In some embodiments, the method is performed at a pressure of about 10 torr. In some embodiments, the method is performed at a pressure of about 10 torr. In some embodiments, the method is performed at a pressure of about 1 torr. In some embodiments, the method is performed at a pressure of less than about 1 torr.

[0467] In some embodiments, the two metathesis reactants are present in equimolar amounts. In some embodiments, the two metathesis reactants are not present in equimolar amounts. In certain embodiments, the two reactants are present in a molar ratio of about 20:1, 19:1, 18:1, 17:1, 16:1, 15:1, 14:1, 13:1, 12:1, 11:1, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, 1:16, 1:17, 1:18, 1:19, or 1:20. In certain embodiments, the two reactants are present in a molar ratio of about 10:1. In certain embodiments, the two reactants are present in a molar ratio of about 7:1. In certain embodiments, the two reactants are present in a molar ratio of about 5:1. In certain embodiments, the two reactants are present in a molar ratio of about 2:1. In certain embodiments, the two reactants are present in a molar ratio of about 1:10. In certain embodiments, the two reactants are present in a molar ratio of about 1:7. In certain embodiments, the two reactants are present in a molar ratio of about 1:5. In certain embodiments, the two reactants are present in a molar ratio of about 1:2.

[0468] In general, the reactions with many of the metathesis catalysts disclosed herein provide yields better than 15%, better than 50%, better than 75%, or better than 90%. In addition, the reactants and products are chosen to provide at least a 5°C difference, a greater than 20°C difference, or a greater than 40°C difference in boiling points. Additionally, the use of metathesis catalysts allows for much faster product formation than byproduct, it is desirable to run these reactions as quickly as practical. In particular, the reactions are performed in less than about 24 hours, less than 12 hours, less than 8 hours, or less than 4 hours.

[0469] One of skill in the art will appreciate that the time, temperature and solvent can depend on each other, and that changing one can require changing the others to prepare the pyrethroid products and intermediates in the methods of the disclosure. The metathesis steps can proceed at a variety of temperatures and times. In general, reactions in the methods of the disclosure are conducted using reaction times of several minutes to several days. For example, reaction times of from about 12 hours to about 7 days can be used. In some embodiments, reaction times of 1-5 days can be used. In some embodiments, reaction times of from about 10 minutes to about 10 hours can be used. In general, reactions in the methods of the disclosure are conducted at a temperature of from about 0 °C to about 200 °C. For example, reactions can be conducted at 15-100 °C. In some embodiments, reaction can be conducted at 20-80 °C. In some embodiments, reactions can be conducted at 100-150 °C.

[0470] Unsaturated fatty esters can be reduced using a suitable reducing agent which selectively reduces the ester to the corresponding aldehyde or alcohol but does not reduce the double bond. An unsaturated fatty ester can be reduced to the corresponding unsaturated fatty aldehyde using di-isobutyl aluminum halide (DIBAL) or Vitride®. The unsaturated fatty-aldehyde can be reduced to the corresponding fatty alcohol with, e.g., DIBAL or Vitride®. In some embodiments, the unsaturated fatty ester can be reduced to the corresponding fatty alcohol using AlH₃ or 9-Borabicyclo(3.3.1)nonane (9-BBN). (See Galatis, P. *Encyclopedia of Reagents for Organic Synthesis*. 2001. New York: John Wiley & Sons; and Carey & Sundberg. *Organic Chemistry. Part B: Reactions and Synthesis*, 5th edition. 2007. New York. Springer Sciences.)

Pheromone Compositions and Uses Thereof

[0471] As described above, products made via the methods described herein are pheromones. Pheromones prepared according to the methods of the invention can be formulated for use as insect control compositions. The pheromone compositions can include a carrier, and/or be contained in a dispenser. The carrier can be, but is not limited to, an inert liquid or solid.

[0472] Examples of solid carriers include but are not limited to fillers such as kaolin, bentonite, dolomite, calcium carbonate, talc, powdered magnesia. Fuller's earth, wax, gypsum, diatomaceous earth, rubber, plastic, China clay, mineral earths such as silicas, silica gels, silicates, attaclay, limestone, chalk, loess, clay, dolomite, calcium sulfate, magnesium sulfate, magnesium oxide, ground synthetic materials, fertilizers such as ammonium sulfate, ammonium phosphate, ammonium nitrate, thiourea and urea, products of vegetable origin such as cereal meals, tree bark meal, wood meal and nutshell meal, cellulose

powders, altopulgit.es, montmorillonites, mica, vermiculites, synthetic silicas and synthetic calcium silicates, or compositions of these.

[0473] Examples of liquid carriers include, but are not limited to, water; alcohols, such as ethanol, butanol or glycol, as well as their ethers or esters, such as methylglycol acetate; ketones, such as acetone, cyclohexanone, methylethyl ketone, methylisobutylketone, or isophorone; alkanes such as hexane, pentane, or heptanes; aromatic hydrocarbons, such as xylenes or alkyl naphthalenes; mineral or vegetable oils; aliphatic chlorinated hydrocarbons, such as trichloroethane or methylene chloride; aromatic chlorinated hydrocarbons, such as chlorobenzenes; water-soluble or strongly polar solvents such as dimethylformamide, dimethyl sulfoxide, or N-methylpyrrolidone; liquefied gases; waxes, such as beeswax, lanolin, shellac wax, caraauba wax, fruit wax (such as bayberry or sugar cane wax) candelilla wax, other waxes such as microcrystalline, ozocerite, ceresin, or montan; salts such as monoethanolamine salt, sodium sulfate, potassium sulfate, sodium chloride, potassium chloride, sodium acetate, ammonium hydrogen sulfate, ammonium chloride, ammonium acetate, ammonium formate, ammonium oxalate, ammonium carbonate, ammonium hydrogen carbonate, ammonium thiosulfate, ammonium hydrogen diphosphate, ammonium dihydrogen monophosphate, ammonium sodium hydrogen phosphate, ammonium thiocyanate, ammonium sulfamate or ammonium carbamate and mixtures thereof. Baits or feeding stimulants can also be added to the carrier.

Synergist

[0474] In some embodiments, the pheromone composition is combined with an active chemical agent such that a synergistic effect results. The synergistic effect obtained by the taught methods can be quantified according to Colby's formula (*i.e.* $(E) = X + Y - (X * Y / 100)$). See Colby, **R. S.**, "Calculating Synergistic and Antagonistic Responses of Herbicide Combinations", 1967 Weeds, vol. 15, pp. 20-22, incorporated herein by reference in its entirety. Thus, by "synergistic" is intended a component which, by virtue of its presence, increases the desired effect by more than an additive amount. The pheromone compositions and adjuvants of the present methods can synergistically increase the effectiveness of agricultural active compounds and also agricultural auxiliary compounds.

[0475] Thus, in some embodiments, a pheromone composition can be formulated with a synergist. The term, "synergist," as used herein, refers to a substance that can be used with a pheromone for reducing the amount of the pheromone dose or enhancing the effectiveness of

the pheromone for attracting at least one species of insect. The synergist may or may not be an independent attractant of an insect **in** the absence of a pheromone.

[0476] In some embodiments, the synergist is a volatile **phytochemical** that attracts at least one species of Lepidoptera. The term, "phytochemical," as used herein, means a compound occurring naturally **in** a plant species. In a particular embodiment, the synergist is selected from the group comprising β -caryophyllene, iso-caryophyllene, α -humulene, **inalool**, Z3-hexenol/yl acetate, β -farnesene, benzaldehyde, phenylacetaldehyde, and combinations thereof.

[0477] The pheromone composition can contain the pheromone and the synergist in a mixed or otherwise combined form, or it may contain the pheromone and the synergist independently in a non-mixed form.

Insecticide

[0478] The pheromone composition can include one or more insecticides. In one embodiment, the insecticides are chemical insecticides known to one skilled in the art. Examples of the chemical insecticides include one or more of **pyrethroid** or **organophosphorus** insecticides, including but are not limited to, **cyfluthrin**, **permethrin**, **cypermethrin**, **bifenthrin**, **fenvalerate**, **flucythrinate**, azinphosmethyl, methyl parathion, **buprofezin**, **pyriproxyfen**, **flonicamid**, **acetamiprid**, **dinotefuran**, **clothianidin**, **acephate**, **malathion**, **quinolphos**, **chlorpyrifos**, **profenophos**, **bendiocarb**, **bifenthrin**, **chlorpyrifos**, **cyfluthrin**, **diazinon**, **pyrethrum**, **fenpropathrin**, **kinoprene**, insecticidal soap or oil, **neonicotinoids**, **diamides**, avermectin and derivatives, **spinosad** and derivatives, **azadirachtin**, **pyridalyl**, and mixtures thereof.

[0479] In another embodiment, the insecticides are one or more biological insecticides known to one skilled in the art. Examples of the biological insecticides include, but are not limited to, **azadirachtin** (neem oil), toxins from natural **pyrethrins**, *Bacillus thuringiensis* and *Beauveria bassiana*, **viruses** (e.g., **CYD-X™**, **CYD-X HP™**, Germstar™, Madex **HP™** and **Spod-X™**), peptides (**Spear-T™**, **Spear-P™**, and **Spear-C™**)

[0480] In another embodiment, the insecticides are insecticides that target the nerve and muscle. Examples include acetylcholinesterase (AChE) inhibitors, such as carbamates (e.g., **methomyl** and **thiodicarb**) and **organophosphates** (e.g., **chlorpyrifos**) **GABA-gated** chloride channel antagonists, such as **cyclodiene organochlorines** (e.g., **endosulfan**) and phenylpyrazoles (e.g., **flpronil**), sodium channel modulators, such as **pyrethrins** and **pyrethroids** (e.g., **cypermethrin** and λ -**cyhalothrin**), nicotinic acetylcholine receptor (nAChR)

agonists, such as neonicotinoids (e.g., acetamiprid, tiacloprid, thiamethoxam), nicotinic acetylcholine receptor (nAChR) allosteric modulators, such as spinosyns (e.g., spinose and spinetoram), chloride channel activators, such as avermectins and milbemycins (e.g., abamectin, emamectin benzoate), Nicotinic acetylcholine receptor (nAChR) blockers, such as bensultap and cartap, voltage dependent sodium channel blockers, such as indoxacarb and metaflumizone, ryanodine receptor modulator, such as diamides (e.g. dhlorantraniliprole and flubendiamide). In another embodiment, the insecticides are insecticides that target respiration. Examples include chemicals that uncouple oxidative phosphorylation via disruption of the proton gradient, such as chlorfenapyr, and mitochondrial complex I electron transport inhibitors.

[0481] In another embodiment, the insecticides are insecticides that target midgut. Examples include microbial disrupters of insect midgut membranes, such as *Bacillus thuringiensis* and *Bacillus sphaericus*.

[0482] In another embodiment, the insecticides are insecticides that target growth and development. Examples include juvenile hormone mimics, such as juvenile hormone analogues (e.g. fenoxycarb), inhibitors of chitin biosynthesis, Type 0, such as benzoylureas (e.g., flufenoxuron, lufenuron, and novaluron), and ecdysone receptor agonists, such as diaeyihydrazines (e.g., methoxyfenozide and tebufenozide)

Stabilizer

[0483] According to another embodiment of the disclosure, the pheromone composition may include one or more additives that enhance the stability of the composition. Examples of additives include, but are not limited to, fatty acids and vegetable oils, such as for example olive oil, soybean oil, corn oil, safflower oil, canola oil, and combinations thereof.

Filler

[0484] According to another embodiment of the disclosure, the pheromone composition may include one or more fillers. Examples of fillers include, but are not limited to, one or more mineral clays (e.g., attapulgate). In some embodiments, the attractant-composition may include one or more organic thickeners. Examples of such thickeners include, but are not limited to, methyl cellulose, ethyl cellulose, and any combinations thereof.

[0485] Solvent

[0486] According to another embodiment, the pheromone compositions of the present disclosure can include one or more solvents. Compositions containing solvents are desirable when a user is to employ liquid compositions which may be applied by brushing, dipping,

rolling, spraying, or otherwise applying the liquid compositions to substrates on which the user wishes to provide a pheromone coating (*e.g.*, a lure). In some embodiments, the solvent(s) to be used is/ are selected so as to solubilize, or substantially solubilize, the one or more ingredients of the pheromone composition. Examples of solvents include, but are not limited to, water, aqueous solvent (*e.g.*, mixture of water and ethanol), ethanol, methanol, chlorinated hydrocarbons, petroleum solvents, turpentine, xylene, and any combinations thereof.

[0487] In some embodiments, the pheromone compositions of the present disclosure comprise organic solvents. Organic solvents are used mainly in the formulation of emulsifiable concentrates, ULV formulations, and to a lesser extent granular formulations. Sometimes mixtures of solvents are used. In some embodiments, the present disclosure teaches the use of solvents including aliphatic paraffinic oils such as kerosene or refined paraffins. In other embodiments, the present disclosure teaches the use of aromatic solvents such as xylene and higher molecular weight fractions of C9 and C10 aromatic solvents. In some embodiments, chlorinated hydrocarbons are useful as co-solvents to prevent cistailization when the formulation is emulsified into water. Alcohols are sometimes used as co-solvents to increase solvent power.

Solubilizing Agent

[0488] In some embodiments, the pheromone compositions of the present disclosure comprise solubilizing agents. A solubilizing agent is a surfactant, which will form micelles in water at concentrations above the critical micelle concentration. The micelles are then able to dissolve or solubilize water-insoluble materials inside the hydrophobic part of the micelle. The types of surfactants usually used for solubilization are non-ionics: sorbitan monooleates; sorbitan monooleate ethoxylates; and methyl oleate esters.

Binder

[0489] According to another embodiment of the disclosure, the pheromone composition may include one or more binders. Binders can be used to promote association of the pheromone composition with the surface of the material on which said composition is coated. In some embodiments, the binder can be used to promote association of another additive (*e.g.*, insecticide, insect growth regulators, and the like) to the pheromone composition and/or the surface of a material. For example, a binder can include a synthetic or natural resin typically used in paints and coatings. These may be modified to cause the coated surface to be friable enough to allow* insects to bite off and ingest the components of the composition (*e.g.*,

insecticide, insect growth regulators, and the like), while still maintaining the structural integrity of the coating.

[0490] Non-limiting examples of binders include polyvinylpyrrolidone, polyvinyl alcohol, partially hydrolyzed polyvinyl acetate, carboxymethylcellulose, starch, vinylpyrrolidone/vinyl acetate copolymers and polyvinyl acetate, or compositions of these; lubricants such as magnesium stearate, sodium stearate, talc or polyethylene glycol, or compositions of these; antifoams such as silicone emulsions, long-chain alcohols, phosphoric esters, acetylene diols, fatty acids or organofluorine compounds, and complexing agents such as: salts of ethylenediaminetetraacetic acid (EDTA), salts of trinitrilotriacetic acid or salts of polyphosphoric acids, or compositions of these.

[0491] In some embodiments, the binder also acts a filler and/ or a thickener. Examples of such binders include, but are not limited to, one or more of shellac, acrylics, epoxies, alkyds, polyurethanes, linseed oil, tung oil, and any combinations thereof.

[0492] Surface-Active Agents

[0493] In some embodiments, the pheromone compositions comprise surface-active agents. In some embodiments, the surface-active agents are added to liquid agricultural compositions. In other embodiments, the surface-active agents are added to solid formulations, especially those designed to be diluted with a carrier before application. Thus, in some embodiments, the pheromone compositions comprise surfactants. Surfactants are sometimes used, either alone or with other additives, such as mmerai or vegetable oils as adjuvants to spray-tank mixes to improve the biological performance of the pheromone on the target. The surface-active agents can be anionic, cationic, or nonionic in character, and can be employed as emulsifying agents, wetting agents, suspending agents, or for other purposes. In some embodiments, the surfactants are non-ionics such as: alky ethoxyiates, linear aliphatic alcohol ethoxyiates, and aliphatic amine ethoxyiates. Surfactants conventionally used in the art of formulation and which may also be used in the present formulations are described, in *McCulcheon's Detergents and Emulsifiers Annual*, MC Publishing **Corp.**, Ridgewood, N.J.,1998, and in *Encyclopedia of Surfactants*, Vol. I-III, Chemical Publishing Co., New York, 1980-81. In some embodiments, the present disclosure teaches the use of surfactants including alkali metal, alkaline earth metal or ammonium salts of aromatic sulfonic acids, for example, ligno-, phenol-, naphthalene- and dibutylnaphthalenesulfonic acid, and of fatty acids of arylsulfonates, of alkyl ethers, of lausyl ethers, of fatty alcohol sulfates and of fatty alcohol glycol ether sulfates, condensates of

sulfonated naphthalene and its derivatives with formaldehyde, condensates of naphthalene or of the naphthalenesulfonic acids with phenol and formaldehyde, condensates of phenol or phenolsulfonic acid with formaldehyde, condensates of phenol with formaldehyde and sodium sulfite, polyoxyethylene octylphenyl ether, ethoxylated isooctyl-, octyl- or nonylphenol, tributylphenyl polyglycol ether, alkylaryl polyether alcohols, isotridecyl alcohol, ethoxylated castor oil, ethoxylated triarylphenols, salts of phosphated triarylphenolethoxylates, lauryl alcohol polyglycol ether acetate, sorbitol esters, lignin-sulfite waste liquors or methylcellulose, or compositions of these.

[0494] In some embodiments, the present disclosure teaches other suitable surface-active agents, including salts of alkyl sulfates, such as diethanolammonium lauryl sulfate; alkylaryl sulfonate salts, such as calcium dodecylbenzenesulfonate; alkylphenol-alkylene oxide addition products, such as nonylphenol-C18 ethoxylate; alcohol-alkylene oxide addition products, such as tndecyl alcohol-C16 ethoxylate; soaps, such as sodium stearate; alkyl naphthalene-sulfonate salts, such as sodium dibutyl-naphthalenesulfonate; dialkyl esters of sulfosuccinate salts, such as sodium di(2-ethylhexyl)sulfosuccinate; sorbitol esters, such as sorbitol oleate; quaternary amines, such as lauryl trimethylammonium chloride; polyethylene glycol esters of fatty acids, such as polyethylene glycol stearate; block copolymers of ethylene oxide and propylene oxide; salts of mono and dialkyl phosphate esters; vegetable oils such as soybean oil, rapeseed/canola oil, olive oil, castor oil, sunflower seed oil, coconut oil, corn oil, cottonseed oil, linseed oil, palm oil, peanut oil, safflower oil, sesame oil, tung oil and the like; and esters of the above vegetable oils, particularly methyl esters.

Wetting Agents

[0495] In some embodiments, the pheromone compositions comprise wetting agents. A wetting agent is a substance that when added to a liquid increases the spreading or penetration power of the liquid by reducing the interfacial tension between the liquid and the surface on which it is spreading. Wetting agents are used for two main functions in agrochemical formulations: during processing and manufacture to increase the rate of wetting of powders in water to make concentrates for soluble liquids or suspension concentrates; and during mixing of a product with water in a spray tank or other vessel to reduce the wetting time of wettable powders and to improve the penetration of water into water-dispersible granules. In some embodiments, examples of wetting agents used in the pheromone compositions of the present disclosure, including wettable powders, suspension concentrates,

and water-dispersible granule formulations are: sodium lauryl sulphate; sodium dioctyl suiphosuccinate; aikyl phenol ethoxyiates; and aliphatic alcohol ethoxyiates.

Dispersing Agent

[0496] In some embodiments, the pheromone compositions of the present disclosure comprise dispersing agents. A dispersing agent is a substance which adsorbs onto the surface of particles and helps to preserve the state of dispersion of the particles and prevents them from reaggregating. In some embodiments, dispersing agents are added to pheromone compositions of the present disclosure to facilitate dispersion and suspension during manufacture, and to ensure the particles redisperse into water in a spray tank. In some embodiments, dispersing agents are used in wettable powders, suspension concentrates, and water-dispersible granules. Surfactants that are used as dispersing agents have the ability to adsorb strongly onto a particle surface and provide a charged or steric barrier to re-aggregation of particles. In some embodiments, the most commonly used surfactants are anionic, non-ionic, or mixtures of the two types.

[0497] In some embodiments, for wettable powder formulations, the most common dispersing agents are sodium lignosulphonates. In some embodiments, suspension concentrates provide very good adsorption and stabilization using polyelectrolytes, such as sodium naphthalene sulphonate formaldehyde condensates. In some embodiments, tristyrilphenol ethoxylated phosphate esters are also used. In some embodiments, such as alkylarylethylene oxide condensates and EO-PO block copolymers are sometimes combined with anionics as dispersing agents for suspension concentrates.

Polymeric Surfactant

[0498] In some embodiments, the pheromone compositions of the present disclosure comprise polymeric surfactants. In some embodiments, the polymeric surfactants have very-long hydrophobic 'backbones' and a large number of ethylene oxide chains forming the 'teeth' of a 'comb' surfactant. In some embodiments, these high molecular weight polymers can give very good long-term stability to suspension concentrates, because the hydrophobic backbones have many anchoring points onto the particle surfaces. In some embodiments, examples of dispersing agents used in pheromone compositions of the present disclosure are: sodium lignosulphonates; sodium naphthalene sulphonate formaldehyde condensates; tristyrilphenol ethoxylate phosphate esters; aliphatic alcohol ethoxyiates; alky ethoxyiates; EO-PO block copolymers; and graft copolymers.

Emulsifying Agent

[0499] In some embodiments, the pheromone compositions of the present disclosure comprise emulsifying agents. An emulsifying agent is a substance, which stabilizes a suspension of droplets of one liquid phase in another liquid phase. Without the emulsifying agent the two liquids would separate into two immiscible liquid phases. In some embodiments, the most commonly used emulsifier blends include alkylphenol or aliphatic alcohol with 12 or more ethylene oxide units and the oil-soluble calcium salt of dodecylbenzene sulphonic acid. A range of hydrophile-lipophile balance ("HLB") values from 8 to 18 will normally provide good stable emulsions. In some embodiments, emulsion stability can sometimes be improved by the addition of a small amount of an EO-PO block copolymer surfactant.

Gelling Agent

[0500] In some embodiments, the pheromone compositions comprise gelling agents. Thickeners or gelling agents are used mainly in the formulation of suspension concentrates, emulsions, and suspoemulsions to modify the rheology or flow properties of the liquid and to prevent separation and settling of the dispersed particles or droplets. Thickening, gelling, and anti-settling agents generally fall into two categories, namely water-insoluble particulates and water-soluble polymers. It is possible to produce suspension concentrate formulations using clays and silicas. In some embodiments, the pheromone compositions comprise one or more thickeners including, but not limited to: montmorillonite, e.g. bentonite; magnesium aluminum silicate; and attapulgite. In some embodiments, the present disclosure teaches the use of polysaccharides as thickening agents. The types of polysaccharides most commonly-used are natural extracts of seeds and seaweeds or synthetic derivatives of cellulose. Some embodiments utilize xanthan and some embodiments utilize cellulose. In some embodiments, the present disclosure teaches the use of thickening agents including, but are not limited to: guar gum; locust bean gum; carrageenan; alginates; methyl cellulose; sodium carboxymethyl cellulose (SCMC); hydroxyethyl cellulose (HEC). In some embodiments, the present disclosure teaches the use of other types of anti-settling agents such as modified starches, polyacrylates, polyvinyl alcohol, and polyethylene oxide. Another good anti-settling agent is xanthan gum.

Anti-Foam Agent

[0501] In some embodiments, the presence of surfactants, which lower interfacial tension, can cause water-based formulations to foam during mixing operations in production and in application through a spray tank. Thus, in some embodiments, in order to reduce the tendency

to foam, anti-foam agents are often added either during the production stage or before filling into bottles/spray tanks. Generally, there are two types of anti-foam agents, namely silicones and nonsilicones. Silicones are usually aqueous emulsions of dimethyl polysiloxane, while the nonsilicone anti-foam agents are water-insoluble oils, such as octanol and nonanol, or silica. In both cases, the function of the anti-foam agent is to displace the surfactant from the air-water interface.

Preservative

[0502] In some embodiments, the pheromone compositions comprise a preservative.

Additional Active Agent

[0503] According to another embodiment of the disclosure, the pheromone composition may include one or more insect feeding stimulants. Examples of insect feeding stimulants include, but are not limited to, crude cottonseed oil, fatty acid esters of phytol, fatty acid esters of geranyl geraniol, fatty acid esters of other plant alcohols, plant extracts, and combinations thereof.

[0504] According to another embodiment of the disclosure, the pheromone composition may include one or more insect growth regulators ("IGRs"). IGRs may be used to alter the growth of the insect and produce deformed insects. Examples of insect growth regulators include, for example, dimilin.

[0505] According to another embodiment of the disclosure, the attractant-composition may include one or more insect sterilants that sterilize the trapped insects or otherwise block their reproductive capacity, thereby reducing the population in the following generation. In some situations allowing the sterilized insects to survive and compete with non-trapped insects for mates is more effective than killing them outright.

Sprayable Compositions

[0506] In some embodiments, the pheromone compositions disclosed herein can be formulated as a sprayable composition (*i.e.*, a sprayable pheromone composition). An aqueous solvent can be used in the sprayable composition, *e.g.*, water or a mixture of water and an alcohol, glycol, ketone, or other water-miscible solvent. In some embodiments, the water content of such mixture is at least about 10%, at least about 20%, at least about 30%, at least about 40%, 50%, at least about 60 %, at least about 70%, at least about 80%, or at least

about 90%. In some embodiments, the sprayable composition is concentrate, *i.e.* a concentrated suspension of the pheromone, and other additives [*e.g.*, a waxy substance, a stabilizer, and the like) in the aqueous solvent, and can be diluted to the final use concentration by addition of solvent (*e.g.*, water).

[0507] In some embodiments, a waxy substance can be used as a carrier for the pheromone and its positional isomer in the sprayable composition. The waxy substance can be, *e.g.*, a biodegradable wax, such as bees wax, carnauba wax and the like, candelilla wax (hydrocarbon wax), montan wax, shellac and similar waxes, saturated or unsaturated fatty-acids, such as lauric, palmitic, oleic or stearic acid, fatty acid amides and esters, hydroxylic fatty acid esters, such as hydroxyethyl or hydroxy-propyl fatty acid esters, fatty alcohols, and low molecular weight polyesters such as polyalkylene succinates.

[0508] In some embodiments, a stabilizer can be used with the sprayable pheromone compositions. The stabilizer can be used to regulate the particle size of concentrate and/or to allow the preparation of a stable suspension of the pheromone composition. In some embodiments, the stabilizer is selected from hydroxylic and/or ethoxylated polymers. Examples include ethylene oxide and propylene oxide copolymer, polyalcohols, including starch, maltodextrin and other soluble carbohydrates or their ethers or esters, cellulose ethers, gelatin, polyacrylic acid and salts and partial esters thereof and the like. In other embodiments, the stabilizer can include polyvinyl alcohols and copolymers thereof, such as partly hydrolyzed polyvinyl acetate. The stabilizer may be used at a level sufficient to regulate particle size and/or to prepare a stable suspension, *e.g.*, between 0.1% and 15% of the aqueous solution.

[0509] In some embodiments, a binder can be used with the sprayable pheromone compositions. In some embodiments, the binder can act to further stabilize the dispersion and/or improve the adhesion of the sprayed dispersion to the target locus (*e.g.*, trap, lure, plant, and the like). The binder can be polysaccharide, such as an alginate, cellulose derivative (acetate, alkyl, carboxymethyl, hydroxyalkyl), starch or starch derivative, dextrin, gum (arable, guar, locust bean, tragacanth, carrageenan, and the like), sucrose, and the like. The binder can also be a non-carbohydrate, water-soluble polymer such as polyvinyl pyrrolidone, or an acidic polymer such as polyacrylic acid or polymethacrylic acid, in acid and/or salt form, or mixtures of such polymers.

Microencapsulated **Pheromones**

[0510] In some embodiments, the pheromone compositions disclosed herein can be formulated as a microencapsulated pheromone, such as disclosed in Iilchev, AL *et al.*, *J. Econ. Entomol.* 2006;99(6):2048-54; and Stelinki, LL *et al.*, *J. Econ. Entomol.* 2007;100(4):1360-9. Microencapsulated pheromones (MECs) are small droplets of pheromone enclosed within polymer capsules. The capsules control the release rate of the pheromone into the surrounding environment, and are small enough to be applied in the same method as used to spray insecticides. The effective field longevity of the microencapsulated pheromone formulations can range from a few days to slightly more than a week, depending on *inter alia* climatic conditions, capsule size and chemical properties.

Slow-Release Formulation

[0511] Pheromone compositions can be formulated so as to provide slow release into the atmosphere, and/or so as to be protected from degradation following release. For example, the pheromone compositions can be included in carriers such as microcapsules, biodegradable flakes and paraffin wax-based matrices. Alternatively, the pheromone composition can be formulated as a slow release sprayable.

[0512] In certain embodiments, the pheromone composition may include one or more polymeric agents known to one skilled in the art. The polymeric agents may control the rate of release of the composition to the environment. In some embodiments, the polymeric attractant-composition is impervious to environmental conditions. The polymeric agent may also be a sustained-release agent that enables the composition to be released to the environment in a sustained manner.

[0513] Examples of polymeric agents include, but are not limited to, celluloses, proteins such as casein, fluorocarbon-based polymers, hydrogenated rosins, lignins, melamine, polyurethanes, vinyl polymers such as polyvinyl acetate (PVAC), polycarbonates, polyvinylidene dinitrile, polyamides, polyvinyl alcohol (PVA), polyamide-aldehyde, polyvinyl aldehyde, polyesters, polyvinyl chloride (PVC), polyethylenes, polystyrenes, polyvinylidene, silicones, and combinations thereof. Examples of celluloses include, but are not limited to, methylcellulose, ethyl cellulose, cellulose acetate, cellulose acetate-butyrate, cellulose acetate-propionate, cellulose propionate, and combinations thereof.

[0514] Other agents which can be used in slow-release or sustained-release formulations include fatty acid esters (such as a sebacate, laurate, palmitate, stearate or arachidate ester) or a fatty alcohols (such as undecanol, dodecanol, tridecanol, tridecenol, tetradecanol,

tetradecenol, tetradecadienol, pentadecanol, pentadecenol, hexadecanol, hexadecenol, hexadecadienol, octadecenol and octadecadienol).

[0515] Pheromones prepared according to the methods of the invention, as well as compositions containing the pheromones, can be used to control the behavior and/or growth of insects in various environments. The pheromones can be used, for example, to attract or repel male or female insects to or from a particular target area. The pheromones can be used to attract insects away from vulnerable crop areas. The pheromones can also be used, for example, to attract insects as part of a strategy for insect monitoring, mass trapping, lure/attract-and-kill or mating disruption.

Lures

[0516] The pheromone compositions of the present disclosure may be coated on or sprayed on a lure, or the lure may be otherwise impregnated with a pheromone composition.

[0517] Traps

[0518] The pheromone compositions of the disclosure may be used in traps, such as those commonly used to attract any insect species, e.g., insects of the order Lepidoptera. Such traps are well known to one skilled in the art, and are commonly used in many states and countries in insect eradication programs. In one embodiment, the trap includes one or more septa, containers, or storage receptacles for holding the pheromone composition. Thus, in some embodiments, the present disclosure provides a trap loaded with at least one pheromone composition. Thus, the pheromone compositions of the present disclosure can be used in traps for example to attract insects as part of a strategy for insect monitoring, mass trapping, mating disruption, or lure/attract and kill for example by incorporating a toxic substance into the trap to kill insects caught.

[0519] Mass trapping involves placing a high density of traps in a crop to be protected so that a high proportion of the insects are removed before the crop is damaged. Lure/attract-and-kill techniques are similar except once the insect is attracted to a lure, it is subjected to a killing agent. Where the killing agent is an insecticide, a dispenser can also contain a bait or feeding stimulant that will entice the insects to ingest an effective amount of an insecticide. The insecticide may be an insecticide known to one skilled in the art. The insecticide may be mixed with the attractant-composition or may be separately present in a trap. Mixtures may perform the dual function of attracting and killing the insect.

[0520] Such traps may take any suitable form, and killing traps need not necessarily incorporate toxic substances, the insects being optionally killed by other means, such as

drowning or electrocution. Alternatively, the traps can contaminate the insect with a fungus or virus that kills the insect later. Even where the insects are not killed, the trap can serve to remove the male insects from the locale of the female insects, to prevent breeding.

[0521] It will be appreciated by a person skilled in the art that a variety of different traps are possible. Suitable examples of such traps include water traps, sticky traps, and one-way traps. Sticky traps come in many varieties. One example of a sticky trap is of cardboard construction, triangular or wedge-shaped in cross-section, where the interior surfaces are coated with a non-drying sticky substance. Insects contact the sticky surface and are caught. Water traps include pans of water and detergent that are used to trap insects. The detergent destroys the surface tension of the water, causing insects that are attracted to the pan, to drown in the water. One-way traps allow an insect to enter the trap but prevent it from exiting. The traps of the disclosure can be colored brightly, to provide additional attraction for the insects.

[0522] In some embodiments, the pheromone traps containing the composition may be combined with other kinds of trapping mechanisms. For example, in addition to the pheromone composition, the trap may include one or more fluorescent lights, one or more sticky substrates and/or one or more colored surfaces for attracting moths. In other embodiments, the pheromone trap containing the composition may not have other kinds of trapping mechanisms.

[0523] The trap may be set at any time of the year in a field. Those of skill in the art can readily determine an appropriate amount of the compositions to use in a particular trap, and can also determine an appropriate density of traps/acre of crop field to be protected.

[0524] The trap can be positioned in an area infested (or potentially infested) with insects. Generally, the trap is placed on or close to a tree or plant. The aroma of the pheromone attracts the insects to the trap. The insects can then be caught, immobilized and/or killed within the trap, for example, by the killing agent present in the trap.

[0525] Traps may also be placed within an orchard to overwhelm the pheromones emitted by the females, so that the males simply cannot locate the females. In this respect, a trap need be nothing more than a simple apparatus, for example, a protected wickable to dispense pheromone.

[0526] The traps of the present disclosure may be provided in made-up form, where the compound of the disclosure has already been applied. In such an instance, depending on the half-life of the compound, the compound may be exposed, or may be sealed in conventional

manner, such as is standard with other aromatic dispensers, the seal only being removed once the trap is in place.

[0527] Alternatively, the traps may be sold separately, and the compound of the disclosure provided in dispensable format so that an amount may be applied to trap, once the trap is in place. Thus, the present disclosure may provide the compound in a sachet or other dispenser.

Dispenser

[0528] Pheromone compositions can be used in conjunction with a dispenser for release of the composition in a particular environment. Any suitable dispenser known in the art can be used. Examples of such dispensers include but are not limited to, aerosol emitters, hand-applied dispensers, bubble caps comprising a reservoir with a permeable barrier through which pheromones are slowly released, pads, beads, tubes rods, spirals or balls composed of rubber, plastic, leather, cotton, cotton wool, wood or wood products that are impregnated with the pheromone composition. For example, polyvinyl chloride laminates, pellets, granules, ropes or spirals from which the pheromone composition evaporates, or rubber septa. One of skill in the art will be able to select suitable carriers and/or dispensers for the desired mode of application, storage, transport or handling.

[0529] In another embodiment, a device may be used that contaminates the male insects with a powder containing the pheromone substance itself. The contaminated males then fly off and provide a source of mating disruption by permeating the atmosphere with the pheromone substance, or by attracting other males to the contaminated males, rather than to real females.

Behavior Modification

[0530] Pheromone compositions prepared according to the methods disclosed herein can be used to control or modulate the behavior of insects. In some embodiments, the behavior of the target insect can be modulated in a tunable manner inter alia by varying the ratio of the pheromone to the positional isomer in the composition such that the insect is attracted to a particular locus but does not contact said locus or such the insect in fact contacts said locus. Thus, in some embodiments, the pheromones can be used to attract insects away from vulnerable crop areas. Accordingly, the disclosure also provides a method for attracting insects to a locus. The method includes administering to a locus an effective amount of the pheromone composition.

[0531] The method of mating disruption may include periodically monitoring the total number or quantity of the trapped insects. The monitoring may be performed by counting the number of insects trapped for a predetermined period of time such as, for example, daily,

Weekly, bi-Weekly, monthly, once-in-three months, or any other time periods selected by the monitor. Such monitoring of the trapped insects may help estimate the population of insects for that particular period, and thereby help determine a particular type and/or dosage of pest control in an integrated pest management system. For example, a discovery of a high insect population can necessitate the use of methods for removal of the insect. Early warning of an infestation in a new habitat can allow action to be taken before the population becomes unmanageable. Conversely, a discovery of a low insect population can lead to a decision that it is sufficient to continue monitoring the population. Insect populations can be monitored regularly so that the insects are only controlled when they reach a certain threshold. This provides cost-effective control of the insects and reduces the environmental impact of the use of insecticides.

Mating Disruption

[0532] Pheromones prepared according to the methods of the disclosure can also be used to disrupt mating. Mating disruption is a pest management technique designed to control insect pests by introducing artificial stimuli (e.g., a pheromone composition as disclosed herein) that confuses the insects and disrupts mating localization and/or courtship, thereby preventing mating and blocking the reproductive cycle.

[0533] In many insect species of interest to agriculture, such as those in the order Lepidoptera, females emit an airborne trail of a specific chemical blend constituting that species' sex pheromone. This aerial trail is referred to as a pheromone plume. Males of that species use the information contained in the pheromone plume to locate the emitting female (known as a "calling" female). Mating disruption exploits the male insects' natural response to follow the plume by introducing a synthetic pheromone into the insects' habitat, which is designed to mimic the sex pheromone produced by the female insect. Thus, in some embodiments, the synthetic pheromone utilized in mating disruption is a synthetically derived pheromone composition comprising a pheromone having a chemical structure of a sex pheromone and a positional isomer thereof which is not produced by the target insect.

[0534] The general effect of mating disruption is to confuse the male insects by masking the natural pheromone plumes, causing the males to follow "false pheromone trails" at the expense of finding mates, and affecting the males' ability to respond to "calling" females. Consequently, the male population experiences a reduced probability of successfully locating and mating with females, which leads to the eventual cessation of breeding and collapse of the insect infestation.

[0535] Strategies of mating disruption include confusion, trail-masking and false-trail following. Constant exposure of insects to a high concentration of a pheromone can prevent male insects from responding to normal levels of the pheromone released by female insects. Trail-masking uses a pheromone to destroy the trail of pheromones released by females. False-trail following is carried out by laying numerous spots of a pheromone in high concentration to present the male with many false trails to follow. When released in sufficiently high quantities, the male insects are unable to find the natural source of the sex pheromones (the female insects) so that mating cannot occur.

[0536] In some embodiments, a wick or trap may be adapted to emit a pheromone for a period at least equivalent to the breeding season(s) of the midge, thus causing mating disruption. If the midge has an extended breeding season, or repeated breeding season, the present disclosure provides a wick or trap capable of emitting pheromone for a period of time, especially about two weeks, and generally between about 1 and 4 weeks and up to 6 weeks, which may be rotated or replaced by subsequent similar traps. A plurality of traps containing the pheromone composition may be placed in a locus, e.g., adjacent to a crop field. The locations of the traps, and the height of the traps from ground may be selected in accordance with methods known to one skilled in the art.

[0537] Alternatively, the pheromone composition may be dispensed from formulations such as microcapsules or twist-ties, such as are commonly used for disruption of the mating of insect pests.

Attract and Kill

[0538] The attract and kill method utilizes an attractant, such as a sex pheromone, to lure insects of the target species to an insecticidal chemical, surface, device, etc., for mass-killing and ultimate population suppression, and can have the same effect as mass-trapping. For instance, when a synthetic female sex pheromone is used to lure male pests, e.g., moths, in an attract-and-kill strategy, a large number of male moths must be killed over extended periods of time to reduce matings and reproduction, and ultimately suppress the pest population. The attract-and-kill approach may be a favorable alternative to mass-trapping because no trap-servicing or other frequent maintenance is required. In various embodiments described herein, a recombinant microorganism can co-express (i) a pathway for production of an insect pheromone and (ii) a protein, peptide, oligonucleotide, or small molecule which is toxic to the insect. In this way, the recombinant microorganism can co-produce substances suitable for use in an attract-and-kill approach.


[0539] As will be apparent to one of skill in the art, the amount of a pheromone or pheromone composition used for a particular application can vary depending on several factors such as the type and level of infestation; the type of composition used; the concentration of the active components; how the composition is provided, for example, the type of dispenser used; the type of location to be treated; the length of time the method is to be used for; and environmental factors such as temperature, wind speed and direction, rainfall and humidity. Those of skill in the art will be able to determine an effective amount of a pheromone or pheromone composition for use in a given application.

[0540] As used herein, an "effective amount" means that amount of the disclosed pheromone composition that is sufficient to affect desired results. An effective amount can be administered in one or more administrations. For example, an effective amount of the composition may refer to an amount of the pheromone composition that is sufficient to attract a given insect to a given locus. Further, an effective amount of the composition may refer to an amount of the pheromone composition that is sufficient to disrupt mating of a particular insect population of interest in a given locality.

EXAMPLES

Example 1. Production of Pheromone Products from **Enzymatically-Derived Gondoic Acid** through Metathesis and Chemical Conversion

[0541] This example illustrates that different fatty acids can be used as a starting material for the biosynthetic production of a pheromone or pheromone precursor. The product obtained from the biosynthetic process disclosed herein can be subject to further chemical conversions to generate different products.



[0543] This prophetic example illustrates that the recombinant microorganisms disclosed herein can be used to create synthetic blends of insect pheromones.

[0545] Similarly, using hexadecyl-ACP (16:ACP), a blend of Z- and E hexadecenyl acetate pheromones (El 1-16:OAc and Z11-16:OAc) can be produced with the recombinant microorganism.

[0546] The microorganism can be engineered with different desaturases, or other enzymes such as reductases, etc. to produce the desired blend of pheromones. One blend of particular relevance capable of being produced using the recombinant microorganisms and methods of the instant invention is a 97:3 ratio of (Z)-11-hexadecenal (Z11-16:Ald) and (Z)-9-hexadecenal (Z9-16:Ald).

Example 3: Expression of transmembrane alcohol-forming reductases in *S. cerevisiae*

Background and Rationale

[0547] Engineering microbial production of insect fatty alcohols from fatty acids entails the functional expression of a synthetic pathway. One such pathway comprises a transmembrane desaturase, and an alcohol-forming reductase to mediate the conversion of fatty acyl-CoA into regio- and stereospecific unsaturated fatty acyl-CoA, and subsequently into fatty-alcohols. A number of genes encoding these enzymes are found in some insects (as well as some microalgae in the case of fatty alcohol reductase) and can be used to construct the synthetic pathway in yeasts, which are preferred production hosts. A number of transmembrane desaturases and alcohol-forming reductase variants will be screened to identify ensembles which allow high level synthesis of a single insect fatty alcohol or a blend of fatty alcohols. Additionally, these enzymes will be screened across multiple hosts (*Saccharomyces cerevisiae*, *Candida tropicalis*, and *Yarrowia lipolytica*) to optimize the search toward finding a suitable host for optimum expression of these transmembrane proteins.

[0548] Summary of Approach

[0549] Three alcohol-forming reductases of insect origin were selected.

[0550] Nucleic acids encoding the reductases were synthesized (synthons) with codon optimization for expression in *S. cerevisiae*.

[0551] Each nucleic acid encoding a given reductase was subcloned into an episomal expression cassette under the Gal 1 promoter.

[0552] *S. cerevisiae* wild-type and beta-oxidation deletion mutant were transformed with expression constructs.

[0553] Heterologous protein was induced by galactose, and functional expression of the reductases was assessed *in vivo* via byconversion of Z11-hexadecenoic acid into Z11-hexadecenol.

[0554] GC-MS analysis was used to identify and quantify metabolites.

[0555] Results

[0556] Alcohol-forming reductase variants were screened for activity in *S. cerevisiae* W303 (wild type) and BY4742 Δ POX1 (beta-oxidation deletion mutant). Z11-hexadecenoic acid was chosen as a substrate in assessing enzyme activity. The *in vivo* byconversion assay showed that the expression of enzyme variants derived from *Spodoptera littoralis*, *Hehcoverpa armigera*, and *Agrotis segetum* (Ding, B-J., Lofstedt, C. Analysis of the *Agrotis segetum* pheromone gland transcriptome in the light of sex pheromone biosynthesis. BMC Genomics 16:711 (2015)) in W303A conferred Z11-hexadecenol production, and reached up to ~37 μ M (8 mg/L), ~70 μ M (~16 mg/L), and 11 μ M (~3 mg/L), respectively, within 48h of protein induction (Figure 5 and Figure 6). Biologically-produced Z11-hexadecenol matched authentic Z11-hexadecenol standard (Bedoukian) as determined via GC-MS (Figure 7). BY4742 Δ POX1 was also explored as an expression host since deletion in the key beta-oxidation pathway enzyme could limit the degradation of Z11-hexadecenoic acid. Expressing the reductase variants in the beta-oxidation deletion mutant, however, reduced the product titer when compared to expression in the wild-type host (Figure 5). One contributing factor of titer reduction when using BY4742 Δ POX1 as a host was the reduction of biomass when compared to W303 (Figure 8).

[0557] Therefore, functional expression of at least two alcohol-forming reductases in *S. cerevisiae* conferred byconversion of Z11-hexadecenoic acid into Z11-hexadecenol.

[0558] Conclusions

[0559] Functional expression of insect transmembrane alcohol-forming reductase in *S. cerevisiae* was demonstrated. Among the reductases tested, the variant derived from *Hehcoverpa armigera* is most active toward Z11-hexadecenoic acid.

[0560] The byconversion of other fatty acid substrates can be explored to assess enzyme plasticity.

[0561] Materials & Methods

[0562] Strain construction and functional expression assay

[0563] *S. cerevisiae* W303 (MATA ura3-1 trp1-1 leu2-3 __112 his3-11 __15 ade2-1 can1-100) and BY4742 (MATa POX1::kanMX his3A1 leu2A0 lys2A0 ura3A0) were used as expression hosts. DNA sequences which encode fatty alcohol reductase variants were redesigned to optimize expression in *S. cerevisiae* (SEQ ID NOs: 1-3). Generated synthons (Genscript) were cloned into pESC-URA vector using BamHI-XhoI sites to facilitate protein expression utilizing the Gall promoter. The resulting plasmid constructs were used to transform W303,

and positive transformants were selected on CM agar medium (with 2% glucose, and lacking uracil) (Teknova). To assess functional expression, two positive transformation clones that have been patched on CM agar medium (with 2% glucose, and lacking uracil) were used to seed CM liquid medium using a 24 deep-well plate format. To induce protein expression, the overnight cultures that had been grown at 28°C were then supplemented with galactose, raffinose, and YNB to a final concentration of 2%, 1%, and 6.7 g/L, respectively. Post 24h of protein induction, the bioconversion substrate Z11-hexadecenoic acid (in ethanol) or heptadecanoic acid (in ethanol) was added to a final concentration of 300 mg/L. Bioconversion assay proceeded for 48 h at 28°C prior to GC-MS analysis.

[0564] Metabolite extraction and GC-MS detection

[0565] The lipids were extracted according to a modified procedure of Hagstrom et al. (2012) (Hagstrom, A. K., Lienard, M. A., Groot, A. T., Hedenstrom, E. & Lofstedt, C. Semi-Selective Fatty Acyl Reductases from Four Heliothine Moths Influence the Specific Pheromone Composition. *PLoS One* 7: e37230 (2012)). 1.5 mL-cell culture was transferred to a 15 mL falcon tube. The cell suspension was acidified with 1 mL 5 N HCl. 5 µL, tetradecanedioic acid (10 mM in ethanol) was added as internal standard. The mixture was extracted by adding 1.5 mL hexane, then shaken for 1 h at 37 °C, 250 rpm. To facilitate phase separation, the sample was centrifuged for 10 min at 2000 g. 1 mL of the organic hexane phase was then transferred to a 1.5 mL plastic tube. The solvent was removed by heating the sample 30 min at 90 °C. After the sample was evaporated to dryness, 50 µL of BSTFA (N,O-bis(trimethylsilyl) trifluoroacetamide containing 1% of trimethylchlorosilane) was added. The 1.5 mL plastic tubes were shaken vigorously two times for 10 s. Prior to the transfer into a screw cap GC glass vial containing a glass insert, the sample was centrifuged for 1 min (13000 rpm). The vials were capped and heated for 30 min at 90°C. The trimethylsilyl-esters, which were generated by this method were subsequently analyzed by GC-MS analysis. GC-MS parameters are specified in Table 6. The use of SIM mode (characteristic product and IS ions) increases detection sensitivity by reducing background noise, allowing detection of the product as low as 2.4 µM (0.6 mg/L). A further reduction in the split ratio offers the possibility to further increase the sensitivity for future applications. A Z11-hexadecenol calibration curve shown in Figure 9 was used to quantify the Z11-hexadecenol produced from yeasts. The bioconversion of heptadecanoic acid was also tested since the easily distinguished heptadecanol product could be used to benchmark successful GC-MS runs. However, none of the reductase tested showed any activity toward heptadecanoic acid.

Table 6. GC-MS parameters

System	Agilent 6890 N GC, ChsmStation G1701EA E.02.01.li77
Column	Rtx-5 30m x 320 μ m x 25 μ m Pressure = 11.74 psi; Flow = 7.1 mL/min
Inlet	Heater = 250°C; Pressure = 11.74 psi; Total Flow (He) = 19.5 mL/min
Carrier	He @ 147 cm/sec, 11.74 psi
Signal	Data rate = 2 Hz/0.1 min
Oven	150°C for 1 min Ramp 12°C/min to 220°C, hold 3 min Ramp .35°C/min to 300°C, hold 4 min
Injection	Split, 250°C Split ratio - 20:1
Detector	HP 5973 MSD in SIM mode (m/z: 297.3 and 387.3), 100 msec Dwell EMV mode: Gain factor 1, 3 min solvent delay, 8.33 cycles/sec
Sample	injection volume = 1 μ L

Example 4: Expression of transmembrane desaturases in *S. cerevisiae*

[0566] Background and Rationale

[0567] Engineering microbial production of insect fatty alcohols from fatty acids requires the functional expression of a synthetic pathway. One such pathway comprises a transmembrane desaturase, and an alcohol-forming reductase to mediate the conversion of fatty acyl-CoA into regio- and stereospecific unsaturated fatty acyl-CoA, and subsequently into fatty alcohols. A number of genes encoding these enzymes are found in some insects as well as some microalgae. A number of transmembrane desaturases and alcohol-forming reductase variants will be screened to identify ensembles which allow high level synthesis of a single insect fatty alcohol or a blend of fatty alcohols. Additionally, these enzymes will be screened across multiple hosts (*Saccharomyces cerevisiae*, *Candida tropicalis*, and *Yarrowia lipolytica*) to optimize the search toward finding a suitable host for optimum expression of these transmembrane proteins.

[0568] Summary of Approach

[0569] A small set of desaturases (insect origin: *Agrotis segetum*, *Trichophisia ni*, *Amyelois iransitella*, *Hehcoverpa zea*, and marine diatom: *Thalassiosira pseudonana*) were selected as a test case to explore and establish functional expression assays, metabolite extraction methods, and analytical chemistry.

[0570] A synthetic cassette for expression of the desaturases in *S. cerevisiae* was constructed. The cassette consists of the OLE1 promoter region, OLE1 N-terminal leader sequence, and VSP13 terminator.

[0571] The expression cassette was tested for functionality via expression of a GFP variant. Validation of the cassette allowed its utilization for exploring expression of insect desaturase.

[0572] *S. cerevisiae* AOLE1 was transformed with expression constructs containing heterologous desaturases. Functionality of the desaturases was assessed via the ability to rescue growth of AOLE1 without exogenous supplementation of unsaturated fatty acid (UFA). *S. cerevisiae* desaturase (OLE1) was used as a positive control of successful complementation.

[0573] Functionality of the desaturase was validated via an *in vivo* bioconversion of hexadecanoic acid (palmitic acid) into (Z)-1 1-hexadecenoic acid (palmitoleic acid).

[0574] GC-MS analysis was used to identify and quantify metabolites.

[0575] Results

[0576] Transmembrane desaturase variants were screened in *S. cerevisiae*. Three variants were initially tested to explore and establish functional expression assays, metabolite extraction methods, and analytical chemistry. To allow functional expression of these desaturases in *S. cerevisiae*, an episomal synthetic expression cassette termed pOLE1 cassette (Figure 10) was constructed, which consisted of an OLE1 promoter region, an N-terminal leader sequence encoding for the first 27 amino acids of *S. cerevisiae* OLE1, and a terminator region of VPS 13 (a protein involved in the protospore membrane formation, the terminator of which has been previously characterized to increase heterologous protein expression potentially by extending mRNA half-life). The functionality of the pOLE1 cassette was validated via its ability to express a GFP (Figure 11A-Figure HE). Subsequently, insect desaturase synthons, and yeast OLE1 synthon were cloned into the pOLE1 cassette, and expressed in *S. cerevisiae* AOLE1 strain. This strain was chosen since deletion of the OLE1 allele (which encodes for palmitoyl:CoA/stearoyl:CoA (z)-9-desaturase) allows its utilization as a tool to screen for functional insect desaturase. Specifically, an active desaturase would allow complementation of growth without requiring exogenous supplementation of UFAs. Expression of OLE1 using pOLE1 cassette complemented growth of AOLE1 growth without UFA (Figure 11A-Figure HE); therefore, it serves as a positive control in the complementation assays. When insect desaturases were expressed, we observed that they rescued AOLE1 growth without UFA at varying degree. On rich medium (YPD) agar plate,

expression of *S. cerevisiae* OLE1 conferred the highest level of growth, followed by *T. ni* desaturase (Figure 12A). The latter indicated that production of unsaturated fatty acyl:CoA by *T. ni* desaturase could act as a surrogate to the missing (Z)-9-hexadecenoyl:CoA biosynthesis in Δ OLE1. Expression of *T. pesiudonema* and *A. segetum* desaturases did not appear to rescue growth on YPD very well (Figure 12A). When patched on minimal medium (CM-Ura glucose) agar plate, only expression of *S. cerevisiae* OLE1 and *T. ni* desaturase rescued Δ OLE1 growth without exogenous UFA (Figure 12B). Expression of *T. pseudonana* and *A. segetum* desaturases did not confer growth of Δ OLE1 on minimal medium agar, suggesting their limited activity in producing UFA (results not shown). Screening a desaturase library in *Candida tropicalis* identified functional expression of *A. transitella* and *H. zea* desaturases. When these desaturases were expressed in Δ OLE1, they conferred growth without UFA on both YPD and CM-Ura glucose media similar to expression of *T. ni* desaturase (Figure 12B).

[0577] Functional expression of the heterologous desaturases was further characterized via *in vivo* byconversion of palmitic acid into insect-specific UFA. Post ~96h-cultivation in minimal medium containing palmitic acid, total fatty acid analysis of *S. cerevisiae* Δ OLE1 expressing *T. ni* desaturase revealed production of a new fatty acid species (Z)-11-hexadecenoic acid that is not present in the control strain which expresses native yeast OLE1 desaturase (Figure 13A-Figure 13B). (Z)-11-hexadecenoic acid is not detected in strains expressing *A. segetum*, or *T. pseudonana* desaturase (results not shown). In addition to (Z)-11-hexadecenoic acid, (Z)-9-hexadecenoic acid was also detected in Δ OLE1 strain expressing *T. ni* desaturase (Figure 13A-Figure 13B). Under the cultivation condition, C16-fatty acid in the Δ OLE1 expressing *T. ni* desaturase is composed of approximately 84.7% hexadecanoic acid, 5.6% (Z)-9-hexadecenoic acid and 9.8% (Z)-11-hexadecenoic acid. In comparison, the C16 fatty acid fraction of Δ OLE1 expressing OLE1 desaturase is composed of approximately 68.6% hexadecanoic acid and 31.4% (Z)-9-hexadecenoic acid. (Z)-11-hexadecenoic acid biosynthesis in Δ OLE1 expressing *T. ni* desaturase account for ~1.5 mg/L. The amount of total fatty acids and each fatty acid within this mixture can be quantified. The biologically produced (Z)-11-hexadecenoic acid also match the retention time and fragmentation pattern of authentic standard (Z)-11-hexadecenoic acid (Larodan) as determined by GC-MS (Figure 14A-Figure 14B). Therefore, the regio- and stereoisomer of the biologically produced (Z)-11-hexadecenoic acid was confirmed. *In vivo* characterization of *A. transitella* and *H. zea* desaturase can also be done.

[0578] In summary, at least three insect desaturases capable of rescuing growth of *S. cerevisiae* AOLE1 without exogenous supplementation of UFA, i.e. (Z)-9-hexadecenoic acid (palmitoleic acid), were identified.

[0579] The extent of growth on rich medium (YPD) of *S. cerevisiae* AOLE1 bearing the expression construct was in the following order of desaturase content: OLE1, *T. ni*, *T. pseudonana*, and *A. segetum*.

[0580] The extent of growth on minimal medium (CM Glucose w/out uracil) of *S. cerevisiae* ΔOLE1 bearing the expression construct was in the following order of desaturase content: OLE1, *T. ni*.

[0581] Complementation assays using *A. transUella* and *H. zea* desaturases were also done, demonstrating functional expression in *Candida tropicalis* shown *via in vivo* byconversion assay. These desaturases also complemented *S. cerevisiae* ΔOEE1 growth on rich and minimal media at least as well as *T. ni* desaturase.

[0582] Expression of *T. pseudonana* and *A. segetum* desaturases did not confer growth of *S. cerevisiae* AOLE1 on minimal medium without UFAs even after an extended incubation period up to 14 days. No (Z)-11-hexadecenoic acid was observed in strains harboring *T. pseudonana* or *A. segetum* desaturase.

[0583] Conclusions

[0584] Functional expression of transmembrane desaturases of insect origin in *S. cerevisiae* has been achieved.

[0585] The activity of a given heterologous desaturase can be assessed from its ability to complement growth of *S. cerevisiae* AOLE1 without exogenous palmitoleic supplementation, and its ability to convert palmitic acid into insect pheromone precursors (Z)-11-hexadecenoic acid.

[0586] Functional expression and/or activity of insect desaturase in *S. cerevisiae* varies widely depending on sequence origin. Variants derived from *T. ni* exhibited the best activity-compared to *A. segetum* and *T. pseudonana*, as measured by the above criteria.

[0587] Desaturases derived from *A. transUella* and *H. zea* complemented AOLE1 as well as *T. ni* desaturase. Bioconversion assays using these desaturases can be done.

[0588] The bioconversion of other fatty acid substrates can be explored to assess enzyme plasticity.

[0589] Materials & Methods

[0590] Strain construction and functional expression assay

[0591] *S. cerevisiae* AOLE1 (MATA OLE1 ::LEU2 ura3-52 his4) was used as an expression host. A synthetic expression cassette termed pOLE1 (Figure 10, SEQ ID NO: 4) which comprises the OLE1 promoter region (SEQ ID NOs: 5 and 6), nucleotides encoding for 27 N-terminal amino acids of the OLE1 leader sequence (SEQ ID NO: 7), and a VPS13 terminator sequence (SEQ ID NO: 8) was created, and cloned into pESC-URA vector in between SacI and EcoRI sites. To test the functionality of the pOLE1 cassette, Dasher GFP synthon was inserted in between SpeI and NotI sites to create pOLE1-GFP plasmid. Competent AOLE1 was transformed with pOLE1-GFP, and plated on CM-Ura glucose agar plate (Teknova) containing UFA (20mm CM-URA glucose agar plate was coated with 100 μ L CM-Ura glucose medium containing 1% tergitol, and 3 μ L palmitoleic acid). After incubation at 30°C for 5 days. Dasher GFP expression was apparent as displayed by green coloration of AOLE1 transformants. This result showed that the pOLE1 cassette was capable of driving heterologous protein expression. Validation of AOLE1 complementation was performed by restoring OLE1 activity. Specifically, native *S. cerevisiae* OLE1 synthon was inserted into pOLE1 cassette devoid of the leader sequence to create pOLE1-OLE1 plasmid. After transformation of AOLE1, and selection on CM-Ura glucose agar containing UFA, single colonies were patched onto YPD and CM-Ura glucose without UFA. After incubation at 30°C for 5 days, growth was observed (Figure 11A-Figure 11E). As expected, Dasher GFP expression could not complement AOLE1 growth without UFA (Figure 11A-Figure 11E). DNA sequences which encode for desaturase variants were synthesized (to include nucleotide changes which remove restriction sites used for cloning purposes), and cloned into pOLE1 using SpeI-NotI sites (Genscript, SEQ ID NOs: 9-13). Complementation assay of AOLE1 with insect desaturases were performed in the same way as with OLE1 desaturase.

[0592] To assess functional expression, two positive transformation clones that had been patched on CM-Ura glucose agar medium containing UFA were inoculated in 1.5 mL CM-Ura glucose liquid medium containing palmitic acid (in ethanol) at a final concentration of 300 mg/L, and with 6.7 g/L of YNB. For (z)-11-hexadecenoic isomer confirmation, a 20 mL culture was generated. Bioconversion assay proceeded for 96 h at 28°C prior to GC-MS analysis.

[0593] Metabolite extraction and GC-MS detection

[0594] Total lipid composition as well as the (Z)-11-hexadecenoic acid quantification was based on modified procedures by Moss et al. (1982) (Moss, C.W., Shinoda, T. & Samuels, J. W. Determination of cellular fatty acid compositions of various yeasts by gas-liquid

chromatography. *J. Clin. Microbiol.* 16: 1073-1079 (1982)) and Yousuf et al (2010) (Yousuf, A., Sannino, F., Addorisio, V. & Pirozzi, D. Microbial Conversion of Olive Oil Mill Wastewaters into Lipids Suitable for Biodiesel Production. *J. Agric. Food Chem.* 58: 8630-8635 (2010)). The pelleted cells (in 1.5 mL plastic tubes), usually about 10 mg to 80 mg, were resuspended in methanol containing 5 % (w/w) of sodium hydroxide. The alkaline cell suspension was transferred into a 1.8 mL screw-cap GC-vial. The mixture was heated for 1 h in the heat block at 90°C. Prior to acidification with 400 2.5 N HCl the vial was allowed to cool to room temperature. 500 μ L chloroform containing 1 mM heptadecanoic were added and the mixture was shaken vigorously, then both aqueous and organic phase were transferred into a 1.5 mL plastic tube. The mixture was centrifuged at 13,000 rpm, afterwards 450 μ L of the organic phase were transferred into a new 1.5 mL plastic tube. The aqueous phase was extracted a second time with 500 μ L chloroform, this time without heptadecanoic acid. The combined organic phases were evaporated at 90°C. After cooling to room temperature, residual fatty acid methyl esters and free fatty acids were dissolved and derivatized in methanol containing 0.2 M TMSH (trimethylsulfonium hydroxide).

[0595] The regioselectivity of biologically produced (Z)-11-hexadecenoic acid was determined by comparing the fragmentation patterns of the dimethyl disulfide (DMDS) derivative with the DMDS derivative of an authentic standard. A yeast culture was split into 12 aliquots (to not change any parameters in the developed procedure). The cells were pelleted, which yielded 63 mg cells (ccw) on average (755 mg from 18 mL culture). The pellets were subjected to base methanolysis as described above. However, after acidification the samples were combined in a 50 mL Falcon tube. The combined sample was extracted two times with 10 mL chloroform. The mixture was centrifuged 10 min at 3000 iprn to achieve a better phase separation. The combined organic phases, which were combined in a new 50 mL Falcon and were washed consecutively with 10 mL brine and 10 mL water. The organic phase was dried with anhydrous sodium sulfate and concentrated *in vacuo*. The concentrated oil was dissolved in 1.5 mL chloroform and transferred to a 1.5 mL plastic tube. The chloroform was evaporated at 90°C. The remaining sample was dissolved in 50 μ L methyl tert-butyl ether (MTBE). The 50 μ L, were split into 1, 5, 10 and 20 μ L and transferred into GC-vials without insert. To each vial 200 μ L DMDS (dimethyl disulfide) and 50 μ L MTBE (containing 60 mg/mL iodine) were added. After the mixture was heated 48 h at 50°C, excess iodine was removed by the addition of 100 μ E saturated sodium thiosulfate solution. The samples were transferred to plastic vials and extracted to times with 500 μ L

dichloromethane. The combined organic phases were transferred to a new 1.5 mL plastic vial and evaporated at 90°C. The samples were taken up in 50 µL DCM and transferred to a GC-vial. The sample was analyzed by GC-MS (Table 7) using the method of Hagstrom et al. (2013) (Hagstrom, A. K. *et al.* A moth pheromone brewery: production of (Z)-II-hexadecenol by heterologous co-expression of two biosynthetic genes from noctuid moth in a yeast cell factory. *Microb. Cell Fact.* 12: 125 (2013)).

Table 7. Analytical parameters used for GC-MS analysis of DMDS-derivatives

System	Agilent 6890 N GC, ChemStation G1701EA E.02.01.1177
Column	Rtx-5 30m x 320 µm x 25 µm Pressure = 11.74 psi; Flow = 7.1 mL/min
inlet	Heater = 250°C; Pressure = 11.74 psi; Total Flow {He} = 19.5 mL/min
Carrier	He @ 147 cm/sec, 11.74 psi
Signal	Data rate = 2 Hz/0.1 min
Oven	80°C for 2 min Ramp 10°C/min to 180°C Ramp 3°C/min to 260°C Ramp 20°C/min to 280°C, hold 10 min
injection	Split, 250°C Split ratio -1:1
Detector	HP 5973 MSD in SCAN mode (mass range: 41 to 550 amu) 100 msec Dwell, EMV mode: Gain factor 1, 3 min solvent delay, 8.33 cycles/sec
Sample	Injection volume = 1 µL

Example 5: *S. cerevisiae* as a production **platform** for insect **fatty** alcohol synthesis

Background and Rationale

[0596] Engineering microbial production of insect fatty alcohols from fatty acids requires the functional expression of a synthetic pathway. One such pathway comprises a transmembrane desaturase, and an alcohol-forming reductase to mediate the conversion of fatty acyl-CoA into regio- and stereospecific unsaturated fatty acyl-CoA, and subsequently into fatty alcohols. A number of genes encoding these enzymes are found in some insects as well as some microalgae. A number of gene variants were screened to identify enzyme activities that allow the creation of pathways capable of high level synthesis of a single or a blend of insect fatty alcohols. Additionally, these enzymes were screened across multiple hosts

(*Saccharomyces cerevisiae*, *Candida tropicalis*, and *Yarrowia lipolytica*) in order to find a suitable host for optimum expression of these transmembrane proteins.

[0597] Summary of Approach

[0598] *S. cerevisiae* was engineered previously to express select functional transmembrane desaturase variants to allow synthesis of (Z)-11-hexadecenoic acid from palmitic acid. This allowed the identification and rank-ordering of the variants based on their bioconversion performance (see Example 4).

[0599] *S. cerevisiae* was engineered previously to express select functional transmembrane reductase variants to allow synthesis of (Z)-11-hexadecenol (Z11-16OH) from (Z)-11-hexadecenoic acid. This allowed the identification and rank-ordering of the variants based on their bioconversion performance (see Example 3).

[0600] Several fatty alcohol pathways comprised of the most active variant desaturases and reductases identified in the previous screens were assembled.

[0601] *S. cerevisiae* W303A and AQLE1 were transformed with the pathway constructs. Functionality of the pathway was assessed via the ability of the recombinant yeasts to synthesize Z11-16OH from palmitic acid.

[0602] GC-MS analysis was used to identify and quantify metabolites.

[0603] Results

[0604] The goal was to engineer one or more insect fatty alcohol biosynthetic pathways in *S. cerevisiae*. Previously, the functional expression of several transmembrane desaturases of insect origin in *S. cerevisiae* was demonstrated (see Example 4). Briefly, heterologous desaturase expression was enabled by designing an expression cassette which consists of an OLE1 promoter region, an N-terminal leader sequence encoding the first 27 amino acids of *S. cerevisiae* OLE1, and a terminator region of VPS13. Screening for active desaturases was done by using two approaches. First, active desaturases were screened for their ability to rescue AOLE1 growth without exogenous addition of unsaturated fatty acid (UFA), and second, active desaturases were screened via an *in vivo* screen for bioconversion of palmitic acid into (Z)-11-hexadecenoic acid. These screening strategies allowed the identification of several active variants, and the rank ordering of their relative activity. Based on these screening results, desaturases from *Trichophisia ni* (TN_desat) and *S. cerevisiae* (SC_desat) were selected for combinatorial expression in fatty alcohol pathways. *S. cerevisiae* desaturase is known to form palmitoleic acid and oleic acid.

[0605] The functional expression of several transmembrane alcohol forming reductases of insect origin in *S. cerevisiae* had also been previously demonstrated (see Example 3). An expression cassette comprising the GAL1 promoter and CYC terminator was used to enable the functional expression of the reductases in *S. cerevisiae*. Screening several reductases via *in vivo* bioconversion of (Z)-11-hexadecenoic acid into Z11-16OH allowed the identification of active variants and rank ordering of their relative activity. Based on this screen, reductases from *Helicoverpa armigera* (HA_{reduc}), and *Spodoptera littoralis* (SL_{reduc}) were chosen for assembly of the fatty alcohol pathways.

[0606] Combinatorial assembly created four fatty alcohol pathways, i.e. TN_{desat} - HA_{reduc}, TN_{desat} - SL_{reduc}, SC_{desat} - HA_{reduc}, and SC_{desat} - SL_{reduc}. Pathways with SC_{desat} served as negative control for insect Z11-16OH synthesis. *S. cerevisiae* AOIE1 and W303A were transformed with constructs harboring these pathways, and transformants that grew on CM-Ura with 2% glucose and coated with pairnitoieic acid were isolated. To test for fatty alcohol production, individual clones were inoculated into CM-Ura medium containing 2% glucose, 1% raffinose, 2% galactose, 300 mg/L palmitic acid, and 360 mg/L pairnitoieic acid were added as bioconversion substrates. Bioconversion using palmitic acid without pairnitoieic was also tested. Post ~96h-cultivation in the presence of palmitic and pairnitoieic acid, culture broth analysis revealed synthesis of ZU-90H as a major C16 alcohol product at ~0.2 mg/L, and ~0.3 mg/L in cultivation of AOIE1 strains harboring SC_{desat}-HA_{reduc}, and TN_{desat}-HA_{reduc}, respectively (Figure 15, Figure 16). A minute amount of Z11-16OH was also detected in pathways with *T. ni* or *S. cerevisiae* desaturase, and *H. armigera* reductase. In general, it was expected that in the presence of palmitic acid and pairnitoieic acid, Z9-16OH synthesis was more favorable than Z11-16OH synthesis because (Z)-11-hexadecenoic acid must be biosynthesized from *T. ni* desaturase, whereas exogenous addition of pairnitoieic acid resulted in a more readily available substrate for synthesis of Z9-16OH. Fatty acid analysis was also performed. The results showed higher accumulation of (Z)-11-hexadecenoic acid (Figure 17) in pathways containing insect desaturase than in pathways expressing *S. cerevisiae* desaturase. Albeit at minute quantities, detection of Z11-16OH, and (Z)-11-hexadecenoic acid from pathways harboring *S. cerevisiae* desaturase (which was unexpected) opens the possibility of a minor $\Delta 11$ desaturation activity by *S. cerevisiae* desaturase. Low level synthesis of Z11-16COOH fatty acid moieties can also be derived from elongation of Z9-14COOH fatty acyl intermediate. The data shown in Figure 15 also showed that in comparison to pathways with *H. armigera* reductase, the

inclusion of *S. littoralis* reductase resulted in the reduction of (up-to -30 fold) in **Z9-160H** titer. No **Z11-160H** could be detected in pathways employing *S. littoralis* reductase. These results are consistent with the reductase screening assay, which showed superior bioconversion of (Z)-1 1-hexadecenoic acid using *H. armigera* reductase in comparison to *S. littoralis* reductase.

[0607] The bioconversion of palmitic acid was also tested alone (without exogenous addition of palmitoleic acid) by Δ OLE1 strains expressing **TN_desat-HA_reduc** and **TN_desat-SL_reduc** (Figure 18). Culture broth analysis determined the synthesis of **Z11-160H** as the dominant unsaturated C16 fatty acid product (Figure 16). In this assay, up to 0.22 mg/L, and 0.05 mg/L **Z11-160H** was synthesized by a pathway harboring *H. armigera* reductase and *S. littoralis* reductase, respectively. The biologically produced **Z11-160H** also matched the retention time and exhibited the characteristic 297.3 m/z peak like the authentic standard **Z11-160H** as determined by GC-MS (SIM). Therefore, the regio- and stereoisomer of the biologically produced **Z11-160H** was confirmed (Figure 19). Furthermore, **Z9-160H** (0.01 mg/L) was also observed in the cultivation of strain co-expressing *T. ni* desaturase and *H. armigera* reductase. This suggested that *T. rii* desaturase may also possess Δ 9 desaturation activity.

[0608] OLE1 deletion impairs growth. Therefore, pathway expression was also explored in W303A, a host with intact OLE1 allele. However, despite growth improvement, pathway expression in this host resulted in more than two-fold reduction of Z11-16QH titers. This result was likely due to the repression of OLE1 promoter (which drove heterologous desaturase expression) by endogenous unsaturated fatty acylCoAs, the products of OLE1. The *S. cerevisiae* OLE1 promoter has been previously characterized with structural regions found to be positively and negatively regulated by saturated and unsaturated fatty acid, respectively (Choi, J.-Y. et al. Regulatory Elements That Control Transcription Activation and Unsaturated Fatty Acid-mediated Repression of the *Saccharomyces cerevisiae* OLE1 Gene. J. Biol. Chem. 271: 3581-3589 (1996)). In addition to cis -transcriptional regulation, unsaturated fatty acids also interact with OLE1 promoter elements to regulate mRNA stability (Gonzales, C. I. et al. Fatty acid-responsive control of mRNA stability. Unsaturated fatty acid-induced degradation of the *Saccharomyces* OLE1 transcript. J. Biol. Chem. 271: 25801-25809 (1996)). Due to this inherent complexity of the OLE1 promoter, the utilization of unregulated orthogonal promoters, such as the OLE1 promoter from *S. kluyveri* (Kajiwar, S. Molecular cloning and characterization of the v9 fatty acid desaturase gene and its

promoter region from *Saccharomyces kluyveri*. FEMS Yeast. Res. 2: 333-339 (2002)) to drive insect desaturase expression can be explored to enhance fatty alcohol production.

[0609] In summary, functional expression of synthetic pheromone pathway variants in *S. cerevisiae* ΔOLE1 resulted in the synthesis of Z11-160H and Z9-160H from palm oil fatty acids (palmitic acid and palmitoleic acid) up to approximately 0.2 mg/L and 0.3 mg/L, respectively.

[0610] The engineered pathway that resulted in the highest fatty alcohols is comprised of *T. ni* desaturase and *H. armigera* reductase.

[0611] Accumulation of (Z)-11-hexadecenoic acid, an intermediate of the pathway, was also observed in strains that produced Z11-160H.

[0612] No Z11-160H was produced and only trace Z9-160H was detected in the negative control strain (harboring vector only).

[0613] The regio- and stereochemistry of the biologically produced Z11-160H were confirmed by comparing the retention time and fragmentation pattern to the authentic standard compound via GC-MS.

[0614] Conclusions

[0615] The engineering of Baker's yeast for synthesis of Z11-160H and Z9-160H, fatty alcohol precursors of insect pheromones, was demonstrated.

[0616] Fatty alcohol production varies depending on the selection of the desaturase and reductase variants.

[0617] Accumulation of (Z)-11-hexadecenoic acid suggested the possibility of further fatty alcohol improvement by increasing the performance of alcohol forming reductase. However, it is also possible that detection of (Z)-11-hexadecenoic acid was due to its incorporation as phospholipid into any membrane other than the endoplasmic reticulum membrane (such as mitochondrial membranes, peroxisome, nuclear envelope, etc), therefore inaccessible to alcohol forming reductase (presumably translocated into the endoplasmic reticulum) which must utilize (Z)-11-hexadecenoic acid in its CoA thioester moiety as its substrate.

[0618] Culture conditions can be explored to increase fatty alcohol titers. The *T. ni* desaturase can be replaced in the pathway by *A. transitella* desaturase, another variant that also showed high activity and rescued ΔOLE1 growth faster than *T. ni* desaturase. The synthetic pathway can be imported into *Candida tropicalis* and *Yarrowia lipolytica*, which are yeasts with high adhesion property to hydrophobic substrates such as palmitic and

palmitoleic acid. By increasing substrate accessibility to the microbial production platform, it is foreseeable that product titer and yield can be improved.

[0619] Materials & Methods

[0620] Strain construction and functional expression assay

[0621] *S. cerevisiae* AOLE1 (MATA OLE1::LEU2 ura3-52 his4), and W303A (MATA ura3-1 trp1-1 leu2-3_112 his3-11_15 ade2-1 can1-100) were used as expression hosts. Modular design allows combinatorial pathway assembly utilizing BamHI and XhoI to excise reductase synthons (see Example 3) and subcloning into plasmids containing pOLE1-desaturase constructs (see Example 4). Competent yeasts were transformed with pathway constructs and plated on CM-Ura glucose agar plate (Teknova). In the case of AOLE1 transformation, colony plating utilized 20mM CM-Ura glucose agar plates that were coated with 100 μ L CM-Ura glucose medium containing 1% tergitol and 3 μ E palmitoleic acid.

[0622] To assess functional expression, transformants were inoculated in ~20 mL CM-Ura liquid medium containing 6.7 g/L of YNB, 2% glucose, 1% raffinose, and 2% galactose. Fatty acid substrates, i.e. palmitic acid (in ethanol), was added at a final concentration of 300 mg/L. Palmitoleic acid was added at a final concentration of 360 mg/L. Bioconversion assay proceeded for 96 h at 28°C prior to GC-MS analysis.

[0623] Metabolite extraction and GC-MS detection

[0624] Fatty acid analysis was as described in Example 4, except that instead of extracting the sample two times, the sample was only extracted once with chloroform containing 1 mM methyl heptadecanoate (C17:0Me). Fatty alcohol analysis was as described in Example 3, except that instead of hexane (containing tetradecanedioic acid), chloroform (containing 1 mM methyl heptadecanoate) was used. The extraction time was reduced from 1 h to 20 s. Afterwards the samples were collected in a 1.8 mL GC vial and not in a 1.5 mL plastic tube. The mass spectrometer was used in SIM mode (m/z 208, 297.3 and 387.3).

Example 6: Expression of transmembrane desaturases in *Candida tropicalis*

Background and Rationale

[0625] Engineering microbial production of insect fatty alcohols from fatty acids requires the functional expression of a synthetic pathway. One such pathway comprises a transmembrane desaturase, and an alcohol-forming reductase to mediate the conversion of fatty acyl-CoA into regio- and stereospecific unsaturated fatty acyl-CoA, and subsequently into fatty alcohols. A number of genes encoding these enzymes are found in some insects as well as

some microalgae. A number of gene variants were screened to identify enzyme activities that allow the creation of pathways capable of high level synthesis of a single or a blend of insect fatty alcohols. Additionally, these enzymes can be screened across multiple hosts (*Saccharomyces cerevisiae*, *Candida tropicalis*, and *Yarrowia lipolytica*) to optimize the search toward finding a suitable host for optimum expression of these transmembrane proteins.

[0626] Summary of Approach

[0627] A small set of desaturases (insect origin: *Agrotis segetum*, *Amyelois transitella*, *Helicoverpa zea*, *Trichoplusia rii*, *Osiriirijurnacalis*, and *Lampronia capilella* and marine diatom: *Thalassiosira pseudonana*) were selected as a test case to explore and establish functional expression assays, metabolite extraction methods, and analytical chemistry.

[0628] Successful integration and functional expression of mCherry control from pXICL expression cassette in SPV053 were confirmed.

[0629] A recombinant desaturase library using the same pXICL vector in SPV053 background was integrated (Figure 20). One variant, the Z11 desaturase of *Agrotis segetum*, was also cloned to produce a protein product with the first 27 amino acids of *Candida albicans* Ole1p fused to the N-terminus of the insect desaturase (SEQ ID NO: 15).

[0630] Functionality of the desaturase was validated via an *in vivo* byconversion of hexadecanoic acid (palmitic acid) into (Z)-11-hexadecenoic acid (palmitvaccenic acid).

[0631] GC-FID and GC-MS analyses were used to identify and quantify metabolites.

[0632] Results

[0633] Library construction

[0634] This study focused on the screening for transmembrane desaturase variants in *C. tropicalis* (SPV053). Five insect desaturases with reported Z11 desaturase activity on palmitoyl-CoA (C16:0) (SEQ ID NOs: 16-19, 23) and three insect desaturases with reported Z9 desaturase activity (SEQ ID NOs: 20-22) were included in the screen. One variant, the Z11 desaturase from *A. segetum* (SEQ ID NO: 16), was also cloned with 27 amino acids of the *Candida albicans* OLE1 N-terminus fused upstream of the insect sequence (Figure 20, SEQ ID NO: 15). At the time of construction, the *A. segetum* Z11 desaturase was believed to be a positive control and the *C. albicans* OLE1 fusion was constructed to test if inclusion of a *Candida* leader sequence would improve functional expression. The construct was designed to mimic those used in *Saccharomyces cerevisiae* desaturase screening (See Example 4). Finally, a control construct expressing mCherry red fluorescent protein (SEQ ID NO: 14)

was included to act as a positive control for integration and expression and a negative control for recombinant desaturase activity (Figure 21A-Figure 21D).

[0635] Transformation efficiencies of linearized plasmids into SPV053 varied greatly across constructs. Despite low efficiencies, at least 3 clonal isolates were identified for each variant (Tables 8 and 9). It had been hypothesized that larger colonies on transformation plates were more likely to be positive integrants because the presence of the Zeocin resistance marker should increase growth rate under Zeocin selection. Analysis of the screening results suggested that the number of large colonies is not correlated to transformation efficiency. Instead total colony (small and large) count correlated best with observed efficiency (Figure 22). In addition, in some cases positive clones were found among the small colonies. It is possible that at lower plating density growth rate may be correlated with integration events (i.e. positive integrants grow faster). A secondary screen of repatching colonies on YPD+Zeocin proved effective in enriching for positive integrants. Fast growing patches were more likely to be positive integrants than the general population of colonies on transformation plates.

Table 8: Desaturase transformations in SPV053. Efficiency of transformation varied across constructs with a relatively high degree of background under Zeocin selection.

specificity	source species	pXICL plasmid	DNA ug	large colonies (control plate)	<i>totsi</i> colonies (control plate)
control	mCherry_Ct	pFV0137	1.1	60 (78)	2,000 (320)
Z11	<i>Agrotis segetum</i> -OIE1_Ca	pFV0138	1.2	120 (78)	>10,000 (320)
	<i>Agrotis segetum</i>	pFV0139	1.3	115 (78)	8,000 (320)
	<i>Amyelois transitella</i>	pFV0140	1.1	220 (78)	5,000 (320)
	<i>Trichoplusia ni</i>	pFV0141	1.1	100 (78)	>10,000 (320)
	<i>Helicoverpa zea</i>	pFV0142	1.0	350 (78)	5,000 (320)
	<i>Thalassiosira pseudonana</i>	pFV0146	1.1	140 (78)	1,500 (320)
Z9	<i>Ostrinia furnacalis</i>	pFV0143	0.9	220 (78)	6,000 (320)
	<i>Lampronia capitella</i>	pFV0144	1.2	230 (78)	5,000 (320)
	<i>Helicoverpa zea</i>	pFV0145	1.2	72 (78)	2,000 (320)

Table 9: Desaturase SPV053 library construction. Five insect desaturases with putative Z11 desaturation activity and 3 insect desaturases with putative Z9 desaturation activity were integrated into the SPV053 background using the pXICL vector. In addition, a control strain expressing mCherry was constructed with the same vector.

specificity	source species	pXICL plasmid	Total positives	Total screened	Fraction positive
control	mCherry_Ct	pPV0137	16	16	1.00
Z11	Agrotis segetum-OLE1_Ca	pPV0138	7	12	0.58
	Agrotis segetum	pPV0139	12	12	1.00
	Amyelois transitella	pPV0140	5	60	0.08
	Trichoplusia ni	pPV0141	6	12	0.50
	Helicoverpa zea	pPV0142	5	120	0.04
	Thalassiosira pseudonana	pPV0143	3	96	0.03
	Ostrinia furnacalis	pPV0143	3	57	0.05
Z9	Lampronia capitella	pPV0144	3	58	0.05
	Hs mcs3/eps zea	pPV0145	3	94	0.33

[0636] Functional expression assay

[0637] Functional expression of the heterologous desaturases was characterized by a series of *in vivo* bioconversion experiments. *C. tropicalis* SPV053 derived strains expressing insect desaturases were cultured in rich (YPD) or defined (CM glucose) media supplemented with ethanol (for induction) and saturated acid substrates (palmitic acid, methyl palmitate, methyl myristate). Small scale (2 ml) cultures were cultivated for a total of 72 hours in 24 deep well plates with substrate added after the initial 24 hours.

[0638] The first screen examined multiple bioconversion media with supplementation of a palmitic acid substrate. Two functional palmitoyl-CoA (Z)-11 desaturases were identified by fatty acid methyl ester (FAME) analysis of the cellular lipid content. Strains expressing *A. transitella* or *H. zea* Z11 desaturases (SPV0305-SPV0310) produced a fatty acid species not observed in the mCherry control strains (SPV0302-SPV0304) which eluted with the (Z)-11-hexadecenoic acid standard (Figure 23). No other tested strains produced non-native fatty acid species (data not shown). Approximate fatty acid composition of the C16-fraction is listed in Table 10. The native palmitoyl-CoA (Z)-9 desaturase is still present in the SPV053 background which means the (Z)-9/(Z)-11 specificity of the desaturases cannot be rigorously determined. Supplementation of palmitic acid in the media increased the (Z)-11/(Z)-9 hexadecenoic acid ratio from 0.6 to 1.4 for *H. zea* desaturase expressing strains. (Z)-11-

hexadecenoic acid titers were observed to be approximately 5.62 mg/L for strains expressing *A. transitelia* desaturase and 5.96 mg/L for strains expressing *H. zea* desaturase. Similar performance was observed with methyl palmitate supplementation (data not shown).

Table 10: Composition of the C16~fatty acid fraction in different *C. tropicalis* SPV053 expressing different desaturases. *NS = no substrate (hexadecanoic acid) was added.

	C16:0	Z9-C16:1	Z11-C16:1	Z11/Z9
	[%]	[%]	[%]	ratio
mCherry	72.9	27.1	0.0	0.0
Hzea-YPD_NS	50.0	30.9	19.1	0.6
Hzea-YPD	58.1	17.5	24.4	1.4
AT-YPD	55.5	14.5	30.0	2.1

[0639] The bioconversion assay was scaled-up to 20 ml in shake flasks in order to generate enough biomass for additional characterization of the putative (Z)-11-hexadecenoic acid species. While the observed species eluted with the (Z)-11-hexadecenoic acid standard and independently of the (Z)-9-hexadecenoic acid standard, it was possible that a different fatty acid isomer (e.g. (E)-9-hexadecenoic acid) could have a similar retention time to (Z)-11-hexadecenoic acid. As different stereoisomers elute differently on the DB-23 the occurrence of (E)-11-hexadecenoic could be excluded. Final confirmation of (Z)-11-hexadecenoic acid production was completed by using mass spectroscopy detection of DMDS derivatized fatty-acids to confirm the 11-regioselectivity. Using this derivatization technique (Z)-11 and (E)-11 isomers could in principle also be resolved. The fragmentation pattern of experimental samples could be matched to the (Z)-11-hexadecenoic acid standard (Figure 24A-24E). Using this technique, production of the specific (Z)-11-hexadecenoic acid regio- and stereoisomer was confirmed for both *A. transitelia* and *H. zea* desaturase expressing strains.

[0640] Finally, methyl myristate (C14:0) was tested as substrate for the entire desaturase library. A non-native fatty acid species which elutes between myristate (C14:0) and (Z)-9-tetradecenoic acid (Z9-C14:1) was observed in strains expressing either *A. transitelia* or *H. zea* Z11 desaturases (Figure 25A). It is hypothesized that this non-native species is (Z)-11-tetradecenoic acid, and this can be confirmed with an authentic standard. In addition, *A. segetum* Z11 desaturase, *O. furnacalis* Z9 desaturase, and *H. zea* Z9 desaturase all produced a shoulder peak which eluted just after the myristate (C14:0) peak (Figure 25B). Other C14 derived species (e.g. tetradecanedioic acid) were observed in all strains. These results suggest that *A. transitelia* and *H. zea* desaturases have some activity on myristoyl-CoA. Confirmation

of unknown species and quantification is required to draw further conclusions about desaturase substrate specificity *in vivo*.

[0641] In summary, two desaturases from *Helicoverpa zea* (AAF81787) and from *Amyelois transitella* (JX964774), were expressed in SPV053 and conferred synthesis of (Z)-11-hexadecenoic acid from either endogenously produced or supplemented palmitic acid.

[0642] Functional expression of *H. zea* and *A. transitella* desaturases in *C. tropicalis* SPV053 was confirmed using an *in vivo* bioconversion assay in both rich (YPD) and defined (CM glucose) media. The active desaturases generated intracellular (Z)-11-hexadecenoic acid which was not observed in mCherry expressing control strains. C16-fatty acid composition of SPV053 expressing *H. zea* desaturase is approximately 50.0% hexadecanoic acid, 30.91% (Z)-9-hexadecenoic acid and 19.1% (Z)-11-hexadecenoic acid. With palmitic acid supplementation the composition is 58.1% hexadecanoic acid, 17.5% (Z)-9-hexadecenoic acid and 24.4% (Z)-11-hexadecenoic acid. The C16-fatty acid composition of SPV053 expressing *A. transitella* desaturase is 55.5% hexadecanoic acid, 14.5% (Z)-9-hexadecenoic acid and 30.0% (Z)-11-hexadecenoic acid. In comparison, SPV053 expressing mCherry produced a C16-fatty acid composition of approximately 72.9% hexadecanoic acid, 27.1% (Z)-9-hexadecenoic acid and no (Z)-11-hexadecenoic acid. (Z)-11-hexadecenoic acid was produced at approximately 5.5 mg/L in both strains expressing functional Z11 desaturases.

[0643] No (Z)-11-hexadecenoic acid was observed in strains harboring *T. ni*, *T. pseudonana*, or *A. segetum* desaturase.

[0644] No difference in fatty acid composition was observed for strains expressing Z9 insect desaturases from *H. zea*, *O. furnacalis*, or *L. capitella*.

[0645] The regio- and stereoisomer of the biologically produced (Z)-11-hexadecenoic acid were confirmed by comparing the retention time and fragmentation pattern of the authentic standard compound via GC-MS after DMDS derivatization.

[0646] Bioconversions of SPV053 expressing *A. transitella* and *H. zea* desaturases with supplementation of methyl myristate produced an unidentified metabolite not observed in the mCherry expressing negative control strain. The GC retention time of this metabolite is found between myristate (C14:0) and (Z)-9-tetradecenoic acid.

[0647] Conclusions

[0648] Functional expression of transmembrane desaturase of insect origin in *C. tropicalis* SPV053 has been achieved.

[0649] The active desaturases identified via screening in *C. tropicalis* also complemented OLE1 function when expressed in *S. cerevisiae* AOLE1 (See Example 4).

[0650] An *in vivo* assay can be used to assay desaturase activity in *C. tropicalis* for non-native fatty acid isomers (e.g. (Z)-11-hexadecenoic acid). Enhanced ratios of non-native fatty acids can be produced with supplementation of saturated acid substrates such as palmitic acid or methyl myristate.

[0651] Functional expression and/or activity of insect desaturases varies widely in *C. tropicalis* SPV053 depending on sequence origin. Similar to results observed in the *S. cerevisiae* screen (See Example 4), *A. segetum* and *T. pseudonana* variants did not produce detectable (Z)-11-hexadecenoic acid. Interestingly, *T. ni* desaturase also failed to produce detectable (Z)-11-hexadecenoic acid under assay conditions. Unlike in the *S. cerevisiae* assay, the *T. ni* expression construct did not include a chimeric OLE1 leader sequence.

[0652] The inclusion of the *C. albicans* OLE1 leader sequence on the functional *H. zea* variant and non-functional *T. ni* variant can be tested.

[0653] The functional expression of additional desaturase variants to identify C14~specific desaturases can be explored.

[0654] Expression of functional desaturase with reductase variants can be done and subsequent screen for unsaturated fatty alcohol production can be performed.

[0655] Materials & Methods

[0656] Strain construction

[0657] A conservative approach was used for receding of genes. Native sequences were unaltered except for replacement of CTG leucine codons with TTA. All genes were cloned into pPV0053 using NcoI and NotI restriction sites by Genscript. After transformation into *E. coli* NEB 10β plasmids were miniprepmed using the Zymoprep Plasmid Miniprep Kit (Zymo Research, Irvine, CA). Plasmids were linearized by digestion with BsiWI (New England Biolabs, Ipswich, MA) before transformation into SPV053. After digestion, DNA was isolated using Clean and Concentrator Kit (Zymo Research, Irvine, CA). Approximately 1 µg of DNA was transformed by electroporation. Instead of incubation with TE+100 mM lithium acetate+DTT, cells were incubated in only TE+100 mM lithium acetate for 2 hours. Positive integrants were found to be site-specific and genotyping was conducted by check PCR. A two-stage approach was adopted for further screening of low efficiency transformations. Approximately 60 colonies were re-patched on YPD+300 µg/ml Zeocin and grown overnight. The subset of patches which grew quickly (dense growth within 24 hours) were

screened by colony PCR. The vast majority of rapid growing patches were identified as positive integrants.

[0658] Functional expression assay

[0659] Palmitic acid supplementation in YPD and CM glucose

[0660] Positive isolates were re-patched onto YPD+300 $\mu\text{g/ml}$ Zeocin and grown overnight and then stored at 4°C. Strains were inoculated from patch plates into 2 ml of YPD in 24 deep well plates (square well, pyramid bottom). Three positive clones were inoculated for each desaturase variant and the mCherry expressing control strain. Deep well plates were incubated at 30°C, 1000 ipm, and 80% humidity in the Infors HT Multitron Pro plate shaker for 24 hrs. After 24 hrs of incubation, cultures were split into equal 1 ml volumes to make two sets of identical plates. Both sets of plates were pelleted by centrifugation at 500xg. One set of plates was resuspended in 2 ml of YPD+0.3% (v/v) ethanol and the second set was resuspended in 2 ml of CM glucose+0.3% ethanol. Ethanol was added at this stage to induce recombinant enzyme expression from the ICL promoter. Cultures were incubated for another 24 hours under the same conditions before 300 mg/L palmitic acid was added to cultures from a 90 g/L stock solution in ethanol. The result was the addition of a fresh 0.3% ethanol in conjunction with the palmitic acid. A subset of strains was also cultured without palmitic acid addition. These cultures had 0.3% ethanol added instead. All cultures were incubated for an additional 24 hrs before a final addition of 0.3% ethanol. After another 24 hr period of incubation, 1.5 ml of each culture was harvested in 1.7 ml microcentrifuge tubes and pelleted. Supernatant was saved in fresh tubes and pellets were processed as described below. A subset of supernatant samples was also extracted to look for free acid in the extracellular medium.

[0661] Repeated screening with alternate substrates

[0662] The mCherry control and confirmed positive variants were rescreened using both palmitic acid and methyl palmitate as substrates. The culturing was conducted as described above with equimolar (1.17 mM) amounts of substrate added from ethanol stock solutions (methyl palmitate 94 g/L stock, 313 mg/L final concentration). The same protocol was also repeated with the full panel of strains using an 84 g/L stock of methyl myristate (04:0). The final concentration of substrate was again 1.17 mM.

[0663] Confirmation of (Z)-11-hexadecenoic acid isomer

[0664] The *in vivo* bioconversion assay was scaled up for confirmation of (Z)-11-hexadecenoic acid synthesis. 2 ml YPD seed cultures of strains SPV0302, SPV0303, and SPV0304 (mCherry), SPV0304, SPV0305, and SPV0306 (*A. trami* *Ua* Z11 desaturase), and

SPV0307, SPV0308, and SPV0309 (*H. zea* Z11 desaturase) were grown overnight at 30°C, 1000 rpm, 80% humidity in the Infers HT Muiltitron plate shaker. 200 µl of overnight culture from each of the three clonal isolates was pooled and inoculated into a single 125 ml baffled flask containing 20 ml YPD. The resulting three flasks were grown for 24 hrs at 30°C and 250 rpm (Infers Flask shaker). Cultures were pelleted by centrifugation at 500xg and resuspended in 20 ml of YPD+0.3%(v/v) ethanol and returned to 125 ml baffled shake flasks. Cultures were incubated for an additional 24 hours before addition of 300 mg/L palmitic acid in a 90 g/L stock in ethanol (221 µl per flask). After 24 hours of incubation another 0.3% (v/v) ethanol (221 µl) was added to each flask for sustained induction. Flasks were incubated for an additional 24 hours before cells were harvested for FAME analysis and DMDS derivatization.

[0665] Metabolite extraction and GC-MS detection

[0666] Total lipid composition as well as the (Z)-11-hexadecenoic acid quantification was based on modified procedures by Moss et al. (1982) and Yousuf et al (2010). The pelleted cells (in 1.5 mL plastic tubes), usually about 10 mg to 80 mg, were resuspended in methanol containing 5 % (w/w) of sodium hydroxide. The alkaline cell suspension was transferred into a 1.8 mL screw-cap GC-vial. The mixture was heated for 1 h in the heat block at 90°C. Prior to acidification with 400 2.5 N HCl the vial was allowed to cool to room temperature. 500 µL chloroform containing 1 mM heptadecanoic were added and the mixture was shaken vigorously, then both aqueous and organic phase were transferred into a 1.5 mL plastic tube. The mixture was centrifuged at 13,000 rpm, afterwards 450 µL of the organic phase were transferred into a new 1.5 mL plastic tube. The aqueous phase was extracted a second time with 500 µL chloroform, this time without heptadecanoic acid. The combined organic phases were evaporated at 90°C. After cooling to room temperature, residual fatty acid methyl esters and free fatty acids were dissolved and derivatized in methanol containing 0.2 M TMSH (trimethylsulfonium hydroxide) .

[0667] The regioselectivity of biologically produced (Z)-11-hexadecenoic acid was determined by comparing the fragmentation patterns of the dimethyl disulfide (DMDS) derivative with the DMDS derivative of an authentic standard. A yeast culture was split into 12 aliquots (to not change any parameters in the developed procedure). The cells were pelleted, which yielded 63 mg cells (ccw) on average (755 mg from 18 mL culture). The pellets were subjected to base methanolysis as described above. However, after acidification the samples were combined in a 50 mL falcon tube. The combined sample was extracted two

times with 10 mL chloroform. The mixture was centrifuged 10 min at 3000 rpm to achieve a better phase separation. The combined organic phases were combined in a new 50 mL falcon and were washed consecutively with 10 mL brine and 10 mL water. The organic phase was dried with anhydrous sodium sulfate and concentrated *in vacuo*. The concentrated oil was dissolved in 1.5 mL chloroform and transferred to a 1.5 mL plastic tube. The chloroform was evaporated at 90°C. The remaining sample was dissolved in 50 µL methyl *tert*-butyl ether (MTBE). The 50 µL were split into 1, 5, 10 and 20 µL and transferred into GC-vials without insert. To each vial 200 µL DMS (dimethyl disulfide) and 50 µL MTBE (containing 60 mg/mL iodine) were added. After the mixture was heated 48 h at 50°C, excess iodine was removed by the addition of 100 µL saturated sodium thiosulfate solution; however, due to excessive formation of detergents from the *Candida* strain, the layer did not mix properly. The samples were therefore diluted in a 15 mL falcon tube to a final sample composition of 200 µL, 3.55 mL MTBE (containing iodine and analyte), 500 µL dichloromethane, 1.5 mL water and 1 mL ethanol. The organic phase was evaporated stepwise at 85°C in a 1.8 mL glass vial. The samples were taken up in 500 µL dichloromethane and the sample was analyzed by **GC-MS** using the method of Hagstrom et al. (2013) as in Example 4.

Example 7: Expression of transmembrane **desaturases** in *Yarrowia lipolytica*

Background and Rationale

[0668] Engineering microbial production of insect fatty alcohols from fatty acids requires the functional expression of a synthetic pathway. One such pathway comprises a transmembrane desaturase, and an alcohol-forming reductase to mediate the conversion of fatty acyl-CoA into regio- and stereospecific unsaturated fatty acyl-CoA, and subsequently into fatty alcohols. A number of genes encoding these enzymes are found in some insects as well as some microalgae. Alternatively, regio- and stereospecific desaturases can be used to produce a microbial oil rich in fatty acid precursors. The microbial oil can then be derivatized and reduced to active ingredients. A number of gene variants were screened to identify enzyme activities that allow the creation of pathways capable of high level synthesis of a single or a blend of insect fatty acids and alcohols. Additionally, these enzymes were screened across multiple hosts (*Saccharomyces cerevisiae*, *Candida viswanathii* (*tropicalis*), and *Yarrowia lipolytica*) to optimize the search toward finding a suitable host for optimum expression of these transmembrane proteins.

[0669] Initial screening of desaturases in *S. cerevisiae* and *C. viswanathii* (*tropicalis*) identified three active Z11-C16:1 desaturase variants from *Amyelopsis transitella*, *Helicoverpa*

zea, and *Trichoplusia ni*. The *S. cerevisiae* screening used coding sequences **with** an N-terminal leader sequence of the *S. cerevisiae* Ole1p Z9 desaturase fused to **the full** length insect Z11 desaturase sequence. This strategy has been used previously in the scientific literature **to** express **eukaryotic** desaturases in *S. cerevisiae*. All three of the above desaturases displayed Z11 desaturase activity with the Ole1p leader fusion when expressed in a OLE1 deletion background. An analogous design with a *C. albicans* Ole1p leader sequence was used with the **Z11** desaturase from *H. zea*. While active, this **Ole1p-H. zea** desaturase fusion did not significantly increase Z11-hexadecenoic acid titer. Additionally, a conservatively optimized *A. transitella* **Z11** desaturase was active in both *S. cerevisiae* and *C. viswanathii*. **The** following study focused on testing the functional expression of the *H. zea*, *T. ni*, **and** *A. transitella* Z11 desaturases **in** two different *Y. lipolytica* strains, SPV140 and SPV300. Both native and *Homo sapiens* **codon** optimized sequences were used **for** the *H. zea* and *T. ni* desaturases while only the native sequence was used for *A. transitella*. Finally, the N-terminus of the *Y. lipolytica* Ole1p Z9 stearyl-CoA desaturase aligns more closely **with** insect desaturases than the N-terminus of Ole1p from either *S. cerevisiae* or *C. albicans*. Based on this alignment two additional desaturase versions were created. A putative leader sequence was swapped from the *Y. lipolytica* Ole1p onto the *T. ni* and *H. zea* desaturases.

[0670] Summary of Approach

[0671] A focused library **of** **Z11** desaturases (insect origin: *Amyelois transitella*, *Helicoverpa zea*, *Trichoplusia ni*), which had observed activity **in** either *S. cerevisiae* or *C. viswanathii* were cloned into a double crossover cassette targeting **the** XPR2 locus **with a** URA3 selection marker. Protein coding sequences use either the native insect sequence (SEQ ID NOs: 24, 25), *Homo sapiens* optimized coding sequence (SEQ ID NOs: 26, 27), or the *Homo sapiens* optimized sequence **with** the N-terminal 84 bases (*H. zea*, SEQ ID NO: 29) or 81 bases (*T. ni*, SEQ ID NO: 28) swapped for the **N-terminal** 96 bases **of** the *Y. lipolytica* OLE1 (YALI0C05951) gene. Unlike in the *S. cerevisiae* and *C. viswanathii* screens, the leader sequence chimeras test a direct swap **of** leader sequences instead **of** concatenating a host leader sequence to the **N-terminus** of the **full length** desaturase coding sequence. Only the native coding sequence was used for the *A. transitella* desaturase (SEQ ID NO: 30).

[0672] Each of the 7 desaturase constructs was transformed into SPV140 (PO1f) and SPV300 (H222 ΔP ΔA ΔF AURAS) and site-specific integrants were confirmed.

[0673] Desaturase activity was tested via an *in vivo* **bioconversion** of **hexadecanoic** acid (palmitic acid) into (Z)-1-**hexadecenoic** acid (**palmitavaccenic** acid) **in** YPD medium.

[0674] GC-FID analyses were used to identify and quantify metabolites.

[0675] Results

[0676] Strain construction

[0677] Desaturase variants were cloned into the pPV101 vector which contains a *Y. lipolytica* expression cassette targeting integration into the XPR2 locus (YALI0F31889g).

[0678] The *T. ni* and *H. zea* desaturases were each synthesized with the native insect sequence (SEQ ID NOs: 24, 25), full length insect sequence codon optimized for *Homo sapiens* (SEQ ID NOs: 26, 27), or with the putative leader sequence replaced by the leader sequence from *Y. lipolytica* OLE1 desaturase (SEQ ID NOs: 28, 29). The *A. transitella* desaturase was also synthesized using the native insect coding sequence (SEQ ID NO: 30). All seven desaturase variants were transformed into SPV140. Based on previous activity results, only the *H. zea* and *A. transitella* desaturase variants were transformed into SPV300.

[0679] Functional expression assay

[0680] Functional activity was assessed by a modification of the protocol used for transmembrane desaturase expression in *C. viswanathii* SPV053 (See Example 6). Briefly, *Y. lipolytica* SPV140 and SPV300 derived strains expressing insect desaturases were cultured in rich (YPD) to generate biomass. Using the YPD generated biomass, small scale (2 ml) cultures were cultivated with palmitic acid for a total of 48 hours in 24 deep well plates (See Materials & Methods for detail).

[0681] In the initial screen of *T. ni*, *H. zea*, and *A. transitella* variants, only *H. zea* desaturase variants that were codon optimized for *Homo sapiens* produced detectable Z11-hexadecenoic acid (Figure 26). Expression of native *H. zea* desaturase conferred production of 100 ± 5 mg/L Z11-hexadecenoic acid and the version with a *Y. lipolytica* OLE1 leader sequence produced 83 ± 11 mg/L. As seen in Figure 26, the distribution of the other major fatty acid species was relatively unaffected by functional desaturase expression. In the active strains, Z11-hexadecenoic acid made up ~10% (g/g) of the fatty acid species (including palmitic acid substrate which may be adsorbed to the outer cell surface).

[0682] A follow up experiment was conducted comparing active variants in the SPV140 background to SPV300 derived desaturase strains. The parent SPV300 and SPV140 expressing hrGFP were used as negative controls. The same bioconversion assay protocol was used. As in SPV140, only *H. sapiens* optimized variants produced detectable activity (Figure 27). SPV300 strains grew to higher final cell densities (SPV300 OD₆₀₀=26-28, SPV140 OD₆₀₀=19-22) (Figure 28). The highest titers were observed for strains expressing

the native *H. zea* Z11-desaturase with *H. sapiens* codon optimization (pPV199). The retested SPV140 strains produced 113 ± 1 mg/L (5.5 ± 0.2 mg/L/OD) Z11-hexadecenoic acid which is 13% higher than titers observed in the first experiment (Figure 29). SPV300 strains expressing the same desaturase generated a wider range of productivity. On average they produced 89 ± 18 mg/L (3.3 ± 1.2 mg/L/OD) Z11-hexadecenoic acid, but one clone produced 124 mg/L (4.6 mg/L/OD) Z11-hexadecenoic acid.

[0683] In summary, only the *H. zea* Z11 desaturase variants with *Homo sapiens* codon optimization produced detectable Z11-hexadecenoic acid. Under the current assay condition, marginally higher titers were observed in the SPV140 background over SPV300. Table 11 summarizes the Z11-hexadecenoic acid titers.

Table 11: Z11-hexadecenoic acid titers obtained from expression of exemplary desaturases in *Yarrowia lipolytica*

Desaturase	Codon optimization	Parent Strain	Z11-hexadecenoic acid titer (mg/L)
Z11 <i>T. ni</i>	Native	SPV140	ND (no detection)
Z11 <i>T. ni</i>	<i>Homo sapiens</i>	SPV140	ND
Y1 OLE1-Z11 <i>T. ni</i>	<i>Homo sapiens</i>	SPV140	ND
Z11 <i>H. zea</i>	Native	SPV140	ND
		SPV300	ND
Z11 <i>H. zea</i>	<i>Homo sapiens</i>	SPV140	100 ± 5
		SPV300	87 ± 18
Y1 OLE1-Z11 <i>H. zea</i>	<i>Homo sapiens</i>	SPV140	83 ± 11
		SPV300	55 ± 1
Z11 <i>A. transitella</i>	Native	SPV140	ND
		SPV300	ND

[0684] In SPV300, one non-site-specific integrant of pPV200 (*Y. lipolytica* OLE1-*H. zea* Z11 desaturase with *Homo sapiens* codon optimization) was tested. This integrant did not produce detectable Z11-hexadecenoic acid, while the two site-specific integrants produced 55 ± 1 mg/L.

[0685] No major hydroxy or diacid peaks were observed from pellets of SPV140 or SPV300 derived strains, and deletion of β -oxidation/co-oxidation genes in SPV300 did not increase Z11-hexadecenoic acid accumulation under the current assay condition (relatively low-substrate concentration, rich medium).

[0686] Conclusions

[0687] The *H. zea* Z11 desaturase is active and confers production of ~ 100 mg/L Z11-hexadecenoic acid, from 500 mg/L palmitic acid substrate. The functional expression was

demonstrated across three positive integrants and replicate experiments in a 24 well plate assay.

[0688] *H. zea* desaturase required codon optimization (*Homo sapiens* or potentially *Y. Upolytica*) for activity in *Y. Upolytica*.

[0689] The *T. ni* Z11 desaturase, while active in *S. cerevisiae*, does not produce detectable Z11-hexadecenoic acid in *Y. Upolytica*.

[0690] The reproducibility of the assay for *Y. Upolytica* strains can be confirmed starting from glycerol stock.

[0691] *A. Iransitella* desaturase can be codon optimized for expression in *Y. Upolytica*.

[0692] Since *Y. Upolytica* is a candidate production host, additional copies of active desaturases can be integrated in *Y. Upolytica*, culture conditions to improve byconversion can be identified, and substrate conversion can be quantified.

[0693] Materials & Methods

[0694] Strain construction

[0695] All desaturase genes were synthesized (Genscript). Either native sequences or *Homo sapiens* codon optimization was used. Synthesized genes were subcloned into pPVIOL. Plasmids were transformed and prepped from *E. coli* EPI400 using the Zyppy Plasmid Miniprep Kit (Zyrno Research, Inane, CA). Approximately ~1-2 µg of linearized DNA was transformed using Frozen-EZ Yeast Transformation II Kit (Zyrno Research, Irvine, CA). The entire transformation mixture was plated on CM glucose -ura agar plates. Positive integrants were found to be site-specific and genotyping was conducted by check PCR.

[0696] Functional expression assay

[0697] Palmitic acid supplementation in YPD

[0698] Positive isolates were re-patched onto YPD, grown overnight, and then stored at 4°C. Strains were inoculated from patch plates into 2 ml of YPD in 24 deep well plates (square well, pyramid bottom). Three positive clones were inoculated for each desaturase variant. Three isolates of pPVIOL in SPV140 and the parent SPV300 were used as negative controls. Deep well plates were incubated at 28°C and 250 rpm in the Infers Multitron refrigerated flask shaker for 24 hrs. After 24 hrs of incubation, a 1 ml volume of each culture was pelleted by centrifugation at 500xg. Each pellet was resuspended in 2 ml of YPD. 500 mg/L palmitic acid was added to cultures from a 90 g/L stock solution in ethanol. The result was the addition of 0.5% ethanol with the palmitic acid substrate. All cultures were incubated for 48 hours before endpoint sampling. Final cell densities were measured with the Tecan Infinite

200pro plate reader. 0.75 or 0.8 ml of each culture was harvested in 1.7 ml microcentrifuge tubes and pelleted. Supernatant was removed and pellets were processed as described below.

[0699] Metabolite extraction and GC-FID analysis

[0700] Total lipid composition as well as the (Z)-11-hexadecenoic acid quantification was based on modified procedures by Moss et al. (1982) and Yousuf et al (2010). The pelleted cells (in 1.5 mL plastic tubes), usually about 10 mg to 80 mg, were resuspended in methanol containing 5 % (w/w) of sodium hydroxide. The alkaline cell suspension was transferred into a 1.8 ml, crimp vial. The mixture was heated for 1 h in the heat block at 90°C. Prior to acidification with 400 2.5 N HCl the vial was allowed to cool to room temperature. 500 µL chloroform containing 1 mM methyl heptadecanoate were added and the mixture was shaken vigorously, then both aqueous and organic phase were transferred into a 1.5 mL plastic tube. The mixture was centrifuged at 13,000 rpm, afterwards 450 µL of the organic phase were transferred into a GC vial. For the analysis of lipids and the quantification of fatty acids 50 µL of 0.2 M TMSH (trimethylsulfonium hydroxide in methanol) was added and the sample analyzed by GC-FID.

Example 8: *Candida viswanathii* (*tropicalis*) as a production platform for insect fatty alcohol synthesis

[0701] Background and Rationale

[0702] Variants of insect transmembrane desaturases and reductases were previously screened and rank-ordered based on their functional expression in either *Candida viswanathii* or *Saccharomyces cerevisiae* (see Examples 3, 4 and 6). *Helicoverpa zea* desaturase and *Helicoverpa armigera* reductase were selected to assemble a synthetic insect fatty alcohol pathway in *C. viswanathii*. Simultaneous expression of codon optimized *H. zea* desaturase under *Candida* isocitrate lyase (ICL) promoter, and codon optimized *H. armigera* reductase under *Candida* transcription elongation factor (TEF) promoter was achieved via genomic integration of the full fatty alcohol pathway. Accumulation of Z11-16OH was achieved in cultures of the recombinant strain (SPV0490) using simple carbon sources and palmitic acid.

[0703] Summary of Approach

[0704] Integration plasmids were designed containing a functional *Helicoverpa zea* desaturase (See Example 6) paired with a *Helicoverpa armigera* reductase driven by a putatively constitutive *C. tropicalis* promoter (pTEF).

[0705] Functionality of the full pathway was assessed via an *in vivo* byconversion of hexadecanoic acid (palmitic acid) into Z11-16OH.

[0706] GC-FID and GC-MS analyses were used to identify and quantify- metabolites.

[0707] Results

[0708] Accumulation of Z11-16OH was detected in cultures of *Candida* engineered to express *H. zea* desaturase under an TCL promoter and *H. armigera* reductase under a TEF promoter (Table 12 and Figure 30).

[0709] Table 12. Tabulated Z11-16OH titers from *Candida viswanathii* bioconversion assay. SPV088 is *C. viswanathii* which was engineered to express mCherry (negative control). SPV0490 is *C. viswanathii* which was engineered to express the insect fatty alcohol pathway.

Z11-16OH titers (mg/L)		
	SPV0488 (negative control)	SPV0490
Sample 1	0.08	1.03
Sample 2	0.07	0.93
Sample 3	0.06	0.88
Average	0.07	0.95
StDev	0.01	0.06

[0710] Materials & Methods

[0711] Strain construction

[0712] The integration plasmid (ppV0228) was designed to contain two expression cassettes. The first cassette contains *H. zea* codon-optimized desaturase (SEQ ID NO: 31) that was driven by the *C. viswanathii* ICL promoter (SEQ ID NO: 33). The second cassette contains codon-optimized *H. armigera* reductase (SEQ ID NO: 32) driven by the *C. tropicalis* TEF promoter (SEQ ID NO: 34). Gene expression in the ICL promoter cassette is terminated by the ICL terminator sequence (SEQ ID NO: 35). Gene expression in the TEF promoter cassette is terminated by the TEF terminator sequence (SEQ ID NO: 36). A conservative approach was used for recoding of genes. Native gene sequences were unaltered except for replacement of CTG leucine codons with TTA. After transformation into *E. coli* NEBIO β , plasmids were miniprep using the Zyppy Plasmid Miniprep Kit (Zymo Research, Irvine, CA). Plasmids were linearized by digestion with BsiWI (New England Biolabs, Ipswich, MA) before transformation into SPV053. After digestion, DNA was isolated using Clean and Concentrator Kit (Zymo Research, Irvine, CA). Approximately 3-5 μ g of DNA was

transformed by electroporation. Positive integrants were found to be site-specific and genotyping was conducted by check PCR. A two-stage approach was adopted for further screening of *S. w* efficiency transformations. Approximately 100 colonies were re-patched on YPD+250 μ g/ml Zeocin and grown overnight. The subset of patches which grew quickly (dense growth within 24 hours) were screened by colony PCR.

[0713] Functional expression assay

[0714] Palmitic acid supplementation in YPD

[0715] Positive isolates were re-patched onto YPD+300 μ g/ml Zeocin, grown overnight and then stored at 4°C. Strains were inoculated from patch plates into 2 ml of YPD in 24 deep well plates (square well, pyramid bottom). Four positive clones were inoculated for each desaturase and reductase variant and three positive clones were inoculated for each desaturase and mCherry expressing control strain. Deep well plates were incubated at 30°C, 1000 rpm, and 80% humidity in the Infers HT Multitron Pro plate shaker for 24 hrs. After 24 hrs of incubation, a 1 ml volume of each culture was pelleted by centrifugation at 500xg. Each pellet was resuspended in 2 ml of YPD+0.3% (v/v) ethanol. Ethanol was added at this stage to induce recombinant enzyme expression from the ICL promoter. Cultures were incubated for another 24 hours under the same conditions before 300 mg/L palmitic acid was added to cultures from a 90 g/L stock solution in ethanol. The result was the addition of a fresh 0.3% ethanol in conjunction with the palmitic acid. All cultures were incubated for an additional 24 hrs before a final addition of 0.3% ethanol. After another 24 hr period of incubation, 1.5 ml of each culture was harvested in 1.7 ml microcentrifuge tubes and pelleted. Supernatant was removed and pellets were processed as described below.

[0716] Metabolite extraction and GC-MS detection

[0717] The pelleted cells (in 1.5 mL plastic tubes), usually about 10 mg to 80 mg, were resuspended in methanol containing 5 % (w/w) of sodium hydroxide. The alkaline cell suspension was transferred into a 1.8 mL crimp vial. The mixture was heated for 1 h in a heat block at 90°C. Prior to acidification with 400 μ L 2.5 N HCl the vial was allowed to cool to room temperature. 500 μ L chloroform containing 1 mM methyl heptadecanoate were added and the mixture was shaken vigorously, then both aqueous and organic phase were transferred into a 1.5 mL plastic tube. The mixture was centrifuged at 13,000 rpm, afterwards 450 μ L of the organic phase were transferred into a GC vial. The organic phase was evaporated in a heat block at 90°C for 30 min. The residue was dissolved in 50 μ L N,O-Bis(trimethylsilyl)trifluoroacetamide containing 1% trimethylchlorosilane. Prior to transfer

into glass inserts the mixture was heated 5 min at 90°C. The samples were analyzed by GC-MS (Table 13).

Table 13. Analytical parameters used for **GC-MS** analysis of metabolites

System	Agilent 6890 N GC, ChemStation G1701EA E.02.01 .1 177
Column	DB23 30 m x 25 μ m x 25 μ m Pressure = 11.80 psi; Flow = 0.6 mL/min
Inlet	Heater = 250°C; Pressure = 11.74 psi; Total Flow {He} = 111 mL/min
Carrier	He @ 29 cm/sec, 11.60 psi
Signal	Data rate = 2 Hz/0.1 min
Oven	150°C for 1 min Ramp 12°C/min to 220°C, hold 3 min Ramp 35°C/min to 300°C, hold 4 min
Injection	Splittless, 250°C
Detector	HP 5973 MSD in SIM mode (m/z: 208.0, 297.3 and 387.3), 100 msec Dwell, EMV mode: Gain factor 1, 2.4 min solvent delay, 3.09 cycles/sec
Sample	Injection volume = 1 μ L

Example 9: Insect fatty alcohol production from *Yarrowia lipolytica*

[0718] Background and Rationale

[0719] *Yarrowia lipolytica* was engineered as a production platform for insect fatty alcohol (Z11-160H and Z9-160H) synthesis from palmitic acid.

[0720] After individually confirming functional expression of a Z11 desaturase (Example 7) and fatty acyl-CoA reductase (FAR), the full Z11-160H and Z9-160H pathways (Bdr) were engineered in *Y. lipolytica*. For the purpose of improving fatty alcohol titers, cultivations designed for promoting growth vs. for eliciting lipid storage were also explored. A growth

condition favors high biomass production, but limits fatty acyl-CoA pool size used by the engineered pathway and directs fatty acyl-CoA intermediates to membrane synthesis. Conversely, a lipid storage condition creates a strong sink for production of fatty acyl-CoAs which is desirable. However, fatty acyl-CoA transport towards lipid bodies creates a strong competition for FAR activity. Under this second scenario, even though Z11-16Acid or Z9-16Acid accumulates in the cell, most of it is inaccessible to the FAR. On the other hand, there may be a continual flux of lipid remobilization under lipid storage conditions which leads to a sustained pool of Z11-16CoA or Z9-16CoA which is available to the FAR.

[0721] Summary of Approach

[0722] Two biodesaturation-reduction (Bar) pathway variants were tested in the H222 $\Delta P\Delta A\Delta F$ (SPV300) background. The first combined recombinant expression of *Helicoverpa zea* Z11 desaturase paired with a *Helicoverpa armigera* fatty acyl-CoA reductase (FAR amino acid sequence set forth in SEQ ID NO: 41) creating a Z11-16QH synthesis pathway. The second combined native *Y. lipolytica* Z9 desaturase activity with *H. armigera* fatty acyl-CoA reductase (FAR) expression creating a Z9-16OH pathway.

[0723] Two integration plasmids were constructed to express the *H. zea* desaturase and the *H. armigera* FAR. The TEF promoter was used for desaturase expression and the EXP1 (export protein) or the TAL1 (transaldolase) promoter was used for reductase expression.

[0724] Successful integration of the Z11-16OH pathway cassette into the H222 $\Delta P\Delta A\Delta P$ (SPV300) background was confirmed by colony PGR.

[0725] Functionality of the full Z11-16OH pathway was assessed via an *in vivo* bioconversion of 16Acid (palmitic acid) into Z11-16OH (Z-11-hexadecenol).

[0726] Functionality of a full Z9-16OH pathway was assessed via an *in vivo* bioconversion of 16Acid (palmitic acid) using previously constructed SPV471 (H222 $\Delta P\Delta A\Delta P$ derived) which expresses the *H. armigera* FAR driven by the TEF promoter.

[0727] GC-MS analysis was used to identify and quantify Z9-16OH and Z11-16OH. GC-FID analysis was used to identify and quantify fatty acids.

[0728] Summary

[0729] Ten isolates expressing the *H. zea* desaturase (pTEF) and *H. armigera* reductase (pEXP1) were screened. The *in vivo* bioconversion assay confirmed Z11-16OH production from all isolates.

[0730] Relatively low, detectable Z11-16OH titers (0.26 ± 0.09 mg/L) were observed in a YPD medium supplemented with 10 g/L methyl palmitate. The Z11-16Acid precursor was measured at 22.0 ± 1.1 mg/L (across clones 2, 4, 9, 17, 23).

[0731] Higher Z11-16OH titers were observed in a semi-defined medium with C:N ratio of -80. Across all 10 isolates Z11-16OH was produced at 2.65 ± 0.36 mg/L. The Z11-16Acid precursor titer was 900 ± 30 mg/L. One isolate (SPV578) produced 3.68 ± 0.31 mg/L Z11-16OH (Z11-16Acid 840 ± 14 mg/L).

[0732] Nine isolates expressing the *H. zea* desaturase (pTEF) and *H. armigera* reductase (pTAL1) were screened. The *in vivo* bioconversion assay confirmed Z11-16OH production from all isolates.

[0733] One isolate (SPV603) produced 6.82 ± 1.11 mg/L Z11-16OH in a semi-defined medium (Z11-16Acid 1.36 g/L).

[0734] The previously tested reductase strain, SPV471 (H222 Δ P Δ A Δ P expressing *H. armigera* FAR), produced 4.30 ± 2.33 mg/L Z9-16OH and 450 ± 80 mg/L Z9-16Acid using a semi-defined medium (C:N ratio of -80).

Table 14: Summary table of Z11/Z9-16OH titers from B_{dr} pathway strains in *in vivo* bioconversion assay.

Strain	Medium	Z11-16OH (mg/L)	Z9-16OH (mg/L)
pTEF- <i>H. zea</i> Z11 desaturase pEXP- <i>H. armigera</i> FAR Clone 17 (SPV578)	Semi-Defined C:N=80	3.99 ± 0.37 {n=4}	0.22 ± 0.03 {n=4}
pTEF- <i>H. zea</i> Z11 desaturase pTAL- <i>H. armigera</i> FAR Clone 9 (SPV603)	Semi-Defined C:N=80	6.82 ± 1.11 {n=2}	0.22 ± 0.01 {n=2}
pOLE1-Y. lipolytica OLE1 (native) pTEF- <i>H. armigera</i> FAR (SPV471)	Semi-Defined C:N=80	0.22 ± 0.03 {n=2}	4.30 ± 2.33 {n=2}

[0735] Results

[0736] Strain construction

[0737] Evidence in the literature suggests both insect desaturases and FARs are localized in the membrane of the endoplasmic reticulum with active sites oriented towards the cytoplasm. Of the functional variants, the Z11 desaturase from *H. zea* and the FAR from *H. armigera* (FAR amino acid sequence set forth in SEQ ID NO: 41) were selected, one hypothesis being that using enzymes from the same genus (*Helicoverpa*) could better conserve protein-protein interactions that may occur in the ER membrane.

[0738] Two new constructs were ordered from Genscript and cloned into the previously-assembled *H. zea* desaturase plasmid, pPV0199. Two FAR synthons with either the EXPI or TAL1 promoter from *Y. lipolytica* were cloned into this expression cassette.

[0739] One dual expression plasmid (with EXPI promoter) was transformed into the parent strain SPV300 (H222 $\Delta\text{po}\chi^1$ $\Delta\text{po}\chi^2$ $\Delta\text{po}\chi^3$ $\Delta\text{po}\chi^4$ $\Delta\text{po}\chi^5$ $\Delta\text{po}\chi^6$ $\Delta\text{adh}1$ $\Delta\text{adh}2$ $\Delta\text{adh}3$ $\Delta\text{adh}4$ $\Delta\text{adh}5$ $\Delta\text{adh}6$ $\Delta\text{adh}7$ Afaoi Aura3). Two different competent cell preparations of the same parent strain were transformed to study variability in strain performance resulting from competent cell preparation. Approximately 25% of URA⁺ clones were confirmed to be targeted integrants at the XPR2 locus (20% for preparation 1, 33% for preparation 2). Two clones from Comp. Cell Preparation 1 and eight targeted clones from Comp. Cell Preparation 2 were selected for screening in the functional expression assay.

[0740] The second dual expression plasmid (with TAL1 promoter) was integrated into the same parent strain (SPV300). Twenty-three colonies were screened by check PCR and 11 were found to be targeted integrants (48%). Nine integrants were selected for screening in the functional expression assay.

[0741] The construct of SPV471 (H222 $\Delta\text{P}\Delta\Delta\Delta\text{P}$ expressing *H. armigera* FAR) was described previously.

[0742] Z11-160H functional expression assay

[0743] An *in vivo*, 24-well plate assay was used to evaluate production of Z11-160H. The assay was based on designs used for screening desaturase and reductase variants as well as conditions used to increase fatty acid accumulation. A rich medium (YPD) and a semi-defined medium were used with 10 g/L methyl palmitate supplemented as bioconversion substrate. The semi-defined medium had a C:N ratio of ~80 and included 5 g/L glycerol and 60 g/L glucose (See Materials & Methods for further details).

[0744] The initial screen of strains harboring the *H. zea* desaturase driven by the TEF promoter and the *H. armigera* FAR (FAR amino acid sequence set forth in SEQ ID NO: 41) driven by the EXPI promoter confirmed that the presence of FAR was required to produce Z11-160H. No hexadecenol was observed from both the parent and desaturase-only control strains under any condition. Under both media conditions Z11-160H and to a lesser extent Z9-160H were detected from clones expressing the full desaturase-reductase pathway. When the conversion was completed in rich medium, 0.26 ± 0.09 mg/L Z11-160H and 0.06 ± 0.01 mg/L Z9-160H were produced (Figure 32A). A 10-fold increase in Z11-160H titer and 3-fold increase in Z9-160H titer was observed when the Semi-Defined medium was used

(Figure 32B). Across all pathway clones 2.65 ± 0.29 mg/L Z11-16OH and 0.18 ± 0.02 mg/L Z9-16OH were produced. The enrichment of Z11-16OH over Z9-16OH supports the potential for engineering a regiospecific Bdr pathway. Consistency between technical replicates varied across clones under the Semi-Defined medium condition. Titer for Clones 2, 4, 6, 9, and 17 were consistent with CVs < 20. Clones 1, 7, and 23 have CVs > 40%. The highest consistent Z11-16OH titer was observed for Clone 17, 3.68 ± 0.31 mg/L (Table 15).

Table 15. Summary table of Z11/Z9-16OH titers for pEXP clones. A population often isolates expressing the *H. zea* desaturase driven by pTEF and *H. armigera* reductase driven by pEXP1, from two independent competent cell preparations, were assayed for Z11-16OH and Z9-16OH production under two different media conditions. Alcohol production across isolates and from select clones are presented.

pTEF-H ₂ deat pEXP-Ha_FAR Clone(s)	Medium	Z11-16OH (mg/L)	Z9-16OH (mg/L)	Z11-16OH fold increase (relative to YPD)	Z9-16OH fold increase (relative to YPD)
All clones	YPD	0.26 ± 0.09	0.35 ± 0.01	-	-
All clones	Semi-Defined	2.65 ± 0.29	0.18 ± 0.02	10	3
Clone 2 (SPV574)	YPD	0.18 ± 0.09	0.05 ± 0.03	-	-
Clone 2 (SPV574)	Semi-Defined	2.08 ± 0.26	0.14 ± 0.04	12	3
Clone 4 (SPV575)	YPD	0.28 ± 0.01	0.11 ± 0.01	-	-
Clone 4 (SPV575)	Semi-Defined	3.24 ± 0.28	0.21 ± 0.03	12	2
Clone 9 (SPV576)	YPD	1.03 ± 0.84	0.35 ± 0.03	-	-
Clone 9 (SPV576)	Semi-Defined	1.56 ± 0.28	0.11 ± 0.02	1.5	2
Clone 23 (SPV577)	YPD	0.16 ± 0.14	0.35 ± 0.05	-	-
Clone 23 (SPV577)	Semi-Defined	3.35 ± 1.85	0.26 ± 0.15	21	5
Clone 17 (SPV578)	YPD	0.19 ± 0.01	0.08 ± 0.01	-	-
Clone 17 (SPV578)	Semi-Defined	3.68 ± 0.31	0.26 ± 0.02	14	4

[0745] The lipid profiles of the full pathway clones were also quantified. For simplicity the 16 carbon fatty acid species are plotted for select clones in Figure 33A-33B. In general, the full Bdr pathway clones accumulated less Z11-16Acid than the desaturase only control ($0.25 < 0.5$ g/L in YPD, $0.8-1.0 < 1.5$ g/L in Semi-Defined). Lower Z11-16Acid titers in full Bdr pathway clones may result from reduced desaturase expression in the dual expression cassette or potentially from Z11-16Acid consumption by FAR and subsequent byproduct pathways. No trend in 16Acid titer was observed in YPD, while 16Acid titers were similar for desaturase only and full pathway strains in the Semi-Defined medium.

[0746] Strains using the second dual expression cassette (pTAL-HaFAR) were assayed under the same Semi-Defined medium condition used to evaluate the pEXP clones. Nine pTAL clones were assayed against SPV300 (parent), SPV575 (pEXP-Ha_FAR Clone 4), and SPV578 (pEXP-Ha_FAR Clone 17) controls. As expected, no alcohol products were

observed from the negative control. Alcohol titers from pEXP positive control strains replicated results observed in the initial assay of pEXP clones (Figure 34, Table 16). Excluding one outlier clone. Clone 9, Z11-160H titer was equivalent from pTAL clones (4.19 ± 0.16 mg/L) and pEXP clones (4.10 ± 0.22 mg/L). Clone 9 produced Z11-160H at 6.82 ± 1.11 mg/L. As in the first assay with pEXP clones, low, but detectable titers of Z9-160H were observed (Figure 34, Table 16).

Table 16. Summary table of **Z11/Z9-160H** titers for **pTAL** clones. A population of nine isolates expressing the *H. zea* desaturase under the TEF promoter and *H. arrnigera* reductase under the TAL promoter were assayed for Z11-160H and Z9-160H production under a Semi-Defined medium condition. Clones were compared to positive controls expressing the *H. zea* desaturase under the TEF promoter and *H. arrnigera* reductase under the EXP promoter. Alcohol production across isolates and from select clones are presented.

pTEF-Hz_desat pEXP-Ha_FAR Clone(s)	Medium	Z11-16OH (mg/L)	Z9-16OH (mg/L)
EXP Clone 4 (SPV575)	Semi-Defined	3.91 ± 0.44	0.15 ± 0.01
EXP Clone 17 (SPV578)	Semi-Defined	4.30 ± 0.16	0.17 ± 0.02
pTAL clones excluding Clone 9	Semi-Defined	4.19 ± 0.16	0.18 ± 0.01
pTAL Clone 9 (SPV503)	Semi-Defined	6.82 ± 1.11	0.23 ± 0.01

[0747] The lipid profiles of all strains in the second (pTAL) full pathway screen were also quantified. For simplicity the 16 carbon fatty acid species are plotted in Figure 35. As expected, Z11-16Acid is present only for strains expressing the desaturase. Complete lipid profiles were similar to those observed previously (Figure 36). Z9-18Acid (oleic acid) was the second most abundant fatty acid species after Z11-16Acid.

[0748] Z9-16GH functional expression assay

[0749] An *in vivo*, flask scale assay was used to test for Z9-160H production. The parent control strain, H222 Δ P Δ A Δ P (SPV300), was compared to a strain expressing *H. arrnigera* FAR which relied on native Z9 desaturase activity to synthesize the Z9-16CoA precursor (SPV471). Biomass was generated through a YPD seed culture, mimicking the plate assay. Bioconversion flasks were inoculated at an initial OD₆₀₀=1 or OD₆₀₀=4 into the same Semi-Defined C:N=80 medium used in the Z11-160H plate assay (See Materials & Methods for details). As expected, control flasks did not produce detectable Z9-160H while SPV471 flasks produced up to 4.30 ± 2.23 mg/L after 24 hours of incubation (Figure 37A-Figure 37B). While there was large variability between replicates, all SPV471 (*H. arrnigera* FAR) replicates exceeded 1 mg/L titer. Increased seeding density did not increase Z9-16Acid or Z9-

160H titer. The precursor Z9-16Acid titer at 24 hours was significantly less (<0.5 g/L) than the Z11-16Acid precursor observed for dual expression cassette strains used to produce Z11-160H. The relative abundance of other fatty acid species was similar to previously observed profiles, with Z9-18Acid as the next most abundant species (Figure 38). Both lipid and alcohol samples were taken over the course of 48 hours to produce a time course of Z9-160H and lipid titers. Z9-160H titer peaked at 24 hours before decreasing over the second day (Figure 39A). Z9-16Acid increased rapidly over the first 24 hours before stabilizing or increasing slowly over the second 24 hours (Figure 39B). Since the employed analytical method utilizes only the cell pellet, the decrease in Z9-160H titer supports the hypothesis of downstream consumption or secretion of the alcohol products. They may be oxidized (co-oxidation), secreted as free alcohol, or derivatized and secreted as an ester. Analysis of supernatant samples using FID and MS SCAN detection revealed no detectable Z9-160H or Z9-16QH derivatives supporting the hypothesis of consumption via oxidation pathways.

[0750] Conclusions

[0751] Combining expression of *Heiicoverpa* Z11 desaturase and fatty acyl-CoA reductase led to production of Z11-160H in *Y. lipolytica* H222 Δ P Δ A Δ P (SPV300) at titers >1 mg/L.

[0752] High C:N ratio conditions improved Z11-160H titer relative to a rich medium condition.

[0753] Under lipid accumulating conditions the combination of native Z9 desaturase and *II. armigera* FAR activities are sufficient for synthesis of >1 mg/L Z9-160H.

[0754] Titers are increased, for example, by deleting pathways consuming fatty alcohol products and/or fatty acid precursors; identifying FAR variants which exhibit higher turnover rate than *II. armigera* FAR; and/or increasing pathway copy number.

[0755] Key undesired byproducts are identified.

[0756] The possibility that some of the fatty alcohol product is converted into fatty acetate by the activity of one or more endogenous acetyltransferases is explored.

[0757] Improved host strains are engineered to eliminate the co-oxidation pathway and components of the lipid storage pathway.

[0758] Materials & Methods

[0759] Strain construction

[0760] All desaturase and reductase genes were ordered from Genscript. Homo sapiens codon optimization was used (Genscript algorithm). The newly synthesized expression cassette was subcloned into pPV199 by Genscript using the SapI restriction site. Plasmids

were transformed and prepped from *E. coli* EP1400 using the Zyppy Plasmid Miniprep Kit (Zymo Research, Irvine, CA). Plasmids were digested with PmeI (New England Biolabs, Ipswich, MA) and purified by gel extraction using Zymoclean Gel DNA recovery Kit (Zymo Research, Irvine, CA). DNA was further concentrated using Clean and Concentrator Kit (Zymo Research, Irvine, CA). Approximately 1-2 µg of DNA was transformed using Frozen-EZ Yeast Transformation II Kit (Zymo Research, Irvine, CA). The manufacturer's protocol was modified as follows: A 2 ml YPD seed culture was inoculated at 9 am the day before competent cell preparation. Tire seed was grown 8 hours (until 5 pm) before 40 ml of YPD in a 250 ml baffled shake flask (or 20 ml in a 125 ml baffled flask) was inoculated to an initial OD600 of 0.0005. The culture was incubated at 28°C and 250 rpm -24 hours. Cells were harvested at an OD600=0.5-1. Instead of resuspending 10 ml of culture in 1 ml of Solution 2 as in the manufacturer's instructions (OD600~10), 10 ml of SPV140 culture was resuspended in 0.5 ml (OD600=20-30). All Solution 2 aliquots were slowly frozen to -80°C by placing the tubes in a closed Styrofoam box before putting in the -80°C freezer. 50 µl aliquots of competent cells in 1.7 ml Eppendorf tubes were thawed on ice, DNA eluted in water was added directly to the cells, and 500 µl of Solution 3 was used to suspend the cells with gentle pipetting. Tubes were incubated at 28°C for 3 hours with gentle vortexing every 30 minutes. The entire transformation mixture was plated on CM glucose -ura agar plates. Positive integrants were found to be site-specific and genotyping was conducted by check PGR.

[0761] Z11-160 H functional expression assay

[0762] Positive isolates were repatched onto YPD, grown overnight, and then stored at 4°C. Strains were inoculated from patch plates into 2 ml of YPD in 24 deepwell plates (square well, pyramid bottom). Replicate inoculations were made from each patch. Negative control strains were struck out on YPD from glycerol stocks and individual colonies were used to inoculate. Deepwell plates were incubated at 28°C and 250 rpm in the Infors Multitron refrigerated flask shaker for 24 hrs. After 24 hrs of incubation, a 0.85 ml volume of each culture was pelleted by centrifugation at 800xg. Each pellet was resuspended in either 2 ml of YPD or Semi-defined medium (described in Table 17 below). 10 g/L methyl palmitate (pre-warmed to ~50°C) was added to cultures. All cultures were incubated for 48 hours before endpoint sampling. Final cell densities were measured with the Tecan Infinite 200pro plate reader. 1.5 ml (alcohol analysis) or 500 µl (lipid analysis) was transferred to 1.7 ml

microcentrifuge tubes and pelleted. Supernatant was transferred to clean tubes and samples were processed as described below.

[00100] Table 17. Semi-defined (C:N=80) medium composition. Components of the semi-defined base medium used to induce lipid storage are described.

Media Component	Conc.	Units
Yeast Extract	2	g/l
Peptone	1	g/l
Potassium phosphate buffer pH7	0.1	M
YNB w/o aa, NH ₄	1.7	g/l
Glucose	50	g/l
Glycerol	5	g/l

Z9-160H functional expression assay

[0763] SPV300 (negative control) and SPV471 were struck out onto YPD agar plates, grown overnight, and then stored at 4°C. Strains were inoculated from colonies into 2 ml of YPD and incubated at 28°C and 250 rpm in 14 ml round bottom culture tubes for ~8 hours. After incubation, 2 ml of culture was used to inoculate 20 ml of YPD in a 125 ml baffled shake flask. Shake flasks were incubated 24 hrs at 28°C and 250 rpm. After incubation, cell density in shake flasks was measured using a Tecan Infinite 200pro plate reader. An appropriate volume of culture was pelleted in order to resuspend cells in 25 ml of Semi-defined C:N=80 medium (see Table 17 above) at an initial OD₆₀₀ = 1 (~1 gDCW/L) or 4 (~4gDCW/L). The resuspended culture was added to 250 ml baffled shake flasks. Neat methyl palmitate was added at 10 g/L final concentration after pre-heating to 50°C. After substrate addition, flasks were incubated at 28°C and 250 rpm for two days. At 12, 18, 24, 36, 42, and 48 hours 500 µl (lipid analysis) and 1.5 ml (alcohol analysis) samples were taken in 1.7 ml microcentrifuge tubes. Samples were pelleted and the supernatant was transferred to a clean microcentrifuge tube.

[0764] Metabolite extraction and GC-MS detection

[0765] Alcohol analysis

[0766] The pelleted cells (in 1.5 mL plastic tubes), usually about 10 mg to 80 mg, were resuspended in methanol containing 5 % (w/w) of sodium hydroxide. The alkaline cell suspension was transferred into a 1.8 mL crimp vial. The mixture was heated for 1 h in the heat block at 90 °C. Prior to acidification with 400 µl, 2.5 N HCl the vial was allowed to cool to room temperature. 500 µL chloroform containing 1 mM methyl heptadecanoate were added and the mixture was shaken vigorously, then both aqueous and organic phase were

transferred into a 1.5 mL plastic tube. The mixture was centrifuged at 13,000 rpm, afterwards 450 μL of the organic phase were transferred into a GC vial. The organic phase was evaporated in a heat block at 90 °C for 30 min. The residue was dissolved in 50 μL N,O-Bis(trimethylsilyl)trifluoroacetamide containing 1 % trimethylchlorosilane. Prior to transfer into glass inserts the mixture was heated 5 min at 90 °C. The samples were analyzed by GC-MS (Table 18).

[0767] Table 18. GC-MS parameters

System	Agilent 6890 N GC, 04 emStat6 n Gi 701EA E.02.01.1177
Column	DB23 30 m x 25 μm x 25 μm Pressure = 11.50 psi; Flow = 0.6 ml/min
Inlet	Hester = 250°C; Pressure = 11.74 psi; Total Flow {He} = 11.1 ml/min
Carrier	He @ 29 cm ³ /sec, 11.60 psi
Signal	Data rate = 2 Hz/0.1 min
Oven	150°C for 1 min Ramp 12°C/min to 220°C, hold 3 min Ramp 35°C/min to 300°C, hold 4 min
Injection	Splitless, 250°C
Detector	Initial strain screening and first 6 cM cal triplicate: HP 5973 MSD in SIM mode {m/z: 205.0, 297.3 and 387.3}, SPV4SS/SPV49G alcohol quantification: HP 5973 MSD in SIM mods {m/z: 284.0 and 297.5}, 100 msec Dwell, EMV mode: Gain factor 1, 2.4 min solvent delay, 3.09 cycles/sec
Sample	Injection volume = 1 μL

[0768]

[0769] Lipid analysis

[0770] Total lipid composition was based on modified procedures by Moss et al. (1982) and Yousuf et al (2010). The pelleted cells (in 1.5 mL plastic tubes), usually about 10 mg to 80 mg, were resuspended in methanol containing 5 % (w/w) of sodium hydroxide. The alkaline cell suspension was transferred into a 1.8 mL glass crimp GC-vial. The mixture was heated for 1 h in the heat block at 90 °C. Prior to acidification with 400 μL 2.5 N HCl, the vial was allowed to cool to room temperature. 500 μL chloroform containing 1 mM methyl heptadecanoate were added and the mixture was shaken vigorously, then both aqueous and organic phase were transferred into a 1.5 mL plastic tube. The mixture was centrifuged at 13,000 rpm, afterwards 450 μL of the organic phase was transferred into a new 1.8 mL glass screw-cap GC-vial. After cooling to room temperature residual fatty acid methyl esters and free fatty acids were dissolved and derivatized in methanol containing 0.2 M TMSH (trimethylsulfonium hydroxide) (Table 19).

Table 19. GC-MS parameters

System	Agilent 8890 GC, ChemStation Rev. B.03.02 (341)
Column	1&W 08-23 30 m x 25 mm x 25 μ m Pressure = 16 psi; Flow = 0.9 ml/min; Run Time = 14.4 min
Met	Heater = 240°C; Pressure = 16 psi; Total Flow (He) = 31.4 ml/min
Carrier	$\frac{3}{4}$ @ 1 ml/min, 9 psi, 35 cm/sec
Signs!	Data rate = 2 Hz/0.1 min
Oven	150°C for 1 min Ramp 12°C/min to 220°C, hold 3 min Ramp 35°C/min to 240°C, hold 6 min Equilibration Time: 2 min
Injection	Split, 240°C Split ratio - 30:1; 29.1 ml/min
Detector	FID 240°C H ₂ # 35.0 ml/min, Air @ 350 ml/min;; Electrometer (Lit Offset) @ 2.0 pA
Sample	injection volume = 1 μ l

Example 10: Production of Z11-14Acid in *Yarrowia lipolytica*

[0771] Background and Rationale

[0772] *Yarrowia lipolytica* was engineered to produce Z11-14Acid, the precursor to target *Lepidoptera* pheromone Z11-14Ac.

[0773] A library of 73 desaturases was chosen to target potential pheromones including Z11-14Ac, Z7-12Ac, Z9E12-14Ac, E8E10-C12OH and Z9E11-14Ac. All desaturases were tested in the H222 APAAAF (SPV300) background.

[0774] Eleven desaturases were identified from literature to have A11 activity (DST001-DST009, DST030, and DST039, Table 20). All desaturases were screened by feeding either methyl palmitate (C16), methyl myristate (C14), or methyl laurate (C12) as substrate, and full product profiles were determined by GC analysis.

[0775] The resulting activity of the purported A11 desaturase library, and other desaturases shown to produce A11 compounds, specifically Z11-14Acid, is discussed.

Table 20. Desaturases discussed in Example 10

Enzyme Code	Organism of origin	GenBank Accession
DST001	<i>Argyrotaenia velutinana</i>	AF416738
DST002	<i>Spodoptera litura</i>	AGH12217.1
DST003	<i>Sesamia inferens</i>	AH21943.1

Enzyme Code	Organism of origin	GenBank Accession
DST004	<i>Manduca sexta</i>	CAJ43430.2
DST005	<i>Ostrinia nubilalis</i>	AF441221
DST006	<i>Helicoverpa zea</i>	AAF81787.1
DST007	<i>Choristoneura rosaceana</i>	AF545481
DST008	<i>Drosophila melanogaster</i>	AJ271414
DST009	<i>Spodoptera littoralis</i>	AY362879
DST030	<i>Lampronia capitella</i>	ABX71630.1
DST039	<i>Amyelois transitella</i>	NP_01299594.1

[0776] Results

[0777] Up to 69 mg/L Z11-14Acid production was observed when feeding 2 g/L methyl myristate to the desaturase library (Figure 41). The current best desaturase, *Helicoverpa zea* (*H_z*) DST (SPV459, encoded by SEQ ID NO: 54), in addition to desaturases DST001 through DST007, DST030 and DST039, produce some amount of Z11-14Acid ranging from 16 mg/L to 69 mg/L. DST001 (*A. vehtinana*), DST004 (*M. sexta*), and DST039 (*A. transitella*) are more specific for Z11-14Acid production than Z11-16Acid production, although these desaturases produce ~20 mg/L Z11-14Acid. Strains producing higher Z11-14Acid titer also produced Z9-14Acid from the methyl myristate substrate at 20-30 mg/L, which was reduced compared to the negative control SPV298. The C14-C18 product profile of *H_z* DST (SPV459) compared to SPV298 is shown in Figure 42.

[0778] Proof-of-concept of Z11-14Acid synthesis is shown. Attempts were made to identify enzymes that had improved Z11-16Acid titer or product specificity over *Helicoverpa zea* DST (1.05 g/L Z11-16Acid; 69 mg/L Z11-14Acid). While there were no desaturases that had higher production than *H_z* DST (SPV459), DST003 (SEQ ID NO: 39) had similar production phenotypes to the *H_z*Desat strain, and DST002 and DST005 had similar Z11-16Acid production with reduced Z11-14Acid. The desaturase in DST006 is genetically equivalent to the *H. zea* desaturase expressed in SPV459 and served as a library control. DST006 produced equivalent levels of Z11-16Acid when fed methyl palmitate; however this strain

produced a lower titer of Z11-14Acid on methyl myristate. Genetic variation in strain background may account for the observed difference.

[0779] DST039 (*A. transitella*) was previously screened under different conditions. In rich media, Z11-16Acid production with the native *A. transitella* coding sequence was not observed. The *H. sapiens* optimized sequence was tested and still no activity was observed with the rich medium condition. In this screen, DST039 was tested in nitrogen limited condition with *Hs* optimized sequence and resulted in 235 mg/L production of Z11-16Acid and 21 mg/L Z11-14Acid on the relevant substrates.

[0780] All products from DST008 (*Drosophila melanogaster*) or DST009 (*Spodoptera littoralis*) in the SPV300 background were not observed.

[0781] Summary

[0782] Z11-14Acid production was observed in ten desaturases with titers ranging from 16 mg/L to 69 mg/L (2 g/L methyl myristate fed).

[0783] *H. zea* DST (SEQ ID NO: 54) remained the best Z11-16Acid producer (>1 g/L when fed with methyl palmitate).

[0784] DST003 (*S. inferens*, SEQ ID NO: 39) has the most similar phenotype to *H. zea* DST.

[0785] DST002 (*S. littoralis*) and DST005 (*O. nubialis*) are more specific than *H. zea* DST for Z11-16Acid production (reduced Z11-14Acid production).

[0786] DST001 (*A. velutina*), DST004 (*M. sexta*), and DST039 (*A. transitella*) are more specific than *H. zea* DST for Z11-14Acid production.

[0787] Conclusions

[0788] Z11-14Acid can be produced with the heterologous expression of specific desaturases in *Yarrowia lipolytica* when feeding methyl myristate.

[0789] Multiple copies of desaturase (identical or combination of sequences) are integrated in improved strain backgrounds for increased Z11-14Acid titer, product specificity, and genetic stability.

[0790] Materials & Methods

[0791] Library Generation

[0792] Desaturase sequences were provided to Genscript for codon optimization (*Homo sapiens* expression organism) cloning into pPV266 (XPR2 locus integration vector with TEF promoter and terminator) using PacI/SapI restriction digestion. Lyophilized DNA was provided as well as EPI400 agar stabs. Desaturase constructs are listed in Table 21.

[0793] Constructs were linearized using PmeI restriction enzyme and directly transformed into host strain SPV300. Transformants were verified by check PCR using primers outside of the XPR2 integration junction and within the pTEF promoter.

Table 21. Desaturase constructs

Enzyme Code	Species	GenBank Accession	E. coli SPV	Plasmid pPV
DST001	<i>Argyrotaenia velutinana</i>	AF416738	SPV0609	pPV0300
DST002	<i>Spodoptera litura</i>	AGH12217.1	SPV0610	pPV0301
DST003	<i>Sesamia inferens</i>	AII21943.1	SPV0611	pPV0302
DST004	<i>Manduca sexta</i>	CAJ43430.2	SPV0612	pPV0303
DST005	<i>Ostrinia nubilalis</i>	AF441221	SPV0613	pPV0304
DST006	<i>Helicoverpa zea</i>	AAF81787.1	SPV0614	pPV0305
DST007	<i>Choristoneura rosaceana</i>	AF545481	SPV0615	pPV0306
DST008	<i>Drosophila melanogaster</i>	AJ271414	SPV0616	pPV0307
DST009	<i>Spodoptera littoralis</i>	AY362879	SPV0617	pPV0308
DST030	<i>Lampronia capitella</i>	ABX71630.1	SPV0638	pPV0329
DST039	<i>Amyelois transitella</i>	NP_001299594.1	SPV0647	pPV0338

[0794] Plasmid Digest

[0795] -10 µg of lyophilized DNA was ordered from Genscript. DNA was resuspended in 50 µL water for a final concentration of ~200ng/µL. 10 µL of DNA was mixed with 1.25 µL 10x CutSmart Buffer and 1.25 µL PmeI restriction enzyme (12.5 µL reaction volume). The reaction was incubated in the PCR machine for 1.5 hours at 37°C and heat inactivated at 65°C for 30 minutes.

[0796] Transformation

[0797] SPV300 competent cells were grown by inoculating a YPD culture at 0.001 OD in a baffled flask and growing until 0.5-1.0 OD. Cells were harvested at 800xg and washed with 0.25x volume of Solution 1 from the Zymo Frozen-EZ 'Transformation II Kit for Yeast. Cells were resuspended in Solution 2 at 1000x concentration of the original culture volume and slowly frozen at -80°C while insulated in a styrofoam container (frozen cells may have better transformation efficiency over fresh). 50 µL of cells were first mixed with the 12.5 µL digestion reaction (no cleanup necessary), and then with 500 µL Solution 3. Transformations were incubated for 3 hours at 28°C without shaking, after which the full transformation mixture was plated to appropriate selective agar media. Petri dishes were incubated for 3-4 days before the appearance of colonies.

[0798] Check PCR

[0799] Transformation colonies were picked to 7 µL water in a PCR plate. 5 µL of cells were patched by multichannel to selective omni trays and grown overnight. The remaining 2 µL of cells were microwaved for 2 minutes before adding 15 µL of PCR master mix.

PCR Master Mix	1X reaction
2x Phusion Master Mix (HF Buffer)	7.5 µL
100µM oPV204 (XPR2 locus F)	0.1 µL
100µM oPV195 (pTEF R)	0.1 µL
Water	7.3 µL

PCR Cycle:

Temp.	Time	Cycles
98°C	2 min	1x
98°C	15 sec	30x
64°C	30 sec	
72°C	60 sec	
72°C	5 min	1x
4°C	∞	1x

[0800] Colony Patching

[0801] Positive clones were re-patched to YPD omni trays in 24-well format including assay controls. Omni trays were grown overnight at 28°C and used to inoculate bioassay cultures.

[0802] Bioassay

[0803] Positive transformants (N=4 clones per construct) were inoculated into 1mL YPD in a 24-well culture plate and incubated for 24 hours in the Infors HT Muiitron Pro at 28°C with 1000 rpm shaking. Cells were pelleted at 800xg and resuspended in S2 media with 5 µL substrate (~2 g/L concentration). 250 µL of culture was sampled into glass crimp top vials after 48 hours of bioconversion.

[0804] S2 Media

[0805] 2 g/L Yeast Extract, 1 g/L Peptone, 0.1M Phosphate buffer, 1.7g/L YNB w/o aa,NH₄, 60 g/L Glucose, 5 g/L Glycerol

[0806] GC Sample Processing

[0807] Front Inlet/Detector:

System 6890 GC, ChemStation Rev. B.03.02 (341)

Column J&W DB-23 30 m x 25 mm x 25 µm

Run Time = 14.4 min

Inlet Heater = 240°C; Pressure = 9.0 psi; Total Flow {H₂} = 36.2 mL/min

Carrier H₂ @ 1.0 mL/min, 9.0 psi, 35 cm/sec

Signal Data rate = 2 Hz/0.1 min

Oven 150°C for 1 min

Ramp 12°C/min to 220°C, hold 3 min

Ramp 35°C/min to 240°C, hold 4 min

Equilibration Time: 2 min

Injection Split, 240°C

Split ratio -- 30:1; 29.1 mL/min

Detector FID, 240°C

H₂ @ 35.0 mL/min, Air @ 350 mL/min

Electrometer {Lit Offset} @ 2.0 pA

Sample Injection volume = 1 μ L,

[0808] Back Inlet/Detector:

System 6890 GC, ChemStation Rev. B.03.02 (341)

Column J&W DB-23 30 m x 25 mm x 25 μ m

Run Time = 14.4 min

Inlet Heater = 240°C; Pressure = 9.8 psi; Total Flow {H2} = 40.1 mL/min

Carrier H2 @ 1.1 mL/min, 9.8 psi, 38 cm/sec

Signal Data rate = 2 Hz/0.1 min

Oven 150°C for 1 min

Ramp 12°C/min to 220°C, hold 3 min

Ramp 35°C/min to 240°C, hold 4 min

Equilibration Time: 2 min

Injection Split, 240°C

Split ratio - 30:1; 32.3 mL/min

Detector FID, 240°C

H2 @ 35.0 mL/min, Air @ 350 mL/min

Electrometer {Lit Offset} @ 2.0 pA

Sample Injection volume = 1 μ L

[0809] TMSH: Trimethylsulfonium Hydroxide (0.2mol/L in Methanol) - VWR **TCT1576-025ML**

Example 11: Production of Z11-160H in *Yarrowia lipolytica* using increased copy number of or engineered variant fatty alcohol forming **fatty acyl-CoA reductases (FARs)**

[0810] Background and Rationale

[0811] Engineering the microbial production of unsaturated insect fatty alcohols requires the functional expression of a synthetic pathway. One such pathway comprises a transmembrane desaturase to mediate the conversion of fatty acyl-CoA into regio- and stereospecific

unsaturated fatty acyl-CoA. An alcohol-forming reductase (FAR) complements the synthetic pathway to produce the respective fatty alcohol

[0812] In some insect species the respective FAR enzymes are activated via site specific dephosphorylation (Jurenka, R. & Rafaeli, A. Regulator}' Role of PBAN in Sex Pheromone Biosynthesis of Heliothis Moths. Front. Endocrinol. (Lausanne). 2, 46 (2011); Gilbert, L. I. Insect Endocrinology. (Academic Press)). Phosphorylation of heterologous!} expressed FAR enzymes in *Y. lipolytica* may lead to inactivation, and result in low fatty alcohol titers. A bioinformatic approach was used to predict phosphorylated residues within HaFAR.

[0813] Alanine substitution of serine and threonine residues has been shown to abolish phosphorylation (Shi, S., Chen, Y., Siewers, V. & Nielsen, J. Improving Production of Malonyl Coenzyme A-Derived Metabolites by Abolishing Snf1-Dependent Regulation of Accl. mBio 5, (2014)). Thus, in addition to increasing FAR gene copy number, the impact of alanine substitutions of several serine residues of an HaFAR enzyme (HaFAR amino acid sequence set forth in SEQ ID NO: 41 and HaFAR nucleotide sequence set forth in SEQ ID NO: 90) on Z11-160H titer was tested.

[0814] Approach

[0815] A second copy of human codon-optimized *H. armigera* FAR gene (HaFAR) was introduced into the chromosome of the Z11-160H producer parent strain. In parallel, the effects of introducing a copy of a mutated *H. armigera* FAR gene variant towards Z11-160H production improvement were also explored. Seven mutated variants were designed with the aim to increase FAR activity by potentially relieving the requirement for dephosphorylation (as observed in some insect species). To this end, several potential phosphorylation sites within the amino acid sequence of the *H. armigera* FAR were identified, and replaced with alanine.

[0816] Results

[0817] Determination of phosphorylated sites in HaFAR

[0818] The server at world wide web address: cbs.dtu.dk/services/NetPhos/ () predicts potential phosphorylation sites based on a database (world wide web address: phospho.elm.eu.org/about.html) of experimentally verified phosphoproteins based on 17 kinases: ATM, CKI, CKII, CaMKII, DNAPK, EGFR, GSK3, INSR, PDKA, PKB, PKC, RSK, SRC, cdc2, cdk5 and p38MAPK.

[0819] The software program predicted 22 serine, 11 threonine and 10 tyrosine as potential phosphorylation sites in *H. armigera* FAR (Figure 43).

[0820] Next, a tailored prediction program to determine phosphorylation sites of the *H. armigera* FAR upon expression in yeasts was applied (world wide web address: cbs.dtu.dk/services/NetPhosYeast/; Biom, N., Gammeltoft, S. & Brunak, S. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. *J. Mol. Biol.* 294, 1351-1362 (1999)). Since in yeast no tyrosine kinases have been identified yet (Ingrell, C. R., Miller, M. L., Jensen, O. N. & Blom, N. NetPhosYeast: prediction of protein phosphorylation sites in yeast. *Bioinforma.* 23, 895-897 (2007)), the yeast-specific software only considers serine and threonine as potential phosphorylation sites. It was striking that both programs predicted the same 11 serine residues to be phosphorylated. In contrast, the yeast specific analysis tool did not predict any phosphorylated threonine residues (Figure 44).

[0821] In a first experiment a small library consisting of 7 Ser to Ala point mutants was tested (Table 22). Three predicted phosphorylation sites were not considered for mutagenesis (position Ser301, Ser386, Ser416 scored barely above the threshold). For the remaining 7 serine residues, alanine substitutions were introduced.

Table 22: Serine to alanine mutant library

<i>Parent strain</i>	<i>Additional Enzyme</i>	<i>Strain #</i>
<i>Y. lipolytica</i> H222ΔPΔΔF <i>xpr2::pTEF-HZ_Z11_desat_Hs-tLIP2-pTAL1-HA_FAR-tXPR2_loxP</i>	HaFAR	SPV916
<i>Y. lipolytica</i> H222ΔPΔΔF <i>xpr2::pTEF-HZ_Z11_desat_Hs-tLIP2-pTAL1-HA_FAR-tXPR2_loxP</i>	HaFAR S60A	SPV909
<i>Y. lipolytica</i> H222ΔPΔΔF <i>xpr2::pTEF-HZ_Z11_desat_Hs-tLIP2-pTAL1-HA_FAR-tXPR2_loxP</i>	HaFAR S195A	SPV910
<i>Y. lipolytica</i> H222ΔPΔΔF <i>xpr2::pTEF-HZ_Z11_desat_Hs-tLIP2-pTAL1-HA_FAR-tXPR2_loxP</i>	HaFAR S298A	SPV911
<i>Y. lipolytica</i> H222ΔPΔΔF <i>xpr2::pTEF-HZ_Z11_desat_Hs-tLIP2-pTAL1-HA_FAR-tXPR2_loxP</i>	HaFAR S378A	SPV912
<i>Y. lipolytica</i> H222ΔPΔΔF <i>xpr2::pTEF-HZ_Z11_desat_Hs-tLIP2-pTAL1-HA_FAR-tXPR2_loxP</i>	HaFAR S394A	SPV913

Parent strain	Additional Enzyme	Strain #
<i>Y. lipolytica</i> H222APAAAF <i>xpr2::pTEF-HZ_Zll_desat_Hs-tUP2-pTALI-HA_FAR-tXPR2JoxP</i>	HaFAR S418A	SPV914
<i>Y. lipolytica</i> H222APAAAF <i>xpr2::pTEF-HZ_Zll_desat_Hs-tUP2-pTALI-HA_FAR-tXPR2_loxP</i>	HaFAR S453A	SPV915

[0822] The HaFAR library was custom synthesized, and subcloned into plasmid pPV234 for expression under TEF promoter, and XPR2 terminator at the AXP locus. Linearized constructs were transformed into strain *Y. lipolytica* H222APAAAF SPV603 which expresses *Il. zea* Zll desaturase (SEQ ID NO: 54) combined with the *Il. armigera* FAR (SEQ ID NO: 41). This approach determined the impact of a second copy e.g. protein expression in addition to the impact of the individual point mutations.

[0823] Four individual clones of positive integrants were tested. Cultivation was performed in 24 well plates. Briefly, 2 mL YPD was inoculated from patches of individual clones and incubated for 24h at 28°C, 1000 rpm. After 24h OD600 was measured and the cells were centrifuged at 1000 rpm (Table 23). The cell pellets were resuspended in 1 mL S2 media and 10 g/L methyl palmitate was added. The cells were incubated for 18h at 28°C, 1000 rpm. Cultivations were stored at -20°C until analyzed. Extraction and analysis was performed according to previously established standard protocols using GC-FID.

Table 23. OD600 measurement of the 24 well plate cultivations (two plates were cultivated in parallel). Each individual well was measured as duplicates upon 1:10 dilution after 24h cultivation in YPD. Calculated OD600 values are given.

				HaFAR S195A Clone 2	HaFAR S195A Clone 2	HaFAR S195A Clone 3	HaFAR S195A Clone 3	HaFAR S298A	HaFAR S298A	SPV603	SPV603		
				HaFAR-GFP	HaFAR-GFP	HaFAR-GFP	HaFAR-GFP	HaFAR-GFP	HaFAR-GFP	HaFAR-GFP	HaFAR-GFP		
OD600	1	2	3	4	5	6	7	8	9	10	11	12	
A	15.392	16.16	17.376	17.976	17.56	18.272	14.188	14.774	14.774	15.708	17.14	17.24	plate2
B	16.62	17.172	18.632	18.596	18.894	18.088	16.082	15.38	16.04	16.03	16.572	16.584	plate2
C	16.978	16.952	18.154	18.224	18.678	19.384	16.062	14.858	15.498	15.58	18.14	17.528	plate2
D	16.596	17.23	17.668	18.842	18.39	18.792	20.678	16.566	16.094	15.904	1.262	1.152	plate2

	HaFAR- GFP	HaFAR- GFP	HaFAR- GFP	HaFAR S60A	HaFAR S195A Clone 2	HaFAR S195A Clone 2	HaFAR S195A Clone 3	HaFAR S195A Clone 3	HaFAR S298A	HaFAR S298A	SPV603	SPV603	
OD600	1	2	3	4	5	6	7	8	9	10	11	12	
E	17.53	17.156	16.78	15.776	17.398	16.736	16.154	15.514	16.748	16.792	18.26	17.322	plate 1
F	18.336	17.928	16.392	15.33	20.018	19.37	15.06	14.266	17.522	17.076	16.724	16.522	plate 1
G	17.16	17.224	15.984	16.194	17.878	17.626	15.372	15.15	16.688	17.022	17.742	16.942	plate 1
H	16.258	16.12	16.134	16.236	16.808	16.176	15.382	14.51	15.456	15.394	7.664	7.956	plate 1
	HaFAR S378A	HaFAR S378A	HaFAR S394A	HaFAR S394A	HaFAR S418A	HaFAR S418A	HaFAR S453A	HaFAR S453A	HaFAR S453A	HaFAR S453A	SPV603	SPV603	
OD600	1	2	3	4	5	6	7	8	9	10	11	12	
A	15.842	15.97	15.31	16.278	16.088	16.302	16.074	15.502	15.34	15.742	16.89	16.062	plate 2
B	16.3	17.306	16.064	16.5	16.64	16.344	15.69	15.598	15.434	15.248	16.674	16.476	plate 2
C	17.088	17.146	15.966	15.472	16.508	16.548	15.82	15.216	15.796	16.098	16.81	17.246	plate 2
D	17.512	17.198	15.15	14.168	16.094	13.93	15.642	15.078	16.77	16.242	0.9	0.864	plate 2
E	16.446	17.014	15.762	16.536	17.188	17.372	16.164	15.892	15.8	16.422	17.998	17.814	plate 1
F	16.982	11.196	16.098	13.148	16.1	12.348	16.688	10.232	15.596	13.068	18.456	16.098	plate 1
G	15.4	15.568	15.236	16.348	15.504	15.824	14.922	15.622	15.11	15.576	17.142	17.672	plate 1
H	17.088	16.63	0.968	1.006	13.82	12.49	15.826	15.27	17.132	16.166	1.082	0.932	plate 1

[0824] As shown in Figure 45, strains expressing a second HaFAR copy encoding a point mutation, **HaFAR-GFP** or **HaFAR*** (where * indicates a second copy of the parental HaFAR enzyme in addition to the existing copy of the parental strain). The copy increased fatty alcohol titers when compared to the parental strain (SPV603). The introduction of HaFAR (S60A), HaFAR (S298A), HaFAR (394A), HaFAR (S453A) was neutral or showed slight increases when compared to the HaFAR double copy strain. In contrast, expression of HaFAR (S418A), and HaFAR (S195A) resulted in a distinct increase of Z11-160H titers.

[0825] Overall, these results suggest that residue 195 and 418 are important for increasing HaFAR activity in *Y. lipolytica*. Their substitutions to alanine may inhibit phosphorylation; therefore, a dephosphorylation mechanism was not required for their enhanced activity.

Among other explanations, the activating effect of the serine to alanine mutation could be from improved protein folding, increased stability or higher protein expression.

[0826] In addition, several fatty acid species were quantified to determine whether the increased Z11-16OH production led to Z11-16Acid depletion. The standard deviations for some samples were very high (Figure 46). In all samples saturated and Z11-16Acid was detected. Quantification of the respective product intermediate Z11-16Acid showed increased consumption for the mutant strains SPV910 and SPV914 expressing HaFAR S195A and HaFAR S418A.

[0827] Chromosomal integration of an additional HaFAR into the parent strain increased the Z11-16OH titer from ~20 mg/L to 40 mg/L in shake flask experiments.

[0828] When HaFAR (Ser195Ala) or HaFAR (Ser418Ala) was introduced, Z11-16OH titer increased from ~40 mg/L to ~120 mg/L or ~80 mg/L, respectively in shake flask experiments.

[0829] The pathway intermediate Z11-16Acid for mutant strains SPV910 harboring HaFAR (Ser195Ala), and SPV914 harboring HaFAR (Ser418Ala) accumulated at ~100mg/L less than the parent strain SPV603.

[0830] Conclusions

[0831] The addition of another *H. armigera* FAR gene into Z11-16OH producer strain marginally increased titer. Introduction of mutated FARs, however, significantly improved Z11-16OH by up to ~7X. This suggests that *Y. lipolytica* phosphorylates FAR enzymes, and that FAR dephosphorylation is a bottleneck for its full activity. The designed mutations in HaFAR may relieve its requirement for dephosphorylation to convert Z11-16Acid into Z11-16OH. It is also possible that the designed mutations improved FAR activity through a dephosphorylation-independent mechanism. Shake flask experiments suggest a direct correlation between biomass, time and fatty alcohol titers.

[0832] Second generation strains are created for further improvement in Z11-16OH by, for example, eliminating lipid storage pathways (e.g. diacylglycerol acetyltransferase (DGAT) gene deletions), and/or eliminating byproduct (hydroxyacid, diacid) pathways.

[0833] Materials & Methods

[0834] Marker rescue of SPV603

[0835] 30 mL of CM minus uracil were inoculated with SPV603 in a 250 mL baffled shake flask. The culture was incubated in a bench top shaker at 250-300 rpm and 28°C. The following morning the OD600 of the culture was measured. Cells were harvested at OD600:

0.6. Cells were pelleted in a falcon tube (800xg, 5 min). Supernatant was removed and wash in ½ volume (15 mL) of Solution 1 from the Zymo kit. Cells were pelleted again (800xg, 5 min) and resuspended in 200 µl of Solution 2. A 50 µl aliquot was used directly in a 1.7 mL Eppendorf tube. Remaining aliquots were stored at -80°C. 10 µl of DNA (1-2 µg) was added and gently mixed with cells. 500 µl of Solution 3 was added and mixed gently. Transformation mix was incubated for ≥3 hours in 28°C plate incubator subsequently washed with 2 mL deionized water (autoclaved). Recovery was performed in 2 mL YPD o/h at 28°C. The transformation mix was plated directly on selection plate. Clones were picked and repatched on URA minus FOA 0.1% and YPD plates. URA removal was confirmed using standard PCR protocols.

[0836] Construction of HaFAR integration cassette

[0837] The HaFAR library was custom synthesized with human codons (Genscript), and subcloned into plasmid pPV234 using the restriction site SpeI and NotI for expression under TEF promoter, and XPR2 terminator at the AXP locus. Linearized constructs were transformed into strain *Y. lipolytica* H222APAAAF SPV603 which expresses *H. zea* Z11 desaturase (SEQ ID NO: 54) combined with the *H. arrnigera* FAR (SEQ ID NO: 41). Amino acid sequences for the variant FARs are set forth in SEQ ID NOs: 42-48. Nucleotide sequences for the variant FARs are set forth in SEQ ID NOs: 83-89.

[0838] Cultivation of HaFAR mutant library in 24 well plates

[0839] In a first round four individual isolate from each transformation was tested. Cultivation was performed in 24 well plates. 2 mL YPD was inoculated from patches of individual clones and incubated for 24h at 28°C, 1000 rpm. After 24h OD600 was measured and the cells were centrifuged at 1000 rpm. The cell pellets were resuspended in 1 mL S2 media and 10 g/L methyl palmitate was added. The cells were incubated for 24h at 28°C, 1000 rpm. Cultivations were stored at -20°C until analyzed. Next, four clones of the best performing positive integrant were tested. Cultivation was performed in 24 well plates. 2 mL YPD was inoculated from patches of individual clones and incubated for ~28h at 28°C, 1000 rpm. After 28h OD600 was measured and the cells were centrifuged at 1000 rpm. The cell pellets were resuspended in 1 mL S2 media and 10 g/L methyl palmitate was added. The cells were incubated for 18h at 28°C, 1000 rpm. Cultivations were stored at -20°C until analyzed.

[0840] Cultivation of HaFAR mutant library in shake flasks

[0841] Shake flask experiment 1: Time-course analysis of fatty alcohol and fatty acid titers during shake flask cultivation

[0842] In a first step a shake flask experiment of the respective strains was performed to analyze fatty alcohol and fatty acid formation over time. The best performing clone of the strains expressing HaFAR, HaFAR SI95A and HaFAR S418A were tested. 10 mL YPD was inoculated from patches of individual clones and incubated for 24h at 28°C, 250 rpm in a 125 mL shake flask. Next, 25 mL YPD were inoculated with 5 mL starter culture in 500 mL shake flasks and incubated for 24h at 28°C, 250 rpm. The cells were harvested and the pellets were resuspended in 15 mL S2 media and 10 g/L methyl palmitate was added. OD600 was measured and subsequently methyl palmitate was added. The cells were incubated for 72h at 28°C, 1000 rpm. 4 x 0.5mL samples were taken every 24h and stored at -20°C until analyzed according to a previously established standard protocol (Figure 47 and Figure 48). To improve sampling and reduce the standard deviation, samples were transferred directly into GC crimp vials and stored until analyzed.

[0843] The OD600 for the strains were: SPV910 - 10.2, SPV914 - 11.5 and SPV916 - 12.3.

[0844] Shake flask experiment 2: Impact of increased biomass on bioconversion

[0845] The time-course experiment revealed a decrease in fatty alcohols over time. Thus, sampling was reduced to 20h. In previous 24 well plate bioconversion experiments the measured biomass was ~ 2x higher compared to the shake flask experiment. Next a shake flask experiment of the respective strains was performed to analyze the impact of biomass on fatty alcohol titers. The overall incubation time was reduced and the biomass was increased during bioconversion phase. The best performing clone of the strains expressing HaFAR SI95A and HaFAR S418A were tested. 20 mL YPD was inoculated from patches of individual clones and incubated for 28h at 28°C, 250 rpm in a 500 mL shake flask. The cells were harvested and the pellets were resuspended in 10 mL S2 media and 10 g/L, OD600 was measured and subsequently methyl palmitate was added. The cells were incubated for 20h at 28°C, 1000 rpm. 4 x 0.5mL samples were taken and analyzed according to a previously established standard protocol (Figure 49).

[0846] The OD600 for the strains were: SPV910 - 24.9 and SPV914 - 24.7.

[0847] Metabolite extraction

[0848] Cell pellets were resuspended with 500 µL 5% NaOH (in methanol) then heated for 1 hour at 85°C. Samples were cooled down and then acidified by adding 400 µL 5N HCl. Next, 500 µL chloroform (containing 1mM C17:0 heptadecanoate internal standard) were added to samples. Samples were mixed vigorously then spun down for 2 minutes at 13,000RPM using a table top centrifuge. 450 µL chloroform were transferred to a new vial

then evaporated at 85°C for ~ 15 minutes. Samples were then resuspended in 50 µL BSTFA (and were now ready for GC analysis). After analysis of the fatty alcohols samples were diluted ~ 1:10 and reran on the GC to improve peak separation of the fatty acid peaks.

[0849] Quantification

[0850] All quantifications were based on the concentration of the internal standard. The concentration of the internal standard C17ME is 1 mM. The final concentration of fatty alcohols as well as fatty acids were calculated based on the effective carbon number compared to the internal standard.

Example 12: Production of fatty alcohol and **fatty acid** in *Yarrowia lipolytica* using second generation strains engineered to eliminate lipid storage pathways or using additional variant fatty alcohol forming fatty **acyl-CoA** reductases (**FARs**)

[0851] The impact of an endogenous diacyl glycerol acyltransferase deletion selected from the group consisting of YALI0E32791g (DGA1) and YALI0D07986g (DGA2) was tested. Each dga gene was deleted individually in the strain SPV735 (AURA, ALeu, leu2::pTEF-HZ_Z11_desat_Hs-tXPR2_loxP). Subsequently, the individual selection marker in each deletion strain SPV957 (Adgal, ALeu, leu2::pTEF-HZ_Z11_desat_Hs-tXPR2_loxP) and SPV959 (Adga2 AURA, leu2::pTEF-HZ_Z11_desat_Hs-tXPR2_loxP) according to standard procedures was performed. The resulting strain SPV1053 (Adgal AURA, ALeu, leu2::pTEF-HZ_Z11_desat_Hs-tXPR2_loxP) and SPV1054 (Adga2 AURA, ALeu, leu2::pTEF-HZ_Z11_desat_Hs-tXPR2_loxP) were used to transform HaFAR and HaFARS195A. The formation of fatty alcohols compared to the strain SPV603 was tested in shake flasks (Figure 50 and Figure 51). The results in shake flasks over time suggest that the deletion of each individual dga gene improves fatty alcohol formation and decreases fatty acid storage.

[0852] Time-course analysis of fatty alcohol and fatty acid titers during shake flask cultivation

[0853] A copy of the enzyme HAFAR (SEQ ID NO: 41) or HaS195A (SEQ ID NO: 43) was introduced into the strain SPV1053 (Adgal AURA, ALeu, leu2::pTEF-HZ_Z11_desat_Hs-tXPR2_loxP) and SPV1054 (Adga2 AURA, ALeu, leu2::pTEF-HZ_Z11_desat_Hs-tXPR2_loxP), each of which expresses H. zea Z11 desaturase (SEQ ID NO: 54) and is deleted for either DGA1 or DGA2 diacylglycerol acyltransferase.

[0854] Cultivation was performed as biological triplicates in shake flasks. The starting culture for each strain was grown in 50 mL YPD in 250 mL shake flask for 28h at 250 rpm,

28°C. Cells were harvested via centrifugation at 800 g for 5 min at room temperature and resuspended in 30 mL S2 media. Cell suspensions were normalized to OD600: ~8. Each starting culture was split in three individual 125 mL shake flasks. 10 g/L methyl palmitate was added. Cultures were incubated for 72h. Sampling was performed every 24h and OD600 for each shake flask was measured. Figure 50 and Figure 51 show fatty alcohol titers and fatty acid titers, respectively, for the time course experiments.

[0855] Extraction of cultivation samples. 0.5 mL of each sample were harvested directly into crimp vials. The crimp vials were centrifuged at 800 g for 5 min. The supernatant was removed and the samples were sealed and stored at -20°C until analysis. Samples were resuspended in 500 µL methanol containing 5% KOH and incubated for 60 min at 65°C to 85 °C. 200 µL 5N HCL was added to each crimp vial after cool down step. 600 µL chloroform containing 1 mM C17Me were added and sealed again. Samples were mixed and centrifuged. 500 µL of the chloroform was transferred to a new GC vial and dried to completeness at 85 °C for 30 min. Samples were resuspend in 100 µL BSTFA and incubated at room temperature for 1h. Samples were analyzed according to standard protocol using gas chromatography.

[0856] Fatty alcohol forming fatty acyl-CoA reductase library screening of new strains in 24 well plates

[0857] A single copy of each respective FAR enzyme from Table 24 was introduced into the strain SPV1054 (Adga2 AURA, Δ*i.e.a.*, *leu2::pTEF-HZ_Z11_desat_Hs-tXPR2_loxP*) expressing *H. zea Z11* desaturase (SEQ ID NO: 54) and deleted for DGA2 diacylglycerol acyltransferase.

[0858] Cultivation was performed as biological quadruplicates in 24 well plates. 2 mL YPD were inoculated from a patch of each individual transformant. 24 well plates were incubated for 28h at 250 rpm, 28°C. Cells were harvested via centrifugation at 800 g for 5 min at room temperature. Cells were resuspended in 1 mL S2 + 60 g/L glycerol and 10 g/L methyl palmitate was added. Cell were incubated for 96h at 1000 rpm, 28°C. Figure 52 and Figure 53 show fatty alcohol titers and fatty acid titers, respectively, for the 24 well plate screening experiments.

[0859] Extraction of cultivation samples. 0.5 mL of each sample were harvested directly into crimp vials. The crimp vials were centrifuged at 800 g for 5 min. The supernatant was removed, and the samples were sealed and stored at -20°C until analysis. Samples were resuspended in 500 µL methanol containing 5% KOH and incubated for 60 min at 65°C to 85 °C. 200 µL 5N HCL was added to each crimp vial after cool down step. 600 µL chloroform

containing 1 mM C17Me were added and sealed again. Samples were mixed and centrifuged. 500 uL of the chloroform was transferred to a new GC vial and dried to completeness at 85 °C for 30 min. Samples were resuspend in 100 uL BSTFA and incubated at room temperature for 1h. Samples were analyzed according to standard protocol using gas chromatography.

Table 24. New FAR enzyme library

Organism	Enzyme ID	Gen ID
<i>Agrotis segetum</i>	FAR027	AID66655.1
<i>Euglena gracilis</i>	FAR028	GU733919
<i>Ostrinia palustralis</i>	FAR029	M1QSS3
<i>Ostrinia latipennis</i>	FAR030	M1RG73
<i>Ostrinia nubilalis</i>	FAR031	FJ807735
<i>Ostrinia nubilalis</i>	FAR032	FJ807736
<i>Ostrinia zealis</i>	FAR033	M1QSS9
<i>Yponomeuta evonymellus</i>	FAR034	GQ907232
<i>Yponomeuta padellus</i>	FAR035	GQ907235
<i>Yponomeuta rorellus</i>	FAR036	GQ907234
<i>Tyto alba</i>	FAR037	JN638549
<i>Ostrinia scapularis</i>	FAR038	EU817405
<i>Spodoptera exigua</i>	FAR039	KR781121.1
<i>Spodoptera littoralis</i>	FAR040	KR781120
<i>H. virescens</i>	FAR041	EZ407233
<i>H. subflexa</i>	FAR042	AFD04726.1
<i>H. amigera</i>	FAR043	AKD01773.1
<i>H. assaulta</i>	FAR044	AFD04727.1

[0860] Additional FAR variants and additional bacterial FAR enzymes are listed in Table 25 and Table 26, respectively. These FAR enzymes are tested as described above for fatty alcohol and fatty acid production.

Table 25. New FAR Enzyme library with phosphorylation point mutants

Amino acid mutations	Enzyme ID
HaFAR S12A	pFAR055
SIFAR S10A	pFAR056
SIFAR S13A	pFAR057

Amino acid mutations	Enzyme ID
SIFAR S61A	pFAR058
SIFAR S104A	pFAR059
SIFAR S310A	pFAR060
SIFAR S314A	pFAR061
SIFAR S419A	pFAR062

Table 26. Additional bacterial FAR enzyme library

Organism	Gen ID
Spongibacter tropicus	WP_022959477.1
Oleiphilus sp. HI0086	KZY30886.1
Marinobacter lipolyticus	WP_012138772.1
Marinobacter antarcticus	WP_072799080.1

SEQUENCE LISTING

SEQ ID NO: 1	Agrotis segetum FAR_s. cerevisiae codon opt
	<p>ATGCCAGT TTTGACTTCTAGAGAA.GATGAAAAGTTGT CAGTTCAGAATTTTACGCTGGTA .AATCTATCTTCGTTACAGGTGGTACTGGTTTCTTGGGTAAAGTTTATTGAAAAGTTGT? GTACT GTTGTCCAGATA TTGATAAAATCTATATGTTAATTAC-AGAAAAGAAAAATTGTCT ATTGATGAAAGAATGTC.AAA.GTTCTTGGATGATCCATTATTTTCTAGA.TTGAAGGAAGAAA GACCTGGTGACTTGGAAGAAGATTGTTTGTATTCCAGGTGACATTACAGCTCCAAATTTGGG TTTATCAGCAGAAAACGAAAGAATTTGTAGAAAAAGTTTCTGTTATTATTAAATTCAAGCT GCAACTGTAAAGTTTAA.TGAACCA.TTGCCAA.TCGCTTGAAGATTAATGTTGAAGGTACAA GAATGTTGTTGGCA TTGTCTAGAAGAATGAAGAGAATCGAAGTTTATTATCATATTTCTAC TGCTTACTCAAATGCATCTTCAGATAGAA TCGTTGTTGATGAAATCTTGATCCAGCTCCA GCAGATA.TGGATCAAGTTTA.CCAATTGGTTAAAGA.TGGTGTTACAGAA.GAAGAAA.CTGAAA GATTGTTGAACGGTTTGCCAAACACTTACACTTTTACTAAGGCTTTGACAGAACATTTGGT T GCAGAACATCAAACATA.CGT CCAACTATCATCATCA.GACCATCTGTTGTTGCTTCAA.TT AAAGATGAACCAATCAGAGGTTGGTTATGTA^TTGGTTTGGTGCTACAGGTATCTCTGTTT TTACTGCAAAGGTTTGAACA.GAGTTTGTGGGTAAAGCTTCAAACA.TCGTTGATGTTAT CCCAGTTGATTACGTGCAAAATTTGGTATTGTTGCTGGTGCAAAATCTGGTGGTCAAAAA TCAGATGATTAATAjGATCTATIACTGTTGTTCTTCAGATTGTiACCCAGTTACTTTGA%GA AAATTATTAAGAGTTTACTGAAGATACTATTAATAATAAGTCTCATATTATGCCATTGCC AGGTTGGTTCGTTTTTACTA%GTACA%GTGGTTGTTGACATTGTT/ %ACTATTATTTTCAA</p>

	<p>ATGTTACCAATGTA TTTGGCTGATGTTTACAGA GTTTTGACAGGTA AAA TCCCAA GATACA TGAAGTTGCATCATTTSGTTATTCAAACAAGATTGGGTATCGATTTCCTTACTTCTCATT ATGGGTTATGAAG7\CAGATAGAGTTAG7\GAATTATTCGGTTCTTTGTC7\TTGGCAG7^%G CA TATGTTTCATGTGA TCCA TCTTCAATCGATTGGACA GATTA TTTGCAA TCATA CTGT? ACGGTGT TAGAAGAT TTTTGAAAAGAAGAAATAA</p>
SEQ ID NO: 2	<p>Spodoptera littoralis PARI __s. cerevisiae codon opt</p> <p>ATGGTTGTTTGA CTTCAAA GGAAAAA TCAAAACA TGTCTGTTGCTGA TTTCTACGC TGGTA AATCT-GTTTTLATTACAGGTGGTAC1-GGTTTCTGGGTAAAGTTTTLATTGAAAAGTTGT-i- GTACT CATGTCCAGAT ATT GWTAAAAT CTATATGTTGAT CAGAGAAAAGAAAGGT CAAT CT ATCAG AGAAAG ATTAA.CTAAAT YGTTGAT GAT CCAATGTTTAATAGAT TGAAGG ATAA.GA GACCAGAL-GATTTGGGTAAAA:OGTTTGTATCCCAGGTGACai-CACAGT-:-CCAGGT-:-:-GGG TATTTCTGAAGAAAACGAAA.CAATCTTGACTGAAAAAGTTTCAGTTGTTATTC.ATTCTGCT GCAACTGTTAAGTTTAATGAJCCATTGGCTACTGCATGGAACGTTAACGTTGAAGGT.AGAA GAAT GAT CAT GG CAT TAT C TGAAGA AGAA TGAAGAG TATCGAAGT TTTTATTTCAT ATTTCTAC TGCTTACACTAACACAAACAGAGCAGTTATTGATGAAGTTTGTATCCACCACCAGCTGAT ATCAAC GAT GTTCAT CAACA TGT TAAAAATGGT GTTACAGAAGAAGAAAC TGAAAAGAT TT TGAACGGTAGACCAACACTTACACTTTTACTAA.GGCTTGA.CTGAACA.TTTGGTTGCAGA AAACCA?.TCATACATGCCAACAAATCATTGTTAGACCATCTATTGTTGGTGTATTA?AGAT GATCCAAATTA GA GGTGGTTGGCTA ATTGGTA TGGTGCA ACAGGTTTGTCA GTTTTA CTG CAAAGGGTTTGAACAGAGTTATATA.TGGTCA.TTCTAACCATGTTGTTGATTGATTCCA.GT TGATTACGTTGCTAATTTGGTTATTGTTGCTGGTGCAAAGACATACCATTCAAACGAAGTT ACTATCTATAACTCTTGTCTTCATCTTGTAAACCAATCACTATGAAGAGATTGGTTGGTT TGTTTATTGATTACACAGTTA?.GCATA?.GTCATACGTTATGCCATTGCCAGGTTGGTATGT TTA.CTCT.AACTACAAGTGGTTGGTTTCTTGGTTACTGTTATTTTCCAAGTTA.TTCCAGCT TACTTAGGTGACATTGGTAGAAGATTGTTAGGTAAAAATCCAAGATACTACAAGTTGCAAA ATTTGGTTGCTCAAACACT^GAAGGAGTTCATTCTTTACATCACATACTTGGGAAATTAA ATCAAAGAGAATTCTGAATTGTTTTCATCTTTGTCTTTGACAGATCAAAGAATGTTTCCA TGTG.ATGCTAACAGAATCGATTGGACAGATTACATCACTGATTACTGTTCTGGTGTAGAC AAT TTTTGAA AAGAT TAAATAA</p>
SEQ ID NO: 3	<p>Helicoverpa armigera FAR3 ____s. cerevisiae codon opt</p> <p>ATGGTTGTTTGTACTTCAAAGGAAACAAAGCCATCTGTTGCTGAATTTTACGCTGGTAAAT CAGTTTTTATT ACA GGTGTACTGGTTTCTTGGGTA AAGTTTTTA TTGAAAAGTTGTGTAC TCTTGTCAGATA.TTGA AAA.TATCT.ATA.TGTTGA.TCAGAGAAAAGAAA.GGTTTGTCAAGTTT CTGAAAGAAT iAA ACAA TTT TTA GA TGAT CCA TTTGTT TACAAGAT TGAAG GAT AAGAGAC C AGCTGATTTGAAAAGA.TTGTTTGTATCCCA.GGTGACA.TCACTGCA.CCAGATTTGGGTA.TT AATTCTGAAai.CGAAAAGATGTTGATTGAAAAGTTTCAGTTATTATTATTCTGCTGCA?. CTGTTAAGTTTAATGAACCATTACCAACAGCTTGAAG7\TTAATGTTGAAGGTACTAG7^T GATGTTGGCATTGTCAAGAAGAATGAAGAGAATCGAAGTTTATTATTCATATTCTACAGCT TACAC TAACACAAACAGAGAAGT TGT TGATGAAAT CT TGAT C CAGC TCCAGCAGATAT CG ATCAAGT T CAT CAAT ACGTTAAGGAT GGTA TCTCAGAA.G AAGAT ACT GAAAAGAT TTTGAA CGGTAGACCA?ACACTTACACTTTTACTAAGGCTTTGACAGAACATTGGTTGCTGAAAA.T CAAGCA.TACGTTCCAACTATTATTGTTAGACCATCTGTTGTTGCTGCAA.TTAAAGA.TGAAC CATTGAAAGGTTGGTTGGTAATTGGTTTGGTGCTACAGGTTTGACTGTTTTTACAGCAAA GGGTTTGAACAGAGTTATATATGGTCATTCTTCATACATCGTTGATTGATCCAGTTGAT TACGTTGCTAATTTGGTTATTGCTGCAGGTGCAAAATCTTCAAAGTCAACAGAATTGAAGG TTTACAACGTGTTCTTCTCATCTTGTAAACCAAGTTACTATCGGTACATTGATGTCAATGTT CGCTGA.TGATGCAA.TTAAACAAAAATCTTACGCTA.TGCC.ATTGCCAGGTTGGTACA .TTTTT ACAAAGT ACAAGT GGT TGGT TTTGTTGTGACAT TTTGTTC CAAGT TAT TCCAG CATACG T TACTGAT TGT CAAGACAT TGTAT CGGTAAATCTC CAAGAT ACAT CAAGT TGCAAT CAT T GGTTAACCAACTAGATCATCTATCGATTTCTTTACAAACCATTCTTGGGTTATGAAGCT</p>

	GATAGA GTT AGA GAA T TGTA CGCTT CA TTGT CTCCAGCTGA TAAGTA CTTATTCCCA TGTG ATCCAA.CTGATATCAACTGGA.CACATTA.CATCCAAGATTACTGTTGGGGTGTTAGA.CATTTC7TGGAAAAAGAAAT CT TAGG A A7A %
SEQ ID NO: 4	pOLE1 cassette CTTGCTG.AAAA GAT GAT G? TCTGAGGTATTCG? ATCGCTAGCTTGATA CGCTT? TAA CAAA AGTAAGCTTTTCGTTTG CAGGTTTGTTACTTTTCTGTACGA&ATGATATCGCTA^GTTTA ? AGTCAT'C? GTGAA? TTCTCAAAAA C? CATGGT? ? CTC CAT CACC CA? TTTCA? TCA TTTGCCGGGCGGAAAAAAAAAAG GAAAAAAAAAAAAAAAAAAAAAT AAATGACACAT GGAA TAAGTCAAGGATTAGCGGATATGTAGTTCAGTCCGGGTATACCATCACGTGATAATAAA TCCAAAT&AGAATGA.GGGGTGCATATCTAATCATTATGCACGTCAAGATTCTCCGT&ACTA TGGCTCTTTTCTGAAGCATTTTTTCGGGCGCCCCGGTGCCAAAACTA%CTCCGAGCCC GGG CATGTCCCGGGGTAGCGGGCCCAACAAGGCGCTTATCTGGTGGGCTTCCGTAGAAGAAA AAA%GCTGTTGAGCGAGCTATTTTCGGGTATCCAGCCTTCTCTGCAGACCGCCCCAGTTGG CTTG GCTCTGGTGTCTGTTTCGTTAGCATC7vCATCGCCTGTGAC7vGGCAG7/GGTAAT7 AJCGGC TTAAGGTTCTCTTCGCA.TAGTCGGCAGCTTCTTTCGGA.CGTTGAA.CACTCAA.CAAACCTT ATCTAGTGCCCAACCAGGTGTGCTTCTACG7/GTCTTGCTiZACTC7\GACACACCTATCCCTA TTGTTACGGCTATGGGATGGCACACAAAGGTGGAATAATAGTAGTTAACAAATATATGCA GCAAA.T CAT CGGCT CCT GGCT CATC GAGT CTTGCAAT CAGCATATACATATA TATAT GGG GG CAGAT CTTGAT TCAT T TATT GTTCTA1 TTCAT CTTTCCTACTTCTGTTTCCGTTTATA i i yTGtAttAG GTAGATAGAACAT CATAGTAATAGATA.GT TGTGGT GATCATA TTATAA C-AGCAC TAA AAC ATT7:C7AiCAAAG7%7VTGCC7YAcTTCTGGAAC TACTAT TG>ATTGAT TGAC GACCAA.TTCCAAAGGATGA.CTCTGCCAGCAGTGGCATTGTGCGACACTAGTGGCGCCGCTC ACATATGAA%GTATATACCCGCTTTTGTACACTATGTAGCTATA%TTCA?.TCGTATTATTG TAG CTCCGCACGACCATG CCTTAG A AATAT CCGCAGCGCG
SEQ ID NO: 5	Extended OLE1 promoter region CTTGCTG.AAAAGAT GAT GTTCTGAGGTATTCGTATCGCTAGCTTGATACGCTTTTAACAAA AGTAAGCTTTTCGTTTG CAGGTTTGTTACTTTTCTGTACGAGATGATATCGCTAAGTTTA TAGTCATCTGTGAAATTTCTCAAAAACCTCATGGTTTCTCCATCACCCATTTTTTCATTICA TTTGCCGGGCGGAAAAAAAAAAGGAAAAAAAAAAAAAAAAAAAAATAATGACACATGGAAA TAAGT CAAGGAT TAGC GGATAT GTAGT TCAGT CCGGGT TAT AC CAT CAC GTGTATAAT AA7A TCCAAATGAGAATGAGGGTGCATATCTAATCATTATGCACGTCAAGATTCTCCGTGACTA TGGCTCTTTTCTGAAGCATTTTTTCGGGCGCCCCGGTGCCAAAACTAACTCCGAGCCC GGG CAT GTCCCGGGGTAGC GGG CCCAACAAAGGCGCTTATCTGGTGGGCTTCCGTAGAA GAAA AAAAGCTGTTGAGCGAGCTATTTTCGGGTATCCAGCCTTCTCTGCAGACCGCCCCAGTTGG CTT GGCT CTGGTGTCTGTTCTAG CAT CACATCGCCTGTGACAGGCAGAGGTAATAACGGC TTAAGGTTCTCTTCGCATAGTCGGCAGCTTTCTTTCGGACGTTGA
SEQ ID NO: 6	OLE1 promoter region ACACTCAACAAACCTTATCTAGTGCCCAACCAGGTGTGCTTCTACGAGTCTTGCTCACTCA GACACACCTATCCCTATTGTTACGGCTATGGGGATGGCACACAAAGGTGGAAATAATAGTA GTTAA.CAAT ATAT GCA GCAAA.T CAT CGGCTCCTGGCT CAT CGAGT CTTGCAAA.T CAGCAT ATA CATATATA TATGGGGGCAGAT CTTGAT TCATTTAT TGTTCTAT TCCAT CTTTCCTACT TCTGTTTCCGTTTATATTTTGTTATAG GTAGAATAGAACAT CAT AGT AAT AGAT AGT TGTG GTGATCATATTATAACAGCACTAAACATTACAACAAAGA
SEQ ID NO: 7	OLE1 27aa leader ATGCCAACTTCTGGAAC TAG TAT TG.AATTGAT TGAC GAC CAAT TTCCAAA GGAT GACTCTG CCAGCAGT GGCAT TGT CGAC

SEQ ID NO: 8	<p>Vspl3 terminator region</p> <p>TCACAT ATGAAAGT ATA TACCCGCTTTT GTACAC TATGTAGCTATAAT TCAATCGTATATAT TGTAGCTCCGCACGACCATGCCTTAGAAATATCCGCAGCGCG</p>
SEQ ID NO: 9	<p><i>T. ni</i> desaturase</p> <p>ATGGCT GTGAT GGCT CAAACAGTACAAGAAACGGCTACAGT GTT GGAAGAGGAAGCT CGCA CAGTGACTCTTGTGGCTCCAAAGACAACGCCAAGGAAATATAAATATATATACACCAACTT TCTTAGATTTTCATATGCGCATTTAGC TGCAT TATA CGGAC TTATTTGTGCTTCA CCTCT GCGAAAT GGGAAAC ATTGCTAT TCTCTTTC GTACTCTTCCACATGTCAAAT ATAGGCA TCA CCGCAG GGGCTCACCGACT CTGGAC TCACAAGAC TTCAAAG CCAAAT TGCCTTTGGAAAT TGTCTCAT GATA TTCAAC TCTTTAGCCTTT CAAAAC ACGGCTAT TACA TGGGCTAGAGAA CAT CGGCTACAT CACAAAT ACAGC GATACT GAT GCT GAT CCCACAAT GCGT CAAGAGG GT TCTTCTA CTGCGAT GTTGGCTGGC TAT TAGT AAAAAAC ATCCCGAT GTCCTGAAAT ATGG AAAACTATAGACATGTCGGATGTATACAATAATCCTGTGTTAAATTTAGAAAAAGTAC GCAGTACCCTTAATTGGAACAGTTTGTCTGCTGCTGCAACTTTGATTCCAGTCTACTGTT GGGGCGAAT CGTGGAAAC AAC GCTTGGCA CATAGCCTTAT TCGATACATATTTCAAT CTTA CGTGACTTTCCTAGTCAACAGTGTGCGCATATCTGGGGAATAAGCCTTATGATAAAAGC ATCTTGCCCGCT CAAAAC CTGCTGGTTTCTTCTCTAGCAAGTGGAGAAG GCTTCCAT AATT ACCAT CAC GTCTTTCATGGGAT TACCGC.ACAGCAG AAT TAGGAAT AAC TTCCTGAAT TT GACGACGCTGTTTCAATGATTTTGTGCTGGTTTGGATGGGCTTATGACTGAAGTCTGTA TCAGAGGATATTATAAAACAGAGAGCTAAACGAACAGGTGACGGTTCTTCAGGGGTCAATTT GGGGAT GGGAC GACAAGAC ATGGAC CGCGATATAAAAT CTAAAG CTAACTATTTTTAT GC TAAAAGGAAT GA</p>
SEQ ID NO: 10	<p><i>A. segetum</i> desaturase</p> <p>ATGGCTCAAGGTGTCCAAACAACCTACGATATTGAGGGAGGA.GGAGCCGTCATTGA.CTTTCG TGGTACCTCAAGAACCGAGAAAGTATCAAATCGTGACCCAAACCTTATCACATTTGGGTA CTGGCATATAGCTGGTTTATACGGGCTATATTTGTGCTTTACTTCGGCAAAATGGCAAACA ATTTTATTCAGTTTCATGCTCGTTGTGTTAGCAGAGTTGGGAATAACAGCCGGCGCTCACA GGTTAT GGGCCCA CAAAAC ATATAAG CGAAGC TTCCCTTACAAAT TATCTGAT GATAC GAACTCCATTGCCTTCCAAA.TTCCGCCATTGATTGGGTGAGGACCACCGTCTCCATCAT AAGTACAGTGACACTGATGCAGACCCTCACAATGCTACTCGTGGTTTCTTCTATTCTCATG TTGGAT GGT TGCTCGTAAG AAAACAT CCAGAAGT CAAGAGAC GTGAAAGGAAT TGACAT GTCTGATATTTACAACAATCCAGT GCT GAGATTCAAAGAAGTATGCTATACCCCTT CATC GGGGCAATGTGCTTCG GAT TAG CAACT TTATCCCTGTTTACTTCTGGGGAGAAAC CTGGA GTAAT GCTTGGCATA TCACTCACTCGGT ACAT CCTCAACCTAAACATTACTTTCCCT GGT CAACAGT GCTGCTCATATCTGGGGATACAAAC CTATYACAT CAAAAT ATTGCCTGCC CAA AAT ATAGCAG TTCCA TAGT AAC CGGCGGCGAAGT TTCCATAAC TACCA CCAC GTT TTTT CTTGGGATTATCGTGCAGCAGAATTGGGGAACAATTATCTTAATTGACGACTAAGTTTCAT AG.ATTTCTTCGCTTG GAT CGGAT GGGCTT.AC GAT CTTAAGAC GGTGTCCAGT GAT GTT.ATA AAAAGTAAGGCGAAAGAACTGGTGTGGACGAATCTTTGGGGTTTAGAAGACAAAGGTG AAG AAGAT TTTT GAAAAT CTGGAAGAC AATTAA</p>
SEQ ID NO: 11	<p><i>T. pseudonana</i> desaturase</p> <p>ACTAGTATGGACTTTCTCTCCGGCGATCCTTTCCGGACACTCGTCCTTGACGACTTGTGTG TCATCGGATTTGCTGCGCGTGGCAATGCTTCTACCCGCGAGCATCGTGGCAAGCCTCG TACATTAAG CAAT GTAAAC TCAAT ACCAGAAT CCA.TGGCAAAT TGTA CGAC CTCTCAT CG TTT CAG CAT CCAGGAGCCCCGT GGCT CTTTCTTT GTT CAAGGTGCGACGG.AA.CAGCTC TATTTGAGTCACACCATCCCTTCATACCTCGAAAGAATCTACTTCAGATCCTCTCCAAGTA CGAG GTTCCGTGAC TGAAGAC TCTGTTTCTTTCAT CGCC.ACCTTAG ACGAAC TCAAT GGT</p>

	<p>GAAT CTCCGTA CGA TTGGAAG GACA TTGAAAA TGA TGATTTCGTATCTGACCTACGAGCTC TCGTAA. TTGAG CA CTTTCTCCTCTCGCCAAGGAAA GGGGAGTTT CACTCGTTGAGTCGT C GAAGGCAACACCTCAGCGGTGGATGGTGGTTCTACTGCTCCTTGCGTCGTTCTTCTCAGC ATCCCATTATATTTGAGTGGTTCGTGGACTTTCGTTGTCGTCACTCCCATCCTCGCTTGGC TGGCGGTGT C AATTA CTGGCAC GAT GCTA CTCAC TTTGCATTGAGCA GCAAC TGGAT TTT GAATGCTGCGCTCCCATATCTCCTCCCTCTCCTATCGAGTCCGTCAATGTGGTATCATCAT CAC GT CAT TGGACA T CAC GCATA CA CCAAC A TTTCCAAAAGAGAT CCA GA TCTTGCTCAC G CTCCACAAC TCAT GAGAGAACACAAGAGT ATCAAAT GGAGAC CAT CTCACT TAAAT CAAAC A CAGCTTCCGCGGAT TCTCTT CAT CTGGTCGATTGCA GTCGGTA TTGGGTTGAAC TTA CTG AAC GAC GTGAGAG CAC TAAC CAAG CTTTCA TA CAACAAC GTTGTTCGGGTG GAGAAGAT GT CATCGTCGGAACATTACTCCATTTCTTGGACGTATGTTGCACATCTTTGTGACTACACT TTGGCCCTTTTGGCGTTTCCGGTGTGGAAGGCCATCGTTTGGGCGACTGTACCGAATGCC ATACT GAGTTT GTGCTT CAT GC TGAATA CGCAAAT CAAT CAC CT CAT CAACACGT GTGCAC ATGCTTCCGATAACAAC TTTTACAAGCATCAAGTTGTAAGTCTCAGAACTTTGGCCGATC AA GTGCC TTTTGCT T CATCTTCTCGGGAGGTCTCAACTACCAAATTAACATCATTTGTG CCGAC GGTGAAC CAT TGCCAT TTGCCAG CT TGGCCCCGGGTGTAGA GCGTTTGTGT AAGA AAC ACGGGGTGACA TA CAAC TCTGTTGAAG GATA CAGAGAG GCCAT CAT TGACACAC TTTGC ACATAC CAAAGAT ATGTGAC GAAG CCTACT GATTGA</p>
SEQ ID NO: 12	<p><i>A. transi tella</i> desaturase</p> <p>ATGGTCCCTAACAAG GGTTCAGT GACGTTTTGTCT GAACAT TCTGAGCCCCAGT TCAC TA AAC TCATA GCTCC A CAAGC AGGGCCGAG GAAAT ACAAGAT AG TGTATCGAAAT TTGCTCAC ATTGCGCTAT TGGCAC TTAT CAG CTGTTTAT GGGCTCTACT TGTGCTTTA CTTGTGCGAAA TGGGCTA CCAT CTTAT TTGCAT TTTTCT TA TA CGTGAT CGCGGAAAT CGGTATAAC A GGTG GCGCTCATAGGCTATGGGCACATCGGACTTATAAAGCCAAGTTGCCTTTAGAGATTTTGT ACTCATAAT GAAC TCTAT TGCCTTCCAAGAC ACTGCTTTT CAC CTGGGCTCGT GATCAC CGC CTTCAT CA CAAAT ATTCCGAT ACTGAC GCTGAT CCCCACAAT GCTA CCAGAG GGT TTTCT ATTCACATGTAGGCTGGCTTTTGGTGAAGAAACACCCTGAAGTCAAAGCAAGAGGAAATA CTGTGCTTAGATGATCTTAAGAATAATCCATTGCTTAAATCCAAAAGAAATACGCTATT CTAGT TA TAGG CAC GTTAT GCTTCTCTTA TGCCAACA TTTGTGCCGTA TA CTTCTGGGGCG AGGGCA TCAGCA CGGCCTGGAA CATCAAT CTAT TGCGATA CGTCATGAATCTTAACAT GAC TTTCTTAGTTAACAGTGCAGCGCATATCTTTGGCAACAACCATACGATAAGAGCATAGCC TCA GT CCAAAALA TTT CAGT TA GCTTA GCTACT TTTGGCGAAG GAT TCCAT AA TTACCAT C A CACT TA CCCCTGGGAT TAT CGTGCGGCAGAAAT TAG GAAAT AAT A GGCTAAAT ATGAC TA C TGCTTTCATAGAT TTCTTCGCTT GAT CGGCTGGGCTTA TGAC TTGAAGT CTGTGCCACAA GAGGCCATTGCAAAAAGGTGTGCGAAAA. CTGGCGATGGAACGGAT. ATGTGGGGTCGAAAAA GATAA</p>
SEQ ID NO: 13	<p><i>H. zea</i> desaturase</p> <p>ATGGCCCAAAG CTAT CAA TCAAC TACGGTTTT GAGT GAG GAGAAAGAAC TAAC ACTGCAAC ATTTGGTGCCCCAAG CAT CGCCCAG GAAGT ATCAAAT AGTGTA TCCGAAC CTCAT TA CGTT TGTTA CTGGCACA TA GCCGGAC TTTAT GGCCTTACTTGT GCTT CAC TTTCT GCTAAAT GG GCTACGATTTTATT CAGCTACATCCTCTTCTGTTAGCAGAAATAGGAATCACGGCTGGCG CTCA CAGAC TCTGGGCC CACAAAAC TTACAAAG CGAAAC TA CCAAT TAGAAAT ACT CTTAAT GGTATTCAACTCCATCGCTTTTCAAACTCAGCCATTGACTGGGTGAGGGACCACCGACTC CACCATAAGTATAGCGATACAGATGCTGATCCCCACAATGCCAGCCGAGGGTTCTTTTATT CCCAT GTA GGAT GGCTACT TGTGAGAAAAC ATCCTGAAGT CAAAAAG CGAG GGAAGAAG T CAATATGTCC^TATTTIW^TW^CAATCCTGTCTGCGGTTTCAGAAAAAATACGCCATACCC TTCATTGGGGCTGTTGTTTCGCCTTACCTACAATGATACCTGTTTACTTCTGGGGAGAAA CCTGGTCCAAT GCT TGGCATA TCAC CATGCTTCGCTA CA TCAT GAACCTCAAT GTCAC CTT TTTGGTAAACAGCGCTGCTCATATATGGGGAACAAGCCTTATGACGCAAAAATATTACCT GCACAAAAT GTA GCTGTGT CGGT CGCCAC TGGTGGAGAAGGT TTCCATAAT TACCAC CAT G</p>

	<p>TCTTCCCTGGGATTATCGAGCAGCGAACTCGGTAACAATAGCCTCAATCTGACGACTAA ATTCATAGATTTATTTCGAGCAATCGGATGGGCATATGATCTGAAGACGGTTTCGGAGGAT ATGATAAAACAAAG GAT TAAAC GCACT GGAGAT GGAAC GGA TcTtTGGGGA Ca CGAACAA ACT GTGAT GAAGT GTGGGAT GTAAAAGATAAAT CAAGTTAA</p>
SEQ ID NO: 14	<p>mCherry <i>c. tropicalis</i> optimized</p> <p>ATGGTTTClAAG GGTAAGAAGACAAC A TGGCAAT CAT CAAG GAAT TTA TgcGTTT TAAG G TCCATA TGG.AAGGCTCCGTTAACGGCCA CGAGT TCGAGAT CGA GGGAGA AAGGTGAG GGTA G ACCATACGAAGGTACTCAAAACGCCAAGTTGAAAGTTACAAAGGGTGGTCCATTGCCATTT GCTTGGGATATCTGTCCC CACAAT TtAT gTACGGAT CAAAG GCATA TGTCAAGC ATCC TG CCGACATCCCAGATTACTTGAAGTTATCCTTTCCAGAAGGTTTAAAGTGGGAGAGAGTTAT GAACTTTGAAGATGGCGGAGTTGTTACTGTTACTCAGGACTCTTCCTTGCAAGATGGTGAA TTTATCTATAAAGTGAAATTGAGAGGTACTAACTTTCCATCCGACGGTCCAGTCATGCAAA AGAAGACAAT GGGTTGGGAG GCTTCTTCC GAAAGAAT GTACCCAGAAGAC GGTGCA TTGAA AGGTGAAATCAAGCAACGTTTAAAGTTGAAGGACGGTGGTCACTACGATGCCGAGGTCAAG ACCACTTA TAAAGCTAAG AAG CCAgTCCAAT TGCCA GGTGCTTA TAAC GTTAA CATCAAG T TAGATAT TACT TCACACAAC GAAGACT ACACAAT CGTTGAACAAT ATGAAAGAGC CGAAGG TAGACATTCTACCGCGGCATGGACGAGTTATATAAGTAG</p>
SEQ ID NO: 15	<p>CaOLE1-A. <i>segetum</i> zll desaturase</p> <p>ATGACTACAGTTGAACAACCTGAACTGTTGATATCACTAAATTGAATGCCATTGCTGCTG GTACTAATAAGAAGGTGCCAATGGCTCAAGGTGTCCAAACAACACGATATTGAGGGAGGA AGAGCCGTCATTGACTTTTCGTGGTACCTCAAGAACCGAGAAAGTATCAAATCGTGATCCCA AAC CTTATCA CATTTGGGTACTGG CATA TAgCTGGT TtATA CGGGCTA TATTTGTGCTTTA CTTCGGCAAAATGGCAAACAATTTTATTGAGTTTCATGCTCGTGTGTGTAGCAGAGTTGGG AAT AAC AGCCGCGCT CACA GGTAT GGGCCACAAAAC ATATAAAG CGAAG CTTCCTTTA CAAAT TAT CTTAAT GATATTAAC TCCAT TGCCTTCCAAAT TCCGCCAT TGAT TGGGTga. GGGACCACCGTCTCCATCATAAGTACAGTGACACTGATGCAGACCCCTCACAATGCTACTCG TGGTTTCTTCTATTCTCATGTTGGATGGTTGCTCGTAAGAAAACATCCAGAAGTCAAGAGA CGTGGAAG GGAAC T TgAGAT GTCTGAT AttTA CA CAAT CCAGT GTTAAGAT TTCAAAGA AGTATGCTATACCTTCATCGGGCAATGTGCTTCGGATTACCAACTTTTATCCCTGTTTA CTTCTGGGGAGAAAC CTGGAGTAAT GCTTGGCATA TCA CCA TGCTTCGGTA CATCCTCAAC CTAAAC ATTA CT TTTCTTAGT CAAC AGT GCTGCTCA TATCTGGGGAT ACAAAC CT TA TGACA TCAAAT ATTGCTGCC CAAAT ATAGCAGT TtCCA TAGTAAC CGGCGGCGAAGT TTCCAT AACTACCACCACGTTTTTTCCTTGGGATTATCGTGCAGCAGAATTGGGGAACAATTATCTT AATTTGACGACTAAGTTCATAGATTTCTTCGCTTGGATCGGATGGGCTTACGATCTTAAGA CGGTGTCCAGTGATGTTATAAAAGTAAGGCGGAAAGAACTGGTGATGGGACGAATCTTTG GGGTTTAGAAGACAAAGGTGAAGAAGATTTTTGAAAATCTGGAAAGACAATTAA</p>
SEQ ID NO: 16	<p>A. <i>segetum</i> zll desaturase</p> <p>ATGGCTCAAGGTGTCCAAACAACCTACGATATTGAGGGAGGAAGAGCCGTCATTGACTTTG TGGTACCTCAAGAACCGAGAAAGTATCAAATCGGTACCCAAACCTTATCACATTTGGGTA CTGGCATATAGCTGGTTTATACGGGCTATATTTGTGCTTTACTTCGGCAAAATGGCAAACA ATTTTATTGAGTTTCATGCTCGTTGTGTAGCAGAGTTGGGAATAACAGCCGCGCTCACA GGTTAT GGGCCACAAAAC ATATAAAG CGAAGC TTCCCTTA CAAA.TTAT CTTAAT GATATT AAACT CCAT TGCCTTCCAAAT TCCGCCAT TGAT TGGGTGAG Gg.acCA CCGTCTCCAT CAT AAGTACAGT GACACT GAT GC.AGACCCTCACAAT GCTACTCGTGGTTTCTTC TAT TCTCAT GTTGAT GGTGCTCG TAAGAAAACATCCAGAAGTCAAGAGACGTGAAAGGAACCTTGACATGTCTGATATTTACAA CAATCCAGTGTTAAGATTTCAAAGAAGTATGCTATACCTTCATCGGGGCAATGTGCTTC GGATTACCAACTTTTATCCCTGTTTACTTCTGGGAGAAACCTGGAGTAATGCTTGGCATA</p>

	<p>TCACCATGCTTCGGTACATCCTCAACCTAAACATTACTTTCTTAGTCAACAGTGCTGCTCA TATCTGGGGATACAAACCTTATGACATCAAAATATTGCCTGCCCAAAATATAGCAGTTTCC A TA G^TAAC CGGCGGCGAAGT TTCCA TAAC TA C_c.acCA CG^T,TTTTTCCTTG GAT TA TCGTG CAGCAGAATTGGGGAACAATTATCTTAATTTGACGACTAAGTTCATAGATTCTTCGCTTG GATCGGATGGGCTTACGATCTTAAGACGGTGTCAGTGATGTTATAAAAAGTAAGGCGGAA AGAACTGGTGATGGGACGAATCTTTGGGGTTTAGAAGACAAAGGTGAAGAAGATTTTTTGA AAAT CTGGAAGAC AAT TAA</p>
SEQ ID NO: 17	<p><i>A. transitella</i> zll desaturase</p> <p>ATGGTCCCTAAC AAG GGTTCCAGT GAC GTTTGTCT GAACAT TCTGAG CCCAGT TCA CTA. AACTCATAGCTCCACAAGCAGGCGGAGGAAATACAAGATAGTGATCGAAATTTGCTCAC ATTCTGGCT^TATTGGCACTTAT CAGCTGTTTATGGGCTCTACT TGTGCTTTA CTTGTGCGAAA TGGGCTACCATCTTATTGCAATTTTCTTATACGTGATCGCGAAATCGGTATAACAGGTG CGCTCATAGGCTATGGGCACATCGGACTTATAAAGCCAAGTTGCCTTTAGAGATTTTGT ACT CAT AAT GAAT TCTAT TGCCTTCCAAGAC ACTGCTTTC.AcCTGGGCTC GAGAT CA CCGC CTTCAT CA CAAAT ATTCTGGAT ACTGAC GCTG^ATCCCCA CAAT GCT^ACCAGAG GGTTTTTCT^T ATTCACATGTAGGCTGGCTTTTGGTGAAGAAACACCTT GAAGT CAAAGCAAGAGGAAAAATA CTTGTCGTTAGAT GAT CTTAAGAAT AAT CCAT^TGCT^TTAAAT TCCAAAAG AAAT ACGC^TATT CTAGT TATAGG CACGTTAT GCTTCCTTAT GCCAAC ATTTGTGCCCCGTA TACTTCTGGGGCG AGGGCATCAGC ^ACGGCCTGGAACAT CAAT CTAT TGCATACGT CAT GAAT CTTAAC ATGAC TTTCTTAGTTAACAGTGCAGCGCATATCTTTGGCAACAACCATACGATAAGAGCATAGCC ^TCAGT CCAAAAT ATT^TCAGT TAG CTTAG CTA CT TTTGGCGAAG GAT TCCAT AAT TAG CAT C ^ACAC^TTA CCCC^TGGGAT TAT CGTGCGGC^AGAAT TAG GAAAT AAT AGG CTAAAT ATG^ACTA C TGCTTTTAT AGAT TTCTTCGCTTG GAT CGGCTGGGCTTATGAC TTGAAGT CTGTGCCACAA GAG GCCATT GCAAAAAG GTGTGCGAAAAC GCGCAT GGAAC GGATAT GTGGG GTC GAAAAA GATAA</p>
SEQ ID NO: 18	<p><i>T. ni</i> Zll desaturase</p> <p>ATGGCT GTGAT GGCT CAAACAGTACAAGAAACGGCTACAGT GTT GGAAGAGGAAGCT CGCA CAGTGACTCTTGTGGCTCCAAAGACAACGCCAAGGAAATATAAATATATATACACCAACTT TCTTA CATTTTTCAT ATGCGCAT TTAGC TGCAT TAT ACGGAC TTTA TTTGTGCTTCA CCTCT GCGA.A.ATGGGAAAC ATTGCTAT TCTCTTTCGT.ACTCTTCCAC ATGTCAAAT ATAGGCAT CA CCGCAGGGGCTCACCGACTCTGGACTCACAAGACTTTCAAAGCCAAATTGCTTTTGAAAT TGTCCT^{c.a.t}GATATTCAAC TCTTTAGC CTTTCAAAC ACGGCTAT TACATGGG CTAGAGAA CAT CGGCTACAT CAC AAAT ACA GCGAT ACT GAT GCTGAT CCCCACAAT GCGT CAAG ^AGGGT TCTTCTA CTGCGAT GTTGCTGGC TAT TAGT AAAAAAC ATCCCGAT GTCTTAAAT ATGG AAAA.AC TATAGAC ATGTGCGAT GTAT.ACAATA.AT CCTGTGTAAAT TTCAAG AAAAAGT A C GCAGTACCCTTAATTGGAACAGTTTGTGCTCTTCCAACCTTTGATTCCAGTCTACTGTT GGGGCGAAT CGTGGAAC AAC GCTTGGA CA TAGCCTT.ATTTGAT A CATATTCAAT CTAA CGTGACTTTCTAGTCAACAGTGCTGCGCATATCTGGGGGAATAAGCCTTATGATAAAAGC ATCTTGCCCGCT CAAAAC T^ATTAGT TTCCTTCTAGCAAGT GGAGAAG GCTTCCAT AAT T ACCAT CAC GTC^TTTCCAT GGGAT TACCGCAC AGCAGAAT TAGGGAAT .aac^TTC^TTAAAT TT GACGACGTTATT CATT GATTTTGTGCTGGTTTGGATGGGCTTATGACTT GAAGT CTGTA ^TCAGAG GAT ATTATAAAACAGAGAGCTAAACGAACAGGTGACGGTTCTTCAGGGGTCATTT GGGGAT GGGAC GACAAAGAC ATGGAC CGCGAT A TAAAT CTAA.AGCTAAC ATTTTTT.ATGC TAAAAAG GAAT G.A</p>
SEQ ID NO: 19	<p><i>if. zea</i> zll desaturase</p> <p>ATGGCCCAAAGCTATCTATCAACTACGGTTTTGAGTGAGGAGAAAGAACTAACATTACAAC ATTTGGTGCCCAAGCATCGCCAGGAAGTATCAATAGTGATCCGAACCTCATTACGTT TGTTACTGGCACATAGCCGACTTTATGGCCTTTACTTGTGCTTCACTTCTGCTAAATGG</p>

	<p>GCTACGATTTTATTTCAGCTACATCCTCTTCGTGTTAGCAGAAATAGGAATCACGGCTGGCG CTCA CAGA CTCTGGGCCCCACAAAAC TTTACAAAG CGAAAC TACCAT TA GAAAT ACT CTTAAT GGTA TTTCAACTCCA TCGCTTTTCAAAAC TCA GCCAT TGA CTGGGTGA GGGGA CCA CCGA CTC CACCATAAGTATAGCGATACAGATGCTGATCCCCACAATGCCAGCCGAGGGTTCTTTTATT CCCAT GTA GGAT GGC TACT TGTGAGAAAAC ATCCTGAAGTCAAAAAG CGAG GGAAAGAAC T CAATATGTCGATATTACAAACAATCCTGTCTTACGGTTTCAGAAAAAATACGCCATACCC TTCATTGGGGCTGTTTGTTCGCCTTACCTACAATGATACCTGTTTACTTCTGGGGAGAAA CCTGGT CCAAT GCTTGGCAT ATCA CCAT GCTTCGCTAG ATCAT GAAC CTCAT GTCA CCTT TTTGGTAAACA GCGCTGCTCATATA TGGGGAAAC AAG CCTTAT GAC GCAAAA ATATTA CCT GCACAAAATGTAGCTGTGTCGGTCGCCACTGGTGGAGAAGGTTTCCATAATTACCACCATG TCTTCCCTGGGATTATCGAGCAGCGGAAC TCGGTAACAATAGCCTCAATTTAACGACTAA ATTCATAGAT TTAT TCGCAG CAAT CGGAT GGGCA TATGA TTAAAGAC GGTTCGGAG GAT ATGATAAAACAAA.G GAT TAAAC GCACT GGAG ATGGAAC GGAT CTTTGGGGACA CGAAC AAA ACT GTGATGAAGT GTGGGAT GTAAAGATAAAT CAAGTTAA</p>
SEQ ID NO: 20	<p><i>o. furnacalis</i> z9 desaturase</p> <p>ATGGCTCCTAATATTAAGGACGGAG CTGATTTGAAC GGAGT TTTATTTGAAGAT GAC GCTA GCACCCCCGATATAGCCCTTGCCACGGCCCCAGT CCAGAAGCAGACAAC TATCCCAGAAA ACTAGT GTGGAGAAAC ATCATA CTC TTTGCATA CCTTCA CCTTGCCGCTGT GTATGGAG CA TAG CTTATTTCTTATTTTCAG CGAAAT GGCAGACAGAT ATT TTTGCCTA CATTCTTACGTGA TCTCAGGACTCGGCATCACAGCGGAGCCACCGCCTTTGGGCGCACAAGTCATACAAGGC TAAGT GGCc.acTTAGAC TCAT TCTTATTAT CTTCAAC A CTGTA TCAT TCCAG GAC TCTGCT CTCGACTGGTCA CGTGACCA CCGCAT GCACCAACAAT ACTCGGAGAC CGACGCCGAC CCGC ACAACGCGACTCGAGGGTTCTTCTCTCTCATATCGGCTGGTTATTAGTCCGAAGCACCC GGAAT TAAAGA GAAGGGCAGGGA TTAGAC TTAAGCGACT TGTA TGCTGAT CCCAT CCTC CGTTCCAGAA GAAGT ACT ATTTACTATTAATGCCTCTTGGCTGCTT CAT CAT GCCGACGG TGGTCCCGGTGACTTCTGGGGTGAGACTTGGACTAACGCTTTCTTCGTCGCCGCTCTT CCGATACACCTTCATCTCAATGTACCTGGTTGGTCAACTCCGCCGCGCACAAGTGGGGC CA CAAG CCCTAT GACA GCAG CAT CAAG CCTTCCGAGAAC CTCTCAGT CTCCTTAT TCGCGT TGGGCGAAG GAT TCCACA7-vcTA CCA CCA CA CAT TCCCTGGGAC TA CAAAAC TGCCGAG CT CGGCAAC AACAGAC TCAAT TTCACAAC AAAC TTCAT CAACT TCTTCGCTAAAAT CGGAT GG GCTTAG GAC TTGAAAAC GGT CTCGAC GAGAT TAT TCAGAAAT AGAGT CAAG CGCACA GGAG ATGGCTCCCACTTATGGGGTTGGGGCGACAAGGATCAACCTAAAGAGGAGGTAAACGC AGC CAT TAGAAT TAAT CCTAAAGAC GAGTAA</p>
SEQ ID NO: 21	<p><i>L. oapitella</i> z9 desaturase</p> <p>ATGCCGCCGAACGTGACAGAGGCGAACGGAGTGTTATTTGAGAATGACGTGCAGACTCCTG ACATGGGGCTAGAAGTGGCCCTGTGCAGAAGGCTGACGAGCGTAAGATCCAGCTCGTTTG GAG GAAC ATCAT CGC' I' TTTGCAT GTCTTCAT TTA GCAG CTGTGTA TGGAG CTAT TTA TTC TTCACCTCGGCTATATGGCAGACAGACATATTTGCATACATCCTTTACGTTATGTCTGGAT TAG GAAT CACGGC GGGAGC GCACAGATTAT GGGCT CATAAGT CATA CAGGCGAAGT GGCC GTTA7-VGATTAAT CCTCGTCGCAT TCAAC ACTTTGGCAT TCCAG GAT TCGGCAAT CGAC TGG GCGCGCGAC CAC CGCAT GCA CCACAAGT ACTCGGAGAC GGAT GCGGAC CCA CA TAAC GCCA CTCGCGGCTTCTTCTTTTCGCACATTTGGTTGGTTA CTCTGCCGAAAAC ACCCGGAG CTA GGCAGG GGCCAG GGCCTCGAC TTAAG TGAC CTCTACGCAGATCCTAT TATTGCTTCCA A AAGAAGT ACTA CTTA TTGTTAAT GCCGTTAGCCTGCTTTGTTCTTCCCAC CATAAT TCCGG TCTACCTCTGGGGCGAG TCCTGGAAAAAC GCGTTCTTCGTAGCTGCAAT GTTCCGTTA CAC GTTTAT CCTCAAC GTAACAT GGCTCGTCAAC TCCGCCGCC CACAAAT GGGGAG GCAAG CCC TATGATAAGAACATCCAGCCCGCTCAGAACATCTCTGTAGCTATCTTCGATTAGGCGAGG GCTTCCAC AAC TACCAC CACA CGTTCCCCTG GGAC TA CAAGAC CGCTGAAT TAGGAAAC AA CAG GTTAAAT TTCACAACT TCGTTTAT CAAT TTCTTCGCAAG CTTCCGAT GGGCCTA CGAC TTAAAGACCGTGTGCGACGAGATTATACAACAGCGGTTAAGAGGACGGGAGATGGGAGCC</p>

	ATCACTTACGGGGCTGGGGCGACCAGGACATACCGGCCGAAGAAGCTCAAGCTGCTTTACG CAT TAAC CGTAAAGAT GAT TAG
SEQ ID NO: 22	<i>H. zea</i> Z ⁹ desaturase ATGGCTCCAAATATATCGGAGGATGTGAACGGGGTGCTCTTCGAGAGTGATGCAGCGACGC CGGACTTAG CGTTAT CCA CGCCGCCTGTGCAGAAG GCTGACAAAC AGGCCCAAG CAAT TAG T GTGGAG GAACAT A CTATTAT TCGCGTA TCTT CAC TTA GCGGCTCTTTA CGGAG GTTA TTTA TTCCTCTTCTCAGCTAAATGGCAGACAGACATATTTGCCTACATCTTATATGTGATCTCCG GGCTTGGTATCAC GGCTGGAG CACA TCGCTTAT GGGCCCA CAAGT CCTA CAAAGC TAAAT G GCCTCTCCGAGTTATCTTAGTCATCTTTAACACAGTGGCATTCCAGGATGCCCTATGGAC TGGGCGCGCGA CCACCGCAT GCATCAC AAGT ACTCGGAAAC CGAT GCTGAT CCTCATAAT G CGAC CCGAG GAT TCTTCTTCTCT CACAT TGGCTGGTTA CTTGT CAGGAAAC ATCCCGAC CT TAAGGAGAAGGCAAGGGACTCGACATGAGCGACTTACTTGCTGACCCCATTTCTCAGTTT CAGAAAAAT A CTA CTTAAT CTTAAT GCCCTTGGCTTGCTTCGT GAT GCCTA CCGTGAT TC CTGTGTACTTCTGGGGTGAAACCTGGACCAACGCATTCTTTGTGGCGCCATGTTCCGCTA CGCGTT CAT CCTAAAT GTGACGTGGCTCGTCAACTCTGCCGCTCACAAGTGGGGAGACAAAG CCCTAG GACAAAAG CAT TAAG CCTTCCGAAAAC TTGTCGGTCGC CAT GTTCGCTCTCG GAG AAGGATTCCACAACCTACCACACACTTTCCTTGGGACTACAAAACCTGCTGAGTTAGGCAA CAACAAAC TCAAC TTCACT ACCAC CTTTATTAAC TTCTTCG TAAAT TGGCTGGGCTTA C GAC TTAAAGAC AGT GTCTG.ATGATATC GTCAAGAAC AGGGTGAAGCGCACT GGTGACGGCT CCCAC CAC TTAT GGGGCTGGGGAG ACGAAAAT CAAT CCAAAGAAG AAAT TGAT GCCGCTAT CAGAAT CAAT CCTAAG GAC GAT TAA
SEQ ID NO: 23	<i>T. pseudonana</i> Z ¹¹ desaturase ATGGACTTTCTCTCCGGCGATCCTTTCCGGACACTCGTCCTTGACAGCACTTGTGTGATCG GATTTGCTGCGGCGTGGAATGCTTCTACCCGCCGAGCATCGTCGGCAAGCCTCGTACATT AAG CAAT GGTAAC TCAAT ACCAGAAT CCAT GGCAAAT TGTA CGAC CTCTCAT CGTTTCA G CAT CCAAGGAG GCCCCGTGGCTCTTTCTCTTGTTCAG GTCGCGAC GGAAC AGCTCTAT TTG AGT CACA CCAT CCTTCATACCTCGAAAGAAT CTA CTTCAGAT CCTCTCCAAGT ACGAG GT TCCGTCTGA CTGAA.GACTCTGTTTCCTTCAT CGCCAC CCTAG ACGAAC TCAAT GGTGAAT CT CCGTACGATTGGAAGGACATTGAAAATGATGATTTCTGATCTGACCTACGAGCTCTCGTAA TTGAG CAC TTTTCTCCTCTCGCCAAGGAAAG GGGAGTTTCAC TCGTTGAGTCGTCTGAAG GC AACACCTCAGCGGTGGATGGTGGTTCTATTACTCCTTGCGTCGTTCTTCCTCAGCATCCCA TTATATTTGAGTGGTTCGTGGACTTTCGTTGTGTCGTCACCTCCATCCTCGCTTGGTTAGCGG TTGTCAA TTA CTGGCAC GAT GCTA CTCAC TTTGCAT TGAGC AGCAAC TGGAT TTTGAAT GC TGCGCTCCCATATCTCCTCCCTCTCCTATCGAGTCCGTCAATGTGGTATCATCATCACGTC ATTGGACA TCA CGCA TACAC CAAC ATTTCAAAAGAGAT CCAGAT CTTGCTCAC GCTCCAC AACTCAT GAGAGAACACAAGAGTAT CAAAT GGAGAC CAT CTCAC TTAAAT CAAACACAGCT TCCGCGGAT TCTCTTCA TCTGGTCGAT TGC.AGT CGGT.ATGGGGTTGAAC TTAT TAAAC GAC GTGAGAGCACTAACCAAGCTTTCATACAACAACGTTGTTGCGGTGGAGAAGATGTCATCGT CGCGAAC ATTA CTCCAT TTCCTTGGAC GTA TGTTCACATACTTTGTG. ACTAGACT TTGGCC CTTTTGGCGTTTCCGGTGTGGAAG GCCAT CGTTTGGGCGAC TGTA CCGAAT GCCA TATTA AGTTTGTGCTT CAT GTTAAATACGCAAAT CAAT CACCT CAT CAACACGTGTGCACATGCTT CCGATAACAACTTTACAAGCATCAAGTTGTAACCTGCTCAGAACTTTGGCCGATCAAGTGC CTTTTGCTTCATCTTCTCGGAGGTCTCAACTACCAAATTGAACATCATTTGTTGCCGACG GTGAACCATTGCCATTTGCCAGCTTTGGCCCCGGGTGTAGAGCGTTTGTGTAAGAAACACG GGGTGAC ATACAAC TCTGTTGAAG GAT ACA GAGA GGCCAT CAT TGCACA CTTTGCACA TAC CAAAGAT ATGTCGAC GAAG CCTACT GAT TGA
SEQ ID NO: 24	Native <i>T. ni</i> Z ¹¹ desaturase ATGGCT GTGAT GGCTCAAACAGT ACAAGAAACGG CTACAGT GTT GGAAGAGGAAG CTCGCA

	<p>CAGTGACTCTTGTGGCTCC^AAGACAACGCCAAGGAAATATAAATATATATACACCAACTT TCTTACATTTTCATATGCGCATTTAGCTGCATTATACGGACTTTATTTGTGCTTCACCTCT GCGAAAT GGGAAACATTGCTATTCTCTTTC GTA CTCTTCCACATGTCAAATATAGGCAT CA CCGCAGGGGCTCACCGACTCTGGACTCA CAAGAC TTTCAAAG CCAAT TGCCTTTGGAAAT TGTCTCATGATATTCAACTCTTTAGCCTTTCAAAACACGGCTATTACATGGGCTAGAGAA CATCGGCTACATCAGAAATACAGCGATACTGATGCTGATCCCCACAATGCGTCAAGAGGGT TCTTCTA CTGCGAT GTTGGCTGGC TAT TAGT AAAAAAAC ATCCCGATGTCTGAAATATGG AAAAAC TATAGAC ATGTGCGATGTATACAAT AATCCTGTGTAAAAAT TTCAGAAAAAGT AC GCAGTACCCTTAATTGGAACAGTTTGTGTTTGTCTGCTGCCAACTTTGATTCCAGTCTACTGTT GGGGCGAAT CGTGGAAACAAC GCTTGGCA CATAGCCTTAT TTCGATACATATTTCAATCTTAA CGTGACTTTCTTAGTCAACAGTGTGCGCATATCTGGGGGAATAAGCCTTATGATAAAAGC ATCTTGCCCGCT CAAAAC CTGCTGGTTTCTCTCCTAG CAAGT GGAGAAG GCTTCCA TAA TT ACCAT CACGTCTTTCCATGGGATTA CCGCACAGCAGAAT TAGGGAATAACTTCTCTGAAT TT GACGACGCTGTTTATTGATTTTGTGCTGTTTGGATGGGCTTATGACTTGAAGTCTGTA TCAGAGGATATTATAAAACAGAGAGCTAAACGAACAGGTGACGGTTCTTCAGGGGTCATTT GGGGATGGGACGACAAAGACATGGACCGCATATAAAATCTAAAGCTAACATTTTTTATGC TAAAAAG GAATGA</p>
SEQ ID NO: 25	<p><i>H. zea</i> Zll desaturase</p> <p>ATGGCCCAAAG CTATCAATCAAC TACGGTTTT GAGTGAG GAGAAAGAAC TAACACTGCAAC ATTTGGTGCCCCAAGCATCGCCAGGAAGTATCAAATAGTGTATCCGAACCTCATTACGTT TGGTTACT GGCA CATAGCCGGACTTTAT GGCCTTTA CTTGTGCTTCACCTCTGCTAAAT GG GCTACGATTTTATTACAGCTACATCTCTCTGTTAGCAGAAATAGGAA .TCACGGCTGGCG CTCACAGAC TCTGGGCC CAAAAAC TTACAAAG CGAAAC TACCATTAGAAAT ACTCTTAAT GGTATTCAACTC CATCGCTTTTCAAACTCAGCCATT GACTGGGTGAGGGACCACC GACTC CACCATAAGTATAGCGATACAGATGCTGATCCCCACAATGCCAGCCGAGGGTTCTTTTATT CCCATGTAGGATGGCTACT TGTGAGAAAAC ATCTGAAAGT CAAAAAG CGAGGGAAGAAC T CAATATGTCGATATTTACAACAATCTGTCTGCGGTTTCAGAAAAATACGCCATACCC TTCATTGGGGCTGTTTGTGCTTACCTACAATGATACCTGTTTACTTCTGGGGAGAAA CCTGGTCCAATGCTTGGCATACTCATGCTTCGCTACATCAT GAAC CTCAAT GTCACCTT TTTGGTAAACAG CGCTGCTCATA TATGGGGAAAC AAG CTTAT GACGCAAAAAT ATTA CCT GCACAAAAT GTAGCTGTGTGCGTGCAC TGGTGGAGAAGGT TTCCATAAT TACCACCATG TCTTCCCTGGGATTATCGAGCAGCGAACTCGGTAACAATAGCCTCAATCTGACGACTAA ATTATAGAT TTATTCGCGACAAT CGGATGGGCA TATGATCTGAAGAC GGTTTCGGAGGAT ATGATAAAACIAAAGGATTAAACGCTCTGGAGATGGAACGGATCTTTGGGGACTTCGAAC^AA ACTGTGATGAAGT GTGGGAT GTAAAAGATAAAT CAAGTTAA</p>
SEQ ID NO: 26	<p><i>T. ni</i> Zll desaturase <i>Homo sapiens</i> optimized</p> <p>ATGGCCGTGATGGCCAGAC CGTGAGGAGAC CGCAACAGT GCTGGAGGAGGAGG CAAGGA CCGTGACACTGGTGGCACCACCAAGACCACACCTAGAAAGTACAAGTATATCTACCAACTT CCTGACCTTCAGCTACGCACACCTGGCCGCCCTGTATGGACTGTACCTGTGCTTTACCTCC GCCAAGTGGGAGACACTGCTGTTCTCTTTTGTGCTGTTCCACATGAGCAATATCGGAATCA CCGCAGGAG CACA CAGGCTGTGGAC CCACAAGAC ATTCAAG GCCAAG CTGCCTCTG GAGAT CGTGCTGATGATCTTCAACTCTCTGGCCTTTCAGAATACCGCCATCACATGGGCCGGGAG CACAGAC TGCAC CACAAGT ATAGCGACACCGATGCA GAC CCACA CAAC GCAAG CAGGGCT TCTT1 'TACTCCCACGTGGGCTGGCTGCT GGT GAAGAAGCACCCCGACGTGCT GAAGTATGG CAAGACAAT CGACAT GTCCGAC GTGTACAACAAT CCCG TGCTGAA GTTTCAGAAGAAGT AT GCCGTGCCTCTGATCGGCACCGTGTGCTTCGCCCTGCCAACACTGATCCCCGTGTATTGTT GGGGCGAGTCTTGAACAATGCCTGGCACATCGCCCTGTTCCGGTACATCTTTAACCTGAA TGTGACCTTTCTGGTGAACCTCCGCCGCCACATCTGGGGCAATAAGCCTTACGACAAGTCT ATCCTGCCAGCCAGAACCTGCTGGTGTCTTCTGCTCTGCGGAGGGCTTTACAATT ATCAC CACGTGTTCCCATGGGACTACAGGAC CGCAGAG CTGGGCAACAAT TTTCTGAACCT</p>

	<p>GACCACACTGTTTCATCGATTTTTGTGCCTGGTTTCGGCTGGGCCTATGACCTGAAGTCTGTG AGC GAG GAT ATCAT CAAGC AGA GGGCAA GAGGACA GGCGAT GGCAGCT CCGGCGT GAT CT GGGGAT GGGACGATAAGGATAT GGACAGAGAT ATCAAGAGC AAGGCCAATATCTTCTACGC CAAG AAG GAG TGA</p>
SEQ ID NO: 27	<p>H. zeae Zll desaturase <i>Homo sapiens</i> optimized</p> <p>ATGGCACAGTCATATCAGAGCACTACCGTCCTGAGCGAAGAGAAGGAAGTACACTGCAGC ACCTGGTCCCA CAGGCATCA CCTAGAAAGT ACCAGAT CGTGTAT CCAAAC CTGAT CACCTT CGGCTACTGGCACATCGCCGGCCTGTACGGCCTGTATCTGTGCTTTACCTCCGCCAAGTGG GCCACAATCCTGTTCTCTTACATCCTGTTTGTGCTGGCAGAGATCGGAATCACCGCAGGAG CA CACAGAC TGTGGGCACAC AAGACAT ATAAG GCCAAG CTGCCCCCTGGAGAT CCTGCTGAT GGTGTTCAACAG CAT CGCCTTTT CAGAAT TCCGCCAT CGAT TGGGTGCGG GAC CACAGAC TG C.ACCACAA GTA CTCCGACA CCGAT GCCGACCCCCA CAAC GCCTCTAG GGGCTTCTTTTATA GCCACGTGGGATGGCTGCTGGTGGGAAGCACCTGAGGTGAAGAAGAGAGCAAGGAGCT GAAT ATGTCTGAT ATCTA CAAC AAT CTGTGCTGCGCTTC CAGAAGAAGT ATGCCAT CCca. TTCATCGGCGCCGTGTGCTTTGCCCTGCCACCATGATCCCCGTGTACTTTTGGGGCGAGA CAT GGAG CAAC GCCTGGCACATc.ACAAT GCTGCGGTA TATCAT GAAC CTGAAT GTg.Ac.AT CCTGGT GAAC TCCGCCGCCCA CATCTGGGGCAAT AAGCCATACGAC GCCAAGAT CCTGCC GCCCAGAAC GTGGCCGT ga.GCGTGGCAAC CGga.GGAGAG GGCTTCCAC AAT TACCAC CAC G TGTTTCCTT GGG.ATAT CGGGCCGCC GAG CTGGGCAAC AAT TCTCTGAAT CTg.Ac.CAAA GTTTCATCGACCTGTTTGGCCCATCGGCTGGGCTATGATCTGAAGACAGTGGCGAGGAC ATGAT CAAGCAGAGGAT CAAGCGCACCGGC GAT GGCACAGACCT GTGGGGGCACGAGCAGA ACT GTGAT GAAGT GTGGGAT GTGAAAGACAAGT CCT CCTAA</p>
SEQ ID NO: 28	<p>y. lipolytica OLE1 leader - T. ni Zll desaturase <i>Homo sapiens</i> optimized</p> <p>ATGGT GAAGAAC GTGGACC.AGGT GGAT CTGTCTCA GGTGg.ACA CCAT CGCAAGCGGAAGGG ATGTGAATTATAAGGT GAAGT ACACATCTGGCGTGAAGACCACCAAGAAAGTACAAGTA TATCTACACCAACTTCTGACATTTTCTTACGCCACCTGGCCGCCCTGTATGGCCTGTAC CTGTGCTTTTACCAGCGCCAAGTGGGAGACACTGCTGTTCTCCTTTGTGCTGTTCCACATGT CTAAT ATCGGAAT CAC CGCA GGAG CACA CA GGCTGTGGAC CCAC AAGACAT TCAAG GCCA A GCTGCCCTTGGAGAT CGTGCTGAT GAT CTTCAAC TCCCTGGCTTTT CAGAAT ACCGCCAT C ACATGGGCCCCGGGAG CACAGAC TGCAC CA AAGT ATTCTGAC ACCg.ATGCA GACCA CACA .AcGCAAG CA.GGGGCTTCTTTT.AcTCCAC GTGGGCTGGCTGCTGGT GAAGAAG CAC CCT GA CGTGCTGAAGTATGGCAAGACAATCGACATGAGCGACGTGTACAACAATCCTGTGCTGAAG TTTCAGAAGAAGTATGCCGTGCCACTGATCGGCACCGTGTGCTTCGCCCTGCCCACTGA TCCCCGTGTACTGTTGGGGCGAGTCTTGAACAATGCCTGGCACATCGCCCTGTTCCGGTA CATCTTTAACCTGAATGTGACCTTTCTGGTGAACAGCGCCGCCACATCTGGGGCAATAAG CCATACg.Ac.AAGTCCAT CCTGCCCGCC CAGAAC CTGCTGGTGTCTTCTTGGCCTCTGGCG AGGGCTTTCACAATTATCACCACGTGTTCCCTTGGGACTACAGGACCGCAGAGCTGGGCAA CAAT TTTCTGAAC CTGAC c.ACA CTGTT CAT CGAT TTTGTGCCTGGTTCGGCTGGGCCTAT GAC CTGAAGT CTGTGAG CGAG GAT ATCA TCAAG CAGAG GGCAAAG AGGACA GCGGATGGCA GCTCCGGCGT GAT CTGGGGAT GGGAC GATAA.GGATA TGGAC AGAGAT ATCAAGT CCAAG GC CAATA TCTTCTA CGCCAAGAAG GAGT GA</p>
SEQ ID NO: 29	<p>y. lipolytica OLE1 leader - H. zeae Zll desaturase <i>Homo sapiens</i> optimized</p> <p>ATGGT GAAAAAC GTGGAC CAAGT Gg.ATCTCTCGCA GGTGg.ACA CCAT TGCCTCCGGCC GAG ATGTCAACTACAAGGTCAAGTACACCTCCGG CGTTCGCAAGTATCAGATCGTGTATCCTAA CCTGATCACCTTCGGCTACTGGCATATCGCTGGACTGTACGGACTGTATCTGTGCTTCACT TCCGCCAAGTGGGCCACCATCCTGTTCTTACATCCTGTTTGTGCTGGCAGAGATCGGAA</p>

	<p>TCACCGCAGGAG CACACAGAC TGTGGGCACACAA GACATATAAGGCCAAG CTGCCACTGGA GAT CCTGCTGAT GGTGTTCAA CAGCAT CGCCTTTCA GAAT TCCGCCAT CGAT TGGGTGCGG GAC CACAGACT GCA CCAAGT A CTCCGACACAGAT GCCGAC CCCACAAC GCCTCTA GGG GCTTCTTTTATAGCCACGTGGGATGGCTGCTGGTGCGGAAGCACCCCTGAGGTGAAGAAGAG AGGCAAGGAGCTGAATATGTCTGATATCTACAACAATCCTGTGCTGCGCTTCCAGAAGAAG TATGCCAT CCCAT TCAT CGGCGCCGTGTGCTTTGCCCTGCCCA CCAT GAT CCCCGTGACT TTTGGGCGGAGACATGGAGCAACGCCTGGCACATCACAATGTGCGGTATATCATGAACCT GAAT GTGACATTCTGGTGAAC TCCGCCGC CACATCTGGGGCAATA_AGCCATACGAC GCC AAGATCCTGCCCGCCAGAACGTGGCCGTGAGCGTGGCAACCGGAGGAGAGGGCTTCCACA ATTA CCAC CAC GTGTTTCCAT GGGAT TA TA GGGCA GCAGAG CTGGGAAAC AAT TCTCTGAA TCTGAC CACAAAG TTCATCGAC CTGTTTGCCGCCAT CGGCTGGGCCTAT GAT CTGAAGACA GTGAGCGAGGACATGATCAAGCAGAGGATCAAGCGCACCGGCGATGGCACAGACCTGTGGG GGCAC GAG CAGAAT TGTGAT GAAGT GTGGGATGT GAAG GATAAAAGC AGTT GA</p>
SF.Q ID NO: 30	<p>Native <i>A. transitella</i> Zll desaturase</p> <p>ATGGTCCCTAACAGGGTTCCAGTGACGTTTTGTCTGAACATTCTGAGCCCCAGTTCACCTA AAC TCATA GCTCCA CAAGC A GGGCCGAG GAAAT A CAAGAT AGT GTATCGAAAT TTGCTCAC ATTGCGCTATTGGCACTTATCAGCTGTTTATGGGCTCTACTTGTGCTTTACTTGTGCGAAA TGGGCTACCATCTTATTGCTTTTTCTTATACGTGATCGCGGAAATCGGTATAACAGGTG GCGCTCATAGGCTATGGGCACATCGGACTTATAAAGCCAAAGTGCCTTTAGAGATTTTGT ACTCATAAT GAAT TCTAT TGCCTTCCAAGAC ACTGCTTTCAC CTGGGCTCGAGAT CAC CGC CTTCAT CACAAAT ATTCCGAT A CTGAC GCTGAT CCCCACAAAT GCTA CCAGAG GGTTTTTCT ATT CACATGTAGGCTGGCTTTTGGTGAAGAAACACCT GAAGT CAAAG CAAGAGGAAAATA CTTGTGTTAGATGATCTTAAGAATAATCCATTGCTTAAATCCAAAAGAAATACGCTATT CTAGT TATA GGCACGTTAT GCTTCTTAT GGC.AACA TTTGTGCCCGTATA CTCTGGGGCG AGGGCAT CAGCAC GGCCTGGAAC ATCAAT CTATTGCGATA CGTCAT GAAT CTTAAC ATGAC TTTCTTAGTTAACAGTGCAGCGCATATCTTTGGCAACAAACCATAACGATAAGAGCATAGCC TCAGTCCAAAATATTTAGTTAGCTTAGCTACTTTTGGCGAAGGATTCATAATTACCATC ACACTTACCCCTGGGATTATCGTGCGGCAGAATTAGGAAATAATAGGCTAAATATGACTAC TGCTTTCA TAGAT TTTCTCGCTTGGAT CGGCTGGGCTTAT GACTTGAAGT CTGTGCCA CAA GAGGCCATTGCAAAAAGGTGTGCGAAAACCTGGCGATGGAACGGATATGTGGGGTCGAAAAA GATAA</p>
SEQ ID NO: 31	<p>pPV0228 ___-___ Zll ___ Helicoverpa zea ___ desaturase</p> <p>ATGGCCCAAAGCTATCAATCAACTACGGTTTTTGAGTGAGGAGAAAGAACTAACATTACAAC ATTTGGTGCCCCAAGCATCGCCAGGAAGTATCAAATAGTGATCCGAACCTCATTACGTT TGGTTACTGGCACATAGCCGACTTTATGGCCTTTACTTGTGCTTCACTTCTGCTAAATGG GCTACGATTTTATTAGCTACATCCTCTTCGTGTTAGCAGAAATAGGAATCACGGCTGGCG CTCACAGACTCTGGGCCACAAAACCTTACAAAGCGAAACTACCATTAGAAATACTCTTAAT GGTATTCAACTCCATCGCTTTTCAAACCTCAGCCATTGACTGGGTGAGGGACCACCGACTC CACCATAAGTATAGCGATACAGATGCTGATCCCCACAATGCCAGCCGAGGGTTCTTTTATT CCCAT GTA GGAT GGC.TA CTTGTGAGAAAAC ATCCTGAAG TCAAAAAG CGAG GGAAAGAAC T CAAT ATGTCCGATA TTTA CAAC AAT CCTGTCTTACGGTTT CAGAAAAAT ACGCCATACCC TTCAATTGGGGCTGTTTGTTCGCTTACCTACAAT GATACCTGTTTACTTCTGGGGAGAAA CCTGGTCCAATGCTTGGCATATCACCATGCTTCGCTACATCATGAACCTCAATGTCACCTT TTTGGTAAACAG CGCTGCTCATATA TGGGGAAAC AAG CCTTAT GAC GCAAAAAT ATTA CCT GCACAAAATGTAGCTGTGTCGGTCGCCACTGGTGGAGAAGGTTTCATAATTACCACCATG TCTTCCCTGG GAT TAT CGAG CAGCGAAC TCGGTAAC AAT AGCCTCAAT TTAAC GAC TAA ATT CATAGATTTATTCGAGCAATC GGAT GGCATATGATTTAAAGACGGTTTCGGAGGAT ATGATAAAACAAAG GAT TAAAC GCACT GGAGAT GGAAC GGAT CTTTGGGGACACGAAC AAA ACT GTGAT GAAGT GTGGGAT GTAAAAGATAAAT CAAGTTAA</p>

SEQ ID NO: 32	<p>pPV022 8__Helicoverpa armigera reductase codon optima zed</p> <p>ATGGTCGTTTAACTTCTAAAGAGACAAAACCTTCAGTAGCTGAGTTTTATGCGGAAAAAT CTGTTTTTATTACGGGTGGCACTGGATTCCCTTGAAAGGTATTTCATAGAGAACTTTTATA TAGCTGTCCAGATATCGAGAATATCTACATGCTCATACGAGAGAAGAAAGGTCTTTCTGTT AGCGAAAGAAT AAAAC AGTTCCCTTGA TGA CCGCTCTTTACCA GA CTAAAAG A CAAAG A C CA GCT GAC TTAGAGAAGAT TGTA TTA TA CCA GGAGAT A TTA CTGCTCCTGAC TTA GGCAT T.AATTCTGAAAAC GA GAAGAT GCTTA TAGAGAAG GTATCGGTGAT TATT CAT TCGGCTGCT ACGGTGAAGTTAATGAGCCTCTCCCTACGGCTTGGAAGATCAACGTGGAAGGAACCAGAA TGAT GTTAGCTTT GAGT CGAAGAAT GAAG CGGAT TGAG GTTTT CAT TCA CA TA TCGAC AGC ATACACGAACACAAACAGGGAAGTGGTTGACGAGATCTTATACCCAGCTCCTGCTGATATC GAC CAAGT T CAT CAGT A TGT CAAAGAT GGAAT CTCTGAG GAAGAC A CTGAGAAAAT A TTAA ATGGTCGTCCAAATACGTACACGTTTACGAAAGCGTTAACTGAGCATTTAGTTGCTGAGAA CCAAGCCTACGTACCCACTATTATCGTCAGGCCGTGAGTCGTGGCAGCAATAAAAGATGAG CCATTAAAAGTTGGTTAGGCAACTGGTTTGGAGCGACTGGTCTCACCGTGTTCACCGCTA AGGGTCTCAACCGAGTCATCTACGGTCATTCTAGCTACATCGTAGACTTAATTCCTGTGGA TTATGTCGCTAATTTAGTGATTGCTGCTGGGCTAAGAGTAGCAAGTCAACTGAGTTGAAG GTATACAACCTGCTGCAGCAGCTCCTGCAATCCCGTCACTATTGGCACGTTAATGAGCATGT TTGCTGACGATGCCATCAAACAGAAGTCGTATGCTATGCCGCTACCGGGTGGTACATATT CACGAAATATAAGTGGTTAGTTCTTCTTTTAACTTCTCTTCCAAGTTATACCGCGTAT GT CACAGAT CTCTCCAG GCACTT GATT GGAAGAGTCCACGGTACATAAAACT CCAAT CAC TAGTAAATCAAACGCGCTCTTCAATCGACTTCTTCACGAATCACCTCGGTGATGAAGGC AGACA GAGT GAGAGA GTTATA TGCGTCTCTTTCCCCCGCAGAC.AAGTA CTTATTTCCCTGT GAT CCTA CGGACATTA ACT GGAC A CATT A CA TA CAAGAC TA CTGTTGGGGAGT CCGACATT TTTTGGAGAAAAAAG C.T.AC GAAT AA</p>
SEQ ID NO: 33	<p>pPV022 8__ICL__promoter</p> <p>TATTAGGCGAAGAGGCATCTAGTAGTAGTGGCAGTGGTGAGAACGTGGGCGCTGCTATAGT GAAGAAT CTCCAGTCGATGGTTAAGAAGAAGAGTGACAAACCAGCAGT GAAT GACTTGTCT GGGTCCGTGAGGAAAAGAAAGAAGCCCGACACAAAGGACAGTAACGTCAAGAAACCCAAGA AATA GGGGGGAC CTGTTTAGAT GTA TA GGAAT AAAAC TCCGAGAT GAT CTCATGTGTAA TGGAGTTGTAATATTGCAAAGGGGAAAATCAAGACTCAAACGTGTGTATGAGTGAGCGTA CGTATATCTCCGAGAGT AGT A TGACAT AAT GAT GACTGTGAAT CAT CGTAAT CTCA CACAA AAACCCCATTTGTCGGCCATATACCACACCAAGCAACACCACATATCCCCCGGAAAAA CGTAAAAAAGAAAC AAT CAAACTACAAC CTACT CCTTGAT CACACAGT CATT GAT CA A GTTACAGTTCCTGCTAGGGAATGACCAAGGTACAAATCAGCACCTAATGGTTAGCACGCT CTCTTACTCTCTCTCACAGT CTTCCGGCCCCCTAT TCAAAAT TCTGc.acTTCCAT TTGAC CC CA GGGT TGGGAAAC AGGGCCA CAAAGAAAAAC CCGAC GTGAAT GAAAAAC TAAGAAAAG AAAAAAAT TATCACAC CAGAAAT TTA CCTAAT TGGGTAAT TCCCAT CGGTGTTTTTCTG GATTGTCGCACGCACGCATGCTGAAAAAGTGTTCGAGTTTGTCTTTGCTTCGGAGTTTC ACGCAAGTTTTTCGATCTCGAACCAGGAGGCGGTGCGCCTTGTGTTTGTGATGTCGTGCT TTGGGTGTTCTAATGTGCTGTTATTGTGCTCTTTTTTTTCTTCTTTTTTTGGTGATCATA TGATATTGCTCGGTAGATTACTTTCTGTGTAGGTATTCTTTTAGACGTTTGGTTATTGGG TAGAT A TGAGAGAGAGAGAGT GGGT GGGGAGGAGTT GGTT GT.AGGAGGG.AC CCCT GGGAG GAAGT GTAGTTGAG TTTTCCCTGAC GAA TGAAAAT ACGTTTTTGAGAAGAT AATACA GGAA AGGTGTGTCGGTGAATTTCCATCTATCCGAGGATATGAGTGGAGGAGAGTCGTGTGCGTGT GGTTAATTTAGGATCAGTGGAACACACAAAGTAAC TAAGACAGAGAGACAGAGAGAAAAAT CTGGGAAGAGACAAAGAGTCAGAGTGTGTGAGTTATTCTGTATTGTGAAATTTTTTTGCC C.AACTACAT .AATA TTGCTGAAA CTAAT TTTACTTAAAAAGAAAAAG CCAAC AAC GTCCCCA G TAAAAC TTTTCTA TAAAT ATCA GCAGT TTTCCCTTCCCTC CAT TCCTCTTCTGTCTTTTT TCTTACTTTCCCTTTTTTATACCTTTTCATTATCATCCTTTATAATTGTCTAACCAACAAC TATATAT CTAT CAA</p>

296

	<p>ATCTGGGCATCAACTCCGAGAATGAGAAGATGCTGATCGAGAAGGTGTCCGTGATCATCCA CTCTGCCGCCA CCGTGAAGT TCAAC GAG CCCCTGCCTACA GCCTGGAA. GAT CAAT GTGGAG GGCA CcA GGAT GA TgctGGCCCT GAGC CGGAGAAT GAAG cGCAT CGAG G TgTTTA TCCA CA TCTCCACAGCCTACACCAACACAAATCGGAGGTGGTGGACGAGATCCTGTACCCAGCCCC CGCCGACA TCGAT CA GgT GCA CcAGT A TGTGAAG GAC GGCA T cA GCGAG GAG gAT A CCGAG AAGATCCTGAACGGCCGGCCAAATACCTACACATTACCAAGGCCCTGACAGAGCACCTGG TGGCCGAGAACCAGGCCTATGTGCCTACCATCATCGTGAGACCATCCGTGGTGGCCGCCAT CAAGGATGAGCCCTGAAGGGATGGCTGGGAACTGGTTCGGAGCAACAGGACTGACCCGTG TTTAcAGCCAA GGGCCTGAAT AGAG TGAT CTAcGGCCACAG CTCCTATATCGTGGAC CTGA TCCCCGTGGATTACGTGGCAAACCTGGTCATCGCAGCAGGAGCCAAGTCTAGCAAGTCTAC CGAGCTGAAGGTGTATAACTGTGTCTCCTCTAGCTGTAATCCTGTGACCATCGGCACACTG ATGTCCATGTTTCGCCGACGATGCCATCAAGCAGAAGTCTTACGCCATGCCTCTGCCAGGCT GGTACATCTTTACAAAGTATAAGTGGCTGGTGTGCTGCTGACCTTCCTGTTTCAGGTGAT CCCAgCCTA CGTGACCGAT CTGTCTAG GCA CCTGATCGGCAAGAG CCCCCGCTATATCAA G CTGCAGTCTCTGGTGAACCAGAC CAGGTCTCTATCGACTTCTTTACAAATCACAGCTGGG TCATGAAG GCCGAT AGGGTGGCGGAGC TGTA CGCCTCTCTGAG CCC TGCCGACAAG TAT CT GTTCCCTGC GAC CCTA CCgAT A T CAAT TGgAC A CA CTACAT CCAGGAT TAT TGTTGGGGC GTGCGCCA CTTCCTGGAGAAGAAG TCCTAT GAgT GAG CCTGAAGAG C</p>
SEQ ID NO: 38	<p>NcoI-pTAL-Alel (insert into pPV247 creating pPV248)</p> <p>CCATGGGTAAGCAGGTGGCTCCGTTTGTGTCTTTGTGTTTTCCCTCCTTTTGGACCAT TTGTGAGCATGTTGCGTAGGTCTGGGTGTTTGACTGTTCAAGTGGTGGATGACGGATGCAT CATCTGACGGCAGAGTGGGTACCTGGCAGTGGCAGGCTCGCAGACGAGGTAGAGAGATTCT GAAAGGAGCCATTGACAGATGGAGAATTGGATACTCCTGATATGCTCCGTTTCCACTTT TGAC GTTGGTg.AcGTGCTCTGgAAC GAC TTTTTTCTTTTCTTTAAAC AAAAAAAGAAA GAAAAAACAATTTACTACTACAGTAGTACACCTCAACATTGGGTCCAGAACGTCCCA ACT GCAT GAGT CACT GGAGT CAT GCCAGGT CGCTAAGGTGCT GTAAATACAACGT CAAT TGAGAG A G_A.CA CA GGCGC_{AG} CGCGCCGAG GGAGAAA CGAGG CAT TTATCTTCTGAC CCTCC TTTTACTCGTAATCTGTATCCCGGAACCGCTCGCATCCATGTTAATTAAATCAACACTT A CACT TGCTTGCTTC_GTATGAT GAAGAT TTCTGACTGGCAAC CC_{AGT} CAG CAG C_{AGAT} TGG GGCAGATGTAGTAATGAAAAACTGCAAGGTGTGACGTTTGAGACACTCCAATTGGTTAG AAAGC GAC AAAGAAGAC GTCGAAAAAT ACCGAAAAAT CGAGT CTTTTCTTTCTGCGTA TTGGGCCCTTCTTGCTC_{CT}TTGCCGCCCTT TCCA CGCTCTTTCACAC CCTCACAC TCCCT GAG CAC TAT GAT CTCAT TGCGCAAT AAGAT A TA CATGCA CGTGCA TTTGGTGAGCA CGCAG AACCTTGTGGGGGAAGATGCCCTAACCTAAGGGCGTTCCATACGGTTCGACAGAGTAAC CTTGCTGTC G_{A,T} TATAAC GCATA TA TAGCCCCCCTTCGGAC CCTCCTTCTGAT TTCTGT TTCTGTA TCAACA TTACACACAAACACACAAT GGTG</p>
SEQ ID NO: 39	<p>pDSTOOS __ Sesamia inferens desaturase</p> <p>MLSQEEPTDTSLVPPAAPRKYQIVPNLITFGYWHLAGLYGLYLCFTSAKWTTILFSFILC VIAETGVTAGAHRLWAHKTYKANLPLQILLMVMNSIAFQNSAIDWVRDHLHHKYSDDAD PHNASRGFFYSHVGWLLVKKHPEVKRKGELDMSDI YSNPVLRFQKQYAI PFIGAVCFILP TVI PVYCWGETWTNAWHITMLRYITNLNVTFLVNSAAHIWGYKPYDENILPAQNIASVIAT CGEGFHNYHHVFPWDYRAAELGNLNLNLTTFIDFFAWLGWAYDLKTVSSDMIKLRAKRTG DGTNLWGEHNDELKEGKED</p>
SEQ ID NO: 40	<p>H. armigera FAR from SEQ ID NO: 37</p> <p>ATGGTGGTGTGACCAGCAAGGAGACAAAGCCTTCCGTGGCCGAGTTCTACGCCGCAAGT CCGTGTTTATCACAGCGGCCACCGCTTCTGGGCAAGGTGTTTATCGAGAAGCTGCTGTA CTCTTGCC CAGAC ATCGAGAAC ATCTATATGCTGAT CCGGGAGAAGAAG GGCCTGAG CGTG TCCGAGAGAAT CAAG CAGTTCTTGGAC GAT CCCCTGTTTACA CGGCTGAAGGACAAGAGAC</p>

	<p>CTGCCGAT CTGGAG AAGA TCGTGCTGAT CCCA GCGGAC A TCA CCGCA CCAGATCTGGGCAT CAACTCCGAGAATGAGAAGATGCTGATCGAGAAGGTGTCCGTGATCATCCACTCTGCCGCC A CCGTGAAGT TCAAC GAGC CCCTGCCTA CA GCCTGGAAGAT CAAT GTGGAG GGCAC CA GGA TGATGCTGGCCCTGAGCCGAGAATGAAGCGCATCGAGGTGTTTATCCACATCTCCACAGC CTACAC CAACAC AAAT CGGGAG GTGGTGGAC GAGAT CCTGTA CCCA GCCCCGCC GAC ATC GAT CA GG TGCAC CA GT ATGTGAAG GAC GGCATCA GCGAGGAG GAT A CCGAGAAGA TCCTGA A CGGCCGGCCAAAT A CCTA CA CATTCAC CAAGG CCCTGACAGAG CAC CTGGTGGCCGAGAA CCAGGCCTATGTGCCTACCATCATCGTGAGACCATCCGTGGTGGCCGCCATCAAGGATGAG CCCCGGAAGGATGGCTGGGAACTGGTTCGGAGCAACAGGACTGACCGTGTTTACAGCCA AGGGCCTGAATAGAGTGATCTACGGCCACAGCTCCTATATCGTGGACCTGATCCCCGTGGA TTACGTGGCAAACCTGGTCATCGCAGCAGGAGCCAAGTCTAGCAAGTCTACCGAGCTGAAG GTGTATAACTGCTGTTCTCTAGCTGTAATCCTGTGACCATCGGCACACTGATGTCCATGT TCGCCGAC GAT GCCAT ca7-VG CAGAAGT CTTA CGCCAT GCCTCTGCCAG GCTGGTAGA TCTT TACAAAGTATAAGTGGTGGTGTGCTGCTGCTGACCTTCTGTTCAGGTATCCCAGCCTAC GTGACCGATCTGTCTAGGCACCTGATCGGCAAGAGCCCCGCTATATCAAGCTGCAGTCTC TGGTGAACCAGACAGGTCTCTATCGACTTCTTTACAAATCACAGCTGGGTGATGAAGGC CGATA GGGTGCGCGAG CTGTA CGCCTCTCTGAG CCCTGCCGAC A₃GT A.TCTGTTCCCTGC GACCCTACCGATATCAATTGGACACACTACATCCAGGATTATTGTTGGGGCGTGCGCCACT TCCTGGAGAAGAAGTCTATGAGTGA</p>
SEQ ID NO: 41	<p>H. armigera alcohol forming redue base (HaFAR),</p> <p>MWLTSKETKPSVAEFYAGK3VFITGGTGFLGKVFIEKLLY3CPDIENI YMLIREKKGLS VSEIKQFLDDPLFTRLKDKRPADLEKIVLI PGDITAPDLGINSENEKMLIEKVS_{VI}IHS AATWFNEPLPTAWKINVEGTRMLALSRRMKRIE_{VI}FIHISTAYTNTNREWEILYPAP ADIDQVHQYVKDGI SEEDTEKILNGRPNTYTFTKALTEHLVAENQAYVPTI IVRPSWAA IKDEPLKGLGNWFGATGLTVFTAKGLNRVIYGHSSYIVDLIPVDYVANLVIAAGAKSSK STELKVYNCCSSSNPVTIGTLM_SMFADDAIKQK3YAMPLPGWYI FTKYKWLVL_{LL}TLFLF QVI PAYVTDLSRHLI GKSPRYIKLQSLVNQTRS SIDFFTNH_SWVMKADRVRELYASLS PA DKYLFPCDPTDINWTHYIQDYCWGVRHFLEKKS_YE</p>
SEQ ID NO: 42	<p>HaFAR S60A</p> <p>MWLTSKETKPSVAEFYAGK3VFITGGTGFLGKVFIEKLLYSCPD_IENI YMLIREKKGLAV 3ERIKQFLDDPLFTRLKDKRPADLEKIVLI PGDITAPDLGIN3ENEKMLIEKVS_{VI}IHSAA TVKFNEPLPTAWKINVEGTRMMLALSRRMKRIE_{VI}FIHISTAYTNTNREVVDEILYPAPADI DQVHQYVKDGI SEEDTEKILNGRPNTYTFTKALTEHLVAENQAYVPTI IVRPSWAAIKDE PLKGWLG_NWFGATGLTVFTAKGLNRVI YGHS3YIVDLI PVDYVANLVIAAGAKSSKSTELK VYNCCSSSNPVTIGTLM_SMFADDAIKQKSYAMPLPGWYIFTKYKWLVL_{LL}TLFLFQVI PAY VTDLSRHLI GKS PRYIKLQSLVNQTRS SIDFFTNH_SWVMKADRVRELYASLS PADKYLFPC DPTDINWTHYIQDYCWGVRHFLEKKS_YE</p>
SEQ ID NO: 43	<p>HaFAR S195A</p> <p>MVLTSKETKPSVAEFYAGKSVFITGGTGFLGKVFIEKLLYSCPD_IENIYMLIREKKGLSV SERIKQFLDDPLFTRLKDKRPADLEKIVLI PGDITAPDLGINSENEKMLIEKVS_{VI}IHSAA TVKFNEPLPTAWKINVEGTRMMLALSRRMKRIE_{VI}FIHISTAYTNTNREVVDEILYPAPADI DQVHQYVKD_GIAEEDTEKILNGRPNTYTFTKALTEHLVAENQAYVPTI IVRPSWAAIKDE PLKGWLG_NWFGATGLTVFTAKGLNRVI YGHSSYI VDLIPVDYVANLVIAAGAKSSKSTELK VYNCCSSSNPVTIGTLM_SMFADDAIKQKSYAMPLPGWYIFTKYKWLVL_{LL}TLFLFQVI PAY VTDLSRHLI GKS PRYIKLQSLVNQTRS SIDFFTNH_SWVMKADRVRELYASLS PADKYLFPC DPTDINWTHYIQDYCWGVRHFLEKKS_YE</p>
SEQ ID NO: 44	<p>HaFAR S298A</p>

	<p>MWLT5KETKPSVAEFYAGKSVFITGGTGFLGKVFIEKLLYSCPD IENI YMLIREKKGLSV SERIKQFLDDPLFTRLKDKRPADLEKI VLI PGDITAPDLGINSENEKMLIEKVSVI IHSAA TVKFNEPLPTAWKINVEGTRMMLALSRRMKRIEVFIHI 3TAYTNTNREVVEILYPAPADI DQVHQYVKDGI SEEDTEKILNGRPNTYTF TKALTEHLVAENQAYVPTI IVRPSWAAIKDE PLKGWLGWFGATGLTVFTAKGLNRVI YGHS SYIVDLI PVDYVANLVIAAGAKASKST ELK VYNCCSSSCNPVTIGTLMMSMFADDAIKQKSYAMPLPGWYIFTKYKWLVLTLTFLFQVI PAY VTDLSRHLI GKS PRYI KLQSLVNQTRS SIDFFTNSWVMKADRVREL YAS LSPADKYLFP DPTDINWTHYIQDYCWGVRHFLEKKSYE</p>
SEQ ID NO: 45	<p>HaEAR S378A</p> <p>MVVLTSKETKPSVAEFYAGKSVFITGGTGFLGKVFIEKLLYSCPD IENIYMLIREKKGLSV SERIKQFLDDPLFTRLKDKRPADLEKI VLI PGDITAPDLGINSENEKMLIEKVSVI IHSAA TVKFNEPLPTAWKINVEGTRMMLALSRRMKRIEVFIHI STAYTNTNREWEILYPAPADI DQVHQYVKDGI SEEDTEKILNGRPNTYT FT KALTEHLVAENQAYVPTI IVRPSWAAIKDE PLKGWLGWFGATGLTVFTAKGLNRVI YGHSS YIVDLIPVDYVANLVIAAGAKSSKSTELK VYNCCSSSCNP\T?IGTLMMSMFADDAIKQKSYAMPLPGWYIFTKYKWLVLTLTFLFQVI PAY VTDLSRHLI GKAPRYI KLQSLVNQTRS SIDFFTNSWVMKADRVRELYASLS PADKYLFP DPTDINWTHYIQDYCWGVRHFLEKKSYE</p>
SEQ ID NO: 46	<p>HaFAR S394A</p> <p>MWLT5KETKPSVAEFYAGKSVFITGGTGFLGKVFIEKLLYSCPD IENI YMLIREKKGLSV SERIKQFLDDPLFTRLKDKRPADLEKI VLI PGDITAPDLGINSENEKMLIEKVSVI IHSAA TVKFNEPLPTAWKINVEGTRMMLALSRRMKRIEVFI HI STAYTNTNREWEILYPAPADI DQVHQYVKDGI SEEDTEKILNGRPNT YTF TKALTEHLVAENQAYVPTI IVRPSWAAIKDE PLKGWLGWFGATGLTVFTAKGLNRVI YGHSS YIVDLI PVDYVANLVIAAGAKSSKSTELK VYNCCSSSCNP\TIGTLMMSMFADDAIKQKSYAMPLPGWYIFTKYKWLVLTLTFLFQVI PAY VTDLSRHLI GKS PRYI KLQSLVNQTRSAI DFFTNSWVMKADRVRELYASLS PADKYLFP DPTDINWTHYIQDYCWGVRHFLEKKSYE</p>
SEQ ID NO: 47	<p>HaFAR S418A</p> <p>MWLT5KETKPSVAEFYAGKSVFITGGTGFLGKVFIEKLLYSCPD IENI YMLIREKKGLSV SERIKQFLDDPLFTRLKDKRPADLEKI VLI PGDITAPDLGINSENEKMLIEKVSVI IHSAA TVKFNEPLPTAWKINVEGTRMMLALSRRMKRIEVFIHI STAYTNTNREWEILYPAPADI DQVHQYVKDGI SEEDTEKILNGRPNT YTF TKALTEHLVAENQAYVPTI IVRPSWAAIKDE PLKGWLGWFGATGLTVFTAKGLNRVI YGHSS YIVDLI PVDYVANLVIAAGAKSSKSTELK VYNCCSSSCNPVTIGTLMMSMFADDAIKQKSYAMPLPGWYIFTKYKWLVLTLTFLFQVI PAY VTDLSRHLI GKS PRYI KLQSLVNQTRS SIDFFTNSWVMKADRVREL YAS LAPADKYLFP DPTDINWTHYIQDYCWGVRHFLEKKSYE</p>
SEQ ID NO: 48	<p>HaEAR S453A</p> <p>MWLT5KETKPSVAEFYAGKSVFITGGTGFLGKVFIEKLLYSCPD IENIYMLIREKKGLSV SERIKQFLDDPLFTRLKDKRPADLEKI VLI PGDITAPDLGINSENEKMLIEKVSVI IHSAA TVKFNEPLPTAWKINVEGTRMMLALSRRMKRIEVFIHI STAYTNTNREWEILYPAPADI DQVHQYVKDGI SEEDTEKILNGRPNTYT FT KALTEHLVAENQAYVPTI IVRPSWAAIKDE PLKGWLGWFGATGLTVFTAKGLNRVI YGHSS YIVDLIPVDYVANLVIAAGAKSSKSTELK VYNCCSSSCNP\TIGTLMMSMFADDAIKQKSYAMPLPGWYIFTKYKWLVLTLTFLFQVI PAY VTDLSRHLI GKS PRYI KLQSLVNQTRS SIDFFTNSWVMKADRVRELYASLS PADKYLFP DPTDINWTHYIQDYCWGVRHFLEKKAYE</p>
SEQ ID NO: 49	Txichoplusia ni desaturase

	MAVMAQTVQETATVLE EEARTV?LVAPKTTPRKYKYIYTNFLTFSYAHLAALYGLYLCFTS AKWETLLFSFVLFHMSNIGITAGAHRLWTHKTFKAKLPLEI VLMI FNSLAFQNTAITWARE HRLHHKYSDDADPHNA3RGFFFYSHVGWLLVKKHPDVLKYGKTIDMSDVYNNPVLKFQKKY AVPLIGTVCFALPTLI PVYCWGESWNNAWHIALFRYI FNLNVTFLVNSAAHIWGNKPYDKS ILPAQNLLVSFLASGEGFHNHYHVPWDYRTAELGNNFLNLTTFLIDFCAWFGWAYDLKSV SEDIKQRAKRTGDGSSGVIWGWDKMDRDIKSKANI FYAKKE
SEQ ID NO: 50	T. pseudonana desaturase encoded by SEQ ID NO: 11 TSMDFLSGDPFRTLVLAAALWIGFAAAWQCFYPPSIVGKPRTLSNGKLNTRIHKLYDLSS FQHPGGPVALSLVQGRDGTALFESHHPFI PRKNLLQIL3KYEVPSTEDSVSFIATLDELNG ESPYDWKDIENDDFVSDLRALVIEHFSPIAKERGVSLESSKATPQRWMMVLLLLASFFLS IPLYLSGSWTEVVVTPILAWLAVWYVraDATHFALSSNWII^AALPyLLPLLSSPSMWYHH HVI GHAYTNI SKRDPDIAHAPQLMREHKS IKWRPSHLNQTQLPRILFIWS IAVGI GLNLL NDVRALTKLSYNNWRVEKMS SSRTLLHFLGRMLHI FVTTLPFLAFPVWKAIVWATVPNA ILSLCFMLNTQTNHLINTCAHASDNNFYKHQWTAONFGRSSAFCFTFSGGLNYQIEHLL PTVNHCHLPALAPGVERLCKKHGVTYNSVEGYREAI IAHFAHTKDMSTKPTD
SEQ ID NO: 51	T. pseudonana zll desaturase encoded by SEQ ID NO: 23 MDFLSGDPFRTLVLAAALWIGFAAAWQCFYPPSIVGKPRTLSNGKLNTRIHKLYDLSSFQ HPGGPVALSLVQGRDGTALFESHHPFI PRKNLLQILSKYEVPSTEDSVSFIATLDELNGES PYDWKDI ENDDFVSDLRALVI EHFS PLAKERGVSLVES SKATPQRWMMVLLLLAS FFLS IP LYL3GSWTFV\^PIL-AWLAVVNYWHDATHFALSSNWILNAALPYLLPLLSSPSMWYHhiiv IGHAYTNI SKRDPDIAHAPQLMREHKS IKWRPSHLNQTQLPRILFIWS IAVGI GLNLLND VRALTKLSYNNW RVEKMSSSRTTLHFLGRMLHI FVTTLPFLAFPVWKAIVWATVPNA IL SLCFMLNTQINHLINTCAHASDNNFYKHQWTAQNFGRSSAFCFI FSGGLNYQIEHLLPT VNHCHLPALAPGVERLCKKHGVTYNSVEGYREAI IAHFAHTKDMSTKPTD
SEQ ID NO: 52	Amyelois transitella desaturase MVPNKGSSDVLSEHSEPQTKLIAPQAGPRKYKIVYRNLLTFGYWHLSAVYGLYLCFTCAK WATILFAFFLYVIAEIGITGGAHRLWAHRTYKAKLPLEILLIMN3IAFQDTAFTWARDHR LHHKYSDDADPHNATRGGFFFYSHVGWLLVKKHPEVKARGKYLSDDLKNNPLKFQKKYAI LVIGTLCFLMPTFVPVYFWGEGISTAWNINLLRY VMNLNMTFLVNSAAHI FGNKPYDKSIA SVQN1 SVSLATFGEGFHNHYHTYPWDYRAAELGNNRLNMTTAFIDFFAWIGWAYDLKSVQ EAIKRCAGTGDGTDWGRKR
SEQ ID NO: 53	Agrotis segetum desaturase MAQGVQTTTILREEEPSLTFWPQEPRKYQIVyPNLITFGYWHIAGLYGLYLCFTSAKWQT TLFSFMLV\1AELGTTAGAHRLWAHRTYKAKLPLQT TLMILNSTAFQN3ATDWVRDHRLLH KYSDDADPHNATRGGFFFYSHVGWLLVRKHPEVKRRGKFLDMSDIYNNPVLRFQKKYAIPI GAMCFGLPTFI PVYFWGETWSNAWHITMLRYILNLNITFLVNSAAHIWGYKPYDIKILPAQ NIAVSIXTGGEVSITTTTFFPDYRAAELGNNYLNLTTFIDFFAWIGWAYDLKTVSSDVI KSKAERTGDGTNLWGLEDKGEEDFLKIWKDN
SEQ ID NO: 54	Helicoverpa zea desaturase MAQSYQ3TTVLSEEKELTLQHLVPQASPRKYQIVYPNLITFGYWHIAGLYGLYLCFTSAKW ATILFSYILFVLAEI GITAGAHRLWAHKT YKAKLPLEI LLMVFN SIAFQNSAI DWVRDHR LHHKYSDDADPHNASRGFFFYSHVGWLLVRKHPEVKKRGKELNMSDIYNNPVLRFQKKYAI P FIGAVCFALPTMI PVYFWGETWSNAWHITMLRYIMNLNVTFLVNSAAHIWGNKPYDAKILP AQNVAVS VATGGEGFHNHYHVPWD YRAAELGNN SLNLTTFKI D1.FAAIGWAYDLKTVS ED

	MIKQRIKRTGDGTDLWGHEQNCDEVWDVKDKSS
SEQ ID NO: 55	<p>Agrotis segetum FAR encoded by SEQ ID NO: 1</p> <p>MPVLTSREDEKLSVPEFYAGKSI FVTGGTGFLGKVFIEKLLYCCPDIDKI YMLIREKKNLS IDERMSKFLDDPLFSRLKEERPGDLEKI VLI PGDITAPNLGLSAENERI TLEKVSVI INSA ATVKFNEPLPIAWKINVEGTRMLLALSRRMKRIEVFIHI STAYSNASSDRI WDEILYPAP ADMDQVYQLVKDGVTEETERLLNGLPNTYTFTKALTEHLVAEHQTYVPTIIIRPSWASI KDEPIRGWLCNWFGATGISVFTAKGLNRVLLGKASNIVDVI PVDYVANLVIVAGAKSGGQK SDELKI YNCCSSDCNPVTLKKI IKEFTEDTIKNKSHIMPLPGWVFVTKYKWLTLTLTI IFQ MLPMYLADVYRVLTGKI PRYMKLHHLVIOTRLGIDFFT3HSWYMKTDVRRELFGLSLAEK HMFPCDPSSIDWTDYLSYCYGVRRFLEKKK</p>
SEQ ID NO: 56	<p>Spodoptera littoralis FAR encoded by SEQ ID NO: 2</p> <p>MVVLTSKEKSNMSVADFYAGKSVFITGGTGFLGKVFIEKLLYSCPDIDKI YMLIREKKGQS IRERLTKIIVDDPLFNRLKDKRPDDLKIVLI PGDITVPGLGI SEENETILTEKVS VVIHSA ATVKFNEPLATAWNVNVEGTRMIMALSRRMKRIEVFIHI STAYTNTNRAVIDEVLYPPPAD INDVHQHVKNGWEEETEKILNGRPNTYTFTKALTEHLVAENQSYMPTI IVRPSIVGAIKD DPIRGWLANWYGAT GLSVFTAKGLNRVIYGH SNHWDL IPVDYVANLVI VAGAKT YHSNEV TIYNSSSSCNPIITMKRLVGLFIDYTVKHKSVMPLPGWYVYSNYKWLVLVTVI FQVI PA YLGDIGRLLGKNPRYKQLQNLVAQTQEAHVFFTSHTWEIKSKRTSELFSSLSLTDQRMFP CDANRIDWTDYITDYCSGVRQ FLEKIK</p>
SEQ ID NO: 57	<p>Helicoverpa armigera FAR encoded by SEQ ID NO: 3 or 32</p> <p>MVVLTSKETKPSVAEFYAGKSVFITGGTGFLGKVFIEKLLYSCPDIDNIYMLIREKKGLSV SERIKQFLDDPLFTRLKDKRPADLEKIVLI PGDITAPDLGINSENEKMLIEKVSVI IHSAA TVKFNEPLPTAWKINVEGTRMMLALSRRMKRIEVFIHI STAYTNTNREVVDIELYPAPADI DQVHQYVKDGI SEEDTEKILNGRPNTYTFTKALTEHLVAENQAYVPTI IVRPSWAAIKDE PLKGWLGWNFGATGLTVFTAKGLNRVI YGHSSYI VDL IPVDYVANLVI AAGAKSSKSTELK VYNCCSSSCNP\TIGTLMSEFADDAIKQKSYAMPLPGWYIFTKYKWLVLVLLTFLFQVI PAY VTDLSRHLIGKSPRYIKLQSLVNQTRSSIDFFTNHWSVMKADRVRELYASLSPADKYLFPK DPTDINWTHYIQDYCWGVRH FLEKKSIE</p>
SEQ ID NO: 58	<p>Ostrinia fu.rnac.alis Z9 desaturase encoded by SEQ ID NO: 20</p> <p>MAPNIKDGA DLNGVLFEDDASTPDYAIATAPVQKADNYPRKLWRNIIIFAYLHIAAWGA YLFLFSKAWQTDI FAYI LYVI SGLGITAGAH RLWAHKSYSKAKW PLRLILII FNTV SFQDSA LDWSRDHRMHKYSSETDADPHNATRGFFFSHIGWLLVRKHPELKRKGGLDLSLYADPIL RFQKKYLLLMPLGCFIMPT\A/PVYF13GETWTNAFFVAALFRYTFILNVTWLVNSAAHKWG HKPYDS SIKPSENLSV SLFALGEGFHNHYHTFPWDYKTA EIGNNRLNFTTNFINFFAKIGW AYDLKTVSDEI IQNRVKRTGDGSHHLWGWDKQPKKEEXTIAAIRINPKDE</p>
SEQ ID NO: 59	<p>Lampronia capitella Z9 desaturase encoded by SEQ ID NO: 21</p> <p>MPPNWEANGVLFENDVQTPDMGLEVAPVQKADERKIQLRNIIAFACLHLAAVYGAYLF FTSAIWQTDIFAYILYVMSGLGITAGAHRLWAHKSYSKAKWPLRLILVAFNTLAFQDSADW ARDHRMHKYSSETDADPHNATRGFFFSHIGWLLCRKHPELKRKGGLDLSLYADPI IRFQ KKYLLLMPLACFVLPTI IPVYLWGESWKNFAFFVAAMFRYTFI LNVTLVNSAAHKWGGKP YDKNIQPAQNI SVAI FALGEGFHNHYHTFPWDYKTAELGNRLNFTTSFINFFASFGWAYD LKTVSDEI IQQRVKRTGDGSHHTRGWGDQDIPAEQAALRINRKDD</p>
SEQ ID NO: 60	<p>Helicoverpa zea Z9 desaturase encoded by SEQ ID NO: 22</p>

	MAPNI SEDVNGVLFESDAATPDALSTPPVQKADNRPKQLVVRNILLFAYLHLAALYGGYL FLFSAKWQTDIFAYILYVISGLGITAGAHRLWAHKSYSKAKWPLEVILVIFNTVAFQDAAMD WARDHRMHKKYSETDADPHNATRGFFFSHIGWLLVRKHPDLKEKGKGLDMSDLLADPILRF QKKYYLILMPLACFVMPVTVIPVYFWGETWTNAFFVAAMFRYAFILNVTWLVNSAAHKWGD PYDKS IKPSENLSVAMFALGEGFHNYHHTFPWDYKIAELGNNKLNFTTTTFINFAKIGWAY DLKTVSSDDIVKNRVKRTGDGSHHLWGWGDENQSKEEIDAIRINPKDD
SEQ ID NO: 61	Txichoplusia ni desaturase with Yarrowia lipolytica OLE1 leader sequence encoded by SEQ ID NO: 23 M' /KNV. 'OQVDLSQVDTIASGRDVNYKVYKTSVKTTPRKYKIYTNFLTFSYAHLAALYGLY LCFTSAKWETLLFSFVLFHMSNIGITAGAHRLWTHKTFKAKLPLEIVLMI FN3LAFQNTAI TWAREHRLHHKYSDDADPHNASRGFFYSHVGWLLVKKHPDVLYKGTIDMSDVYNNPVLK FQKKYAVPLIGTVCFALPTLI PVYCWGESWNNAWHIALFRYIFNLNVTFLVNSAAHIWGNK PYDKSILPAQNLLVSFLASGEGFHNYHHVFPWDYRTAELGNNFLNLTTLFIDFAWFGWAY DLK3VSEDI IKQRAKRTGDGSSGV IWGWDDKMDRDIKSKANIFYAKKE
SEQ ID NO: 62	Helicoverpa zea desaturase with Yarrowia lipolytica OLE1 leader sequence encoded by SEQ ID NO: 29 MVKNVDQVDLSQVDTIASGRDVNYfCVKYTSVGRKYQIVYPNLITFGYWHIAGLYGLYLCFT SAKWATI LFSYI LFLVAEI GITAGAHRLWAHKTAKLPLEI LLMVFNS IAFQN3AI DWVR DHRLHHKYSDDADPHNASRGFFYSHVGWLLVRKHPEVKRGKELNMSDIYNNPVLRFQKK YAI PFIGAVCFALPTMI P\YFWGETWSNAWHITMLRYIMNLNVTFL\NSAAHIWGNKPYDA KILPAQNVAVSVATGGEGFHNYHHVFPWDYRAAELGNN3LNLTTKFIDLFAAIGWAYDLKT VSEDMIKQRIKRTGDGTDLWGHEQNCDEVWDVKDKSS
SEQ ID NO: 63	Agrotis segetum desaturase with Candida albicans OLE1 leader sequence encoded by SEQ ID NO: 15 MTTVEQLETVDITKLNAIAAGTNKKVPMAQGVQTTTILREEEPSLTFV^/PQEPKRYQIVYP NLITFGYWHIAGLYGLYLCFTSAKWQTTILFSFMLWLAELGITAGAHRLWAHKTYS KAKLPL Q IILMILN5IAFQNSAIDWVRDHRLHHKY5DTDADPHNATRGFFY3HVGWLLVRKHPEVKR RGKELDMSDIYNNPVLRFQKKYAI PFIGAMCFLPTFI PVYFWGETWSNAWHITMLRYILN LNITFLVN SAAHIWGYKPYDIKILPAQNI AVSIVTGGEVSI TTTTFFPWDYRAAELGNNYL NLTTKFIDFFAWIGWAYDLKTVSSDVIKSKAERTGDGTNLWGLEDKGEEDFLKIWKDN
SEQ ID NO: 64	Amyelois transitella desaturase from DTU WO 2016/207339_SEQ ID NO: 2 MVPNKGSSDVLSEHSEPQFTKLIAPQAGPRKYKIVYRNLLTFGYWHL SAVYGLYLCFTCAK WATILFAFFLWIAEIGITGGAHRLWAHRTYKAKLPLEILLIMNSIAFQDTAFTWARDHR LHHKYSDDADPHNATRGFFYSHVGWLLVKKHPEVKARGKYLSDDLKNNPLLKFQKKYAI LVIGTLCFLMPTFVPVYFWGEGI STAWNINLLRYVMNLNMTFLVNSAAHI FGNKPYDKSIA SVQNI SVSLATFGEGFHNYHHTYPWDYRAAELGNNRLNMTTAFIDFFAWIGWAYDLKSVPO EAIKRCAGTGDGTDMMWGRKR
SEQ ID NO: 65	Spodoptera littoralis desaturase from DTU WO 2016/207339_SEQ ID NO: 41 MAQCVQTTTILEQKEEKTVTLLVPQAGKRKFEIVYFNI ITFAYWHIAGLYGLYLCFTSTKW ATVLFSSFFLEVVAEVGVTAGSHRLWSHKTYKAKLPLQILLMVMNSIAFQNTVIDWRDHRL HHKYSDDADPHNASRGFFY3HVGWLLVRKHDPVKKRGKEIDI SDIYNNPVLRFQKKYAI FIGAVCFVLPPTLI PVYGWGETWTNAWHVAMLRIMNLNVTFLVNSAAHI YGKRPYDKKILP SQNIAVS IATFGEGFHNYHHVFPWDYRAAELGNNSLNFPTKFI DFFAWIGWAYDLK

	TVSKEMIKQRSKRTGDGTNLWGLEDVDPEDLKNTKGE
SEQ ID NO: 66	<p>Agrotis segetum desaturase from DTU WO 2016/207339 _SEQ ID NO: 43</p> <p>I^QGVQTTTILREEEPSLTEVVPQEPRKYQIVYPNLITFGYWHIAGLYGLYLCFTSAKWQT ILFSFMLVIVIAELGITAGAHRLWAHKTYKAKLPLQI ILMILNSIAFQNSAIDliVRDHRLLH KYSDTDADPHNATRGFFYSHVGWLLVRKHPEWRRGKFT,nMSDTYNNPVLRFOKKYATPFI GAMCFGLPTFI PVYFWGETWSNAWHITMLRYILNLNITFLVNSAAHIWGYKPYDIKILPAQ NIAVS IVTGGEVS ITTTFFPDYRAAELGNNYLNLTTKFI DFFAWI GWAYDLKTVS SDVI KSKAERTGDGTNLWGLEDKGEEDFLKIWKDN</p>
SEQ ID NO: 67	<p>Trichoplusia ni desaturase from DTU WO 2016/207339 _SEQ ID NO: 45</p> <p>MAVMAQTVQETATVLEEEARTVTLVAPKTTPRKYKYIYTNFLTFSYAHLAALYGLYLCFTS AKWETLLFSFVLFHMSNIGITAGAHRLWTHKTFKAKLPLEI VLMIFN5LAFQNTAITWARE HRLHHKYSDDADPHNASRGFFYSHVGWLLVKKHDPVLKYGKTIDM5DVYNNPVLKFQKKY AVPLIGTVCFALPTLI PVYCWGESWNNAWHIALFRYI FNLNVTFLVNSAAHIWGNKPYDKS ILPAQNLLVSFLASGEGFHNYHHVFPWDYRTAELGNNFLNLTTLFIDFCAWFGWAYDLK3V SEDIKQRAKRTGDGSSGVIWGWDKMDRDIKSKANI FYAKKE</p>
SEQ ID NO: 68	<p>Amyelois transitella desaturase from DTU WO 2016/207339 _SEQ ID NO: 1</p> <p>atgggttccaaa caaggggtt cctctgat gllllgtctgaacallctgaacca caatlca cca agllgatgtgctccacaagct gggtccaga aagta caaaatcggtt tacaga aacttggtgac cttcggttactggcatttg tctgctgtttatgg tttgtacttggtttcacttggtgtaag tgggtactatatttg ttcgctttctctcttg tacgtta tgcgcgaatttg tattactgg tg gtgct cat agatlat gggtcat agaa cttacaaagccaagttgcca ttggaaatcttggt gllgat catgaact ccallg cctlccaagat a ct g ct tttactl gggttagagat cat aga ttgcatca caagtactctgata ctgatgctgatcca cataatgctactagagggtttctct actctcatgttggttggttggttggttaagaaacaccagaagtttaaggctagaggtaagta cttgctcttggtgacttgagaacaacct ttggtgaagttccaaaagaag tacgccatt ttggtcattggta ctttggtcttttgatgcc aacttctggtccagtttactt ttggggtg aaggf alttctact gcct ggaa callaacllgttaagat a cgt cat gaacllgaacatgac ctlltggglaact ccgctg ctcatttttggtaacaagc catacgataagt ct at cgcc tctgt tcaaaacatctctg tttctttggctactttcggtgaaggtttccataactaccatc atacttatccatgggattacagagctgctgaattggg taacaatagattgaatatgaccac cgctlcattg atttctt tgcttggtat tgggtgg cctacgattt gaaatctgllccacaa gaagctattgctaagagatgtgctaaaactgggtgatgggtactgatgtggggtagaaaga gatga</p>
SEQ ID NO: 69	<p>Spodoptera littoralis desaturase from DTU WO 2016/207339 _SEQ ID NO: 40</p> <p>ggacactgacatggactgaaggag tagagaatcgcccggtggag ttggccttcatttbcag tctta tctctcgggtgttatggf agtcacllat atcggtallaa aat aagt gaataaggct t gtaaaaatggcgcaatgtgtacaaa caacaa cgalttl ggaacaaaaaga agagaaaa cag taactttgctggtacctaagcggaagagggaagtttgaaattgtgtattttaatatcat caccttcgcttactggcatatagctggactata tggcctttatttgcttcaacttcaaca aaat ggg cga cag ltttattctcattct lltatttcgtcgtagcaga agtaggggt caggg ctggctccacaga ctttggt cgcataaaact tacaag caaa act a cctttacaaattc t gct aatgggtgat gaatlcccttgcat llcaaaacacagt caltga ttgggtga gagaccat cgactccatcataagtatagcgacactgatgccgatccccataatgcctcccgaggatttt tctattcgacgtcggttggtgctgttgtagaaaaacacctgatgtcaagaacgaggaaa ggaaattgatatactgatatttacaacaatccggtactgagg ttccagaagaagtacgca attcc lllcatcggggcaglltgttt cgtctta ccaacallgatacgggttta cggttggg gagaaacctggactaa tgcctggcagctcgccatgctgcggta cattatgaac llaacgt</p>

	<p>caccttcctggtcaacagcgctgctcatatata tggaaagagaccttatgacaagaagatc ctaccatctcaaaacatagctgtgtccattgcaacctttggggaagggtttccataattatc atcatgttatttc catgggattatctgcgcagctgaac1tgg3aataaacagttt gaatttccc taCgaaattttattga tttctttgctgga tCggatggg CgtatgaCctaaaga ctggttCg a.agaaatgataaaaacaaaggtcaaaaag. actggtgatggaaactaatct. ttggggg. tag aagatgtggataccccggaggattttaaaaaatacaaaaaggcgaataggcaaaccttaaac tcaaacagtgagggtttaatgtgaba bttagaattagaa ttaattbatttgaaattaaa bga agggtt btgg ataactgtt t. baataa baaaaatagtttt tCgattaa attccttagatt at tttaaagg aaatgta taaggtaCtCgcgtggttagc aaCccagcagtcCctgtttatCgtg ttbbatgaabtlaltcbatgaatgtagatgtcgcataaaattttaa aatgtbgcabttgta baatt bbacba bgaataa taaatttAbttttaaaaaaaaaaaaaaaaaaaaaaaaaaaa aaaaaa</p>
SEQ ID NO: 70	<p>Agrobis segetum desaturase from DTU WO 2016/207339 _SEQ ID NO: 42</p> <p>atgg ctcaag gtgtcCaaacaaCtacgatattgaggg aggaagag CcgtcattgactttCg tgg tacctcaag aaccgaga aagtatc aaatcgt gtaCccaaacCttatcacatttggg ta ctggca tatag ctggttta bacgggcba babtbg tgccttacttcggcaaaatggcaaca attttattcagttt catgtc gtgtgt tagCagagttgggaa taacAgccGgcgtcaca ggttatgggc ccacaaaacatataaag Cgaagcttccctt acaaat tatcctgatgatact gaactcca ttgccttCcaaaattCcgccattgattggg tgaggg aCcacgtct ccatcat aagtacagtgcactgatgcagaccctcacaatgctactcgtggtttcttctattctcatg ttggabggtttgc bgtgaagaaaacatccagaagbcaagagacgtggaaaggaaac bga cat gtCtgata tttaacaacatcca gtgctgagatttcaa aagAagtatgcta taCcttc atc ggg gcaatgt gcttcggattaccaacttttctc Cctgtttacttct ggggagaaaCctgga gtaatg cttggcAtatCaccatgcttcgg taCatectCaacctaaacAttactt tCctggt caacagtgcgtccta tatctggggatacaaacctta tgacatcaaatattgctgcctca aatatagcagtt tccatag taaccggcgcggaag tttccataactaccaccag tttttc cttgggattatcgt gcagcAgaattggggaaacaattatcttaaat ttgac gactaAgttcat agattttcttCg C11ggatCggatgggctt acgatctt AagaCgggtgtCagtgatgtt ata aaaagtaaggcggaagaactggtgatgggacgaatctttggggtttagaagacaagggtg aagaag a111111gaaaatctggaa agaca111aa</p>
SEQ ID NO: 71	<p>Trichoplusia ni desaturase from DTU WO 2016/207339 _SEQ ID NO: 44</p> <p>atggctgtgatggct caaacagtacaAgaacggct acagt gttggaagaggaagc tCgca cagtgaCtcttgtggctCaaagAcaaCgccaaggaaatataaatatatatataca Ccaactt tC11acal111cAtatg Cgcal11lagctgCattatacg gac111atttgtg C11acCtCt gcgaatgggaaca ttgctatttcttttCgtactct tccaca tgtcaaa tataggca tea cgcaggggctcaccgactctggactcacaagactttcaagccaaa ttgcctttggaat tgtcctcatgatattc aactc tttageett tcaaaacacggct attacatgggctagagaa categg CtacatCacaAataCagega tactgatgCtgatCccacaatgCgtcaagagggt tC11ctactCgcatg11ggctgg Ctattag taaaaaaacatccgat gtcCtgaaatattg aaaaacta tagacatg teggatg tatacaa taatcctgtgttaaaatttcagaaaaagtac gcagtacccttaa ttggaacagtttg ttttgccttccaactttgat tccagtctactgtt ggggcggaatcgtggaacacgcttgga catagecttattte gatacata ttcaatc ttaa cgtgacttt cctagtc aaCagtg ctgCgcatatCtggggg aataagecttatga taaaagc atcttgcccgctcaaaacctgctggtttccttctagcaagtggaagggttccataatt accatc acgtcttt ccAtgggallacgcacage aga11lagggaa taac11cctgaa111 gacgacgtgttcattgat tttgtgcctgggttgatgggcttatgacttgagttcgtgta tcagaggatattataaa acAgagagctaaa cgaaca ggtgAcggttcttc aggggt cattt ggggatgggAcgaCaaagacat ggacCgcgAtataaaAtctaaagctaacatttttt atgc taaaaagg aatga</p>
SEQ ID NO: 72	<p>Spodoptera exigua FAR- like protein VIII nucleotide sequence (Genbank ID KR781121.1, codon optimized)</p> <p>ATGGTGGTGCT GAC CA.GCAAG GA.GAAGTCC.AACA TGTCTGTGGCC GAC TTCT7\CGCCGGCA AGTCCGTGTTTATCACAGGCGGCACCGGCTTCCTGGGCAAGGTGTTTATCGAGAAGCTGCT GTACT CTTGCCCA.GACA TCGATAAGAT CTAT ATGCTGAT CCGGGAGAAGAAG GGCCAGAG C</p>

	<p>ATCAGGGAGCGCCTGACCAAGATCGTGGACGATCCCCTGTTCAATAGGCTGAAGGAGAAGC GCCCTGGCGACCTGGATAAGATCGTGCTGATCCCAAGCGATGTGACAGTGCCCCGGCCTGGG CATCTCCGACGAGAACGAGGCCATCCTGATCGATAAGGTGTCTGTGGTCATCCACAGCGCC GCCACAGTGAAGTTCAATGAGCCCCCTGGAGACCGCCTGGAACGTGAATGTGGAGGGCACAA GGATGATCATGGCCCTGTCTCGGAAGATGAAGAGAATCGAGATCTTTATCCACATCAGCAC CGCCTACA CCAACA CAAATA GGGCAGT GGTGGAC GA GGTGCTGTACCA CCTCCAGCCGAC ATCAACGAGGTGCACCAGTATGTGAAGAATGGCATCACAGAGGAGGAGACCGAGAAGATCC TGAAC GGCAGG CCAATA CCTA CA CATTCA CCAAGGCCCTGAC CGAGCA CCTGGTGGCAGA GAACCAGGCCATATATGCCCTACAATCATCGTGC GGCCATCCATCGTGGGCGCCATCAAGGAC GAT CCTAT CAGAG GCTGGCTGG CAAAC TGGTA CGGAGCAACA GGACT GAGCGTGTTC CCG CCAAG GGCCTGAAT CGCGT GAT CTA CGGCCAGA GCAGCCA CGTGGTGGAC CTGAT CCCTGT GGATTATGTGGCAAACCTGGTCATCGTGGCAGGAGCAAAGACATACCGGTCCAACGAGGTG ACCATCTATAATTCTTGCTCTAGCTCCTGTAATCCAATCACATGGAGCGGTGGTGGGCC TGTTTCATCGACGATACAGTGAAGCACAAACAGCTACGTGATGCCCTGCCTGGCTGGTACGT GTATTCCAATTACCGTGGCTGGTGTATCTGGTGACCATCATCTTTCAGATGATCCCAGCC TATCTGGCAGACATCGGCCGGAGACTGCTGGGCAAGAATCCAGATACTATAAGCTGCAGT CCCTGGTGG CACAGAC CCAGGAGG CAGT GCACT TCTTTACAT CTCA CA CCTGGGAGAT CA A GAG CAAGAG GACCTCCGAGCTGTTCCGCTCTCTGAGCCACACAGAC CAGCGCATCTTTCCT TGCGATGCCAAGAAGATCGACTGGACAGATTACATCACCGATATTGTAGCGGCGTGCGGC AGT TCCTGGAGAAGAAGAAGT GA</p>
SEQ ID NO: 73	<p>Spodoptera exigua EAR-like protein VIII amino acid sequence (Genbank ID ALJ94061.1)</p> <p>MWLTSKEKSNMSVADFYAGKSVFITGGTGFLGK^/FIEKLLYSCPDIDKI YMLIREKKQS IRERLTKIVDDPLFNRLKEKRPGLDKIVLI PGDVTVPGLGI SDENEAILIDKVSWIH3A ATVKFNEPLETAWN NVNVEGTRMIMALSRKMKRIEI FIHI STAYTNTNRAWDEVLYPPPAD INEVHQYVKNGITEEETEKILNGRPNTYFTFKALTEHLVAENQAYMPTI IVRPSIVGAIKD DPIRGWLANWYGATGLSVFTAKGLNRVI YGQSSHVVDLI PVDY\ANLVIVAGAKTYRSNEV TIYNSCSSSNPITMERLVGLFIDDTVKHNSYVMPLPGWYVYSNYRWLVYLVITII FQMI PA YLADIGRRLLGKNPRYYKLQSLVAQTQEAHVFFTSHTWEIKSKRT3ELFA5L3HTDQRI FP CDAKKIDWTDYITDYCSGVRQFLEKKK</p>
SEQ ID NO: 74	<p>Euglena gracilis fatty acyl-coenzyme A reductase nucleotide sequence, codon optimized</p> <p>ATGAACGACTTCTACGCCGGCAAGGGCGTGTTTCTGACAGGCGTGACCGGCTTCGTGGGCA AGATGGTGGTGGAGAAGATCCTGCGGTCTCTGCCAACCGTGGGCGAGGCTGTATGTGCTGGT GCGCCCAAAGG CAGGCACAGAT CCTCAC CAGAGAC TGACAG CGAAGTGTGGAGCAGCGCC GGATTGACGTGGT GAG GGA GAAAGTGGGAGGAC CTGCAGC CTTGCATGCACTGAT CCGCG AGAAGGTGGTGCTGTGCCAGGCGACATGGTGAAGGATAGGTTTGGCCTGGACGATGCAGC ATACCGCTCCCTGGCAGCCAACGTGAATGTGATCATCCACATGGCCGCCACAATCGACTTC ACCGAGAGGCTGGATGTGGCCGTGTCTCTGAACGTGCTGGGCACAGTGCGGGTGCTGACCC TGGCAAGGAGAGCCAGAGAGCTGGGCGCCCTGCACAGCGTGGTGACGTGTCCACCTGTCTA CGTGAACCTCCAATCAGCCCCCTGGCGCCCGGCTGAGAGAGCAGCTGTATCCCTGCCTTTT GACCCACGGGAGATGTGCACAAGAAT CTTGGACA TGAGCCCTCGGGAGAT CGATCTGTTTCG GCCACA GCTGCTGAAG CAGTA CGGCTTCCC CAATA CCTATA CCTTCAC CAAGT GCATGGC AGAGCAGCTGGGCGCCAGATCGCACACGACCTGCCATTGCGCATCTTTAGACCAGCAATC ATCGGAGCCGCCCTGTCCGAGCCATTTCCCGGCTGGTGCATTCTGCCAGCGCCTGTGGAG CCGTGTTCTGGCAGT GGGACTGGGCGTGCTGCAGGAG CTGCAGGGAAAC GCCTCTAGCGT GTGCGACCTGATCCCTGTGGATCA .CGTGGTGAATATGCTGCTGGTGACAGCA_GCATATA .CC GCATCTGCCCCACCAGCCGACCCTAGCCCATCCTCTCTGGCCCTGTCCCCTCCACAGCTGC CACTGGCCACACTGCCCCCTGGCACCGTGGCAGATGTGCCAATCTACCAGTGTGGCACCTC TGCCGGCCCTAACGCCGTGAATTGGGGCAGGATCAAGGTGAGCCTGGTGGAGTATTGGAAC GCACACC CAATCGCAAAGAC CAAGGCAGCAATCGCCCTGCTGCCCGTGTGGAGGTTTCGAGC</p>

	<p>TGAGC TTTCTGCTGAAGAG GCGCCTGCCTGCAAC AGCCCTGTCCCTGGTGGCCTCTCTGCC AGGCGCATCCGCCGCCGTGCGGAGACAGGCAGAGCAGACAGAGCGGCTGGTGGGCAAGATG AGAAAGCTGGTGGACACCTTTTCAGTCTTCGTGTTTTGGGCCTGGTACTTCCAGACAGAGA GCAGCGCCAGGCTGCTGGCCTCTCTGTGCCAGAGGACCGCGAGACCTTTAACTGGGACCC CAGGAGGAT CGGAT GGAGGGCCT GGGT GGAGAATTACT GTTAT GGCCT GGT GCGGTAT GTG CTGAAGCAGCCAATCGGCGATAGACCACCAGTGGCAGCAGAGGAGCTGGCAAGCAATAGGT TCCTGCGCGCCATGCTGTGA</p>
SEQ ID NO: 75	<p>Euglena gracilis fatty acyl-coenzyme A reductase amino acid sequence (ADI60057.1)</p> <p>MMDFYAGKGWLTGWGFVGMVVEKILRSLPTVGRLYVLVRPKAGTDPHQRLHSEVWSSA GFDWREKVGGPAAFDALI REKVVPVPGDMVKDRFGLDDAAYRS JAANvNvIIHMAATIDF TERLDVAVSLNVLGTVRVLTLARRARELGALHSVVHVSTCyVNSNQPPGARLREQLYPLPF DPREMCTRILDMSPREIDLFGPQLLKQYGFNTYTFTKMA.EQLGAQIAHDLPAIFRPAI IGAALSEPFPGWCDASACGAWLAVGLGVQLBQGNASSVCDLIPVDHVNMMLLVTAAYT ASAPPADPSPSSIJaSPQPLPLATLPPGTADVPIYHCGTSAGPNAVNWGRKIVSLVBYWN AHPIAKTKAAIALLPVWRFELSFLKRRLPATALLSLVASLPGASAAVRRQAEQTERLVGKM RKLVDTFQSFVFWAWYFQTESSARLLASLCPEDRETFTNWDPRRIGWRAWVENYCyGLVRYV LKQPIGDRP PVAEE ELA_{SN}RFLRAM L</p>
SEQ ID NO: 76	<p>Yponomeuta evonymellus fatty-acyl CoA reductase II nucleotide sequence, codon optimized</p> <p>ATGGTGCAGCTGAAGGAGGACTCCGTGGCCGCCTTTTACGCCGAGAAGTCTATCTTCATCA CAGGCGGCACCGGCTTTCTGGCAAGGTGCTGATCGAGAAGCTGCTGTACTCTGCAAGGC CGTGACCAGATCTATGTGCTGATCCGGAAGAAGAAGGATCAGACACCTTCTGAGCGCATC GCCAG CTGCTGGAGT CTGAG CTGTTCA GCCGGCTGAGAAAG GAC GATCCAAG CGCCCTGA AGAAGGTGGTGGCCGTGGTGGGCGACCTGACCATGCCTAACCTGGGACTGAGCGCCGAGT GCAGGATCTGATCGTGACAAAGGTGTCCATCA.TCTTCCACGTGGCCGCCACCGTGAAGTTT AAC GAGAG GATGAAGAAT GCCCTGGC CAACAAT GTGGAG GCCA CCAGAGAAGT GAT CAAC C TGTGCCACCGCTGGAGAAGGTGGACGCCTTCATCCACGTGTCCACAGCCTATTCTAATAC CGATCAGAAGGTGGTGGAGGAGCGCGTGTACCCACCTCCAGCACCTCTGAGCGAGGTGTAT GCCTTTGT GAC CAAC AAT GGCGAC GATATGGACATCAT CCAGAAC CTGCTGAAT GGCCGGC CAAT ACCTACACATA TACCAAG GCCCTGGCCGAG GAC ATCGTGTCTGAAG GAG CACGGCGG CAT CCCTA CAGCCAT CAT CAGAC CAAG CAT CGTGTGTCCGTGCT GAAG GAG CCCAT CCCT GGCTGGCTGGACAAC TGGAAAT GGAC CAAC CGGAC TGCTGCAC GCCAG CTCCCAGG GAGTGC ACTGCTCCATGCTGGGCTCTGGCAGCAACGTGGCCGACCTGATCCCTGTGGACATCGTGAC AAATCT GAT GAT CGTGGTGGCCTCTCGGTGCAAGAAGAGCAACGGCCT GAAG GTGTACAAT TCCTGTTCTGGCAC CACAAC CCATCGCCTATCAGGCCCTCAC CAAGAT GTTCTGGAT A GCTGTATCTCCAGGGCTGGAACAAGGTGCCATTCCCCATGCTGCTGTTTGTGAAGTGGGC CTTCTGAATCGCGTGTGAAGTTCTTCTGTGTCATCGTGCCATTCTTTCTGATCGACGTG TACCTGCGGTTCTTTGGCAAGCCCAATTACATGAGAATGATCACATATACCAAGAAGGCCG AGGATCTGAT GACATCTTTA CCTCTCAC GAGTGGCAG TTCAAG GAC GGCAAC GTGCGGGA TCTGATCAATATGATGAGCCCCGAGGATAGAAAGATCTTTTACTGCGACCCCGATGAGATC CAC TGGAAG CCTTA CTTCGAC GAT TAT TCGTGGGCGTGT TAAGT ATCTGCTGAAGAG GA AGGTGTGA</p>
SEQ ID NO: 77	<p>Yponomeuta evonymellus fatty-acyl CoA reductase II amino acid sequence (ADD62439.1)</p> <p>MVQLKEDSVAAFYAEKSI FITGGTGFLGKVLIEKLLYSCKAVDQIYVLIRKKKDQTPSERI AQLLESELFSRLRKDDPSALKKWPGDLTMPNLGLSAAVQDLIVTKVSI IFHVAATVKF NFRMKNALANNVEAT REV INLCHRLEKVD AF IHVSTAY SNTDQKWE ERVY PPPAP LSEVY AFVTNNGDDMDI IQNLLNGRPNTYTYTKALAEDIVLKEHGGI PTAIRPS IVLSVLKEPI P GWLNDNMGPPTGLLHASSQGWCSMLGSGSNVADLIPVDIVTNMIWASRCKKSNGLKVYN SC5GTTNPIAYQAFTKMFLDSCI 5RGWNKVPFPMLLFVKWAFLNRLKFFLVIVPFFLIDV</p>

	YLRFFGKPNYMRMIT YTKKAEDLMTFFTSHEWQFKDGNVRDLINMMSPEDRKI FYCDPDEI HWKPYFDDYCVGVFKYLLKRKV
SEQ ID NO: 78	Drosophila melanogaster fatty acid desaturase (Q9N9Z8) mapys riyhqdk sretgvl feddaqtvdsdl ttdrfqlkraekrrlplvwrniilfalvh laa1yg1hsiftrakla111faag1yiigmlgvtagahrlwahrtykak wplrlillvifnt iafqdavywardhrvhhkysetdadphnatrgf ffshvgwllckkhpdikekgrgldlsd lraddilmfqrkhyiilmlacflvptvipmvynetlasswf vatmfrwcfqlnmtwlvn saahkfgnrpydktmnptgnaf vsa ftfgegwhnyhha fpwdyktaewgcyslnittaf id ifakigwayd1ktvapdvigrrvrlr tgdgshelwggwgdld taedarxivllvdksr
SEQ ID NO: 79	Lampronia capitella acyl-CoA-delta 11-desaturase (ABX71630 .1) mppyæevdtnhifeedisheeskalp1vapqadnrkpeivp1n1itfgygh1aaiygi ylcft sakwativf afvlyicaelgi tagahrlwshrsyaklplrlilllf ntla fqnta idwvrdhrmhkysdtdadphna trgffshvgwlltrkhpevkrrgkdidmndiyndsl 1 kfqkkyaipfvglvcfvptln^rayfwnetlnnswhiatmlryivnlmt flvnsaahiwg ykpydksikpvqiitvsililgegfhiiyhvfwpdyrtselgndf lnfttlfirilfakigw aydlktasdkvvaarrk rtgdgtlnlgwedksineeerqaatvlypnkylnlkd
SEQ ID NO: 80	Cydia pomonella desaturase (AIM40221.1) m _a pnvtdvrigv1 fesdaatpd1a1anapvqqaddspriyvwrniilf aylhiaaly ggy1 f lvsakwqt difayflyvasglgitagahrlwahksyakwpl rlilvifntiafqdsaidw ardhrmhkysdtdadphnatrgffshvgwllvrkhpe1krkgk1d1sd1yadpi1rfq kkyylilmlacflvptvipvylwrietwt naf fvaalf ryafilnvtwlvnsaahkwgdkp ydksikpsenis vslfafgegfhnyhhtfpwdyktaelssnrlnf ttkfinffakigwayd mktvsdeiiqkr vnrtdgshhlwggwgdldhskee vnaavriupkdd
SEQ ID NO: 81	Spodoptera exigua FAR-like protein VII nucleotide sequence (K80S977.1), codon optimized ATGACGTATAGACAAATAAATGAATTTGATGCTGAAAAGTTTACGGCAGCTACAGTACCGA CAAGCTACGTAT CAGTACCAGATTTTATGCGGGCAAGACAATTTTATCACTGGTGGAAC TGGATTTCTTGGAAAAGGTGTTCTAGAGAAACTTCTTACAGTTGTAAAGATGTTGAAACC GTA TA CA TTTTGAT CAGAGAGAAAAAG GCAAAAC A CCTCAG CAAAGAGT TGAAGAT CTTT TTAAC AAA CCGAT TTTCTCAAGAT TGAAA CAGAAGGAC TCTCAGTGTATGAAGAAAGTCAC TGCAATAATTGGTGACCTTAGTGAACCTGGTCTTGGCATATCAAAGATGATGAAGAACTA CTTTTGCAAAAGGTATCTGTAGTATTCCATGTCGAGCCAATGTTTCAAGTTTACAAGGAAT TCAAAGAGATTATAAATACGAATGTTGGTGGGACAAAATACGTACTCCAATTGTGTCAGCG AATAAAAGAT ATTAAG GCAT TTGTCCAT ATTTCCA CAGCCTA CTGTCA CAC.AGAC CAAAAG GTATAGAAGAGAGAAT ATACCCCCCTCCAGCAGAAC TCAGTGAAGTCTGAAGTTCCTTC AGCAGCCA CAGCATGAC AAGAAAC AGAT TAAGGAAT TATTTAAGAAAC AAC CAAAC AGT TA CACCTTTGCCAAG GCTTTAGCAGAAAC CTAG ATTGCTGAGAAC TGCGGAC GCGTCCCCA CA ATTATCATCAGAC CTTCTAT TAT ATCAGCAT CAC TGAAAGAG CCGCTACCAG GAT GGGTGG ATTCAT GGAAC GGAG CCACAGGCCTCAT CACAGCTAG CTAG AAC GCGGCCAAC AGAGT GCT TCTCGGCGAAG GCAG CAACTTCCTCGAC CTGAT CCCAGT TGAC TTTGTTGCTAAC CTGGCA ATTGTAGCTGCTGCTAAAT GTACTAGCTCTTT GAAAGT TTA CAAT TgcTgcTcaag CGGAT GTAAC CCTTTAAC ATTGAAAC AAT TGGT CAG CCACATGAATAAT GTCGGAT TTGATAAAAA CGTCTCCATAATATTCACCAATAACAAAGCCTCGCTTCCACATTGACATTTTCTCTCAA ACAAC GCCAT CTTTCAC CGCTGAT ATGTTTCTGAGAGT CAC GGGAAAGT CAC CAAG GTA CA TGAAAATCCAGT CAAAAC TGAC CATCGCTCGGAAT GCCTTAAAT TTTTTC.acCTGT CAT TC CTGGGTCATGAAGGCTGATAATTCTAGAAGACTGTATGCTTCTTGTGTCATTACACGACCGA CATACGTTCCCTTGTGATCCTACAGACATAGACTGGAAGAA.GTACATAAATATATACATAG AAG GAAT TAAT CAGT TCTTAAT GAAGAAAC GTAGT TAA
SEQ ID NO: 82	Spodoptera exigua FAR-like protein VII amino acid

	<p>sequence (AI S85928.1)</p> <p>MTYRQINEFDAEKFT«ATVPTSYSVSPDFY\GKTI FITGGTGFLG:WFLEKLLYSCKDVET VYI LI REKKGKTPQQRVEDLNFNPI FSRLKQKDSQCMKKVTAI I GDLSEPLGI SKDDEEL LLQKVSWFHVAANVQFYKEFKEI INTNVGGTKYVLQLCQRI KDI KAFVHI STAYCHTDOK VT,RF,RIYPPPAEL3EVLKFLPPPQHDKKPI KELFKKQPNSYTFALCALAETYIAENCGRVPT IIIRPS IISASLKEPLPGWVDSWNGATGLITAS YNGANRVLLGEGSN FLDLI PVDFVANLA IVAAAKCTS SLKVYNCCSSGCNPLTLKQLVSHMNNVGFKNVS I I FTNNKASLSTLTFFLQ TTPSEFADMFRLRVTGKS PRYMKIQSKLTIARNALNFFTCHSVJYMKADNSRRLYASLSLHDR HTFPCDPTDIDWKYINYI EGINOFLMKKRS</p>
SEQ ID NO: 83	<p>HaFAR S60A FAR2</p> <p>ATGGTGGTGCTGACCTCCAAGGAGACAAAGCCCTCTGTGGCCGAGTTCTACGCCGGCAAGA GCGTGTTTCATCACAGGCGGCACCGGCTTCCTGGGCAAGGTGTTTATCGAGAAGCTGCTGTA CAGCTGCCCTGACATCGAGAACA TCTATATGCTGATCCGGGAGAAGAAGGGCCTGGCCGTG TCCGAGAGAATCAAGCAGTTCCTGGA C GATCCCCTGTT TACAAGGCTGAAGGACAAGCGCC CTGCCGATCTGGAGAAGATCGTGCTGATCCAGGCGACATCACCGCACCAGATCTGGGCAT CAACAGCGAGAATGAGAAGATGCTGATCGAGAAGGTGAGCGTGATCATCCA CTCCGCCGCC ACCGTGAAGTTC AACGAGCC CCTGCCTACAGCCT GGAAGATCAATGTGGAGGCAACCAGGA TGATGCTGGCCCTGTCTCG GAGAATGAAGCGCATCGAGGTGTTTATCCACATCAGCACA GC CTACACCAACACAAATAGGGAGGTGGTGACGAGATCCTGTACCCAGCCCCGCCGACATC GATCAGGTGCACCAATGTGAAGGACGGCATCAGCAGGAGGATACCGAGAAGATCCTGA ACGCGAGACCCAATACCTACCA T TACCAAGGCCCTGACAGAGCACCTGGTGCC GAGAA CCAGGCCTATGTGCCTACCATCATCGTGAGACCATCCGTGGTGCCGCCATCAAGGATGAG CCTCTGAAGGGATGGCTGGGAACTGGTTCGGAGCAACAGGACTGACCGTGTTTACAGCCA AGGGCCTGAATAGAGTGATCTACGGCCACAGCTCCTATATCGTGACCTGATCCCAGTGGA TTACGTGGCAAACCTGGTCATCGCAGCAGGAGCCAAGTCTAGCAAGTCCACCGAGCTGAAG GTGTATAACTGCTGTTCTCTAGCTGTAATCCCGTGACCATCGGCACACTGATGAGCATGT TCGCCGACGATGCCATCAAGCAGAAGT CCTACGCCATGCCTCTGCCAGGCTGGTACATCTT TACAAAGTATAAGTGGCTGGTGCTGCTGCTGACCTTCCTGTTTCAGGTGATCCCTGCCTAC GTGACCGACCTGTCTAGGCACCTGATCGGCAAGAGCCCACGCTATATCAAGCTGCAGAGCC TGGTGAACCAGAC CAGGTCTCTATCGACTTCTTTACAAATCACTCCTGGGT CATGAAGGC CGATAGGGTGCGCGAGCTGTACGCATCTCTGAGCCCAGCCGACAAGTATCTGTCTCCCTTGC GACCCAACCGATATCAAXTGACACACTACATCCAGGATTATTGTTGGGGCGTGCGCCACT TTCTGGAGAAGAAGTCTATGAGTGA</p>
SEQ ID NO: 84	<p>HaFAR 3195A FAR3</p> <p>ATGGTGGTGCTGACCTCCAAGGAGACAAAGCCCTCTGTGGCCGAGTTCTACGCCGGCAA.GA GCGTGTTTCATCACAGGCGGCACCGGCTTCCTGGGCAAGGTGTTTATCGAGAAGCTGCTGTA CAGCTGCCCTGACATCGAGAACA TCTATATGCTGATCCGGGAGAAGAAGGGCCTGAGCGTG TCCGAGAGAATCAAGCAGTTCCTGGACGATCCCCTGTTTACAAGGCTGAAGGACAAGCGCC CTGCCGATCTGGAGAAGATCGTGCTGATCCAGGCGACATCACCGCACCAGATCTGGGCAT CAACAGCGAGAATGAGAAGATGCTGATCGAGAAGGTGAGCGTGATCATCCACTCCGCCGCC ACCGTGAAGTTCAA.CGAGCCCCTGCCTACAGCCTGGAAGATCAATGTGGAGGGCACCAGGA TGATGCTGGCCCTGTCTCGAGAATGAAGCGCATCGAGGTGTTTATCCACATCAGCACAGC CTACACCAACACAAATAGGGAGGTGGTGACGAGATCCTGTACCCAGCCCCGCCGACATC GATCAGGTGCACCAATGTGAAGGACGGCATCGCCGAGGAGGATACCGAGAAGATCCTGA ACGGCAGACCCAATACCTACACATTCACCAAGGCCCTGACAGAGCACCTGGTGCCGAGAA CCAGGCCTATGTGCCTACCATCATCGTGAGACCATCCGTGGTGCCGCCATCAAGGATGAG CCTCTGAAGGGATGGCTGGGAACTGGTTCGGAGCAACAGGACTGACCGTGTTTACAGCCA AGGGCCTGAATAGAGTGATCTACGGCCACAGCTCCTATATCGTGACCTGATCCCAGTGGA TTACGTGGCAAACCTGGTCATCGCAGCAGGAGCCAAGTCTAGCAAGTCCACCGAGCTGAAG GTGTATAACTGCTGTTCTCTAGCTGTAATCCCGTGACCATCGGCACACTGATGAGCATGT TCGCCGACGATGCCATCAAGCAGAAGT CCTACGCCATGCCTCTGC CAGGCTGGTACATCTT</p>

	<p>TACAAAGTATAAGTGGCTGGTGTCTGTCTG/W;CTTCCTGTTTCAGGTCATCCCTGCCTAC GTGACCGACCTGTCTAGGCACCTGATCGGCAAGAGCCCACGCTATATCAAGCTGCAGAGCC TGGTGAAC CAGAC CAGGT CCT CTAT CGAC T T C T T A CAAAT CA CTCCTGGGT CA T GAAG GC CGA T A GGGT GCGCGAG CT G T A CGCAT CT C T T GAG CCCA GCCGACAAGT A T C T GT T CCC T T GC GAC CCAAC CGATA T CAACT GGACA CACTA CAT CCA GGAT TAT TGTTGGGGCGTGCGC CA CT T T C T GGAGAAGAAG T C C TAT G A GT GA</p>
SEQ ID NO: 85	<p>H₂FAR S298A FAR⁴</p> <p>ATGGTGGTGTCTGACCTCCAAGGAGACAAAGCCCTCTGTGGCCGAGTTCTACGCCGCAAGA GCGTGTTCATCACAGGCGGCACCGCTTCCTGGGCAAGGTGTTTATCGAGAAGCTGCTGTA CAGCTGCCCTGACATCGAGAACATCTATATGCTGATCCGGGAGAAGAAGGGCTGAGCGTG TCCGAGAGAAT CAAG CAGT T C C T T GGAC GAT CCCCTGTT TA CAAG GCT GAAG GACAAG CGCC C T T GCCGAT CT GGAG A A GAT CG T T GCT GAT CCCA GGC GAC A T C A C C G C A C C A G A T C T G G G C A T CAACAG CGAGAAT GAGAAGAT GCT GAT CGAGAAG GT GAGCGT GAT CAT CCA CTCGCCGCC A CCGT GAAGT T CAAC GAGC CCCT GCCTA CA GCCT GGAAGAT CAAT GT GGAG GGCAC CA GGA. TGATGTGGCCCTGTCTCGGAGAATGAAGCGCATCGAGGTGTTTATCCACATCAGCACAGC CTACAC CAAC A CAAAT AGG GAG GT GGT GGAC GAGAT CCT GTA CCCA G C C C C C G C C GACAT C GATCAGGTGCACCAGTATGTGA A G G A C G G C A T C A G C G A G G A G G A T A C C G A G A A G A T C C T G A A C G G C A G A C C C A A T A C C T A C A C A T T C A C C A A G G C C C T G A C A G A G C A C C T G G T G G C C G A G A A CCAGGCCTATGTGCCTACCATCATCGTGAGACCATCCGTGGTGGCCGCCATCAAGGATGAG CCTCTGAAGGGATGGCTGGGAACTGGTTCGGAGCAACAGGACTGACCGTGTTTACAGCCA AGGGCCTGAATAGAGTGATCTACGGCCACAGCTCCTATATCGTGGACCTGATCCCAGTGGA TTACGTGGCAAAC C T GGT CAT CGCAGC A G G A G C C A A G G C C A G C A A G T C C A C C G A G C T G A A G GTGTATAACTGCTGTTCTCTAGCTGTAATCCCGTGACCATCGGCACACTGATGAGCATGT TCGCCGAC GAT GCCAT CA7-VG CAGAAGT CCTA CGCCAT GCCT CT GCCAG GCT GG T A G A T C T T TACAAAGTATAAGTGGCTGGTGTCTGTCTGTCTGACCTTCCTGTTTCAGGTCATCCCTGCCTAC GTGAC CGAC CT GT CTA GGCA CCT GAT CGGCAAGAG CCCA CGCTAT AT C A A G C T G C A G A G C C TGGTGAACCAGACCAGGTCCTCTATCGACTTCTTTACAAATCACTCCTGGGTGATGAAGGC CGATA GGGT GCGCGAG CT GTA CGCAT CT CT GAG CCCAG CCGACAAGT A T C T G T T C C C T T G C GACCCAACCGATATCAACTGGACACACTACATCCAGGATTATTGTTGGGGCGTGCGCCACT T T C T G G A G A A G A A G T C C T A T G A G T G A</p>
SEQ ID NO: 86	<p>H₂FAR 3378A FAR⁵</p> <p>ATGGTGGTGTCTGACCT CCAAGGAGACAAAGC CCT CTGTGGCCGAGTT CTAC GCCGGCAAGA GCGTGTTCATCACAGGCGGCACCGCTTCCTGGGCAAGGTGTTTATCGAGAAGCTGCTGTA CAG CT GCCCT GACA T C GAGAAC A T C T A T A T G C T G A T C C G G G A G A A G A A G G G C C T G A G C G T G TCCGAGAGAATCAAGCAGTTCTTGACGATCCCCGTGTTTACAAGGTGAAGGACAAGCGCC C T T GCCGAT CT GGAGAAGAT C G T G C T G A T C C C A G G C G A C A T C A C C G C A C A G A T C T G G G C A T CAACAG CGAGAAT GAGAAGAT G C T G A T C G A G A A G G T G A G C G T G A T C A T C C A C T C C G C C G C C ACCGTGAAGTTCAACGAGCCCCCTGCCTACAGCCTGGAAGATCAATGTGGAGGGCACCAGGA T G A T G C T G G C C C T G T C T C G G A G A A T G A A G C G C A T C G A G G T G T T A T C C A C A T C A G C A C A G C CTACAC CAACA C A A A T A G G G A G G T G G T G G A C G A G A T C C T G T A C C C A G C C C C C G C C G A C A T C GATCAGGTGCACCAGTATGTGAAGGACGGCATCAGCGAGGAGGATACCGAGAAGATCCTGA ACGGCAGACCCAATACCTACACATTACCAAGGCCCTGACAGAGCACCTGGTGGCCGAGAA CCAGGCCTATGTGCCTACCATCATCGTGAGACCATCCGTGGTGGCCGCCATCAAGGATGAG CCTCTGAAGGGATGGCTGGGAACTGGTTCGGAGCAACAGGACTGACCGTGTTTACAGCCA AGGGCCTGAATAGAGTGATCTACGGCCACAGCTCCTATATCGTGGACCTGATCCCAGTGGA TTACGTGGCAAACCTGGTCATCGCAGCAGGAGCCAAGTCTAGCAAGTCCACCGAGCTGAAG GTGTATAACTGCTGTTCTCTAGCTGTAATCCCGTGACCATCGGCACACTGATGAGCATGT TCGCCGAC GAT GCCAT CAAG CAGAAGT CCTA CGCCAT GCCTCTGC CAG GCT GGTA CAT CT T TACAAAGTATAAGTGGCTGGTGTCTGTCTGTCTGACCTTCCTGTTTCAGGTCATCCCTGCCTAC GTGACC GA C C T G T C T A G G C A C T G A T C G G C A A G G C C C A C G C T A T A T C A A G C T G C A G A G C C</p>

	<p>TGGTGAACCGACAGCCAGGCTCCTCTATCGACTTCCTTTACAAATCACTCTGGGTCATGAAGGC CGATAGGGTGC GCGAGCTGTACGCATCTCTGAGCCAGCCGACAAGTATCTGTTCCCTTGC GA^CCCAACCGATA^TCAACTGGACACAC^TA^CATCCAAGGATTA^TTGTTGGGGCGTGCGC CAC^T T^TCTGGAGAAGAAGTCCTATGAGTGA</p>
SEQ ID NO: 87	<p>HaFAR s394A FAR6</p> <p>ATGGTGGTGTGCTGACCTCCAAGGAGACAAAGCCCTCTGTGGCCGAGTTCTACGCCGCAAGA GCGTGTTTCATCACAGGCGGCACCGGCTTCCTGGGCAAGGTGTTTATCGAGAAGCTGCTGTA CAGCTGCCCTGACATCGAGAACATCTATATGCTGATCCGGGAGAAGAAGGGCCTGAGCGTG TCCGAGAGAATCAAGCAGTTCC^TGGACGATCCCCTGTT TAC^AAGGCTGAAGGACAAGCGCC CTGCCGATCTGGAGAAGAT^TCGTGCTGATCCCA^GGCGACATCACCGCACCAGATCTGGGCAT CAACAGCGAGAATGAGAAGATGCTGATCGAGAAGGTGAGCGTGATCATCCA^TCCGCCGCC ACCGTGAAGTTCAACGAGCCCTGCCTACAGCCTGGAAGATCAATGTGGAGGGCACCAGGA TGATGCTGGCCCTGTCTCGGAGAATGAAGCGCATCGAGGTGTTTATCCACATCAGCACAGC CTACACCAACACAAATAGGGAGGTGGTGGACGAGATCCTGTACCCAGCCCCCGCCGACATC GATCAGGTGCACCAGTATGT GAAGGACGGCATCAGCGAGGAGGATACC GAGAAGATCCTGA ACGGCAGACCCAATACCTACACATTCACCAAGGCCCTGACAGAGCACCTGGTGGCC GAGAA CCAGGCCTATGTGCCTACCATCATCGTGAGACCATCCGTGGTGGCCGCCATCAAGGATGAG CCTCTGAAGGATGGCTGGGAACTGGTTCGGAGCAACAGGACTGACCGTGTTTACAGCCA AGGGCCTGAATAGAGTGATCTACGGCCACAGCTCCTATATCGTGGACCTGATCCAGTGA TTACGTGGCAAACCTGGTATCGCAGCAGGAGCCAAGTCTAGCAAGTCCACCGAGCTGAAG GTGTATAACTGCTGTTCTCTAGCTGTAATCCCGTGACCATCGGCACACTGATGAGCATGT TCGCCGACGATGCCATCAAGCAGAAGTCCTACGCCATGCCTCTGCCAGGCTGGTACATCTT TACAAAGTATAAGTGCGTGGTGTGCTGCTGCTGACCTTCCTGTTTCAGGTATCCCTGCCTAC GTGACCGACCTGTCT^AAGCACCT^TGATCGGCAAGAGCCCACGCTATATCAAGCTGCAGAGCC TGGTGAACCGACACAGGTCCGCCATCGACTTCTTTACAAATCACTCCTGGGTCATGAAGGC CGATAGGGTGC GCGAGCTGTACGCATCTCTGAGCCCAGCCGACAAAGTATCTGTTCCCTTGC GACCCAACCGATATCAACTGGACACACTACATCCAGGATTATTGTTGGGGCGTGCGCCACT TTCTGGAGAAGAAGTCCTATGAGTGA</p>
SEQ ID NO: 88	<p>HaFAR S418A FAR7</p> <p>ATGGTGGTGTGCTGACCTCCAAGGAGACAAAGCCCTCTGTGGCCGAGTTCTACGCCGCAAGA GCGTGTTTCATCACAGGCGGCACCGGCTTCCTGGGCAAGGTGTTTATCGAGAAGCTGCTGTA CAGCTGCCCTGACATCGAGAACATCTATATGCTGATCCGGGAGAAGAAGGGCCTGAGCGTG TCCGAGAGAATCAAGCAGTTCC^TGGACGATCCCCTGTTTACAAAGGCTGAAGGAC^AAGCGCC CTGCCGATCTGGAGAAGATCGTGCTGATCCCA^GGCGACATCACCGCACCAGATCTGGGCAT CAACAGCGAGAATGAGAAGATGCTCATCGAGAAGGTGAGCGTGATCATCCA^TCCGCCGCC ACCGTGAAGTTCAACGAGCCCTGCCTACAGCCTGGAAGATCAATGTGGAGGGCACCAGGA TGATGCTGGCCCTGTCTCG GAGAATGAAGCGCATCGAGGTGTTTATCCACATCA^GCACAGC CTACACCAACACAAATAGGGAGGTGGTGGAC GAGAT^TCCTGTACCCAGCCCCCGCCGACATC GATCAGGTGCACCAGTATGT GAAGGACGGCATCAGCGAGGAGGATACCGAGAAGATCCTGA ACGGCAGACCCAATACCTACACATTCACCAAGGCCCTGACAGAGCACCTGGTGGCCGAGAA CCAGGCCTATGTGCCTACCATCATCGTGAGACCATCCGTGGTGGCCGCCATCAAGGATGAG CCTCTGAAGGATGGCTGGGAACTGGTTCGGAGCAACAGGACTGACCGTGTTTACAGCCA AGGGCCTGAATAGAGTGATCTACGGCCACAGTCTCCTATATCGTGGACCTGATCCAGTGA TTACGTGGCAAACCTGGTATCGCAGCAGGAGCCAAGTCTAGCAAGTCCACCGAGCTGAAG GTGTATAACTGCTGTTCTCTAGCTGTAATCCCGTGACCATCGGCACACTGATGAGCATGT TCGCCGACGATGCCATCAAGCAGAAGTCCTACGCCATGCCTCTGCCAGGCTGGTACATCTT TACAAAGTATAAGTGCGTGGTGTGCTGCTGCTGACCTTCCTGTTT CAGGTATCCCTGCCTAC GTGACCGACCTGTCTAGGCACCTGATCGGCAAGAGCCCACGCTATATCAAGCTGCAGAGCC TGGTGAACCGACACAGGTCTCTATCGACTTCTTTACAAATCACTCCTGGGT CATGAAGGC CGATAGGGTGC GCGAGCTGTACGCATCTCTGGCCCCAGCCGACAAAGTATCTGT^TCCCTTGC</p>

	GACCCMC CGATATCAACTGGA CACACTA CATCCA GGAT ^T ATTGTTGGGGCGTGC GCCACT TTCTGGAGAAGAAG ^T CCTATGA GTGA
SEQ ID NO: 89	Ha FAR S453A FAR ⁸ ATGGTGGTGCTGACCTCCAAGGAGACAAAGCCCTCTGTGGCCGAGTTCTACGCCGGCAAGA GCGTGTTTCATCACAGGCGGCACCGCTTCCTGGGCAAGGTGTTTATCGAGAAGCTGCTGTA CAGCTGCCCTGACATCGAGAACA ^T CTATATGCTGATCCGGGAGAAGAAGGGCC ^T GAGCGTG TCCGAGAGA ^A ATCAAGC ^A GTTCC ^T GGACGA ^T CCCCTGTTTACA ^A GGC ^T GA ^A GGACAAGCGCC CTGCCGATCTGGAGAAGATCGTGCTGATCCCAAGCGACATCA CCGCACCAGATCTGGGCAT CAACAGCGAGAATGAGAAGATGCTGATCGAGAAGGTGAGCGTGATCATCCA TCCGCCGCC ACCGTGAAGTTCAACGAGCCCTGCCTACAGCCTGGAAGATCAATGTGGAGGGCACCAGGA TGATGCTGGCCCTGTCTCG GAGAATGAAGCGCATCGAGGTGTTTATCCACATCAGCACAGC CTACACCAACACAAATAGGGAGGTGGTGGACGAGATCCTGTACCCAGCCCCGCCGACATC GATCAGGTGCACCA ^T GTGAAGGACGGCATCAGCAGGAGGATACCGAGAAGATCCTGA ACGGCAGACCCAATACCTACACATTCACCAAGCCCTGACAGAGCACCTGGTGGCC GAGAA CCAGGCCTATGTGCCTACCATCATCGTGAGACCATCCGTGGTGGCCGCCATCAAGGATGAG CCTCTGAAGGGATGGCTGGGAAACTGGTTCGGAGCAACAGGACTGACCGTGTTTACAGCCA AGGGCCTGAATAGAGTGATCTACGGCCACAGCTCCTATATCGTGGACCTGATCCCAGTGGA TTACGTGGCAAACCTGGTCATCGCAGCAGGAGCCAAGTCTAGCAAGTCCACCGAGCTGAAG GTGTATAACTGCTGTTCTCTAGCTGTAATCCCGTGACCATCGGCACACTGATGAGCATGT TCGCCGACGA.TGCCATCAAGCAGAAGT CCTACGCCATGCCTCTGCCAGGCTGGTACATCTT TACAAAGTATAAGTGGCTGGTGTGCTGCTGACCTTCCTGTTTCAGGTCATCCCTGCCTAC GTGACCGACCTGTCTAGGCACCTGATCGGCAAGAGCCCACGCTATATCAAGCTGCAGAGCC TGGTGAACCAGACCAAGTCTCTATCGAC ^T TCTTTACAAATCACTCCTGGGT CATGAAGGC CGATAGGGTGCGCGAG-CTGTA CGCATCTCTGAGCCCAGCCGACAAGTATCTGTTCCCTTGC GACCCAACCGATATCAACTGGACACACTACATCCAGGATTATTGTTGGGGCGTGCGCCACT TTCTGGAGAAGAAGGCCTATGA GTGA
SEQ ID NO: 90	Codon optimi zed wi l d type HaFAR (FAR ⁹ ; St rain SPV916) ATGGTGGTGCTGACCTCCAAGGAGACAAAGCCCTCTGTGGCCGAGTTCTACGCCGGCAAGA GCGTGTTTCATCACAGGCGGCACCGCTTCCTGGGCAAGGTGTTTATCGAGAAGCTGCTGTA CAGCTGCCCTGACATCGAGAACA ^T CTATATGCTGATCCGGGAGAAGAAGGGCCTGAGCGTG TCCGAGAGAATCAAGCAGTTCTGGACGATCCCCTGTTTACAAGGCTGAAGGACAAGCGCC CTGCCGATCTGGAGAAGATCGTGCTGATCCAGGCGAC ^A TCACCGCACCAGATCTGGGCAT CAACAGCGAGAATGAGAAGATGCTCATCGAGAAG ^G TGAGCGTGATCATCCACTCCGCCGCC ACCGTGAAGTTCAACGAGCCCCTGCCTACAGCCTGGAAGATCAATGTGGAGGGCACCAGGA TGATGCTGGCCCTGTCTCGAGAATGAAGCGCATCGAGG ^T GTT ^T ATCCACATCAGCACAGC CTACACCAACACAAATAGGGAGGTGGTGGACGAGATCCTGTACCCAGCCCCGCC GACATC GATCAGGTGCACCA ^T GTGAAGGACGGCATCAGCAGGAGGAT ^A CCGAGAAGATCCTGA ACGGCAGACCCAATACCTACACATTACCAAGGCCCTGACAGAGCACCTGGTGGCCGAGAA CCAGGCCTATGTGCCTACCATCATCGTGAGACCATCCGTGGTGGCCGCCATCAAGGATGAG CCTCTGAAGGGATGGCTGGGAAACTGGTTCGGAGCAACAGGACTGACCGTGTTTACAGCCA AGGGCCTGAATAGAGTGATCTACGGCCACAGCTCCTATATCGTGGACCTGATCCCAGTGGA TTACGTGGCAAACCTGGTCATCGCAGCAGGAGCCAAGTCTAGCAAGTCCACC GAGCTGAAG GTGTATAACTGCTGTTCTCTAGCTGTAATCCCGTGACCATCGGCACACTGATGAGCATGT TCGCCGACGATGCCATC ^A AGCAGAAGT CCTACGCCATGCCTCTGC CAGGCTGGTACATCTT TACAAAGTATAAGTGGCTGGTGTGCTGCTGACCTTCCTGTTTCAGGTCATCCCTGCCTAC GTGACCGACCTGTCTAGGCACCTGATCGGCAAGAGCCCACGCTATATCAAGCTGCAGAGCC TGGTGAACCAGACCAAGTCTCTATCGACTTCTTTACAAATCACTCCTGGGT CATGAAGGC CGATAGGGTGCGCGAGCTGTACGCATCTCTGAGCCCAGCCGACAAGTATCTGTTCCCTTGC GACCCAACCGATATCAACTGGACACACTACATCCAGGATTATTGTTGGGGCGTGCGCCACT

	TTCTGGAGAGAAG TCCTATGAGTGA
SEQ ID NO: 91	<p>PdDGAT1A (<i>Phoenix dactylifera</i> DGAT1A)</p> <p>ATGGCCATCCCATCCGATAGAGAGACCCTGGAGAGGGCACCAGAGCCTTCTCCAGCAAGCG ACCTGCAGAGCTCCCTGCGGAGAAGGCTGCACTCTACCGTGGCAGCAGTGGTGGTGCCAGA TTCTAGCTCCAAGACATCTAGCCCCAGCGCCGAGAACCTGACCACAGACAGCGGAGAGGAT TCCAAGGGGCGACACCTCCTCTGACGCCGATACAAGGGATAGGGTGGTGGACGGA.GTGGATA GGGAGGAGGAGAACAAGACCGTGAGCGTGCTGAATGGCAGACA GTACGAGGACGGAAGCGG CAGGGGACAGGGACAGGGCACAGGCGGCGCTGCCCGCCAAGTTTCTGTATAGGGCATCT GCCCCTGCACACAGGAAGGTGAAGGAGAGCCaCTGAGCTCCGATGCCATCTTCAAGCAGA GCCACGCCGCTGCTGAACCTGTGCATCGTGGTGTGATCGCCGTGAACCTCCAGGCTGAT CATCGAGAATCTGATGAAGTACGGCCTGCTGATCCGCGCGGCTATTGGTTTCTAGCAAG TCCCTGCGGGAC TGGCCTCTGCTGATGTGTCTG.acCCTGCCAGCATTTCTCTGGGAG CCTTCATGGTGGAGAAGCTGGCCAGCACAATTCATCTCCGAGTCTGTGGTATCAGCCT GCACGTGATCATCACACAGCCGAGCTGCTGTACCCAGTGTGATCGTATCCTGAGATGCGAT TCTGCCGTGTGAGCGGCATCACACTGATGCTGTTTGCCAGCGTGGTGTGGCTGAAGCTGG TGTCTACGCCCACACAACATGACATGAGGACACTGAGCAAGTCCATCG.ACAAGGAGGA TATGTACTCCAAGTGTCAGAGATCGATA.ATCTGAAGGGCGACTCCTTTAAGTCTCTGGTG TATTTTCATGGTGGCCCCca.CCCTGTGCTACAGCCAAGCTA.TCCAAGGACCACTGCATCA GGAAGGGATGGGTATCCGCCAGGTGGTGAAGCTGGTCATCTTACCAGCGCTGATGGGCTT CATCATCGAGCAGTACATCAACCCATCGTGCAAGATTCCAGCACCCTCTGAAGGGCAAC TTTCTGAATGCCATCGAGCGGGTGTGAAGCTGTCTGTGCCACCCTGTACGTGTGGCTGT GCATGTCTATTGTTTCTTCACTGTGGCTGAACATCTGGCCGAGCTGCTGTGCTTTGG CGATAGAGAGTCTACAAGGACTGGTGAACGCCAAGACAATCGAGGAGTATTGGAGGATG TGGA.ATATGCTGTGCA CCGCTGGATGATCCGGCACA TCTAGTTCCTTGTCTGAGAAATG GCCTGCCAAGGGCCGTGGCCATCTGATCTCCTTTCTGGTGTCTGCCATCTCCACGAGAT CTGCATCGCCGTGCCCTGTCA CATCTTTAAGTCTGGGCCTTTATCGGCATCATGTCCAG ATCCCCCTGGTCATCCTGACCAAGTATCTGCAGCACAAGTTTACAACTCCATGGTGGGCA ATATGATCTTCTGGTCTTTTCTCTATCCTGGGCCAGCCTATGTGCGTGTCTGTACTA TCACGACGTGATGAATAGAAAGGTGAGGACCGAGTGA</p>
SEQ ID NO: 92	<p>PdDGAT1A (<i>Phoenix dactylifera</i> DGAT1A) protein encoded by SEQ ID NO 91</p> <p>MAIPSDRETLERAPEPSPASDLQSSLRRRLHSTVAA\ 'WPD3SSKTSSPSAENLTTDSGED SRGDTSSDADTRDRVVDGVDRF.F.RNKTVSVLNGRQYEDGGGRGQGQGTGGVPAKFLYRAS APAHRKVKESPLSSDAI FKQSHAGLNLNCIWLiAVNSRL11ENLMKYGLLIRAGYWFSSK SLRDWPLLMLCLTLPAPPLGAFMVEKLAQHNFI SESWI SLHVI ITTAELLYPVIVILRCD SAVLSGITLMLFASVWLKLVSYAHTNYDMRTLKSIDKEDMYSKPEIDNLKGDSEFKSLV YFI»P/APTLCYOPSPYRPTTCIRKGWVIRQWKLVI FTGLMGFI IEQYINPIVQNSQHPLKGN FLNAIERVLKLSVPTLYVWLCMFYCFHLLWNLIAELLCFGDFREFYKDtIWNNAKTIEEYWRM WNMPVHRWMIRHIFPCLRNGLPRAVALISFLVSAIFHEICIAVPCHI FKFWAFIGIMFQ IPLVI LTKYLQHKFTN5MVGNMI FWFFFSILGQPMCVLLYYHDMNRKVRTE</p>
SEQ ID NO: 93	<p>TEF Promoter for enzyme expression</p> <p>GAGACCGGGTTGGCGGC GCAATTTGTGTCCAAAAACAGCCCCAAT TGCCCCAAT TGACCC CAAAAT TGACCCAGTAGCGGGCCCAAC CCCGCGAGAG CCCCTTCTCCCA CATATCAAAC CTCCCCGGTTCACACTTGCCGTTAAGGGCGTAGGGTACTGCAGTCTGGAATCTACGCT TGTTTCAGACTTTGTACTAGTTTCTTTGTCTGGCCATCCGGGTAAACCATGCCGACGCAAA ATAGACTACTGAAATTTTTTGTCTTGTGGTGGGACTTTAGCCAAGGTATAAAAAGAC ACCGTCCCCGAAT TACCTTCTCTCTCTTTCTCTCTCTCTCTCTCTCTGTCAAC TCACACCCGAA TCGTTAAGCATTTCTCTGAGTATAAGAATCATTC.AAA</p>

SEQ ID NO: 94	<p>DST076_coding_sequence Z9 Desaturase</p> <p>ATGCACATCGAGTCTGAGAACTGCCCCGGCAGGTTTAAGGAGGTGAACATGGCCCCCTAATG CCA CCGA TGCCAATGGCGTGCTGTTT GAGAC CGA TGCCGCCA CA CCTGAC CTGGCCCTGCC A CA CGCA CCTGTGCA G CAGGCCGAC AAC TA C C C A A A G A A G T A C G T G T G G C G C A A T A T C A T C CTGTTTGCCTACCTGCACATCGCCGCCCTGTACGGCGGCTATCTGTTTCTGTTCCACGCCA AGTGGCAGACCGATATCTTCGCCTACATCCTGTATGTGATGTCTGGACTGGGAATCACAGC AGGAGCACACAGGCT GTGGGCCCCA CAAGAG CTA CAAG GCCAAGT GGCCTCTGAGAC TGAT C CTGGTCAT CT T C A A C A C A C T G G C C T T T C A G G A C T C T G C C A T C G A T T G G A G C A G G G A C C A C C GCAT GCACCA CAAGT ATTCCGAGAC CGAC GCCGAT CCCCACAAT GCCA CA CGGGGCTTCTT TTTCTCTCACAT CGGCTGGCTGCTGGTGCG GAAG CA CCCTGAG CTGAAGAGAAAG GGCAAG GGCCTGGACCTGTCCGAT CTGTATGCCGACCCAATCCTGAGATTTAGAGAAGT ACTATC TGATCCTGATGCCCCTGACCTGTTTCGTGCTGCCAACAGTGATCCCCGTGTACTATTGGGG CGAGAC CTGGACAAAC GCCTTTTTTCGTGGCCGCCCTGTTTA GGTA CGCCTTCAT CCTGAAC GTGACCTGGCTGGTGAATAGCGCCGCCACAAGTGGGGCGATAAGCCTTATGACCGCAACA TCAAG CCAT CCGAGAAT ATCAGCGTGTCCA TGTTCGCCCTGGGC GAG GGCTTCACAAAC TA CCACCACA CCTTCCCAT GGGAT TATAAGA CAGC CGAGCTGGGC A A A T A T G C T G A A C T T C A C C A C A A A C T T C A T C A A C T T C T T C G C C A A G A T C G G C T G G G C T A C G A T C T G A A G A C C G T G T CCGACGAGATCGTGCCTCTAGAGCAAAGAGGACAGGCGACGGAAGCCACCACCTGTGGGG ATGGGGCGACAAG GAT CAC TCCAG GGAG GAG ATGGCTGCCGCCAT CCGCAT CCAC CCCAA G GACGATTGA</p>
SEQ ID NO: 95	<p>DST076_amino_acid Z9 Desaturase encoded by SEQ ID NO 94</p> <p>MHI ESENCPRFKEVNMAPNATDANGVLFETDAATPDLALPHAPVQQADN YPKKYVWRNII LFAYLHIAALYGGYLFHFHAKWQTDIFAYILYVMSGLGITAGAHRLWAHKSYKAKVJPLRLI LVI FNTLAFQDS AIDWSRDRMHKHYSETDADPHNATR GFFFSHIGWLLVRKHPELKRKGK GLDLS DLYADPILRFQKKYILIMPLTCFVLPTVI PVYYWGETWNTAFFVAALFRYAFILN VTWLWSAAHKWGD KPYDRNIKPSENISVSMFALGEGFHNHHTFPWDYKTAELGNMNLNF TTNFINF FAKIGWAYDLKTV3DEIVRSRAKRTGDGSHHLWGWDKDSREEMAAAIRIHPK DD</p>
SEQ ID NO: 96	<p>DST180_coding_sequence Z9 Desaturase</p> <p>ATGGCCCCAAA CATCTCTGAC GAT GTGAAT GGCGTGCTGTTTGAGAGCGAT GCAG CAAC A C CAG ACCTGGCCCTGGC A G C C C C C T G T G C A G A A G G C C G A T A A C C G G C C C A A G C A G T A C G T GTGGAGAAAT ATCCTGCTGTTG CA TA TCTGCAC GCCGCCGCCCTGTACGGC GGCTA TCTG TTTCTGACAAGCGCCAAGTGGCAGACCGACGTGTTTCGCCTACATCCTGTATGTGATGTCCG GACTGGGAATCACAGCAGGAGCACACAGGCTGTGGGCACACAAGTCTTACAAGGCCAAGTG GCCCCTGAAAGTGATCCTGAT CAT CT T T A A C A C C A T C G C C T T T C A G A C G C A G C A A T G G A T TGGGCAAGGGACCACAGAATGCACCACAAGTATAGCGAGACAGACGCCGATCCTCACAATG Cc.AcCAG GGGCTTCTTTTCTCCACAT CGGCTGGCTGCTGGTGC GCAAG c.AcCAGAT CT GAAGGAGAAGGCAAGGGCCTGGACATGAGCGATCTGCAGGCCGACCCCATCCTGCGGTTT CAGAAGAAGT A C T A T C T G C T G C T G A T G C C T C T G C C T G C T T T G T G A T G C C A A C A G T G A T C C CCGTGTA CTCTGGGGCGAGAC CTGGAAC AATGCCTTTTTCGTGGCCGCCAT GTTGA GA TA TGCCTTCATCCTGAACGTGACCTGGCTGGTGAATCCGCCGCCACAAGTGGGGCGATAAG CCTTAG G.AC.AAGAGCAT CAAG CCAT CCGAGAAC ATga.gCGTGGCCAT GTTGGCCTGGGCG AGGGCTTCACAATTACCACCACACATTCCCCTGGGATTATAAGACCGCCGAGCTGGGCAA CAAT AAG CTGAAC TTTA CC.ACAACCTTCAT CAAC TTCTTCG CAAGC TGGGCTGGGCTAC GACATGAAGAC AGT GTCCGAC GATA TCGTGAAG AACA GGGTGAAG CGCAC CGGCGATGGAT CTCAC CAC CTGTGGGga.TGGGGCGACAAGAAC CAGAG CAAG GAG GAGAT CGCCTCCGC CAT</p>

	CCGGATCAATCCTAAGGACGATGA
SEQ ID NO: 97	<p>DST180__amino__acid Z9 Desaturase encoded by SEQ ID NO: 96</p> <p>MAPNI SDDWGVLFESDAATPDALASPPVQKADNRPKQYWRNILLFAYLHAAALYGGYL FLT3AKWQTDVFAYILYVMSGLGITAGAHRLWAHKSYPKAKWPLKVILI I FNTIAFQDAAMD WARDHRMHKYSYETDADPHNATRGFFFSHIGWLLVRKHPDLKEKGKGLDMSDLQADPILRF QKKYYLLLM PLAC FVM PTVI PVYFWGETWNNAFFVAAMFRYAFI LNVTLVNSAAHKWGDK PYDKSIKPSENMSVAMFALGEGFHNHHTFPWDYKTAELGNNKLNFTTTFINFFAKLGWAY DMKTVSDDIVKNRVKRTGDGSHHLWGWDKNQSKKEIASAIRINPKDD</p>
SEQ ID NO: 98	<p>DST181__coding__sequence Z9 Desaturase</p> <p>ATGgccccAAAC ATcTcTgAG GAT GCCAA TGGCGTGCTGTTT GAGAG CGAT GCA GCAACAC CA GACCTGGCcCtGGCAAG CCCACcTGTGCA GAAG GCAGAC AAC AGGccCAAGcAGTACGT GTGGAGAAATATCATCTGTTTGCCTATCTGCACCTGGCCGCCCTGTACGGCGGCTATCTG TTTCTGTTcAGCGCCAAGTGGCAGACAGACGTGTTCCGCTACATCTGTATGTGATGTCCG GACTGGGAATCACCGCAGGAGCACACAGACTGTGGGCACACAAGTCTTACAAGGCCAAGTG GcCcCTGAAAGT GA TcCtGA Tcat cTtTAAC accATcGcCTTTcAGGAC GCA GCA ATGgAT TggGCAAGGgAC CACAGA7-VTGCACCAC AAGTATAGCGAGACAGACGC cGATCCTCACAATG CCACCAGGGGCTTCTTTTCTCCACATCGGCTGGCTGCTGGTGCGCAAGCACCCAGACCT GAAGAAGAAGGGCAAGGGCCTGGACATGAGCGATCTGCTGAACGACCCCATCCTGAAGTTT cAGAAGAA GTa CTAT CtGcT GcT GATgCcT CtGGCcT GcTcTGTGATGCCAAC AAT GATcc CCGTGTACCTGTGGGGCGAGACATGGACCAATGCCTTTTCTGGCCGCCATGTTTCGGTA TGCCTTCATCCTGAACGTGACCTGGCTGGTGAATCCGCCGCCCACAAAGTGGGGCGATAAG cCTTAGGACAAGAG CAT CAAG CCAT CCGAGAAC CTGTCTGTGGC CAT GTTGGCCCTGGGCG AGGGCTTcCACAAT TAcCA CcACACa TtCCcTGGGAT TA TA AGACCGccGAGcTGGGcAA CCAGAAGCTGAACCTCACACAACTTCATCAACTTTTTCGCCAAGCTGGGCTGGGCCTAC GAC ATGAAGAC AGT GTCCG.AC GAT ATC GTGAAGAAT AGGGTGAAG CGCA CCGGCGAT GgAT cTcACCA cCTGTGGGgAT GGGGCGcCAAGAAC CAGAG CAAG GAG GAG ATcGccTcCGccAT CCGGAT CAAT CCTAAG GAC GAT TGA</p>
SEQ ID NO: 99	<p>DST181__amino__acid Z9 Desaturase encoded by SEQ ID NO: 93</p> <p>MAPNI SEDANGVLFESDAATPDALASPPVQKADNRPKQYVWRNI ILFAYLHLAALYGGYL FLFSAKiJQTDVFAYILYV>ISGLGITAGAHRLWAHKSYPKAK5'fPLKVILI I FNTIAFQDAAMD WARDHRMHKYSYETDADPHNATRGFFFSHIGWLLVRKHPDLKKKGKGLDMSDLLNDPILKF QKKYYLLLMPLACFVMPTMI PVYLWGETWTNAFFVAAMFRYAFILN\T?WLVN3AAHKWGDK PYDKSIKPSENLSVAMFALGEGFHNHHTFPWDYKTAELGNQKLNFTTTFINFFAKLGWAY DMKTV5DDIVKNRVKRTGDGSHHLWGWDKNQSKKEIASAIRINPKDD</p>
SEQ ID NO: 100	<p>DSX183__coding__sequence Z9 Desaturase</p> <p>ATGGCCCCAAACATCAGCGAGGATGTGAATGGCGTGCTGTTTCGAGTCCGATCCCGCCACAC CAGAC CTGGCCCTGTC TA CCCCCA cCTGTGcAGAAG GcAGAC AAC AGG CcCAAG CAG CTGGT GTGGAGAAATATCTGTGTTTGCATACCTGCACCTGGCAGCACAGTACGGAGGCTATCTG TTTCTGTTCTCTGCCAAGTGGCAGACAGATATCTTCGCTACATCTGTATGTGATCAGCG GACTGGGAATCACCGCAGGAGCACACCGGCTGTGGGCCcACAAGTCTTACAAGGCCAAGTG GCCTCTGAGAGTGATCCTGGTcATCTTCAACACCGTGGCCTTTcAGGACGcGCAATGGAT TGgGcAA GgGAC cACAAGAAT GCA CCA CAAGT ATTCTGAGAC AGAC GCCGAT cCTcACAAT G ccAcCAGGgGcTtCTTTTcCAGccAcATcGcctGGcTgcTGGTgcGCAAG cAccCAGAT cT</p>

	<p>GAAGGAGAAGGGCAAGGGCCTGGACATGAGCGATCTGCTGGCCGACCCCATCCTGAGGTTT CAGAAG AAGTAcTATCTGATCCTGATGCCTCTGGCCTGCTTTGTGATGCCAAC AGTGATCC CCGTGTAcTtTcTGGGGCGAGAC ATGGAC CAAC GCCTTTT'i'CGTGGCCGCATGTtTCGCTA TGCCTTCATCCTGAACGTGACCTGGCTGGTGAATTCTGCCGCCACAAAGTGGGGCGATAAG CCTTAG GAC AAGAG CA TCAAG Cca TCCGAGAAC CTGTCTGTGGC CAT GTTTGCCCTGGGCG AGGGCTTCCACAATTACCACCACACATTCCCCTGGGACTATAAGACCGCCGAGCTGGGCAA CAAT AAG CTGAAC TTTA Cca CAAC CTT CAT CAAC TTCTTCG CAAGAT CGGCTGGGCC TAT GATCTGAAGAC AGT GTCCG.AC GATA TCGTGAAGAAT AGGGTGAAGAG GAC CGGCAC GAA GCCACCACCTGTGGGGCTGGGGCGATGAGAACCAGTCCAAGGAGGAGATCGACGCCCCAT CCGGAT CAAT CCTAAG GAC GAT TGA</p>
SEQ ID NO: 101	<p>DST183_amino_acid Z9 Desaturase encoded by SEQ ID NO: 100</p> <p>MAPNISEDVNGVLFESDAATPDLALSTPPVQKADNRPKQLVtiRNILLEAYLiLAAQYGGYL FLFsAKWQTDIFAY ILYVI SGLGITAGAH RLWAHKSYKAKW PLRVI LVI FNTVAFQDAAMD WARDHRMHHKYSETDADPHNATRGFFFSHIGWLLVRKHPDLKEKGKGLDMSDLLADPILRF QKKYyLiLmPLACFVMP T V I P V Y F W G E T W T N A F F V A A M F R Y A F I L N V T W L V N S A A H K W G D K PYDKSIKPSENLSVAMFALGEGFHNHYHTFPWDYKTAELGNNKLNFTTTTFINFFAKIGWAY DLKTVSDDIVKN RVKRTGDGSHHLWGWGDENQSKEE IDAAIRINPKDD</p>
SEQ ID NO: 102	<p>DSX189_coding_sequence Z9 Desaturase</p> <p>ATGGCCCCTAACGTGACCGAGGAGAATGGCGTGCTGTTTCGAGTCTGATGCAGCAACACCTG ACCTGGCCCTGGCAAGAGAGCCAGTGCAGCAGGCAGATAGCTCCCCACGGGTGTACGTGTG GAGAAACATCATCCTGTTTGCCTATCTGCACATCGCCCGCTGTACGGCGGCTATCTGTTT CTGTTCTCGCCAAGTGGCAGACCGACATCTTCGCTACCTGCTGTATGTGGCCTCTGGAC TGGGAATCACAGCAGGAGCACACAGGCTGTGGGCCACAAGAGCTACAAGGCCAAGTGGCC CCTGAGAC TGAT CCTGAC CAT CTTTAAC A Cca CA G CTTTTCAGGACAG CGCCATCGAT TGG GCCCCGGACCACAGAATGCACCACAAGTATTCGAGACCGACGCCGATCCCCACAATGCCA CAAG GGGCTTCTTTTCTCCCA CAT CGGCTGGCTGCTGGT GAG GAAGCACCCCTGAG CTGA GCGCAAGGGCAAGGGCCTGGACCTGTCTGATCTGTACGCCGATCCTATCCTCGCTTTCAG AAGAAG TACTAT CTGAT CCTGAT GCAC TGGCCTGCTTCAT CCTGCCCA CCGTGAT CCCCCG TGTACCTGTGGAACGAGACATGGAGCAATGCCTTTTTCGTGGCCGCCCTGTTTCGGTATAC CTTCAT CCTGAACGTGACAT GGCTGGTGAAT TCCGCCGCCCA CAAGT GGGCGAT AAG Cca TACGACAAGTCCATCAAGCCCTCTGAGAAGCTGTCTGTGAGCCTGTTTGCCTTCGGCGAGG GCTTTCa CAAT TACcAC CACA CcTtCCcAT GGGAT Ta TAAGAC AGCCGAG CTGGGCAAC CA CCGGCTGAACCTTACCACAAAGTTTCATCAACTTTTTCGCCAAGATCGGCTGGGCCTATGAT ATGAAGAC CGTGTCTCAC GAGAT CGTGCA GcAGAG GGTGAAGAG GACAG GCGAC GGAAG CC ACCACCTGTGGGGATGGGGCGACAAGGATCACGCACAG GAGGAGATCGACGCCCCATCAG AAT CAAT CCCAAG GAC GAT TGA</p>
SEQ ID NO: 103	<p>DST189_amino_acid Z9 Desaturase encoded by SEQ ID NO: 102</p> <p>MAPNVT EENGVL FESDAAT PDLALARE PVQQAD SSPRVYVWRN 11LFAYLH IAAVYGGYL F LFsAKWQTDIFAYLLYYAS GLGITAGAH RLWAHKSYKAKWPLRLiLTI FNTTAFQ DSA IDW ARDHRMHHKYSETDADPHNATRGFFFSHIGWLLVRKHPELKRKGKGLDLSLDLYADPILRFQ KKYYLiLmPLACFILPTVI PVYLWNETWSNAFFVAALFRYTFILNVTWLWSAAHKWGDKP YDKSIKPSENLSVSLFAFGEFHNHYHTFPWDYKTAELGNHRLNFTTKFlnFFAKIGWAYD MKTVSHEIVQQRVKRTGDGSHHLWGWGDKDHAQEE IDAAIRINPKDD</p>
SEQ ID NO: 104	<p>DST192_coding_sequence ZS Desaturase</p> <p>ATGGATTTTCTGAAC GAGAT CGAC AAT TGCCCCGAG CGGCTGA GAAAG CCAGAGAAGAT GG</p>

	CCCCAACGTGACCGAGGAGAATGGCGTGCTGTT' CGAGTCCGATGCAGCAACCCAGACCT GGCCCTGGCAAGGACACCTGTGGAGCAGGCCGACGATTCTCCAAGGATCTACGTGTGGCGC AACATCATCCTGTTTGCCTATCTGCACCTGGCCGCCATCTACGGCGGCTATCTGTTTCTGT TCTCCGCCAAGTGGCAGACCGATATCTTCGCCTACCTGCTGTATGTGGCATCTGGACTGGG AATCACAGCAGGAGCACACAGGCTGTGGGCACACAAGAGCTACAAGGCCAAGTGGCCTCTG CGCCTGAT CCTGAC CATCTT _T A _A ACAAT CGCCTTTCAGGACA GCGCCAT CGAT _T TGGGCCA GGGAC CA CCGCA TGCA CCAC AAGT ATTCCGAGAC CGAC GCCGAT CCACACAAT GCCA CA CG GGGCTTCTTTTCTCT CACA TCGGAT GGCTGCTGGTGCG GAAG CAC CCAGAG CTGAAGAGA AAG GGCAAG GGCCTGGAC CTGTCTGAT CTGTACAGCGAT CCCAT CCTGAGAT TTCAGAAGA AGTACTATATGATCCTGATGCCTCTGGCCTGTTTCATCCTGCCACCGTGATCCCCGTGTA TATGTGGAACGAGACATGGAGCAATGCCTTTTTCGTGGCCGCCCTGTTTAGGTATACCTTC ATCCTGAACGTGACATGGCTGGTGAATCCGCCGCCACAAGTGGGGCGATAAGCCTTACG ACAAGT CCAT CAAG CCAT CTGAGAAC ATGAG CGTGTCCCTGTTTGCCTTCG _G CGAG GGCTT _T TCACAAT TA CCAC CAC ACCTTCCCTTGGGAC TATAAGACAG CCGAG CTGGGCAAC CAC CGG CTGAAC TTCAC CACAAAGT TCAT CAAC TTCTTCGC CAAGAT CGGCTGGGCC TAT GAT ATGA AGACCGTGTCTCAGGAGATCGTGCAGCAGCGGGTGAAGAGAACAGGCGACGGAAGCCACCA CCTGTGGGGAT GGGGCGAC AAG GAT CAC GCACAG GAG GAGAT CAACGCCGCCAT CCGCAT C AAT CC _A AAGGACGATT GA
SEQ ID NO: 105	DST192 ___amino ___acid Z9 Desaturase encoded by SEQ ID NO: 104 MDFLNEIDNCPERLRKPEKMAPNWEENGVLFSDAATPDI^LARTPVEQADDSPRI YVWR N I I L FAYLHLAAI YGGYLF L FSAKWQTDI FAYLLYVASGLGITAGAHRLWAHKSYKAX' iPL RLILTI FNTIAFQDSAIDWARDHRMHKYS ETDADPHNATRGFFFSHIGWLLVRKHPELKR KGKGLDLS DLYSDPILRFQKKYYMILMPLACFILPTVI PVYMWNETWSNAFFVAALFRYTF ILNVTWLVN SA %HKWGD KPYDKSIKPS ENMSVSLFA FGEGFHN YHHTFPWDYKTA ELGNHR LNFTTKF INFFAKIGWAYDMKTVSQEIVQQRVKRTGDG3HHLWGWDKDHAQEEINAAIRI NPKDD

[0861] The foregoing detailed description has been given for clearness of understanding only and no unnecessary limitations should be understood there from as modifications will be obvious to those skilled in the art.

[0862] While the disclosure has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the disclosure following, in general, the principles of the disclosure and including such departures from the present disclosure as come within known or customary practice within the art to which the disclosure pertains and as may be applied to the essential features hereinbefore set forth and as follows in the scope of the appended claims.

INCORPORATION BY REFERENCE

[0863] All references, articles, publications, patents, patent publications, and patent applications cited herein are incorporated by reference in their entireties for all purposes. The current application hereby incorporates by reference each of the following in its entirety: U.S.

Provisional Application Serial No. 62/257,054, filed November 18, 2015, U.S. Provisional Application Serial No. 62/351,605, filed June 17, 2016, and PCX application no. PCT/US2016/062852, filed November 18, 2016.

[0864] However, mention of any reference, article, publication, patent, patent publication, and patent application cited herein is not, and should not be taken as, an acknowledgment or any form of suggestion that they constitute valid prior art or form part of the common general knowledge in any country in the world.

Further Embodiments of the Invention

[0865] Other subject matter contemplated by the present disclosure is set out in the following numbered embodiments:

1. A recombinant *Yarrowia lipoytica* microorganism capable of producing a mono- or poly-unsaturated C₆-C₂₄ fatty alcohol from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid, wherein the recombinant *Yarrowia lipoytica* microorganism comprises:

(a) at least one nucleic acid molecule encoding a fatty acyl desaturase having at least 95% sequence identity to a fatty acyl desaturase selected from the group consisting of SEQ ID NOs: 39, 54, 60, 62, 78, 79, 80, 95, 97, 99, 101, 103, and 105 that catalyzes the conversion of a saturated C₆-C₂₄ fatty acyl-CoA to a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA; and

(b) at least one nucleic acid molecule encoding a fatty alcohol forming fatty acyl reductase having at least 95% sequence identity to a fatty alcohol forming fatty acyl reductase selected from the group consisting of SEQ ID NOs: 41-48, 57, 73, 75 and 77 that catalyzes the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA from (a) into the corresponding mono- or poly-unsaturated C₆-C₂₄ fatty alcohol.

2. The recombinant *Yarrowia lipoytica* microorganism of embodiment 1, wherein the recombinant *Yarrowia lipoytica* microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous enzymes that catalyzes a reaction in a pathway that competes with the biosynthesis pathway for the production of a mono- or poly-unsaturated C₆-C₂₄ fatty alcohol.

3. The recombinant *Yarrowia lipolytica* microorganism of embodiments 1 or 2, wherein the recombinant *Yarrowia lipolytica* microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous enzyme selected from the following:

- (i) one or more acyl-CoA oxidase selected from the group consisting of YALI0E32835g (POX1), YALI0F10857g (PGX2), YALI0D24750g (POX3), YALI0E27654g (POX4), YALI0C23859g (POX5), YALI0E06567g (POX6);
- (ii) one or more (fatty) alcohol dehydrogenase selected from the group consisting of YALI0F09603g (FADH), YALI0D25630g (ADFH), YALI0E17787g (ADH2), YALI0A16379g (ADH3), YALI0E15818g (ADH4), YALI0D02167g (ADH5), YALI0A15147g (ADH6), YALI0E07766g (ADH7);
- (iii) a (fatty) alcohol oxidase YALI0B14014g (FAO1);
- (iv) one or more cytochrome P450 enzyme selected from the group consisting of YALI0E25982g (ALK1), YALI0F01320g (ALK2), YALI0E23474g (ALK3), YALI0B13816g (ALK4), YALI0B13838g (ALK5), YALI0B01848g (ALK6), YALI0A15488g (ALK7), YALI0C12122g (ALK8), YALI0B06248g (ALK9), YALI0B20702g (ALK10), YALI0C10054g (ALK11) and YALI0A20130g (ALK12); and
- (v) one or more diacylglycerol acyltransferase selected from the group consisting of YALI0E32791g (DGA1) and YALI0D07986g (DGA2).

4. The recombinant *Yarrowia lipolytica* microorganism of embodiments 1 or 2, wherein the recombinant *Yarrowia lipolytica* microorganism comprises a deletion of one or more endogenous enzyme selected from the following:

- (i) one or more acyl-CoA oxidase selected from the group consisting of YALI0E32835g (POX1), YALI0F10857g (POX2), YALI0D24750g (POX3), YALI0E27654g (POX4), YALI0C23859g (POX5), YALI0E06567g (POX6);
- (ii) one or more (fatty) alcohol dehydrogenase selected from the group consisting of YALI0F09603g (FADH), YALI0D25630g (ADH1), YALI0E17787g (ADH2),

YALI0A16379g (ADH3), YALI0E15818g (ADH4), YALI0D02167g (ADH5), YALI0A15147g (ADH6), YALI0E07766g (ADH7);

(iii) a (fatty) alcohol oxidase YALI0B14014g (FAOI);

(iv) one or more cytochrome P450 enzyme selected from the group consisting of YALI0E25982g (ALKi), YALI0F01320g (ALK2), YALI0E23474g (ALK3), YALI0B13816g (ALK4), YALI0B13838g (ALK5), YALI0B01848g (ALK6), YAU0A15488g (ALK7), (YALI0CI2122g (ALK8), YALI0BQ6248g (ALK9), YALI0B20702g (ALKIO), YALI0C10054g (ALK11) and YALI0A20130g (ALK12); and

(v) one or more diacylglycerol acyltransferase selected from the group consisting of YALI0E32791g (DGA1) and YALI0D07986g (DGA2).

5. The recombinant *Yarrowia lipolytica* microorganism of any one of embodiments 1-4, wherein the fatty acyl desaturase catalyzes the conversion of a saturated fatty acyl-CoA into a mono- or poly-unsaturated intermediate selected from Z9-14:Acyl-CoA, Z11-14:Acyl-CoA, Ell-14:Acyl-CoA, Z9-16:Acyl~CoA, and Z11-16:Acyl-CoA.

6. The recombinant *Yarrowia lipolytica* microorganism of any one of embodiments 1-5, wherein the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol is selected from the group consisting of Z9-14:OH, Z11-14:OH, Ell-14:OH, Z9-16:OH, Z11-16:OH, Z11-13-16:QH, and Z13-18:OH.

7. The recombinant *Yarrowia lipolytica* microorganism of any one of embodiments 1-6, wherein the recombinant *Yarrowia lipolytica* microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase or an alcohol dehydrogenase capable of catalyzing the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol into a corresponding C₆-C₂₄ fatty aldehyde.

8. The recombinant *Yarrowia lipolytica* microorganism of embodiment 7, wherein the alcohol dehydrogenase is selected from Table 3a.

9. The recombinant *Yarrowia lipolytica* microorganism of embodiments 7 or 8, wherein the C₆-C₂₄ fatty aldehyde is selected from the group consisting of Z9-14:Ald, Z11-14:Ald, E11-14:Ald, Z9-16:Ald, Z11-16:Ald, Z11Z13-16:Ald and Z13-18:Ald.

10. The recombinant *Yarrowia lipolytica* microorganism of any one of embodiments 1-9, wherein the recombinant *Yarrowia lipolytica* microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol into a corresponding C₆-C₂₄ fatty acetate.

11. The recombinant *Yarrowia lipolytica* microorganism of embodiment 10, wherein the acetyl transferase is selected from Table 5d.

12. The recombinant *Yarrowia lipolytica* microorganism of embodiments 10 or 11, wherein the C₆-C₂₄ fatty acetate is selected from the group consisting of Z9-14:Ac, Z11-14:Ac, E11-14:Ac, Z9-16:Ac, Z11-16:Ac, Z11Z13-16:Ac, and Z13-18:Ac.

13. The recombinant *Yarrowia lipolytica* microorganism of any one of embodiments 1-12, wherein the recombinant *Yarrowia lipolytica* microorganism further comprises:

at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase or an alcohol dehydrogenase capable of catalyzing the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol into a corresponding C₆-C₂₄ fatty aldehyde; and

at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol into a corresponding C₆-C₂₄ fatty acetate.

14. The recombinant *Yarrowia lipolytica* microorganism of embodiment 13, wherein the mono- or poly-unsaturated **C6-C24** fatty aldehyde and C_{6-C24} fatty acetate is selected from the group consisting of Z9-14:Ac, Z11-14:Ac, Ell-14:Ac, Z9-16:Ac, Z11-16:Ac, Z11Z13-16:Ac, Z13-18:Ac, Z9-14:Ald, Z11-14:Ald, Ell-14:Ald, Z9-16:Ald, Z11-16:Ald, Z11Z13-16:Ald and Z13-18:Ald.

15. The recombinant *Yarrowia lipolytica* microorganism of any one of embodiments 1-14, wherein the fatty acyl desaturase does not comprise a fatty acyl desaturase comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 64, 65, 66 and 67.

16. The recombinant *Yarrowia lipolytica* microorganism of any one of embodiments 1-15, wherein the fatty acyl desaturase does not comprise a fatty acyl desaturase selected from an *Arnyelois transitella*, *Spodoptera littoralis*, *Agrotis segelurn*, or *Trichoplusia rii* derived desaturase.

17. A method of producing a mono- or poly-unsaturated **C6-C24** fatty alcohol from an endogenous or exogenous source of saturated C_{6-C24} fatty acid, comprising: cultivating the recombinant *Yarrowia lipolytica* microorganism of any one of embodiments 1-16 in a culture medium containing a feedstock that provides a carbon source adequate for the production of the mono- or poly-unsaturated C_{6-C24} fatty alcohol.

18. The method of embodiment 17, wherein the mono- or poly-unsaturated C_{6-C24} fatty alcohol is selected from the group consisting of Z9-14:OH, Z11-14:OH, Ell-14:OH, Z9-16:OH, Z11-16OH, Z11Z13-16:OH, and Z13-18:OH.

19. The method of embodiments 17 or 18, wherein the recombinant *Yarrowia lipolytica* microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous enzyme selected from the following:

- (i) one or more acyl-CoA oxidase selected from the group consisting of YALI0E32835g (POX1), YALI0F10857g (POX2), YALI0D24750g (POX3), YALI0E27654g (POX4), YALI0C23859g (PQX5), YALI0E06567g (POX6);
- (ii) one or more (fatty) alcohol dehydrogenase selected from the group consisting of YALI0F09603g (FADH), YALI0D25630g (ADH1), YAU0E17787g (ADH2), YALI0A16379g (ADH3), YALI0E15818g (ADH4), YALI0D02167g (ADH5), YALI0A15147g (ADH6), YALI0E07766g (ADH7);
- (iii) a (fatty) alcohol oxidase YALI0B14014g (FAO!);
- (iv) one or more cytochrome P450 enzyme selected from the group consisting of YALI0E25982g (ALKi), YALI0F01320g (ALK2), YALI0E23474g (ALK3), YALI0B13816g (ALK4), YALI0B13838g (ALK5), YALI0B01848g (ALK6), YALI0A15488g (ALK7), (YALI0C12122g (ALK8), YALI0B06248g (ALK9), YALI0B20702g (ALKIO), YALI0C10054g (ALK11) and YALI0A20130g (ALK12); and
- (v) one or more diacylglycerol acyltransferase selected from the group consisting of YALI0E32791g (DGA1) and YALI0D07986g (DGA2).
20. The method of embodiments 17 or 18, further comprising a step of recovering the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol.
21. The method of embodiment 20, wherein said recovery step comprises distillation.
22. The method of embodiment 20, wherein said recovery step comprises membrane-based separation.
23. A method of producing a mono- or poly-unsaturated C₆-C₂₄ fatty aldehyde from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid, comprising; cultivating the recombinant *Yarrowia lipolytica* microorganism of any one of embodiment 1-16 in a culture

medium containing a feedstock that provides a carbon source adequate for the production of the mono- or poly-unsaturated C_6-C_{24} fatty aldehyde.

24. The method of embodiment 23, wherein the C_6-C_{24} fatty aldehyde is selected from the group consisting of Z9-14:Ald, Z11-14:Ald, E11-14:Ald, Z9-16:Ald, Z11-16:Ald, Z11Z13-16:Ald and Z13-18:Ald.

25. The method of embodiments 23 or 24, further comprising a step of recovering the mono- or poly-unsaturated C_6-C_{24} fatty aldehyde.

26. The method of embodiment 25, wherein said recovery step comprises distillation.

27. The method of embodiment 25, wherein said recovery step comprises membrane-based separation.

28. A method of producing a mono- or poly-unsaturated C_6-C_{24} fatty acetate from an endogenous or exogenous source of saturated C_6-C_{24} fatty acid, comprising: cultivating the recombinant *Yarrowia lipolytica* microorganism of any one of embodiments 1-16 in a culture medium containing a feedstock that provides a carbon source adequate for the production of the mono- or poly-unsaturated C_6-C_{24} fatty acetate.

29. The method of embodiment 28, wherein the C_6-C_{24} fatty acetate is selected from the group consisting of Z9-14:Ac, Z11-14:Ac, E11-14:Ac, Z9-16:Ac, Z11-16:Ac, Z11Z13-16:Ac, and Z13-18:Ac.

30. The method of embodiment 28, further comprising a step of recovering the mono- or poly-unsaturated C_6-C_{24} fatty acetate.

31. The method of embodiment 28, wherein said recovery step comprises distillation.

32. The method of embodiment 28, wherein said recovery step comprises membrane-based separation.

33. A method of producing a mono- or poly-unsaturated C₆-C₂₄ fatty aldehyde and C₆-C₂₄ fatty acetate from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid, comprising: cultivating the recombinant *Yarrowia lipolytica* microorganism of any one of embodiments 1-16 in a culture medium containing a feedstock that provides a carbon source adequate for the production of the mono- or poly-unsaturated C₆-C₂₄ fatty aldehyde and C₆-C₂₄ fatty acetate.

34. The method of embodiment 33, wherein the mono- or poly-unsaturated C₆-C₂₄ fatty aldehyde and C₆-C₂₄ fatty acetate is selected from the group consisting of Z9-14:Ac, Z11-14:Ac, H11-14:Ac, Z9-16:Ac, Z11-16:Ac, Z11Z13-16:Ac, Z13-18:Ac, Z9-14:Ald, Z11-14:Ald, E11-14:Ald, Z11-16:Ald, Z11Z13-16:Ald and Z13-18:Ald.

35. A method of engineering a *Yarrowia lipolytica* microorganism that is capable of producing a mono- or poly-unsaturated C₆-C₂₄ fatty alcohol from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid, wherein the method comprises introducing into a *Yarrowia lipolytica* microorganism the following:

(a) at least one nucleic acid molecule encoding a fatty acyl desaturase having at least 95% sequence identity to a fatty acyl desaturase selected from the group consisting of SEQ ID NOs: 39, 54, 60, 62, 78, 79, 80, 95, 97, 99, 101, 103, and 105 that catalyzes the conversion of a saturated C₆-C₂₄ fatty acyl-CoA to a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA; and

(b) at least one nucleic acid molecule encoding a fatty alcohol forming fatty acyl reductase having at least 95% sequence identity to a fatty alcohol forming fatty acyl reductase selected from the group consisting of SEQ ID NOs: 41-48, 57, 73, 75 and 77 that catalyzes the conversion of the mono- or poly-unsaturated C_6-C_{24} fatty acyl-CoA from (a) into the corresponding mono- or poly-unsaturated C_6-C_{24} fatty alcohol.

36. The method of embodiment 35, wherein the method further comprises introducing into the *Yarrowia lipolytica* microorganism one or more modifications comprising a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous enzymes that catalyzes a reaction in a pathway that competes with the biosynthesis pathway for the production of a mono- or poly-unsaturated C_6-C_{24} fatty alcohol.

37. The method of embodiment 35 or 36, wherein the *Yarrowia lipolytica* microorganism is MATA ura3-302::SUC2 $\Delta pox1 \Delta pox2 \Delta pox3 \Delta pox4 \Delta pox5 \Delta pox6$ Afadh $\Delta adh1 \Delta adh2 \Delta adh3 \Delta adh4 \Delta adh5 \Delta adh6 \Delta adh7 \Delta fao1$::URA3.

38. The method of any one of embodiments 35-37, wherein the method further comprises introducing into the *Yarrowia lipolytica* microorganism one or more modifications comprising a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous enzyme selected from the following:

(i) one or more acyl-CoA oxidase selected from the group consisting of YALI0E32835g (POX1), YALI0F10857g (POX2), YALI0D2475Gg (POX3), YALI0E27654g (POX4), YALI0C23859g (POX5), YALI0E06567g (POX6);

(ii) one or more (fatty) alcohol dehydrogenase selected from the group consisting of YALI0F09603g (FADH), YALI0D25630g (ADH1), YALI0E17787g (ADH2), YALI0A16379g (ADH3), YALI0E15818g (ADH4), YALI0D02167g (ADH5), YALI0A15147g (ADH6), YALI0E07766g (ADH7);

(iii) a (fatty) alcohol oxidase YALI0B14014g (FAOI);

(iv) one or more cytochrome P450 enzyme selected from the group consisting of YALI0E25982g (ALK1), YALI0F01320g (ALK2), YALI0E23474g (ALK3),

YALI0B13816g (ALK4), **YALI0B 13838g (ALK5)**, YALT0B01848g (ALK6), YALI0A1 5488g (ALK7), (YALI0C 12122g (ALK8), YALR)B06248g (ALK9), YALI0B20702g (ALK10), YALI0C10054g (ALK11) and YALI0A20130g (ALK12); and

(v) one or more diacylglycerol acyltransferase selected from the group consisting of YALI0E32791g (DGA1) and **YAL10D07986g (DGA2)**.

39. The method of any one of embodiments 35-38, wherein the fatty acyl desaturase catalyzes the conversion of a fatty acyl-CoA into a mono- or **poly-unsaturated intermediate** selected from **Z9-14:Acyl-CoA**, **Z11-14:Acyl-CoA**, **E11-14:Acyl-CoA**, Z9-16:Acyl-CoA, and **Z11-16:Acyl-CoA**.

40. The method of any one of embodiments 35-39, wherein the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol is selected from the group consisting of Z9-14:QH, **Z11-14:OR**, E11-14:OH, Z9-16:OH, Z11-16:OH, Z11Z13-16:OH, and / 13-18:OH.

41. The method of any one of embodiments 35-40, wherein the method further comprises introducing into or expressing **in** the recombinant *Yarrowia lipolytica* microorganism at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase or an alcohol dehydrogenase capable of catalyzing the conversion **of the** mono- or poly-unsaturated C₆-C₂₄ fatty alcohol **into** a corresponding C₆-C₂₄ fatty aldehyde.

42. The method of embodiment **41**, wherein the alcohol dehydrogenase is selected from **Table 3a**.

43. The method of embodiment 41, wherein the CVC24 **fatty** aldehyde is selected from the group consisting of **Z9-14:Ald**, / 11-14:Ald, **E11-14:Ald**, Z9-16:Ald, Z11-16:Ald, **Z11Z13-16:Ald** and **Z13-18:Ald**.

44. The method of any one of embodiment 35-43, wherein the method further comprises introducing into or expressing in the recombinant *Yarrowia lipolytica* microorganism at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol into a corresponding C₆-C₂₄ fatty acetate.

45. The method of embodiment 44, wherein the acetyl transferase is selected from Table 5d.

46. The method of embodiment 44, wherein the C₆-C₂₄ fatty acetate is selected from the group consisting of Z9-14:Ac, Z11-14:Ac, E11-14:Ac, Z9-16:Ac, Z11-16:Ac, Z11Z13-16:Ac, and Z13-18:Ac.

47. The method of any one of embodiments 35-46, wherein the method further comprises introducing into or expressing in the recombinant *Yarrowia lipolytica* microorganism:

at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase or an alcohol dehydrogenase capable of catalyzing the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol into a corresponding C₆-C₂₄ fatty aldehyde; and

at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol into a corresponding C₆-C₂₄ fatty acetate.

48. The method of any one of embodiments 35-47, wherein the mono- or poly-unsaturated C₆-C₂₄ fatty aldehyde and C₆-C₂₄ fatty acetate is selected from the group consisting of Z9-14:Ac, Z11-14:Ac, E11-14:Ac, Z9-16:Ac, Z11-16:Ac, Z11Z13-16:Ac, Z13-18:Ac, Z9-14:Ald, Z11-14:Ald, E11-14:Ald, Z9-16:Ald, Z11-16:Ald, Z11Z13-16:Ald and Z13-18:Ald.

49. The method of any one of embodiments 35-48, wherein the fatty acyl desaturase does not comprise a fatty acyl desaturase comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 64, 65, 66 and 67.

50. The method of any one of embodiments 35-49, wherein the fatty acyl desaturase does not comprise a fatty acyl desaturase selected from an *Amyelois transitella*, *Spodoptera littoralis*, *Agrotis segetum*, or *Trichoplusia ni* derived desaturase.

51. The method of any one of embodiments 17-22, wherein the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol is converted into a corresponding C₆-C₂₄ fatty aldehyde using chemical methods.

53. The method of any one of embodiments 17-22, wherein the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol is converted into a corresponding C₆-C₂₄ fatty acetate using chemical methods.

54. The method of embodiment 53, wherein the chemical methods utilize a chemical agent selected from the group consisting of acetyl chloride, acetic anhydride, butyryl chloride, butyric anhydride, propanoyl chloride and propionic anhydride in the presence of 4-*N*, *N*-dimethylaminopyridine (DMAP) or sodium acetate to esterify the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol to the corresponding C₆-C₂₄ fatty acetate.

55. A recombinant microorganism capable of producing a mono- or poly-unsaturated ≤ C₁₈ fatty alcohol from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid, wherein the recombinant microorganism comprises:

(a) at least one exogenous nucleic acid molecule encoding a fatty acyl desaturase that catalyzes the conversion of a saturated C₆-C₂₄ fatty acyl-CoA to a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA;

(b) at least one exogenous nucleic acid molecule encoding an acyl-CoA oxidase that catalyzes the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA from (a)

into a mono- or poly-unsaturated $\leq C_{15}$ fatty acyl-CoA after one or more successive cycle of acyl-CoA oxidase activity, with a given cycle producing a mono- or poly-unsaturated ~~C4-C22~~ fatty acyl-CoA intermediate with a two carbon truncation relative to a starting mono- or poly-unsaturated C_{6-C24} fatty acyl-CoA substrate in that cycle; and

(c) at least one exogenous nucleic acid molecule encoding a fatty alcohol forming fatty acyl reductase that catalyzes the conversion of the mono- or poly-unsaturated $\leq C_{15}$ fatty acyl-CoA from (b) into the corresponding mono- or poly-unsaturated $\leq C_{15}$ fatty alcohol.

56. The recombinant microorganism of embodiment 55, wherein the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an acyltransferase that preferably stores $\leq C_{15}$ fatty acyl-CoA.

57. The recombinant microorganism of any one of embodiments 55-56, wherein the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an acyltransferase that preferably stores $\leq C_{15}$ fatty acyl-CoA, and wherein the acyltransferase is selected from the group consisting of glycerol-3-phosphate acyl transferase (GPAT), lysophosphatidic acid acyltransferase (LPAAT), glycerolphospholipid acyltransferase (GPLAT) and diacylglycerol acyltransferases (DGAT).

58. The recombinant microorganism of any one of embodiments 55-57, wherein the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an acyltransferase that preferably stores $\leq C_{15}$ fatty acyl-CoA, and wherein the acyltransferase is selected from Table Sb.

59. The recombinant microorganism of any one of embodiments 55-58, wherein the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an acylglycerol lipase that preferably hydrolyzes ester bonds of $>C_{16}$, of $>C_{14}$, of $>C_{12}$ or of $>C_{10}$ acylglycerol substrates.

60. The recombinant microorganism of any one of embodiments 55-59, wherein the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an acylglycerol lipase that preferably hydrolyzes ester bonds of >C16, of >C14, of >C12 or of >C10 acylglycerol substrates, and wherein the acylglycerol lipase is selected from Table 5c.

61. The recombinant microorganism of any one of embodiments 55-60, wherein the recombinant microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous enzymes that catalyzes a reaction in a pathway that competes with the biosynthesis pathway for the production of a mono- or poly-unsaturated \leq C₁₈ fatty alcohol.

62. The recombinant microorganism of any one of embodiments 55-61, wherein the recombinant microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous enzyme selected from:

- (i) one or more acyl-CoA oxidase;
- (ii) one or more acyltransferase;
- (iii) one or more acylglycerol lipase and/or sterol ester esterase;
- (iv) one or more (fatty) alcohol dehydrogenase;
- (v) one or more (fatty) alcohol oxidase; and
- (vi) one or more cytochrome P450 monooxygenase.

63. The recombinant microorganism of any one of embodiments 55-62, wherein the recombinant microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous acyl-CoA oxidase enzyme selected from the group consisting of *Y. lipolytica* POX1(YALI0E32835g), *Y. lipolytica* POX2(YALI0F10857g), *Y. lipolytica* POX3(YALI0D24750g), *Y. lipolytica* POX4(YALI0E27654g), *Y. lipolytica* POX5(YALI0C23859g), *Y. lipolytica* POX6(YALI0E06567g); *S. cerevisiae*

POX1(YGL205W); *Candida* **POX2** (Ca019.1655, Ca0 19.9224, CTRG_02374, M18259), *Candida* **POX4** (Ca019.1652, Ca019.9221, CTRG_02377, M12160), and *Candida* **POX5** (Ca019.5723, Ca019. 13146, CTRG_02721, M12161).

64. The recombinant microorganism of any one of embodiments 55-63, wherein the recombinant microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous acyltransferase enzyme selected from the group consisting of *Y. lipolytica* YALI0C00209g, *Y. lipolytica* YALI0E18964g, *Y. lipolytica* YALI0F19514g, *Y. lipolytica* YALI0C14014g, *Y. lipolytica* YALI0E16797g, *Y. lipolytica* YALI0E32769g, and *Y. lipolytica* YALI0D07986g, *S. cerevisiae* YBLO1lw, *S. cerevisiae* YDL052c, *S. cerevisiae* YOR175C, *S. cerevisiae* YPR139C, *S. cerevisiae* YNR008w, and *S. cerevisiae* YOR245c, and *Candida* I503_02577, *Candida* CTRG_02630, *Candida* CaO 19.250, *Candida* Ca019.7881, *Candida* CTRG_02437, *Candida* Ca019.1881, *Candida* CaO 19.9437, *Candida* CTRG_01687, *Candida* CaO 19.1043, *Candida* Ca019.8645, *Candida* CTRG_04750, *Candida* CaO 19.13439, *Candida* CTRG_04390, *Candida* CaO 19.6941, *Candida* CaO19.14203, and *Candida* CTRG_06209.

65. The recombinant microorganism of any one of embodiments 55-64, wherein the recombinant microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous acylglycerol lipase and/or sterol ester esterase enzyme selected from the group consisting of *Y. lipolytica* YALI0E32035g, *Y. lipolytica* YALI0D17534g, *Y. lipolytica* YALIOFIOOIOg, *Y. lipolytica* YALI0C14520g, and *Y. lipolytica* YALI0E00528g, *S. cerevisiae* YKL140w, *S. cerevisiae* YMR313c, *S. cerevisiae* YKR089c, *S. cerevisiae* YOR081c, *S. cerevisiae* YKL094W, *S. cerevisiae* YLL012W, and *S. cerevisiae* YLR020C, and *Candida* CaO19.2050, *Candida* Ca019.9598, *Candida* CTRG_01138, *Candida* W5Q_03398, *Candida* CTRG_00057, *Candida* Ca019.5426, *Candida* Ca019.12881, *Candida* CTRG_06185, *Candida* Ca019.4864, *Candida* CaO19.12328, *Candida* CTRG_03360, *Candida* CaO19.6501, *Candida* CaO19.13854, *Candida* CTRG_05049, *Candida* Ca019.1887, *Candida* Ca019.9443, *Candida* CTRG_01683, and *Candida* CTRG_04630.

66. The method of any one of embodiments 55-65, wherein the recombinant microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous cytochrome P450 monooxygenases selected from the group consisting of *Y. lipolytica* YALI0E25982g (ALK1), *Y. lipolytica* YALT0F01320g (ALK2), *Y. lipolytica* YALI0E23474g (ALK3), *Y. lipolytica* YALI0B138I6g (ALK4), *Y. lipolytica* YALI0B13838g (ALK5), *Y. lipolytica* YALI0B01848g (ALK6), *Y. lipolytica* YAU0A15488g (ALK7), *Y. lipolytica* YALI0C12122g (ALK8), *Y. lipolytica* YALI0B06248g (ALK9), *Y. lipolytica* YALI0B20702g (ALK10), *Y. lipolytica* YALI0C10054g (ALK11) and *Y. lipolytica* YALI0A20130g (ALK12).

67. The recombinant microorganism of any one of embodiments 55-66, wherein the fatty acyl desaturase is selected from an *Argyrotaenia veitiana*, *Spodoptera litura*, *Sesamia inferens*, *Manduca sexta*, *Ostrinia nubilalis*, *Heliothis zea*, *Choristoneura rosaceana*, *Drosophila melanogaster*, *Spodoptera littoralis*, *Lampronia capitella*, *Amyelois transitella*, *Trichoplusia ni*, *Agrotis segetum*, *Ostrinia furnicalis*, and *Thalassiosira pseudonana* derived fatty acyl desaturase.

68. The recombinant microorganism of any one of embodiments 55-67, wherein the fatty acyl desaturase has at least 95% sequence identity to a fatty acyl desaturase selected from the group consisting of: SEQ ID NOs: 39, 49-54, 58-63, 78-80 and GenBank Accession nos. AF416738, AGH12217.1, A1121943.1, CAJ43430.2, AF441221, AAF81787.1, AF545481, AJ271414, AY362879, ABX71630.1, NP001299594.1, Q9N9Z8, ABX71630.1 and AIM40221.1.

69. The recombinant microorganism of any one of embodiments 55-68, wherein the acyl-CoA oxidase is selected from Table 5a.

70. The recombinant microorganism of any one of embodiments 55-69, wherein the fatty alcohol forming fatty acyl reductase is selected from an *Agrotis segetum*, *Spodoptera exigua*.

Spodoptera littoralis, *Euglena gracilis*, *Yponomeuta evonymellus* and *Helicoverpa armigera* derived fatty alcohol forming fatty acyl reductase.

71. The recombinant microorganism of any one of embodiments 55-70, wherein the fatty-alcohol forming fatty acyl reductase has at least 95% sequence identity to a fatty alcohol forming fatty acyl reductase selected from the group consisting of: SEQ ID NOs: 1-3, 32, 41-48, 55-57, 73, 75, 77 and 82.

72. The recombinant microorganism of any one of embodiments 55-71, wherein the fatty acyl desaturase catalyzes the conversion of a fatty acyl-CoA into a mono- or poly-unsaturated intermediate selected from E5-10:Acyl-CoA, E7-12:Acyl-CoA, E9-14:Acyl-CoA, E11-16:Acyl-CoA, E13-18:Acyl-CoA, Z7-12:Acyl-CoA, Z9-14:Acyl-CoA, Z11-16:Acyl-CoA, Z13-18:Acyl-CoA, Z8-12:Acyl-CoA, Z10-14:Acyl-CoA, Z12-16:Acyl-CoA, Z14-18:Acyl-CoA, Z7-10:Acyl-CoA, Z9-12:Acyl-CoA, Z11-14:Acyl-CoA, Z13-16:Acyl-CoA, Z15-18:Acyl-CoA, E7-10:Acyl-CoA, E9-12:Acyl-CoA, E11-14:Acyl-CoA, E13-16:Acyl-CoA, E15-18:Acyl-CoA, E5Z7-12:Acyl-CoA, E7Z9-12:Acyl-CoA, E9Z11-14:Acyl-CoA, E11Z13-16:Acyl-CoA, E13Z15-18:Acyl-CoA, E6E8-10:Acyl-CoA, E8E10-12:Acyl-CoA, E10E12-14:Acyl-CoA, E12E14-16:Acyl-CoA, Z5E8-10:Acyl-CoA, Z7E10-12:Acyl-CoA, Z9E12-14:Acyl-CoA, Z11E14-16:Acyl-CoA, Z13E16-18:Acyl-CoA, Z3-10:Acyl-CoA, Z5-12:Acyl-CoA, Z7-14:Acyl-CoA, Z9-16:Acyl-CoA, Z11-18:Acyl-CoA, Z3Z5-10:Acyl-CoA, Z5Z7-12:Acyl-CoA, Z7Z9-14:Acyl-CoA, Z9Z11-16:Acyl-CoA, Z11Z13-16:Acyl-CoA, and Z13Z15-18:Acyl-CoA.

73. The recombinant microorganism of any one of embodiments 55-72, wherein the mono- or poly-unsaturated \leq Cis fatty alcohol is selected from the group consisting of E5-10:OH, Z8-12:OH, Z9-12:OH, Z11-14:OH, Z11-16:OH, E11-14:OH, E8E10-12:OH, E7Z9-12:OH, Z11Z13-16OH, Z9-14:OH, Z9-16:OH, and Z13-18:OH.

74. The recombinant microorganism of any one of embodiments 55-73, wherein the recombinant microorganism further comprises at least one endogenous or exogenous nucleic

add molecule encoding an aldehyde forming fatty acyl-CoA reductase capable of catalyzing the conversion of the mono- or poly-unsaturated \leq Cis fatty alcohol into a corresponding \leq Cis fatty aldehyde.

75. The recombinant microorganism of embodiment 74, wherein the aldehyde forming fatty acyl-CoA reductase is selected from the group consisting of *Acinetobacter calcoaceticus* A0A1C4HN78, *A. calcoaceticus* N9DA85, *A. calcoaceticus* R8XW24, *A. calcoaceticus* A0A1A0GGM5, *A. calcoaceticus* A0AU7N158, and *Nostoc punctijorme* YP_001865324.

76. The recombinant microorganism of any one of embodiments 55-75, wherein the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase or an alcohol dehydrogenase capable of catalyzing the conversion of the mono- or poly-unsaturated \leq Cis fatty alcohol into a corresponding \leq Cis fatty aldehyde.

77. The recombinant microorganism of any one of embodiments 55-76, wherein the \leq Cis fatty aldehyde is selected from the group consisting of Z9-16:Ald, Z11-16:Ald, Z11Z13-16:Ald, and Z13-18:Ald.

78. The recombinant microorganism of any one of embodiments 55-77, wherein the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated \leq Cis fatty alcohol into a corresponding \leq Cis fatty acetate.

79. The recombinant microorganism of embodiment 78, wherein the acetyl transferase is selected from Table 5d.

80. The recombinant microorganism of embodiment 78, wherein the $\leq C_{18}$ fatty acetate is selected from the group consisting of E5-10:Ac, Z7-12:Ac, Z8-12:Ac, Z9-12:Ac, E7Z9-12:Ac, Z9-14:Ac, Z9E12-14:Ac, Z11-14:Ac, E11-14:Ac, Z12-16:Ac, and Z11-16:Ac.

81. The recombinant microorganism of any one of embodiments 55-80, wherein the recombinant microorganism further comprises:

at least one endogenous or exogenous nucleic acid molecule encoding an enzyme selected from an alcohol oxidase, an alcohol dehydrogenase, and an aldehyde forming fatty acyl-CoA reductase capable of catalyzing the conversion of the mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol into a corresponding $\leq C_{18}$ fatty aldehyde; and

at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol into a corresponding $\leq C_{18}$ fatty acetate.

82. The recombinant microorganism of embodiment 81, wherein the mono- or poly-unsaturated $\leq C_{18}$ fatty aldehyde and $\leq C_{18}$ fatty acetate is selected from the group consisting of E5-10:Ac, Z7-12:Ac, Z8-12:Ac, Z9-12:Ac, E7Z9-12:Ac, Z9-14:Ac, Z9E12-14:Ac, E11-14:Ac, Z11-14:Ac, Z11-16:Ac, Z12-16:Ac, Z9-16:Ald, Z11-16:Ald, Z12-16:Ald, and Z13-18:Ald.

83. The recombinant microorganism of any one of embodiments 55-82, wherein the recombinant microorganism is a yeast selected from the group consisting of *Yarrowia lipolytica*, *Saccharomyces cerevisiae*, *Candida albicans*, *Candida tropicalis* and *Candida viswanatkii*.

84. A method of producing a mono- or poly-unsaturated $\leq C_{24}$ fatty alcohol from an endogenous or exogenous source of saturated C₂₂-C₂₄ fatty acid, comprising; cultivating the recombinant microorganism of any one of embodiment 55-83 in a culture medium containing

a feedstock that provides a carbon source adequate for the production of the mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol.

85. The method of embodiment 84, wherein the mono- or poly-unsaturated $\leq C_{18}$ fatty-alcohol is selected from the group consisting of E5-10:OH, Z8-12:OH, Z9-12:OH, Z11-14:OH, Z1M6:OH, E11-14:OH, E8E10-12:OH, E7Z9-12:QH, Z11Z13-16GH, Z9-14:OH, Z9-16:OH, and Z13-18:OH.

86. The method of any one of embodiments 84-85, further comprising a step of recovering the mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol.

87. The method of embodiment 86, wherein said recovery step comprises distillation.

88. The method of embodiment 86, wherein said recovery step comprises membrane-based separation.

89. A method of engineering a microorganism that is capable of producing a mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol from an endogenous or exogenous source of saturated C_6 - C_{24} fatty acid, wherein the method comprises introducing into a microorganism the following:

(a) at least one exogenous nucleic acid molecule encoding a fatty acyl desaturase that catalyzes the conversion of a saturated C_6 - C_{24} fatty acyl-CoA to a corresponding mono- or poly-unsaturated **C6-C24** fatty acyl-CoA:

(b) at least one exogenous nucleic acid molecule encoding an acyl-CoA oxidase that catalyzes the conversion of the mono- or poly-unsaturated C_6 - C_{24} fatty acyl-CoA from (a) into a mono- or poly-unsaturated $\leq C_{18}$ fatty acyl-CoA after one or more successive cycle of acyl-CoA oxidase activity, with a given cycle producing a mono- or poly-unsaturated C_4 - C_{22}

fatty acyl-CoA intermediate with a two carbon truncation relative to a starting mono- or poly-unsaturated C_6-C_{24} fatty acyl-CoA substrate in that cycle: and

(c) at least one exogenous nucleic acid molecule encoding a fatty alcohol forming fatty acyl reductase that catalyzes the conversion of the mono- or poly-unsaturated $\leq C_{18}$ fatty acyl-CoA from (b) into the corresponding mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol.

90. The method of embodiment 89, wherein the microorganism is MATA ura3-302::SUC2 $\Delta pox1$ $\Delta pox2$ $\Delta pox3$ $\Delta pox4$ $\Delta pox5$ $\Delta pox6$ Afadh $\Delta adh1$ Aadh2 Aadh3 Aadh4 $\Delta adh5$ Aadli6 $\Delta adh7$ Afaol ::URA3.

91. The method of any one of embodiments 89-90, wherein the method further comprises introducing into the microorganism at least one endogenous or exogenous nucleic acid molecule encoding an acyltransferase that preferably stores $\leq C_{18}$ fatty acyl-CoA.

92. The method of any one of embodiments 89-91, wherein the method further comprises introducing into the microorganism at least one endogenous or exogenous nucleic acid molecule encoding an acyltransferase that preferably stores $\leq C_{18}$ fatty acyl-CoA, and wherein the acyltransferase is selected from the group consisting of glycerol-3-phosphate acyl transferase (GPAT), lysophosphatidic acid acyltransferase (LPAAT), glycerolphospholipid acyltransferase (GPLAT) and diacylglycerol acyltransferases (DGAT).

93. The method of any one of embodiments 89-92, wherein the method further comprises introducing into the microorganism at least one endogenous or exogenous nucleic acid molecule encoding an acyltransferase that preferably stores $\leq C_{18}$ fatty acyl-CoA, and wherein the acyltransferase is selected from Table 5b.

94. The method of any one of embodiments 89-93, wherein the method further comprises introducing into the microorganism at least one endogenous or exogenous nucleic acid

molecule encoding an acviglycerol lipase that preferably hydrolyzes ester bonds of >C16, of >C14, of >C12 or of >C10 acviglycerol substrates.

95. The method of any one of embodiments 89-94, wherein the method further comprises introducing into the microorganism at least one endogenous or exogenous nucleic acid molecule encoding an acviglycerol lipase that preferably hydrolyzes ester bonds of >C16, of >C14, of >C12 or of >C10 acviglycerol substrates, and wherein the acviglycerol lipase is selected from Table 5c.

96. The method of any one of embodiments 89-95, wherein the method further comprises introducing into the microorganism one or more modifications comprising a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous enzyme that catalyzes a reaction in a pathway that competes with the biosynthesis pathway for the production of a mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol.

97. The method of any one of embodiments 89-96, wherein the method further comprises introducing into the microorganism one or more modifications comprising a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous enzyme selected from:

- (i) one or more acyl-CoA oxidase;
- (ii) one or more acyltransferase;
- (iii) one or more acviglycerol lipase and/or sterol ester esterase;
- (iv) one or more (fatty) alcohol dehydrogenase;
- (v) one or more (fatty) alcohol oxidase; and
- (vi) one or more cytochrome P450 monooxygenase.

98. The method of any one of embodiments 89-97, wherein the method further comprises introducing into the microorganism one or more modifications comprising a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous acyl-CoA oxidase enzyme selected from the group consisting of *Y. lipolytica* POX1(YALI0E32835g), *Y. lipolytica* POX2(YALI0F10857g), *Y. lipolytica* POX3(YALI0D24750g), *Y. lipolytica* POX4(YALI0E27654g), *Y. lipolytica* POX5(YAL10C23859g), *Y. lipolytica* POX6(YALI0E06567g); *S. cerevisiae* POX1(YGL205W); *Candida* POX2 (Ca0 19.1655, Ca01 9.9224, CTRG_02374, M18259), *Candida* POX4 (Ca019.1652, Ca0 19.9221, CTRG_02377, M12160), and *Candida* POX5 (Ca019.5723, Ca019.13146, CTRG_02721, M12161).

99. The method of any one of embodiments 89-98, wherein the method further comprises introducing into the microorganism one or more modifications comprising a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous acyltransferase enzyme selected from the group consisting of *Y. lipolytica* YALI0C00209g, *Y. lipolytica* YALI0E18964g, *Y. lipolytica* YALI0F195 14g, *Y. lipolytica* YALIOC14014g, *Y. lipolytica* YAL10E16797g, *Y. lipolytica* YAL10E32769g, and *Y. lipolytica* YAL10D07986g, *S. cerevisiae* YBLO1lw, *S. cerevisiae* YDL052c, *S. cerevisiae* YOR175C, *S. cerevisiae* YPR139C, *S. cerevisiae* YNR008w, and *S. cerevisiae* YOR245c, and *Candida* T503_02577, *Candida* CTRG_02630, *Candida* Ca019.250, *Candida* Ca019.7881, *Candida* CTRG_02437, *Candida* Ca019.1881, *Candida* Ca019.9437, *Candida* CTRG_01687, *Candida* Ca019.1043, *Candida* Ca0 19.8645, *Candida* CTRG_04750, *Candida* Ca019. 13439, *Candida* CTRG_04390, *Candida* Ca019.6941, *Candida* Ca019.14203, and *Candida* CTRG_06209.

100. The method of any one of embodiments 89-99, wherein the method further comprises introducing into the microorganism one or more modifications comprising a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous acylglycerol lipase and/or sterol ester esterase enzyme selected from the group consisting of *Y. lipolytica* YALI0E32035g, *Y. lipolytica* YALI0D17534g, *Y. lipolytica* YALIOFIOOIOg, *Y. lipolytica* YALIOC14520g, and *Y. lipolytica* YALI0E00528g, *S. cerevisiae* YKL140w, *S. cerevisiae* YMR313C, *S. cerevisiae* YKR089c, *S. cerevisiae* YOROSlc, *S. cerevisiae* YKL094W, *S.*

cerevisiae YLL012W, and *S. cerevisiae* YLR020C, and *Candida* CaO19.2050, *Candida* Ca019.9598, *Candida* CTRG_01138, *Candida* W5QJJ3398, *Candida* CTRG_00057, *Candida* CaO19.5426, *Candida* CaO19.12881, *Candida* CTRG_06185, *Candida* CaO19.4864, *Candida* Ca019.12328, *Candida* CTRG_03360, *Candida* CaO19.6501, *Candida* Ca019.13854, *Candida* CTRG_05049, *Candida* CaO19.1887, *Candida* CaO19.9443, *Candida* CTRG_01683, and *Candida* CTRG_04630.

101. The method of any one of embodiments 89-100, wherein the method further comprises one or more modifications comprising a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous cytochrome P450 monooxygenases selected from the group consisting of *Y. lipolytica* YALI0E25982g (ALK1), *Y. lipolytica* YALI0F01320g (ALK2), *Y. lipolytica* YALI0E23474g (ALK3), *Y. lipolytica* YALI0B13816g (ALK4), *Y. lipolytica* YALI0B13838g (ALK5), *Y. lipolytica* YALI0B01848g (ALK6), *Y. lipolytica* YALI0A15488g (ALK7), *Y. lipolytica* YAU0C12122g (ALK8), *Y. lipolytica* YALI0B06248g (ALK9), *Y. lipolytica* YALI0B20702g (ALK10), *Y. lipolytica* YALI0C10054g (ALK11) and *Y. lipolytica* YALI0A20130g (ALK12).

102. The method of any one of embodiments 89-101, wherein the fatty acyl desaturase is selected from an *Argyrotaenia velutinana*, *Spodoptera litura*, *Sesamia inferens*, *Manduca sexta*, *Ostrinia nubilalis*, *Helicoverpa zea*, *Chorisioneiira rosaceana*, *Drosophila melanogaster*, *Spodoptera littoralis*, *Lampronia capitella*, *Amyeloides transitella*, *Trichoplusia ni*, *Agrotis segetum*, *Ostrinia firnicalis*, and *Thalassiosira pseudonana* derived fatty acyl desaturase.

103. The method of any one of embodiments 89-102, wherein the fatty acyl desaturase has at least 95% sequence identity to a fatty acyl desaturase selected from the group consisting of: SEQ ID NOs: 39, 49-54, 58-63, and GenBank Accession nos. AF416738, AGH12217.1, A1121943.1, CAJ43430.2, AF441221, AAF81787.1, AF545481, AJ271414, AY362879, ABX71630.1, NP001299594.1, Q9N9Z8, ABX71630.1 and AIM40221.1.

104. The method of any one of embodiments 89-103, wherein the acyl-CoA oxidase is selected from Table 5a.

105. The method of any one of embodiments 89-104, wherein the fatty alcohol forming fatty acyl reductase is selected from an *Agrotis segetum*, *Spodopiera exigua*, *Spodoptera littoralis*, *Euglena gracilis*, *Yponomeuta evonymellus* and *Helicoverpa armigera* derived fatty alcohol forming fatty acyl reductase.

106. The method of any one of embodiments 89-105, wherein the fatty alcohol forming fatty acyl reductase has at least 90% sequence identity to a fatty alcohol forming fatty acyl reductase selected from the group consisting of: SEQ ID NOs: 1-3, 32, 41-48, 55-57, 73, 75, 77 and 82.

107. The method of any one of embodiments 89-106, wherein the fatty acyl desaturase catalyzes the conversion of a fatty acyl-CoA into a mono- or poly-unsaturated intermediate selected from E5-10:Acyl-CoA, E7-12:Acyl-CoA, E9-14:Acyl-CoA, E11-16:Acyl-CoA, E13-18:Acyl-CoA, Z7-12:Acyl-CoA, Z9-14:Acyl-CoA, Z11-16:Acyl-CoA, Z13-18:Acyl-CoA, Z8-12:Acyl-CoA, Z10-14:Acyl-CoA, Z12-16:Acyl-CoA, Z14-18:Acyl-CoA, Z7-10:Acyl-CoA, Z9-12:Acyl-CoA, Z11-14:Acyl-CoA, Z13-16:Acyl-CoA, Z15-18:Acyl-CoA, E7-10:Acyl-CoA, E9-12:Acyl-CoA, E11-14:Acyl-CoA, E13-16:Acyl-CoA, E15-18:Acyl-CoA, E5Z7-12:Acyl-CoA, E7Z9-12:Acyl-CoA, E9Z11-14:Acyl-CoA, E11Z13-16:Acyl-CoA, E13Z15-18:Acyl-CoA, E6E8-10:Acyl-CoA, E8E10-12:Acyl-CoA, E10E12-14:Acyl-CoA, E12E14-16:Acyl-CoA, Z5E8-10:Acyl-CoA, Z7E10-12:Acyl-CoA, Z9E12-14:Acyl-CoA, Z11E14-16:Acyl-CoA, Z13E16-18:Acyl-CoA, Z3-10:Acyl-CoA, Z5-12:Acyl-CoA, Z7-14:Acyl-CoA, Z9-16:Acyl-CoA, Z11-18:Acyl-CoA, Z3Z5-10:Acyl-CoA, Z5Z7-12:Acyl-CoA, Z7Z9-14:Acyl-CoA, Z9Z11-16:Acyl-CoA, Z11Z13-16:Acyl-CoA, and Z13Z15-18:Acyl-CoA.

108. The method of any one of embodiments 89-107, wherein the mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol is selected from the group consisting of E5-10:OH, Z8-

12:OH, Z9-12:OH, Z11-14:OH, Z11-16:OH, E11-14:OH, E8E10-12:OH, E7Z9-12:OH, Z11Z13-16:OH, Z15-14:OH, Z9-16:OH, and Z13-18:OH.

109. The method of any one of embodiments 89-108, wherein the method further comprises introducing into the microorganism at least one endogenous or exogenous nucleic acid molecule encoding an aldehyde forming fatty acyl-CoA reductase capable of catalyzing the conversion of the mono- or poly-unsaturated \leq Cis fatty alcohol into a corresponding \leq Cis fatty aldehyde.

110. The method of embodiment 109, wherein the aldehyde forming fatty acyl-CoA reductase is selected from the group consisting of *Acinetobacter calcoaceticus* A0A1C4HN78, *A. calcoaceticus* N9DA85, *A. calcoaceticus* R8XW24, *A. calcoaceticus* A0A1A0GGM5, *A. calcoaceticus* A0A117N158, and *Nostoc punctiforme* YPjOO1865324.

111. The method of any one of embodiments 89-110, wherein the method further comprises introducing into the microorganism at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase or an alcohol dehydrogenase capable of catalyzing the conversion of the mono- or poly-unsaturated \leq Cis fatty alcohol into a corresponding \leq Cis fatty aldehyde.

112. The method of any one of embodiments 109-111, wherein the \leq Cis fatty aldehyde is selected from the group consisting of Z9-16:Ald, Z11-16:Ald, Z11Z13-16:Ald, and Z13-18:Ald.

113. The method of any one of embodiments 89-112, wherein method further comprises introducing into the microorganism at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated \leq Cis fatty alcohol into a corresponding \leq Cis fatty acetate.

114. The method of embodiment 113, wherein the acetyl transferase is selected from Table 5d.

115. The method of any one of embodiment 113-114, wherein the \leq C₁₈ fatty acetate is selected from the group consisting of E5-10:Ac, Z7-12:Ac, Z8-12:Ac, Z9-12:Ac, E7Z9-12:Ac, Z9-14:Ac, Z9E12-14:Ac, E11-14:Ac, Z9-16:Ac, Z11-14:Ac and Z11-16:Ac.

116. The method of any one of embodiments 89-115, wherein the method further comprises introducing into the microorganism:

at least one endogenous or exogenous nucleic acid molecule encoding an enzyme selected from an alcohol oxidase, an alcohol dehydrogenase, and an aldehyde forming fatty acyl-CoA reductase capable of catalyzing the conversion of the mono- or poly-unsaturated \leq C₁₈ fatty-alcohol into a corresponding \leq C₁₈ fatty aldehyde; and

at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated \leq C₁₈ fatty alcohol into a corresponding \leq C₁₈ fatty acetate.

117. The method of embodiment 116, wherein the mono- or poly-unsaturated \leq C₁₈ fatty aldehyde and \leq C₁₈ fatty acetate is selected from the group consisting of E5-10:Ac, Z7-12:Ac, Z8-12:Ac, Z9-12:Ac, E7Z9-12:Ac, Z9-14:Ac, Z9E12-14:Ac, Z11-14:Ac, E11-14:Ac, Z11-16:Ac, Z9-16:Ald, Z9-16:Ac, Z11-16:Ald, Z11Z13-16:Ald, and Z13-18:Ald.

118. A method of producing a mono- or poly-unsaturated \leq C₁₈ fatty aldehyde from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid, comprising: cultivating the recombinant microorganism of any one of embodiments 74-76 in a culture medium containing a feedstock that provides a carbon source adequate for the production of the mono- or poly-unsaturated \leq C₁₈ fatty aldehyde.

119. The method of embodiment 118, wherein the \leq Cis fatty aldehyde is selected from the group consisting of Z9-16:Ald, Z11-16:Ald, Z11Z13-16:Ald, and Z13-18:Ald.

120. The method of any one of embodiments 118-119, further comprising a step of recovering the mono- or poly-unsaturated \leq Cis fatty aldehyde.

121. The method of embodiment 120, wherein said recovery step comprises distillation.

122. The method of embodiment 120, wherein said recovery step comprises membrane-based separation.

123. A method of producing a mono- or poly-unsaturated \leq Cis fatty acetate from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid, comprising; cultivating the recombinant microorganism of any one of embodiments 78-80 in a culture medium containing a feedstock that provides a carbon source adequate for the production of the mono- or poly-unsaturated \leq Cis fatty acetate.

124. The method of embodiment 123, wherein the mono- or poly-unsaturated \leq Cis fatty-acetate is selected from the group consisting of E5-10:Ac, Z7-12:Ac, Z8-12:Ac, Z9-12:Ac, E7Z9-12:Ac, Z9-14:Ac, Z9E12-14:Ac, / i1-14:Ac, E11-14:Ac, Z9-16:Ac, and Z11-16:Ac.

125. The method of any one of embodiments 123-124, further comprising a step of recovering the mono- or poly-unsaturated \leq Cis fatty acetate.

126. The method of embodiment 125, wherein said recovery step comprises distillation.

127. The method of embodiment 125, wherein said recover,' step comprises membrane-based separation.

128. The method of any one of embodiments 89-115, wherein the recombinant microorganism is a yeast selected from the group consisting of *Yarrowia lipolytica*, *Saccharomyces cerevisiae*, *Candida albicans*, *Candida viswanatkii* and *Candida iropicalis*.

129. The method of any one of embodiments 89-115, wherein the mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol is converted into a corresponding $\leq C_{18}$ fatty aldehyde using chemical methods.

130. The method of embodiment 129, wherein the chemical methods are selected from TEMPO-bleach, TEMPO-copper-air, TEMPO-PhI(OAc)₂, Swern oxidation and noble metal-air.

131. The method of any one of embodiments 89-115, wherein the mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol is converted into a corresponding $\leq C_{18}$ fatty acetate using chemical methods.

132. The method of embodiment 131, wherein the chemical methods utilize a chemical agent selected from the group consisting of acetyl chloride, acetic anhydride, butyryl chloride, butyric anhydride, propanoyl chloride and propionic anhydride in the presence of 4-*N,N*-dimethylaminopyridine (DMAP) or sodium acetate to esterify the mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol to the corresponding $\leq C_{18}$ fatty acetate.

CLAIMS:

1. A recombinant *Yarrowia lipoytica* microorganism capable of producing a mono- or poly-unsaturated C₆-C₂₄ fatty alcohol from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid, wherein the recombinant *Yarrowia lipoytica* microorganism comprises:

(a) at least one nucleic acid molecule encoding a fatty acyl desaturase having at least 95% sequence identity to a fatty acyl desaturase selected from the group consisting of SEQ ID NOs: 39, 54, 60, 62, 78, 79, 80, 95, 97, 99, 101, 103, and 105 that catalyzes the conversion of a saturated C₆-C₂₄ fatty acyl-CoA to a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA; and

(b) at least one nucleic acid molecule encoding a fatty alcohol forming fatty acyl reductase having at least 95% sequence identity to a fatty alcohol forming fatty acyl reductase selected from the group consisting of SEQ ID NOs: 41-48, 57, 73, 75 and 77 that catalyzes the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA from (a) into the corresponding mono- or poly-unsaturated C₆-C₂₄ fatty alcohol.

2. The recombinant *Yarrowia lipoytica* microorganism of claim 1, wherein the recombinant *Yarrowia lipoytica* microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous enzymes that catalyzes a reaction in a pathway that competes with the biosynthesis pathway for the production of a mono- or poly-unsaturated C₆-C₂₄ fatty alcohol.

3. The recombinant *Yarrowia lipoytica* microorganism of claim 1, wherein the recombinant *Yarrowia lipoytica* microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous enzyme selected from the following:

(i) one or more acyl-CoA oxidase selected from the group consisting of YALI0E32835g (POX1), YALI0F10857g (POX2), YALI0D24750g (POX3), YALI0E27654g (POX4), YALI0C23859g (POX5), YALI0E06567g (POX6);

(ii) one or more (fatty) alcohol dehydrogenase selected from the group consisting of YALI0F09603g (FADH), YALI0D25630g (ADH1), YALI0E17787g (ADH2), YALI0A16379g (ADH3), YALI0E15818g (ADH4), YALI0D02167g (ADH5), YALI0A15147g (ADH6), YALI0E07766g (ADH7);

(iii) a (fatty) alcohol oxidase YALI0B14014g (FAOI);

(iv) one or more cytochrome P450 enzyme selected from the group consisting of YALI0E25982g (ALK1), YALI0F01320g (ALK2), YALI0E23474g (ALK3), YALI0B13816g (ALK4), YALI0B13838g (ALK5), YALI0B01848g (ALK6), YALI0A15488g (ALK7), (YALI0C12122g (ALK8), YALI0B06248g (ALK9), YALI0B20702g (ALK10), YALI0C10054g (ALK11) and YALI0A20130g (ALK12); and

(v) one or more diacylglycerol acyltransferase selected from the group consisting of YALI0E32791g (DGA1) and YALI0D07986g (DGA2).

4. The recombinant *Yarrowia lipolytica* microorganism of claim 1, wherein the recombinant *Yarrowia lipolytica* microorganism comprises a deletion of one or more endogenous enzyme selected from the following:

(i) one or more acyl-CoA oxidase selected from the group consisting of YALI0E32835g (FOX1), YALI0F10857g (POX2), YALI0D24750g (POX3), YALI0E27654g (POX4), YALI0C23859g (POX5), YALI0E06567g (POX6);

(ii) one or more (fatty) alcohol dehydrogenase selected from the group consisting of YALI0F09603g (FADH), YALI0D25630g (ADH1), YALI0E17787g (ADH2), YALI0A16379g (ADH3), YALI0E15818g (ADH4), YALI0D02167g (ADH5), YALI0A15147g (ADH6), YALI0E07766g (ADH7);

(iii) a (fatty) alcohol oxidase YALI0B14014g (FAOI);

(iv) one or more cytochrome P450 enzyme selected from the group consisting of YALI0E25982g (ALK1), YALI0F01320g (ALK2), YALI0E23474g (ALK3), YALI0B13816g (ALK4), YALI0B13838g (ALK5), YALI0B01848g (ALK6), YALI0A15488g (ALK7), (YALI0C12122g (ALK8), YALI0B06248g (ALK9), YALI0B20702g (ALK10), YALI0C10054g (ALK11) and YALI0A20130g (ALK12); and

(v) one or more diacylglycerol acyltransferase selected from the group consisting of YALI0E32791g (DGA1) and YALI0D07986g (DGA2).

5. The recombinant *Yarrowia lipolytica* microorganism of claim 1, wherein the fatty acyl desaturase catalyzes the conversion of a saturated fatty acyl-CoA into a mono- or poly-unsaturated intermediate selected from Z9-14:Acyl-CoA, Z11-14:Acyl-CoA, E11-14:Acyl-CoA, Z9-16:Acyl-CoA, and Z11-16:Acyl-CoA.

6. The recombinant *Yarrowia lipolytica* microorganism of claim 1, wherein the mono- or poly-unsaturated C6-C24 fatty alcohol is selected from the group consisting of Z9-14:OH, Z11-14:OH, E11-14:OH, Z9-16:OH, Z11-16:OH, Z11-Z13-16:OH, and Z13-18:OH.

7. The recombinant *Yarrowia lipolytica* microorganism of claim 1, wherein the recombinant *Yarrowia lipolytica* microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase or an alcohol dehydrogenase capable of catalyzing the conversion of the mono- or poly-unsaturated C6-C24 fatty alcohol into a corresponding C6-C24 fatty aldehyde.

8. The recombinant *Yarrowia lipolytica* microorganism of claim 7, wherein the alcohol dehydrogenase is selected from Table 3a.

9. The recombinant *Yarrowia lipolytica* microorganism of claim 7, wherein the C6-C24 fatty aldehyde is selected from the group consisting of Z9-14:Ald, Z11-14:Ald, E11-14:Ald, Z9-16:Ald, Z11-16:Ald, Z11-Z13-16:Ald and Z13-18:Ald.

10. The recombinant *Yarrowia lipolytica* microorganism of claim 1, wherein the recombinant *Yarrowia lipolytica* microorganism further comprises at least one endogenous or

exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol into a corresponding C₆-C₂₄ fatty acetate.

11. The recombinant *Yarrowia Upoiytica* microorganism of claim 10, wherein the acetyl transferase is selected from Table 5d.

12. The recombinant *Yarrowia Upoiytica* microorganism of claim 10, wherein the C₆-C₂₄ fatty acetate is selected from the group consisting of Z9-14:Ac, Z11-14:Ac, Ell-14:Ac, Z9-16:Ac, Z11-16:Ac, Z13-16:Ac, and Z13-18:Ac.

13. The recombinant *Yarrowia Upoiytica* microorganism of claim 1, wherein the recombinant *Yarrowia Upoiytica* microorganism further comprises:

at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase or an alcohol dehydrogenase capable of catalyzing the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol into a corresponding C₆-C₂₄ fatty aldehyde; and

at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol into a corresponding C₆-C₂₄ fatty acetate.

14. The recombinant *Yarrowia Upoiytica* microorganism of claim 13, wherein the mono- or poly-unsaturated C₆-C₂₄ fatty aldehyde and C₆-C₂₄ fatty acetate is selected from the group consisting of Z9-14:Ac, Z11-14:Ac, Ell-14:Ac, Z9-16:Ac, Z11-16:Ac, Z13-16:Ac, Z13-18:Ac, Z9-14:Ald, Z11-14:Ald, Ell-14:Ald, Z9-16:Ald, Z11-16:Ald, Z13-16:Ald and Z13-18:Ald.

15. The recombinant *Yarrowia Upoiytica* microorganism of claim 1, wherein the fatty acyl desaturase does not comprise a fatty acyl desaturase comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 64, 65, 66 and 67.

16. The recombinant *Yarrowia lipolytica* microorganism of claim 1, wherein the fatty acyl desaturase does not comprise a fatty acyl desaturase selected from an *Amyelois trcmsitella*, *Spodoptera littoralis*, *Agrotis segetum*, or *Trichoplusia ni* derived desaturase.

17. A method of producing a mono- or poly-unsaturated C6-C24 fatty alcohol from an endogenous or exogenous source of saturated C6-C24 fatty acid, comprising: cultivating the recombinant *Yarrowia lipolytica* microorganism of claim 1 in a culture medium containing a feedstock that provides a carbon source adequate for the production of the mono- or poly-unsaturated C6-C24 fatty alcohol.

18. The method of claim 17, wherein the mono- or poly-unsaturated C6-C24 fatty alcohol is selected from the group consisting of Z9-14:OH, Z11-14:OH, E11-14:OH, Z9-16:OH, Z11-16:OH, Z11-13-16:OH, and Z13-18:OH.

19. The method of claim 17, wherein the recombinant *Yarrowia lipolytica* microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous enzyme selected from the following;

(i) one or more acyl-CoA oxidase selected from the group consisting of YALI0E32835g (POX1), YALI0F10857g (POX2), YALI0D24750g (POX3), YALI0E27654g (POX4), YALI0C23859g (POX5), YALI0E06567g (POX6);

(ii) one or more (fatty) alcohol dehydrogenase selected from the group consisting of YALI0F09603g (FADH), YALI0D25630g (ADH1), YALI0E17787g (ADH2), YALI0A16379g (ADH3), YALI0E15818g (ADH4), YALI0D02167g (ADH5), YALI0A15147g (ADH6), YALI0E07766g (ADH7);

(iii) a (fatty) alcohol oxidase YALI0B14014g (FAO1);

(iv) one or more cytochrome P450 enzyme selected from the group consisting of YALI0E25982g (ALK1), YALI0F01320g (ALK2), YALI0E23474g (ALK3),

YALI0B13816g (ALK4), YALI0B13838g (ALK5), YALT0B01848g (ALK6), YALi0A15488g (ALK7), (YALI0C12122g (ALK8), YALiOB06248g (ALK9), YALI0B20702g (ALK10), YAU0C10054g (ALK11) and YALi0A20130g (Alk12); and

(v) one or more diacylglycerol acyltransferase selected from the group consisting of YALI0E32791g (DGA1) and YAL10D07986g (DGA2).

20. **The** method of claim 17, further comprising a step of recovering the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol.

21. The method of claim 20, wherein said recover}' step comprises distillation.

22. The method of claim 20, wherein said recover}' step comprises membrane -based separation.

23. A method of producing a mono- or poly-unsaturated C₆-C₂₄ fatty aldehyde from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid, comprising: cultivating the recombinant *Yarrowia lipolytica* microorganism of claim 7 in a culture medium containing a feedstock that provides a carbon source adequate for the production of the mono- or poly-unsaturated C₆-C₂₄ **fatty** aldehyde.

24. **The** method of claim 23, wherein **the** C₆-C₂₄ fatty aldehyde is selected from the group consisting of Z9-14:Ald, Z11-14:Ald, E1M4:Ald, Z9-16:Ald, Z11-16:AlL, Z11Z13-16:Ald and Z13-18:Ald.

25. **The** method of claim 23, further comprising a step **of** recovering the mono- or poly-unsaturated C₆-C₂₄ fatty aldehyde.

26. The method of claim 25, wherein said recovery' step comprises distillation.
27. The method of claim 25, wherein said recovery step comprises membrane-based separation.
28. A method of producing a mono- or poly-unsaturated C₆-C₂₄ fatty acetate from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid, comprising: cultivating the recombinant *Yarrowia lipolytica* microorganism of claim 10 in a culture medium containing a feedstock that provides a carbon source adequate for the production of the mono- or poly-unsaturated C₆-C₂₄ fatty acetate.
29. The method of claim 28, wherein the C₆-C₂₄ fatty acetate is selected from the group consisting of Z9-14:Ac, Z11-14:Ac, E11-14:Ac, Z9-16:Ac, Z11-16:Ac, Z11Z13-16:Ac, and Z13-18:Ac.
30. The method of claim 28, further comprising a step of recovering the mono- or poly-unsaturated C₆-C₂₄ fatty acetate.
31. The method of claim 28, wherein said recovery step comprises distillation.
32. The method of claim 28, wherein said recovery step comprises membrane -based separation.
33. A method of producing a mono- or poly-unsaturated C₆-C₂₄ fatty aldehyde and C₆-C₂₄ fatty acetate from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid, comprising: cultivating the recombinant *Yarrowia lipolytica* microorganism of claim 13 in a

culture medium containing a feedstock that provides a carbon source adequate for the production of the mono- or poly-unsaturated C_6-C_{24} fatty aldehyde and C_6-C_{24} fatty acetate.

34. The method of claim 33, wherein the mono- or poly-unsaturated C_6-C_{24} fatty aldehyde and C_6-C_{24} fatty acetate is selected from the group consisting of **Z9-14:Ac**, **Z11-14:Ac**, **Ell-14:Ac**, **Z9-16:Ac**, **Z11-16:Ac**, / 11Z13-16:Ac, **Z13-18:Ac**, **Z9-14:Ald**, **Z11-14:Ald**, **Ell-14:Ald**, /9-16:Ald, **Z11-16:Ald**, **Z11Z13-16:Ald** and **Z13-18:Ald**.

35. A method of engineering a *Yarrowia lipolytica* microorganism that is capable of producing a mono- or poly-unsaturated C_6-C_{24} **fatty** alcohol from an endogenous or exogenous source of saturated C_6-C_{24} fatty acid, wherein the method comprises introducing into a *Yarrowia lipolytica* microorganism the following:

(a) at least one nucleic acid molecule encoding a fatty **acyl** desaturase having at least 95% sequence identity to a fatty acyl desaturase selected from the group consisting of SEQ ID NOs: 39, 54, 60, 62, 78, 79, 80, 95, 97, 99, 101, 103, and 105 that catalyzes the conversion of a saturated C_6-C_{24} fatty⁷ **acyl-CoA** to a corresponding mono- or poly-unsaturated C_6-C_{24} fatty **acyl-CoA**; and

(b) at least one nucleic acid molecule encoding a fatty alcohol **forming** fatty acyl reductase having at least 95% sequence identity to a fatty alcohol **forming** fatty acyl reductase selected from the group consisting of SEQ ID NOs: 41-48, 57, 73, 75 and 77 that catalyzes the conversion of the mono- or poly-unsaturated C_6-C_{24} fatty **acyl-CoA** from (a) into the corresponding mono- or poly-unsaturated C_6-C_{24} fatty alcohol.

36. **The method of** claim 35, wherein **the** method further comprises introducing into **the** *Yarrowia lipolytica* microorganism one or more modifications comprising a deletion, disnption, mutation, and/or reduction in the activity of one or more endogenous enzymes that catalyzes a reaction in a patiiway that competes with the biosynthesis pathway **for the** production of a mono- or poly-unsaturated C_6-C_{24} **fatty** alcohol.

37. The method of claim 35, wherein the *Yarrowia lipolytica* microorganism is MATA ura3-302::SUC2 $\Delta pox1 \Delta pox2 \Delta pox3 \Delta pox4 \Delta pox5 \Delta pox6$ Afadh $\Delta adh1$ Aadh2 Aadh3 Aadh4 Aadh5 Aadh6 Aadh7 *Mao1*::URA3.

38. The method of claim 35, wherein the method further comprises introducing into the *Yarrowia lipolytica* microorganism one or more modifications comprising a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous enzyme selected from the following:

- (i) one or more acyl-CoA oxidase selected from the group consisting of YALI0E32835g (POX1), YALI0F10857g (POX2), YALI0D24750g (POX3), YALI0E27654g (POX4), YALI0C23859g (POX5), YALI0E06567g (POX6);
- (ii) one or more (fatty) alcohol dehydrogenase selected from the group consisting of YALI0F09603g (FADH), YALI0D25630g (ADH1), YALI0E17787g (ADH2), YALI0A16379g (ADH3), YALI0E15818g (ADH4), YALI0D02167g (ADH5), YALI0A15147g (ADH6), YALI0E07766g (ADH7);
- (iii) a (fatty) alcohol oxidase YALI0B14014g (FAOI);
- (iv) one or more cytochrome P450 enzyme selected from the group consisting of YALI0E25982g (ALK1), YALI0F01320g (ALK2), YALI0E23474g (ALK3), YALI0B13816g (ALK4), YALI0B13838g (ALK5), YALI0B01848g (ALK6), YALI0A15488g (ALK7), (YALI0C12122g (ALK8), YALI0B06248g (ALK9), YALI0B20702g (ALK10), YALI0C10054g (ALK11) and YALI0A20130g (ALK12); and
- (v) one or more diacylglycerol acyltransferase selected from the group consisting of YALI0E32791g (DGA1) and YALI0D07986g (DGA2).

39. The method of claim 35, wherein the fatty acyl desaturase catalyzes the conversion of a fatty acyl-CoA into a mono- or poly-unsaturated intermediate selected from Z9-14:Acyl-CoA, Z11-14:Acyl-CoA, E11-14:Acyl-CoA, Z9-16:Acyl-CoA, and Z11-16:Acyl-CoA.

40. The method of claim 35, wherein the mono- or poly-unsaturated C_6-C_{24} fatty alcohol is selected from the group consisting of Z9-14:GH, Z11-14:OH, E11-14:OH, Z9-16:OH, Z11-16:OH, Z11Z13-16:OH, and Z13-18:OH.

41. The method of claim 35, wherein the method further comprises introducing into or expressing in the recombinant *Yarrowia lipolytica* microorganism at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase or an alcohol dehydrogenase capable of catalyzing the conversion of the mono- or poly-unsaturated C_6-C_{24} fatty alcohol into a corresponding C_6-C_{24} fatty aldehyde.

42. The method of claim 41, wherein the alcohol dehydrogenase is selected from Table 3a.

43. The method of claim 41, wherein the C_6-C_{24} fatty aldehyde is selected from the group consisting of Z9-14:Ald, Z11-14:Ald, E11-14:Ald, Z9-16:Ald, Z11-16:Ald, Z11Z13-16:Ald and Z13-18:Ald.

44. The method of claim 35, wherein the method further comprises introducing into or expressing in the recombinant *Yarrowia lipolytica* microorganism at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated C_6-C_{24} fatty alcohol into a corresponding C_6-C_{24} fatty acetate.

45. The method of claim 44, wherein the acetyl transferase is selected from Table 5d.

46. The method of claim 44, wherein the C_6-C_{24} fatty acetate is selected from the group consisting of Z9-14:Ac, Z11-14:Ac, E11-14:Ac, Z9-16:Ac, Z11-16:Ac, Z11Z13-16:Ac, and Z13-18:Ac.

47. The method of claim 35, wherein the method further comprises introducing into or expressing in the recombinant *Yarrowia lipolytica* microorganism:

at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase or an alcohol dehydrogenase capable of catalyzing the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol into a corresponding C₆-C₂₄ fatty aldehyde; and

at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol into a corresponding C₆-C₂₄ fatty acetate.

48. The method of claim 47, wherein the mono- or poly-unsaturated C₆-C₂₄ fatty aldehyde and C₆-C₂₄ fatty acetate is selected from the group consisting of Z9-14:Ac, Z11-14:Ac, E11-14:Ac, Z12-16:Ac, / 11-16:Ac, Z11/13-16:Ac, Z13-18:Ac, Z9-14:Ald, / 11-14:Ald, E11-14:Ald, Z9-16:Ald, Z11-16:Ald, Z11/Z13-16:Ald and Z13-18:Ald.

49. The method of claim 35, wherein the fatty acyl desaturase does not comprise a fatty acyl desaturase comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 64, 65, 66 and 67.

50. The method of claim 35, wherein the fatty acyl desaturase does not comprise a fatty acyl desaturase selected from an *Amyelois transitella*, *Spodoptera lateralis*, *Agrotis segetium*, or *Trichoplusia ni* derived desaturase.

51. The method of claim 17, wherein the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol is converted into a corresponding C₆-C₂₄ fatty aldehyde using chemical methods.

52. The method of claim 17, comprising the step of recovering the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol.

53. The method of claim 17, wherein the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol is converted into a corresponding C₆-C₂₄ fatty acetate using chemical methods.

54. The method of claim 53, wherein the chemical methods utilize a chemical agent selected from the group consisting of acetyl chloride, acetic anhydride, butyryl chloride, butyric anhydride, propanoyl chloride and propionic anhydride in the presence of 4-*N,N*-dimethylaminopyridine (DMAP) or sodium acetate to esterify the mono- or poly-unsaturated C₆-C₂₄ fatty alcohol to the corresponding C₆-C₂₄ fatty acetate.

55. A recombinant microorganism capable of producing a mono- or poly-unsaturated \leq C₁₈ fatty alcohol from an endogenous or exogenous source of saturated C₆-C₂₄ fatty acid, wherein the recombinant microorganism comprises:

(a) at least one exogenous nucleic acid molecule encoding a fatty acyl desaturase that catalyzes the conversion of a saturated C₆-C₂₄ fatty acyl-CoA to a corresponding mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA;

(b) at least one exogenous nucleic acid molecule encoding an acyl-CoA oxidase that catalyzes the conversion of the mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA from (a) into a mono- or poly-unsaturated \leq C₁₆ fatty acyl-CoA after one or more successive cycle of acyl-CoA oxidase activity, with a given cycle producing a mono- or poly-unsaturated C₄-C₂₂ fatty acyl-CoA intermediate with a two carbon truncation relative to a starting mono- or poly-unsaturated C₆-C₂₄ fatty acyl-CoA substrate in that cycle; and

(c) at least one exogenous nucleic acid molecule encoding a fatty alcohol forming fatty acyl reductase that catalyzes the conversion of the mono- or poly-unsaturated \leq C₁₆ fatty acyl-CoA from (b) into the corresponding mono- or poly-unsaturated \leq C₁₈ fatty alcohol.

56. The recombinant microorganism of claim 55, wherein the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an acyltransferase that preferably stores \leq C₁₆ fatty acyl-CoA.

57. The recombinant microorganism of claim 55, wherein the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an acyltransferase that preferably stores $\leq C_{18}$ fatty acyl-CoA, and wherein the acyltransferase is selected from the group consisting of glycerol-3-phosphate acyl transferase (GPAT), lysophosphatidic acid acyltransferase (LPAAT), glycerolphospholipid acyltransferase (GPLAT) and diacylglycerol acyltransferases (DGAT).

58. The recombinant microorganism of claim 55, wherein the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an acyltransferase that preferably stores $\leq C_{18}$ fatty acyl-CoA, and wherein the acyltransferase is selected from Table 5b.

59. The recombinant microorganism of claim 55, wherein the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an acylglycerol lipase that preferably hydrolyzes ester bonds of $>C_{16}$, of $>C_{14}$, of $>C_{12}$ or of $>C_{10}$ acylglycerol substrates.

60. The recombinant microorganism of claim 55, wherein the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an acylglycerol lipase that preferably hydrolyzes ester bonds of $>C_{16}$, of $>C_{14}$, of $>C_{12}$ or of $>C_{10}$ acylglycerol substrates, and wherein the acylglycerol lipase is selected from Table 5c.

61. The recombinant microorganism of claim 55, wherein the recombinant microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous enzymes that catalyzes a reaction in a pathway that competes with the biosynthesis pathway for the production of a mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol.

62. The recombinant microorganism of claim 55, wherein the recombinant microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous enzyme selected from:

- (i) one or more acyl-CoA oxidase;
- (ii) one or more acyltransferase;
- (iii) one or more acylglycerol lipase and/or sterol ester esterase;
- (iv) one or more (fatty) alcohol dehydrogenase;
- (v) one or more (fatty) alcohol oxidase; and
- (vi) one or more cytochrome P450 monooxygenase.

63. The recombinant microorganism of claim 55, wherein the recombinant microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous acyl-CoA oxidase enzyme selected from the group consisting of *Y. lipolytica* POX1(YALI0E32835g), *Y. lipolytica* POX2(YALI0F10857g), *Y. lipolytica* POX3(YALI0D24750g), *Y. lipolytica* POX4(YALI0E27654g), *Y. lipolytica* POX5(YALI0C23859g), *Y. lipolytica* POX6(YALI0E06567g); *S. cerevisiae* POX1(YGL205W); *Candida* POX2 (Ca019.1655, Ca019.9224, CTRG_02374, M18259), *Candida* POX4 (Ca019.1652, Ca019.9221, CTRG_Q2377, M12160), and *Candida* POX5 (Ca019.5723, Ca019.13146, CTRG_02721, M12161).

64. The recombinant microorganism of claim 55, wherein the recombinant microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous acyltransferase enzyme selected from the group consisting of *Y. lipolytica* YALT0C00209g, *Y. lipolytica* YALI0E18964g, *Y. lipolytica* YALI0F19514g, *Y. lipolytica* YALI0C14014g, *Y. lipolytica* YALI0E16797g, *Y. lipolytica* YALI0E32769g, and *Y. lipolytica* YALI0D07986g, *S. cerevisiae* YBLO1w, *S. cerevisiae* YDL052c, *S. cerevisiae* YOR175C, *S. cerevisiae* YPR139C, *S. cerevisiae* YNR008w, and *S. cerevisiae* YOR245c,

and *Candida* I503_02577, *Candida* CTRG_02630, *Candida* CaO19.250, *Candida* Ca019.7881, *Candida* CTRG_02437, *Candida* Ca019.1881, *Candida* Ca019.9437, *Candida* CTRG_01687, *Candida* CaO19.1043, *Candida* Ca019.8645, *Candida* CTRG_04750, *Candida* Ca019.13439, *Candida* CTRG_04390, *Candida* CaO19.6941, *Candida* CaO19.14203, and *Candida* CTRG_06209.

65. The recombinant microorganism of claim 55, wherein the recombinant microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous acylglycerol lipase and/or sterol ester esterase enzyme selected from the group consisting of *Y. lipolytica* YAL10E32035g, *Y. lipolytica* YALI0D17534g, *Y. lipolytica* YALI0F10010g, *Y. lipolytica* YALI0C14520g, and *Y. lipolytica* YALI0E00528g, *S. cerevisiae* YKLMOw, *S. cerevisiae* YMR3I3c, *S. cerevisiae* YKR089c, *S. cerevisiae* YOROB1c, *S. cerevisiae* YKL094W, *S. cerevisiae* YLL012W, and *S. cerevisiae* YLR020C, and *Candida* CaO19.2050, *Candida* CaO19.9598, *Candida* CTRG_01138, *Candida* W5Q_03398, *Candida* CTRG_00057, *Candida* CaO19.5426, *Candida* Ca019.12881, *Candida* CTRG_06185, *Candida* CaO19.4864, *Candida* Ca019.12328, *Candida* CTRG_03360, *Candida* CaO19.6501, *Candida* Ca019.13854, *Candida* CTRG_05049, *Candida* Ca019.1887, *Candida* Ca019.9443, *Candida* CTRG_01683, and *Candida* CTRG_04630.

66. The method of claim 55, wherein the recombinant microorganism comprises a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous cytochrome P450 monooxygenases selected from the group consisting of *Y. lipolytica* YALI0E25982g (ALK1), *Y. lipolytica* YALI0F01320g (ALK2), *Y. lipolytica* YALI0E23474g (ALK3), *Y. lipolytica* YALI0B13816g (ALK4), *Y. lipolytica* YALI0B13838g (ALK5), *Y. lipolytica* YALT0B01848g (AEK6), *Y. lipolytica* YALI0A15488g (ALK7), *Y. lipolytica* YALI0C12122g (ALK8), *Y. lipolytica* YALI0B06248g (ALK9), *Y. lipolytica* YALI0B20702g (ALK10), *Y. lipolytica* YALI0C10054g (ALK11) and *Y. lipolytica* YALI0A20130g (ALK12).

67. The recombinant microorganism of claim 55, wherein the fatty acyl desaturase is selected from an *Argyrotaenia velutana*, *Spodoptera litura*, *Sesamia inferens*, *Manduca sexta*, *Ostrinia nubilalis*, *Helicoverpa zea*, *Choristoneura rosaceana*, *Drosophila melanogaster*, *Spodoptera littoralis*, *Lampronia capitella*, *Amyelois transitella*, *Trichoplusia ni*, *Agrotis segeium*, *Ostrinia furnicalis*, and *Thalassiosira pseidonana* derived fatty acyl desaturase.

68. The recombinant microorganism of claim 55, wherein the fatty acyl desaturase has at least 95% sequence identity to a fatty acyl desaturase selected from the group consisting of: SEQ ID NOs: 39, 49-54, 58-63, 78-80 and GenBank Accession nos. AF416738, AGH12217.1, AII21943.1, CAJ43430.2, AF441221, AAF81787.1, AF545481, AJ271414, AY362879, ABX71630.1, NP001299594.1, Q9N9Z8, ABX71630.1 and AIM40221 .1.

69. The recombinant microorganism of claim 55, wherein the acyl-CoA oxidase is selected from Table 5a.

70. The recombinant microorganism of claim 55, wherein the fatty alcohol forming fatty acyl reductase is selected from an *Agrotis segeium*, *Spodoptera exigua*, *Spodoptera littoralis*, *Euglena gracilis*, *Yponomeuta evonymellus* and *Helicoverpa armigera* derived fatty alcohol forming fatty acyl reductase.

71. The recombinant microorganism of claim 55, wherein the fatty alcohol forming fatty acyl reductase has at least 95% sequence identity to a fatty alcohol forming fatty acyl reductase selected from the group consisting of: SEQ ID NOs: 1-3, 32, 41-48, 55-57, 73, 75, 77 and 82.

72. The recombinant microorganism of claim 55, wherein the fatty acyl desaturase catalyzes the conversion of a fatty acyl-CoA into a mono- or poly-unsaturated intermediate selected from E5-10:Acyl-CoA, E7-12:Acyl-CoA, E9-14:Acyl-CoA, E11-16:Acyl-CoA,

E13-18:Acyl-CoA, Z7-12: Acyl-CoA, Z9-14:Acyl-CoA, Z11-16:Acyl-CoA, Z13-18:Acyl-CoA, Z8-12:Acyl-CoA, Z10-14:Acyl-CoA, Z12-16:Acyl-CoA, Z14-18:Acyl-CoA, Z7-10:Acyl-CoA, Z9-12:Acyl-CoA, Z11-14:Acyl-CoA, Z13-16:Acyl-CoA, Z15-18:Acyl-CoA, E7-10:Acyl-CoA, E9-12:Acyl-CoA, E11-14:Acyl-CoA, E13-16:Acyl-CoA, E15-18:Acyl-CoA, E5Z7-12:Acyl-CoA, E7Z9-12:Acyl-CoA, E9Z11-14:Acyl-CoA, E11Z13-16:Acyl-CoA, E13Z15-18:Acyl-CoA, E6E8-10:Acyl-CoA, E8E10-12:Acyl-CoA, E10E12-14:Acyl-CoA, E12E14-16:Acyl-CoA, Z5E8-10:Acyl-CoA, Z7E10-12:Acyl-CoA, Z9E12-14:Acyl-CoA, Z11E14-16:Acyl-CoA, Z13E16-18:Acyl-CoA, Z3-10:Acyl-CoA, Z5-12:Acyl-CoA, Z7-14:Acyl-CoA, Z9-16:Acyl-CoA, Z11-18:Acyl-CoA, Z3Z5-10:Acyl-CoA, Z5Z7-12:Acyl-CoA, Z7Z9-14:Acyl-CoA, Z9Z11-16:Acyl-CoA, Z11Z13-16:Acyl-CoA, and Z13Z15-18:Acyl-CoA.

73. The recombinant microorganism of claim 55, wherein the mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol is selected from the group consisting of E5-10:OH, Z8-12:OH, Z9-12:OH, Z11-14:OH, Z11-16:OH, E11-14:OH, E8E10-12:OH, E7Z9-12:OH, Z11Z13-16OH, Z9-14:OH, Z9-16:OH, and Z13-18:OH.

74. The recombinant microorganism of claim 55, wherein the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an aldehyde forming fatty acyl-CoA reductase capable of catalyzing the conversion of the mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol into a corresponding $\leq C_{18}$ fatty aldehyde.

75. The recombinant microorganism of claim 74, wherein the aldehyde forming fatty acyl-CoA reductase is selected from the group consisting of *Acinetobacter calcoaceticus* A0A1C4HN78, *A. calcoaceticus* N9DA85, *A. calcoaceticus* R8XW24, *A. calcoaceticus* A0A1A0GGM5, *A. calcoaceticus* A0A117N158, *mdNostoc punchforme* YP_001865324.

76. The recombinant microorganism of claim 55, wherein the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid

molecule encoding an alcohol oxidase or an alcohol dehydrogenase capable of catalyzing the conversion of the mono- or poly-unsaturated \leq Cis fatty alcohol into a corresponding \leq Cis fatty aldehyde.

77. The recombinant microorganism of claim 74 or 76, wherein the \leq Cis fatty aldehyde is selected from the group consisting of Z9-16:Aki, Z11-16:Ald, Z11Z13-16:Ald, and Z13-18:Ald.

78. The recombinant microorganism of claim 55, wherein the recombinant microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated \leq Cis fatty alcohol into a corresponding \leq Cm fatty acetate.

79. The recombinant microorganism of claim 78, wherein the acetyl transferase is selected from Table 5d.

80. The recombinant microorganism of claim 78, wherein the \leq Cis fatty acetate is selected from the group consisting of E5-10:Ac, Z7-12:Ac, Z8-12:Ac, Z9-12:Ac, E7Z9-12:Ac, Z9-14:Ac, Z9E12-14:Ac, Z11-14:Ac, E11-14:Ac, Z9-16:Ac, and Z11-16:Ac.

81. The recombinant microorganism of claim 55, wherein the recombinant microorganism further comprises:

at least one endogenous or exogenous nucleic acid molecule encoding an enzyme selected from an alcohol oxidase, an alcohol dehydrogenase, and an aldehyde forming fatty acyl-CoA reductase capable of catalyzing the conversion of the mono- or poly-unsaturated \leq Cis fatty-alcohol into a corresponding \leq Cis fatty aldehyde; and

at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol into a corresponding $\leq C_{18}$ fatty acetate.

82. The recombinant microorganism of claim 81, wherein the mono- or poly-unsaturated $\leq C_{18}$ fatty aldehyde and $\leq C_{18}$ fatty acetate is selected from the group consisting of E5-10:Ac, Z7-12:Ac, Z8-12:Ac, Z9-12:Ac, E7Z9-12:Ac, Z9-14:Ac, Z9E12-14:Ac, E11-14:Ac, Z11-14:Ac, Z11-16:Ac, Z9-16:Ac, Z9-16:Ald, Z11-16:Ald, Z13-16:Ald, and Z13-18:Ald.

83. The recombinant microorganism of claim 55, wherein the recombinant microorganism is a yeast selected from the group consisting of *Yarrowia lipolytica*, *Saccharomyces cerevisiae*, *Candida albicans*, *Candida tropicalis* and *Candida viswanathii*.

84. A method of producing a mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol from an endogenous or exogenous source of saturated $C_{6-C_{24}}$ fatty acid, comprising: cultivating the recombinant microorganism of claim 55 in a culture medium containing a feedstock that provides a carbon source adequate for the production of the mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol.

85. The method of claim 84, wherein the mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol is selected from the group consisting of E5-10:OH, Z8-12:OH, Z9-12:OH, Z11-14:OH, Z11-16:OH, E11-14:OH, E8E10-12:OH, E7Z9-12:OH, Z11Z13-16OH, Z9-14:OH, Z9-16:OH, and Z13-18:OH.

86. The method of claim 84, further comprising a step of recovering the mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol.

87. The method of claim 86, wherein said recovery step comprises distillation.

88. The method of claim 86, wherein said recovery step comprises membrane-based separation.

89. A method of engineering a microorganism that is capable of producing a mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol from an endogenous or exogenous source of saturated C_6 - C_{24} fatty acid, wherein the method comprises introducing into a microorganism the following:

(a) at least one exogenous nucleic acid molecule encoding a fatty acyl desaturase that catalyzes the conversion of a saturated C_6 - C_{24} fatty acyl-CoA to a corresponding mono- or poly-unsaturated C_6 - C_{24} fatty acyl-CoA;

(b) at least one exogenous nucleic acid molecule encoding an acyl-CoA oxidase that catalyzes the conversion of the mono- or poly-unsaturated C_6 - C_{24} fatty acyl-CoA from (a) into a mono- or poly-unsaturated $\leq C_{18}$ fatty acyl-CoA after one or more successive cycle of acyl-CoA oxidase activity, with a given cycle producing a mono- or poly-unsaturated C_4 - C_{22} fatty acyl-CoA intermediate with a two carbon truncation relative to a starting mono- or poly-unsaturated C_6 - C_{24} fatty acyl-CoA substrate in that cycle; and

(c) at least one exogenous nucleic acid molecule encoding a fatty alcohol forming fatty acyl reductase that catalyzes the conversion of the mono- or poly-unsaturated $\leq C_{18}$ fatty acyl-CoA from (b) into the corresponding mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol.

90. The method of claim 89, wherein the microorganism is MATA ura3-302::SUC2 $\Delta pox1 \Delta pox2 \Delta pox3 \Delta pox4 \Delta pox5 \Delta pox6$ Afadh Aadhl Aadh2 AadhS Aadh4 AadhS Aadh6 Aadh7 Afaol::URA3.

91. The method of claim 89, wherein the method further comprises introducing into the microorganism at least one endogenous or exogenous nucleic acid molecule encoding an acyltransferase that preferably stores $\leq C_{18}$ fatty acyl-CoA.

92. The method of claim 89, wherein the method further comprises introducing into the microorganism at least one endogenous or exogenous nucleic acid molecule encoding an acyltransferase that preferably stores $\leq C_{18}$ fatty acyl-CoA, and wherein the acyltransferase is selected from the group consisting of glycerol-3-phosphate acyl transferase (GPAT), lysophosphatidic acid acyltransferase (LPAAT), glycerolphospholipid acyltransferase (GPLAT) and diacylglycerol acyltransferases (DGAT).

93. The method of claim 89, wherein the method further comprises introducing into the microorganism at least one endogenous or exogenous nucleic acid molecule encoding an acyltransferase that preferably stores $\leq C_{18}$ fatty acyl-CoA, and wherein the acyltransferase is selected from Table 5b.

94. The method of claim 89, wherein the method further comprises introducing into the microorganism at least one endogenous or exogenous nucleic acid molecule encoding an acylglycerol lipase that preferably hydrolyzes ester bonds of $>C_{16}$, of $>C_{14}$, of $>C_{12}$ or of $>C_{10}$ acylglycerol substrates.

95. The method of claim 89, wherein the method further comprises introducing into the microorganism at least one endogenous or exogenous nucleic acid molecule encoding an acylglycerol lipase that preferably hydrolyzes ester bonds of $>C_{16}$, of $>C_{14}$, of $>C_{12}$ or of $>C_{10}$ acylglycerol substrates, and wherein the acylglycerol lipase is selected from Table 5c.

96. The method of claim 89, wherein the method further comprises introducing into the microorganism one or more modifications comprising a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous enzyme that catalyzes a reaction in a pathway that competes with the biosynthesis pathway for the production of a mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol.

97. The method of claim 89, wherein the method further comprises introducing into the microorganism one or more modifications comprising a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous enzyme selected from:

- (i) one or more acyl-CoA oxidase;
- (ii) one or more acyltransferase;
- (iii) one or more acylglycerol lipase and/or sterol ester esterase;
- (iv) one or more (fatty) alcohol dehydrogenase;
- (v) one or more (fatty) alcohol oxidase; and
- (vi) one or more cytochrome P450 monooxygenase.

98. The method of claim 89, wherein the method further comprises introducing into the microorganism one or more modifications comprising a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous acyl-CoA oxidase enzyme selected from the group consisting of *Y. lipolytica* POX1(YALI0E32835g), *Y. lipolytica* POX2(YALI0F10857g), *Y. lipolytica* POX3(YALI0D24750g), *Y. lipolytica* POX4(YALI0E27654g), *Y. lipolytica* POX5(YALI0C23859g), *Y. lipolytica* POX6(YALI0E06567g); *S. cerevisiae* POX1(YGL205W); *Candida* POX2 (Ca019.1655, Ca019.9224, CTRG_02374, M18259), *Candida* POX4 (Ca019.1652, Ca019.9221, CTRG_02377, M12160), and *Candida* POX5 (Ca019.5723, Ca019.13146, CTRG_02721, M12161).

99. The method of claim 89, wherein the method further comprises introducing into the microorganism one or more modifications comprising a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous acyltransferase enzyme selected from the group consisting of *Y. lipolytica* YALI0C00209g, *Y. lipolytica* YAL10E18964g, *Y. lipolytica* YAL10F19514g, *Y. lipolytica* YALI0C14014g, *Y. lipolytica* YALI0E16797g, *Y. lipolytica* YALI0E32769g, and *Y. lipolytica* YALI0D07986g, *S. cerevisiae* YBL01 Iw, *S. cerevisiae* YDL052c, *S. cerevisiae* YOR175C, *S. cerevisiae* YPR139C, *S. cerevisiae* YNR008w, and *S. cerevisiae* YOR245c, and *Candida* 1503_02577, *Candida* CTRG_02630, *Candida*

CaO 19.250, *Candida* Ca019.7881, *Candida* CTRG_02437, *Candida* Ca019.1881, *Candida* Ca019.9437, *Candida* CTRG_01687, *Candida* CaO 19.1043, *Candida* Ca019.8645, *Candida* CTRG_04750, *Candida* CaO 19.13439, *Candida* CTRG_04390, *Candida* Ca019.6941, *Candida* CaO 19.14203, and *Candida* CTRG_06209.

100. The method of claim 89, wherein the method further comprises introducing into the microorganism one or more modifications comprising a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous acylglycerol lipase and/or sterol ester esterase enzyme selected from the group consisting of *Y. lipolytica* YAL10E32035g, *Y. lipolytica* YAL10D17534g, *Y. lipolytica* YAL10F10010g, *Y. lipolytica* YAL10C14520g, and *Y. lipolytica* YAL10E00528g, *S. cerevisiae* YKL140w, *S. cerevisiae* YMR313c, *S. cerevisiae* YKR089c, *S. cerevisiae* YOR081c, *S. cerevisiae* YKL094W, *S. cerevisiae* YLL012W, and *S. cerevisiae* YLR020C, and *Candida* CaO19.2050, *Candida* Ca019.9598, *Candida* CTRG_051138, *Candida* W5Q_03398, *Candida* CTRG_00057, *Candida* Ca019.5426, *Candida* Ca019.12881, *Candida* CTRG_06185, *Candida* CaO 19.4864, *Candida* Ca019.12328, *Candida* CTRG_03360, *Candida* CaO19.6501, *Candida* Ca019.13854, *Candida* CTRG_05049, *Candida* Ca019.1887, *Candida* CaO 19.9443, *Candida* CTRG_01683, and *Candida* CTRG_04630.

101. The method of claim 89, wherein the method further comprises one or more modifications comprising a deletion, disruption, mutation, and/or reduction in the activity of one or more endogenous cytochrome P450 monooxygenases selected from the group consisting of *Y. lipolytica* YAL10E25982g (ALKi), *Y. lipolytica* YAL10F01 320g (ALK2), *Y. lipolytica* YAL10E23474g (ALK3), *Y. lipolytica* YAL10B13816g (ALK4), *Y. lipolytica* YAL10B13838g (ALK5), *Y. lipolytica* YAL10B01848g (ALK6), *Y. lipolytica* YAL10A15488g (ALK7), *Y. lipolytica* **YAL10C12122g** (ALK8), *Y. lipolytica* YAL10B06248g (ALK.9), *Y. lipolytica* YAL10B20702g (ALK10), *Y. lipolytica* YAL10C10054g (ALK11) and *Y. lipolytica* YALX0A20130g (ALKI 2).

102. The method of claim 89, wherein the fatty acyl desaturase is selected from an *Argyroiaenia velutinana*, *Spodoptera litura*, *Sesamia inferens*, *Manduca sexta*, *Ostrinia nubilalis*, *Helicoverpa zea*, *Choristoneura rosaceana*, *Drosophila melanogaster*, *Spodoptera littoralis*, *Lampronia capitella*, *Amyelois transitella*, *Trichoplusia ni*, *Agrotis segetum*, *Ostrinia jurnicalis*, and *Thalassiosira pseudonana* derived fatty acyl desaturase.

103. The method of claim 89, wherein the fatty acyl desaturase has at least 95% sequence identity to a fatty acyl desaturase selected from the group consisting of: SEQ ID NOs: 39, 49-54, 58-63, and GenBank Accession nos. AF416738, AGH12217.1, AII21943.1, CAJ43430.2, AF441221, AAF81787.1, AF545481, AJ271414, AY362879, ABX71630.1, NP001299594.1, Q9N9Z8, ABX71630.1 and AIM40221.1.

104. The method of claim 89, wherein the acyl-CoA oxidase is selected from Table 5a.

105. The method of claim 89, wherein the fatty alcohol forming fatty acyl reductase is selected from an *Agrotis segetum*, *Spodoptera exigua*, *Spodoptera littoralis*, *Euglena gracilis*, *Yponomeia evonymellus* and *Helicoverpa armigera* derived fatty alcohol forming fatty acyl reductase.

106. The method of claim 89, wherein the fatty alcohol forming fatty acyl reductase has at least 90% sequence identity to a fatty alcohol forming fatty acyl reductase selected from the group consisting of: SEQ ID NOs: 1-3, 32, 41-48, 55-57, 73, 75, 77 and 82.

107. The method of claim 89, wherein the fatty acyl desaturase catalyzes the conversion of a fatty acyl-CoA into a mono- or poly-unsaturated intermediate selected from E5-10:Acyl-CoA, E7-12:Acyl-CoA, E9-14:Acyl-CoA, EU-16:Acyl-CoA, E13-18:Acyl-CoA, Z7-12:Acyl-CoA, 7.9-14:Acyl-CoA, Z11-16:Acyl-CoA, Z13-18:Acyl-CoA, Z8-12:Acyl-CoA, Z10-14:Acyl-CoA, Z12-16:Acyl-CoA, Z14-18:Acyl-CoA, Z7-10:Acyl-CoA, Z9-12:Acyl-CoA, Z11-14:Acyl-CoA, Z13-16:Acyl-CoA, Z15-18:Acyl-CoA, E7-10:Acyl-CoA, E9-

12:Acyl-CoA, E11-14:Acyl-CoA, E13-16:Acyl-CoA, E15-18:Acyl-CoA, E5Z7-12:Acyl-CoA, E7Z9-12:Acyl-CoA, E9Z11-14:Acyl-CoA, E11Z13-16:Acyl-CoA, E13Z15-18:Acyl-CoA, E6E8-10:Acyl-CoA, E8E10-12:Acyl-CoA, E10E12-14:Acyl-CoA, E12E14-16:Acyl-CoA, Z5E8-10:Acyl-CoA, Z7E10-12:Acyl-CoA, Z9E12-14:Acyl-CoA, Z11E14-16:Acyl-CoA, Z13E16-18:Acyl-CoA, Z3-10:Acyl-CoA, Z5-12:Acyl-CoA, Z7-14:Acyl-CoA, Z9-16:Acyl-CoA, Z11-18:Acyl-CoA, Z3Z5-10:Acyl-CoA, Z5Z7-12:Acyl-CoA, Z7Z9-14:Acyl-CoA, Z9Z11-16:Acyl-CoA, Z11Z13-16:Acyl-CoA, and Z13Z15-18:Acyl-CoA.

108. The method of claim 89, wherein the mono- or poly-unsaturated \leq C₁₈ fatty alcohol is selected from the group consisting of E5-10:GH, Z8-12:OH, Z9-12:QH, Z11-14:OH, Z13-16:OH, E11-14:OH, E8E10-12:OH, E7Z9-12:OH, Z11Z13-16:OH, Z9-14:OH, Z9-16:OH, and Z13-18:OH.

109. The method of claim 89, wherein the method further comprises introducing into the microorganism at least one endogenous or exogenous nucleic acid molecule encoding an aldehyde forming fatty acyl-CoA reductase capable of catalyzing the conversion of the mono- or poly-unsaturated \leq C₁₈ fatty alcohol into a corresponding \leq C₁₈ fatty aldehyde.

110. The method of claim 109, wherein the aldehyde forming fatty acyl-CoA reductase is selected from the group consisting of *Acinetobacter calcoaceticus* A0A1C4HN78, *A. calcoaceticus* N9DA85, *A. calcoaceticus* R8XW24, *A. calcoaceticus* A0A1A0GGM5, *A. calcoaceticus* A0A117N158, and *Nostoc punctiforme* YP_001865324.

111. The method of claim 89, wherein the method further comprises introducing into the microorganism at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase or an alcohol dehydrogenase capable of catalyzing the conversion of the mono- or poly-unsaturated \leq C₁₈ fatty alcohol into a corresponding \leq C₁₈ fatty aldehyde.

112. The method of claim 109 or 111, wherein the $\leq C_{18}$ fatty aldehyde is selected from the group consisting of Z9-16:Ald, Z11-16:Ald, Z11Z13-16:Ald, and Z13-18:Ald.

113. The method of claim 89, wherein method further comprises introducing into the microorganism at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol into a corresponding $\leq C_{18}$ fatty acetate.

114. The method of claim 113, wherein the acetyl transferase is selected from Table 5d.

115. The method of claim 113, wherein the $\leq C_{18}$ fatty acetate is selected from the group consisting of E5-10:Ac, Z7-12:Ac, Z8-12:Ac, Z9-12:Ac, E7Z9-12:Ac, Z9-14:Ac, Z9E12-14:Ac, E11-14:Ac, Z9-16:Ac, Z11-16:Ac and Z11-16:Ac.

116. The method of claim 89, wherein the method further comprises introducing into the microorganism:

at least one endogenous or exogenous nucleic acid molecule encoding an enzyme selected from an alcohol oxidase, an alcohol dehydrogenase, and an aldehyde forming fatty acyl-CoA reductase capable of catalyzing the conversion of the mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol into a corresponding $\leq C_{18}$ fatty aldehyde; and

at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated $\leq C_{18}$ fatty alcohol into a corresponding $\leq C_{18}$ fatty acetate.

117. The method of claim 116, wherein the mono- or poly-unsaturated $\leq C_{18}$ fatty aldehyde and $\leq C_{18}$ fatty acetate is selected from the group consisting of E5-10:Ac, Z7-12:Ac, Z8-12:Ac, Z9-12:Ac, E7Z9-12:Ac, Z9-14:Ac, Z9E12-14:Ac, Z11-14:Ac, E11-14:Ac, Z11-16:Ac, Z9-16:Ald, Z9-16:Ac, Z11-16:Ald, Z11Z13-16:Ald, and Z13-18:Ald.

118. A method of producing a mono- or poly-unsaturated \leq Cis fatty aldehyde from an endogenous or exogenous source of saturated C_{6-C24} fatty acid, comprising: cultivating the recombinant microorganism of claim 74 or 76 in a culture medium containing a feedstock that provides a carbon source adequate for the production of the mono- or poly-unsaturated \leq Cis fatty aldehyde.

119. The method of claim 118, wherein the \leq Cis fatty aldehyde is selected from the group consisting of Z9-16:Ald, ~~Z~~11-16:Ald, Z11Z13-16:Ald, and Z13-18:Ald.

120. The method of claim 118, further comprising a step of recovering the mono- or poly-unsaturated \leq Cis fatty aldehyde.

121. The method of claim 120, wherein said recovery step comprises distillation.

122. The method of claim 120, wherein said recovery step comprises membrane-based separation.

123. A method of producing a mono- or poly-unsaturated \leq Cis fatty acetate from an endogenous or exogenous source of saturated C_{6-C24} fatty acid, comprising: cultivating the recombinant microorganism of claim 78 in a culture medium containing a feedstock that provides a carbon source adequate for the production of the mono- or poly-unsaturated \leq Cis fatty acetate.

124. The method of claim 123, wherein the mono- or poly-unsaturated \leq Cis fatty acetate is selected from the group consisting of E5-10:Ac, Z7-12:Ac, Z8-12:Ac, Z9-12:Ac, E7Z9-12:Ac, Z9-14:Ac, Z9E12-14:Ac, Z11-14:Ac, E11-14:Ac, Z9-16:Ac, and Z11-16:Ac,

125. The **method** of claim 123, **further** comprising a step of recovering the mono- or poly-unsaturated $\leq C_{18}$ fatty acetate.

126. **The** method of claim 125, wherein said **recovery** step comprises distillation.

127. **The** method of claim 125, wherein said recovery step comprises membrane-based separation.

128. The method of claim 89, wherein the recombinant microorganism is a yeast selected from the group consisting of *Yarrowia lipolytica*, *Saccharomyces cerevisiae*, *Candida albicans*, *Candida viswanathii* and *Candida tropicalis*.

129. *The* method of claim 89, wherein the mono- or **poly-un** saturated $\leq C_{18}$ **fatty** alcohol is converted **into** a corresponding $\leq C_{18}$ **fatty** aldehyde using chemical methods.

130. The method of claim 129, wherein the chemical methods are selected from TEMPO-bleach, TEMPO-copper-air, TEMPO-PhI(OAc)₂, **Swern** oxidation and noble metal-air.

131. The **method** of claim 89, wherein the mono- or **poly-unsaturated** $\leq C_{18}$ **fatty** alcohol is converted into a corresponding $\leq C_{18}$ fatty acetate using chemical methods.

132. The method of claim 131, wherein the chemical methods utilize a chemical agent selected from the group consisting of acetyl chloride, acetic **anhydride**, **butyryl** chloride, butyric anhydride, **propanoyl** chloride and propionic anhydride **in** the presence **of** 4-*N*, *N*-

dimethylaminopyridine (DMAP) or sodium acetate to esterify the mono- or **poly-unsaturated** $\leq C_{18}$ fatty alcohol to the corresponding $\leq C_{18}$ fatty acetate.




FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9




FIGURE 10





FIGURE 11

A.



B.





FIGURE 12






FIGURE 14




FIGURE 15




FIGURE 16




FIGURE 17




FIGURE 18




FIGURE 19




FIGURE 21




FIGURE 22





FIGURE 23






FIGURE 25




FIGURE 26




FIGURE 27




FIGURE 28




FIGURE 29




FIGURE 30




FIGURE 31




FIGURE 32




FIGURE 33




FIGURE 34




FIGURE 35




FIGURE 36




FIGURE 37




FIGURE 38




FIGURE 39




FIGURE 40




FIGURE 41




FIGURE 42




FIGURE 43




FIGURE 44




FIGURE 45




FIGURE 46




FIGURE 47




FIGURE 48





FIGURE 49






FIGURE 51




FIGURE 52




FIGURE 53




FIGURE 54

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 18/33151

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - C12P 7/04, 7/24, 7/64; C12N 9/02, 9/10 (2018.01)**CPC - C12Y 114/19005, 102/01084, 103/03006, 203/01086; C12P 7/10, 7/24, 7/6409, 6/7427**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History Document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History Document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History Document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2016/207339 A1 (DANMARKS TEKNISKE UNIVERSITET) 29 December 2016 (29.12.2016). Especially pg 15 ln 15-16, pg 18 ln 18-21, pg 22 ln 21-26, pg 28 ln 26 continued to pg 29 ln 9, pg 91 ln 5, pg 71 ln 17-21, claim 1	1-16, 55-83
Y	Uniprot Accession A0A178WDE4. Acyl-coenzyme A oxidase, 12 April 2017 [online]. [Retrieved on 10 August 2018]. Retrieved from the internet: <URL: https://www.uniprot.org/uniprot/A0A178WDE4.txt?version=7 >. Especially pg 1	55-83
Y	WO 2016/099568 A1 (DOW AGROSCIENCES, LLC) 23 June 2016 (23.06.2016). Especially pg 7 ln 11-12, SEQ ID NO: 27	1-16, 68
Y	WO 2015/171057 A1 (HOFVANDER et al.) 12 November 2015 (12.12.2015). Especially SEQ ID NO: 7	1-16, 71
Y	GenBank Accession AAL49962.1. Diacylglycerol acyltransferase 1 [Bos Taurus], 11 February 2002 [online]. [Retrieved 21 September 2002]. Retrieved from the internet: <URL: https://www.ncbi.nlm.nih.gov/protein/AAL49962.1/ > Especially pg 1	56-58
Y	EBI Accession EAY76846. Oryza sativa triacylglycerol lipase, 29 December 2008 [online]. [Retrieved 21 September 2008]. Retrieved from the internet: <URL: https://www.ebi.ac.uk/ena/data/view/EAY76846&display=text >. Especially pg 1.	59-60



Further documents are listed in the continuation of Box C.



See patent family annex.

*

Special categories of cited documents:

"A"

document defining the general state of the art which is not considered to be of particular relevance

"E"

earlier application or patent but published on or after the international filing date

"L"

document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O"

document referring to an oral disclosure, use, exhibition or other means

"P"

document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

21 September 2018

Date of mailing of the international search report

15 OCT 2018

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents

P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300

PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 18/33151

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 2016/0304913 A1 (TECHNISCHE UNIVERSITÄT DRESDEN) 20 October 2016 (20.10.2016) Especially para [0036].	3-4, 62-63
Y	BREDEWEG et al. A molecular genetic toolbox for <i>Yarrowia lipolytica</i> . Biotechnol Biofuels ePub 3 Jan 2017 Vol 10 No 2 Pages 1-22. Especially pg 6 col 2 para 1, pg 8 Table 3.	64-65
Y	TAKAI et al. Construction and characterization of a <i>Yarrowia lipolytica</i> mutant lacking genes encoding cytochromes P450 subfamily 52. Fungal Genet Biol January 2012 Vol 49 No 1 Pages 58-64. Especially abstract.	66
Y	Uniprot Accession R8XW24. <i>Acinetobacter calcoaceticus</i> Fatty acyl-CoA reductase, 13 April 2013 [online]. [Retrieved 21 September 2018]. Retrieved from the internet: <URL: https://www.uniprot.org/uniprot/R8XW24.txt?version=14 >. Especially P9 1-	75
Y	GenBank Accession KTA99184.1 Alcohol O-acetyltransferase 2 [<i>Candida glabrata</i>], 9 February 2016 [online]. [Retrieved 21 September 2018]. Retrieved from the internet: <URL: https://www.ncbi.nlm.nih.gov/protein/KTA99184.1/ >. Especially pg 1.	11, 79
Y	GenBank Accession AKD01723.1 Alcohol dehydrogenase 12 [<i>Helicoverpa armigera</i>], 25 April 2015 [online]. [retrieved 21 September 2018]. Retrieved from the internet URL: https://www.ncbi.nlm.nih.gov/protein/AKD01723.1/ > Especially pg 1. olecular genetic toolbox for <i>Yarrowia lipolytica</i>	8

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 18/33151

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
 - a. ☒ forming part of the international application as filed:

☒ in the form of an Annex C/ST.25 text file.
☐ on paper or in the form of an image file.
 - b. ☐ furnished together with the international application under PCT Rule *liter.* 1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
 - c. ☒ furnished subsequent to the international filing date for the purposes of international search only:

☐ in the form of an Annex C/ST.25 text file (Rule *liter.* 1(a)).
☐ on paper or in the form of an image file (Rule *liter.* 1(b) and Administrative Instructions, Section 713).
2. ☐ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments:

GenCore ver 6.4.1 SEQ ID NOs: 39, 41, 46, 54, 60, 64

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 18/33151

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

— Go to Extra Sheet for continuation-----

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Claims 1-16, 55-83

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

Continuation of Box III: Observations where Unity of Invention is lacking

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I: Claims 1-16, 55-83, drawn to a recombinant *Yarrowia lipolytica* microorganism composition capable of producing a mono- or poly-unsaturated C6-C24 fatty alcohol.

Group II: Claims 17-54, 84-132, drawn to a method of engineering a *Yarrowia lipolytica* microorganism that is capable of producing a mono- or poly-unsaturated C6-C24 fatty acid, or downstream C6-C24 fatty aldehydes, C6-C24 fatty acetates.

The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Special Technical Features:

Group I has the special technical feature of a recombinant *Yarrowia lipolytica* microorganism composition, not required by Group II.

Group II has the special technical feature of specific method steps for engineering a *Yarrowia lipolytica* microorganism, not required by Group I.

Common Technical Feature:

Groups I and II share the special technical features of:

1. (claim 1): 1. A recombinant *Yarrowia lipolytica* microorganism capable of producing a mono- or poly-unsaturated C6-C24 fatty alcohol from an endogenous or exogenous source of saturated C6-C24 fatty acid, wherein the recombinant *Yarrowia lipolytica* microorganism comprises:
(a) at least one nucleic acid molecule encoding a fatty acyl desaturase that catalyzes the conversion of a saturated C6-C24 fatty acyl-CoA to a corresponding mono- or polyunsaturated C6-C24 fatty acyl-CoA; and
(b) at least one nucleic acid molecule encoding a fatty alcohol forming fatty acyl reductase that catalyzes the conversion of the mono- or poly-unsaturated C6-C24 fatty acyl-CoA from (a) into the corresponding mono- or poly-unsaturated C6-C24 fatty alcohol.

2. Group II claim 17 depends from Group I claim 1.

3. Group II claim 23 depends from Group I claim 7.

4. Group II claim 28 depends from Group I claim 10.

5. Group II claim 33 depends from Group I claim 13.

6. Group II claim 84 depends from Group I claim 55.

7. Group II claim 118 depends from Group I claims 74 or 76.

8. Group II claim 123 depends from Group I claim 78.

9. Groups I and II share the common technical feature of a fatty acyl desaturase such as SEQ ID NO: 60.

10. Groups I and II share the common technical feature of a fatty acyl reductase such as SEQ ID NO: 41.

However, said common technical features do not represent a contribution over the prior art, and are obvious over WO 2016/207339 A1 to Danmarks Tekniske Universitet (hereinafter "DTU"), in view of the Uniprot Accession A0A178WDE4 titled "Acyl-coenzyme A oxidase" (hereinafter "Uniprot A0A178WDE4") (published 12 April 2017 [online]. [Retrieved on 10 August 2018] Available on the internet: <URL: <https://www.uniprot.org/uniprot/A0A178WDE4.txt?version=7>>), in view of WO 2016/099568 A1 to Dow Agrosciences, LLC (hereinafter "Dow"), in further view of WO 2015/171057 A1 to Hofvander et al. (hereinafter "Hofvander").

-----continued on next sheet-----

— continued from previous sheet—

As to common technical feature #1 (claim 1) and common technical feature #2, DTU discloses a recombinant *Yarrowia lipolytica* microorganism (claim 3; "the yeast is selected from the group *Yarrowia lipolytica*) capable of producing a mono- or poly-unsaturated C6-C24 fatty alcohol (Field of Invention: "Herein are disclosed methods for production of (Z)A 1-hexadecen-1-ol in a yeast cell") from an endogenous or exogenous source of saturated C6-C24 fatty acid, wherein the recombinant *Yarrowia lipolytica* microorganism comprises:

(a) at least one nucleic acid molecule encoding a fatty acyl desaturase that catalyzes the conversion of a saturated C6-C24 fatty acyl-CoA to a corresponding mono- or polyunsaturated C6-C24 fatty acyl-CoA (claim 1; "A method for production of (Z)-1 1-hexadecen-1-ol in a yeast cell, said method comprising the steps of: i) providing a yeast cell capable of synthesizing hexadecanoyl-CoA, said yeast cell further capable of expressing: a delta. 11-desaturase selected from the group XXXXX"); and
 (b) at least one nucleic acid molecule encoding a fatty alcohol forming fatty acyl reductase that catalyzes the conversion of the mono- or poly-unsaturated C6-C24 fatty acyl-CoA from (a) (claim 1; "and an alcohol-forming fatty acyl-CoA reductase (FAR) selected from the group XXXX") into the corresponding mono- or poly-unsaturated C6-C24 fatty alcohol (claim 1; "expressing said delta. 11-desaturase and said FAR from said yeast cell; and iii) incubating said yeast cell in a medium, Whereby the delta. 11-desaturase is capable of converting at least part of said hexadecanoyl-CoA to (Z)1 1-hexadecenoyl-CoA; and said FAR is capable of converting at least part of said (Z) 11- hexadecenoyl-CoA to (Z)-1 1-hexadecenol, thereby obtaining (Z)-1 1-hexadecen-1-ol with a titre of at least 0.2 mg/L").

As to common technical feature #3 (claim 7), DTU discloses the recombinant *Yarrowia lipolytica* microorganism of claim 1 wherein the recombinant *Yarrowia lipolytica* further comprises at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase or an alcohol dehydrogenase capable of catalyzing the conversion of the mono- or poly-unsaturated C6-C24 fatty alcohol into a corresponding C6-C24 fatty aldehyde (Field of Invention: "Also disclosed are methods for production of (Z)A 1-hexadecenal in a yeast cell"; pg 27 ln 1-3; "Alternatively, the oxidation of (Z)-1 1-hexadecen-1-ol to (Z)A -hexadecenal can be performed enzymatically by alcohol dehydrogenases").

As to common technical feature #4 (claim 10), DTU discloses the recombinant *Yarrowia lipolytica* microorganism of claim 1, wherein the recombinant *Yarrowia lipolytica* microorganism further comprises at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated C6-C24 fatty alcohol into a corresponding C6-C24 fatty acetate. (Field of Invention: "Also disclosed are methods for production of (Z)A 1-hexadecen-1-yl acetate in a yeast cell"; pg 18 ln 18-21; "In some embodiments, this is done by further expressing an acetyltransferase (AcT, EC 2.3.1.84) or overexpressing a native acetyltransferase from said yeast cell, wherein said acetyltransferase is capable of converting at least part of the (Z)-1 1-hexadecen-1-ol into (Z)-1 1-hexadecen-1-yl acetate, thereby further producing (Z)-1 1-hexadecen-1-yl acetate").

As to common technical feature #5 (claim 13), DTU discloses "The recombinant *Yarrowia lipolytica* microorganism of claim 1, wherein the recombinant *Yarrowia lipolytica* microorganism further comprises:
 at least one endogenous or exogenous nucleic acid molecule encoding an alcohol oxidase or an alcohol dehydrogenase capable of catalyzing the conversion of the mono- or polyunsaturated C6-C24 fatty alcohol into a corresponding C6-C14 fatty aldehyde (pg 27 ln 1-3); and at least one endogenous or exogenous nucleic acid molecule encoding an acetyl transferase capable of catalyzing the conversion of the mono- or poly-unsaturated C6-C24 fatty alcohol into a corresponding C6-C24 fatty acetate (pg 18 ln 18-21).

As to common technical feature #6 (claim 55), DTU teaches concerning a recombinant microorganism capable of producing a mono- or poly-unsaturated <C18 fatty alcohol from an endogenous or exogenous source of saturated C6-C24 fatty acid, wherein the recombinant microorganism comprises:

(a) at least one exogenous nucleic acid molecule encoding a fatty acyl desaturase that catalyzes the conversion of a saturated C6-C24 fatty acyl-CoA to a corresponding mono- or poly-unsaturated C4-C24 fatty acyl-CoA (claim 1)
 (c) at least one exogenous nucleic acid molecule encoding a fatty alcohol forming fatty acyl reductase that catalyzes the conversion of the mono- or poly-unsaturated <C18 fatty acyl-CoA from (b) into the corresponding mono- or poly-unsaturated < C18 fatty alcohol (claim 1).

DTU does not teach (b) at least one exogenous nucleic acid molecule encoding an acyl-CoA oxidase that catalyzes the conversion of the mono- or poly-unsaturated C6-C24 fatty acyl-CoA from (a) into a mono- or polyunsaturated <C18 fatty acyl-CoA after one or more successive cycle of acyl-CoA oxidase activity, with a given cycle producing a mono- or poly-unsaturated C6-C22 fatty acyl-CoA intermediate with a two carbon truncation relative to a starting mono- or polyunsaturated C6-C24 fatty acyl-CoA substrate in that cycle and [claim limitation (c) as above.

However, claim limitation (b) is obvious because an artisan of ordinary skill in the art would have simply added an exogenous enzyme to the microbial host such as *A. thaliana* acyl-coenzyme A oxidase [i.e. acyl-CoA oxidase] as taught by Uniprot A0A178WDE4, because Uniprot A0A178WDE4 indicates that the function of the acyl-CoA oxidase is fatty acid beta oxidation (pg 1), where it was well-known in the art that fatty acid beta oxidation begins with the addition of coenzyme A to a fatty acid [as in claim limitation step (a)], and occurs by successive cycles of reactions during each of which the fatty acid is shortened by a two-carbon fragment removed as acetyl coenzyme A., thus obviating the claim.

As to common technical feature #7, (claim 74), said common technical feature is virtually identical to common technical feature #3, as indicated above, to produce a fatty acid aldehyde.

As to common technical feature #8 (claim 78), said common technical feature is virtually identical to common technical feature #4, as indicated above, to produce a fatty acid acetate.

-----continued on next sheet-----

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 18/33151

— continued from previous sheet—

As to common technical feature #9, fatty acyl desaturase SEQ ID NO: 60 was known in the art, as disclosed by Dow (SEQ ID NO: 27; AA 1-353 100% sequence identity).

As to common technical feature #10, a fatty acyl reductase SEQ ID NO: 41 was known in the art, as disclosed by Hofvander (SEQ ID NO: 7; AA 1-455 100% sequence identity).

As the common technical features were known in the art at the time of the invention, they cannot be considered common special technical features that would otherwise unify the groups. The inventions lack unity with one another.

Therefore, Groups I and II lack unity of invention under PCT Rule 13 because they do not share a same or corresponding special technical feature.

Note concerning claim 66: The preamble of claim 66 is written "the method of claim 55", whereas claim 55 is a recombinant microorganism composition. For the purposes of the International Search & Opinion, claim 66 is reformulated to "66. The recombinant microorganism of claim 55,"

=====